<?xml version="1.0" encoding="UTF-8"?>
<drugbank xmlns="http://www.drugbank.ca" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.drugbank.ca http://www.drugbank.ca/docs/drugbank.xsd" version="4.3">
    <drug type="biotech" created="2005-06-13" updated="2015-02-23">
        <drugbank-id primary="true">DB00001</drugbank-id>
        <drugbank-id>BIOD00024</drugbank-id>
        <drugbank-id>BTD00024</drugbank-id>
        <name>Lepirudin</name>
        <description>Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.</description>
        <cas-number>120993-53-5</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16244762&#13;
            # Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16690967&#13;
            # Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16241940&#13;
            # Askari AT, Lincoff AM: Antithrombotic Drug Therapy in Cardiovascular Disease. 2009 Oct; pp. 440–. ISBN 9781603272346. "Google books":http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440. </general-references>
        <synthesis-reference/>
        <indication>For the treatment of heparin-induced thrombocytopenia</indication>
        <pharmacodynamics>Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</pharmacodynamics>
        <mechanism-of-action>Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. </mechanism-of-action>
        <toxicity>In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</toxicity>
        <metabolism>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</metabolism>
        <absorption>Bioavailability is 100% following injection.</absorption>
        <half-life>Approximately 1.3 hours</half-life>
        <protein-binding/>
        <route-of-elimination>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</route-of-elimination>
        <volume-of-distribution>* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]&#13;
            * 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]&#13;
            * 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]&#13;
            * 32.1 L [HIT patients (n = 73)]</volume-of-distribution>
        <clearance>* 164 ml/min [Healthy 18-60 yrs]&#13;
            * 139 ml/min [Healthy 65-80 yrs]&#13;
            * 61 ml/min [renal impaired]&#13;
            * 114 ml/min [HIT (Heparin-induced thrombocytopenia)]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Hirudin variant-1</synonym>
        </synonyms>
        <products>
            <product>
                <name>Refludan</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02240996</dpd-id>
                <started-marketing-on>2000-01-31</started-marketing-on>
                <ended-marketing-on>2013-07-26</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Refludan</name>
                <ingredients>Lepirudin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Bayer Healthcare</name>
                <url>http://www.bayerhealthcare.com</url>
            </packager>
            <packager>
                <name>Berlex Labs</name>
                <url>http://www.berlex.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Bayer healthcare pharmaceuticals inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Refludan 50 mg vial</description>
                <cost currency="USD">273.19</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antithrombins</category>
                <mesh-id/>
            </category>
            <category>
                <category>Fibrinolytic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>50 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AE02">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AE">Direct thrombin inhibitors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:12.04.12</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1339104</number>
                <country>Canada</country>
                <approved>1997-07-29</approved>
                <expires>2014-07-29</expires>
            </patent>
            <patent>
                <number>5180668</number>
                <country>United States</country>
                <approved>1993-01-19</approved>
                <expires>2010-01-19</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00001 sequence
                LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP
                EEYLQ</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>65 °C</value>
                <source>Otto, A. &amp; Seckler, R. Eur. J. Biochem. 202:67-73 (1991)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.777</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>4.04</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>6963.4250</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C287H440N80O110S6</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>11916</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D06880</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>50419-150-57</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA450195</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01050</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Lepirudin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/lepirudin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/lepirudin.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00278</smpdb-id>
                <name>Lepirudin Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00001</drugbank-id>
                        <name>Lepirudin</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000048</id>
                <name>Prothrombin</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10505536&#13;
                    # Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10912644&#13;
                    # Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11055889&#13;
                    # Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11467439&#13;
                    # Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11807012&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00734" source="Swiss-Prot">
                    <name>Prothrombin</name>
                    <general-function>Involved in blood clotting cascade</general-function>
                    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C</specific-function>
                    <gene-name>F2</gene-name>
                    <locus>11p11-q12</locus>
                    <cellular-location>Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.7</theoretical-pi>
                    <molecular-weight>70037.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3535</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M17262</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339641</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00734</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>THRB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Activated Factor II [IIa]</synonym>
                        <synonym>Coagulation factor II</synonym>
                        <synonym>EC 3.4.21.5</synonym>
                        <synonym>Prothrombin precursor</synonym>
                        <synonym>Thrombin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prothrombin precursor
                        MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
                        VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
                        NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
                        CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
                        QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
                        DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
                        DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
                        DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
                        VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
                        RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
                        GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1869 bp
                        ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
                        CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
                        GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC
                        GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
                        GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
                        GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
                        AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
                        GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
                        GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
                        TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
                        GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
                        TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
                        CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
                        TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
                        GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
                        GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
                        CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
                        CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
                        GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
                        CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
                        GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
                        GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG
                        ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
                        CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
                        GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
                        GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
                        AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
                        CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
                        GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
                        CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
                        GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
                        GGAGAGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>thrombin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-11-10">
        <drugbank-id primary="true">DB00002</drugbank-id>
        <drugbank-id>BIOD00071</drugbank-id>
        <drugbank-id>BTD00071</drugbank-id>
        <name>Cetuximab</name>
        <description>Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.</description>
        <cas-number>205923-56-4</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.</indication>
        <pharmacodynamics>Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.</pharmacodynamics>
        <mechanism-of-action>Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.</mechanism-of-action>
        <toxicity>Single doses of cetuximab higher than 500 mg/m&lt;sup&gt;2&lt;/sup&gt; have not been tested. There is no experience with overdosage in human clinical trials.&#13;
&#13;
        </toxicity>
        <metabolism/>
        <absorption/>
        <half-life>114 hrs</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Anti EGFR</synonym>
            <synonym language="" coder="">IMC-C225</synonym>
        </synonyms>
        <products>
            <product>
                <name>Erbitux</name>
                <ndc-id>66733-948_8518fcc5-91cf-46e6-8fd2-b7d8418200a1</ndc-id>
                <ndc-product-code>66733-948</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2004-02-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2 mg/mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA125084</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Erbitux</name>
                <ndc-id>66733-958_8518fcc5-91cf-46e6-8fd2-b7d8418200a1</ndc-id>
                <ndc-product-code>66733-958</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2007-10-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2 mg/mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA125084</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Erbitux</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02271249</dpd-id>
                <started-marketing-on>2008-10-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Erbitux</name>
                <ingredients>Cetuximab</ingredients>
            </mixture>
            <mixture>
                <name>Erbitux</name>
                <ingredients>Cetuximab</ingredients>
            </mixture>
            <mixture>
                <name>Erbitux</name>
                <ingredients>Cetuximab</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Cardinal Health</name>
                <url>http://www.cardinal.com</url>
            </packager>
            <packager>
                <name>Catalent Pharma Solutions</name>
                <url>http://www.catalent.com</url>
            </packager>
            <packager>
                <name>ImClone Systems Inc.</name>
                <url>http://www.imclone.com</url>
            </packager>
            <packager>
                <name>Oso Biopharmaceuticals Manufacturing LLC</name>
                <url/>
            </packager>
        </packagers>
        <manufacturers/>
        <prices/>
        <categories>
            <category>
                <category>Antineoplastic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>2 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>2 mg/mL</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L01XC06">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L01">ANTINEOPLASTIC AGENTS</level>
                <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
                <level code="L01XC">Monoclonal antibodies</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents>
            <patent>
                <number>1340417</number>
                <country>Canada</country>
                <approved>1999-03-02</approved>
                <expires>2016-03-02</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;Cetuximab heavy chain
                QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN
                TPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA
                STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
                LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSPKSCDKTHTCPPCPAPELL
                GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
                YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
                DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
                RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
            <sequence format="FASTA">&gt;Cetuximab light chain
                DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS
                RFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP
                SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
                LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGA</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
                <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.413</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.48</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>145781.6000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C6484H10042N1732O2023S36</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13175</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>66733-948-23</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00228</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10040</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Cetuximab</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/erbitux.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/cetuximab.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00474</smpdb-id>
                <name>Cetuximab Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00002</drugbank-id>
                        <name>Cetuximab</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00533</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects>
            <effect>
                <protein-name>Low affinity immunoglobulin gamma Fc region receptor II-a</protein-name>
                <gene-symbol>FCGR2A</gene-symbol>
                <uniprot-id>P12318</uniprot-id>
                <rs-id>rs1801274</rs-id>
                <allele/>
                <defining-change>H allelle</defining-change>
                <description>Increased progression free survival</description>
                <pubmed-id>17704420</pubmed-id>
            </effect>
            <effect>
                <protein-name>Low affinity immunoglobulin gamma Fc region receptor III-A</protein-name>
                <gene-symbol>FCGR3A</gene-symbol>
                <uniprot-id>P08637</uniprot-id>
                <rs-id>rs396991</rs-id>
                <allele/>
                <defining-change>A &gt; C</defining-change>
                <description>Better response to drug therapy (longer progression free survival) with the F allele</description>
                <pubmed-id>17704420</pubmed-id>
            </effect>
        </snp-effects>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000767</id>
                <name>Epidermal growth factor receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10480573&#13;
                    # Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10601294&#13;
                    # Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10628369&#13;
                    # Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11408594&#13;
                    # Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11431346&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00533" source="Swiss-Prot">
                    <name>Epidermal growth factor receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>Isoform 2/truncated isoform may act as an antagonist</specific-function>
                    <gene-name>EGFR</gene-name>
                    <locus>7p12</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. Isoform 2:Secreted protein</cellular-location>
                    <transmembrane-regions>646-668</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.67</theoretical-pi>
                    <molecular-weight>134279.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3236</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>EGFR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>EGFR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X00588</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>757924</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00533</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>EGFR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>Epidermal growth factor receptor precursor</synonym>
                        <synonym>Receptor tyrosine-protein kinase ErbB-1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Epidermal growth factor receptor precursor
                        MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
                        VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
                        VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
                        QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
                        TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
                        VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
                        NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
                        ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
                        FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
                        LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
                        GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
                        ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
                        GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
                        CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
                        RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
                        GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
                        FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
                        QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
                        SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
                        TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
                        APQSSEFIGA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;3633 bp
                        ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG
                        GCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG
                        TTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG
                        GTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG
                        ACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT
                        TTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA
                        GTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA
                        CAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG
                        AGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC
                        CAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG
                        GGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC
                        GGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC
                        ACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC
                        AAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC
                        CCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG
                        GTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA
                        GACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA
                        GGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA
                        AACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC
                        TTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA
                        ATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT
                        GAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC
                        GTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT
                        GTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG
                        TTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG
                        GCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC
                        AGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAG
                        CTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA
                        GAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
                        CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG
                        GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC
                        CATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG
                        CCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG
                        GCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG
                        AGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC
                        CAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC
                        GGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT
                        CCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC
                        GATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC
                        TGCCTCACCTCCACCGTGCAACTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC
                        TATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG
                        ATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC
                        AGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA
                        CTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG
                        ATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC
                        GGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC
                        AGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC
                        ATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG
                        TTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC
                        ATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC
                        CTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG
                        CAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA
                        ACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC
                        AAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC
                        AGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG
                        CCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC
                        AGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC
                        ACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA
                        GGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA
                        GCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC
                        GCGCCACAAAGCAGTGAATTTATTGGAGCATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000901</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                <organism>Human</organism>
                <actions/>
                <references># Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16336752</references>
                <known-action>unknown</known-action>
                <polypeptide id="O75015" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils</specific-function>
                    <gene-name>FCGR3B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.71</theoretical-pi>
                    <molecular-weight>26216.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3620</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16863</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31322</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O75015</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16b antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-beta</synonym>
                        <synonym>Fc-gamma RIIIb</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIb</synonym>
                        <synonym>IgG Fc receptor III-1</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-B precursor
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
                        VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
                        AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0002093</id>
                <name>Complement C1r subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P00736" source="Swiss-Prot">
                    <name>Complement C1r subcomponent</name>
                    <general-function/>
                    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system</specific-function>
                    <gene-name>C1R</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.24</theoretical-pi>
                    <molecular-weight>80174.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1246</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04701</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29539</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00736</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1r subcomponent precursor</synonym>
                        <synonym>Complement component 1, r subcomponent</synonym>
                        <synonym>EC 3.4.21.41</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1r subcomponent
                        MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
                        QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
                        SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
                        ELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
                        DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
                        RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
                        DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
                        ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
                        TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
                        SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
                        EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
                        RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2118 bp
                        ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
                        ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
                        AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
                        CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
                        GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
                        GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
                        TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
                        GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
                        TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
                        GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
                        GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
                        AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
                        GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
                        GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
                        AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
                        CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
                        ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
                        GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
                        GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
                        AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
                        CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
                        GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
                        GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
                        AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
                        ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
                        GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
                        CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
                        AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
                        CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
                        AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
                        GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
                        GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
                        GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
                        AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
                        AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
                        ATGGAGGAGGAGGACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0002094</id>
                <name>Complement C1q subcomponent subunit A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02745" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit A</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QA</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.45</theoretical-pi>
                    <molecular-weight>26017.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1241</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF135157</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4894854</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02745</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit A
                        MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
                        TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
                        RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
                        GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
                        IFPSA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
                        GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
                        AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
                        ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
                        AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA
                        GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
                        CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
                        GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
                        TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
                        GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
                        GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
                        CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
                        ATCTTCCCATCTGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0002095</id>
                <name>Complement C1q subcomponent subunit B</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02746" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit B</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QB</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.87</theoretical-pi>
                    <molecular-weight>26460.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1242</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X03084</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>573114</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit B
                        MKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK
                        GLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI
                        AFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV
                        NLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF
                        SGFLLFPDMEA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;688 bp
                        CCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG
                        GACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC
                        AGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA
                        TCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG
                        AGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC
                        TGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT
                        GATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC
                        CGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT
                        GCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT
                        CCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA
                        GGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT
                        CCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0002096</id>
                <name>Complement C1q subcomponent subunit C</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02747" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit C</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QC</gene-name>
                    <locus>1p36.11</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>25774.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1245</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF087892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33150626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QC_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit C precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit C
                        MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
                        GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
                        VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
                        LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
                        LLFPD</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
                        CTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
                        CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
                        GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
                        CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
                        CCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
                        GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
                        AACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC
                        AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
                        CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
                        CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
                        GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
                        CTGCTCTTCCCCGACTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0002097</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17704420</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08637" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis</specific-function>
                    <gene-name>FCGR3A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>209-229</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.21</theoretical-pi>
                    <molecular-weight>29089.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3619</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X52645</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31324</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16a antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-alpha</synonym>
                        <synonym>Fc-gamma RIIIa</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIa</synonym>
                        <synonym>IgG Fc receptor III-2</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-A
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
                        VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
                        KDHKFKWRKDPQDK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;765 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA
                        AAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG
                        AAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0001529</id>
                <name>Complement C1s subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P09871" source="Swiss-Prot">
                    <name>Complement C1s subcomponent</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4</specific-function>
                    <gene-name>C1S</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.59</theoretical-pi>
                    <molecular-weight>76685.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1247</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X06596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>763110</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P09871</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1S_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>C1 esterase</synonym>
                        <synonym>Complement C1s subcomponent precursor</synonym>
                        <synonym>EC 3.4.21.42</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1s subcomponent precursor
                        MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
                        LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
                        TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
                        TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
                        VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
                        NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
                        IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
                        CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
                        REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
                        MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
                        EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
                        TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2067 bp
                        ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
                        GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
                        GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
                        CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
                        AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
                        GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
                        ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
                        GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
                        GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
                        ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
                        AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
                        GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
                        GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
                        ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
                        AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
                        AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
                        TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
                        TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
                        ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
                        GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
                        TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
                        TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
                        GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
                        GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
                        AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
                        AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
                        GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
                        ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
                        GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
                        CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
                        GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
                        GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
                        CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
                        ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
                        GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="9">
                <id>BE0000710</id>
                <name>High affinity immunoglobulin gamma Fc receptor I</name>
                <organism>Human</organism>
                <actions/>
                <references># Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7547242</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12314" source="Swiss-Prot">
                    <name>High affinity immunoglobulin gamma Fc receptor I</name>
                    <general-function>Involved in receptor signaling protein activity</general-function>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. High affinity receptor</specific-function>
                    <gene-name>FCGR1A</gene-name>
                    <locus>1q21.2-q21.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>293-313</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.08</theoretical-pi>
                    <molecular-weight>42632.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3613</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X14356</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31332</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12314</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCGR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD64 antigen</synonym>
                        <synonym>Fc-gamma RI</synonym>
                        <synonym>FcRI</synonym>
                        <synonym>High affinity immunoglobulin gamma Fc receptor I precursor</synonym>
                        <synonym>IgG Fc receptor I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin gamma Fc receptor I precursor
                        MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
                        TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
                        ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
                        ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
                        TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
                        IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
                        LQEGVHRKEPQGAT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1125 bp
                        ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
                        AAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
                        TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
                        ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
                        GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
                        CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
                        GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
                        GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
                        AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
                        ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
                        CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
                        CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
                        ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
                        GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
                        CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
                        ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
                        AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC
                        CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
                        CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="10">
                <id>BE0002098</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17704420</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12318" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens</specific-function>
                    <gene-name>FCGR2A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.78</theoretical-pi>
                    <molecular-weight>34990.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3616</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31932</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182474</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-a</synonym>
                        <synonym>Fc-gamma-RIIa</synonym>
                        <synonym>FcRII-a</synonym>
                        <synonym>IgG Fc receptor II-a</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-a precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-a
                        MAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
                        TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
                        SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS
                        HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
                        CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
                        KNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;954 bp
                        ATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
                        CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
                        GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
                        ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
                        CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
                        GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
                        TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
                        CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
                        AAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
                        CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
                        GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
                        GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
                        TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
                        CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
                        TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
                        AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="11">
                <id>BE0002099</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31994" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis</specific-function>
                    <gene-name>FCGR2B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.12</theoretical-pi>
                    <molecular-weight>34044.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3618</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U87560</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4099445</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31994</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-b</synonym>
                        <synonym>Fc-gamma-RIIb</synonym>
                        <synonym>FcRII-b</synonym>
                        <synonym>IgG Fc receptor II-b</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-b precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-b
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
                        LEEPDDQNRI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;930 bp
                        ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG
                        TGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG
                        GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
                        CTGGAAGAGCCTGATGACCAGAACCGTATT</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="12">
                <id>BE0002100</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31995" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells</specific-function>
                    <gene-name>FCGR2C</gene-name>
                    <locus>1q23.3</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>224-246</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.9</theoretical-pi>
                    <molecular-weight>35578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:15626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X17652</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>32074</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31995</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2C_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-c</synonym>
                        <synonym>Fc-gamma-RIIc</synonym>
                        <synonym>FcRII-c</synonym>
                        <synonym>IgG Fc receptor II-c</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-c precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-c
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
                        APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;972 bp
                        ATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
                        AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
                        GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
                        GCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC
                        AGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-11-16">
        <drugbank-id primary="true">DB00003</drugbank-id>
        <drugbank-id>BIOD00001</drugbank-id>
        <drugbank-id>BTD00001</drugbank-id>
        <name>Dornase alfa</name>
        <description>Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity. </description>
        <cas-number>9003-98-9</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8792953 &#13;
            # Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010 Mar 17;3:CD001127. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20238314 &#13;
            # Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, Ankele C, Hofbeck M, Baden W: Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009;23(1-3):205-10. Epub 2009 Feb 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19255515 &#13;
            # Roche Products Limited. Pulmozyme. 1st ed. Newmarket, Auckland: N.p., 2014. Web. 11 Nov. 2014.&#13;
            #Glowm.com,. 'Dornase Alfa'. N.p., 2014. Web. 11 Nov. 2014.</general-references>
        <synthesis-reference/>
        <indication>Used as adjunct therapy in the treatment of cystic fibrosis. </indication>
        <pharmacodynamics>Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals. </pharmacodynamics>
        <mechanism-of-action>Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.</mechanism-of-action>
        <toxicity>Adverse reactions occur at a frequency of &lt; 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old. </toxicity>
        <metabolism>While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids. </metabolism>
        <absorption>Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no matter the dose administered. Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.</absorption>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution>In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation.</volume-of-distribution>
        <clearance>Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Deoxyribonuclease I</synonym>
            <synonym language="" coder="">Deoxyribonuclease-1 precursor</synonym>
            <synonym language="" coder="">DNase</synonym>
            <synonym language="" coder="">DNase I</synonym>
            <synonym language="" coder="">rhDNase</synonym>
        </synonyms>
        <products>
            <product>
                <name>Pulmozyme</name>
                <ndc-id>50242-100_1f306717-b937-4efc-a269-bcadda447cce</ndc-id>
                <ndc-product-code>50242-100</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1993-12-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>1 mg/mL</strength>
                <route>respiratory (inhalation)</route>
                <fda-application-number>BLA103532</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pulmozyme 1mg/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02046733</dpd-id>
                <started-marketing-on>1994-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>1 mg</strength>
                <route>inhalation</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Viscozyme</name>
                <company>Roche (Chile)</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Pulmozyme</name>
                <ingredients>Dornase alfa</ingredients>
            </mixture>
            <mixture>
                <name>Pulmozyme 1mg/ml</name>
                <ingredients>Dornase alfa</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Cardinal Health</name>
                <url>http://www.cardinal.com</url>
            </packager>
            <packager>
                <name>Catalent Pharma Solutions</name>
                <url>http://www.catalent.com</url>
            </packager>
            <packager>
                <name>F Hoffmann-La Roche Ltd.</name>
                <url>http://www.roche.com</url>
            </packager>
            <packager>
                <name>Genentech Inc.</name>
                <url>http://www.gene.com</url>
            </packager>
            <packager>
                <name>Meda AB</name>
                <url>http://www.meda.se</url>
            </packager>
            <packager>
                <name>Medpointe Pharmaceuticals</name>
                <url/>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Genentech, Inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Lufyllin 200 mg tablet</description>
                <cost currency="USD">3.21</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Lufyllin-gg tablet</description>
                <cost currency="USD">3.84</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Lufyllin-GG 200-200 mg tablet</description>
                <cost currency="USD">3.99</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Lufyllin-400 tablet</description>
                <cost currency="USD">4.62</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Lufyllin 400 mg tablet</description>
                <cost currency="USD">4.81</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Pulmozyme 1 mg/ml ampul</description>
                <cost currency="USD">37.05</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Pulmozyme 1 mg/ml Solution 2.5ml Plastic Container</description>
                <cost currency="USD">77.06</cost>
                <unit>plastic</unit>
            </price>
            <price>
                <description>Lufyllin-GG 100-100 mg/15ml Elixir</description>
                <cost currency="USD">0.6</cost>
                <unit>ml</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Enzymes</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Solution</form>
                <route>respiratory (inhalation)</route>
                <strength>1 mg/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>inhalation</route>
                <strength>1 mg</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes>
            <ahfs-code>44:00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2137237</number>
                <country>Canada</country>
                <approved>2004-10-26</approved>
                <expires>2013-05-28</expires>
            </patent>
            <patent>
                <number>2184581</number>
                <country>Canada</country>
                <approved>2005-02-22</approved>
                <expires>2015-02-28</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;Dornase alfa sequence
                LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP
                DTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS
                RFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ
                WSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG
                LSDQLAQAISDHYPVEVMLK</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>67 °C</value>
                <source>Chan, H.K. et al., Pharm Res. 13:756-761 (1996)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.083</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>4.58</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>29253.9000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1321H1999N339O396S9</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>650</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M55983</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10318</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P24855</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Dornase_alfa</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/pulmozyme.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/dornase-alfa.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0004796</id>
                <name>DNA</name>
                <organism>Human</organism>
                <actions/>
                <references># Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8792953</references>
                <known-action>yes</known-action>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-14">
        <drugbank-id primary="true">DB00004</drugbank-id>
        <drugbank-id>BIOD00084</drugbank-id>
        <drugbank-id>BTD00084</drugbank-id>
        <name>Denileukin diftitox</name>
        <description>A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.</description>
        <cas-number>173146-27-5</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17187516&#13;
            # Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ: Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr;48(4):808-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17454642</general-references>
        <synthesis-reference/>
        <indication>For treatment of cutaneous T-cell lymphoma</indication>
        <pharmacodynamics>Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.</pharmacodynamics>
        <mechanism-of-action>Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>70-80 min</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution>* 0.06 to 0.09 L/kg</volume-of-distribution>
        <clearance>* 0.6 - 2.0 mL/min/kg [Lymphoma]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Diphtheria toxin precursor</synonym>
            <synonym language="" coder="">DT</synonym>
            <synonym language="" coder="">NAD(+--diphthamide ADP- ribosyltransferase)</synonym>
        </synonyms>
        <products>
            <product>
                <name>Ontak</name>
                <ndc-id>62856-603_f2eba925-c3a4-45db-a391-23e7a11bdb24</ndc-id>
                <ndc-product-code>62856-603</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2008-10-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>150 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA103767</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Ontak</name>
                <ingredients>Denileukin diftitox</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Eisai Inc.</name>
                <url>http://www.eisai.com</url>
            </packager>
            <packager>
                <name>Hollister-Stier Laboratories LLC</name>
                <url>http://www.hollisterstier.com</url>
            </packager>
            <packager>
                <name>Ligand Pharmaceuticals Inc.</name>
                <url>http://www.ligand.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Ontak 150 mcg/ml vial</description>
                <cost currency="USD">878.4</cost>
                <unit>ml</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antineoplastic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous</route>
                <strength>150 ug/mL</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L01XX29">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L01">ANTINEOPLASTIC AGENTS</level>
                <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
                <level code="L01XX">Other antineoplastic agents</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00004 sequence
                MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK
                YDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVG
                TEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMY
                EYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVS
                EEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEK
                TTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYN
                FVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYK
                NPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVI
                VLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.301</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.45</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>57647.3000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C2560H4042N678O799S17</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>62856-603-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>V01536</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164750594</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P00587</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Denileukin_diftitox</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/denileukin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/denileukin-diftitox.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000658</id>
                <name>Interleukin-2 receptor subunit alpha</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2786749&#13;
                    # Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3124610&#13;
                    # Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18684057&#13;
                    # Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17187516&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P01589" source="Swiss-Prot">
                    <name>Interleukin-2 receptor subunit alpha</name>
                    <general-function>Involved in interleukin-2 receptor activity</general-function>
                    <specific-function>Receptor for interleukin-2</specific-function>
                    <gene-name>IL2RA</gene-name>
                    <locus>10p15-p14</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>241-259</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.49</theoretical-pi>
                    <molecular-weight>30819.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6008</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL2RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL2RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X01057</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33813</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01589</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL2RA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD25 antigen</synonym>
                        <synonym>IL-2 receptor alpha subunit</synonym>
                        <synonym>IL-2-RA</synonym>
                        <synonym>IL2-RA</synonym>
                        <synonym>Interleukin-2 receptor alpha chain precursor</synonym>
                        <synonym>p55</synonym>
                        <synonym>TAC antigen</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interleukin-2 receptor alpha chain precursor
                        MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS
                        GSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS
                        LPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP
                        QLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ
                        VAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;819 bp
                        ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG
                        GCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC
                        TACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC
                        GGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT
                        CAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA
                        CAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC
                        CTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT
                        CATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC
                        AGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC
                        CAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG
                        GCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT
                        CAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG
                        GTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC
                        TGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000651</id>
                <name>Interleukin-2 receptor subunit beta</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15811959&#13;
                    # Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16516670&#13;
                    # Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18684057&#13;
                    # Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17187516&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P14784" source="Swiss-Prot">
                    <name>Interleukin-2 receptor subunit beta</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2</specific-function>
                    <gene-name>IL2RB</gene-name>
                    <locus>22q13|22q13.1</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>241-265</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.68</theoretical-pi>
                    <molecular-weight>61118.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6009</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL2RB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL2RB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M26062</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>307048</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P14784</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL2RB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD122 antigen</synonym>
                        <synonym>High affinity IL-2 receptor subunit beta</synonym>
                        <synonym>IL-2 receptor</synonym>
                        <synonym>Interleukin-2 receptor subunit beta precursor</synonym>
                        <synonym>P70-75</synonym>
                        <synonym>p75</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interleukin-2 receptor beta chain precursor
                        MAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ
                        VHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA
                        IQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE
                        APLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT
                        IPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV
                        QKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT
                        NQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT
                        FPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP
                        DLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ
                        ELQGQDPTHLV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1656 bp
                        ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT
                        ACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG
                        AGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA
                        GTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT
                        CAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA
                        GTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC
                        ATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT
                        GTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC
                        TTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG
                        GCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA
                        GACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG
                        AGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC
                        ATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA
                        GTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT
                        AACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC
                        CAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT
                        GAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG
                        GACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC
                        AACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG
                        TACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC
                        ACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC
                        TTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC
                        CCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA
                        GAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA
                        GACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC
                        CCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG
                        GAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA
                        GAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0002102</id>
                <name>Cytokine receptor common subunit gamma</name>
                <organism>Human</organism>
                <actions/>
                <references># Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15811959&#13;
                    # Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16516670&#13;
                    # Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11707860</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31785" source="Swiss-Prot">
                    <name>Cytokine receptor common subunit gamma</name>
                    <general-function/>
                    <specific-function>Common subunit for the receptors for a variety of interleukins</specific-function>
                    <gene-name>IL2RG</gene-name>
                    <locus>Xq13.1</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>263-283</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.31</theoretical-pi>
                    <molecular-weight>42287.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6010</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL2RG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL2RG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>D11086</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>219890</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31785</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL2RG_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD132 antigen</synonym>
                        <synonym>Cytokine receptor common gamma chain precursor</synonym>
                        <synonym>Gamma-C</synonym>
                        <synonym>IL-2R gamma chain</synonym>
                        <synonym>Interleukin- 2 receptor gamma chain</synonym>
                        <synonym>p64</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytokine receptor common gamma chain
                        MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV
                        QCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK
                        EIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN
                        HCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW
                        SHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV
                        TEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP
                        PCYTLKPET</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1110 bp
                        ATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA
                        GTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC
                        TTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT
                        CAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC
                        CAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG
                        AAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG
                        GAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA
                        CAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA
                        ACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC
                        CACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA
                        TCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG
                        TTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG
                        AGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG
                        GAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT
                        TTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT
                        ACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT
                        CTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG
                        GCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC
                        CCATGTTACACCCTAAAGCCTGAAACCTGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-11-11">
        <drugbank-id primary="true">DB00005</drugbank-id>
        <drugbank-id>BIOD00052</drugbank-id>
        <drugbank-id>BTD00052</drugbank-id>
        <name>Etanercept</name>
        <description>Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids</description>
        <cas-number>185243-69-0</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># http://www.genome.jp/dbget-bin/www_bget?D00742&#13;
            #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Etanercept; [updated 2014 Sept 24 cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=4&amp;sid=eeea413d-1490-4efa-bf5d-71f40e1986a1%40sessionmgr111&amp;hid=123&amp;bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&amp;AN=232781</general-references>
        <synthesis-reference>Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, "Crystals of etanercept and methods of making thereof." U.S. Patent US07276477, issued October 02, 2007.</synthesis-reference>
        <indication>For treatment of severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis.</indication>
        <pharmacodynamics>Tumor necrosis factor TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in tissues and fluids of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis. Etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.</pharmacodynamics>
        <mechanism-of-action>There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption>Bioavailability following sub-Q administration is approximately 60%. Peak plasma concentrations achieved within 69 hours. </absorption>
        <half-life>102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>* 160 +/- 80 mL/hr [RA patients]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">CD120b</synonym>
            <synonym language="" coder="">p75</synonym>
            <synonym language="" coder="">p80 TNF-alpha receptor</synonym>
            <synonym language="" coder="">TNF-R2</synonym>
            <synonym language="" coder="">Tumor necrosis factor receptor 2</synonym>
            <synonym language="" coder="">Tumor necrosis factor receptor superfamily member 1B precursor</synonym>
            <synonym language="" coder="">Tumor necrosis factor receptor type II</synonym>
        </synonyms>
        <products>
            <product>
                <name>Enbrel</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242903</dpd-id>
                <started-marketing-on>2001-03-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; liquid; powder for solution</dosage-form>
                <strength>25 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Enbrel</name>
                <ndc-id>58406-435_a4b46c16-aa8a-4789-98db-0df4d9eb5110</ndc-id>
                <ndc-product-code>58406-435</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-10-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>50 mg/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103795</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Enbrel</name>
                <ndc-id>58406-445_a4b46c16-aa8a-4789-98db-0df4d9eb5110</ndc-id>
                <ndc-product-code>58406-445</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-11-10</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>50 mg/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103795</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Enbrel</name>
                <ndc-id>58406-455_a4b46c16-aa8a-4789-98db-0df4d9eb5110</ndc-id>
                <ndc-product-code>58406-455</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-11-10</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>25 mg/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103795</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Enbrel</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02274728</dpd-id>
                <started-marketing-on>2005-12-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>50 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Enbrel Sureclick</name>
                <company/>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Enbrel</name>
                <ingredients>Etanercept</ingredients>
            </mixture>
            <mixture>
                <name>Enbrel</name>
                <ingredients>Etanercept</ingredients>
            </mixture>
            <mixture>
                <name>Enbrel</name>
                <ingredients>Etanercept</ingredients>
            </mixture>
            <mixture>
                <name>Enbrel</name>
                <ingredients>Etanercept + Water</ingredients>
            </mixture>
            <mixture>
                <name>Enbrel</name>
                <ingredients>Etanercept</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Amgen Inc.</name>
                <url>http://www.amgen.com</url>
            </packager>
            <packager>
                <name>Boehringer Ingelheim Ltd.</name>
                <url>http://www.boehringer-ingelheim.com</url>
            </packager>
            <packager>
                <name>DSM Corp.</name>
                <url>http://www.dsm.com</url>
            </packager>
            <packager>
                <name>Immunex Corp.</name>
                <url/>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
                <url>http://www.vetter-pharma.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Amgen Inc. + Wyeth + Takeda</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Enbrel 25 mg kit</description>
                <cost currency="USD">250.37</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Enbrel 50 mg/ml sureclick syr</description>
                <cost currency="USD">488.74</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Enbrel 4 25 mg Kit (1 Box = 1 Kit = Four 25 mg Vials)</description>
                <cost currency="USD">1016.57</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Enbrel (1 Box = 1 Kit = Four 50 mg Syringes) 3.92ml Box</description>
                <cost currency="USD">2033.14</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Enbrel SureClick (1 Box Contains Four 50 mg Prefilled Autoinjectors)</description>
                <cost currency="USD">2033.14</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Kit; liquid; powder for solution</form>
                <route>subcutaneous</route>
                <strength>25 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>25 mg/.5mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>50 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>50 mg/mL</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L04AB01">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L04">IMMUNOSUPPRESSANTS</level>
                <level code="L04A">IMMUNOSUPPRESSANTS</level>
                <level code="L04AB">Tumor necrosis factor alpha (TNF-α) inhibitors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>92:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2123593</number>
                <country>Canada</country>
                <approved>2000-03-14</approved>
                <expires>2013-09-14</expires>
            </patent>
            <patent>
                <number>2476934</number>
                <country>Canada</country>
                <approved>2009-06-16</approved>
                <expires>2023-02-27</expires>
            </patent>
            <patent>
                <number>36755</number>
                <country>United States</country>
                <approved>2000-06-27</approved>
                <expires>2012-10-23</expires>
            </patent>
            <patent>
                <number>7276477</number>
                <country>United States</country>
                <approved>2007-10-02</approved>
                <expires>2024-07-29</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB01281</drugbank-id>
                <name>Abatacept</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00026</drugbank-id>
                <name>Anakinra</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08879</drugbank-id>
                <name>Belimumab</name>
                <description>Etanercept may enhance the adverse/toxic effect of Belimumab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06168</drugbank-id>
                <name>Canakinumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08904</drugbank-id>
                <name>Certolizumab pegol</name>
                <description>Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab pegol.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00531</drugbank-id>
                <name>Cyclophosphamide</name>
                <description>Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06643</drugbank-id>
                <name>Denosumab</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00065</drugbank-id>
                <name>Infliximab</name>
                <description>Etanercept may enhance the immunosuppressive effect of Infliximab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01097</drugbank-id>
                <name>Leflunomide</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00108</drugbank-id>
                <name>Natalizumab</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00337</drugbank-id>
                <name>Pimecrolimus</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06372</drugbank-id>
                <name>Rilonacept</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01656</drugbank-id>
                <name>Roflumilast</name>
                <description>May enhance the immunosuppressive effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06688</drugbank-id>
                <name>Sipuleucel-T</name>
                <description>Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06273</drugbank-id>
                <name>Tocilizumab</name>
                <description>May enhance the immunosuppressive effect of Anti-TNF Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08895</drugbank-id>
                <name>Tofacitinib</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08895</drugbank-id>
                <name>Tofacitinib</name>
                <description>Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00072</drugbank-id>
                <name>Trastuzumab</name>
                <description>May enhance the neutropenic effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09033</drugbank-id>
                <name>Vedolizumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt; Etanercept Sequence
                LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDST
                YTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRK
                CRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTS
                TSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSC
                DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
                GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
                GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
                DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>71 °C (whole mAb)</value>
                <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.529</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.89</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>51234.9000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C2224H3475N621O698S36</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12032</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C07897</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D00742</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>58406-455-04</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M32315</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA449515</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P20333</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Etanercept</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/etanercept.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/etanercept.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000704</id>
                <name>Tumor necrosis factor</name>
                <organism>Human</organism>
                <actions>
                    <action>antibody</action>
                </actions>
                <references># Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10206649&#13;
                    # Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10338381&#13;
                    # Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10357816&#13;
                    # Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10375846&#13;
                    # Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10405518&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P01375" source="Swiss-Prot">
                    <name>Tumor necrosis factor</name>
                    <general-function>Involved in tumor necrosis factor receptor binding</general-function>
                    <specific-function>Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin 1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation</specific-function>
                    <gene-name>TNF</gene-name>
                    <locus>6p21.3</locus>
                    <cellular-location>Cell membrane; single-pass type II membrane protein. Processed form:Secreted protein. Also exists as</cellular-location>
                    <transmembrane-regions>36-56</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.92</theoretical-pi>
                    <molecular-weight>25645.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>TNF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>TNF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M16441</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339741</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01375</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TNFA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Cachectin</synonym>
                        <synonym>TNF-a</synonym>
                        <synonym>TNF-alpha</synonym>
                        <synonym>Tumor necrosis factor ligand superfamily member 2</synonym>
                        <synonym>Tumor necrosis factor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tumor necrosis factor precursor
                        MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR
                        EEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR
                        DNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE
                        TPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG
                        ACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC
                        GTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG
                        GAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT
                        TCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG
                        CAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA
                        GATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC
                        AAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC
                        GTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG
                        ACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC
                        CAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT
                        GCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00229</identifier>
                            <name>TNF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cytokine activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tumor necrosis factor receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000949</id>
                <name>Tumor necrosis factor receptor superfamily member 1B</name>
                <organism>Human</organism>
                <actions/>
                <references># Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>unknown</known-action>
                <polypeptide id="P20333" source="Swiss-Prot">
                    <name>Tumor necrosis factor receptor superfamily member 1B</name>
                    <general-function>Involved in tumor necrosis factor receptor activity</general-function>
                    <specific-function>Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity</specific-function>
                    <gene-name>TNFRSF1B</gene-name>
                    <locus>1p36.3-p36.2</locus>
                    <cellular-location>Isoform 1:Cell membrane; single-pass type I membrane protein. Isoform 2:Secreted protein. TBP-II:Sec</cellular-location>
                    <transmembrane-regions>258-287</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.22</theoretical-pi>
                    <molecular-weight>48291.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11917</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>TNFRSF1B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>TNFRSF1B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M32315</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>189186</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P20333</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TNR1B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD120b antigen</synonym>
                        <synonym>Etanercept</synonym>
                        <synonym>p75</synonym>
                        <synonym>p80 TNF-alpha receptor</synonym>
                        <synonym>TNF-R2</synonym>
                        <synonym>Tumor necrosis factor receptor 2</synonym>
                        <synonym>Tumor necrosis factor receptor superfamily member 1B precursor</synonym>
                        <synonym>Tumor necrosis factor receptor type II</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tumor necrosis factor receptor superfamily member 1B precursor
                        MAPVAVWAALAVGLELWAAAHALPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPG
                        QHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTC
                        RPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICR
                        PHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTS
                        FLLPMGPSPPAEGSTGDFALPVGLIVGVTALGLLIIGVVNCVIMTQVKKKPLCLQREAKV
                        PHLPADKARGTQGPEQQHLLITAPSSSSSSLESSASALDRRAPTRNQPQAPGVEASGAGE
                        ARASTGSSDSSPGGHGTQVNVTCIVNVCSSSDHSSQCSSQASSTMGDTDSSPSESPKDEQ
                        VPFSKEECAFRSQLETPETLLGSTEEKPLPLGVPDAGMKPS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1386 bp
                        ATGGCGCCCGTCGCCGTCTGGGCCGCGCTGGCCGTCGGACTGGAGCTCTGGGCTGCGGCG
                        CACGCCTTGCCCGCCCAGGTGGCATTTACACCCTACGCCCCGGAGCCCGGGAGCACATGC
                        CGGCTCAGAGAATACTATGACCAGACAGCTCAGATGTGCTGCAGCAAATGCTCGCCGGGC
                        CAACATGCAAAAGTCTTCTGTACCAAGACCTCGGACACCGTGTGTGACTCCTGTGAGGAC
                        AGCACATACACCCAGCTCTGGAACTGGGTTCCCGAGTGCTTGAGCTGTGGCTCCCGCTGT
                        AGCTCTGACCAGGTGGAAACTCAAGCCTGCACTCGGGAACAGAACCGCATCTGCACCTGC
                        AGGCCCGGCTGGTACTGCGCGCTGAGCAAGCAGGAGGGGTGCCGGCTGTGCGCGCCGCTG
                        CGCAAGTGCCGCCCGGGCTTCGGCGTGGCCAGACCAGGAACTGAAACATCAGACGTGGTG
                        TGCAAGCCCTGTGCCCCGGGGACGTTCTCCAACACGACTTCATCCACGGATATTTGCAGG
                        CCCCACCAGATCTGTAACGTGGTGGCCATCCCTGGGAATGCAAGCATGGATGCAGTCTGC
                        ACGTCCACGTCCCCCACCCGGAGTATGGCCCCAGGGGCAGTACACTTACCCCAGCCAGTG
                        TCCACACGATCCCAACACACGCAGCCAACTCCAGAACCCAGCACTGCTCCAAGCACCTCC
                        TTCCTGCTCCCAATGGGCCCCAGCCCCCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTT
                        CCAGTTGGACTGATTGTGGGTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGTGAAC
                        TGTGTCATCATGACCCAGGTGAAAAAGAAGCCCTTGTGCCTGCAGAGAGAAGCCAAGGTG
                        CCTCACTTGCCTGCCGATAAGGCCCGGGGTACACAGGGCCCCGAGCAGCAGCACCTGCTG
                        ATCACAGCGCCGAGCTCCAGCAGCAGCTCCCTGGAGAGCTCGGCCAGTGCGTTGGACAGA
                        AGGGCGCCCACTCGGAACCAGCCACAGGCACCAGGCGTGGAGGCCAGTGGGGCCGGGGAG
                        GCCCGGGCCAGCACCGGGAGCTCAGATTCTTCCCCTGGTGGCCATGGGACCCAGGTCAAT
                        GTCACCTGCATCGTGAACGTCTGTAGCAGCTCTGACCACAGCTCACAGTGCTCCTCCCAA
                        GCCAGCTCCACAATGGGAGACACAGATTCCAGCCCCTCGGAGTCCCCGAAGGACGAGCAG
                        GTCCCCTTCTCCAAGGAGGAATGTGCCTTTCGGTCACAGCTGGAGACGCCAGAGACCCTG
                        CTGGGGAGCACCGAAGAGAAGCCCCTGCCCCTTGGAGTGCCTGATGCTGGGATGAAGCCC
                        AGTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00020</identifier>
                            <name>TNFR_c6</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tumor necrosis factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>death receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cytokine and chemokine mediated signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0000710</id>
                <name>High affinity immunoglobulin gamma Fc receptor I</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12314" source="Swiss-Prot">
                    <name>High affinity immunoglobulin gamma Fc receptor I</name>
                    <general-function>Involved in receptor signaling protein activity</general-function>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. High affinity receptor</specific-function>
                    <gene-name>FCGR1A</gene-name>
                    <locus>1q21.2-q21.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>293-313</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.08</theoretical-pi>
                    <molecular-weight>42632.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3613</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X14356</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31332</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12314</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCGR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD64 antigen</synonym>
                        <synonym>Fc-gamma RI</synonym>
                        <synonym>FcRI</synonym>
                        <synonym>High affinity immunoglobulin gamma Fc receptor I precursor</synonym>
                        <synonym>IgG Fc receptor I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin gamma Fc receptor I precursor
                        MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
                        TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
                        ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
                        ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
                        TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
                        IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
                        LQEGVHRKEPQGAT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1125 bp
                        ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
                        AAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
                        TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
                        ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
                        GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
                        CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
                        GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
                        GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
                        AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
                        ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
                        CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
                        CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
                        ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
                        GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
                        CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
                        ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
                        AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC
                        CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
                        CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0002097</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                <organism>Human</organism>
                <actions/>
                <references># Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15457442&#13;
                    # Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15526004</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08637" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis</specific-function>
                    <gene-name>FCGR3A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>209-229</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.21</theoretical-pi>
                    <molecular-weight>29089.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3619</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X52645</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31324</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16a antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-alpha</synonym>
                        <synonym>Fc-gamma RIIIa</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIa</synonym>
                        <synonym>IgG Fc receptor III-2</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-A
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
                        VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
                        KDHKFKWRKDPQDK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;765 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA
                        AAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG
                        AAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0002098</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                <organism>Human</organism>
                <actions/>
                <references># Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15457442&#13;
                    # Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15526004</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12318" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens</specific-function>
                    <gene-name>FCGR2A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.78</theoretical-pi>
                    <molecular-weight>34990.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3616</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31932</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182474</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-a</synonym>
                        <synonym>Fc-gamma-RIIa</synonym>
                        <synonym>FcRII-a</synonym>
                        <synonym>IgG Fc receptor II-a</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-a precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-a
                        MAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
                        TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
                        SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS
                        HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
                        CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
                        KNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;954 bp
                        ATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
                        CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
                        GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
                        ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
                        CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
                        GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
                        TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
                        CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
                        AAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
                        CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
                        GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
                        GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
                        TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
                        CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
                        TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
                        AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0002099</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31994" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis</specific-function>
                    <gene-name>FCGR2B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.12</theoretical-pi>
                    <molecular-weight>34044.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3618</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U87560</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4099445</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31994</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-b</synonym>
                        <synonym>Fc-gamma-RIIb</synonym>
                        <synonym>FcRII-b</synonym>
                        <synonym>IgG Fc receptor II-b</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-b precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-b
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
                        LEEPDDQNRI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;930 bp
                        ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG
                        TGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG
                        GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
                        CTGGAAGAGCCTGATGACCAGAACCGTATT</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0002100</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                <organism>Human</organism>
                <actions/>
                <references># Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10800083&#13;
                    # Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7535196</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31995" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells</specific-function>
                    <gene-name>FCGR2C</gene-name>
                    <locus>1q23.3</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>224-246</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.9</theoretical-pi>
                    <molecular-weight>35578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:15626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X17652</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>32074</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31995</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2C_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-c</synonym>
                        <synonym>Fc-gamma-RIIc</synonym>
                        <synonym>FcRII-c</synonym>
                        <synonym>IgG Fc receptor II-c</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-c precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-c
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
                        APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;972 bp
                        ATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
                        AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
                        GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
                        GCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC
                        AGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0001087</id>
                <name>Lymphotoxin-alpha</name>
                <organism>Human</organism>
                <actions/>
                <references># Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11302411&#13;
                    # Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, Fendly BM, Lipari MT, Goeddel DV: Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem. 1992 Oct 15;267(29):21172-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1328224&#13;
                    # Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15005015&#13;
                    # Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15033655&#13;
                    # Kang CP, Lee KW, Yoo DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005 Apr;44(4):547-52. Epub 2005 Feb 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15695296</references>
                <known-action>unknown</known-action>
                <polypeptide id="P01374" source="Swiss-Prot">
                    <name>Lymphotoxin-alpha</name>
                    <general-function>Involved in tumor necrosis factor receptor binding</general-function>
                    <specific-function>Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo</specific-function>
                    <gene-name>LTA</gene-name>
                    <locus>6p21.3</locus>
                    <cellular-location>Homotrimer:Secreted protein. Heterotrimer:Membrane</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.36</theoretical-pi>
                    <molecular-weight>22297.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6709</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LTA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LTA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X01393</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>34445</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01374</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TNFB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>LT-alpha</synonym>
                        <synonym>Lymphotoxin-alpha precursor</synonym>
                        <synonym>TNF-beta</synonym>
                        <synonym>Tumor necrosis factor ligand superfamily member 1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Lymphotoxin-alpha precursor
                        MTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHST
                        LKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAY
                        SPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQ
                        LSTHTDGIPHLVLSPSTVFFGAFAL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;618 bp
                        ATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTC
                        CTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTC
                        ACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACC
                        CTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGA
                        GCAAACACGGACCGTGCCTTCCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTG
                        GTCCCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCTAC
                        TCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGCCCATGAGGTCCAGCTCTTCTCCTCC
                        CAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCCAGGGCTGCAG
                        GAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCCAGCTCACCCAGGGAGACCAG
                        CTATCCACCCACACAGATGGCATCCCCCACCTAGTCCTCAGCCCTAGTACTGTCTTCTTT
                        GGAGCCTTCGCTCTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00229</identifier>
                            <name>TNF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cytokine activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tumor necrosis factor receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="9">
                <id>BE0000901</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                <organism>Human</organism>
                <actions/>
                <references># Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10800083&#13;
                    # Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F: Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):249-53. Epub 2007 Mar 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17387033&#13;
                    # Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15457442&#13;
                    # Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15526004</references>
                <known-action>unknown</known-action>
                <polypeptide id="O75015" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils</specific-function>
                    <gene-name>FCGR3B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.71</theoretical-pi>
                    <molecular-weight>26216.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3620</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16863</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31322</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O75015</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16b antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-beta</synonym>
                        <synonym>Fc-gamma RIIIb</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIb</synonym>
                        <synonym>IgG Fc receptor III-1</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-B precursor
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
                        VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
                        AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="10">
                <id>BE0001529</id>
                <name>Complement C1s subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P09871" source="Swiss-Prot">
                    <name>Complement C1s subcomponent</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4</specific-function>
                    <gene-name>C1S</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.59</theoretical-pi>
                    <molecular-weight>76685.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1247</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X06596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>763110</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P09871</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1S_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>C1 esterase</synonym>
                        <synonym>Complement C1s subcomponent precursor</synonym>
                        <synonym>EC 3.4.21.42</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1s subcomponent precursor
                        MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
                        LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
                        TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
                        TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
                        VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
                        NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
                        IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
                        CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
                        REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
                        MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
                        EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
                        TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2067 bp
                        ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
                        GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
                        GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
                        CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
                        AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
                        GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
                        ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
                        GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
                        GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
                        ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
                        AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
                        GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
                        GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
                        ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
                        AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
                        AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
                        TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
                        TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
                        ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
                        GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
                        TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
                        TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
                        GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
                        GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
                        AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
                        AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
                        GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
                        ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
                        GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
                        CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
                        GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
                        GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
                        CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
                        ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
                        GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="11">
                <id>BE0002093</id>
                <name>Complement C1r subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P00736" source="Swiss-Prot">
                    <name>Complement C1r subcomponent</name>
                    <general-function/>
                    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system</specific-function>
                    <gene-name>C1R</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.24</theoretical-pi>
                    <molecular-weight>80174.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1246</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04701</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29539</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00736</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1r subcomponent precursor</synonym>
                        <synonym>Complement component 1, r subcomponent</synonym>
                        <synonym>EC 3.4.21.41</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1r subcomponent
                        MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
                        QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
                        SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
                        ELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
                        DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
                        RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
                        DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
                        ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
                        TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
                        SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
                        EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
                        RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2118 bp
                        ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
                        ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
                        AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
                        CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
                        GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
                        GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
                        TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
                        GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
                        TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
                        GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
                        GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
                        AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
                        GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
                        GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
                        AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
                        CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
                        ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
                        GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
                        GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
                        AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
                        CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
                        GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
                        GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
                        AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
                        ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
                        GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
                        CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
                        AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
                        CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
                        AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
                        GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
                        GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
                        GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
                        AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
                        AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
                        ATGGAGGAGGAGGACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="12">
                <id>BE0002094</id>
                <name>Complement C1q subcomponent subunit A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02745" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit A</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QA</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.45</theoretical-pi>
                    <molecular-weight>26017.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1241</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF135157</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4894854</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02745</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit A
                        MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
                        TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
                        RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
                        GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
                        IFPSA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
                        GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
                        AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
                        ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
                        AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA
                        GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
                        CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
                        GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
                        TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
                        GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
                        GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
                        CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
                        ATCTTCCCATCTGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="13">
                <id>BE0002095</id>
                <name>Complement C1q subcomponent subunit B</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02746" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit B</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QB</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.87</theoretical-pi>
                    <molecular-weight>26460.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1242</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X03084</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>573114</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit B
                        MKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK
                        GLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI
                        AFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV
                        NLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF
                        SGFLLFPDMEA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;688 bp
                        CCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG
                        GACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC
                        AGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA
                        TCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG
                        AGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC
                        TGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT
                        GATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC
                        CGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT
                        GCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT
                        CCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA
                        GGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT
                        CCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="14">
                <id>BE0002096</id>
                <name>Complement C1q subcomponent subunit C</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02747" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit C</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QC</gene-name>
                    <locus>1p36.11</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>25774.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1245</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF087892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33150626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QC_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit C precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit C
                        MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
                        GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
                        VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
                        LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
                        LLFPD</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
                        CTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
                        CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
                        GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
                        CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
                        CCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
                        GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
                        AACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC
                        AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
                        CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
                        CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
                        GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
                        CTGCTCTTCCCCGACTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme position="15">
                <id>BE0000262</id>
                <name>Prostaglandin G/H synthase 2</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Bawolak MT, Touzin K, Moreau ME, Desormeaux A, Adam A, Marceau F: Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: effects of LPS, anti-inflammatory and anti-hypertensive drugs. Regul Pept. 2008 Feb 7;146(1-3):157-68. Epub 2007 Sep 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17931716&#13;
                    # Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Bramanti P, Cuzzocrea S: Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther. 2006 Mar;316(3):1006-16. Epub 2005 Nov 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16303916</references>
                <known-action>unknown</known-action>
                <polypeptide id="P35354" source="Swiss-Prot">
                    <name>Prostaglandin G/H synthase 2</name>
                    <general-function>Involved in peroxidase activity</general-function>
                    <specific-function>May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity</specific-function>
                    <gene-name>PTGS2</gene-name>
                    <locus>1q25.2-q25.3</locus>
                    <cellular-location>Microsome; microsomal membrane; peripheral membrane protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.41</theoretical-pi>
                    <molecular-weight>68997.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PTGS2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PTGS2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L15326</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>291988</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P35354</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PGH2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>COX-2</synonym>
                        <synonym>Cyclooxygenase- 2</synonym>
                        <synonym>EC 1.14.99.1</synonym>
                        <synonym>PGH synthase 2</synonym>
                        <synonym>PGHS-2</synonym>
                        <synonym>PHS II</synonym>
                        <synonym>Prostaglandin G/H synthase 2 precursor</synonym>
                        <synonym>Prostaglandin H2 synthase 2</synonym>
                        <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prostaglandin G/H synthase 2 precursor
                        MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
                        TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
                        GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
                        NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
                        QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
                        VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
                        NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
                        AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
                        YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
                        GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
                        STEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1815 bp
                        ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
                        TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
                        AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
                        ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
                        TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
                        TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
                        GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
                        GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
                        AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
                        AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
                        AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
                        GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
                        CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
                        TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
                        GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
                        GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
                        ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
                        TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
                        AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
                        TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
                        CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
                        GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCACTGACCAG
                        AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
                        TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
                        TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
                        GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
                        ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
                        GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
                        TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
                        GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
                        TCGACTGAACTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF03098</identifier>
                            <name>An_peroxidase</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>antioxidant activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peroxidase activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00006</drugbank-id>
        <drugbank-id>BIOD00076</drugbank-id>
        <drugbank-id>BTD00076</drugbank-id>
        <name>Bivalirudin</name>
        <description>Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. </description>
        <cas-number>128270-60-0</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16466327&#13;
            # Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17381384&#13;
            # Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16553503&#13;
            # Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11156732&#13;
            # Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21108549&#13;
            # Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16614733&#13;
            # Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12851152</general-references>
        <synthesis-reference>Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, "Process for production of Bivalirudin." U.S. Patent US20070093423, issued April 26, 2007.</synthesis-reference>
        <indication>For treatment of heparin-induced thrombocytopenia and for the&#13;
            prevention of thrombosis. Bivalirudin is indicated for use in&#13;
            patients undergoing percutaneous coronary intervention (PCI), in&#13;
            patients at moderate to high risk acute coronary syndromes due to&#13;
            unstable angina or non-ST segment elevation in whom a PCI is planned.</indication>
        <pharmacodynamics>Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.  The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin. </pharmacodynamics>
        <mechanism-of-action>Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.</mechanism-of-action>
        <toxicity>Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.</toxicity>
        <metabolism>80% proteolytic cleavage</metabolism>
        <absorption>Following intravenous administration, bivalirudin exhibits linear&#13;
            pharmacokinetics .  The mean steady state concentration is 12.3 +/-&#13;
            1.7mcg/mL after administration of an intravenous bolus of 1mg/kg&#13;
            followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.</absorption>
        <half-life>* Normal renal function: 25 min (in normal conditions)&#13;
            * Creatinine clearance 10-29mL/min: 57min&#13;
            * Dialysis-dependant patients: 3.5h</half-life>
        <protein-binding>Other than thrombin and red blood cells, bivalirudin does not bind to&#13;
            plasma proteins.</protein-binding>
        <route-of-elimination>Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.</route-of-elimination>
        <volume-of-distribution>0.2L/kg</volume-of-distribution>
        <clearance>* 3.4 mL/min/kg [Normal renal function]&#13;
            * 3.4 mL/min/kg [mild renal function]&#13;
            * 2.7 mL/min/kg [moderate renal function]&#13;
            * 2.8 mL/min/kg [severe renal function]&#13;
            * 1 mL/min/kg [Dialysis-dependent patients]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Angiomax</name>
                <ndc-id>55154-2275_799d3b00-809b-4abc-989c-05faccec49f8</ndc-id>
                <ndc-product-code>55154-2275</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-12-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020873</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Angiomax</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246533</dpd-id>
                <started-marketing-on>2003-05-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Angiomax</name>
                <ndc-id>65293-001_3ff32af9-cb93-41e5-99ef-a7c162b35d92</ndc-id>
                <ndc-product-code>65293-001</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-12-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020873</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Bivalirudin</name>
                <ndc-id>0409-8300_4530ae1c-394e-44f4-89c0-bacb0e6991a0</ndc-id>
                <ndc-product-code>0409-8300</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-07-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>ANDA090811</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Bivalirudin</name>
                <ndc-id>0409-8300_fa3b34fe-d666-42e6-a1d4-3dbcfab7a384</ndc-id>
                <ndc-product-code>0409-8300</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-07-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>ANDA090816</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Bivalirudin</name>
                <ndc-id>0781-3158_def5f702-a45c-4a38-a49b-a017bb7f5f3c</ndc-id>
                <ndc-product-code>0781-3158</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-06-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020873</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Angiox</name>
                <company/>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Bivalirudin</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Bivalirudin</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Bivalirudin</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Angiomax</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Angiomax</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Angiomax</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Ben Venue Laboratories Inc.</name>
                <url>http://www.benvenue.com</url>
            </packager>
            <packager>
                <name>Oryx Pharmaceuticals Inc.</name>
                <url/>
            </packager>
            <packager>
                <name>Sepracor Pharmaceuticals Inc.</name>
                <url>http://www.sepracor.com</url>
            </packager>
            <packager>
                <name>The Medicines Co.</name>
                <url>http://www.themedicinescompany.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">The medicines co</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Angiomax 250 mg vial</description>
                <cost currency="USD">780.0</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antithrombins</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>250 mg</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>intravenous</route>
                <strength>250 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AE06">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AE">Direct thrombin inhibitors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:12.04.12</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2065150</number>
                <country>Canada</country>
                <approved>1999-12-14</approved>
                <expires>2010-08-17</expires>
            </patent>
            <patent>
                <number>5196404</number>
                <country>United States</country>
                <approved>1993-05-23</approved>
                <expires>2010-05-23</expires>
            </patent>
            <patent>
                <number>7582727</number>
                <country>United States</country>
                <approved>2009-01-27</approved>
                <expires>2029-01-27</expires>
            </patent>
        </patents>
        <food-interactions>
            <food-interaction>Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark</food-interaction>
            <food-interaction>Echinacea</food-interaction>
        </food-interactions>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00009</drugbank-id>
                <name>Alteplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00029</drugbank-id>
                <name>Anistreplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06605</drugbank-id>
                <name>Apixaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04272</drugbank-id>
                <name>Citric Acid</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06695</drugbank-id>
                <name>Dabigatran etexilate</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01254</drugbank-id>
                <name>Dasatinib</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01609</drugbank-id>
                <name>Deferasirox</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB03619</drugbank-id>
                <name>Deoxycholic Acid</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00304</drugbank-id>
                <name>Desogestrel</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00266</drugbank-id>
                <name>Dicoumarol</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00378</drugbank-id>
                <name>Dydrogesterone</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09075</drugbank-id>
                <name>Edoxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08794</drugbank-id>
                <name>Ethyl biscoumacetate</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06730</drugbank-id>
                <name>Gestodene</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00078</drugbank-id>
                <name>Ibritumomab</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09053</drugbank-id>
                <name>Ibrutinib</name>
                <description>May enhance the adverse/toxic effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09079</drugbank-id>
                <name>Nintedanib</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08935</drugbank-id>
                <name>Obinutuzumab</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00686</drugbank-id>
                <name>Pentosan Polysulfate</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00498</drugbank-id>
                <name>Phenindione</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00946</drugbank-id>
                <name>Phenprocoumon</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00396</drugbank-id>
                <name>Progesterone</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00015</drugbank-id>
                <name>Reteplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01207</drugbank-id>
                <name>Ridogrel</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06228</drugbank-id>
                <name>Rivaroxaban</name>
                <description>Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00086</drugbank-id>
                <name>Streptokinase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06206</drugbank-id>
                <name>Sugammadex</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06271</drugbank-id>
                <name>Sulodexide</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00031</drugbank-id>
                <name>Tenecteplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09070</drugbank-id>
                <name>Tibolone</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00932</drugbank-id>
                <name>Tipranavir</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00013</drugbank-id>
                <name>Urokinase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00163</drugbank-id>
                <name>Vitamin E</name>
                <description>May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09030</drugbank-id>
                <name>Vorapaxar</name>
                <description>May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Bivalirudin sequence
                FPRPGGGGNGDFEEIPEEYL</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.985</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>3.91</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>2180.2853</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C98H138N24O33</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12945</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D03136</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>65293-001-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10032</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Bivalirudin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/angiomax.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/bivalirudin.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00277</smpdb-id>
                <name>Bivalirudin Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00006</drugbank-id>
                        <name>Bivalirudin</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000048</id>
                <name>Prothrombin</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11060732&#13;
                    # Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11504570&#13;
                    # Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11833835&#13;
                    # Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11923794&#13;
                    # Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11929334&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00734" source="Swiss-Prot">
                    <name>Prothrombin</name>
                    <general-function>Involved in blood clotting cascade</general-function>
                    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C</specific-function>
                    <gene-name>F2</gene-name>
                    <locus>11p11-q12</locus>
                    <cellular-location>Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.7</theoretical-pi>
                    <molecular-weight>70037.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3535</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M17262</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339641</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00734</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>THRB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Activated Factor II [IIa]</synonym>
                        <synonym>Coagulation factor II</synonym>
                        <synonym>EC 3.4.21.5</synonym>
                        <synonym>Prothrombin precursor</synonym>
                        <synonym>Thrombin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prothrombin precursor
                        MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
                        VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
                        NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
                        CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
                        QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
                        DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
                        DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
                        DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
                        VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
                        RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
                        GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1869 bp
                        ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
                        CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
                        GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC
                        GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
                        GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
                        GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
                        AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
                        GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
                        GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
                        TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
                        GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
                        TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
                        CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
                        TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
                        GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
                        GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
                        CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
                        CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
                        GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
                        CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
                        GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
                        GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG
                        ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
                        CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
                        GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
                        GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
                        AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
                        CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
                        GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
                        CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
                        GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
                        GGAGAGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>thrombin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme position="1">
                <id>BE0001075</id>
                <name>Myeloperoxidase</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. Epub 2008 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18701766[</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05164" source="Swiss-Prot">
                    <name>Myeloperoxidase</name>
                    <general-function>Involved in peroxidase activity</general-function>
                    <specific-function>Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity</specific-function>
                    <gene-name>MPO</gene-name>
                    <locus>17q23.1</locus>
                    <cellular-location>Lysosome</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.14</theoretical-pi>
                    <molecular-weight>83870.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:7218</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>MPO</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>MPO</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J02694</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>189040</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05164</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PERM_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 1.11.1.7</synonym>
                        <synonym>MPO</synonym>
                        <synonym>Myeloperoxidase precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Myeloperoxidase precursor
                        MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
                        LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
                        VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
                        NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
                        QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
                        PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
                        GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
                        REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
                        SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
                        GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
                        AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
                        LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
                        NSYPRDFVNCSTLPALNLASWREAS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2238 bp
                        ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT
                        GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG
                        GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG
                        TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG
                        CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC
                        TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC
                        GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC
                        ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC
                        CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC
                        AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG
                        GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC
                        GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT
                        CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC
                        CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC
                        TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC
                        CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC
                        GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC
                        ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG
                        GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC
                        AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG
                        GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT
                        CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG
                        AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG
                        GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT
                        TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC
                        GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA
                        CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA
                        GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG
                        AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG
                        CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT
                        GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG
                        CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC
                        GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC
                        CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG
                        GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC
                        CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC
                        AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC
                        TGGAGGGAAGCCTCCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF03098</identifier>
                            <name>An_peroxidase</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>antioxidant activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peroxidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>oxygen and reactive oxygen species metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to oxidative stress</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00007</drugbank-id>
        <drugbank-id>BIOD00009</drugbank-id>
        <drugbank-id>BTD00009</drugbank-id>
        <name>Leuprolide</name>
        <description>Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.</description>
        <cas-number>53714-56-0</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15568711&#13;
            # Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15780490&#13;
            # Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16370917&#13;
            # Sequence Information "Link":http://www.freepatentsonline.com/EP1790656.html&#13;
            # "RxMed":http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html</general-references>
        <synthesis-reference>Daniel Kadzimirzs, Gerhard Jas, Volker Autze, "Solution-Phase Synthesis of Leuprolide and Its Intermediates." U.S. Patent US20090005535, issued January 01, 2009.</synthesis-reference>
        <indication>For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty</indication>
        <pharmacodynamics>Used in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.</pharmacodynamics>
        <mechanism-of-action>Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.</mechanism-of-action>
        <toxicity>In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.</toxicity>
        <metabolism>Primarily degraded by peptidase and not by cytochrome P450 enzymes.</metabolism>
        <absorption>Bioavailability by subcutaneous administration is comparable to that by intravenous administration.</absorption>
        <half-life>~3 hours</half-life>
        <protein-binding>43% to 49%</protein-binding>
        <route-of-elimination>Excretion in urine</route-of-elimination>
        <volume-of-distribution>* 27 L [intravenous bolus administration to healthy male volunteers]</volume-of-distribution>
        <clearance>* 8.34 L/h [healthy male receiving a 1-mg IV bolus]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts>
            <salt>
                <drugbank-id primary="true">DBSALT000105</drugbank-id>
                <name>Leuprolide acetate</name>
                <cas-number>74381-53-6</cas-number>
                <inchikey>InChIKey=RGLRXNKKBLIBQS-XNHQSDQCSA-N</inchikey>
            </salt>
        </salts>
        <synonyms>
            <synonym language="" coder="">(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone</synonym>
            <synonym language="" coder="">L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide</synonym>
            <synonym language="" coder="">Leuprorelin</synonym>
            <synonym language="" coder="">Leuprorelina</synonym>
            <synonym language="" coder="">Leuproreline</synonym>
            <synonym language="" coder="">Leuprorelinum</synonym>
            <synonym language="" coder="">PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5</synonym>
            <synonym language="" coder="">PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet</synonym>
        </synonyms>
        <products>
            <product>
                <name>Eligard 22.5mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02248240</dpd-id>
                <started-marketing-on>2003-12-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>28.2 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eligard 30 mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02248999</dpd-id>
                <started-marketing-on>2004-04-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>35.8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eligard 45 mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02268892</dpd-id>
                <started-marketing-on>2005-08-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>58.2 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eligard 7.5mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02248239</dpd-id>
                <started-marketing-on>2003-12-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>10.2 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Leuprolide Acetate</name>
                <ndc-id>0185-7400_db12d309-92e5-47f0-84d7-aba74956f6e0</ndc-id>
                <ndc-product-code>0185-7400</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1998-08-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>1 mg/.2mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>ANDA074728</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Leuprolide Acetate Injection</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02240264</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>liquid</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00727695</dpd-id>
                <started-marketing-on>1985-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>liquid</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00884502</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>3.75 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239833</dpd-id>
                <started-marketing-on>1999-09-13</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>30 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239834</dpd-id>
                <started-marketing-on>1999-09-13</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>11.25 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00836273</dpd-id>
                <started-marketing-on>1989-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>7.5 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230248</dpd-id>
                <started-marketing-on>1997-01-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>22.5 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02148722</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>11.25 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lupron Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02148730</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release</dosage-form>
                <strength>15 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Zeulide Depot</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02429977</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for suspension, sustained-release; kit</dosage-form>
                <strength>5.06 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Enantone</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Leuplin</name>
                <company>Takeda</company>
            </international-brand>
            <international-brand>
                <name>LeuProMaxx</name>
                <company>Baxter/Teva</company>
            </international-brand>
            <international-brand>
                <name>Leupromer</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Lutrate</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Memryte</name>
                <company>Curaxis</company>
            </international-brand>
            <international-brand>
                <name>Prostap 3</name>
                <company>Takeda UK</company>
            </international-brand>
            <international-brand>
                <name>Prostap SR</name>
                <company>Takeda UK</company>
            </international-brand>
            <international-brand>
                <name>Viadur</name>
                <company>Bayer AG</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Leuprolide Acetate</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Eligard 7.5mg</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Eligard 22.5mg</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Eligard 30 mg</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Eligard 45 mg</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Lupron Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Leuprolide Acetate Injection</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
            <mixture>
                <name>Zeulide Depot</name>
                <ingredients>Leuprolide</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Abbott Laboratories Ltd.</name>
                <url>http://www.abbott.com</url>
            </packager>
            <packager>
                <name>Cardinal Health</name>
                <url>http://www.cardinal.com</url>
            </packager>
            <packager>
                <name>Eon Labs</name>
                <url/>
            </packager>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>Oso Biopharmaceuticals Manufacturing LLC</name>
                <url/>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Sanofi-Aventis Inc.</name>
                <url>http://www.sanofi-aventis.com</url>
            </packager>
            <packager>
                <name>Sun Pharmaceutical Industries Ltd.</name>
                <url>http://www.sunpharma.com</url>
            </packager>
            <packager>
                <name>Takeda Pharmaceutical Co. Ltd.</name>
                <url>http://www.takeda.com</url>
            </packager>
            <packager>
                <name>Teva Pharmaceutical Industries Ltd.</name>
                <url>http://www.tevapharm.com</url>
            </packager>
            <packager>
                <name>Tolmar Inc.</name>
                <url>http://www.tolmar.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Leuprolide 2wk 1 mg/0.2 ml kit</description>
                <cost currency="USD">385.33</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Leuprolide Acetate 1 mg/0.2ml Kit 2.8ml 2-Week Kit</description>
                <cost currency="USD">400.74</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Eligard 7.5 mg syringe</description>
                <cost currency="USD">493.2</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Lupron 2-wk 1 mg/0.2 ml kit</description>
                <cost currency="USD">594.37</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Eligard 22.5 mg syringe</description>
                <cost currency="USD">1479.6</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Eligard 30 mg syringe</description>
                <cost currency="USD">1972.8</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Eligard 45 mg syringe</description>
                <cost currency="USD">2959.2</cost>
                <unit>syringe</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antineoplastic Agents, Hormonal</category>
                <mesh-id/>
            </category>
            <category>
                <category>Fertility Agents, Female</category>
                <mesh-id/>
            </category>
            <category>
                <category>Estrogen Antagonists</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>subcutaneous</route>
                <strength>28.2 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>subcutaneous</route>
                <strength>35.8 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>subcutaneous</route>
                <strength>58.2 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>subcutaneous</route>
                <strength>10.2 mg</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>1 mg/.2mL</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>subcutaneous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>intramuscular</route>
                <strength>11.25 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>intramuscular</route>
                <strength>15 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>intramuscular</route>
                <strength>22.5 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>intramuscular</route>
                <strength>3.75 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>intramuscular</route>
                <strength>30 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release</form>
                <route>intramuscular</route>
                <strength>7.5 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for suspension, sustained-release; kit</form>
                <route>intramuscular</route>
                <strength>5.06 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L02AE02">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L02">ENDOCRINE THERAPY</level>
                <level code="L02A">HORMONES AND RELATED AGENTS</level>
                <level code="L02AE">Gonadotropin releasing hormone analogues</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>10:00.00</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00414</drugbank-id>
                <name>Acetohexamide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06203</drugbank-id>
                <name>Alogliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08907</drugbank-id>
                <name>Canagliflozin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00672</drugbank-id>
                <name>Chlorpropamide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09066</drugbank-id>
                <name>Corifollitropin Alfa</name>
                <description>Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01120</drugbank-id>
                <name>Gliclazide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00222</drugbank-id>
                <name>Glimepiride</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01251</drugbank-id>
                <name>Gliquidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01016</drugbank-id>
                <name>Glyburide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01306</drugbank-id>
                <name>Insulin Aspart</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01307</drugbank-id>
                <name>Insulin Detemir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00047</drugbank-id>
                <name>Insulin Glargine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01309</drugbank-id>
                <name>Insulin Glulisine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00046</drugbank-id>
                <name>Insulin Lispro</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00030</drugbank-id>
                <name>Insulin Regular</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08914</drugbank-id>
                <name>Insulin, isophane</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09083</drugbank-id>
                <name>Ivabradine</name>
                <description>May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08882</drugbank-id>
                <name>Linagliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00331</drugbank-id>
                <name>Metformin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00834</drugbank-id>
                <name>Mifepristone</name>
                <description>May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00912</drugbank-id>
                <name>Repaglinide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06335</drugbank-id>
                <name>Saxagliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01124</drugbank-id>
                <name>Tolbutamide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04876</drugbank-id>
                <name>Vildagliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Leuprolide
                PHWSYLLR</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>0.1</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>1209.3983</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C59H84N16O12</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>1756</identifier>
            </external-identifier>
            <external-identifier>
                <resource>ChEBI</resource>
                <identifier>6427</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C07612</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D08113</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0024-0793-75</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA450203</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Leuprolide</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/eligard.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/leuprolide.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000203</id>
                <name>Gonadotropin-releasing hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16809153&#13;
                    # Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10687850&#13;
                    # Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9625809&#13;
                    # Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15758569&#13;
                    # Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10394541</references>
                <known-action>yes</known-action>
                <polypeptide id="P30968" source="Swiss-Prot">
                    <name>Gonadotropin-releasing hormone receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for gonadotropin releasing hormone (GnRH) that mediate the action of GnRH to stimulate the secretion of the gonadotropic hormones (LH and FSH). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act a an inhibitor of GnRH-R signaling</specific-function>
                    <gene-name>GNRHR</gene-name>
                    <locus>4q21.2</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>39-58
                        78-97
                        116-137
                        165-184
                        213-232
                        282-300
                        307-326</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.93</theoretical-pi>
                    <molecular-weight>37731.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4421</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GNRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GNRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L03380</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>183422</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>256</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>31</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P30968</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GNRHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GnRH receptor</synonym>
                        <synonym>GnRH-R</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Gonadotropin-releasing hormone receptor
                        MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL
                        QKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL
                        KLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM
                        IHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR
                        VLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL
                        SDPVNHFFFLFAFLNPCFDPLIYGYFSL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;987 bp
                        ATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC
                        ATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG
                        GTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT
                        CAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA
                        AAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG
                        TGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA
                        AAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC
                        CTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT
                        GGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG
                        ATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC
                        AGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC
                        ATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG
                        GTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA
                        GCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG
                        ACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG
                        TCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA
                        CTTATCTATGGATATTTTTCTCTGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>gonadotropin-releasing hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-14">
        <drugbank-id primary="true">DB00008</drugbank-id>
        <drugbank-id>BIOD00043</drugbank-id>
        <drugbank-id>BTD00043</drugbank-id>
        <name>Peginterferon alfa-2a</name>
        <description>Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. The resultant protein is 165 amino acids. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.</description>
        <cas-number>198153-51-4</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.</indication>
        <pharmacodynamics>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacodynamics>
        <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>Terminal half life is 80 hours (range 50 to 140 hours).</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Pegasys</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02248077</dpd-id>
                <started-marketing-on>2003-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>180 mcg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegasys</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02248078</dpd-id>
                <started-marketing-on>2003-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>180 mcg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegasys</name>
                <ndc-id>0004-0350_95a6b02c-0779-4ee8-966e-f31625cd7ab7</ndc-id>
                <ndc-product-code>0004-0350</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2002-10-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>180 ug/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103964</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pegasys</name>
                <ndc-id>0004-0357_95a6b02c-0779-4ee8-966e-f31625cd7ab7</ndc-id>
                <ndc-product-code>0004-0357</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-03-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>180 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103964</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pegasys</name>
                <ndc-id>0004-0360_95a6b02c-0779-4ee8-966e-f31625cd7ab7</ndc-id>
                <ndc-product-code>0004-0360</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-11-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>135 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103964</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pegasys</name>
                <ndc-id>0004-0365_95a6b02c-0779-4ee8-966e-f31625cd7ab7</ndc-id>
                <ndc-product-code>0004-0365</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-11-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>180 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103964</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pegasys Rbv</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02253410</dpd-id>
                <started-marketing-on>2004-05-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution; tablet</dosage-form>
                <strength>180 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegasys Rbv</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02253429</dpd-id>
                <started-marketing-on>2004-05-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution; tablet</dosage-form>
                <strength>180 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Pegasys</name>
                <ingredients>Peginterferon alfa-2a</ingredients>
            </mixture>
            <mixture>
                <name>Pegasys</name>
                <ingredients>Peginterferon alfa-2a</ingredients>
            </mixture>
            <mixture>
                <name>Pegasys</name>
                <ingredients>Peginterferon alfa-2a</ingredients>
            </mixture>
            <mixture>
                <name>Pegasys</name>
                <ingredients>Peginterferon alfa-2a</ingredients>
            </mixture>
            <mixture>
                <name>Pegasys</name>
                <ingredients>Peginterferon alfa-2a</ingredients>
            </mixture>
            <mixture>
                <name>Pegasys</name>
                <ingredients>Peginterferon alfa-2a</ingredients>
            </mixture>
            <mixture>
                <name>Pegasys Rbv</name>
                <ingredients>Peginterferon alfa-2a + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegasys Rbv</name>
                <ingredients>Peginterferon alfa-2a + Ribavirin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>F Hoffmann La Roche Ltd.</name>
                <url>http://www.roche.com</url>
            </packager>
            <packager>
                <name>F Hoffmann-La Roche Ltd.</name>
                <url>http://www.roche.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Pegasys 180 mcg/ml vial</description>
                <cost currency="USD">642.64</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Pegasys 180 mcg/0.5 ml conv.pk</description>
                <cost currency="USD">2533.2</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Pegasys (1 Kit = Four 180 mcg/ml Vials Prefilled Syringes) Box</description>
                <cost currency="USD">2634.53</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>135 ug/.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>180 ug/.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>180 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>180 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution; tablet</form>
                <route>oral; subcutaneous</route>
                <strength>180 mcg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L03AB11">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AB">Interferons</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>08:18.20</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2172664</number>
                <country>Canada</country>
                <approved>2000-10-03</approved>
                <expires>2016-03-26</expires>
            </patent>
            <patent>
                <number>2203480</number>
                <country>Canada</country>
                <approved>2009-06-30</approved>
                <expires>2017-04-23</expires>
            </patent>
        </patents>
        <food-interactions>
            <food-interaction>Recommended adequate hydration.</food-interaction>
        </food-interactions>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00041</drugbank-id>
                <name>Aldesleukin</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04817</drugbank-id>
                <name>Metamizole</name>
                <description>May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00333</drugbank-id>
                <name>Methadone</name>
                <description>Interferons (Alfa) may increase the serum concentration of Methadone.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00811</drugbank-id>
                <name>Ribavirin</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01265</drugbank-id>
                <name>Telbivudine</name>
                <description>Peginterferon alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00697</drugbank-id>
                <name>Tizanidine</name>
                <description>CYP1A2 Inhibitors (Weak) may increase the serum concentration of Tizanidine.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00495</drugbank-id>
                <name>Zidovudine</name>
                <description>Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Peginterferon alfa-2a sequence
                CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
                QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
                KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C</value>
                <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.99</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>60000.0000</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13246</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00207</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164749390</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01563</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Peginterferon_alfa-2a</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/pegasys.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/peginterferon-alfa-2a.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000385</id>
                <name>Interferon alpha/beta receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717&#13;
                    # Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16953837&#13;
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P48551" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 2</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity</specific-function>
                    <gene-name>IFNAR2</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>244-264</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.11</theoretical-pi>
                    <molecular-weight>57759.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5433</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L42243</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>995300</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P48551</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>IFN-R</synonym>
                        <synonym>Interferon alpha/beta receptor 2</synonym>
                        <synonym>Interferon-alpha/beta receptor beta chain precursor</synonym>
                        <synonym>Type I interferon receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor beta chain precursor
                        MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
                        IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
                        SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
                        HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
                        SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
                        MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
                        DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
                        ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
                        FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
                        ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
                        TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
                        ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
                        GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
                        AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
                        AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
                        ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
                        GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
                        CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
                        ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
                        ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
                        TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
                        ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
                        AATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT
                        ATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT
                        GAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT
                        GGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA
                        GACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG
                        CCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT
                        CCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA
                        ATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT
                        GACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG
                        GATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC
                        TTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC
                        ACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000661</id>
                <name>Interferon alpha/beta receptor 1</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717&#13;
                    # Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16953837&#13;
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P17181" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 1</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves</specific-function>
                    <gene-name>IFNAR1</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>437-457</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.56</theoretical-pi>
                    <molecular-weight>63526.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5432</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03171</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>306914</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P17181</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>Interferon-alpha/beta receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor alpha chain precursor
                        MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
                        FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
                        TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
                        ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
                        NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
                        GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
                        VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
                        FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
                        YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
                        EDESESKTSEELQQDFV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1674 bp
                        ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG
                        TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
                        ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
                        TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
                        AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
                        AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
                        ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
                        GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
                        TTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
                        GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
                        AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
                        ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
                        AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
                        TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
                        CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
                        GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
                        GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
                        TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
                        GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
                        GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
                        GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
                        TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
                        GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
                        TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
                        TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
                        AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
                        GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
                        GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-01-09">
        <drugbank-id primary="true">DB00009</drugbank-id>
        <drugbank-id>BIOD00050</drugbank-id>
        <drugbank-id>BTD00050</drugbank-id>
        <name>Alteplase</name>
        <description>Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells</description>
        <cas-number>105857-23-6</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli</indication>
        <pharmacodynamics>Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.</pharmacodynamics>
        <mechanism-of-action>Alteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">t-PA</synonym>
            <synonym language="" coder="">t-plasminogen activator</synonym>
            <synonym language="" coder="">Tissue-type plasminogen activator precursor</synonym>
            <synonym language="" coder="">tPA</synonym>
        </synonyms>
        <products>
            <product>
                <name>Activase Rt-pa</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02225689</dpd-id>
                <started-marketing-on>1998-04-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>liquid; powder for solution</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Activase Rt-pa</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02147440</dpd-id>
                <started-marketing-on>1996-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>liquid; powder for solution</dosage-form>
                <strength>100 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Activase Rt-pa Inj</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00771473</dpd-id>
                <started-marketing-on>1987-12-31</started-marketing-on>
                <ended-marketing-on>1998-07-31</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>29 m</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Cathflo</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02245859</dpd-id>
                <started-marketing-on>2002-09-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>instillation</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Cathflo Activase</name>
                <ndc-id>50242-041_162fe6a5-4dc6-46b5-8206-24a0af55f2d1</ndc-id>
                <ndc-product-code>50242-041</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2001-09-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>2.2 mg/2mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA103172</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lysatec Rt - Pa</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02009285</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>1997-08-26</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Cathflo Activase</name>
                <ingredients>Alteplase</ingredients>
            </mixture>
            <mixture>
                <name>Activase Rt-pa</name>
                <ingredients>Alteplase + Water</ingredients>
            </mixture>
            <mixture>
                <name>Activase Rt-pa</name>
                <ingredients>Alteplase + Water</ingredients>
            </mixture>
            <mixture>
                <name>Cathflo</name>
                <ingredients>Alteplase</ingredients>
            </mixture>
            <mixture>
                <name>Lysatec Rt - Pa</name>
                <ingredients>Alteplase + Water</ingredients>
            </mixture>
            <mixture>
                <name>Activase Rt-pa Inj</name>
                <ingredients>Alteplase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Genentech Inc.</name>
                <url>http://www.gene.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Cathflo activase 2 mg vial</description>
                <cost currency="USD">106.33</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Activase 50 mg vial</description>
                <cost currency="USD">2389.85</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Activase 100 mg vial</description>
                <cost currency="USD">4779.71</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Thrombolytic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid; powder for solution</form>
                <route>intravenous</route>
                <strength>100 mg</strength>
            </dosage>
            <dosage>
                <form>Liquid; powder for solution</form>
                <route>intravenous</route>
                <strength>50 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>29 m</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>instillation</route>
                <strength>1 mg</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>intravenous</route>
                <strength>2.2 mg/2mL</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>50 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AD02">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AD">Enzymes</level>
            </atc-code>
            <atc-code code="S01XA13">
                <level code="S">SENSORY ORGANS</level>
                <level code="S01">OPHTHALMOLOGICALS</level>
                <level code="S01X">OTHER OPHTHALMOLOGICALS</level>
                <level code="S01XA">Other ophthalmologicals</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:12.20</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00233</drugbank-id>
                <name>Aminosalicylic Acid</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00261</drugbank-id>
                <name>Anagrelide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06605</drugbank-id>
                <name>Apixaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06692</drugbank-id>
                <name>Aprotinin</name>
                <description>May diminish the therapeutic effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00278</drugbank-id>
                <name>Argatroban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01294</drugbank-id>
                <name>Bismuth Subsalicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00006</drugbank-id>
                <name>Bivalirudin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06441</drugbank-id>
                <name>Cangrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01166</drugbank-id>
                <name>Cilostazol</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00215</drugbank-id>
                <name>Citalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04272</drugbank-id>
                <name>Citric Acid</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00758</drugbank-id>
                <name>Clopidogrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06695</drugbank-id>
                <name>Dabigatran etexilate</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran etexilate.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06754</drugbank-id>
                <name>Danaparoid</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06700</drugbank-id>
                <name>Desvenlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00586</drugbank-id>
                <name>Diclofenac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00266</drugbank-id>
                <name>Dicoumarol</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00861</drugbank-id>
                <name>Diflunisal</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01551</drugbank-id>
                <name>Dihydrocodeine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00975</drugbank-id>
                <name>Dipyridamole</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00476</drugbank-id>
                <name>Duloxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09075</drugbank-id>
                <name>Edoxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01240</drugbank-id>
                <name>Epoprostenol</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00063</drugbank-id>
                <name>Eptifibatide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01175</drugbank-id>
                <name>Escitalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08794</drugbank-id>
                <name>Ethyl biscoumacetate</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00749</drugbank-id>
                <name>Etodolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00573</drugbank-id>
                <name>Fenoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08976</drugbank-id>
                <name>Floctafenine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00472</drugbank-id>
                <name>Fluoxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00712</drugbank-id>
                <name>Flurbiprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01050</drugbank-id>
                <name>Ibuprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01088</drugbank-id>
                <name>Iloprost</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00328</drugbank-id>
                <name>Indomethacin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01009</drugbank-id>
                <name>Ketoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00465</drugbank-id>
                <name>Ketorolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08918</drugbank-id>
                <name>Levomilnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01397</drugbank-id>
                <name>Magnesium salicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00784</drugbank-id>
                <name>Mefenamic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00814</drugbank-id>
                <name>Meloxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04896</drugbank-id>
                <name>Milnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00461</drugbank-id>
                <name>Nabumetone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08813</drugbank-id>
                <name>Nadroparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00788</drugbank-id>
                <name>Naproxen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00727</drugbank-id>
                <name>Nitroglycerin</name>
                <description>May decrease the serum concentration of Alteplase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00991</drugbank-id>
                <name>Oxaprozin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00715</drugbank-id>
                <name>Paroxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00498</drugbank-id>
                <name>Phenindione</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00946</drugbank-id>
                <name>Phenprocoumon</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00554</drugbank-id>
                <name>Piroxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06209</drugbank-id>
                <name>Prasugrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06228</drugbank-id>
                <name>Rivaroxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01399</drugbank-id>
                <name>Salsalate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01104</drugbank-id>
                <name>Sertraline</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00605</drugbank-id>
                <name>Sulindac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06271</drugbank-id>
                <name>Sulodexide</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01600</drugbank-id>
                <name>Tiaprofenic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08816</drugbank-id>
                <name>Ticagrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00208</drugbank-id>
                <name>Ticlopidine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06822</drugbank-id>
                <name>Tinzaparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00775</drugbank-id>
                <name>Tirofiban</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00500</drugbank-id>
                <name>Tolmetin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00285</drugbank-id>
                <name>Venlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06684</drugbank-id>
                <name>Vilazodone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09030</drugbank-id>
                <name>Vorapaxar</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09068</drugbank-id>
                <name>Vortioxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Alteplase sequence
                SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG
                TCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA
                LAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC
                YFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK
                PWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS
                PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH
                KEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL
                SPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG
                PLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>60 °C</value>
                <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.516</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.61</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>59042.3000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C2569H3928N746O781S40</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>7297</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D02837</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>L00153</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164776730</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P00750</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Alteplase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/alteplas.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/alteplase.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00280</smpdb-id>
                <name>Alteplase Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00009</drugbank-id>
                        <name>Alteplase</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000211</id>
                <name>Plasminogen</name>
                <organism>Human</organism>
                <actions>
                    <action>activator</action>
                </actions>
                <references># Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235&#13;
                    # Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656&#13;
                    # Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00747" source="Swiss-Prot">
                    <name>Plasminogen</name>
                    <general-function>Involved in plasmin activity</general-function>
                    <specific-function>Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo</specific-function>
                    <gene-name>PLG</gene-name>
                    <locus>6q26</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.25</theoretical-pi>
                    <molecular-weight>90569.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9071</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X05199</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>387026</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PLMN_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.7</synonym>
                        <synonym>Plasminogen precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen precursor
                        MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
                        CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
                        GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
                        CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
                        LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
                        AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
                        QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
                        LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
                        CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
                        PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
                        RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
                        PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
                        LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
                        GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2433 bp
                        ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
                        CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
                        CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
                        TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
                        AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
                        TCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT
                        GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
                        ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
                        GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
                        TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
                        ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
                        CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
                        CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC
                        CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
                        GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
                        GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT
                        GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
                        CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
                        CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
                        GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
                        TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
                        CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
                        GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
                        GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC
                        TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
                        CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
                        AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
                        CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
                        GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
                        GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
                        AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
                        GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
                        CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
                        CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
                        GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
                        ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
                        CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
                        TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
                        GGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
                        GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
                        ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00024</identifier>
                            <name>PAN_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>plasmin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000538</id>
                <name>Fibrinogen alpha chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235&#13;
                    # Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656&#13;
                    # Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
                <known-action>yes</known-action>
                <polypeptide id="P02671" source="Swiss-Prot">
                    <name>Fibrinogen alpha chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation</specific-function>
                    <gene-name>FGA</gene-name>
                    <locus>4q28</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.87</theoretical-pi>
                    <molecular-weight>94974.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3661</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF361104</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>13591824</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02671</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FIBA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Fibrinogen alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]
                        MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
                        NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
                        NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
                        RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
                        LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
                        GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
                        NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
                        SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
                        EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
                        VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
                        YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
                        VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
                        GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
                        NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
                        VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2601 bp
                        ATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA
                        GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
                        GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
                        AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
                        TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
                        GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
                        AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
                        CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
                        GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
                        CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
                        CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
                        TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
                        CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
                        TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
                        TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
                        GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
                        TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
                        ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
                        AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
                        GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
                        GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
                        AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
                        GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
                        TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
                        GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
                        TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
                        GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
                        GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
                        AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
                        AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
                        TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
                        AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
                        TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
                        GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
                        GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
                        GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
                        GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
                        CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
                        ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
                        AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
                        GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
                        TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
                        GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
                        AGGCCCCTTGTGACCCAATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00147</identifier>
                            <name>Fibrinogen_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0000717</id>
                <name>Urokinase plasminogen activator surface receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q03405" source="Swiss-Prot">
                    <name>Urokinase plasminogen activator surface receptor</name>
                    <general-function>Involved in U-plasminogen activator receptor activity</general-function>
                    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form</specific-function>
                    <gene-name>PLAUR</gene-name>
                    <locus>19q13</locus>
                    <cellular-location>Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.64</theoretical-pi>
                    <molecular-weight>36978.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9053</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X51675</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>37605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q03405</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>UPAR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD87 antigen</synonym>
                        <synonym>Monocyte activation antigen Mo3</synonym>
                        <synonym>U- PAR</synonym>
                        <synonym>uPAR</synonym>
                        <synonym>Urokinase plasminogen activator surface receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Urokinase plasminogen activator surface receptor precursor
                        MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
                        ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
                        GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
                        FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
                        MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
                        QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1008 bp
                        ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
                        TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
                        CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
                        GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
                        ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
                        GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
                        GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
                        GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
                        AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
                        TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
                        GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
                        GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
                        ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA
                        AGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG
                        AACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC
                        CAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC
                        CTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00021</identifier>
                            <name>UPAR_LY6</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>U-plasminogen activator receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0000240</id>
                <name>Plasminogen activator inhibitor 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05121" source="Swiss-Prot">
                    <name>Plasminogen activator inhibitor 1</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis</specific-function>
                    <gene-name>SERPINE1</gene-name>
                    <locus>7q21.3-q22</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.22</theoretical-pi>
                    <molecular-weight>45061.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8583</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04429</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>35272</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05121</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAI1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Endothelial plasminogen activator inhibitor</synonym>
                        <synonym>PAI</synonym>
                        <synonym>PAI-1</synonym>
                        <synonym>Plasminogen activator inhibitor 1 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen activator inhibitor 1 precursor
                        MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
                        GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
                        FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
                        DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
                        GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
                        FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
                        STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1209 bp
                        ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
                        GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
                        AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
                        GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
                        ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
                        CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC
                        TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
                        CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
                        GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
                        GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
                        CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
                        TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
                        GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
                        GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
                        CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
                        TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
                        ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
                        GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
                        TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
                        TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
                        GAACCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-20">
        <drugbank-id primary="true">DB00010</drugbank-id>
        <drugbank-id>BIOD00033</drugbank-id>
        <drugbank-id>BTD00033</drugbank-id>
        <name>Sermorelin</name>
        <description>Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues</description>
        <cas-number>86168-78-7</cas-number>
        <groups>
            <group>approved</group>
            <group>withdrawn</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For the treatment of dwarfism, prevention of HIV-induced weight loss</indication>
        <pharmacodynamics>Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans.</pharmacodynamics>
        <mechanism-of-action>Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>11-12 min</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products/>
        <international-brands>
            <international-brand>
                <name>Geref</name>
                <company>Serono Pharma</company>
            </international-brand>
        </international-brands>
        <mixtures/>
        <packagers>
            <packager>
                <name>Chengdu Shengnuo Bio Pharmaceutical Co. Ltd.</name>
                <url/>
            </packager>
            <packager>
                <name>Letco Medical Inc.</name>
                <url>http://www.letcomedical.com</url>
            </packager>
            <packager>
                <name>Live Well Drugstore LLC</name>
                <url>http://www.livewelldrugstore.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Emd serono inc</manufacturer>
        </manufacturers>
        <prices/>
        <categories>
            <category>
                <category>Hormone Replacement Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages/>
        <atc-codes>
            <atc-code code="H01AC04">
                <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
                <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
                <level code="H01A">ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</level>
                <level code="H01AC">Somatropin and somatropin agonists</level>
            </atc-code>
            <atc-code code="V04CD03">
                <level code="V">VARIOUS</level>
                <level code="V04">DIAGNOSTIC AGENTS</level>
                <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
                <level code="V04CD">Tests for pituitary function</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00010 sequence
                YADAIFTNSYRKVLGQLSARKLLQDIMSRQ</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.330</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>9.99</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>3357.8820</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C149H246N44O42S</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C08192</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164749110</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Sermorelin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/sermorelin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/sermorelin-acetate.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000625</id>
                <name>Growth hormone-releasing hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14499707&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="Q02643" source="Swiss-Prot">
                    <name>Growth hormone-releasing hormone receptor</name>
                    <general-function>Involved in G-protein coupled receptor activity</general-function>
                    <specific-function>Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion</specific-function>
                    <gene-name>GHRHR</gene-name>
                    <locus>7p14</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>133-152
                        163-181
                        205-227
                        241-262
                        281-304
                        330-348
                        362-381</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.73</theoretical-pi>
                    <molecular-weight>47402.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4266</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GHRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GHRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L01406</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>183173</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>247</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>29</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q02643</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GHRHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GHRH receptor</synonym>
                        <synonym>GRF receptor</synonym>
                        <synonym>GRFR</synonym>
                        <synonym>Growth hormone-releasing hormone receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Growth hormone-releasing hormone receptor precursor
                        MDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWD
                        GLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLA
                        EEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVF
                        LKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRR
                        AFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLF
                        LNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPL
                        ELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLT
                        SMC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1272 bp
                        ATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTA
                        TTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCC
                        TGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGAT
                        GGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGAT
                        TTCTTCTCTCACTTCAGCTCAGAGTCAGGGGCTGTGAAACGGGATTGTACTATCACTGGC
                        TGGTCTGAGCCCTTTCCACCTTACCCTGTGGCCTGCCCTGTGCCTCTGGAGCTGCTGGCT
                        GAGGAGGAATCTTACTTCTCCACAGTGAAGATTATCTACACCGTGGGCCATAGCATCTCT
                        ATTGTAGCCCTCTTCGTGGCCATCACCATCCTGGTTGCTCTCAGGAGGCTCCACTGCCCC
                        CGGAACTACGTCCACACCCAGCTGTTCACCACTTTTATCCTCAAGGCGGGACGTGTGTTC
                        CTGAAGGATGCTGCCCTTTTCCACAGCGACGACACTGACCACTGCAGCTTCTCCACTGTT
                        CTATGCAAGGTCTCTGTGGCCGCCTCCCATTTCGCCACCATGACCAACTTCAGCTGGCTG
                        TTGGCAGAAGCCGTCTACCTGAACTGCCTCCTGGCCTCCACCTCCCCCAGCTCAAGGAGA
                        GCCTTCTGGTGGCTGGTTCTCGCTGGCTGGGGGCTGCCCGTGCTCTTCACTGGCACGTGG
                        GTGAGCTGCAAACTGGCCTTCGAGGACATCGCGTGCTGGGACCTGGACGACACCTCCCCC
                        TACTGGTGGATCATCAAAGGGCCCATTGTCCTCTCGGTCGGGGTGAACTTTGGGCTTTTT
                        CTCAATATTATCCGCATCCTGGTGAGGAAACTGGAGCCAGCTCAGGGCAGCCTCCATACC
                        CAGTCTCAGTATTGGCGTCTCTCCAAGTCGACACTTTTCCTGATCCCACTCTTTGGAATT
                        CACTACATCATCTTCAACTTCCTGCCAGACAATGCTGGCCTGGGCATCCGCCTCCCCCTG
                        GAGCTGGGACTGGGTTCCTTCCAGGGCTTCATTGTTGCCATCCTCTACTGCTTCCTCAAC
                        CAAGAGGTGAGGACTGAGATCTCACGGAAGTGGCATGGCCATGACCCTGAGCTTCTGCCA
                        GCCTGGAGGACCCGTGCTAAGTGGACCACGCCTTCCCGCTCGGCGGCAAAGGTGCTGACA
                        TCTATGTGCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00002</identifier>
                            <name>7tm_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02793</identifier>
                            <name>HRM</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasoactive intestinal polypeptide receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>secretin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-09-23">
        <drugbank-id primary="true">DB00011</drugbank-id>
        <drugbank-id>BIOD00096</drugbank-id>
        <drugbank-id>BTD00096</drugbank-id>
        <drugbank-id>DB00084</drugbank-id>
        <name>Interferon alfa-n1</name>
        <description>Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues</description>
        <cas-number>74899-72-2</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference>Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov, "Method for producing human leukocyte interferon alpha-2." U.S. Patent US4680260, issued January, 1982.</synthesis-reference>
        <indication>For treatment of venereal or genital warts caused by the Human Papiloma Virus</indication>
        <pharmacodynamics>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacodynamics>
        <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>1.2 hours (mammalian reticulocytes, in vitro); &amp;gt;20 hours (yeast, in vivo); &amp;gt;10 hours (Escherichia coli, in vivo).</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Interferon alpha-2</synonym>
            <synonym language="" coder="">Interferon alpha-A</synonym>
            <synonym language="" coder="">Interferon alpha-n1 (Ins)</synonym>
            <synonym language="" coder="">LeIF A</synonym>
        </synonyms>
        <products>
            <product>
                <name>Wellferon Inj 10 000 000unit/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01959069</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>2000-08-01</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>10000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Wellferon Inj 3000000unit/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01959077</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>2000-08-01</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>3000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Wellferon</name>
                <company>GlaxoSmithKline</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Wellferon Inj 10 000 000unit/ml</name>
                <ingredients>Interferon alfa-n1</ingredients>
            </mixture>
            <mixture>
                <name>Wellferon Inj 3000000unit/ml</name>
                <ingredients>Interferon alfa-n1</ingredients>
            </mixture>
        </mixtures>
        <packagers/>
        <manufacturers/>
        <prices/>
        <categories>
            <category>
                <category>Antiviral Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Immunologic Factors</category>
                <mesh-id/>
            </category>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; subcutaneous</route>
                <strength>10000000 unit</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; subcutaneous</route>
                <strength>3000000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L03AB06">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AB">Interferons</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents/>
        <food-interactions>
            <food-interaction>Avoid alcohol.</food-interaction>
        </food-interactions>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00011 sequence
                CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
                QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
                KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C</value>
                <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.336</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.99</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>19241.1000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C860H1353N227O255S9</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>7651</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00207</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164746538</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01563</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links/>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000385</id>
                <name>Interferon alpha/beta receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10822464&#13;
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P48551" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 2</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity</specific-function>
                    <gene-name>IFNAR2</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>244-264</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.11</theoretical-pi>
                    <molecular-weight>57759.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5433</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L42243</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>995300</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P48551</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>IFN-R</synonym>
                        <synonym>Interferon alpha/beta receptor 2</synonym>
                        <synonym>Interferon-alpha/beta receptor beta chain precursor</synonym>
                        <synonym>Type I interferon receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor beta chain precursor
                        MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
                        IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
                        SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
                        HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
                        SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
                        MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
                        DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
                        ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
                        FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
                        ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
                        TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
                        ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
                        GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
                        AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
                        AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
                        ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
                        GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
                        CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
                        ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
                        ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
                        TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
                        ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
                        AATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT
                        ATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT
                        GAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT
                        GGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA
                        GACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG
                        CCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT
                        CCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA
                        ATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT
                        GACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG
                        GATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC
                        TTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC
                        ACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000661</id>
                <name>Interferon alpha/beta receptor 1</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10822464&#13;
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P17181" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 1</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves</specific-function>
                    <gene-name>IFNAR1</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>437-457</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.56</theoretical-pi>
                    <molecular-weight>63526.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5432</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03171</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>306914</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P17181</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>Interferon-alpha/beta receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor alpha chain precursor
                        MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
                        FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
                        TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
                        ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
                        NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
                        GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
                        VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
                        FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
                        YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
                        EDESESKTSEELQQDFV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1674 bp
                        ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG
                        TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
                        ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
                        TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
                        AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
                        AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
                        ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
                        GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
                        TTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
                        GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
                        AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
                        ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
                        AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
                        TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
                        CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
                        GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
                        GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
                        TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
                        GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
                        GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
                        GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
                        TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
                        GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
                        TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
                        TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
                        AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
                        GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
                        GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2011-09-03">
        <drugbank-id primary="true">DB00012</drugbank-id>
        <drugbank-id>BIOD00032</drugbank-id>
        <drugbank-id>BTD00032</drugbank-id>
        <name>Darbepoetin alfa</name>
        <description>Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.</description>
        <cas-number>11096-26-7</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For the treatment of anemia (from renal transplants or certain HIV treatment)</indication>
        <pharmacodynamics>Darbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.</pharmacodynamics>
        <mechanism-of-action>Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with&#13;
            progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Epoetin</synonym>
            <synonym language="" coder="">Erythropoietin precursor</synonym>
        </synonyms>
        <products>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-002_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-002</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-09-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>25 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-003_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-003</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-09-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>40 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-004_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-004</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-09-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>60 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-005_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-005</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-09-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-006_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-006</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-09-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-021_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-021</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>40 ug/.4mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-023_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-023</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>60 ug/.3mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-025_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-025</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 ug/.5mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-027_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-027</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-09-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>150 ug/.3mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-028_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-028</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>200 ug/.4mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-032_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-032</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-06-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>500 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-053_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-053</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-09-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>150 ug/.75mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-057_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-057</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>25 ug/.42mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-098_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-098</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>10 ug/.4mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-110_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-110</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>300 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp</name>
                <ndc-id>55513-111_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668</ndc-id>
                <ndc-product-code>55513-111</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>300 ug/.6mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103951</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391767</dpd-id>
                <started-marketing-on>2014-01-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391775</dpd-id>
                <started-marketing-on>2014-03-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391783</dpd-id>
                <started-marketing-on>2014-02-10</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391791</dpd-id>
                <started-marketing-on>2014-04-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>500 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391805</dpd-id>
                <started-marketing-on>2014-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>500 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391821</dpd-id>
                <started-marketing-on>2013-11-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>500 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02392313</dpd-id>
                <started-marketing-on>2013-08-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>25 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02392321</dpd-id>
                <started-marketing-on>2014-03-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>40 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02392348</dpd-id>
                <started-marketing-on>2014-03-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02392356</dpd-id>
                <started-marketing-on>2014-04-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02392364</dpd-id>
                <started-marketing-on>2014-02-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>500 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246353</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>15 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246356</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>60 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246359</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>325 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246354</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on>2015-08-04</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>25 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246355</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on>2015-08-04</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>40 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246357</dpd-id>
                <started-marketing-on>2002-08-20</started-marketing-on>
                <ended-marketing-on>2015-08-04</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>100 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246358</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on>2015-08-04</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>200 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391732</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>40 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246360</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on>2015-08-04</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>500 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391813</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>500 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391848</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>500 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391740</dpd-id>
                <started-marketing-on>2013-12-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Aranesp        -(hsa-free)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02391759</dpd-id>
                <started-marketing-on>2014-05-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Aranesp        -(hsa-free)</name>
                <ingredients>Darbepoetin alfa</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Amgen Inc.</name>
                <url>http://www.amgen.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Amgen Inc.</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Aranesp 25 mcg/ml vial</description>
                <cost currency="USD">156.36</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Aranesp (Albumin Free) 25 mcg/ml vial</description>
                <cost currency="USD">162.61</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Aranesp 40 mcg/ml vial</description>
                <cost currency="USD">250.2</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Aranesp 60 mcg/ml vial</description>
                <cost currency="USD">375.3</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Aranesp (Albumin Free) 60 mcg/ml vial</description>
                <cost currency="USD">390.31</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Aranesp 100 mcg/ml vial</description>
                <cost currency="USD">625.44</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Aranesp 200 mcg/ml vial</description>
                <cost currency="USD">1250.88</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Aranesp 300 mcg/ml vial</description>
                <cost currency="USD">1876.32</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Aranesp (Albumin Free) 300 mcg/ml vial</description>
                <cost currency="USD">1951.37</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Aranesp (Albumin Free) 100 mcg/0.5ml Solution (1 Box = Four 0.5ml Syringes)</description>
                <cost currency="USD">2601.83</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Aranesp (Albumin Free) 100 mcg/ml Solution Four 1ml Vials Per Box</description>
                <cost currency="USD">2601.83</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Aranesp (Albumin Free) 150 mcg/0.75ml Solution (1 Box = Four 0.75ml Vials)</description>
                <cost currency="USD">3902.75</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Hematinics</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-anemic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>10 ug/.4mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>100 ug/.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>150 ug/.3mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>200 ug/.4mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>25 ug/.42mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>300 ug/.6mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>40 ug/.4mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>500 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>60 ug/.3mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>100 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>150 ug/.75mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>200 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>25 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>300 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>40 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>60 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>100 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>15 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>200 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>25 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>325 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>40 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>500 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>60 mcg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B03XA02">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B03">ANTIANEMIC PREPARATIONS</level>
                <level code="B03X">OTHER ANTIANEMIC PREPARATIONS</level>
                <level code="B03XA">Other antianemic preparations</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:16.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2147124</number>
                <country>Canada</country>
                <approved>2002-11-05</approved>
                <expires>2014-08-16</expires>
            </patent>
            <patent>
                <number>2165694</number>
                <country>Canada</country>
                <approved>2003-03-18</approved>
                <expires>2010-10-15</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00480</drugbank-id>
                <name>Lenalidomide</name>
                <description>Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01041</drugbank-id>
                <name>Thalidomide</name>
                <description>Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00012 sequence
                APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA
                VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS
                PPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>53 °C</value>
                <source>Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.188</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.75</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>18396.1000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C815H1317N233O241S5</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12550</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X02158</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164743138</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01588</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Darbepoetin_alfa</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/aranesp.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/darbepoetin-alfa-albumin.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000654</id>
                <name>Erythropoietin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16505108&#13;
                    # Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17575216&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P19235" source="Swiss-Prot">
                    <name>Erythropoietin receptor</name>
                    <general-function>Involved in transmembrane receptor activity</general-function>
                    <specific-function>Isoform EPOR-T, missing the cytoplasmic tail, acts as a dominant-negative receptor of EPOR-mediated signaling</specific-function>
                    <gene-name>EPOR</gene-name>
                    <locus>19p13.3-p13.2</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. Isoform EPOR-S:Secreted protein. Isoform EPOR-S </cellular-location>
                    <transmembrane-regions>251-273</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.37</theoretical-pi>
                    <molecular-weight>55066.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3416</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>EPOR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>EPOR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M60459</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182245</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P19235</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>EPOR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EPO-R</synonym>
                        <synonym>Erythropoietin receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Erythropoietin receptor precursor
                        MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
                        VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL
                        ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY
                        EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
                        SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH
                        KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG
                        SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS
                        AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
                        SDGPYSNPYENSLIPAAEPLPPSYVACS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1527 bp
                        ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT
                        GGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC
                        TTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG
                        GTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC
                        TACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT
                        GGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA
                        GAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT
                        GAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC
                        CACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC
                        GAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG
                        GGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC
                        CGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG
                        TCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG
                        GTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG
                        AAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC
                        AAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC
                        ACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG
                        ACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC
                        AGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG
                        CCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC
                        TCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT
                        GCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA
                        CTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT
                        GACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA
                        TCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG
                        CCCCCCAGCTATGTGGCTTGCTCTTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-20">
        <drugbank-id primary="true">DB00013</drugbank-id>
        <drugbank-id>BIOD00030</drugbank-id>
        <drugbank-id>BTD00030</drugbank-id>
        <name>Urokinase</name>
        <description>Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator</description>
        <cas-number>9039-53-6</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
            <group>withdrawn</group>
        </groups>
        <general-references># Housley C: Contract purchasing means a buyer's market. Dimens Health Serv. 1976 Apr;53(4):16, 19-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5328</general-references>
        <synthesis-reference>Koji Sasaki, Yasukazu Harada, "Urokinase preparation for oral administration." U.S. Patent US4258030, issued November, 1975.</synthesis-reference>
        <indication>Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.</indication>
        <pharmacodynamics>Urokinase is used for the treatment of pulmonary embolisms. The low molecular weight form of human urokinase consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Urokinase is an enzyme (protein) produced by the kidney, and found in the urine. There are two forms of urokinase which differ in molecular weight but have similar clinical effects. Urokinase is the low molecular weight form. Urokinase acts on the endogenous fibrinolytic system. It converts plasminogen to the enzyme plasmin. Plasmin degrades fibrin clots as well as fibrinogen and some other plasma proteins.</pharmacodynamics>
        <mechanism-of-action>Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins.</mechanism-of-action>
        <toxicity/>
        <metabolism>Proteolysis</metabolism>
        <absorption/>
        <half-life>12 minutes. Small fractions of the administered dose are excreted in bile and urine</half-life>
        <protein-binding/>
        <route-of-elimination>Urokinase administered by intravenous infusion is rapidly cleared by the liver. Small fractions of the administered dose are excreted in bile and urine</route-of-elimination>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">U-plasminogen activator</synonym>
            <synonym language="" coder="">uPA</synonym>
            <synonym language="" coder="">Urokinase-type plasminogen activator precursor</synonym>
        </synonyms>
        <products>
            <product>
                <name>Kinlytic (urokinase for Injection)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00749702</dpd-id>
                <started-marketing-on>1988-12-31</started-marketing-on>
                <ended-marketing-on>2009-10-28</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>250000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kinlytic Open-cath</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00886777</dpd-id>
                <started-marketing-on>1991-12-31</started-marketing-on>
                <ended-marketing-on>2009-10-28</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>5000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Abbokinase</name>
                <company>Abbott Laboratories</company>
            </international-brand>
            <international-brand>
                <name>Kinlytic</name>
                <company>Microbix Biosystems Inc.</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Kinlytic Open-cath</name>
                <ingredients>Urokinase</ingredients>
            </mixture>
            <mixture>
                <name>Kinlytic (urokinase for Injection)</name>
                <ingredients>Urokinase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>ImaRx Therapeutics</name>
                <url>http://www.imarx.com</url>
            </packager>
            <packager>
                <name>Microbix Biosystems Inc.</name>
                <url>http://www.microbix.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Microbix biosystems inc</manufacturer>
        </manufacturers>
        <prices/>
        <categories>
            <category>
                <category>Thrombolytic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>250000 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>5000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AD04">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AD">Enzymes</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:12.20</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00233</drugbank-id>
                <name>Aminosalicylic Acid</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00261</drugbank-id>
                <name>Anagrelide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06605</drugbank-id>
                <name>Apixaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06692</drugbank-id>
                <name>Aprotinin</name>
                <description>Aprotinin may diminish the therapeutic effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00278</drugbank-id>
                <name>Argatroban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01294</drugbank-id>
                <name>Bismuth Subsalicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00006</drugbank-id>
                <name>Bivalirudin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06441</drugbank-id>
                <name>Cangrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01166</drugbank-id>
                <name>Cilostazol</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00215</drugbank-id>
                <name>Citalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00758</drugbank-id>
                <name>Clopidogrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06695</drugbank-id>
                <name>Dabigatran etexilate</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06754</drugbank-id>
                <name>Danaparoid</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06700</drugbank-id>
                <name>Desvenlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00586</drugbank-id>
                <name>Diclofenac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00861</drugbank-id>
                <name>Diflunisal</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01551</drugbank-id>
                <name>Dihydrocodeine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00975</drugbank-id>
                <name>Dipyridamole</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00476</drugbank-id>
                <name>Duloxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09075</drugbank-id>
                <name>Edoxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01240</drugbank-id>
                <name>Epoprostenol</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00063</drugbank-id>
                <name>Eptifibatide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01175</drugbank-id>
                <name>Escitalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00749</drugbank-id>
                <name>Etodolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00573</drugbank-id>
                <name>Fenoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08976</drugbank-id>
                <name>Floctafenine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00472</drugbank-id>
                <name>Fluoxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00712</drugbank-id>
                <name>Flurbiprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01050</drugbank-id>
                <name>Ibuprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01088</drugbank-id>
                <name>Iloprost</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00328</drugbank-id>
                <name>Indomethacin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01009</drugbank-id>
                <name>Ketoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00465</drugbank-id>
                <name>Ketorolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08918</drugbank-id>
                <name>Levomilnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01397</drugbank-id>
                <name>Magnesium salicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00784</drugbank-id>
                <name>Mefenamic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00814</drugbank-id>
                <name>Meloxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04896</drugbank-id>
                <name>Milnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00461</drugbank-id>
                <name>Nabumetone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08813</drugbank-id>
                <name>Nadroparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00788</drugbank-id>
                <name>Naproxen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00991</drugbank-id>
                <name>Oxaprozin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00715</drugbank-id>
                <name>Paroxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00554</drugbank-id>
                <name>Piroxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06209</drugbank-id>
                <name>Prasugrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06228</drugbank-id>
                <name>Rivaroxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01399</drugbank-id>
                <name>Salsalate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01104</drugbank-id>
                <name>Sertraline</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00605</drugbank-id>
                <name>Sulindac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01600</drugbank-id>
                <name>Tiaprofenic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08816</drugbank-id>
                <name>Ticagrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00208</drugbank-id>
                <name>Ticlopidine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06822</drugbank-id>
                <name>Tinzaparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00775</drugbank-id>
                <name>Tirofiban</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00500</drugbank-id>
                <name>Tolmetin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00285</drugbank-id>
                <name>Venlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06684</drugbank-id>
                <name>Vilazodone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09030</drugbank-id>
                <name>Vorapaxar</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09068</drugbank-id>
                <name>Vortioxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00013 sequence
                KPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMS
                PCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHND
                IALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMT
                VVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVS
                WGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>76 °C at pH 4.5</value>
                <source>Nowak, U.K. et al., Biochemistry 33:2951-2960 (1994)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.466</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.66</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>31126.5000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1376H2145N383O406S18</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>2012</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>24430-1003-1</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X02419</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA451836</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P00749</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Urokinase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/pharmclips2.cgi?keyword=%20Abbokinase%AE</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/mtm/urokinase.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00284</smpdb-id>
                <name>Urokinase Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00013</drugbank-id>
                        <name>Urokinase</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000211</id>
                <name>Plasminogen</name>
                <organism>Human</organism>
                <actions>
                    <action>activator</action>
                </actions>
                <references># Zhang X, Zhou H, Shen G, Liu Z, Hu Y, Wei W, Song S: Study on the mechanism of the annexin II-mediated co-assembly of t-PA and plasminogen. J Huazhong Univ Sci Technolog Med Sci. 2002;22(1):21-3, 76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12658774&#13;
                    # Lopez-Alemany R, Longstaff C, Hawley S, Mirshahi M, Fabregas P, Jardi M, Merton E, Miles LA, Felez J: Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol. 2003 Apr;72(4):234-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12666133&#13;
                    # Hashimoto M, Oiwa K, Matsuo O, Ueshima S, Okada K, Okada Y, Okamoto S, Giddings JC, Yamamoto J: Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thromb Haemost. 2003 May;89(5):820-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12719778&#13;
                    # Guda K, Claffey KP, Dong M, Nambiar PR, Rosenberg DW: Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog. 2003 May;37(1):51-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12720300&#13;
                    # Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12745435&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00747" source="Swiss-Prot">
                    <name>Plasminogen</name>
                    <general-function>Involved in plasmin activity</general-function>
                    <specific-function>Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo</specific-function>
                    <gene-name>PLG</gene-name>
                    <locus>6q26</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.25</theoretical-pi>
                    <molecular-weight>90569.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9071</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X05199</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>387026</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PLMN_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.7</synonym>
                        <synonym>Plasminogen precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen precursor
                        MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
                        CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
                        GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
                        CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
                        LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
                        AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
                        QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
                        LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
                        CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
                        PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
                        RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
                        PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
                        LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
                        GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2433 bp
                        ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
                        CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
                        CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
                        TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
                        AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
                        TCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT
                        GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
                        ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
                        GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
                        TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
                        ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
                        CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
                        CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC
                        CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
                        GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
                        GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT
                        GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
                        CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
                        CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
                        GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
                        TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
                        CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
                        GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
                        GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC
                        TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
                        CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
                        AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
                        CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
                        GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
                        GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
                        AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
                        GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
                        CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
                        CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
                        GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
                        ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
                        CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
                        TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
                        GGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
                        GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
                        ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00024</identifier>
                            <name>PAN_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>plasmin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000717</id>
                <name>Urokinase plasminogen activator surface receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003 Mar 3;160(5):781-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12615913&#13;
                    # Fuchs T, Allgayer H: Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis. Biol Chem. 2003 May;384(5):755-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12817472&#13;
                    # Kanse SM, Chavakis T, Al-Fakhri N, Hersemeyer K, Monard D, Preissner KT: Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1. J Cell Sci. 2004 Jan 26;117(Pt 3):477-85. Epub 2003 Dec 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14679304&#13;
                    # Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D: Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol. 2004 Jan 1;172(1):540-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14688365&#13;
                    # Guerrero J, Santibanez JF, Gonzalez A, Martinez J: EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res. 2004 Jan 1;292(1):201-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14720519&#13;
                    # Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Aboody KS: Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One. 2007 Feb 28;2(2):e243. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17327908</references>
                <known-action>yes</known-action>
                <polypeptide id="Q03405" source="Swiss-Prot">
                    <name>Urokinase plasminogen activator surface receptor</name>
                    <general-function>Involved in U-plasminogen activator receptor activity</general-function>
                    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form</specific-function>
                    <gene-name>PLAUR</gene-name>
                    <locus>19q13</locus>
                    <cellular-location>Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.64</theoretical-pi>
                    <molecular-weight>36978.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9053</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X51675</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>37605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q03405</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>UPAR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD87 antigen</synonym>
                        <synonym>Monocyte activation antigen Mo3</synonym>
                        <synonym>U- PAR</synonym>
                        <synonym>uPAR</synonym>
                        <synonym>Urokinase plasminogen activator surface receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Urokinase plasminogen activator surface receptor precursor
                        MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
                        ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
                        GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
                        FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
                        MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
                        QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1008 bp
                        ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
                        TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
                        CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
                        GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
                        ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
                        GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
                        GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
                        GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
                        AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
                        TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
                        GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
                        GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
                        ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA
                        AGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG
                        AACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC
                        CAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC
                        CTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00021</identifier>
                            <name>UPAR_LY6</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>U-plasminogen activator receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0000895</id>
                <name>Urokinase-type plasminogen activator</name>
                <organism>Human</organism>
                <actions/>
                <references># Bell WR: Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3 Suppl 2:S34-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12556741&#13;
                    # Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12579271&#13;
                    # Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2003 May;14(5):1254-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12707394&#13;
                    # Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12745435&#13;
                    # Wielockx B, Libert C: Serine proteases of the fibrinolysis pathway are not involved in lethal hepatitis and fibrinogen breakdown induced by tumor necrosis factor. Cytokine. 2003 Mar 21;21(6):281-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12824001</references>
                <known-action>yes</known-action>
                <polypeptide id="P00749" source="Swiss-Prot">
                    <name>Urokinase-type plasminogen activator</name>
                    <general-function>Involved in chemotaxis and signal transduction activity</general-function>
                    <specific-function>Specifically cleave the zymogen plasminogen to form the active enzyme plasmin</specific-function>
                    <gene-name>PLAU</gene-name>
                    <locus>10q24</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.48</theoretical-pi>
                    <molecular-weight>48526.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9052</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLAU</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLAU</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X02419</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>1834524</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00749</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>UROK_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.73</synonym>
                        <synonym>U-plasminogen activator</synonym>
                        <synonym>uPA</synonym>
                        <synonym>Urokinase-type plasminogen activator precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Urokinase-type plasminogen activator precursor
                        MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQ
                        HCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN
                        YCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKII
                        GGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLG
                        RSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICL
                        PSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKML
                        CAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR
                        SHTKEENGLAL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1296 bp
                        ATGAGAGCCCTGCTGGCGCGCCTGCTTCTCTGCGTCCTGGTCGTGAGCGACTCCAAAGGC
                        AGCAATGAACTTCATCAAGTTCCATCGAACTGTGACTGTCTAAATGGAGGAACATGTGTG
                        TCCAACAAGTACTTCTCCAACATTCACTGGTGCAACTGCCCAAAGAAATTCGGAGGGCAG
                        CACTGTGAAATAGATAAGTCAAAAACCTGCTATGAGGGGAATGGTCACTTTTACCGAGGA
                        AAGGCCAGCACTGACACCATGGGCCGGCCCTGCCTGCCCTGGAACTCTGCCACTGTCCTT
                        CAGCAAACGTACCATGCCCACAGATCTGATGCTCTTCAGCTGGGCCTGGGGAAACATAAT
                        TACTGCAGGAACCCAGACAACCGGAGGCGACCCTGGTGCTATGTGCAGGTGGGCCTAAAG
                        CCGCTTGTCCAAGAGTGCATGGTGCATGACTGCGCAGATGGAAAAAAGCCCTCCTCTCCT
                        CCAGAAGAATTAAAATTTCAGTGTGGCCAAAAGACTCTGAGGCCCCGCTTTAAGATTATT
                        GGGGGAGAATTCACCACCATCGAGAACCAGCCCTGGTTTGCGGCCATCTACAGGAGGCAC
                        CGGGGGGGCTCTGTCACCTACGTGTGTGGAGGCAGCCTCATGAGCCCTTGCTGGGTGATC
                        AGCGCCACACACTGCTTCATTGATTACCCAAAGAAGGAGGACTACATCGTCTACCTGGGT
                        CGCTCAAGGCTTAACTCCAACACGCAAGGGGAGATGAAGTTTGAGGTGGAAAACCTCATC
                        CTACACAAGGACTACAGCGCTGACACGCTTGCTCACCACAACGACATTGCCTTGCTGAAG
                        ATCCGTTCCAAGGAGGGCAGGTGTGCGCAGCCATCCCGGACTATACAGACCATCTGCCTG
                        CCCTCGATGTATAACGATCCCCAGTTTGGCACAAGCTGTGAGATCACTGGCTTTGGAAAA
                        GAGAATTCTACCGACTATCTCTATCCGGAGCAGCTGAAAATGACTGTTGTGAAGCTGATT
                        TCCCACCGGGAGTGTCAGCAGCCCCACTACTACGGCTCTGAAGTCACCACCAAAATGCTG
                        TGTGCTGCTGACCCACAGTGGAAAACAGATTCCTGCCAGGGAGACTCAGGGGGACCCCTC
                        GTCTGTTCCCTCCAAGGCCGCATGACTTTGACTGGAATTGTGAGCTGGGGCCGTGGATGT
                        GCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTACCCTGGATCCGC
                        AGTCACACCAAGGAAGAGAATGGCCTGGCCCTCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0001088</id>
                <name>Tissue-type plasminogen activator</name>
                <organism>Human</organism>
                <actions/>
                <references># Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12745435&#13;
                    # Lindholt JS, Jorgensen B, Shi GP, Henneberg EW: Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003 Jun;25(6):546-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12787697&#13;
                    # Aleman C, Alegre J, Monasterio J, Segura RM, Armadans L, Angles A, Varela E, Ruiz E, Fernandez de Sevilla T: Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond). 2003 Nov;105(5):601-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12826021&#13;
                    # Wells RG, Havens PL: Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology. 2003 Aug;228(2):370-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12893898&#13;
                    # Stief TW, Bunder R, Richter A, Maisch B, Renz H, Fareed J: In vitro simulation of therapeutic plasmatic fibrinolysis. Clin Appl Thromb Hemost. 2003 Jul;9(3):211-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14507109</references>
                <known-action>yes</known-action>
                <polypeptide id="P00750" source="Swiss-Prot">
                    <name>Tissue-type plasminogen activator</name>
                    <general-function>Involved in plasminogen activator activity</general-function>
                    <specific-function>Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration</specific-function>
                    <gene-name>PLAT</gene-name>
                    <locus>8p12</locus>
                    <cellular-location>Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.81</theoretical-pi>
                    <molecular-weight>62917.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9051</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLAT</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLAT</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L00153</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339834</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00750</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TPA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Alteplase</synonym>
                        <synonym>EC 3.4.21.68</synonym>
                        <synonym>Reteplase</synonym>
                        <synonym>t- PA</synonym>
                        <synonym>t-plasminogen activator</synonym>
                        <synonym>Tissue-type plasminogen activator precursor</synonym>
                        <synonym>tPA</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tissue-type plasminogen activator precursor
                        MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPV
                        LRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCE
                        IDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCR
                        NPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWN
                        SMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCG
                        LRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQ
                        ERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCA
                        QESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQH
                        LLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQK
                        DVPGVYTKVTNYLDWIRDNMRP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1689 bp
                        ATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTT
                        TCGCCCAGCCAGGAAATCCATGCCCGATTCAGAAGAGGAGCCAGATCTTACCAAGTGATC
                        TGCAGAGATGAAAAAACGCAGATGATATACCAGCAACATCAGTCATGGCTGCGCCCTGTG
                        CTCAGAAGCAACCGGGTGGAATATTGCTGGTGCAACAGTGGCAGGGCACAGTGCCACTCA
                        GTGCCTGTCAAAAGTTGCAGCGAGCCAAGGTGTTTCACCGGGGGCACCTGCCAGCAGGCC
                        CTGTACTTCTCAGATTTCGTGTGCCAGTGCCCCGAAGGATTTGCTGGGAAGTGCTGTGAA
                        ATAGATACCAGGGCCACGTGCTACGAGGACCAGGGCATCAGCTACAGGGGCACGTGGAGC
                        ACAGCGGAGAGTGGCGCCGAGTGCACCAACTGGAACAGCAGCGCGTTGGCCCAGAAGCCC
                        TACAGCGGGCGGAGGCCAGATGCCATCAGGCTGGGCCTGGGGAACCACAACTACTGCAGA
                        AACCCAGATCGAGACTCAAAGCCCTGGTGCTACGTCTTTAAGGCGGGGAAGTACAGCTCA
                        GAGTTCTGCAGCACCCCTGCCTGCTCTGAGGGAAACAGTGACTGCTACTTTGGGAATGGG
                        TCAGCCTACCGTGGCACGCACAGCCTCACCGAGTCGGGTGCCTCCTGCCTCCCGTGGAAT
                        TCCATGATCCTGATAGGCAAGGTTTACACAGCACAGAACCCCAGTGCCCAGGCACTGGGC
                        CTGGGCAAACATAATTACTGCCGGAATCCTGATGGGGATGCCAAGCCCTGGTGCCACGTG
                        CTGAAGAACCGCAGGCTGACGTGGGAGTACTGTGATGTGCCCTCCTGCTCCACCTGCGGC
                        CTGAGACAGTACAGCCAGCCTCAGTTTCGCATCAAAGGAGGGCTCTTCGCCGACATCGCC
                        TCCCACCCCTGGCAGGCTGCCATCTTTGCCAAGCACAGGAGGTCGCCCGGAGAGCGGTTC
                        CTGTGCGGGGGCATACTCATCAGCTCCTGCTGGATTCTCTCTGCCGCCCACTGCTTCCAG
                        GAGAGGTTTCCGCCCCACCACCTGACGGTGATCTTGGGCAGAACATACCGGGTGGTCCCT
                        GGCGAGGAGGAGCAGAAATTTGAAGTCGAAAAATACATTGTCCATAAGGAATTCGATGAT
                        GACACTTACGACAATGACATTGCGCTGCTGCAGCTGAAATCGGATTCGTCCCGCTGTGCC
                        CAGGAGAGCAGCGTGGTCCGCACTGTGTGCCTTCCCCCGGCGGACCTGCAGCTGCCGGAC
                        TGGACGGAGTGTGAGCTCTCCGGCTACGGCAAGCATGAGGCCTTGTCTCCTTTCTATTCG
                        GAGCGGCTGAAGGAGGCTCATGTCAGACTGTACCCATCCAGCCGCTGCACATCACAACAT
                        TTACTTAACAGAACAGTCACCGACAACATGCTGTGTGCTGGAGACACTCGGAGCGGCGGG
                        CCCCAGGCAAACTTGCACGACGCCTGCCAGGGCGATTCGGGAGGCCCCCTGGTGTGTCTG
                        AACGATGGCCGCATGACTTTGGTGGGCATCATCAGCTGGGGCCTGGGCTGTGGACAGAAG
                        GATGTCCCGGGTGTGTACACCAAGGTTACCAACTACCTAGACTGGATTCGTGACAACATG
                        CGACCGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00039</identifier>
                            <name>fn1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>plasminogen activator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0000240</id>
                <name>Plasminogen activator inhibitor 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12579271&#13;
                    # Shetty S, Bdeir K, Cines DB, Idell S: Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem. 2003 May 16;278(20):18124-31. Epub 2003 Mar 17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12642587&#13;
                    # Hellgren M: Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12709915&#13;
                    # Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12745435&#13;
                    # Gerstein ES, Shcherbakov AM, Kaz'min AI, Ognerubov NA, Kushlinskii NE: [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer] Vopr Onkol. 2003;49(2):165-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12785198</references>
                <known-action>yes</known-action>
                <polypeptide id="P05121" source="Swiss-Prot">
                    <name>Plasminogen activator inhibitor 1</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis</specific-function>
                    <gene-name>SERPINE1</gene-name>
                    <locus>7q21.3-q22</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.22</theoretical-pi>
                    <molecular-weight>45061.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8583</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04429</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>35272</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05121</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAI1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Endothelial plasminogen activator inhibitor</synonym>
                        <synonym>PAI</synonym>
                        <synonym>PAI-1</synonym>
                        <synonym>Plasminogen activator inhibitor 1 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen activator inhibitor 1 precursor
                        MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
                        GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
                        FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
                        DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
                        GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
                        FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
                        STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1209 bp
                        ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
                        GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
                        AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
                        GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
                        ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
                        CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC
                        TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
                        CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
                        GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
                        GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
                        CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
                        TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
                        GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
                        GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
                        CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
                        TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
                        ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
                        GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
                        TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
                        TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
                        GAACCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0000969</id>
                <name>Plasminogen activator inhibitor 2</name>
                <organism>Human</organism>
                <actions/>
                <references># Swartz JM, Bystrom J, Dyer KD, Nitto T, Wynn TA, Rosenberg HF: Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol. 2004 Oct;76(4):812-9. Epub 2004 Jul 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15277569&#13;
                    # Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle RM, Grimminger F, Seeger W, Gunther A: Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost. 2004 Sep;92(3):529-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15351849&#13;
                    # Iglesias D, Alegre J, Aleman C, Ruiz E, Soriano T, Armadans LI, Segura RM, Angles A, Monasterio J, de Sevilla TF: Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J. 2005 Jan;25(1):104-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15640330&#13;
                    # Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brunner N, Sweep CG, Duffy MJ: Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005 Jul;14(1):235-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15944795&#13;
                    # Fernandez-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sanchez-Prieto R, Fabra A, Ramon Y Cajal S: Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect. Int J Oncol. 2006 Jan;28(1):143-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16327990</references>
                <known-action>yes</known-action>
                <polypeptide id="P05120" source="Swiss-Prot">
                    <name>Plasminogen activator inhibitor 2</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell- derived PAI-1</specific-function>
                    <gene-name>SERPINB2</gene-name>
                    <locus>18q21.3</locus>
                    <cellular-location>Cytoplasm. Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.34</theoretical-pi>
                    <molecular-weight>46597.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8584</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINB2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINB2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J02685</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>189545</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05120</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAI2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Monocyte Arg-serpin</synonym>
                        <synonym>PAI-2</synonym>
                        <synonym>Placental plasminogen activator inhibitor</synonym>
                        <synonym>Plasminogen activator inhibitor 2 precursor</synonym>
                        <synonym>Urokinase inhibitor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen activator inhibitor 2 precursor
                        MEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF
                        NEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN
                        YLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK
                        IPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK
                        LNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM
                        AEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV
                        DVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1248 bp
                        ATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA
                        AAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC
                        ATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT
                        AATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG
                        TTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA
                        GATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGGAT
                        TATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA
                        TATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA
                        TGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA
                        ATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT
                        GCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT
                        CCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG
                        CTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA
                        GATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG
                        CTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG
                        GCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC
                        AGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC
                        TCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG
                        GATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA
                        ACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCGTTTCTTTTTCTTATTATGCAT
                        AAGATAACCAAGTGCATTTTATTTTTCGGCAGATTTTGCTCACCCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0002112</id>
                <name>Plasma serine protease inhibitor</name>
                <organism>Human</organism>
                <actions/>
                <references># Uhrin P, Schofer C, Zaujec J, Ryban L, Hilpert M, Weipoltshammer K, Jerabek I, Pirtzkall I, Furtmuller M, Dewerchin M, Binder BR, Geiger M: Male fertility and protein C inhibitor/plasminogen activator inhibitor-3 (PCI): localization of PCI in mouse testis and failure of single plasminogen activator knockout to restore spermatogenesis in PCI-deficient mice. Fertil Steril. 2007 Oct;88(4S):1049-1057. Epub 2007 Apr 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17434507&#13;
                    # Espana F, Navarro S, Medina P, Zorio E, Estelles A: The role of protein C inhibitor in human reproduction. Semin Thromb Hemost. 2007 Feb;33(1):41-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17253188&#13;
                    # Odet F, Guyot R, Leduque P, Le Magueresse-Battistoni B: Evidence for similar expression of protein C inhibitor and the urokinase-type plasminogen activator system during mouse testis development. Endocrinology. 2004 Mar;145(3):1481-9. Epub 2003 Nov 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14645112</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05154" source="Swiss-Prot">
                    <name>Plasma serine protease inhibitor</name>
                    <general-function/>
                    <specific-function>Inhibits activated protein C as well as plasminogen activators</specific-function>
                    <gene-name>SERPINA5</gene-name>
                    <locus>14q32.1</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.76</theoretical-pi>
                    <molecular-weight>45702.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8723</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINA5</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINA5</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J02639</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>180550</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05154</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IPSP_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Acrosomal serine protease inhibitor</synonym>
                        <synonym>PAI-3</synonym>
                        <synonym>PAI3</synonym>
                        <synonym>PCI</synonym>
                        <synonym>Plasma serine protease inhibitor precursor</synonym>
                        <synonym>Plasminogen activator inhibitor 3</synonym>
                        <synonym>Protein C inhibitor</synonym>
                        <synonym>Serpin A5</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasma serine protease inhibitor
                        MQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAA
                        PSQNIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQ
                        PRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQT
                        KGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSRED
                        QYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLE
                        LYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGT
                        RAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1221 bp
                        ATGCAGCTCTTCCTCCTCTTGTGCCTGGTGCTTCTCAGCCCTCAGGGGGCCTCCCTTCAC
                        CGCCACCACCCCCGGGAGATGAAGAAGAGAGTCGAGGACCTCCATGTAGGTGCCACGGTG
                        GCCCCCAGCAGCAGAAGGGACTTTACCTTTGACCTCTACAGGGCCTTGGCTTCCGCTGCC
                        CCCAGCCAGAACATCTTCTTCTCCCCTGTGAGCATCTCCATGAGCCTGGCCATGCTCTCC
                        CTGGGGGCTGGGTCCAGCACAAAGATGCAGATCCTGGAGGGCCTGGGCCTCAACCTCCAG
                        AAAAGCTCAGAGAAGGAGCTGCACAGAGGCTTTCAGCAGCTCCTTCAGGAACTCAACCAG
                        CCCAGAGATGGCTTCCAGCTGAGCCTCGGCAATGCCCTTTTCACCGACCTGGTGGTAGAC
                        CTGCAGGACACCTTCGTAAGTGCCATGAAGACGCTGTACCTGGCAGACACTTTCCCCACC
                        AACTTTAGGGACTCTGCAGGGGCCATGAAGCAGATCAATGATTATGTGGCAAAGCAAACG
                        AAGGGCAAGATTGTGGACTTGCTTAAGAACCTCGATAGCAATGCGGTCGTGATCATGGTG
                        AATTACATCTTCTTTAAAGCTAAGTGGGAGACAAGCTTCAACCACAAAGGCACCCAAGAG
                        CAAGACTTCTACGTGACCTCGGAGACTGTGGTGCGGGTACCCATGATGAGCCGCGAGGAT
                        CAGTATCACTACCTCCTGGACCGGAACCTCTCCTGCAGGGTGGTGGGGGTCCCCTACCAA
                        GGCAATGCCACGGCTTTGTTCATTCTCCCCAGTGAGGGAAAGATGCAGCAGGTGGAGAAT
                        GGACTGAGTGAGAAAACGCTGAGGAAGTGGCTTAAGATGTTCAAAAAGAGGCAGCTCGAG
                        CTTTACCTTCCCAAATTCTCCATTGAGGGCTCCTATCAGCTGGAGAAAGTCCTCCCCAGT
                        CTGGGGATCAGTAACGTCTTCACCTCCCATGCTGATCTGTCCCGCATCAGCAACCACTCA
                        AATATCCAGGTGTCTGAGATGGTGCACAAAGCTGTGGTGGAGGTGGACGAGTCGGGAACC
                        AGAGCAGCGGCAGCCACGGGGACAATCTTCACTTTCAGGTCGGCCCGCCTGAACTCTCAG
                        AGGCTAGTGTTCAACAGGCCCTTTCTGATGTTCATTGTGGATAACAACATCCTCTTCCTT
                        GGCAAAGTGAACCGCCCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0000942</id>
                <name>Low-density lipoprotein receptor-related protein 2</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Kanalas JJ: Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase. Biochim Biophys Acta. 1993 Nov 25;1225(1):101-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8241286&#13;
                    # Kanalas JJ: Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys. 1992 Dec;299(2):255-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1280065&#13;
                    # Korenberg JR, Argraves KM, Chen XN, Tran H, Strickland DK, Argraves WS: Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1). Genomics. 1994 Jul 1;22(1):88-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7959795</references>
                <known-action>unknown</known-action>
                <polypeptide id="P98164" source="Swiss-Prot">
                    <name>Low-density lipoprotein receptor-related protein 2</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release</specific-function>
                    <gene-name>LRP2</gene-name>
                    <locus>2q24-q31</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>4424-4446</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.68</theoretical-pi>
                    <molecular-weight>521933.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6694</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LRP2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LRP2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U33837</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>1809240</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P98164</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LRP2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Glycoprotein 330</synonym>
                        <synonym>gp330</synonym>
                        <synonym>Low-density lipoprotein receptor-related protein 2 precursor</synonym>
                        <synonym>Megalin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low-density lipoprotein receptor-related protein 2 precursor
                        MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI
                        GCAVVTCQQGYFKCQSEGQCIPSSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC
                        IPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT
                        EICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV
                        CDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN
                        TSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ
                        KCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES
                        QNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK
                        IYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER
                        AFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL
                        IPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT
                        NPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR
                        GIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA
                        NRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL
                        FFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD
                        GLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL
                        KSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE
                        PPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI
                        PAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE
                        KNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC
                        IGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS
                        DEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL
                        GHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL
                        LANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV
                        ASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR
                        RVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD
                        PRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD
                        YMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM
                        YNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC
                        LRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE
                        IHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL
                        IANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH
                        LECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY
                        EVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL
                        FSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV
                        DVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY
                        FTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL
                        DCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP
                        YGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE
                        VNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS
                        LHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV
                        IASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY
                        LYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL
                        TGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI
                        NTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC
                        GASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC
                        DYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR
                        TCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH
                        WYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR
                        HQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC
                        GYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG
                        SDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS
                        GCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP
                        GYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR
                        LYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN
                        GGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII
                        STKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI
                        YWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC
                        LIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD
                        GSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ
                        CANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC
                        GDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH
                        PVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH
                        YNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA
                        YCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH
                        EVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL
                        GCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH
                        CRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD
                        EEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY
                        VMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF
                        WTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD
                        GTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI
                        FHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP
                        CRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL
                        AIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI
                        DRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE
                        IVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP
                        AKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;13968 bp
                        ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA
                        GCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC
                        ATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT
                        GGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC
                        ATCCCCAGCTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT
                        CAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT
                        ATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT
                        GACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC
                        AGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT
                        GAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT
                        GTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGATGAACATGCTTGCAACTATCCG
                        ACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT
                        TGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT
                        CATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC
                        TCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC
                        ACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG
                        TGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC
                        AATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG
                        AAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG
                        CGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT
                        GGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT
                        CAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG
                        ACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG
                        GTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA
                        ATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT
                        CGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT
                        GTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG
                        GCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT
                        GGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC
                        ATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC
                        ATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA
                        AAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG
                        GCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC
                        AATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTTCTCAGCCACAGAACA
                        GATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT
                        GAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT
                        GGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT
                        TCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG
                        TCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT
                        AACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG
                        ACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA
                        GTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA
                        TTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC
                        CTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT
                        GCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT
                        GGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC
                        ATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG
                        AAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG
                        AAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT
                        AACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC
                        CCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA
                        CCACCCACGGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC
                        AATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT
                        GGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT
                        CCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC
                        TGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG
                        TGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA
                        AAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA
                        TGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG
                        GTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT
                        ATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCG
                        GGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT
                        GGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT
                        GATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC
                        GGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT
                        GATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT
                        GGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT
                        GGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT
                        ACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA
                        CTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT
                        AGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG
                        TTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG
                        GCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA
                        TTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC
                        TTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA
                        AGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT
                        CGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG
                        AGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT
                        CCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG
                        CGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC
                        TGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT
                        TACATGGACTTTTGCGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG
                        ATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT
                        GCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG
                        TATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC
                        GTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT
                        CATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC
                        TTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC
                        CTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT
                        TTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA
                        ATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG
                        GGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT
                        AGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG
                        ATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT
                        GCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC
                        GCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC
                        CTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA
                        GGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGGATGATCCTGGTACACCAGCTT
                        TCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT
                        GAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT
                        GTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT
                        GGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG
                        TTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA
                        TATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG
                        TCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG
                        GATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT
                        GATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT
                        GGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT
                        TTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC
                        CGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG
                        AACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT
                        GACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA
                        GTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG
                        ATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT
                        TATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC
                        TTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC
                        AACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG
                        GTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG
                        CCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG
                        AATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC
                        TTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT
                        GTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC
                        TCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC
                        ATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT
                        TATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC
                        ACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC
                        CTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC
                        TTCCGGGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT
                        GAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG
                        ACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC
                        TATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA
                        TATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC
                        AACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG
                        GGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG
                        GGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT
                        GGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT
                        AATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC
                        TGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT
                        GATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC
                        AATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC
                        AATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC
                        ACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT
                        TTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC
                        ACTCACACATGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT
                        TGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT
                        CACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA
                        AGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG
                        CACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT
                        CCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC
                        GGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT
                        GGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC
                        TATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG
                        AACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA
                        TCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC
                        AAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT
                        TTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT
                        GGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT
                        TACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT
                        TTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA
                        GGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT
                        CTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC
                        CTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA
                        TTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC
                        AAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT
                        TCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT
                        GGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT
                        GATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG
                        GGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC
                        TCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC
                        TGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC
                        ACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT
                        TATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT
                        AGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT
                        AGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC
                        CTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT
                        CAACTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT
                        AACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT
                        GGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC
                        AGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT
                        GGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG
                        TGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG
                        GATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT
                        CGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT
                        GGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC
                        TTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT
                        GGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT
                        CCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT
                        GGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA
                        GAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT
                        TACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT
                        GAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC
                        GCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA
                        TACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA
                        TGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT
                        GTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT
                        GAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT
                        AGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC
                        ATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG
                        GGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC
                        CAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT
                        GACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC
                        TGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT
                        GACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC
                        AATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT
                        GAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT
                        GTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC
                        CCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC
                        GTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT
                        GTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT
                        TCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC
                        TGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC
                        AACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC
                        AATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT
                        GGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT
                        GAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT
                        GGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC
                        TTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC
                        CTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA
                        GAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA
                        TGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG
                        TGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA
                        GGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG
                        GCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG
                        CTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA
                        TCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT
                        GACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA
                        TTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG
                        GTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG
                        ATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG
                        AATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG
                        ATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT
                        GCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC
                        ACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00057</identifier>
                            <name>Ldl_recept_a</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00058</identifier>
                            <name>Ldl_recept_b</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07974</identifier>
                            <name>EGF_2</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="9">
                <id>BE0001656</id>
                <name>Suppressor of tumorigenicity 14 protein</name>
                <organism>Human</organism>
                <actions/>
                <references># Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem. 2004 Apr 9;279(15):14899-908. Epub 2004 Jan 27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14747469&#13;
                    # Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P: Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem. 2003 Sep 19;278(38):36341-9. Epub 2003 Jun 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12815039</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q9Y5Y6" source="Swiss-Prot">
                    <name>Suppressor of tumorigenicity 14 protein</name>
                    <general-function>Involved in protease activity</general-function>
                    <specific-function>Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site</specific-function>
                    <gene-name>ST14</gene-name>
                    <locus>11q24-q25</locus>
                    <cellular-location>Membrane; single-pass type II membrane protein (Probable)</cellular-location>
                    <transmembrane-regions>56-76</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.53</theoretical-pi>
                    <molecular-weight>94770.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11344</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>ST14</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>ST14</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF118224</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>6647302</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q9Y5Y6</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>ST14_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.109</synonym>
                        <synonym>Matriptase</synonym>
                        <synonym>Membrane-type serine protease 1</synonym>
                        <synonym>MT-SP1</synonym>
                        <synonym>Prostamin</synonym>
                        <synonym>Serine protease 14</synonym>
                        <synonym>Serine protease TADG-15</synonym>
                        <synonym>Tumor-associated differentially-expressed gene 15 protein</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Suppressor of tumorigenicity protein 14
                        MGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAA
                        VLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKV
                        KDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVM
                        LPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPA
                        HARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPS
                        YNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHY
                        PPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTS
                        NSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDH
                        SDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSK
                        SQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEK
                        DCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYID
                        DRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKP
                        AEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLL
                        PQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYT
                        RLPLFRDWIKENTGV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2568 bp
                        ATGGGGAGCGATCGGGCCCGCAAGGGCGGAGGGGGCCCGAAGGACTTCGGCGCGGGACTC
                        AAGTACAACTCCCGGCACGAGAAAGTGAATGGCTTGGAGGAAGGCGTGGAGTTCCTGCCA
                        GTCAACAACGTCAAGAAGGTGGAAAAGCATGGCCCGGGGCGCTGGGTGGTGCTGGCAGCC
                        GTGCTGATCGGCCTCCTCTTGGTCTTGCTGGGGATCGGCTTCCTGGTGTGGCATTTGCAG
                        TACCGGGACGTGCGTGTCCAGAAGGTCTTCAATGGCTACATGAGGATCACAAATGAGAAT
                        TTTGTGGATGCCTACGAGAACTCCAACTCCACTGAGTTTGTAAGCCTGGCCAGCAAGGTG
                        AAGGACGCGCTGAAGCTGCTGTACAGCGGAGTCCCATTCCTGGGCCCCTACCACAAGGAG
                        TCGGCTGTGACGGCCTTCAGCGAGGGCAGCGTCATCGCCTACTACTGGTCTGAGTTCAGC
                        ATCCCGCAGCACCTGGTGGAGGAGGCCGAGCGCGTCATGGCCGAGGAGCGCGTAGTCATG
                        CTGCCCCCGCGGGCGCGCTCCCTGAAGTCCTTTGTGGTCACCTCAGTGGTGGCTTTCCCC
                        ACGGACTCCAAAACAGTACAGAGGACCCAGGACAACAGCTGCAGCTTTGGCCTGCACGCC
                        CGCGGTGTGGAGCTGATGCGCTTCACCACGCCCGGCTTCCCTGACAGCCCCTACCCCGCT
                        CATGCCCGCTGCCAGTGGGCCCTGCGGGGGGACGCCGACTCAGTGCTGAGCCTCACCTTC
                        CGCAGCTTTGACCTTGCGTCCTGCGACGAGCGCGGCAGCGACCTGGTGACGGTGTACAAC
                        ACCCTGAGCCCCATGGAGCCCCACGCCCTGGTGCAGTTGTGTGGCACCTACCCTCCCTCC
                        TACAACCTGACCTTCCACTCCTCCCAGAACGTCCTGCTCATCACACTGATAACCAACACT
                        GAGCGGCGGCATCCCGGCTTTGAGGCCACCTTCTTCCAGCTGCCTAGGATGAGCAGCTGT
                        GGAGGCCGCTTACGTAAAGCCCAGGGGACATTCAACAGCCCCTACTACCCAGGCCACTAC
                        CCACCCAACATTGACTGCACATGGAACATTGAGGTGCCCAACAACCAGCATGTGAAGGTG
                        CGCTTCAAATTCTTCTACCTGCTGGAGCCCGGCGTGCCTGCGGGCACCTGCCCCAAGGAC
                        TACGTGGAGATCAATGGGGAGAAATACTGCGGAGAGAGGTCCCAGTTCGTCGTCACCAGC
                        AACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTC
                        TTAGCTGAATACCTCTCCTACGACTCCAGTGACCCATGCCCGGGGCAGTTCACGTGCCGC
                        ACGGGGCGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGACCAC
                        AGCGATGAGCTCAACTGCAGTTGCGACGCCGGCCACCAGTTCACGTGCAAGAACAAGTTC
                        TGCAAGCCCCTCTTCTGGGTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAG
                        CAGGGGTGCAGTTGTCCGGCCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCTCTCGAAA
                        AGCCAGCAGTGCAATGGGAAGGACGACTGTGGGGACGGGTCCGACGAGGCCTCCTGCCCC
                        AAGGTGAACGTCGTCACTTGTACCAAACACACCTACCGCTGCCTCAATGGGCTCTGCTTG
                        AGCAAGGGCAACCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAG
                        GACTGCGACTGTGGGCTGCGGTCATTCACGAGACAGGCTCGTGTTGTTGGGGGCACGGAT
                        GCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATC
                        TGCGGTGCTTCCCTCATCTCTCCCAACTGGCTGGTCTCTGCCGCACACTGCTACATCGAT
                        GACAGAGGATTCAGGTACTCAGACCCCACGCAGTGGACGGCCTTCCTGGGCTTGCACGAC
                        CAGAGCCAGCGCAGCGCCCCTGGGGTGCAGGAGCGCAGGCTCAAGCGCATCATCTCCCAC
                        CCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTGGAGAAACCG
                        GCAGAGTACAGCTCCATGGTGCGGCCCATCTGCCTGCCGGACGCCTCCCATGTCTTCCCT
                        GCCGGCAAGGCCATCTGGGTCACGGGCTGGGGACACACCCAGTATGGAGGCACTGGCGCG
                        CTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTG
                        CCGCAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCCTCAGCGGCGGCGTGGACTCC
                        TGCCAGGGTGATTCCGGGGGACCCCTGTCCAGCGTGGAGGCGGATGGGCGGATCTTCCAG
                        GCCGGTGTGGTGAGCTGGGGAGACGGCTGCGCTCAGAGGAACAAGCCAGGCGTGTACACA
                        AGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACACTGGGGTATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00057</identifier>
                            <name>Ldl_recept_a</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01390</identifier>
                            <name>SEA</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="10">
                <id>BE0002113</id>
                <name>Nidogen-1</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Stephens RW, Aumailley M, Timpl R, Reisberg T, Tapiovaara H, Myohanen H, Murphy-Ullrich J, Vaheri A: Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin. Eur J Biochem. 1992 Aug 1;207(3):937-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1499567</references>
                <known-action>unknown</known-action>
                <polypeptide id="P14543" source="Swiss-Prot">
                    <name>Nidogen-1</name>
                    <general-function/>
                    <specific-function>Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell- extracellular matrix interactions</specific-function>
                    <gene-name>NID1</gene-name>
                    <locus>1q43</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.96</theoretical-pi>
                    <molecular-weight>136454.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:7821</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>NID1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>NID1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M30269</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>189209</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P14543</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>NID1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Entactin</synonym>
                        <synonym>Nidogen-1 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Nidogen-1
                        MLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDLELEDGDDFVSPALELS
                        GALRFYDRSDIDAVYVTTNGIIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKV
                        YYREDLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESVAPYQGPSRDPDQKGKRNTFQ
                        AVLASSDSSSYAIFLYPEDGLQFHTTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA
                        NDRESIENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTEDGAEYDDEDEDYDLAT
                        TRLGLEDVGTTPFSYKALRRGGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETF
                        HQQHPQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVHAECRDYATGFCCSCVAGYTG
                        NGRQCVAEGSPQRVNGKVKGRIFVGSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV
                        GYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTFVGHPGNLVIKQRFSGI
                        DEHGHLTIDTELEGRVPQIPFGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGAS
                        PSRIYTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFVLYNQEEKILRYAFSNSIGPV
                        REGSPDALQNPCYIGTHGCDTNAACRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV
                        CGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCETGLHNCDIPQRAQCIYT
                        GGSSYTCSCLPGFSGDGQACQDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCV
                        PGEVEKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDAHGHYAPTQCHGSTGYCWCVD
                        RDGREVEGTRTRPGMTPPCLSTVAPPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE
                        GNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGRASLHGGEPTTIIRQDL
                        GSPEGIAVDHLGRNIFWTDSNLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYW
                        TDWNRDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFSSQLCWVDAGTNRAECLNPSQ
                        PSRRKALEGLQYPFAVTSYGKNLYFTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT
                        ALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCIERK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;3744 bp
                        ATGTTGGCCTCGAGCAGCCGGATCCGGGCTGCGTGGACGCGGGCGCTGCTGCTGCCGCTG
                        CTGCTGGCGGGGCCTGTGGGCTGCCTGAGCCGCCAGGAGCTCTTTCCCTTCGGCCCCGGA
                        CAGGGGGACCTGGAGCTGGAGGACGGGGATGACTTCGTCTCTCCTGCCCTGGAGCTGAGT
                        GGGGCGCTCCGCTTCTACGACAGATCCGACATCGACGCAGTCTACGTCACCACAAATGGC
                        ATCATTGCTACGAGTGAACCCCCGGCCAAAGAATCCCATCCCGGGCTCTTCCCACCAACA
                        TTCGGTGCAGTCGCCCCTTTCCTGGCGGACTTGGACACGACCGATGGCCTGGGGAAGGTT
                        TATTATCGAGAAGACTTATCCCCCTCCATCACTCAGCGAGCAGCAGAGTGTGTCCACAGA
                        GGGTTCCCGGAGATCTCTTTCCAGCCTAGTAGCGCGGTGGTTGTCACTTGGGAATCCGTG
                        GCCCCCTACCAAGGGCCCAGCAGGGACCCAGACCAGAAAGGCAAGAGAAACACGTTCCAG
                        GCTGTTCTAGCCTCCTCTGATTCCAGCTCCTATGCCATTTTCCTTTATCCTGAGGATGGT
                        CTGCAGTTCCATACGACATTCTCAAAGAAGGAAAACAACCAAGTTCCTGCCGTGGTTGCA
                        TTCAGTCAAGGTTCAGTGGGATTCTTATGGAAGAGCAACGGAGCTTATAACATATTTGCT
                        AATGACAGGGAATCAATTGAAAATTTGGCCAAGAGTAGTAACTCTGGGCAGCAGGGTGTC
                        TGGGTGTTTGAGATTGGGAGTCCAGCCACCACCAATGGCGTGGTGCCTGCAGACGTGATC
                        CTCGGAACTGAAGATGGGGCAGAGTATGATGATGAGGATGAAGATTATGACCTGGCGACC
                        ACTCGTCTGGGCCTGGAGGATGTGGGCACCACGCCCTTCTCCTACAAGGCTCTGAGAAGG
                        GGAGGTGCTGACACATACAGTGTGCCCAGCGTCCTCTCCCCGCGCCGGGCAGCTACCGAA
                        AGGCCCCTTGGACCTCCCACAGAGAGAACCAGGTCTTTCCAGTTGGCAGTGGAGACTTTT
                        CACCAGCAGCACCCTCAGGTCATAGATGTGGATGAAGTTGAGGAAACAGGAGTTGTTTTC
                        AGCTATAACACGGATTCCCGCCAGACGTGTGCTAACAACAGACACCAGTGCTCGGTGCAC
                        GCAGAGTGCAGGGACTACGCCACGGGCTTCTGCTGCAGCTGTGTCGCTGGCTATACGGGC
                        AATGGCAGGCAATGTGTTGCAGAAGGTTCCCCCCAGCGAGTCAATGGCAAGGTGAAAGGA
                        AGGATCTTTGTGGGGAGCAGCCAGGTCCCCATTGTCTTTGAGAACACTGACCTCCACTCT
                        TACGTAGTAATGAACCACGGGCGCTCCTACACAGCCATCAGCACCATTCCCGAGACCGTT
                        GGATATTCTCTGCTTCCACTGGCCCCAGTTGGAGGCATCATTGGATGGATGTTTGCAGTG
                        GAGCAGGACGGATTCAAGAATGGGTTCAGCATCACCGGGGGTGAGTTCACTCGCCAGGCT
                        GAGGTGACCTTCGTGGGGCACCCGGGCAATCTGGTCATTAAGCAGCGGTTCAGCGGCATC
                        GATGAGCATGGGCACCTGACCATCGACACGGAGCTGGAGGGCCGCGTGCCGCAGATTCCG
                        TTCGGCTCCTCCGTGCACATTGAGCCCTACACGGAGCTGTACCACTACTCCACCTCAGTG
                        ATCACTTCCTCCTCCACCCGGGAGTACACGGTGACTGAGCCCGAGCGAGATGGGGCATCT
                        CCTTCACGCATCTACACTTACCAGTGGCGCCAGACCATCACCTTCCAGGAATGCGTCCAC
                        GATGACTCCCGGCCAGCCCTGCCCAGCACCCAGCAGCTCTCGGTGGACAGCGTGTTCGTC
                        CTGTACAACCAGGAGGAGAAGATCTTGCGCTACGCTTTCAGCAACTCCATTGGGCCTGTG
                        AGGGAAGGCTCCCCTGATGCTCTTCAGAATCCCTGCTACATCGGCACTCATGGGTGTGAC
                        ACCAACGCGGCCTGTCGCCCTGGTCCCAGGACACAGTTCACCTGCGAGTGCTCCATCGGC
                        TTCCGAGGAGACGGGCGAACCTGCTATGATATTGATGAATGTTCAGAACAACCCTCAGTG
                        TGTGGGAGCCACACAATCTGCAATAATCACCCAGGAACCTTCCGCTGCGAGTGTGTGGAG
                        GGCTACCAGTTTTCAGATGAGGGAACGTGTGTGGCTGTCGTGGACCAGCGCCCCATCAAC
                        TACTGTGAAACTGGCCTTCATAACTGCGACATACCCCAGCGGGCCCAGTGTATCTACACA
                        GGAGGCTCCTCCTACACCTGTTCCTGCTTGCCAGGCTTTTCTGGGGATGGCCAAGCCTGC
                        CAAGATGTAGATGAATGCCAGCCAAGCCGATGTCACCCTGACGCCTTCTGCTACAACACT
                        CCAGGCTCTTTCACGTGCCAGTGCAAACCTGGTTATCAGGGAGACGGCTTCCGTTGCGTG
                        CCCGGAGAGGTGGAGAAAACCCGGTGCCAGCACGAGCGAGAACACATTCTCGGGGCAGCG
                        GGGGCGACAGACCCACAGCGACCCATTCCTCCGGGGCTGTTCGTTCCTGAGTGCGATGCG
                        CACGGGCACTACGCGCCCACCCAGTGCCACGGCAGCACCGGCTACTGCTGGTGCGTGGAT
                        CGCGACGGCCGCGAGGTGGAGGGCACCAGGACCAGGCCCGGGATGACGCCCCCGTGTCTG
                        AGTACAGTGGCTCCCCCGATTCACCAAGGACCTGCGGTGCCTACCGCCGTGATCCCCTTG
                        CCTCCTGGGACCCATTTACTCTTTGCCCAGACTGGGAAGATTGAGCGCCTGCCCCTGGAG
                        GGAAATACCATGAGGAAGACAGAAGCAAAGGCGTTCCTTCATGTCCCGGCTAAAGTCATC
                        ATTGGACTGGCCTTTGACTGCGTGGACAAGATGGTTTACTGGACGGACATCACTGAGCCT
                        TCCATTGGGAGAGCTAGTCTACATGGTGGAGAGCCAACCACCATCATTAGACAAGATCTT
                        GGAAGTCCAGAAGGTATCGCTGTTGATCACCTTGGCCGCAACATCTTCTGGACAGACTCT
                        AACCTGGATCGAATAGAAGTGGCGAAGCTGGACGGCACGCAGCGCCGGGTGCTCTTTGAG
                        ACTGACCTGGTGAATCCCAGAGGCATTGTAACGGATTCCGTGAGAGGGAACCTTTACTGG
                        ACAGACTGGAACAGAGATAACCCCAAGATTGAAACTTCCTACATGGACGGCACGAACCGG
                        AGGATCCTTGTGCAGGATGACCTGGGCTTGCCCAATGGACTGCACTTCGATGCGTTCTCA
                        TCTCAGCTCTGCTGGGTGGATGCAGGCACCAATCGGGCGGAATGCCTGAACCCCAGTCAG
                        CCCAGCAGACGCAAGGCTCTCGAAGGGCTCCAGTATCCTTTTGCTGTGACGAGCTACGGG
                        AAGAATCTGTATTTCACAGACTGGAAGATGAATTCCGTGGTTGCTCTCGATCTTGCAATT
                        TCCAAGGAGACGGATGCTTTCCAACCCCACAAGCAGACCCGGCTGTATGGCATCACCACG
                        GCCCTGTCTCAGTGTCCGCAAGGCCATAACTACTGCTCAGTGAACAATGGCGGCTGCACC
                        CACCTATGCTTGGCCACCCCAGGGAGCAGGACCTGCCGTTGCCCTGACAACACCTTGGGA
                        GTTGACTGTATCGAACGGAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00058</identifier>
                            <name>Ldl_recept_b</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00086</identifier>
                            <name>Thyroglobulin_1</name>
                        </pfam>
                        <pfam>
                            <identifier>PF06119</identifier>
                            <name>NIDO</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07474</identifier>
                            <name>G2F</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell adhesion</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell-substrate adhesion</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell-matrix adhesion</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="small molecule" created="2005-06-13" updated="2013-09-16">
        <drugbank-id primary="true">DB00014</drugbank-id>
        <drugbank-id>BIOD00113</drugbank-id>
        <drugbank-id>BTD00113</drugbank-id>
        <name>Goserelin</name>
        <description>Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.</description>
        <cas-number>65807-02-5</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference>Kripa S. Srivastava, Matthew R. Davis, "Solid Phase Peptide for the Production of Goserelin." U.S. Patent US20100311946, issued December 09, 2010.</synthesis-reference>
        <indication>Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.</indication>
        <pharmacodynamics>The pharmacokinetics of goserelin have been determined in both male and female healthy volunteers and patients. In these studies, goserelin was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.</pharmacodynamics>
        <mechanism-of-action>Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.</mechanism-of-action>
        <toxicity>No experience of overdosage from clinical trials.</toxicity>
        <metabolism>Hepatic</metabolism>
        <absorption>Inactive orally, rapidly absorbed following subcutaneous administration.</absorption>
        <half-life>4-5 hours</half-life>
        <protein-binding>27.3%</protein-binding>
        <route-of-elimination>Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.</route-of-elimination>
        <volume-of-distribution>* 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]</volume-of-distribution>
        <clearance>* 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]</clearance>
        <classification>
            <description>This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.</description>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic compounds</kingdom>
            <superclass>Organic acids and derivatives</superclass>
            <class>Carboxylic acids and derivatives</class>
            <subclass>Amino acids, peptides, and analogues</subclass>
            <alternative-parent>Alpha amino acid amides</alternative-parent>
            <alternative-parent>Amphetamines and derivatives</alternative-parent>
            <alternative-parent>Azacyclic compounds</alternative-parent>
            <alternative-parent>Carbonyl compounds</alternative-parent>
            <alternative-parent>Carboximidamides</alternative-parent>
            <alternative-parent>Carboxylic acid hydrazides</alternative-parent>
            <alternative-parent>Dialkyl ethers</alternative-parent>
            <alternative-parent>Guanidines</alternative-parent>
            <alternative-parent>Heteroaromatic compounds</alternative-parent>
            <alternative-parent>Hydrazinecarboxamides</alternative-parent>
            <alternative-parent>Hydrocarbon derivatives</alternative-parent>
            <alternative-parent>Imidazoles</alternative-parent>
            <alternative-parent>Indoles</alternative-parent>
            <alternative-parent>Lactams</alternative-parent>
            <alternative-parent>N-acyl amines</alternative-parent>
            <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
            <alternative-parent>N-acylpyrrolidines</alternative-parent>
            <alternative-parent>Phenols and derivatives</alternative-parent>
            <alternative-parent>Phenylpropylamines</alternative-parent>
            <alternative-parent>Primary alcohols</alternative-parent>
            <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
            <alternative-parent>Pyrrolidine-2-ones</alternative-parent>
            <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
            <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
            <alternative-parent>Semicarbazides</alternative-parent>
            <alternative-parent>Substituted pyrroles</alternative-parent>
            <alternative-parent>Tertiary amines</alternative-parent>
            <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
            <alternative-parent>Tryptamines and derivatives</alternative-parent>
            <substituent>2-pyrrolidone</substituent>
            <substituent>Alcohol</substituent>
            <substituent>Alpha peptide</substituent>
            <substituent>Alpha-amino acid amide</substituent>
            <substituent>Amine</substituent>
            <substituent>Amphetamine or derivatives</substituent>
            <substituent>Aromatic heteropolycyclic compound</substituent>
            <substituent>Azacycle</substituent>
            <substituent>Azole</substituent>
            <substituent>Benzenoid</substituent>
            <substituent>Carbonyl group</substituent>
            <substituent>Carboxamide group</substituent>
            <substituent>Carboximidamide</substituent>
            <substituent>Carboxylic acid amide</substituent>
            <substituent>Carboxylic acid hydrazide</substituent>
            <substituent>Dialkyl ether</substituent>
            <substituent>Ether</substituent>
            <substituent>Fatty acyl</substituent>
            <substituent>Fatty amide</substituent>
            <substituent>Guanidine</substituent>
            <substituent>Heteroaromatic compound</substituent>
            <substituent>Hydrazinecarboxamide</substituent>
            <substituent>Hydrocarbon derivative</substituent>
            <substituent>Imidazole</substituent>
            <substituent>Indole</substituent>
            <substituent>Indole or derivatives</substituent>
            <substituent>Lactam</substituent>
            <substituent>Monocyclic benzene moiety</substituent>
            <substituent>N-acyl-alpha amino acid or derivatives</substituent>
            <substituent>N-acyl-amine</substituent>
            <substituent>N-acylpyrrolidine</substituent>
            <substituent>N-substituted-alpha-amino acid</substituent>
            <substituent>Organic 1,3-dipolar compound</substituent>
            <substituent>Organoheterocyclic compound</substituent>
            <substituent>Organonitrogen compound</substituent>
            <substituent>Organooxygen compound</substituent>
            <substituent>Phenol</substituent>
            <substituent>Phenylpropylamine</substituent>
            <substituent>Primary alcohol</substituent>
            <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
            <substituent>Pyrrole</substituent>
            <substituent>Pyrrolidine</substituent>
            <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
            <substituent>Pyrrolidine-2-carboxamide</substituent>
            <substituent>Pyrrolidone</substituent>
            <substituent>Secondary carboxylic acid amide</substituent>
            <substituent>Semicarbazide</substituent>
            <substituent>Substituted pyrrole</substituent>
            <substituent>Tertiary amine</substituent>
            <substituent>Tertiary carboxylic acid amide</substituent>
            <substituent>Triptan</substituent>
        </classification>
        <salts>
            <salt>
                <drugbank-id primary="true">DBSALT000093</drugbank-id>
                <name>Goserelin acetate</name>
                <cas-number/>
                <inchikey>InChIKey=IKDXDQDKCZPQSZ-JHYYTBFNSA-N</inchikey>
            </salt>
        </salts>
        <synonyms>
            <synonym language="" coder="">Goserelin</synonym>
            <synonym language="" coder="">Goserelin acetate</synonym>
            <synonym language="" coder="">ICI-118630</synonym>
            <synonym language="" coder="">Zoladex</synonym>
        </synonyms>
        <products>
            <product>
                <name>Zoladex</name>
                <ndc-id>0310-0950_51881b14-e43f-46f0-af20-93413460c37f</ndc-id>
                <ndc-product-code>0310-0950</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2003-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>implant</dosage-form>
                <strength>3.6 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019726</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Zoladex</name>
                <ndc-id>0310-0951_ed24c6da-3f20-4330-b813-cdc1d5d1df16</ndc-id>
                <ndc-product-code>0310-0951</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2003-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>implant</dosage-form>
                <strength>10.8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020578</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Zoladex Inj Depot 3.6mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02049325</dpd-id>
                <started-marketing-on>1994-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>implant</dosage-form>
                <strength>3.6 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Zoladex La Inj Depot 10.8mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02225905</dpd-id>
                <started-marketing-on>1996-08-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>implant</dosage-form>
                <strength>10.8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Zoladex</name>
                <ingredients>Goserelin</ingredients>
            </mixture>
            <mixture>
                <name>Zoladex</name>
                <ingredients>Goserelin</ingredients>
            </mixture>
            <mixture>
                <name>Zoladex Inj Depot 3.6mg</name>
                <ingredients>Goserelin</ingredients>
            </mixture>
            <mixture>
                <name>Zoladex La Inj Depot 10.8mg</name>
                <ingredients>Goserelin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>AstraZeneca Inc.</name>
                <url>http://www.astrazeneca.ca</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Astrazeneca uk ltd</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Zoladex 3.6 mg implant syringe</description>
                <cost currency="USD">451.19</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Zoladex 10.8 mg implant syringe</description>
                <cost currency="USD">1380.65</cost>
                <unit>syringe</unit>
            </price>
        </prices>
        <categories/>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Implant</form>
                <route>subcutaneous</route>
                <strength>10.8 mg</strength>
            </dosage>
            <dosage>
                <form>Implant</form>
                <route>subcutaneous</route>
                <strength>3.6 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L02AE03">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L02">ENDOCRINE THERAPY</level>
                <level code="L02A">HORMONES AND RELATED AGENTS</level>
                <level code="L02AE">Gonadotropin releasing hormone analogues</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>68:18.00</ahfs-code>
            <ahfs-code>92:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>7118552</number>
                <country>United States</country>
                <approved>2002-04-13</approved>
                <expires>2022-04-13</expires>
            </patent>
            <patent>
                <number>7500964</number>
                <country>United States</country>
                <approved>2001-02-26</approved>
                <expires>2021-02-26</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00414</drugbank-id>
                <name>Acetohexamide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06203</drugbank-id>
                <name>Alogliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08907</drugbank-id>
                <name>Canagliflozin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00672</drugbank-id>
                <name>Chlorpropamide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09066</drugbank-id>
                <name>Corifollitropin Alfa</name>
                <description>Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01120</drugbank-id>
                <name>Gliclazide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00222</drugbank-id>
                <name>Glimepiride</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01251</drugbank-id>
                <name>Gliquidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01016</drugbank-id>
                <name>Glyburide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01306</drugbank-id>
                <name>Insulin Aspart</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01307</drugbank-id>
                <name>Insulin Detemir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00047</drugbank-id>
                <name>Insulin Glargine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01309</drugbank-id>
                <name>Insulin Glulisine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00046</drugbank-id>
                <name>Insulin Lispro</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00030</drugbank-id>
                <name>Insulin Regular</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08914</drugbank-id>
                <name>Insulin, isophane</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09083</drugbank-id>
                <name>Ivabradine</name>
                <description>May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08882</drugbank-id>
                <name>Linagliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00331</drugbank-id>
                <name>Metformin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00834</drugbank-id>
                <name>Mifepristone</name>
                <description>May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00912</drugbank-id>
                <name>Repaglinide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06335</drugbank-id>
                <name>Saxagliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01124</drugbank-id>
                <name>Tolbutamide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04876</drugbank-id>
                <name>Vildagliptin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
        </drug-interactions>
        <calculated-properties>
            <property>
                <kind>logP</kind>
                <value>0.3</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>logS</kind>
                <value>-4.7</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>Water Solubility</kind>
                <value>2.83e-02 g/l</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>logP</kind>
                <value>-5.2</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>IUPAC Name</kind>
                <value>(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Traditional IUPAC Name</kind>
                <value>(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(3H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>1269.4105</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Monoisotopic Weight</kind>
                <value>1268.641439486</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>SMILES</kind>
                <value>CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C59H84N18O14</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>InChI</kind>
                <value>InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>InChIKey</kind>
                <value>InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Polar Surface Area (PSA)</kind>
                <value>495.89</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Refractivity</kind>
                <value>325.84</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Polarizability</kind>
                <value>131.22</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Rotatable Bond Count</kind>
                <value>33</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>H Bond Acceptor Count</kind>
                <value>18</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>H Bond Donor Count</kind>
                <value>17</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>pKa (strongest acidic)</kind>
                <value>9.27</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>pKa (strongest basic)</kind>
                <value>10.82</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Physiological Charge</kind>
                <value>2</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Number of Rings</kind>
                <value>6</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Bioavailability</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Rule of Five</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Ghose Filter</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>MDDR-Like Rule</kind>
                <value>1</value>
                <source>ChemAxon</source>
            </property>
        </calculated-properties>
        <experimental-properties>
            <property>
                <kind>Water Solubility</kind>
                <value>Soluble</value>
                <source/>
            </property>
            <property>
                <kind>logP</kind>
                <value>-2</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>11167</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D00573</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0310-0951-30</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164747674</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Goserelin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/goserel.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/goserelin.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000134</id>
                <name>Lutropin-choriogonadotropic hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20053189</references>
                <known-action>yes</known-action>
                <polypeptide id="P22888" source="Swiss-Prot">
                    <name>Lutropin-choriogonadotropic hormone receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase</specific-function>
                    <gene-name>LHCGR</gene-name>
                    <locus>2p21</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>364-385
                        396-416
                        440-462
                        483-505
                        526-549
                        571-594
                        606-627</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>78617.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6585</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M73746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>903746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>254</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>30</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P22888</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LSHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>LH/CG-R</synonym>
                        <synonym>LHR</synonym>
                        <synonym>LSH- R</synonym>
                        <synonym>Luteinizing hormone receptor</synonym>
                        <synonym>Lutropin-choriogonadotropic hormone receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Lutropin-choriogonadotropic hormone receptor precursor
                        MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP
                        VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI
                        NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK
                        LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY
                        GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF
                        SKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD
                        FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS
                        QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL
                        RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF
                        IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT
                        VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT
                        SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2058 bp
                        ATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG
                        CTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC
                        CTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA
                        GTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG
                        ATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA
                        ATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT
                        CCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG
                        AAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC
                        ACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT
                        GGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG
                        GAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA
                        GGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA
                        GAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA
                        CAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT
                        AGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA
                        CAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC
                        TGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC
                        ATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG
                        GGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT
                        TTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA
                        GCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA
                        GGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC
                        ACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC
                        CAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT
                        CTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC
                        CCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT
                        GTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC
                        CCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC
                        TTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA
                        GTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT
                        TCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT
                        CTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA
                        GATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT
                        CAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT
                        CGCTACACAGAGTGTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>lutropin-choriogonadotropic hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="1">
                <id>BE0000203</id>
                <name>Gonadotropin-releasing hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20053189</references>
                <known-action>yes</known-action>
                <polypeptide id="P30968" source="Swiss-Prot">
                    <name>Gonadotropin-releasing hormone receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for gonadotropin releasing hormone (GnRH) that mediate the action of GnRH to stimulate the secretion of the gonadotropic hormones (LH and FSH). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act a an inhibitor of GnRH-R signaling</specific-function>
                    <gene-name>GNRHR</gene-name>
                    <locus>4q21.2</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>39-58
                        78-97
                        116-137
                        165-184
                        213-232
                        282-300
                        307-326</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.93</theoretical-pi>
                    <molecular-weight>37731.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4421</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GNRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GNRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L03380</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>183422</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>256</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>31</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P30968</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GNRHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GnRH receptor</synonym>
                        <synonym>GnRH-R</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Gonadotropin-releasing hormone receptor
                        MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL
                        QKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL
                        KLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM
                        IHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR
                        VLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL
                        SDPVNHFFFLFAFLNPCFDPLIYGYFSL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;987 bp
                        ATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC
                        ATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG
                        GTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT
                        CAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA
                        AAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG
                        TGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA
                        AAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC
                        CTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT
                        GGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG
                        ATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC
                        AGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC
                        ATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG
                        GTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA
                        GCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG
                        ACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG
                        TCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA
                        CTTATCTATGGATATTTTTCTCTGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>gonadotropin-releasing hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2010-09-29">
        <drugbank-id primary="true">DB00015</drugbank-id>
        <drugbank-id>BIOD00013</drugbank-id>
        <drugbank-id>BTD00013</drugbank-id>
        <name>Reteplase</name>
        <description>Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).</description>
        <cas-number>133652-38-7</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction</indication>
        <pharmacodynamics>Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.</pharmacodynamics>
        <mechanism-of-action>Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">t- PA</synonym>
            <synonym language="" coder="">t-plasminogen activator</synonym>
            <synonym language="" coder="">Tissue-type plasminogen activator precursor</synonym>
            <synonym language="" coder="">tPA</synonym>
        </synonyms>
        <products>
            <product>
                <name>Retavase</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02233013</dpd-id>
                <started-marketing-on>1999-02-19</started-marketing-on>
                <ended-marketing-on>2013-08-29</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>10.4 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Retavase</name>
                <ingredients>Reteplase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>EKR Therapeutics Inc.</name>
                <url>http://www.ekrtx.com</url>
            </packager>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>PDL BioPharma Inc.</name>
                <url>http://www.pdl.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Retavase vial half-kit</description>
                <cost currency="USD">2605.93</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Fibrinolytic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Thrombolytic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>10.4 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AD07">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AD">Enzymes</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents>
            <patent>
                <number>2107476</number>
                <country>Canada</country>
                <approved>2007-12-18</approved>
                <expires>2012-04-15</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00233</drugbank-id>
                <name>Aminosalicylic Acid</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00261</drugbank-id>
                <name>Anagrelide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06605</drugbank-id>
                <name>Apixaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06692</drugbank-id>
                <name>Aprotinin</name>
                <description>May diminish the therapeutic effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00278</drugbank-id>
                <name>Argatroban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01294</drugbank-id>
                <name>Bismuth Subsalicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00006</drugbank-id>
                <name>Bivalirudin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06441</drugbank-id>
                <name>Cangrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01166</drugbank-id>
                <name>Cilostazol</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00215</drugbank-id>
                <name>Citalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04272</drugbank-id>
                <name>Citric Acid</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00758</drugbank-id>
                <name>Clopidogrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06695</drugbank-id>
                <name>Dabigatran etexilate</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran etexilate.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06754</drugbank-id>
                <name>Danaparoid</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06700</drugbank-id>
                <name>Desvenlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00586</drugbank-id>
                <name>Diclofenac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00266</drugbank-id>
                <name>Dicoumarol</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00861</drugbank-id>
                <name>Diflunisal</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01551</drugbank-id>
                <name>Dihydrocodeine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00975</drugbank-id>
                <name>Dipyridamole</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00476</drugbank-id>
                <name>Duloxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09075</drugbank-id>
                <name>Edoxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01240</drugbank-id>
                <name>Epoprostenol</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00063</drugbank-id>
                <name>Eptifibatide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01175</drugbank-id>
                <name>Escitalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08794</drugbank-id>
                <name>Ethyl biscoumacetate</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00749</drugbank-id>
                <name>Etodolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00573</drugbank-id>
                <name>Fenoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08976</drugbank-id>
                <name>Floctafenine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00472</drugbank-id>
                <name>Fluoxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00712</drugbank-id>
                <name>Flurbiprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01050</drugbank-id>
                <name>Ibuprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01088</drugbank-id>
                <name>Iloprost</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00328</drugbank-id>
                <name>Indomethacin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01009</drugbank-id>
                <name>Ketoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00465</drugbank-id>
                <name>Ketorolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08918</drugbank-id>
                <name>Levomilnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01397</drugbank-id>
                <name>Magnesium salicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00784</drugbank-id>
                <name>Mefenamic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00814</drugbank-id>
                <name>Meloxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04896</drugbank-id>
                <name>Milnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00461</drugbank-id>
                <name>Nabumetone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08813</drugbank-id>
                <name>Nadroparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00788</drugbank-id>
                <name>Naproxen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00991</drugbank-id>
                <name>Oxaprozin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00715</drugbank-id>
                <name>Paroxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00498</drugbank-id>
                <name>Phenindione</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00946</drugbank-id>
                <name>Phenprocoumon</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00554</drugbank-id>
                <name>Piroxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06209</drugbank-id>
                <name>Prasugrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06228</drugbank-id>
                <name>Rivaroxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01399</drugbank-id>
                <name>Salsalate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01104</drugbank-id>
                <name>Sertraline</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00605</drugbank-id>
                <name>Sulindac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06271</drugbank-id>
                <name>Sulodexide</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01600</drugbank-id>
                <name>Tiaprofenic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08816</drugbank-id>
                <name>Ticagrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00208</drugbank-id>
                <name>Ticlopidine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06822</drugbank-id>
                <name>Tinzaparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00775</drugbank-id>
                <name>Tirofiban</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00500</drugbank-id>
                <name>Tolmetin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00285</drugbank-id>
                <name>Venlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06684</drugbank-id>
                <name>Vilazodone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09030</drugbank-id>
                <name>Vorapaxar</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09068</drugbank-id>
                <name>Vortioxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00015 sequence
                SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYC
                RNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAA
                IFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKF
                EVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELS
                GYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHD
                ACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>60 °C</value>
                <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.435</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>6.86</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>39589.6000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1736H2671N499O522S22</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>11534</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>24477-041-02</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>L00153</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164743728</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P00750</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Reteplase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/reteplase.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/reteplase.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00285</smpdb-id>
                <name>Reteplase Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00015</drugbank-id>
                        <name>Reteplase</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000211</id>
                <name>Plasminogen</name>
                <organism>Human</organism>
                <actions>
                    <action>activator</action>
                </actions>
                <references># Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464
                    # Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235
                    # Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00747" source="Swiss-Prot">
                    <name>Plasminogen</name>
                    <general-function>Involved in plasmin activity</general-function>
                    <specific-function>Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo</specific-function>
                    <gene-name>PLG</gene-name>
                    <locus>6q26</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.25</theoretical-pi>
                    <molecular-weight>90569.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9071</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X05199</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>387026</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PLMN_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.7</synonym>
                        <synonym>Plasminogen precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen precursor
                        MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
                        CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
                        GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
                        CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
                        LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
                        AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
                        QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
                        LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
                        CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
                        PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
                        RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
                        PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
                        LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
                        GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2433 bp
                        ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
                        CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
                        CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
                        TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
                        AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
                        TCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT
                        GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
                        ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
                        GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
                        TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
                        ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
                        CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
                        CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC
                        CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
                        GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
                        GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT
                        GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
                        CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
                        CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
                        GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
                        TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
                        CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
                        GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
                        GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC
                        TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
                        CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
                        AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
                        CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
                        GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
                        GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
                        AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
                        GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
                        CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
                        CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
                        GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
                        ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
                        CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
                        TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
                        GGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
                        GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
                        ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00024</identifier>
                            <name>PAN_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>plasmin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000538</id>
                <name>Fibrinogen alpha chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235
                    # Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656
                    # Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
                <known-action>yes</known-action>
                <polypeptide id="P02671" source="Swiss-Prot">
                    <name>Fibrinogen alpha chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation</specific-function>
                    <gene-name>FGA</gene-name>
                    <locus>4q28</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.87</theoretical-pi>
                    <molecular-weight>94974.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3661</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF361104</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>13591824</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02671</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FIBA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Fibrinogen alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]
                        MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
                        NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
                        NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
                        RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
                        LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
                        GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
                        NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
                        SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
                        EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
                        VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
                        YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
                        VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
                        GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
                        NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
                        VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2601 bp
                        ATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA
                        GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
                        GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
                        AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
                        TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
                        GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
                        AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
                        CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
                        GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
                        CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
                        CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
                        TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
                        CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
                        TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
                        TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
                        GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
                        TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
                        ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
                        AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
                        GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
                        GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
                        AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
                        GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
                        TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
                        GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
                        TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
                        GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
                        GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
                        AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
                        AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
                        TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
                        AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
                        TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
                        GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
                        GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
                        GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
                        GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
                        CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
                        ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
                        AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
                        GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
                        TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
                        GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
                        AGGCCCCTTGTGACCCAATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00147</identifier>
                            <name>Fibrinogen_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0000717</id>
                <name>Urokinase plasminogen activator surface receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q03405" source="Swiss-Prot">
                    <name>Urokinase plasminogen activator surface receptor</name>
                    <general-function>Involved in U-plasminogen activator receptor activity</general-function>
                    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form</specific-function>
                    <gene-name>PLAUR</gene-name>
                    <locus>19q13</locus>
                    <cellular-location>Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.64</theoretical-pi>
                    <molecular-weight>36978.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9053</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X51675</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>37605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q03405</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>UPAR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD87 antigen</synonym>
                        <synonym>Monocyte activation antigen Mo3</synonym>
                        <synonym>U- PAR</synonym>
                        <synonym>uPAR</synonym>
                        <synonym>Urokinase plasminogen activator surface receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Urokinase plasminogen activator surface receptor precursor
                        MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
                        ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
                        GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
                        FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
                        MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
                        QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1008 bp
                        ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
                        TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
                        CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
                        GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
                        ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
                        GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
                        GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
                        GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
                        AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
                        TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
                        GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
                        GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
                        ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA
                        AGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG
                        AACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC
                        CAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC
                        CTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00021</identifier>
                            <name>UPAR_LY6</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>U-plasminogen activator receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0000240</id>
                <name>Plasminogen activator inhibitor 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05121" source="Swiss-Prot">
                    <name>Plasminogen activator inhibitor 1</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis</specific-function>
                    <gene-name>SERPINE1</gene-name>
                    <locus>7q21.3-q22</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.22</theoretical-pi>
                    <molecular-weight>45061.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8583</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04429</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>35272</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05121</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAI1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Endothelial plasminogen activator inhibitor</synonym>
                        <synonym>PAI</synonym>
                        <synonym>PAI-1</synonym>
                        <synonym>Plasminogen activator inhibitor 1 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen activator inhibitor 1 precursor
                        MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
                        GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
                        FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
                        DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
                        GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
                        FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
                        STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1209 bp
                        ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
                        GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
                        AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
                        GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
                        ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
                        CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC
                        TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
                        CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
                        GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
                        GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
                        CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
                        TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
                        GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
                        GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
                        CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
                        TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
                        ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
                        GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
                        TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
                        TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
                        GAACCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2011-08-02">
        <drugbank-id primary="true">DB00016</drugbank-id>
        <drugbank-id>BIOD00103</drugbank-id>
        <drugbank-id>BTD00103</drugbank-id>
        <name>Epoetin alfa</name>
        <description>Human erythropoietin (recombinant), produced by CHO cells.</description>
        <cas-number>113427-24-0</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For treatment of anemia (from renal transplants or certain HIV treatment)</indication>
        <pharmacodynamics>Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.</pharmacodynamics>
        <mechanism-of-action>Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>* 20.2 +/- 15.9 mL/h/kg [150 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]&#13;
            * 23.6 +/- 9.5 mL/h/kg [150 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]&#13;
            * 9.2 +/- 4.7 mL/h/kg [40,000 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]&#13;
            * 13.9 +/- 7.6 mL/h/kg [40,000 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Erythropoietin precursor</synonym>
        </synonyms>
        <products>
            <product>
                <name>Epogen</name>
                <ndc-id>55513-126_89a8e8ee-9d7a-422f-9271-6563fabf6f69</ndc-id>
                <ndc-product-code>55513-126</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1989-06-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2000 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103234</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Epogen</name>
                <ndc-id>55513-144_89a8e8ee-9d7a-422f-9271-6563fabf6f69</ndc-id>
                <ndc-product-code>55513-144</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1993-08-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10000 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103234</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Epogen</name>
                <ndc-id>55513-148_89a8e8ee-9d7a-422f-9271-6563fabf6f69</ndc-id>
                <ndc-product-code>55513-148</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1993-08-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>4000 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103234</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Epogen</name>
                <ndc-id>55513-267_89a8e8ee-9d7a-422f-9271-6563fabf6f69</ndc-id>
                <ndc-product-code>55513-267</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1990-04-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>3000 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103234</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Epogen</name>
                <ndc-id>55513-283_89a8e8ee-9d7a-422f-9271-6563fabf6f69</ndc-id>
                <ndc-product-code>55513-283</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1994-12-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10000 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103234</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Epogen</name>
                <ndc-id>55513-478_89a8e8ee-9d7a-422f-9271-6563fabf6f69</ndc-id>
                <ndc-product-code>55513-478</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1997-03-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>20000 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103234</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Eprex Sterile Solution</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243239</dpd-id>
                <started-marketing-on>2005-08-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>20000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02288680</dpd-id>
                <started-marketing-on>2007-11-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>30000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 10000iu/1.0ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231587</dpd-id>
                <started-marketing-on>1997-09-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 10000iu/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02126591</dpd-id>
                <started-marketing-on>1990-12-31</started-marketing-on>
                <ended-marketing-on>2014-10-09</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>10000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 1000iu/0.5ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231583</dpd-id>
                <started-marketing-on>1997-09-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 20000iu/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02206072</dpd-id>
                <started-marketing-on>1996-10-02</started-marketing-on>
                <ended-marketing-on>2010-04-29</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>20000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 2000iu/0.5ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231584</dpd-id>
                <started-marketing-on>1997-09-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 2000iu/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02126575</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>2014-09-25</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>2000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 3000iu/0.3ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231585</dpd-id>
                <started-marketing-on>1997-09-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>3000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 40000iu/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02240722</dpd-id>
                <started-marketing-on>1999-12-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>40000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 4000iu/0.4ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231586</dpd-id>
                <started-marketing-on>1997-09-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>4000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 4000iu/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02126583</dpd-id>
                <started-marketing-on>1990-12-31</started-marketing-on>
                <ended-marketing-on>2014-10-09</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>4000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 5000iu/0.5ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243400</dpd-id>
                <started-marketing-on>2002-07-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>5000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 6000 Iu/0.6 Ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243401</dpd-id>
                <started-marketing-on>2001-02-20</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>6000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Eprex Sterile Solution 8000 Iu/0.8 Ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243403</dpd-id>
                <started-marketing-on>2001-02-20</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>8000 unit</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Binocrit</name>
                <company>Sandoz</company>
            </international-brand>
            <international-brand>
                <name>Epocept</name>
                <company>Lupin pharma</company>
            </international-brand>
            <international-brand>
                <name>Epofit</name>
                <company>Intas pharma</company>
            </international-brand>
            <international-brand>
                <name>Epogin</name>
                <company>Chugai</company>
            </international-brand>
            <international-brand>
                <name>Eprex</name>
                <company>Janssen-Cilag. Ortho Biologics LLC</company>
            </international-brand>
            <international-brand>
                <name>Nanokine</name>
                <company>Nanogen Pharmaceutical biotechnology, Vietnam)</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Epogen</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Epogen</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Epogen</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Epogen</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Epogen</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Epogen</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 1000iu/0.5ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 2000iu/0.5ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 3000iu/0.3ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 4000iu/0.4ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 10000iu/1.0ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 40000iu/ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 5000iu/0.5ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 6000 Iu/0.6 Ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 8000 Iu/0.8 Ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 10000iu/ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 4000iu/ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 2000iu/ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Eprex Sterile Solution 20000iu/ml</name>
                <ingredients>Epoetin alfa</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Amgen Inc.</name>
                <url>http://www.amgen.com</url>
            </packager>
            <packager>
                <name>Centocor Ortho Biotech Inc.</name>
                <url>http://www.centocororthobiotech.com</url>
            </packager>
            <packager>
                <name>DSM Corp.</name>
                <url>http://www.dsm.com</url>
            </packager>
            <packager>
                <name>Janssen-Ortho Inc.</name>
                <url>http://www.janssen-ortho.com</url>
            </packager>
            <packager>
                <name>JHP Pharmaceuticals LLC</name>
                <url>http://www.jhppharma.com</url>
            </packager>
            <packager>
                <name>Ortho-McNeil-Janssen Pharmaceuticals Inc.</name>
                <url>http://www.ortho-mcneil.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Epogen 2000 unit/ml vial</description>
                <cost currency="USD">34.14</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Procrit 2000 unit/ml vial</description>
                <cost currency="USD">37.09</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Epogen 3000 unit/ml vial</description>
                <cost currency="USD">47.53</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Procrit 3000 unit/ml vial</description>
                <cost currency="USD">55.63</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Epogen 4000 unit/ml vial</description>
                <cost currency="USD">61.34</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Procrit 4000 unit/ml vial</description>
                <cost currency="USD">74.17</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Epogen 10000 unit/ml vial</description>
                <cost currency="USD">151.8</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Epogen 20000 unit/ml vial</description>
                <cost currency="USD">303.6</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Epogen 10000 unit/ml Solution 2ml Vial</description>
                <cost currency="USD">315.74</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Procrit 10000 unit/ml Solution 2ml Vial</description>
                <cost currency="USD">358.02</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Procrit 20000 unit/ml Solution</description>
                <cost currency="USD">378.14</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Procrit 20000 unit/ml vial</description>
                <cost currency="USD">388.97</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Epogen 40000 unit/ml vial</description>
                <cost currency="USD">640.37</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Procrit 10000 unit/ml vial</description>
                <cost currency="USD">710.87</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Procrit 40000 unit/ml vial</description>
                <cost currency="USD">767.03</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Epogen 10000 unit/ml Solution 1 Box Contains Ten 1ml Vials</description>
                <cost currency="USD">1578.72</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Epogen 20000 unit/ml Solution 1 Box Contains Ten 1ml Vials</description>
                <cost currency="USD">3157.44</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Epogen 40000 unit/ml Solution 1 Box Contains Ten 1ml Vials</description>
                <cost currency="USD">6852.3</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Hematinics</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-anemic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>10000 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>2000 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>20000 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>3000 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>4000 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>20000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>30000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>10000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>1000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>2000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>3000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>40000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>4000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>5000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>6000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>8000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes>
            <ahfs-code>20:16.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1339047</number>
                <country>Canada</country>
                <approved>1997-05-27</approved>
                <expires>2014-05-27</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00480</drugbank-id>
                <name>Lenalidomide</name>
                <description>Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01041</drugbank-id>
                <name>Thalidomide</name>
                <description>Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00016 sequence
                APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA
                VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS
                PPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>53 °C</value>
                <source>Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)</source>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.75</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>18396.1000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C815H1317N233O241S5</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>299</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>55513-126-10</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X02158</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10072</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01588</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Epoetin_alfa</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/epoetin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/epoetin-alfa.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000654</id>
                <name>Erythropoietin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16505108&#13;
                    # Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17575216&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P19235" source="Swiss-Prot">
                    <name>Erythropoietin receptor</name>
                    <general-function>Involved in transmembrane receptor activity</general-function>
                    <specific-function>Isoform EPOR-T, missing the cytoplasmic tail, acts as a dominant-negative receptor of EPOR-mediated signaling</specific-function>
                    <gene-name>EPOR</gene-name>
                    <locus>19p13.3-p13.2</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. Isoform EPOR-S:Secreted protein. Isoform EPOR-S </cellular-location>
                    <transmembrane-regions>251-273</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.37</theoretical-pi>
                    <molecular-weight>55066.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3416</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>EPOR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>EPOR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M60459</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182245</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P19235</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>EPOR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EPO-R</synonym>
                        <synonym>Erythropoietin receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Erythropoietin receptor precursor
                        MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
                        VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL
                        ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY
                        EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
                        SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH
                        KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG
                        SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS
                        AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
                        SDGPYSNPYENSLIPAAEPLPPSYVACS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1527 bp
                        ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT
                        GGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC
                        TTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG
                        GTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC
                        TACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT
                        GGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA
                        GAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT
                        GAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC
                        CACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC
                        GAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG
                        GGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC
                        CGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG
                        TCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG
                        GTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG
                        AAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC
                        AAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC
                        ACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG
                        ACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC
                        AGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG
                        CCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC
                        TCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT
                        GCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA
                        CTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT
                        GACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA
                        TCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG
                        CCCCCCAGCTATGTGGCTTGCTCTTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-08-07">
        <drugbank-id primary="true">DB00017</drugbank-id>
        <drugbank-id>BIOD00025</drugbank-id>
        <drugbank-id>BTD00025</drugbank-id>
        <name>Salmon Calcitonin</name>
        <description>Synthetic peptide, 32 residues long formulated as a nasal spray.</description>
        <cas-number>47931-85-1</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Sanofi-Aventis Canada Inc. Calcimar Solution. Laval, Quebec: N.p., 2014. &#13;
            #Lexicomp. Calcitonin. N.p., 2014. Web. 11 Nov. 2014.</general-references>
        <synthesis-reference>Marcos C. Poblet, Berta P. Obiols, Gemma J. Farres, "Procedure for preparing salmon calcitonin." U.S. Patent US5527881, issued October, 1991.</synthesis-reference>
        <indication>Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.  </indication>
        <pharmacodynamics>Calcitonin inhibits bone resorption by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass and a reduction in plasma calcium levels. It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secretion of water, sodium, potassium, and chloride.</pharmacodynamics>
        <mechanism-of-action>Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.</mechanism-of-action>
        <toxicity>Salmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers. While research in animals have shown a decrease in fetal weight, no studies have yet shown similar results in humans. It is recommended however to proceed carefully when administering salmon calcitonin to pregnant women and consider if the benefits outweigh the risks. Because of its protein nature, salmon calcitonin may provoke an allergy reaction (bronchospams and swelling of the tongue/throat) that can turn into a full-blown anaphylactic response. The manufacturer also reports an increase in the risk of malignancies from oral route (0.7%) to intranasal route (2.4%) compared to placebo. The same may apply to IV, IM and SC routes since the systemic exposure is higher in those cases.&#13;
            Nausea is noticeable in some patients but tends to decrease with continued administration. Rhinitis, headaches and back pain have also been reported among others. </toxicity>
        <metabolism>Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. It is also metabolized in the blood and the peripheral tissue. </metabolism>
        <absorption>Salmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Via the nasal route, the bioavailability varies between 3 to 5% relative to IM.</absorption>
        <half-life>Half-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes </half-life>
        <protein-binding>30 to 40%</protein-binding>
        <route-of-elimination>Urine. Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.</route-of-elimination>
        <volume-of-distribution>0.15 to 0.3 L/kg</volume-of-distribution>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Calcimar</synonym>
            <synonym language="" coder="">Calcitonin (Salmon Synthetic)</synonym>
            <synonym language="" coder="">Calcitonin 1 precursor</synonym>
            <synonym language="" coder="">Calcitonin Salmon</synonym>
            <synonym language="" coder="">Calcitonin-salmon</synonym>
            <synonym language="" coder="">Calcitonin, salmon</synonym>
            <synonym language="" coder="">Cibacalcin</synonym>
            <synonym language="" coder="">Fortical</synonym>
            <synonym language="" coder="">Miacalcin</synonym>
            <synonym language="" coder="">Salmon calcitonin</synonym>
            <synonym language="" coder="">Salmotonin</synonym>
        </synonyms>
        <products>
            <product>
                <name>Apo-calcitonin Injectable</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246058</dpd-id>
                <started-marketing-on>2003-05-01</started-marketing-on>
                <ended-marketing-on>2013-08-02</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>200 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Apo-calcitonin Nasal Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02247585</dpd-id>
                <started-marketing-on>2003-09-12</started-marketing-on>
                <ended-marketing-on>2013-10-01</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>200 unit</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Calcimar Solution Inj 200unit/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01926691</dpd-id>
                <started-marketing-on>1983-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Calcitonin (salmon) Injection, BP</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02383233</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Calcitonin Salmon</name>
                <ndc-id>54868-6323_495988fd-328f-485b-9dc8-cfc1a47baa05</ndc-id>
                <ndc-product-code>54868-6323</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-12-09</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>200 [iU]/.09mL</strength>
                <route>nasal</route>
                <fda-application-number>ANDA076979</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Calcitonin Salmon</name>
                <ndc-id>49884-161_35e3dd68-677f-45e9-b4bf-f30fa2a34367</ndc-id>
                <ndc-product-code>49884-161</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-06-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>200 [iU]/.09mL</strength>
                <route>nasal</route>
                <fda-application-number>ANDA076979</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Calcitonin Salmon</name>
                <ndc-id>0781-6320_99e9e62b-9796-42ec-8f69-551dabf92ec1</ndc-id>
                <ndc-product-code>0781-6320</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-08-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>200 [iU]</strength>
                <route>nasal</route>
                <fda-application-number>NDA020313</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Calcitonin Salmon</name>
                <ndc-id>60505-0823_af648eda-ff07-596c-b25a-d1d3d57a4890</ndc-id>
                <ndc-product-code>60505-0823</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2008-12-09</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>200 [iU]</strength>
                <route>nasal</route>
                <fda-application-number>ANDA076396</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Caltine Inj 100 Unit/ml (1ml Amp)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02007134</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>2014-07-25</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>100 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Caltine Inj 100unit/ml (0.5ml Amp)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01940376</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>2002-01-30</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>100 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Fortical</name>
                <ndc-id>54868-5499_5855b6df-3949-4d36-b210-0fa2e5db974d</ndc-id>
                <ndc-product-code>54868-5499</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-12-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>2200 [iU]/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA021406</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Fortical</name>
                <ndc-id>0245-0008_2905a738-af8b-4baa-9c2f-67769897220c</ndc-id>
                <ndc-product-code>0245-0008</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-08-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>2200 [iU]/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA021406</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Miacalcin</name>
                <ndc-id>54766-149_c83870aa-b4eb-49d4-8790-a78dd66b1d1b</ndc-id>
                <ndc-product-code>54766-149</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1986-07-03</started-marketing-on>
                <ended-marketing-on>2018-03-31</ended-marketing-on>
                <dosage-form>injection, solution</dosage-form>
                <strength>200 [iU]/mL</strength>
                <route>intramuscular</route>
                <fda-application-number>NDA017808</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Miacalcin</name>
                <ndc-id>0078-0149_223dc129-c720-41ba-a4e6-d879ea89431d</ndc-id>
                <ndc-product-code>0078-0149</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1986-07-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>200 [iU]/mL</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number>NDA017808</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Miacalcin</name>
                <ndc-id>0078-0311_bbd80843-5b89-4b66-b1d2-c5c5a28c346e</ndc-id>
                <ndc-product-code>0078-0311</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-08-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>200 [iU]</strength>
                <route>nasal</route>
                <fda-application-number>NDA020313</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Miacalcin Injection 200iu/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02144301</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>liquid</dosage-form>
                <strength>200 unit</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Miacalcin Nasal Spray 200 Iu</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02240775</dpd-id>
                <started-marketing-on>1999-09-08</started-marketing-on>
                <ended-marketing-on>2013-10-01</ended-marketing-on>
                <dosage-form>spray</dosage-form>
                <strength>200 unit</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pro-calcitonin - 200</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02311046</dpd-id>
                <started-marketing-on>2008-07-04</started-marketing-on>
                <ended-marketing-on>2011-07-27</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>200 unit</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sandoz-calcitonin Ns</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02261766</dpd-id>
                <started-marketing-on>2004-12-01</started-marketing-on>
                <ended-marketing-on>2013-10-01</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>200 unit</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Calcimar</name>
                <company/>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Miacalcin</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Miacalcin</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Fortical</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Calcitonin Salmon</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Calcitonin Salmon</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Miacalcin</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Fortical</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Calcitonin Salmon</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Calcitonin Salmon</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Calcimar Solution Inj 200unit/ml</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Caltine Inj 100 Unit/ml (1ml Amp)</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Caltine Inj 100unit/ml (0.5ml Amp)</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Miacalcin Nasal Spray 200 Iu</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Apo-calcitonin Injectable</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Apo-calcitonin Nasal Spray</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Sandoz-calcitonin Ns</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Pro-calcitonin - 200</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Miacalcin Injection 200iu/ml</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
            <mixture>
                <name>Calcitonin (salmon) Injection, BP</name>
                <ingredients>Salmon Calcitonin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Apotex Inc.</name>
                <url>http://www.apotex.com</url>
            </packager>
            <packager>
                <name>Novartis AG</name>
                <url>http://www.novartis.com</url>
            </packager>
            <packager>
                <name>Par Pharmaceuticals</name>
                <url>http://www.parpharm.com</url>
            </packager>
            <packager>
                <name>Sandoz</name>
                <url>http://www.sandoz.ca</url>
            </packager>
            <packager>
                <name>Upsher Smith Laboratories</name>
                <url>http://www.upsher-smith.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Sanofi aventis us llc</manufacturer>
            <manufacturer generic="false">Astrazeneca lp</manufacturer>
            <manufacturer generic="false">Novartis pharmaceuticals corp</manufacturer>
            <manufacturer generic="false">Apotex inc</manufacturer>
            <manufacturer generic="false">Par pharmaceutical inc</manufacturer>
            <manufacturer generic="false">Upsher smith laboratories inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Caltine 100 (100 Iu/Ml) 100 iu/ml</description>
                <cost currency="USD">8.81</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Calcimar 200 iu/ml</description>
                <cost currency="USD">29.94</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Miacalcin 200 unit/ml vial</description>
                <cost currency="USD">30.73</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Fortical 200 unit nasal spray</description>
                <cost currency="USD">34.3</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Calcitonin-salmon 200 unit sp</description>
                <cost currency="USD">39.51</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Miacalcin 200 unit nasal spray</description>
                <cost currency="USD">44.68</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Miacalcin For Inj, 2 unit = 1 Box 2ml Vial</description>
                <cost currency="USD">63.59</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Calcitonin (Salmon) 200 unit/act Solution 3.7ml Bottle</description>
                <cost currency="USD">123.28</cost>
                <unit>bottle</unit>
            </price>
            <price>
                <description>Miacalcin 200 unit/act Solution 3.7ml Bottle</description>
                <cost currency="USD">139.39</cost>
                <unit>bottle</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Bone Density Conservation Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Antihypercalcemic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-Osteporotic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; subcutaneous</route>
                <strength>200 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>nasal</route>
                <strength>200 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>200 unit</strength>
            </dosage>
            <dosage>
                <form>Spray, metered</form>
                <route>nasal</route>
                <strength>200 [iU]/.09mL</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; subcutaneous</route>
                <strength>100 unit</strength>
            </dosage>
            <dosage>
                <form>Spray, metered</form>
                <route>nasal</route>
                <strength>2200 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intramuscular</route>
                <strength>200 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>200 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Spray, metered</form>
                <route>nasal</route>
                <strength>200 [iU]</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; intravenous; subcutaneous</route>
                <strength>200 unit</strength>
            </dosage>
            <dosage>
                <form>Spray</form>
                <route>nasal</route>
                <strength>200 unit</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>nasal</route>
                <strength>200 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="H05BA01">
                <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
                <level code="H05">CALCIUM HOMEOSTASIS</level>
                <level code="H05B">ANTI-PARATHYROID AGENTS</level>
                <level code="H05BA">Calcitonin preparations</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>68:24.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>5733569</number>
                <country>United States</country>
                <approved>1995-03-31</approved>
                <expires>2015-03-31</expires>
            </patent>
            <patent>
                <number>6440392</number>
                <country>United States</country>
                <approved>2001-02-02</approved>
                <expires>2021-02-02</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00017 sequence
                CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.537</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.86</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>3431.8530</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C145H240N44O48S2</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13186</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C06865</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D00249</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>60505-0823-6</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>Y00765</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA448715</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01263</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Calcitonin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/calcit.htm</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000431</id>
                <name>Calcitonin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Bouizar Z, Fouchereau-Peron M, Taboulet J, Moukhtar MS, Milhaud G: Purification and characterization of calcitonin receptors in rat kidney membranes by covalent cross-linking techniques. Eur J Biochem. 1986 Feb 17;155(1):141-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3004987&#13;
                    # Stroop SD, Moore EE: Intracellular calcium increases mediated by a recombinant human calcitonin receptor. J Bone Miner Res. 1995 Apr;10(4):524-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7610922&#13;
                    # Sarkar A, Dickerson IM: Cloning, characterization, and expression of a calcitonin receptor from guinea pig brain. J Neurochem. 1997 Aug;69(2):455-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9231703&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>unknown</known-action>
                <polypeptide id="P30988" source="Swiss-Prot">
                    <name>Calcitonin receptor</name>
                    <general-function>Involved in calcitonin receptor activity</general-function>
                    <specific-function>This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin</specific-function>
                    <gene-name>CALCR</gene-name>
                    <locus>7q21.3</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>154-173
                        197-216
                        237-259
                        277-296
                        313-336
                        360-377
                        390-411</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.71</theoretical-pi>
                    <molecular-weight>57304.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1440</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CALCR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CALCR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L00587</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>179880</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>43</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>11</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P30988</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CALCR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Calcitonin receptor precursor</synonym>
                        <synonym>CT-R</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Calcitonin receptor precursor
                        MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQ
                        QLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFK
                        HPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRKLTTIF
                        PLNWKYRKALSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHF
                        FHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVY
                        FNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKA
                        TMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKR
                        QWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIP
                        LNIIEQESSA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1473 bp
                        ATGAGGTTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACC
                        CCAATTCTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTT
                        TACGTCGTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAG
                        CAGTTACCCGCATACCAAGGAGAAGGTCCATATTGCAATCGCACCTGGGATGGATGGCTG
                        TGCTGGGATGACACACCGGCTGGAGTATTGTCCTATCAGTTCTGCCCAGATTATTTTCCG
                        GATTTTGATCCATCAGAAAAGGTTACAAAATACTGTGATGAAAAAGGTGTTTGGTTTAAA
                        CATCCTGAAAACAATCGAACCTGGTCCAACTATACTATGTGCAATGCTTTCACTCCTGAG
                        AAACTGAAGAATGCATATGTTCTGTACTATTTGGCTATTGTGGGTCATTCTTTGTCAATT
                        TTCACCCTAGTGATTTCCCTGGGGATTTTCGTGTTTTTCAGAAAATTGACAACTATTTTT
                        CCTTTGAATTGGAAATATAGGAAGGCATTGAGCCTTGGCTGCCAAAGGGTAACCCTGCAC
                        AAGAACATGTTTCTTACTTACATTCTGAATTCTATGATTATCATCATCCACCTGGTTGAA
                        GTAGTACCCAATGGAGAGCTCGTGCGAAGGGACCCGGTGAGCTGCAAGATTTTGCATTTT
                        TTCCACCAGTACATGATGGCCTGCAACTATTTCTGGATGCTCTGTGAAGGGATCTATCTT
                        CATACACTCATTGTCGTGGCTGTGTTTACTGAGAAGCAACGCTTGCGGTGGTATTATCTC
                        TTGGGCTGGGGGTTCCCGCTGGTGCCAACCACTATCCATGCTATTACCAGGGCCGTGTAC
                        TTCAATGACAACTGCTGGCTGAGTGTGGAAACCCATTTGCTTTACATAATCCATGGACCT
                        GTCATGGCGGCACTTGTGGTCAATTTCTTCTTTTTGCTCAACATTGTCCGGGTGCTTGTG
                        ACCAAAATGAGGGAAACCCATGAGGCGGAATCCCACATGTACCTGAAGGCTGTGAAGGCC
                        ACCATGATCCTTGTGCCCCTGCTGGGAATCCAGTTTGTCGTCTTTCCCTGGAGACCTTCC
                        AACAAGATGCTTGGGAAGATATATGATTACGTGATGCACTCTCTGATTCATTTCCAGGGC
                        TTCTTTGTTGCGACCATCTACTGCTTCTGCAACAATGAGGTCCAAACCACCGTGAAGCGC
                        CAATGGGCCCAATTCAAAATTCAGTGGAACCAGCGTTGGGGGAGGCGCCCCTCCAACCGC
                        TCTGCTCGCGCTGCAGCCGCTGCTGCGGAGGCTGGCGACATCCCAATTTACATCTGCCAT
                        CAGGAGCCGAGGAATGAACCAGCCAACAACCAAGGCGAGGAGAGTGCTGAGATCATCCCT
                        TTGAATATCATAGAGCAAGAGTCATCTGCTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00002</identifier>
                            <name>7tm_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02793</identifier>
                            <name>HRM</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>secretin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcitonin receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2010-09-29">
        <drugbank-id primary="true">DB00018</drugbank-id>
        <drugbank-id>BIOD00023</drugbank-id>
        <drugbank-id>BTD00023</drugbank-id>
        <name>Interferon alfa-n3</name>
        <description>Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).</description>
        <cas-number/>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Sturgill MG, Rashidbaigi A, Liao MJ, Zhao XX, Hua J, Trout R, Knill JR, Grasing KW: Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity. J Clin Pharmacol. 2000 Jun;40(6):606-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10868311</general-references>
        <synthesis-reference/>
        <indication>For the intralesional treatment of refractory or recurring external condylomata acuminata.</indication>
        <pharmacodynamics>Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.</pharmacodynamics>
        <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products/>
        <international-brands>
            <international-brand>
                <name>Alferon</name>
                <company>Interferon Sciences Inc.</company>
            </international-brand>
            <international-brand>
                <name>Alferon LDO</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Alferon N Injection</name>
                <company/>
            </international-brand>
        </international-brands>
        <mixtures/>
        <packagers>
            <packager>
                <name>Hemispherx Biopharma Inc.</name>
                <url>http://www.hemispherx.net</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Alferon n 5 million unit vial</description>
                <cost currency="USD">412.87</cost>
                <unit>ml</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages/>
        <atc-codes/>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00041</drugbank-id>
                <name>Aldesleukin</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04817</drugbank-id>
                <name>Metamizole</name>
                <description>May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00333</drugbank-id>
                <name>Methadone</name>
                <description>Interferons (Alfa) may increase the serum concentration of Methadone.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00811</drugbank-id>
                <name>Ribavirin</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00495</drugbank-id>
                <name>Zidovudine</name>
                <description>Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00018 sequence (alpha-2A)
                CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
                QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
                KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
            <sequence format="FASTA">&gt;DB00018 sequence (alpha-2B)
                CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
                QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR
                KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
            <sequence format="FASTA">&gt;DB00018 sequence (alpha-2C)
                CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMI
                QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR
                KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C</value>
                <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.99</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164746228</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/interferon-alfa-n3-solution.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000661</id>
                <name>Interferon alpha/beta receptor 1</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
                    # Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P17181" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 1</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves</specific-function>
                    <gene-name>IFNAR1</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>437-457</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.56</theoretical-pi>
                    <molecular-weight>63526.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5432</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03171</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>306914</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P17181</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>Interferon-alpha/beta receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor alpha chain precursor
                        MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
                        FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
                        TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
                        ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
                        NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
                        GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
                        VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
                        FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
                        YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
                        EDESESKTSEELQQDFV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1674 bp
                        ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG
                        TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
                        ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
                        TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
                        AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
                        AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
                        ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
                        GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
                        TTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
                        GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
                        AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
                        ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
                        AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
                        TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
                        CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
                        GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
                        GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
                        TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
                        GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
                        GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
                        GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
                        TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
                        GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
                        TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
                        TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
                        AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
                        GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
                        GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000385</id>
                <name>Interferon alpha/beta receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
                    # Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815
                    # Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16953837
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P48551" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 2</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity</specific-function>
                    <gene-name>IFNAR2</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>244-264</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.11</theoretical-pi>
                    <molecular-weight>57759.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5433</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L42243</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>995300</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P48551</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>IFN-R</synonym>
                        <synonym>Interferon alpha/beta receptor 2</synonym>
                        <synonym>Interferon-alpha/beta receptor beta chain precursor</synonym>
                        <synonym>Type I interferon receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor beta chain precursor
                        MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
                        IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
                        SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
                        HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
                        SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
                        MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
                        DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
                        ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
                        FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
                        ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
                        TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
                        ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
                        GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
                        AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
                        AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
                        ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
                        GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
                        CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
                        ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
                        ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
                        TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
                        ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
                        AATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT
                        ATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT
                        GAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT
                        GGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA
                        GACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG
                        CCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT
                        CCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA
                        ATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT
                        GACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG
                        GATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC
                        TTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC
                        ACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2011-12-20">
        <drugbank-id primary="true">DB00019</drugbank-id>
        <drugbank-id>BIOD00094</drugbank-id>
        <drugbank-id>BTD00094</drugbank-id>
        <name>Pegfilgrastim</name>
        <description>PEGylated (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation.</description>
        <cas-number>208265-92-3</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Yang BB, Kido A: Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011 May 1;50(5):295-306. doi: 10.2165/11586040-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21456630</general-references>
        <synthesis-reference/>
        <indication>Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant</indication>
        <pharmacodynamics>Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.</pharmacodynamics>
        <mechanism-of-action>Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>15-80 hrs</half-life>
        <protein-binding/>
        <route-of-elimination>Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. Pegylation of filgrastim renders renal clearance insignificant, which was demonstrated in bilaterally nephrectomized rats and confirmed in subjects with renal impairment. As a result, the neutrophil-mediated clearance is the predominant elimination pathway for pegfilgrastim. During chemotherapy-induced neutropenia, the clearance of pegfilgrastim is significantly reduced and the concentration of pegfilgrastim is sustained until onset of neutrophil recovery.</route-of-elimination>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">G-CSF</synonym>
            <synonym language="" coder="">Granulocyte colony-stimulating factor precursor</synonym>
            <synonym language="" coder="">Lenograstim</synonym>
            <synonym language="" coder="IUPAC">N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)</synonym>
            <synonym language="" coder="">Pluripoietin</synonym>
        </synonyms>
        <products>
            <product>
                <name>Neulasta</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02249790</dpd-id>
                <started-marketing-on>2004-03-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Neulasta</name>
                <ndc-id>55513-190_46514a8d-2de6-484b-9f40-0f3bd19458c6</ndc-id>
                <ndc-product-code>55513-190</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2002-04-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection</dosage-form>
                <strength>6 mg/.6mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA125031</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Neulasta</name>
                <ingredients>Pegfilgrastim</ingredients>
            </mixture>
            <mixture>
                <name>Neulasta</name>
                <ingredients>Pegfilgrastim</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Amgen Inc.</name>
                <url>http://www.amgen.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Neulasta 6 mg/0.6ml Solution 0.6ml Syringe</description>
                <cost currency="USD">4026.05</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Neulasta 6 mg/0.6 ml syringe</description>
                <cost currency="USD">4102.37</cost>
                <unit>syringe</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Antineutropenic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms/>
        <dosages>
            <dosage>
                <form>Injection</form>
                <route>subcutaneous</route>
                <strength>6 mg/.6mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>10 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L03AA13">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AA">Colony stimulating factors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:16.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1339071</number>
                <country>Canada</country>
                <approved>1997-07-29</approved>
                <expires>2014-07-29</expires>
            </patent>
            <patent>
                <number>1341537</number>
                <country>Canada</country>
                <approved>2007-07-31</approved>
                <expires>2024-07-31</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt; Pegfilgrastim sequence
                MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWA
                PLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQ
                QMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>60 °C</value>
                <source>Luo, P., Protein Science 11:1218-1226 (2002)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>0.209</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.65</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>18802.8000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C845H1343N223O243S9</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12313</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D06889</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>55513-190-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X03438</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164781387</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P09919</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Pegfilgrastim</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/neulasta.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/pegfilgrastim.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000793</id>
                <name>Granulocyte colony-stimulating factor receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17001306&#13;
                    # Elsasser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G: The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003 Aug 28;22(36):5646-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12944913&#13;
                    # Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17127322&#13;
                    # Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16033816&#13;
                    # Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients] Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15949269&#13;
                    # Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA: Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15082029</references>
                <known-action>yes</known-action>
                <polypeptide id="Q99062" source="Swiss-Prot">
                    <name>Granulocyte colony-stimulating factor receptor</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>Receptor for granulocyte colony-stimulating factor. In addition it may function in some adhesion or recognition events at the cell surface</specific-function>
                    <gene-name>CSF3R</gene-name>
                    <locus>1p35-p34.3</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. Isoform GCSFR2:Secreted protein (Probable). Isof</cellular-location>
                    <transmembrane-regions>628-650</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.14</theoretical-pi>
                    <molecular-weight>92157.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2439</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CSF3R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CSF3R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X55721</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31697</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q99062</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CSF3R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD114 antigen</synonym>
                        <synonym>G-CSF-R</synonym>
                        <synonym>Granulocyte colony-stimulating factor receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Granulocyte colony-stimulating factor receptor precursor
                        MARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ
                        ILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG
                        YPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK
                        DGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE
                        AAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA
                        TAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP
                        LEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT
                        PVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME
                        QNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK
                        TWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL
                        MAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP
                        SVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL
                        PTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL
                        TPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2511 bp
                        ATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC
                        GGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT
                        CCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG
                        ATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT
                        GGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC
                        TGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC
                        TACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC
                        ATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT
                        TTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG
                        GACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC
                        ATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT
                        CCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA
                        GCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG
                        CACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA
                        CTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC
                        ACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC
                        TGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA
                        TGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC
                        CTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG
                        GCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT
                        TCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGCCCCACC
                        CCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA
                        GACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG
                        ATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA
                        CAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT
                        GAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC
                        TACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG
                        ACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC
                        CACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC
                        TCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC
                        ATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC
                        CCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC
                        TGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA
                        AGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG
                        GATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG
                        GAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC
                        CCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC
                        CAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA
                        AGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC
                        ACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG
                        GTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC
                        CTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                        <pfam>
                            <identifier>PF06328</identifier>
                            <name>Lep_receptor_Ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000394</id>
                <name>Neutrophil elastase</name>
                <organism>Human</organism>
                <actions/>
                <references># Carter CR, Whitmore KM, Thorpe R: The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14657210&#13;
                    # Jian MY, Koizumi T, Tsushima K, Fujimoto K, Kubo K: Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats. Inflammation. 2004 Dec;28(6):327-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16245075&#13;
                    # Pelus LM, Bian H, King AG, Fukuda S: Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood. 2004 Jan 1;103(1):110-9. Epub 2003 Sep 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12958067&#13;
                    # Druhan LJ, Ai J, Massullo P, Kindwall-Keller T, Ranalli MA, Avalos BR: Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 2005 Jan 15;105(2):584-91. Epub 2004 Sep 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15353486&#13;
                    # Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ: Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007 Aug 15;110(4):1317-25. Epub 2007 May 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17475913</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08246" source="Swiss-Prot">
                    <name>Neutrophil elastase</name>
                    <general-function>Involved in elastase activity and cytokine binding</general-function>
                    <specific-function>Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis</specific-function>
                    <gene-name>ELANE</gene-name>
                    <locus>19p13.3</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>7-26</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.41</theoretical-pi>
                    <molecular-weight>28518.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3309</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>ELA2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>ELA2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>Y00477</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>296665</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08246</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>ELNE_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Bone marrow serine protease</synonym>
                        <synonym>EC 3.4.21.37</synonym>
                        <synonym>Elastase-2</synonym>
                        <synonym>HLE</synonym>
                        <synonym>Human leukocyte elastase</synonym>
                        <synonym>Leukocyte elastase precursor</synonym>
                        <synonym>Medullasin</synonym>
                        <synonym>Neutrophil elastase</synonym>
                        <synonym>PMN elastase</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Leukocyte elastase precursor
                        MTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI
                        APNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVI
                        LQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSL
                        CRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVN
                        WIDSIIQRSEDNPCPHPRDPDPASRTH</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;804 bp
                        ATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTG
                        CTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCG
                        TGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATT
                        GCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTG
                        CGGGTGGTCCTGGGAGCCCATAACCTCTCGCGGCGGGAGCCCACCCGGCAGGTGTTCGCC
                        GTGCAGCGCATCTTCGAAAACGGCTACGACCCCGTAAACTTGCTCAACGACATCGTGATT
                        CTCCAGCTCAACGGGTCGGCCACCATCAACGCCAACGTGCAGGTGGCCCAGCTGCCGGCT
                        CAGGGACGCCGCCTGGGCAACGGGGTGCAGTGCCTGGCCATGGGCTGGGGCCTTCTGGGC
                        AGGAACCGTGGGATCGCCAGCGTCCTGCAGGAGCTCAACGTGACGGTGGTGACGTCCCTC
                        TGCCGTCGCAGCAACGTCTGCACTCTCGTGAGGGGCCGGCAGGCCGGCGTCTGTTTCGGG
                        GACTCCGGCAGCCCCTTGGTCTGCAACGGGCTAATCCACGGAATTGCCTCCTTCGTCCGG
                        GGAGGCTGCGCCTCAGGGCTCTACCCCGATGCCTTTGCCCCGGTGGCACAGTTTGTAAAC
                        TGGATCGACTCTATCATCCAACGCTCCGAGGACAACCCCTGTCCCCACCCCCGGGACCCG
                        GACCCGGCCAGCAGGACCCACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-10-03">
        <drugbank-id primary="true">DB00020</drugbank-id>
        <drugbank-id>BIOD00035</drugbank-id>
        <drugbank-id>BTD00035</drugbank-id>
        <name>Sargramostim</name>
        <description>Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.</description>
        <cas-number>83869-56-1</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references/>
        <synthesis-reference>Kaname Sugimoto, "Process for the production of human colony-stimulating factor." U.S. Patent US4621050, issued May, 1983.</synthesis-reference>
        <indication>For the treatment of cancer and bone marrow transplant</indication>
        <pharmacodynamics>Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.</pharmacodynamics>
        <mechanism-of-action>Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>* 420 mL/min/m2 [Normal people with liquid LEUKINE (IV)]&#13;
            * 431 mL/min/m2 [Normal people with lyophilized LEUKINE (IV)]&#13;
            * 549 mL/min/m2 [Normal people with liquid LEUKINE (SC)]&#13;
            * 529 mL/min/m2 [Normal people with lyophilized LEUKINE (SC)]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">GM-CSF</synonym>
        </synonyms>
        <products>
            <product>
                <name>Leukine</name>
                <ndc-id>58468-0180_4c805287-5661-452a-91c6-da688bebc400</ndc-id>
                <ndc-product-code>58468-0180</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2010-03-15</started-marketing-on>
                <ended-marketing-on>2016-06-30</ended-marketing-on>
                <dosage-form>injection, powder, for solution</dosage-form>
                <strength>250 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103362</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Leukine</name>
                <ndc-id>0024-5843_95b04916-3ce2-4785-b102-35b1d3984d59</ndc-id>
                <ndc-product-code>0024-5843</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-05-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, for solution</dosage-form>
                <strength>250 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103362</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Leukine</name>
                <ndc-id>0024-5844_95b04916-3ce2-4785-b102-35b1d3984d59</ndc-id>
                <ndc-product-code>0024-5844</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1996-12-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>liquid</dosage-form>
                <strength>500 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>BLA103362</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Leucomax</name>
                <company>Novartis</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Leukine</name>
                <ingredients>Sargramostim</ingredients>
            </mixture>
            <mixture>
                <name>Leukine</name>
                <ingredients>Sargramostim</ingredients>
            </mixture>
            <mixture>
                <name>Leukine</name>
                <ingredients>Sargramostim</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Bayer Healthcare</name>
                <url>http://www.bayerhealthcare.com</url>
            </packager>
            <packager>
                <name>Genzyme Inc.</name>
                <url>http://www.genzyme.ca</url>
            </packager>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>Kramer-Novis</name>
                <url>http://www.kramernovis.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Wyeth Pharmaceuticals</name>
                <url>http://www.wyeth.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Leukine 250 mcg vial</description>
                <cost currency="USD">204.79</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Bio-immunex capsule</description>
                <cost currency="USD">0.42</cost>
                <unit>capsule</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, powder, for solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>250 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intravenous; subcutaneous</route>
                <strength>500 ug/mL</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L03AA09">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AA">Colony stimulating factors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents>
            <patent>
                <number>1341150</number>
                <country>Canada</country>
                <approved>2000-12-05</approved>
                <expires>2017-12-05</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00290</drugbank-id>
                <name>Bleomycin</name>
                <description>Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00531</drugbank-id>
                <name>Cyclophosphamide</name>
                <description>May enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00020 sequence
                APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE
                LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFD
                CWEPVQE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.05</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>14434.5000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C639H1006N168O196S8</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>50419-002-33</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M13207</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164748631</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P04141</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Sargramostim</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/sargramostim.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/sargramostim.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000628</id>
                <name>Granulocyte-macrophage colony-stimulating factor receptor subunit alpha</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17090651&#13;
                    # Chen J, Carcamo JM, Golde DW: The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling. J Biol Chem. 2006 Aug 4;281(31):22421-6. Epub 2006 Jun 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16760463&#13;
                    # Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17522711&#13;
                    # Xiao R, Zhang R, Wang YL, Zhu ZL, Chen T, Yang JH: [Expression of soluble GM-CSF-Ralpha in patients with acute myeloid leukemia] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):225-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16638185&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P15509" source="Swiss-Prot">
                    <name>Granulocyte-macrophage colony-stimulating factor receptor subunit alpha</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>Low affinity receptor for granulocyte-macrophage colony- stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells</specific-function>
                    <gene-name>CSF2RA</gene-name>
                    <locus>Xp22.32 and Yp11.3</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. Isoform 3:Secreted protein (Probable) protein. I</cellular-location>
                    <transmembrane-regions>321-346</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.81</theoretical-pi>
                    <molecular-weight>46207.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2435</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CSF2RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CSF2RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X17648</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>32089</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P15509</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CSF2R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD116 antigen</synonym>
                        <synonym>CDw116</synonym>
                        <synonym>GM-CSF-R-alpha</synonym>
                        <synonym>GMR</synonym>
                        <synonym>Granulocyte-macrophage colony-stimulating factor receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Granulocyte-macrophage colony-stimulating factor receptor alpha chain precursor
                        MLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKC
                        FLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTA
                        AQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHL
                        DNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQP
                        RTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAAD
                        VRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVP
                        QIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1203 bp
                        ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTG
                        ATCCCAGAGAAATCGGATCTGCGAACAGTGGCACCAGCCTCTAGTCTCAATGTGAGGTTT
                        GACTCCAGGACGATGAATTTAAGCTGGGACTGCCAAGAAAACACAACCTTCAGCAAGTGT
                        TTCTTAACTGACAAGAAGAACAGAGTCGTGGAACCCAGGCTCAGTAACAACGAATGTTCG
                        TGCACATTTCGTGAAATTTGTCTGCATGAAGGAGTCACATTTGAGGTTCACGTGAATACT
                        AGTCAAAGAGGATTTCAACAGAAACTGCTTTATCCAAATTCAGGAAGGGAGGGTACCGCT
                        GCTCAGAATTTCTCCTGTTTCATCTACAATGCGGATTTAATGAACTGTACCTGGGCGAGG
                        GGTCCGACGGCCCCCCGTGACGTCCAGTATTTTTTGTACATACGAAACTCAAAGAGAAGG
                        AGGGAGATCCGGTGTCCTTATTACATACAAGACTCAGGAACCCATGTGGGATGTCACCTG
                        GATAACCTGTCAGGATTAACGTCTCGCAATTACTTTCTGGTTAACGGAACCAGCCGAGAA
                        ATTGGCATCCAATTCTTTGATTCACTTTTGGACACAAAGAAAATAGAACGATTCAACCCT
                        CCCAGCAATGTCACCGTACGTTGCAACACGACGCACTGCCTCGTACGGTGGAAACAGCCC
                        AGGACCTATCAGAAGCTGTCGTACCTGGACTTTCAGTACCAGCTGGACGTCCACAGAAAG
                        AATACCCAGCCTGGCACGGAAAACCTACTGATTAATGTTTCTGGTGATTTGGAAAATAGA
                        TACAACTTTCCAAGCTCTGAGCCCAGAGCAAAACACAGTGTGAAGATCAGAGCTGCAGAC
                        GTCCGCATCTTGAATTGGAGCTCCTGGAGTGAAGCCATTGAATTTGGTTCTGACGACGGG
                        AACCTCGGCTCTGTGTACATTTATGTGCTCCTAATCGTGGGAACCCTTGTCTGTGGCATC
                        GTCCTCGGCTTCCTCTTTAAAAGGTTCCTTAGGATACAGCGGCTGTTCCCGCCAGTTCCA
                        CAGATCAAAGACAAACTGAATGATAACCATGAGGTGGAAGACGAGATCATCTGGGAGGAA
                        TTCACCCCAGAGGAAGGGAAAGGCTACCGCGAAGAGGTCTTGACCGTGAAGGAAATTACC
                        TGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0001036</id>
                <name>Interleukin-3 receptor subunit alpha</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Eksioglu EA, Mahmood SS, Chang M, Reddy V: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol. 2007 Aug;35(8):1163-71. Epub 2007 Jun 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17562355&#13;
                    # Sakhno LV, Leplina OIu, Tikhonova MA, Raspai ZhM, Gileva IP, Nikonov SD, Zhdanov OA, Ostanin AA, Chernykh ER: [Characteristics of A-interferon-generated dendritic cells in patients with pulmonary tuberculosis] Probl Tuberk Bolezn Legk. 2007;(3):42-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17500228&#13;
                    # Ward KA, Stewart LA, Schwarer AP: CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy. 2006;8(2):130-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16698686&#13;
                    # Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17522711</references>
                <known-action>yes</known-action>
                <polypeptide id="P26951" source="Swiss-Prot">
                    <name>Interleukin-3 receptor subunit alpha</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>This is a receptor for interleukin-3</specific-function>
                    <gene-name>IL3RA</gene-name>
                    <locus>Xp22.3 or Yp11.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>306-325</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.32</theoretical-pi>
                    <molecular-weight>43330.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6012</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL3RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL3RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M74782</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>186331</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P26951</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL3RA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD123 antigen</synonym>
                        <synonym>IL-3R-alpha</synonym>
                        <synonym>Interleukin-3 receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interleukin-3 receptor alpha chain precursor
                        MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM
                        PAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL
                        SCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS
                        HILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL
                        QIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN
                        TRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG
                        KAGLEECLVTEVQVVQKT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1137 bp
                        ATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAG
                        GAAGATCCAAACCCACCAATCACGAACCTAAGGATGAAAGCAAAGGCTCAGCAGTTGACC
                        TGGGACCTTAACAGAAATGTGACCGATATCGAGTGTGTTAAAGATGCCGACTATTCTATG
                        CCGGCAGTGAACAATAGCTATTGCCAGTTTGGAGCAATTTCCTTATGTGAAGTGACCAAC
                        TACACCGTCCGAGTGGCCAACCCACCATTCTCCACGTGGATCCTCTTCCCTGAGAACAGT
                        GGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGATTTCTTG
                        AGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTGTACTTG
                        AACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCTCAGGGA
                        ACACGTATCGGGTGTCGTTTCGATGACATCTCTCGACTCTCCAGCGGTTCTCAAAGTTCC
                        CACATCCTGGTGCGGGGCAGGAGCGCAGCCTTCGGTATCCCCTGCACAGATAAGTTTGTC
                        GTCTTTTCACAGATTGAGATATTAACTCCACCCAACATGACTGCAAAGTGTAATAAGACA
                        CATTCCTTTATGCACTGGAAAATGAGAAGTCATTTCAATCGCAAATTTCGCTATGAGCTT
                        CAGATACAAAAGAGAATGCAGCCTGTAATCACAGAACAGGTCAGAGACAGAACCTCCTTC
                        CAGCTACTCAATCCTGGAACGTACACAGTACAAATAAGAGCCCGGGAAAGAGTGTATGAA
                        TTCTTGAGCGCCTGGAGCACCCCCCAGCGCTTCGAGTGCGACCAGGAGGAGGGCGCAAAC
                        ACACGTGCCTGGCGGACGTCGCTGCTGATCGCGCTGGGGACGCTGCTGGCCCTGGTCTGT
                        GTCTTCGTGATCTGCAGAAGGTATCTGGTGATGCAGAGACTCTTTCCCCGCATCCCTCAC
                        ATGAAAGACCCCATCGGTGACAGCTTCCAAAACGACAAGCTGGTGGTCTGGGAGGCGGGC
                        AAAGCCGGCCTGGAGGAGTGTCTGGTGACTGAAGTACAGGTCGTGCAGAAAACTTGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0002115</id>
                <name>Cytokine receptor common subunit beta</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Shen Y, Baker E, Callen DF, Sutherland GR, Willson TA, Rakar S, Gough NM: Localization of the human GM-CSF receptor beta chain gene (CSF2RB) to chromosome 22q12.2--&gt;q13.1. Cytogenet Cell Genet. 1992;61(3):175-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1424804</references>
                <known-action>yes</known-action>
                <polypeptide id="P32927" source="Swiss-Prot">
                    <name>Cytokine receptor common subunit beta</name>
                    <general-function/>
                    <specific-function>High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor</specific-function>
                    <gene-name>CSF2RB</gene-name>
                    <locus>22q13.1</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>444-460</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.21</theoretical-pi>
                    <molecular-weight>97336.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2436</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CSF2RB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CSF2RB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M59941</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>487425</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P32927</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL3RB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD131 antigen</synonym>
                        <synonym>CDw131</synonym>
                        <synonym>Cytokine receptor common beta chain precursor</synonym>
                        <synonym>GM-CSF/IL-3/IL-5 receptor common beta-chain</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytokine receptor common beta chain
                        MVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVT
                        LIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLG
                        TRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQD
                        SWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPG
                        DEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSL
                        HTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWET
                        MKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTG
                        YNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPN
                        PSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIE
                        DPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSR
                        SLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQ
                        GAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFT
                        PNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSP
                        RNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPS
                        SPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2694 bp
                        ATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGC
                        CTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACC
                        AGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACC
                        CTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGAC
                        ATGCCCTGGTCAGCCTGCCCCCATCCCCGCTGCGTGCCCAGGAGATGTGTCATTCCCTGC
                        CAGAGTTTTGTCGTCACTGACGTTGACTACTTCTCATTCCAACCAGACAGGCCTCTGGGC
                        ACCCGGCTCACCGTCACTCTGACCCAGCATGTCCAGCCTCCTGAGCCCAGGGACCTGCAG
                        ATCAGCACCGACCAGGACCACTTCCTGCTGACCTGGAGTGTGGCCCTTGGGAGTCCCCAG
                        AGCCACTGGTTGTCCCCAGGGGATCTGGAGTTTGAGGTGGTCTACAAGCGGCTTCAGGAC
                        TCTTGGGAGGACGCAGCCATCCTCCTCTCCAACACCTCCCAGGCCACCCTGGGGCCAGAG
                        CACCTCATGCCCAGCAGCACCTACGTGGCCCGAGTACGGACCCGCCTGGCCCCAGGTTCT
                        CGGCTCTCAGGACGTCCCAGCAAGTGGAGCCCAGAGGTTTGCTGGGACTCCCAGCCAGGG
                        GATGAGGCCCAGCCCCAGAACCTGGAGTGCTTCTTTGACGGGGCCGCCGTGCTCAGCTGC
                        TCCTGGGAGGTGAGGAAGGAGGTGGCCAGCTCGGTCTCCTTTGGCCTATTCTACAAGCCC
                        AGCCCAGATGCAGGGGAGGAAGAGTGCTCCCCAGTGCTGAGGGAGGGGCTCGGCAGCCTC
                        CACACCAGGCACCACTGCCAGATTCCCGTGCCCGACCCCGCGACCCACGGCCAATACATC
                        GTCTCTGTTCAGCCAAGGAGGGCAGAGAAACACATAAAGAGCTCAGTGAACATCCAGATG
                        GCCCCTCCATCCCTCAACGTGACCAAGGATGGAGACAGCTACAGCCTGCGCTGGGAAACA
                        ATGAAAATGCGATACGAACACATAGACCACACATTTGAGATCCAGTACAGGAAAGACACG
                        GCCACGTGGAAGGACAGCAAGACCGAGACCCTCCAGAACGCCCACAGCATGGCCCTGCCA
                        GCCCTGGAGCCCTCCACCAGGTACTGGGCCAGGGTGAGGGTCAGGACCTCCCGCACCGGC
                        TACAACGGGATCTGGAGCGAGTGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTG
                        CCTATGTGGGTGCTGGCCCTCATCGTGATCTTCCTCACCATCGCTGTGCTCCTGGCCCTC
                        CGCTTCTGTGGCATCTACGGGTACAGGCTGCGCAGAAAGTGGGAGGAGAAGATCCCCAAC
                        CCCAGCAAGAGCCACCTGTTCCAGAACGGGAGCGCAGAGCTTTGGCCCCCAGGCAGCATG
                        TCGGCCTTCACTAGCGGGAGTCCCCCACACCAGGGGCCGTGGGGCAGCCGCTTCCCTGAG
                        CTGGAGGGGGTGTTCCCTGTAGGATTCGGGGACAGCGAGGTGTCACCTCTCACCATAGAG
                        GACCCCAAGCATGTCTGTGATCCACCATCTGGGCCTGACACGACTCCAGCTGCCTCAGAT
                        CTACCCACAGAGCAGCCCCCCAGCCCCCAGCCAGGCCCGCCTGCCGCCTCCCACACACCT
                        GAGAAACAGGCTTCCAGCTTTGACTTCAATGGGCCCTACCTGGGGCCGCCCCACAGCCGC
                        TCCCTACCTGACATCCTGGGCCAGCCGGAGCCCCCACAGGAGGGTGGGAGCCAGAAGTCC
                        CCACCTCCAGGGTCCCTGGAGTACCTGTGTCTGCCTGCTGGGGGGCAGGTGCAACTGGTC
                        CCTCTGGCCCAGGCGATGGGACCGGGACAGGCCGTGGAAGTGGAGAGAAGGCCGAGCCAG
                        GGGGCTGCAGGGAGTCCCTCCCTGGAGTCCGGGGGAGGCCCTGCCCCTCCTGCTCTTGGG
                        CCAAGGGTGGGAGGACAGGACCAAAAGGACAGCCCTGTGGCTATACCCATGAGCTCTGGG
                        GACACTGAGGACCCTGGAGTGGCCTCTGGTTATGTCTCCTCTGCAGACCTGGTATTCACC
                        CCAAACTCAGGGGCCTCGTCTGTCTCCCTAGTTCCCTCTCTGGGCCTCCCCTCAGACCAG
                        ACCCCCAGCTTATGTCCTGGGCTGGCCAGTGGACCCCCTGGAGCCCCAGGCCCTGTGAAG
                        TCAGGGTTTGAGGGCTATGTGGAGCTCCCTCCAATTGAGGGCCGGTCCCCCAGGTCACCA
                        AGGAACAATCCTGTCCCCCCTGAGGCCAAAAGCCCTGTCCTGAACCCAGGGGAACGCCCG
                        GCAGATGTGTCCCCAACATCCCCACAGCCCGAGGGCCTCCTTGTCCTGCAGCAAGTGGGC
                        GACTATTGCTTCCTCCCCGGCCTGGGGCCCGGCCCTCTCTCGCTCCGGAGTAAACCTTCT
                        TCCCCGGGACCCGGTCCTGAGATCAAGAACCTAGACCAGGCTTTTCAAGTCAAGAAGCCC
                        CCAGGCCAGGCTGTGCCCCAGGTGCCCGTCATTCAGCTCTTCAAAGCCCTGAAGCAGCAG
                        GACTACCTGTCTCTGCCCCCTTGGGAGGTCAACAAGCCTGGGGAGGTGTGTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>interleukin receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cytokine and chemokine mediated signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0002116</id>
                <name>Syndecan-2</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Modrowski D, Basle M, Lomri A, Marie PJ: Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem. 2000 Mar 31;275(13):9178-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10734053</references>
                <known-action>unknown</known-action>
                <polypeptide id="P34741" source="Swiss-Prot">
                    <name>Syndecan-2</name>
                    <general-function/>
                    <specific-function>Cell surface proteoglycan that bears heparan sulfate</specific-function>
                    <gene-name>SDC2</gene-name>
                    <locus>8q22-q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>145-169</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.48</theoretical-pi>
                    <molecular-weight>22174.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:10659</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SDC2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SDC2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J04621</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>386787</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P34741</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>SDC2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Fibroglycan</synonym>
                        <synonym>Heparan sulfate proteoglycan core protein</synonym>
                        <synonym>HSPG</synonym>
                        <synonym>SYND2</synonym>
                        <synonym>Syndecan-2 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Syndecan-2
                        MRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGAD
                        EDVESPELTTTRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERK
                        MDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYD
                        LGERKPSSAAYQKAPTKEFYA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;606 bp
                        ATGCGGCGCGCGTGGATCCTGCTCACCTTGGGCTTGGTGGCCTGCGTGTCGGCGGAGTCG
                        AGAGCAGAGCTGACATCTGATAAAGACATGTACCTTGACAACAGCTCCATTGAAGAAGCT
                        TCAGGAGTGTATCCTATTGATGACGATGACTACGCTTCTGCGTCTGGCTCGGGAGCTGAT
                        GAGGATGTAGAGAGTCCAGAGCTGACTACATCTCGACCACTTCCAAAGATACTGTTGACT
                        AGTGCTGCTCCAAAAGTGGAAACCACGACGCTGAATATACAGAACAAGATACCTGCTCAG
                        ACAAAGTCACCTGAAGAAACTGATAAAGAGAAAGTTCACCTCTCTGACTCAGAAAGGAAA
                        ATGGACCCAGCCGAAGAGGATACAAATGTGTATACTGAGAAACACTCAGACAGTCTGTTT
                        AAACGGACAGAAGTCCTAGCAGCTGTCACTGCTGGTGGAGTTATTGGCTTTCTCTTTGCA
                        ATTTTTCTTATCCTGCTGTTGGTGTATCGCATGAGAAAGAAGGATGAAGGAAGCTATGAC
                        CTTGGAGAACGCAAACCATCCAGTGCTGCTTATCAGAAGGCACCTACTAAGGAGTTTTAT
                        GCGTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01034</identifier>
                            <name>Syndecan</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cytoskeletal protein binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0002114</id>
                <name>Bone marrow proteoglycan</name>
                <organism>Human</organism>
                <actions/>
                <references># Menon K, Wu Y, Haas J, Sahu SK, Yang B, Zaheer A: Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice. Neurosci Res. 2007 Jun;58(2):156-63. Epub 2007 Feb 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17383764&#13;
                    # Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol. 2006 Mar;117(3):590-6. Epub 2006 Feb 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16522458&#13;
                    # Kang JH, Lee DH, Seo HM, Park JS, Nam KH, Shin SY, Park CS, Chung IY: Regulation of Functional Phenotypes of Cord-blood-derived Eosinophils by {gamma}-secretase Inhibitor. Am J Respir Cell Mol Biol. 2007 Jun 28;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17600316</references>
                <known-action>unknown</known-action>
                <polypeptide id="P13727" source="Swiss-Prot">
                    <name>Bone marrow proteoglycan</name>
                    <general-function/>
                    <specific-function>Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA</specific-function>
                    <gene-name>PRG2</gene-name>
                    <locus>11q12</locus>
                    <cellular-location>Note=The proform is secreted</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.64</theoretical-pi>
                    <molecular-weight>25232.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9362</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PRG2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PRG2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>Y00809</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>34476</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P13727</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PRG2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>BMPG</synonym>
                        <synonym>Bone-marrow proteoglycan precursor</synonym>
                        <synonym>Proteoglycan 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Bone-marrow proteoglycan
                        MKLPLLLALLFGAVSALHLRSETSTFETPLGAKTLPEDEETPEQEMEETPCRELEEEEEW
                        GSGSEDASKKDGAVESISVPDMVDKNLTCPEEEDTVKVVGIPGCQTCRYLLVRSLQTFSQ
                        AWFTCRRCYRGNLVSIHNFNINYRIQCSVSALNQGQVWIGGRITGSGRCRRFQWVDGSRW
                        NFAYWAAHQPWSRGGHCVALCTRGGYWRRAHCLRRLPFICSY</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;669 bp
                        ATGAAACTCCCCCTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGG
                        TCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAG
                        ACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGG
                        GGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCA
                        GATATGGTGGACAAAAACCTTACGTGTCCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC
                        ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGGTGAGAAGTCTTCAGACGTTTAGTCAA
                        GCTTGGTTTACTTGCCGGAGGTGCTACAGGGGCAACCTGGTTTCCATCCACAACTTCAAT
                        ATTAATTATCGAATCCAGTGTTCTGTCAGCGCGCTCAACCAGGGTCAAGTCTGGATTGGA
                        GGCAGGATCACAGGCTCGGGTCGCTGCAGACGCTTTCAGTGGGTTGACGGCAGCCGCTGG
                        AACTTTGCGTACTGGGCTGCTCACCAGCCCTGGTCCCGCGGTGGTCACTGCGTGGCCCTG
                        TGTACCCGAGGAGGCTACTGGCGTCGAGCCCACTGCCTCAGAAGACTTCCTTTCATCTGT
                        TCCTACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00059</identifier>
                            <name>Lectin_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>carbohydrate binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>sugar binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00021</drugbank-id>
        <drugbank-id>BIOD00039</drugbank-id>
        <drugbank-id>BTD00039</drugbank-id>
        <name>Secretin</name>
        <description>This drug is the synthetic form of natural secretin.  It is prepared using solid phase peptide synthesis.  Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small  intestine’s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.</description>
        <cas-number/>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references/>
        <synthesis-reference>Martin Bickel, Rolf Geiger, Richard Leeb, Walter Petri, "Secretin preparations with intensified and protracted action, process for their manufacture, their use as well as dihydroxybenzoyl-L-tyrosine." U.S. Patent US4302448, issued August, 1964.</synthesis-reference>
        <indication>For diagnosis of pancreatic exocrine dysfunction and gastrinoma</indication>
        <pharmacodynamics>Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.</pharmacodynamics>
        <mechanism-of-action>Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Secretin Inj 75unit/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00874000</dpd-id>
                <started-marketing-on>1990-12-31</started-marketing-on>
                <ended-marketing-on>1999-08-04</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>75 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>SecreFlo</name>
                <company>Repligen Corp</company>
            </international-brand>
            <international-brand>
                <name>Secremax</name>
                <company>Repligen Corp</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Secretin Inj 75unit/vial</name>
                <ingredients>Secretin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Professional Co.</name>
                <url/>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Ferring pharmaceuticals inc</manufacturer>
            <manufacturer generic="false">Chirhoclin inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Secretin-mannitol powder</description>
                <cost currency="USD">1.43</cost>
                <unit>g</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Diagnostic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>75 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="V04CK01">
                <level code="V">VARIOUS</level>
                <level code="V04">DIAGNOSTIC AGENTS</level>
                <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
                <level code="V04CK">Tests for pancreatic function</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB08897</drugbank-id>
                <name>Aclidinium</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00321</drugbank-id>
                <name>Amitriptyline</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00543</drugbank-id>
                <name>Amoxapine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00572</drugbank-id>
                <name>Atropine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00972</drugbank-id>
                <name>Azelastine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00245</drugbank-id>
                <name>Benzatropine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00835</drugbank-id>
                <name>Brompheniramine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00748</drugbank-id>
                <name>Carbinoxamine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00341</drugbank-id>
                <name>Cetirizine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01114</drugbank-id>
                <name>Chlorphenamine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00477</drugbank-id>
                <name>Chlorpromazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00283</drugbank-id>
                <name>Clemastine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00771</drugbank-id>
                <name>Clidinium</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01242</drugbank-id>
                <name>Clomipramine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00318</drugbank-id>
                <name>Codeine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01176</drugbank-id>
                <name>Cyclizine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00924</drugbank-id>
                <name>Cyclobenzaprine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00979</drugbank-id>
                <name>Cyclopentolate</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00434</drugbank-id>
                <name>Cyproheptadine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00496</drugbank-id>
                <name>Darifenacin</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01151</drugbank-id>
                <name>Desipramine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00967</drugbank-id>
                <name>Desloratadine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00405</drugbank-id>
                <name>Dexbrompheniramine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00804</drugbank-id>
                <name>Dicyclomine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01501</drugbank-id>
                <name>Difenoxin</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00985</drugbank-id>
                <name>Dimenhydrinate</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01075</drugbank-id>
                <name>Diphenhydramine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01081</drugbank-id>
                <name>Diphenoxylate</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00280</drugbank-id>
                <name>Disopyramide</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01142</drugbank-id>
                <name>Doxepin</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00366</drugbank-id>
                <name>Doxylamine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00450</drugbank-id>
                <name>Droperidol</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01288</drugbank-id>
                <name>Fenoterol</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06702</drugbank-id>
                <name>Fesoterodine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00950</drugbank-id>
                <name>Fexofenadine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01148</drugbank-id>
                <name>Flavoxate</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00875</drugbank-id>
                <name>Flupentixol</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00623</drugbank-id>
                <name>Fluphenazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00588</drugbank-id>
                <name>Fluticasone Propionate</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00986</drugbank-id>
                <name>Glycopyrrolate</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00502</drugbank-id>
                <name>Haloperidol</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00557</drugbank-id>
                <name>Hydroxyzine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00424</drugbank-id>
                <name>Hyoscyamine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00458</drugbank-id>
                <name>Imipramine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00332</drugbank-id>
                <name>Ipratropium bromide</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01247</drugbank-id>
                <name>Isocarboxazid</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01106</drugbank-id>
                <name>Levocabastine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06282</drugbank-id>
                <name>Levocetirizine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00455</drugbank-id>
                <name>Loratadine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00408</drugbank-id>
                <name>Loxapine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00934</drugbank-id>
                <name>Maprotiline</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00737</drugbank-id>
                <name>Meclizine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04843</drugbank-id>
                <name>Mepenzolate</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01403</drugbank-id>
                <name>Methotrimeprazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01171</drugbank-id>
                <name>Moclobemide</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00540</drugbank-id>
                <name>Nortriptyline</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00334</drugbank-id>
                <name>Olanzapine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00768</drugbank-id>
                <name>Olopatadine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01173</drugbank-id>
                <name>Orphenadrine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01062</drugbank-id>
                <name>Oxybutynin</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00850</drugbank-id>
                <name>Perphenazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00780</drugbank-id>
                <name>Phenelzine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01100</drugbank-id>
                <name>Pimozide</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06153</drugbank-id>
                <name>Pizotifen</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00433</drugbank-id>
                <name>Prochlorperazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00387</drugbank-id>
                <name>Procyclidine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00420</drugbank-id>
                <name>Promazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01069</drugbank-id>
                <name>Promethazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00782</drugbank-id>
                <name>Propantheline</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00344</drugbank-id>
                <name>Protriptyline</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01224</drugbank-id>
                <name>Quetiapine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00747</drugbank-id>
                <name>Scopolamine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01591</drugbank-id>
                <name>Solifenacin</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00679</drugbank-id>
                <name>Thioridazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01623</drugbank-id>
                <name>Thiothixene</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01409</drugbank-id>
                <name>Tiotropium</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01036</drugbank-id>
                <name>Tolterodine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00752</drugbank-id>
                <name>Tranylcypromine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00831</drugbank-id>
                <name>Trifluoperazine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00376</drugbank-id>
                <name>Trihexyphenidyl</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00662</drugbank-id>
                <name>Trimethobenzamide</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00726</drugbank-id>
                <name>Trimipramine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00427</drugbank-id>
                <name>Triprolidine</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00209</drugbank-id>
                <name>Trospium</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09076</drugbank-id>
                <name>Umeclidinium</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01624</drugbank-id>
                <name>Zuclopenthixol</name>
                <description>Anticholinergic Agents may diminish the therapeutic effect of Secretin.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00021 sequence
                HSDGTFTSELSRLRDSARLQRLLQGLV</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.463</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>9.45</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>3056.4000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C130H219N43O42</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>2067</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164760844</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Secretin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/secretin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/human_secretin.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000318</id>
                <name>Secretin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P47872" source="Swiss-Prot">
                    <name>Secretin receptor</name>
                    <general-function>Involved in G-protein coupled receptor activity</general-function>
                    <specific-function>This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase</specific-function>
                    <gene-name>SCTR</gene-name>
                    <locus>2q14.1</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>144-167
                        175-194
                        217-240
                        255-276
                        295-317
                        344-362
                        370-392</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.77</theoretical-pi>
                    <molecular-weight>50207.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:10608</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SCTR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SCTR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U20178</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>662796</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>252</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>29</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P47872</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>SCTR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>SCT-R</synonym>
                        <synonym>Secretin receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Secretin receptor precursor
                        MRPHLSPPLQQLLLPVLLACAAHSTGALPRLCDVLQVLWEEQDQCLQELSREQTGDLGTE
                        QPVPGCEGMWDNISCWPSSVPGRMVEVECPRFLRMLTSRNGSLFRNCTQDGWSETFPRPN
                        LACGVNVNDSSNEKRHSYLLKLKVMYTVGYSSSLVMLLVALGILCAFRRLHCTRNYIHMH
                        LFVSFILRALSNFIKDAVLFSSDDVTYCDAHRAGCKLVMVLFQYCIMANYSWLLVEGLYL
                        HTLLAISFFSERKYLQGFVAFGWGSPAIFVALWAIARHFLEDVGCWDINANASIWWIIRG
                        PVILSILINFILFINILRILMRKLRTQETRGNEVSHYKRLARSTLLLIPLFGIHYIVFAF
                        SPEDAMEIQLFFELALGSFQGLVVAVLYCFLNGEVQLEVQKKWQQWHLREFPLHPVASFS
                        NSTKASHLEQSQGTCRTSII</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1323 bp
                        ATGCGTCCCCACCTGTCGCCGCCGCTGCAGCAGCTACTACTGCCGGTGCTGCTCGCCTGC
                        GCCGCGCACTCGACTGGAGCCCTTCCCCGACTATGTGACGTGCTACAAGTGCTGTGGGAA
                        GAGCAAGACCAGTGCCTGCAGGAACTCTCCAGAGAGCAGACAGGAGACCTGGGCACGGAG
                        CAGCCAGTGCCAGGTTGTGAGGGGATGTGGGACAACATAAGCTGCTGGCCCTCTTCTGTG
                        CCGGGCCGGATGGTGGAGGTGGAATGCCCGAGATTCCTCCGGATGCTCACCAGCAGAAAT
                        GGTTCCTTGTTCCGAAACTGCACACAGGATGGCTGGTCAGAAACCTTCCCCAGGCCTAAT
                        CTGGCCTGTGCGGTTAATGTGAACGACTCTTCCAACGAGAAGCGGCACTCCTACCTGCTG
                        AAGCTGAAAGTCATGTACACCGTGGGCTACAGCTCCTCCCTGGTCATGCTCCTGGTCGCC
                        CTTGGCATCCTCTGTGCTTTCCGGAGGCTCCACTGCACTCGCAACTACATCCACATGCAC
                        CTGTTCGTGTCCTTCATCCTTCGTGCCCTGTCCAACTTCATCAAGGACGCCGTGCTCTTC
                        TCCTCAGATGATGTCACCTACTGCGATGCCCACAGGGCGGGCTGCAAGCTGGTCATGGTG
                        CTGTTCCAGTACTGCATCATGGCCAACTACTCCTGGCTGCTGGTGGAAGGCCTCTACCTT
                        CACACACTCCTCGCCATCTCCTTCTTCTCTGAAAGAAAGTACCTCCAGGGATTTGTGGCA
                        TTCGGATGGGGTTCTCCAGCCATTTTTGTTGCTTTGTGGGCTATTGCCAGACACTTTCTG
                        GAAGATGTTGGGTGCTGGGACATCAATGCCAACGCATCCATCTGGTGGATCATTCGTGGT
                        CCTGTGATCCTCTCCATCCTGATTAATTTCATCCTTTTCATAAACATTCTAAGAATCCTG
                        ATGAGAAAACTTAGAACCCAAGAAACAAGAGGAAATGAAGTCAGCCATTATAAGCGCCTG
                        GCCAGGTCCACTCTCCTGCTGATCCCCCTCTTTGGCATCCACTACATCGTCTTCGCCTTC
                        TCCCCAGAGGACGCTATGGAGATCCAGCTGTTTTTTGAACTAGCCCTTGCGTCATTCCAG
                        GGACTGGTGGTGGCCGTCCTCTACTGCTTCCTCAACGGGGAGGTGCAGCTGGAGGTTCAG
                        AAGAAGTGGCAGCAATGGCACCTCCGTGAGTTCCCACTGCACCCCGTGGCCTCCTTCAGC
                        AACAGCACCAAGGCCAGCCACTTGGAGCAGAGCCAGGGCACCTGCAGGACCAGCATCATC
                        TGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00002</identifier>
                            <name>7tm_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02793</identifier>
                            <name>HRM</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>secretin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasoactive intestinal polypeptide receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2010-09-29">
        <drugbank-id primary="true">DB00022</drugbank-id>
        <drugbank-id>BIOD00048</drugbank-id>
        <drugbank-id>BTD00048</drugbank-id>
        <name>Peginterferon alfa-2b</name>
        <description>Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of &lt;i&gt;Escherichia coli&lt;/i&gt; bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.</description>
        <cas-number>99210-65-8</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.</indication>
        <pharmacodynamics>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacodynamics>
        <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption>Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t&amp;frac12; k&lt;sub&gt;a&lt;/sub&gt;) was 4.6 hours.&#13;
        </absorption>
        <half-life>The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.&#13;
&#13;
        </half-life>
        <protein-binding/>
        <route-of-elimination>Renal elimination accounts for 30% of the clearance.</route-of-elimination>
        <volume-of-distribution/>
        <clearance>* Oral cl=22 mL/hr∙kg [patients with HCV infection]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246026</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>50 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246030</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>150 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246027</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on>2013-01-23</ended-marketing-on>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>80 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246028</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on>2013-01-23</ended-marketing-on>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>100 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246029</dpd-id>
                <started-marketing-on>2002-08-13</started-marketing-on>
                <ended-marketing-on>2013-01-23</ended-marketing-on>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>120 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02254581</dpd-id>
                <started-marketing-on>2004-09-17</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>80 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02254603</dpd-id>
                <started-marketing-on>2004-09-17</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>100 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02254638</dpd-id>
                <started-marketing-on>2004-09-17</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>120 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegetron</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02254646</dpd-id>
                <started-marketing-on>2004-09-17</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>150 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pegintron</name>
                <ndc-id>0085-1297_b5ad295a-003e-438a-9932-d789ece6fe7a</ndc-id>
                <ndc-product-code>0085-1297</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2001-01-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>120 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103949</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pegintron</name>
                <ndc-id>0085-1316_b5ad295a-003e-438a-9932-d789ece6fe7a</ndc-id>
                <ndc-product-code>0085-1316</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2001-01-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>80 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103949</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pegintron</name>
                <ndc-id>0085-1323_b5ad295a-003e-438a-9932-d789ece6fe7a</ndc-id>
                <ndc-product-code>0085-1323</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2001-01-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>50 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103949</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Pegintron</name>
                <ndc-id>0085-1370_b5ad295a-003e-438a-9932-d789ece6fe7a</ndc-id>
                <ndc-product-code>0085-1370</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2001-01-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>150 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103949</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Unitron Peg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242966</dpd-id>
                <started-marketing-on>2001-03-27</started-marketing-on>
                <ended-marketing-on>2012-02-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>74 mcg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Unitron Peg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242967</dpd-id>
                <started-marketing-on>2001-03-27</started-marketing-on>
                <ended-marketing-on>2012-02-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>118.4 mcg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Unitron Peg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242968</dpd-id>
                <started-marketing-on>2001-03-27</started-marketing-on>
                <ended-marketing-on>2012-02-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>177.6 mcg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Unitron Peg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242969</dpd-id>
                <started-marketing-on>2001-03-27</started-marketing-on>
                <ended-marketing-on>2012-02-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>222 mcg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Victrelis Triple</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02371448</dpd-id>
                <started-marketing-on>2011-08-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>80 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Victrelis Triple</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02371456</dpd-id>
                <started-marketing-on>2011-08-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>100 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Victrelis Triple</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02371464</dpd-id>
                <started-marketing-on>2011-08-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>120 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Victrelis Triple</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02371472</dpd-id>
                <started-marketing-on>2011-08-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>capsule; powder for solution</dosage-form>
                <strength>150 mcg</strength>
                <route>oral; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>PEG-Intron</name>
                <company>Schering Corp</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Pegintron</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Pegintron</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Pegintron</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Pegintron</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Victrelis Triple</name>
                <ingredients>Peginterferon alfa-2b + Boceprevir + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Victrelis Triple</name>
                <ingredients>Peginterferon alfa-2b + Boceprevir + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Victrelis Triple</name>
                <ingredients>Peginterferon alfa-2b + Boceprevir + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Victrelis Triple</name>
                <ingredients>Peginterferon alfa-2b + Boceprevir + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Unitron Peg</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Unitron Peg</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Unitron Peg</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Unitron Peg</name>
                <ingredients>Peginterferon alfa-2b</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
            <mixture>
                <name>Pegetron</name>
                <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Schering Corp.</name>
                <url>http://www.schering.de</url>
            </packager>
            <packager>
                <name>Schering-Plough Inc.</name>
                <url>http://www.schering-plough.ca</url>
            </packager>
            <packager>
                <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
                <url>http://www.vetter-pharma.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Peg-Intron 50 mcg kit</description>
                <cost currency="USD">553.4</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron redipen 50 mcg</description>
                <cost currency="USD">553.4</cost>
                <unit>redipen</unit>
            </price>
            <price>
                <description>Peg-Intron redipen 80 mcg</description>
                <cost currency="USD">581.02</cost>
                <unit>redipen</unit>
            </price>
            <price>
                <description>Peg-Intron 50 mcg/0.5ml Kit</description>
                <cost currency="USD">607.19</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron 80 mcg Kit</description>
                <cost currency="USD">609.26</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron redipen 120 mcg</description>
                <cost currency="USD">610.09</cost>
                <unit>redipen</unit>
            </price>
            <price>
                <description>Peg-Intron Redipen 80 mcg/0.5ml Kit</description>
                <cost currency="USD">637.49</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron 120 mcg Kit</description>
                <cost currency="USD">639.74</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron redipen 150 mcg 4pk</description>
                <cost currency="USD">640.6</cost>
                <unit>redipen</unit>
            </price>
            <price>
                <description>Peg-Intron redipen 150 mcg</description>
                <cost currency="USD">640.61</cost>
                <unit>redipen</unit>
            </price>
            <price>
                <description>Peg-Intron Redipen 120 mcg/0.5ml Kit</description>
                <cost currency="USD">669.39</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron 150 mcg Kit</description>
                <cost currency="USD">671.74</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron Redipen 150 mcg/0.5ml Kit</description>
                <cost currency="USD">702.87</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box</description>
                <cost currency="USD">2428.8</cost>
                <unit>kit</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Capsule; powder for solution</form>
                <route>oral; subcutaneous</route>
                <strength>100 mcg</strength>
            </dosage>
            <dosage>
                <form>Capsule; powder for solution</form>
                <route>oral; subcutaneous</route>
                <strength>120 mcg</strength>
            </dosage>
            <dosage>
                <form>Capsule; powder for solution</form>
                <route>oral; subcutaneous</route>
                <strength>150 mcg</strength>
            </dosage>
            <dosage>
                <form>Capsule; powder for solution</form>
                <route>oral; subcutaneous</route>
                <strength>50 mcg</strength>
            </dosage>
            <dosage>
                <form>Capsule; powder for solution</form>
                <route>oral; subcutaneous</route>
                <strength>80 mcg</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>subcutaneous</route>
                <strength>120 ug/.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>subcutaneous</route>
                <strength>150 ug/.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>subcutaneous</route>
                <strength>50 ug/.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>subcutaneous</route>
                <strength>80 ug/.5mL</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>118.4 mcg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>177.6 mcg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>222 mcg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>74 mcg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L03AB10">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AB">Interferons</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>08:18.20</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1341567</number>
                <country>Canada</country>
                <approved>2008-02-19</approved>
                <expires>2025-02-19</expires>
            </patent>
            <patent>
                <number>2329474</number>
                <country>Canada</country>
                <approved>0002-02-26</approved>
                <expires>2016-10-31</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00041</drugbank-id>
                <name>Aldesleukin</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00969</drugbank-id>
                <name>Alosetron</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01223</drugbank-id>
                <name>Aminophylline</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00321</drugbank-id>
                <name>Amitriptyline</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00543</drugbank-id>
                <name>Amoxapine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01238</drugbank-id>
                <name>Aripiprazole</name>
                <description>CYP2D6 Inhibitors (Weak) may increase the serum concentration of Aripiprazole.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06216</drugbank-id>
                <name>Asenapine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00289</drugbank-id>
                <name>Atomoxetine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00195</drugbank-id>
                <name>Betaxolol</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09128</drugbank-id>
                <name>Brexpiprazole</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01558</drugbank-id>
                <name>Bromazepam</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00241</drugbank-id>
                <name>Butalbital</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00201</drugbank-id>
                <name>Caffeine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01197</drugbank-id>
                <name>Captopril</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01136</drugbank-id>
                <name>Carvedilol</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00608</drugbank-id>
                <name>Chloroquine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01114</drugbank-id>
                <name>Chlorphenamine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00477</drugbank-id>
                <name>Chlorpromazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01242</drugbank-id>
                <name>Clomipramine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01242</drugbank-id>
                <name>Clomipramine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00318</drugbank-id>
                <name>Codeine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00924</drugbank-id>
                <name>Cyclobenzaprine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00851</drugbank-id>
                <name>Dacarbazine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01151</drugbank-id>
                <name>Desipramine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00514</drugbank-id>
                <name>Dextromethorphan</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01551</drugbank-id>
                <name>Dihydrocodeine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01142</drugbank-id>
                <name>Doxepin</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00997</drugbank-id>
                <name>Doxorubicin</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00476</drugbank-id>
                <name>Duloxetine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09039</drugbank-id>
                <name>Eliglustat</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01195</drugbank-id>
                <name>Flecainide</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00472</drugbank-id>
                <name>Fluoxetine</name>
                <description>Peginterferon alfa-2b may decrease the serum concentration of Fluoxetine.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00623</drugbank-id>
                <name>Fluphenazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00499</drugbank-id>
                <name>Flutamide</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00317</drugbank-id>
                <name>Gefitinib</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00502</drugbank-id>
                <name>Haloperidol</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04946</drugbank-id>
                <name>Iloperidone</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00458</drugbank-id>
                <name>Imipramine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06706</drugbank-id>
                <name>Isometheptene</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00281</drugbank-id>
                <name>Lidocaine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00934</drugbank-id>
                <name>Maprotiline</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04817</drugbank-id>
                <name>Metamizole</name>
                <description>May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00333</drugbank-id>
                <name>Methadone</name>
                <description>Interferons (Alfa) may increase the serum concentration of Methadone.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01577</drugbank-id>
                <name>Methamphetamine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00264</drugbank-id>
                <name>Metoprolol</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00379</drugbank-id>
                <name>Mexiletine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00379</drugbank-id>
                <name>Mexiletine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00370</drugbank-id>
                <name>Mirtazapine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00370</drugbank-id>
                <name>Mirtazapine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01149</drugbank-id>
                <name>Nefazodone</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00540</drugbank-id>
                <name>Nortriptyline</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00334</drugbank-id>
                <name>Olanzapine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00715</drugbank-id>
                <name>Paroxetine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00850</drugbank-id>
                <name>Perphenazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01100</drugbank-id>
                <name>Pimozide</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01100</drugbank-id>
                <name>Pimozide</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01621</drugbank-id>
                <name>Pipotiazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08910</drugbank-id>
                <name>Pomalidomide</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01087</drugbank-id>
                <name>Primaquine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01035</drugbank-id>
                <name>Procainamide</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00420</drugbank-id>
                <name>Promazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01069</drugbank-id>
                <name>Promethazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00571</drugbank-id>
                <name>Propranolol</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00571</drugbank-id>
                <name>Propranolol</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00344</drugbank-id>
                <name>Protriptyline</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00980</drugbank-id>
                <name>Ramelteon</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01367</drugbank-id>
                <name>Rasagiline</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00811</drugbank-id>
                <name>Ribavirin</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00268</drugbank-id>
                <name>Ropinirole</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00296</drugbank-id>
                <name>Ropivacaine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09118</drugbank-id>
                <name>Stiripentol</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00675</drugbank-id>
                <name>Tamoxifen</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09071</drugbank-id>
                <name>Tasimelteon</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01265</drugbank-id>
                <name>Telbivudine</name>
                <description>Peginterferon alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04844</drugbank-id>
                <name>Tetrabenazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00277</drugbank-id>
                <name>Theophylline</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00679</drugbank-id>
                <name>Thioridazine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01623</drugbank-id>
                <name>Thiothixene</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00373</drugbank-id>
                <name>Timolol</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00697</drugbank-id>
                <name>Tizanidine</name>
                <description>CYP1A2 Inhibitors (Weak) may increase the serum concentration of Tizanidine.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01036</drugbank-id>
                <name>Tolterodine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00831</drugbank-id>
                <name>Trifluoperazine</name>
                <description>May increase the serum concentration of CYP1A2 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00726</drugbank-id>
                <name>Trimipramine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00285</drugbank-id>
                <name>Venlafaxine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09068</drugbank-id>
                <name>Vortioxetine</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00495</drugbank-id>
                <name>Zidovudine</name>
                <description>Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01624</drugbank-id>
                <name>Zuclopenthixol</name>
                <description>May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00022 sequence
                CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
                QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
                KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C</value>
                <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.99</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>31000.0000</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12036</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0085-1323-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164784024</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01563</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Peginterferon_alfa-2b</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/peginterferon.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/peginterferon-alfa-2b.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000661</id>
                <name>Interferon alpha/beta receptor 1</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
                    # Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815
                    # Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16953837
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P17181" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 1</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves</specific-function>
                    <gene-name>IFNAR1</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>437-457</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.56</theoretical-pi>
                    <molecular-weight>63526.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5432</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03171</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>306914</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P17181</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>Interferon-alpha/beta receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor alpha chain precursor
                        MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
                        FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
                        TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
                        ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
                        NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
                        GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
                        VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
                        FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
                        YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
                        EDESESKTSEELQQDFV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1674 bp
                        ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG
                        TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
                        ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
                        TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
                        AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
                        AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
                        ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
                        GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
                        TTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
                        GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
                        AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
                        ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
                        AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
                        TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
                        CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
                        GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
                        GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
                        TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
                        GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
                        GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
                        GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
                        TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
                        GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
                        TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
                        TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
                        AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
                        GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
                        GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000385</id>
                <name>Interferon alpha/beta receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
                    # Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717
                    # Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815
                    # Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16953837
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P48551" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 2</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity</specific-function>
                    <gene-name>IFNAR2</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>244-264</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.11</theoretical-pi>
                    <molecular-weight>57759.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5433</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L42243</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>995300</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P48551</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>IFN-R</synonym>
                        <synonym>Interferon alpha/beta receptor 2</synonym>
                        <synonym>Interferon-alpha/beta receptor beta chain precursor</synonym>
                        <synonym>Type I interferon receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor beta chain precursor
                        MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
                        IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
                        SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
                        HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
                        SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
                        MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
                        DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
                        ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
                        FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
                        ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
                        TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
                        ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
                        GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
                        AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
                        AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
                        ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
                        GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
                        CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
                        ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
                        ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
                        TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
                        ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
                        AATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT
                        ATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT
                        GAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT
                        GGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA
                        GACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG
                        CCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT
                        CCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA
                        ATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT
                        GACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG
                        GATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC
                        TTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC
                        ACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-11-13">
        <drugbank-id primary="true">DB00023</drugbank-id>
        <drugbank-id>BIOD00011</drugbank-id>
        <drugbank-id>BTD00011</drugbank-id>
        <name>Asparaginase</name>
        <description>L-asparagine amidohydrolase from E. coli</description>
        <cas-number>9015-68-3</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R: Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007 Jun 7;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17554375&#13;
            # http://www.google.com/patents/EP2046369A2</general-references>
        <synthesis-reference>Masao Nambu, "Process for producing immobilized L-asparaginase preparations for the therapy of leukemia." U.S. Patent US4617271, issued January, 1977.</synthesis-reference>
        <indication>For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma</indication>
        <pharmacodynamics>In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.</pharmacodynamics>
        <mechanism-of-action>Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>8-30 hrs</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Asparaginase (E. coli)</synonym>
            <synonym language="" coder="">L-asparagine amidohydrolase</synonym>
            <synonym language="" coder="">Putative L-asparaginase precursor</synonym>
        </synonyms>
        <products>
            <product>
                <name>Erwinase</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02237815</dpd-id>
                <started-marketing-on>2009-07-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>10000 unit</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kidrolase</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01926438</dpd-id>
                <started-marketing-on>1974-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>10000 unit</strength>
                <route>intramuscular; intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Elspar</name>
                <company>Merck &amp; Co. Inc</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Kidrolase</name>
                <ingredients>Asparaginase</ingredients>
            </mixture>
            <mixture>
                <name>Erwinase</name>
                <ingredients>Asparaginase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Lundbeck Inc.</name>
                <url>http://www.lundbeckinc.com</url>
            </packager>
            <packager>
                <name>Merck &amp; Co.</name>
                <url>http://www.merck.com</url>
            </packager>
            <packager>
                <name>Prescript Pharmaceuticals</name>
                <url>http://www.prescript.net</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Elspar 10000 unit vial</description>
                <cost currency="USD">74.6</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antineoplastic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; intravenous; subcutaneous</route>
                <strength>10000 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; intravenous</route>
                <strength>10000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L01XX02">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L01">ANTINEOPLASTIC AGENTS</level>
                <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
                <level code="L01XX">Other antineoplastic agents</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>10:00.00</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt; Elspar Sequence
                QMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDE
                THELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMER
                VSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTG
                GMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAE
                ACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTV
                ATQ</sequence>
            <sequence format="FASTA">&gt;sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2
                MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNA
                VPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYF
                LDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGR
                DVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVY
                NYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGAT
                TQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>0.059</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>4.67</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>31731.9000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1377H2208N382O442S17</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>2433</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>U00096</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA448492</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P37595</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Asparaginase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/asparaginase.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/asparaginase.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0004798</id>
                <name>L-asparagine</name>
                <organism>Human</organism>
                <actions>
                    <action>other/unknown</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17264295&#13;
                    # Wenner KA, Vieira Pinheiro JP, Escherich G, Wessalowski R, Jorch N, Wolff J, Stehn M, Kohlschutter A, Boos J, Janka-Schaub GE: Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005 Nov-Dec;217(6):321-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16307417&#13;
                    # Appel IM, Pinheiro JP, den Boer ML, Lanvers C, Reniers NC, Boos J, Pieters R: Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003 Nov;17(11):2254-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14523472</references>
                <known-action>yes</known-action>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-10-14">
        <drugbank-id primary="true">DB00024</drugbank-id>
        <drugbank-id>BIOD00020</drugbank-id>
        <drugbank-id>BTD00020</drugbank-id>
        <name>Thyrotropin Alfa</name>
        <description>Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit is nearly identical to that of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The alpha subunit is thought to be the effector region responsible for stimulation of adenylate cyclase (involved the generation of cAMP). The beta subunit (TSHB) is unique to TSH, and therefore determines its receptor specificity. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.</description>
        <cas-number>9002-71-5</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Lexicomp&#13;
            #Product label </general-references>
        <synthesis-reference>19366632</synthesis-reference>
        <indication>For detection of residueal or recurrent thyroid cancer</indication>
        <pharmacodynamics>Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification. Thyrogen is an exogenous source of human TSH that offers an additional diagnostic tool in the follow-up of patients with a history of well-differentiated thyroid cancer.</pharmacodynamics>
        <mechanism-of-action>Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.</mechanism-of-action>
        <toxicity>No difference in efficacy and toxicity between adult and geriatric patients. No studies in lactating women, pregnant women and pediatrics. Cautionary administration is advised. </toxicity>
        <metabolism/>
        <absorption>Time to peak: Median: 10 hours (range: 3-24 hours)&#13;
            After a single intramuscular injection of 0.9 mg of thyrotropin alfa: Cmax= 116+38mU/L, Tmax=22+8.5 hours. AUC=5088+1728 mU·hr/L.</absorption>
        <half-life>25 ± 10 hours</half-life>
        <protein-binding/>
        <route-of-elimination>kidney and liver</route-of-elimination>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">rTSH</synonym>
            <synonym language="" coder="">Thyroid stimulating hormone</synonym>
            <synonym language="" coder="">Thyrotrophin-alfa</synonym>
            <synonym language="" coder="">Thyrotrophin-alpha</synonym>
            <synonym language="" coder="">Thyrotropin</synonym>
            <synonym language="" coder="">Thyrotropin-a</synonym>
            <synonym language="" coder="">Thyrotropin-alpha</synonym>
            <synonym language="" coder="">Thytrophin</synonym>
            <synonym language="" coder="">TSH</synonym>
        </synonyms>
        <products>
            <product>
                <name>Thyrogen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246016</dpd-id>
                <started-marketing-on>2002-08-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.9 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Thyrogen</name>
                <ndc-id>58468-0030_b9da8016-40ba-4e81-85c8-911862339cee</ndc-id>
                <ndc-product-code>58468-0030</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1998-11-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, for solution</dosage-form>
                <strength>.9 mg/mL</strength>
                <route>intramuscular</route>
                <fda-application-number>NDA020898</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Thyrogen</name>
                <ingredients>Thyrotropin Alfa</ingredients>
            </mixture>
            <mixture>
                <name>Thyrogen</name>
                <ingredients>Thyrotropin Alfa</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Genzyme Inc.</name>
                <url>http://www.genzyme.ca</url>
            </packager>
            <packager>
                <name>Organon Pharmaceuticals</name>
                <url>http://www.organonshop.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Sanofi aventis us llc</manufacturer>
            <manufacturer generic="false">Genzyme corp</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Thyrogen 1.1 mg vial</description>
                <cost currency="USD">1196.4</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Diagnostic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, powder, for solution</form>
                <route>intramuscular</route>
                <strength>.9 mg/mL</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular</route>
                <strength>0.9 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="H01AB01">
                <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
                <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
                <level code="H01A">ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</level>
                <level code="H01AB">Thyrotropin</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>36:60.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>5840566</number>
                <country>United States</country>
                <approved>1995-11-24</approved>
                <expires>2015-11-24</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;Alpha chain
                APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
                VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
            <sequence format="FASTA">&gt;Beta chain
                FCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYR
                TVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>55 °C</value>
                <source/>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.330</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.50</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>22672.9000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C975H1513N267O304S26</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12790</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>58468-1849-4</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M16647</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164746560</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01225</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/thyrotropin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/thyrotropin-alfa.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000490</id>
                <name>Thyrotropin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Szkudlinski MW: Recombinant human thyrotropins of the twenty-first century. Expert Opin Pharmacother. 2004 Dec;5(12):2435-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15571461&#13;
                    # Conway GS: Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf). 1996 Dec;45(6):657-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9039330&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P16473" source="Swiss-Prot">
                    <name>Thyrotropin receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (GPA2+GPB5)</specific-function>
                    <gene-name>TSHR</gene-name>
                    <locus>14q31</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>414-441
                        451-473
                        495-517
                        538-560
                        581-602
                        626-649
                        661-682</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.98</theoretical-pi>
                    <molecular-weight>86831.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:12373</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>TSHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>TSHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M73747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>903760</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>255</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>30</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P16473</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TSHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Thyroid-stimulating hormone receptor</synonym>
                        <synonym>Thyrotropin receptor precursor</synonym>
                        <synonym>TSH-R</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Thyrotropin receptor precursor
                        MRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI
                        ETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD
                        ALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL
                        TLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA
                        LPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM
                        CNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE
                        DEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIV
                        VWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSE
                        YYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACA
                        IMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCC
                        YVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSK
                        ILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQ
                        VQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2292 bp
                        ATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGC
                        GGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACC
                        TGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATT
                        GAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGA
                        ATCTACGTATCTATAGATGTGACTCTGCAGCAGCTGGAATCACACTCCTTCTACAATTTG
                        AGTAAAGTGACTCACATAGAAATTCGGAATACCAGGAACTTAACTTACATAGACCCTGAT
                        GCCCTCAAAGAGCTCCCCCTCCTAAAGTCCTTGGCATTTTCAAACACTGGACTTAAAATG
                        TTCCCTGACCTGACCAAAGTTTATTCCACTGATATATTCTTTATACTTGAAATTACAGAC
                        AACCCTTACATGACGTCAATCCCTGTGAATGCTTTTCAGGGACTATGCAATGAAACCTTG
                        ACACTGAAGCTGTACAACAATGGCTTTACTTCAGTCCAAGGATATGATTTCTTTGGGACA
                        AAGCTGGATGCTGTTTACCTAAACAAGAATAAATACCTGACAGTTATTGACAAAGATGCA
                        TTTGGAGGAGTATACAGTGGACCAAGCTTGCTGGACGTGTCTCAAACCAGTGTCACTGCC
                        CTTCCATCCAAAGGCCTGGAGCACCTGAAGGAACTGATAGCAAGAAACAGCTGGACTCTT
                        AAGAAACTTGCACTTTCCTTGAGTTTCCTTCACCTCACACGGGCTGACCTTTCTTACCCA
                        AGCCACTGCTGTGCTTTTAAGAATCAGAAGAAAATCAGAGGAATCCTTGAGTCCTTGATG
                        TGTAATGAGAGCAGTATCGAGACGTTGCGCCAGAGAAAATCTGTGAATGCCTTGAATAGC
                        CCCCTCCACCAGGAATATGAAGAGAATCTGGGTGACAGCATTGTTGGGTACAAGGAAAAG
                        TCCAAGTTCCAGGATACTCATAACAACGCTCATTATTACGTCTTCTTTGAAGAACAAGAG
                        GATGAGATCATTGGTTTTGGCCAGGAGCTCAAAAACCCCCAGGAAGAGACTCTACAAGCT
                        TTTGACAGCCATTATGACTACACCATATGTGGGGACAGTGAAGACATGGTGTGTACCCCC
                        AAGTCCGATGAGTTCAACCCGTGTGAAGACATAATGGGCTACAAGTTCCTGAGAATTGTG
                        GTGTGGTTCGTTAGTCTGCTGGCTCTCCTGGGCAATGTCTTTGTCCTGCTTATTCTCCTC
                        ACCAGCCACTACAAACTGAACGTCCCCCGCTTTCTCATGTGCAACCTGGCCTTTGCGGAT
                        TTCTGCATGGGGATGTACCTGCTCCTCATCGCCTCTGTAGACCTCTACACTCACTCTGAG
                        TACTACAACCATGCCATCGACTGGCAGACAGGCCCTGGGTGCAACACGGCTGGTTTCTTC
                        ACTGTCTTTGCAAGCGAGTTATCGGTGTATACGCTGACGGTCATCACCCTGGAGCGCTGG
                        TATGCCATCACCTTCGCCATGGCCCTGGACCGGAAGATCCGCCTCAGGCACGCATGTGCC
                        ATCATGGTTGGGGGCTGGGTTTGCTGCTTCCTTCTCGCCCTGCTTCCTTTGGTGGGAATA
                        AGTAGCTATGCCAAAGTCAGTATCTGCCTGCCCATGGACACCGAGACCCCTCTTGCTCTG
                        GCATATATTGTTTTTGTTCTGACGCTCAACATAGTTGCCTTCGTCATCGTCTGCTGCTGT
                        TATGTGAAGATCTACATCACAGTCCGAAATCCGCACAACCCAGGGGACAAAGATACCAAA
                        ATTGCCAAGAGGATGGCTGTGTTGATCTTCACCGACTTCACGTGCATGGCCCCAATCTCA
                        TTCTATGCTGTGTCAGCAATTCTGAACAAGCCTCTCATCACTGTTAGCAACTCCAAAATC
                        TTGCTGGTACTCTTCTATCCAATTAACTCCTGTGCCAATCCATTCCTCTATGCTATTTTC
                        ACCAAGGCCTTCCAGAGGGATGTGTTCATCCTACTCAGCAAGTTTGGCATCTGTAAACGC
                        CAGGCTCAGGCATACCGGGGGCAGAGGGTTCCTCCAAAGAACAGCACTGATATTCAGGTT
                        CAAAAGGTTACCCACGACATGAGGCAGGGTCTCCACAACATGGAAGATGTCTATGAACTG
                        ATTGAAAACTCCCATCTAACCCCAAAGAAGCAAGGCCAAATCTCAGAAGAGTATATGCAA
                        ACGGTTTTGTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00560</identifier>
                            <name>LRR_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00025</drugbank-id>
        <drugbank-id>BIOD00029</drugbank-id>
        <drugbank-id>BTD00029</drugbank-id>
        <name>Antihemophilic Factor</name>
        <description>Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells</description>
        <cas-number/>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an "inhibitor-stop" technique. Biochem J. 1975 Sep;150(3):553-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2157</general-references>
        <synthesis-reference>James W. Bloom, "Warm ethanol method for preparation of low fibrinogen antihemophilic factor." U.S. Patent US4478825, issued June, 1955.</synthesis-reference>
        <indication>For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.</indication>
        <pharmacodynamics>Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.</pharmacodynamics>
        <mechanism-of-action>Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>8.4-19.3 hrs</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>* 4.1 mL/h•kg [Previously treated pediatric patients]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">AHF</synonym>
            <synonym language="" coder="">Factor VIII</synonym>
        </synonyms>
        <products>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02284154</dpd-id>
                <started-marketing-on>2006-10-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02284162</dpd-id>
                <started-marketing-on>2006-10-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02365944</dpd-id>
                <started-marketing-on>2012-01-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02365952</dpd-id>
                <started-marketing-on>2012-03-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02337193</dpd-id>
                <started-marketing-on>2010-01-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>3000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02365979</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02365987</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02284138</dpd-id>
                <started-marketing-on>2006-10-06</started-marketing-on>
                <ended-marketing-on>2013-10-08</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02284146</dpd-id>
                <started-marketing-on>2006-10-06</started-marketing-on>
                <ended-marketing-on>2013-10-08</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Advate</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02313111</dpd-id>
                <started-marketing-on>2008-09-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>2000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Factorate Inj 15unit/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00611131</dpd-id>
                <started-marketing-on>1984-12-31</started-marketing-on>
                <ended-marketing-on>1999-12-15</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>15 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Helixate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02308592</dpd-id>
                <started-marketing-on>2009-09-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>2000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Helixate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02342723</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>3000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Helixate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243186</dpd-id>
                <started-marketing-on>2008-04-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Helixate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243187</dpd-id>
                <started-marketing-on>2008-04-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Helixate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243188</dpd-id>
                <started-marketing-on>2008-04-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Hemofil M</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00808709</dpd-id>
                <started-marketing-on>1988-12-31</started-marketing-on>
                <ended-marketing-on>2006-05-19</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1700 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Hyate C Inj Vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00738859</dpd-id>
                <started-marketing-on>1986-12-31</started-marketing-on>
                <ended-marketing-on>1996-09-25</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>700 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Koate-hp - Pws IV 1000iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02187841</dpd-id>
                <started-marketing-on>1997-01-23</started-marketing-on>
                <ended-marketing-on>2000-08-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Koate-hp Unj</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00836419</dpd-id>
                <started-marketing-on>1989-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-25</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>1800 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate - Pws IV 1000I.U./vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02178834</dpd-id>
                <started-marketing-on>1996-07-09</started-marketing-on>
                <ended-marketing-on>2002-08-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate - Pws IV 250I.U./vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02178818</dpd-id>
                <started-marketing-on>1996-11-20</started-marketing-on>
                <ended-marketing-on>2002-08-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate - Pws IV 500I.U./vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02178826</dpd-id>
                <started-marketing-on>1996-11-20</started-marketing-on>
                <ended-marketing-on>2002-08-01</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242489</dpd-id>
                <started-marketing-on>2004-03-31</started-marketing-on>
                <ended-marketing-on>2009-08-06</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02254476</dpd-id>
                <started-marketing-on>2006-08-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242490</dpd-id>
                <started-marketing-on>2000-09-29</started-marketing-on>
                <ended-marketing-on>2009-08-06</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02254484</dpd-id>
                <started-marketing-on>2005-09-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242491</dpd-id>
                <started-marketing-on>2000-09-29</started-marketing-on>
                <ended-marketing-on>2009-08-06</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02254492</dpd-id>
                <started-marketing-on>2005-09-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs     -(with Bio-set)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02342758</dpd-id>
                <started-marketing-on>2010-05-11</started-marketing-on>
                <ended-marketing-on>2015-07-07</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>3000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs     -(with Bio-set)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02302225</dpd-id>
                <started-marketing-on>2008-08-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>2000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02291517</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02291525</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02291533</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02302217</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>2000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02342731</dpd-id>
                <started-marketing-on>2015-07-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>3000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Pws 1000iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02042517</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-25</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Pws 250iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02042495</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-25</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kogenate Pws 500iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02042509</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-25</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kryobulin Vh 1000 Unit/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00719838</dpd-id>
                <started-marketing-on>1988-12-31</started-marketing-on>
                <ended-marketing-on>1998-08-13</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kryobulin Vh 500 Unit/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00719811</dpd-id>
                <started-marketing-on>1987-12-31</started-marketing-on>
                <ended-marketing-on>1998-08-13</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Monoclate-p  -  200-350iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02215144</dpd-id>
                <started-marketing-on>2001-06-27</started-marketing-on>
                <ended-marketing-on>2008-10-16</ended-marketing-on>
                <dosage-form>solution; kit</dosage-form>
                <strength>2.5 ml</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Monoclate-p  -  400-700iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02215152</dpd-id>
                <started-marketing-on>2001-06-27</started-marketing-on>
                <ended-marketing-on>2008-10-16</ended-marketing-on>
                <dosage-form>solution; kit</dosage-form>
                <strength>5 ml</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Monoclate-p  -  800-1500iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02215160</dpd-id>
                <started-marketing-on>2001-06-27</started-marketing-on>
                <ended-marketing-on>2008-10-16</ended-marketing-on>
                <dosage-form>solution; kit</dosage-form>
                <strength>10 ml</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Profilate Heat Treated-wet Method Inj</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00740780</dpd-id>
                <started-marketing-on>1988-12-31</started-marketing-on>
                <ended-marketing-on>1997-11-12</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Recombinate Pws Inj 1000I.U./vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02015137</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>2009-02-12</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Recombinate Pws Inj 250I.U./vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02015129</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>2009-02-12</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Recombinate Pws Inj 500I.U./vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02015145</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>2009-02-12</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>500 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Bioclate</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Helixate</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Hyate:C</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Koate-HP</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Kogenate</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Monarc-M</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>ReFacto</name>
                <company/>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Helixate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Helixate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Helixate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs     -(with Bio-set)</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Helixate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Koate-hp Unj</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kryobulin Vh 1000 Unit/vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Hyate C Inj Vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Recombinate Pws Inj 250I.U./vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Recombinate Pws Inj 1000I.U./vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Recombinate Pws Inj 500I.U./vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Pws 250iu/vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Pws 500iu/vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Pws 1000iu/vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Koate-hp - Pws IV 1000iu/vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Monoclate-p  -  200-350iu/vial</name>
                <ingredients>Water + Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Monoclate-p  -  400-700iu/vial</name>
                <ingredients>Water + Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Monoclate-p  -  800-1500iu/vial</name>
                <ingredients>Water + Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate - Pws IV 250I.U./vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate - Pws IV 500I.U./vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate - Pws IV 1000I.U./vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Factorate Inj 15unit/ml</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kryobulin Vh 500 Unit/vial</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs     -(with Bio-set)</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Profilate Heat Treated-wet Method Inj</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Hemofil M</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Kogenate Fs     -(with Vial Adapter)</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Helixate Fs</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
            <mixture>
                <name>Advate</name>
                <ingredients>Antihemophilic Factor</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Baxter International Inc.</name>
                <url>http://www.baxter.com</url>
            </packager>
            <packager>
                <name>Bayer Healthcare</name>
                <url>http://www.bayerhealthcare.com</url>
            </packager>
            <packager>
                <name>CSL Behring LLC</name>
                <url>http://www.cslbehring.com</url>
            </packager>
            <packager>
                <name>GlaxoSmithKline Inc.</name>
                <url>http://www.gsk.com</url>
            </packager>
            <packager>
                <name>Grifols SA</name>
                <url>http://www.grifols.com</url>
            </packager>
            <packager>
                <name>Ipsen Pharmaceuticals Inc.</name>
                <url>http://www.ipsen.com</url>
            </packager>
            <packager>
                <name>Octapharma USA</name>
                <url>http://www.octapharma.com</url>
            </packager>
            <packager>
                <name>Talecris Biotherapeutics</name>
                <url>http://www.talecris.com</url>
            </packager>
            <packager>
                <name>Wyeth Pharmaceuticals</name>
                <url>http://www.wyeth.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Monoclate-p 1000 unit kit</description>
                <cost currency="USD">1.01</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Monoclate-p 1500 unit kit</description>
                <cost currency="USD">1.01</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Monoclate-p 250 unit kit</description>
                <cost currency="USD">1.01</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Monoclate-p 500ahfu kit</description>
                <cost currency="USD">1.01</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Alphanate 1000-1500 unit vial</description>
                <cost currency="USD">1.2</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Alphanate 250-500 unit vial</description>
                <cost currency="USD">1.2</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Humate-p 1000 unit kit</description>
                <cost currency="USD">1.2</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Humate-p 1200 unit kit</description>
                <cost currency="USD">1.2</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Humate-p 2000 unit kit</description>
                <cost currency="USD">1.2</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Humate-p 2400 unit kit</description>
                <cost currency="USD">1.2</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Humate-p 500 unit kit</description>
                <cost currency="USD">1.2</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Humate-p 600 unit kit</description>
                <cost currency="USD">1.2</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Koate-dvi 1000 unit kit</description>
                <cost currency="USD">1.31</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Koate-dvi 250 unit kit</description>
                <cost currency="USD">1.31</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Koate-dvi 500 unit kit</description>
                <cost currency="USD">1.31</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Refacto 1000 unit vial</description>
                <cost currency="USD">1.31</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Refacto 2000 unit vial</description>
                <cost currency="USD">1.31</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Refacto 250 unit vial</description>
                <cost currency="USD">1.31</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Refacto 500 unit vial</description>
                <cost currency="USD">1.31</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Hemofil m 1701-2000 unit vial</description>
                <cost currency="USD">1.34</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Hemofil m 220-400 unit vial</description>
                <cost currency="USD">1.34</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Hemofil m 401-800 unit vial</description>
                <cost currency="USD">1.34</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Hemofil m 801-1700 unit vial</description>
                <cost currency="USD">1.34</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Wilate 450-450 unit kit</description>
                <cost currency="USD">1.38</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Wilate 900-900 unit kit</description>
                <cost currency="USD">1.38</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Helixate fs 1000 unit vial</description>
                <cost currency="USD">1.56</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Helixate fs 250 unit vial</description>
                <cost currency="USD">1.56</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Helixate fs 3000 unit vial</description>
                <cost currency="USD">1.56</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Helixate fs 500 unit vial</description>
                <cost currency="USD">1.56</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Xyntha 1000 unit kit</description>
                <cost currency="USD">1.66</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Xyntha 2000 unit kit</description>
                <cost currency="USD">1.66</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Xyntha 250 unit kit</description>
                <cost currency="USD">1.66</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Xyntha 500 unit kit</description>
                <cost currency="USD">1.66</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Advate 1201-1800 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Advate 1801-2400 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Advate 200-400 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Advate 2400-3600 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Advate 401-800 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Advate 801-1200 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Kogenate fs 1000 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Kogenate fs 250 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Kogenate fs 3000 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Kogenate fs 500 unit vial</description>
                <cost currency="USD">1.68</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Coagulants</category>
                <mesh-id/>
            </category>
            <category>
                <category>Thrombotic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>1500 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>3000 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>15 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>1000 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>250 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>500 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>1700 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>700 unit</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intravenous</route>
                <strength>1800 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>2000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution; kit</form>
                <route>intravenous</route>
                <strength>2.5 ml</strength>
            </dosage>
            <dosage>
                <form>Solution; kit</form>
                <route>intravenous</route>
                <strength>5 ml</strength>
            </dosage>
            <dosage>
                <form>Solution; kit</form>
                <route>intravenous</route>
                <strength>10 ml</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intravenous</route>
                <strength>1000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes>
            <ahfs-code>20:28.16</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1339477</number>
                <country>Canada</country>
                <approved>1997-09-23</approved>
                <expires>2014-09-23</expires>
            </patent>
            <patent>
                <number>2124690</number>
                <country>Canada</country>
                <approved>2007-09-11</approved>
                <expires>2013-10-01</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00025 sequence
                ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFN
                IAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ
                REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR
                EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNR
                SLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLL
                MDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF
                DDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG
                RKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGI
                TDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNME
                RDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAG
                VQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKH
                KMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYE
                DSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMP
                KIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQ
                LHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDN
                TSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSW
                GKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSL
                LIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQK
                KEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEG
                QNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEK
                KETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNR
                TKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRL
                PLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI
                PQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKK
                NNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHI
                YQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSK
                LLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKP
                EIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIY
                DEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTD
                GSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGA
                EPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHT
                NTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHA
                INGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYP
                GVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITAS
                GQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQ
                FIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRS
                TLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWR
                PQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKV
                KVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.533</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>6.97</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>264725.5000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C11794H18314N3220O3553S83</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>745</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>9847</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0026-3782-20</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M14113</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164750168</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P00451</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Antihemophilic_Factor</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/hemofilm.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/antihemophilic-factor-human.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000216</id>
                <name>Coagulation factor X</name>
                <organism>Human</organism>
                <actions>
                    <action>activator</action>
                </actions>
                <references># BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)] Pathol Biol (Paris). 1959 Dec;7:2477-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13801371&#13;
                    # LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF STUART FACTOR (FACTOR X) BY ACTIVATED ANTIHEMOPHILIC FACTOR (ACTIVATED FACTOR 8). Biochemistry. 1965 Jan;4:113-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14285227&#13;
                    # Radnoff OD, Saito H: Inhibition of Hageman factor, plasma thromboplastin antecedent, thrombin and other clotting factors by phenylglyoxal hydrate (38500). Proc Soc Exp Biol Med. 1975 Jan;148(1):177-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/236567&#13;
                    # Orthner CL: Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography. J Lab Clin Med. 1984 Nov;104(5):816-28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6436416&#13;
                    # Freedman J, Mody M, Lazarus AH, Dewar L, Song S, Blanchette VS, Garvey MB, Ofosu FA: Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Am J Hematol. 2002 Mar;69(3):192-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11891806</references>
                <known-action>yes</known-action>
                <polypeptide id="P00742" source="Swiss-Prot">
                    <name>Coagulation factor X</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting</specific-function>
                    <gene-name>F10</gene-name>
                    <locus>13q34</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>7-26</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.74</theoretical-pi>
                    <molecular-weight>54732.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3528</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F10</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F10</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>K03194</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182841</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00742</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FA10_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Coagulation factor X precursor</synonym>
                        <synonym>EC 3.4.21.6</synonym>
                        <synonym>Stuart factor</synonym>
                        <synonym>Stuart- Prower factor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Coagulation factor X precursor
                        MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
                        TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN
                        CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR
                        KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE
                        CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE
                        AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI
                        VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG
                        GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE
                        VITSSPLK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1433 bp
                        CCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCA
                        ACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGAC
                        ACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTG
                        AGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAAGATGGCGACCAGTGTGAGA
                        CCAGTCCTTGCCAGAACCAGGGCAAATGTAAAGACGGCCTCGGGGAATACACCTGCACCT
                        GTTTAGAAGGATTCGAAGGCAAAAACTGTGAATTATTCACACGGAAGCTCTGCAGCCTGG
                        ACAACGGGGACTGTGACCAGTTCTGCCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCG
                        CCCGCGGGTACACCCTGGCTGACAACGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCT
                        GTGGGAAACAGACCCTGGAACGCAGGAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCG
                        GGGAGGCCCCTGACAGCATCACATGGAAGCCATATGATGCAGCCGACCTGGACCCCACCG
                        AGAACCCCTTCGACCTGCTTGACTTCAACCAGACGCAGCCTGAGAGGGGCGACAACAACC
                        TCACCAGGATCGTGGGAGGCCAGGAATGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGC
                        TCATCAATGAGGAAAACGAGGGTTTCTGTGGTGGAACTATTCTGAGCGAGTTCTACATCC
                        TAACGGCAGCCCACTGTCTCTACCAAGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGA
                        ACACGGAGCAGGAGGAGGGCGGTGAGGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACA
                        ACCGGTTCACAAAGGAGACCTATGACTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCA
                        TCACCTTCCGCATGAACGTGGCGCCTGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCA
                        CGCTGATGACGCAGAAGACGGGGATTGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCC
                        GGCAGTCCACCAGGCTCAAGATGCTGGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGC
                        TGTCCAGCAGCTTCATCATCACCCAGAACATGTTCTGTGCCGGCTACGACACCAAGCAGG
                        AGGATGCCTGCCAGGGGGACAGCGGGGGCCCGCACGTCACCCGCTTCAAGGACACCTACT
                        TCGTGACAGGCATCGTCAGCTGGGGAGAGAGCTGTGCCCGTAAGGGGAAGTACGGGATCT
                        ACACCAAGGTCACCGCCTTCCTCAAGTGGATCGACAGGTCCATGAAAACCAGGGGCTTGC
                        CCAAGGCCAAGAGCCATGCCCCGGAGGTCATAACGTCCTCTCCATTAAAGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000364</id>
                <name>Coagulation factor IX</name>
                <organism>Human</organism>
                <actions>
                    <action>cofactor</action>
                </actions>
                <references># Hule V: [Factor IX inhibitor (antihemophilic factor B, PTC) in a woman] Vnitr Lek. 1975 Mar;21(3):274-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1119107&#13;
                    # Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K: Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985 Jul 2;24(14):3736-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2994716&#13;
                    # LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF ANTIHEMOPHILIC FACTOR (FACTOR 8) BY ACTIVATED CHRISTMAS FACTOR (ACTIVATED FACTOR9 9). Biochemistry. 1964 Nov;3:1720-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14240634&#13;
                    # Hoofnagle JH, Gerety RJ, Thiel J, Barker LF: The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med. 1976 Jul;88(1):102-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/932529&#13;
                    # Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC: Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang. 1984;46(1):36-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6422634</references>
                <known-action>yes</known-action>
                <polypeptide id="P00740" source="Swiss-Prot">
                    <name>Coagulation factor IX</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa</specific-function>
                    <gene-name>F9</gene-name>
                    <locus>Xq27.1-q27.2</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.16</theoretical-pi>
                    <molecular-weight>51779.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3551</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F9</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F9</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>K02402</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182609</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00740</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FA9_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Christmas factor</synonym>
                        <synonym>Coagulation factor IX precursor</synonym>
                        <synonym>EC 3.4.21.22</synonym>
                        <synonym>Plasma thromboplastin component</synonym>
                        <synonym>PTC</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Coagulation factor IX precursor
                        MQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNL
                        ERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCP
                        FGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGR
                        VSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPW
                        QVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRII
                        PHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVF
                        HKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVE
                        GTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1389 bp
                        ATGCAGCGCGTGAACATGATCATGGCAGAATCACCAAGCCTCATCACCATCTGCCTTTTA
                        GGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATT
                        CTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTT
                        GAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAACCACGAGAAGTTTTTGAAAAC
                        ACTGAAAAGACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAAT
                        CCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCC
                        TTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGA
                        TGCGAGCAGTTTTGTAAAAATAGTGCTGATAACAAGGTGGTTTGCTCCTGTACTGAGGGA
                        TATCGACTTGCAGAAAACCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGA
                        GTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGGCTGTTTTTCCTGATGTGGAC
                        TATGTAAATCCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAGGCACCCAATCA
                        TTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGG
                        CAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAA
                        TGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGT
                        GAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAGCAATT
                        ATTCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTG
                        GAACTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAG
                        GAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGCAAGAGTC
                        TTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGA
                        GCCACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTC
                        CATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTG
                        GAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGC
                        AAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAG
                        CTCACTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0001043</id>
                <name>von Willebrand factor</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10938981&#13;
                    # Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA: Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002 Feb;87(2):224-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11858481&#13;
                    # Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA: Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov;9(6):688-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14750934&#13;
                    # Smith KJ, Lusher JM, Cohen AR, Salzman P: Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol. 1990 Apr;27(2 Suppl 2):25-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2128855&#13;
                    # Altieri DC, Capitanio AM, Mannucci PM: von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol. 1986 Aug;63(4):703-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2942172</references>
                <known-action>yes</known-action>
                <polypeptide id="P04275" source="Swiss-Prot">
                    <name>von Willebrand factor</name>
                    <general-function>Involved in chaperone binding</general-function>
                    <specific-function>Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma</specific-function>
                    <gene-name>VWF</gene-name>
                    <locus>12p13.3</locus>
                    <cellular-location>Secreted protein. Note=Localized to storage granules</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.21</theoretical-pi>
                    <molecular-weight>309301.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:12726</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>VWF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>VWF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04385</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>37947</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P04275</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>VWF_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>von Willebrand factor precursor</synonym>
                        <synonym>vWF</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;von Willebrand factor precursor
                        MIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYL
                        LAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYL
                        ETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTL
                        TSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPL
                        VDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGME
                        YRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPG
                        TSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQD
                        HSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDIQLPLLKGDL
                        RIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSG
                        LAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVS
                        PLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQ
                        CGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPED
                        IFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADN
                        LRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGE
                        TVKIGCNTCVCRDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGS
                        NPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGR
                        YIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVD
                        FGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPY
                        LDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGY
                        ECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCE
                        VAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVE
                        DISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVE
                        YHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRI
                        ALLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVL
                        SSVDELEQQRDEIVSYLCDLAPEAPPPTLPPHMAQVTVGPGLLGVSTLGPKRNSMVLDVA
                        FVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGD
                        ILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLP
                        GDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTL
                        SPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITT
                        IDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILV
                        TDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTM
                        VTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCD
                        RGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNK
                        EQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEV
                        NVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRD
                        GTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFY
                        AICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHC
                        DGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQI
                        CTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHC
                        ERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVN
                        STVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAV
                        MGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQ
                        WASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERME
                        ACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGEC
                        CGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHK
                        CLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMY
                        SIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;8442 bp
                        ATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACC
                        CTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGT
                        GACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTC
                        CTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAG
                        AGAGTGAGCCTCTCCGTGTATCTTGGGGAATTTTTTGACATCCATTTGTTTGTCAATGGT
                        ACCGTGACACAGGGGGACCAAAGAGTCTCCATGCCCTATGCCTCCAAAGGGCTGTATCTA
                        GAAACTGAGGCTGGGTACTACAAGCTGTCCGGTGAGGCCTATGGCTTTGTGGCCAGGATC
                        GATGGCAGCGGCAACTTTCAAGTCCTGCTGTCAGACAGATACTTCAACAAGACCTGCGGG
                        CTGTGTGGCAACTTTAACATCTTTGCTGAAGATGACTTTATGACCCAAGAAGGGACCTTG
                        ACCTCGGACCCTTATGACTTTGCCAACTCATGGGCTCTGAGCAGTGGAGAACAGTGGTGT
                        GAACGGGCATCTCCTCCCAGCAGCTCATGCAACATCTCCTCTGGGGAAATGCAGAAGGGC
                        CTGTGGGAGCAGTGCCAGCTTCTGAAGAGCACCTCGGTGTTTGCCCGCTGCCACCCTCTG
                        GTGGACCCCGAGCCTTTTGTGGCCCTGTGTGAGAAGACTTTGTGTGAGTGTGCTGGGGGG
                        CTGGAGTGCGCCTGCCCTGCCCTCCTGGAGTACGCCCGGACCTGTGCCCAGGAGGGAATG
                        GTGCTGTACGGCTGGACCGACCACAGCGCGTGCAGCCCAGTGTGCCCTGCTGGTATGGAG
                        TATAGGCAGTGTGTGTCCCCTTGCGCCAGGACCTGCCAGAGCCTGCACATCAATGAAATG
                        TGTCAGGAGCGATGCGTGGATGGCTGCAGCTGCCCTGAGGGACAGCTCCTGGATGAAGGC
                        CTCTGCGTGGAGAGCACCGAGTGTCCCTGCGTGCATTCCGGAAAGCGCTACCCTCCCGGC
                        ACCTCCCTCTCTCGAGACTGCAACACCTGCATTTGCCGAAACAGCCAGTGGATCTGCAGC
                        AATGAAGAATGTCCAGGGGAGTGCCTTGTCACAGGTCAATCACACTTCAAGAGCTTTGAC
                        AACAGATACTTCACCTTCAGTGGGATCTGCCAGTACCTGCTGGCCCGGGATTGCCAGGAC
                        CACTCCTTCTCCATTGTCATTGAGACTGTCCAGTGTGCTGATGACCGCGACGCTGTGTGC
                        ACCCGCTCCGTCACCGTCCGGCTGCCTGGCCTGCACAACAGCCTTGTGAAACTGAAGCAT
                        GGGGCAGGAGTTGCCATGGATGGCCAGGACGTCCAGCTCCCCCTCCTGAAAGGTGACCTC
                        CGCATCCAGCATACAGTGACGGCCTCCGTGCGCCTCAGCTACGGGGAGGACCTGCAGATG
                        GACTGGGATGGCCGCGGGAGGCTGCTGGTGAAGCTGTCCCCCGTCTATGCCGGGAAGACC
                        TGCGGCCTGTGTGGGAATTACAATGGCAACCAGGGCGACGACTTCCTTACCCCCTCTGGG
                        CTGGCGGAGCCCCGGGTGGAGGACTTCGGGAACGCCTGGAAGCTGCACGGGGACTGCCAG
                        GACCTGCAGAAGCAGCACAGCGATCCCTGCGCCCTCAACCCGCGCATGACCAGGTTCTCC
                        GAGGAGGCGTGCGCGGTCCTGACGTCCCCCACATTCGAGGCCTGCCATCGTGCCGTCAGC
                        CCGCTGCCCTACCTGCGGAACTGCCGCTACGACGTGTGCTCCTGCTCGGACGGCCGCGAG
                        TGCCTGTGCGGCGCCCTGGCCAGCTATGCCGCGGCCTGCGCGGGGAGAGGCGTGCGCGTC
                        GCGTGGCGCGAGCCAGGCCGCTGTGAGCTGAACTGCCCGAAAGGCCAGGTGTACCTGCAG
                        TGCGGGACCCCCTGCAACCTGACCTGCCGCTCTCTCTCTTACCCGGATGAGGAATGCAAT
                        GAGGCCTGCCTGGAGGGCTGCTTCTGCCCCCCAGGGCTCTACATGGATGAGAGGGGGGAC
                        TGCGTGCCCAAGGCCCAGTGCCCCTGTTACTATGACGGTGAGATCTTCCAGCCAGAAGAC
                        ATCTTCTCAGACCATCACACCATGTGCTACTGTGAGGATGGCTTCATGCACTGTACCATG
                        AGTGGAGTCCCCGGAAGCTTGCTGCCTGACGCTGTCCTCAGCAGTCCCCTGTCTCATCGC
                        AGCAAAAGGAGCCTATCCTGTCGGCCCCCCATGGTCAAGCTGGTGTGTCCCGCTGACAAC
                        CTGCGGGCTGAAGGGCTCGAGTGTACCAAAACGTGCCAGAACTATGACCTGGAGTGCATG
                        AGCATGGGCTGTGTCTCTGGCTGCCTCTGCCCCCCGGGCATGGTCCGGCATGAGAACAGA
                        TGTGTGGCCCTGGAAAGGTGTCCCTGCTTCCATCAGGGCAAGGAGTATGCCCCTGGAGAA
                        ACAGTGAAGATTGGCTGCAACACTTGTGTCTGTCGGGACCGGAAGTGGAACTGCACAGAC
                        CATGTGTGTGATGCCACGTGCTCCACGATCGGCATGGCCCACTACCTCACCTTCGACGGG
                        CTCAAATACCTGTTCCCCGGGGAGTGCCAGTACGTTCTGGTGCAGGATTACTGCGGCAGT
                        AACCCTGGGACCTTTCGGATCCTAGTGGGGAATAAGGGATGCAGCCACCCCTCAGTGAAA
                        TGCAAGAAACGGGTCACCATCCTGGTGGAGGGAGGAGAGATTGAGCTGTTTGACGGGGAG
                        GTGAATGTGAAGAGGCCCATGAAGGATGAGACTCACTTTGAGGTGGTGGAGTCTGGCCGG
                        TACATCATTCTGCTGCTGGGCAAAGCCCTCTCCGTGGTCTGGGACCGCCACCTGAGCATC
                        TCCGTGGTCCTGAAGCAGACATACCAGGAGAAAGTGTGTGGCCTGTGTGGGAATTTTGAT
                        GGCATCCAGAACAATGACCTCACCAGCAGCAACCTCCAAGTGGAGGAAGACCCTGTGGAC
                        TTTGGGAACTCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAAAGTGCCTCTGGAC
                        TCATCCCCTGCCACCTGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGT
                        AGAATCCTTACCAGTGACGTCTTCCAGGACTGCAACAAGCTGGTGGACCCCGAGCCATAT
                        CTGGATGTCTGCATTTACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTC
                        TGCGACACCATTGCTGCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGG
                        AGGACGGCCACATTGTGCCCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTAT
                        GAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCCT
                        GAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGGG
                        AAAATCCTGGATGAGCTTTTGCAGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAG
                        GTGGCTGGCCGGCGTTTTGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAG
                        CACTGCCAGATTTGCCACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCG
                        GGAGGCCTGGTGGTGCCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAG
                        GACATCTCGGAACCGCCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTCTTC
                        CTGCTGGATGGCTCCTCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTG
                        GTGGACATGATGGAGCGGCTGCGCATCTCCCAGAAGTGGGTCCGCGTGGCCGTGGTGGAG
                        TACCACGACGGCTCCCACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTG
                        CGGCGCATTGCCAGCCAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGTC
                        TTGAAATACACACTGTTCCAAATCTTCAGCAAGATCGACCGCCCTGAAGCCTCCCGCATC
                        GCCCTGCTCCTGATGGCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTAC
                        GTCCAGGGCCTGAAGAAGAAGAAGGTCATTGTGATCCCGGTGGGCATTGGGCCCCATGCC
                        AACCTCAAGCAGATCCGCCTCATCGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTG
                        AGCAGTGTGGATGAGCTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTT
                        GCCCCTGAAGCCCCTCCTCCTACTCTGCCCCCCCACATGGCACAAGTCACTGTGGGCCCG
                        GGGCTCTTGGGGGTTTCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCG
                        TTCGTCCTGGAAGGATCGGACAAAATTGGTGAAGCCGACTTCAACAGGAGCAAGGAGTTC
                        ATGGAGGAGGTGATTCAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTG
                        CAGTACTCCTACATGGTGACCGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGAC
                        ATCCTGCAGCGGGTGCGAGAGATCCGCTACCAGGGCGGCAACAGGACCAACACTGGGCTG
                        GCCCTGCGGTACCTCTCTGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCG
                        CCCAACCTGGTCTACATGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCT
                        GGAGACATCCAGGTGGTGCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAG
                        AGGATTGGCTGGCCCAATGCCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGAG
                        GCTCCTGACCTGGTGCTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCTC
                        TCCCCTGCACCTGACTGCAGCCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCC
                        AGTTTCCCAGCTTCTTATTTTGATGAAATGAAGAGTTTCGCCAAGGCTTTCATTTCAAAA
                        GCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTATGGAAGCATCACCACC
                        ATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTGAGCCTTGTGGACGTC
                        ATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGCTTTGCTGTGCGATAC
                        TTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTC
                        ACGGACGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGAGTG
                        ACAGTGTTCCCTATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCA
                        GGCCCAGCAGGCGACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCATG
                        GTCACCTTGGGCAATTCCTTCCTCCACAAACTGTGCTCTGGATTTGTTAGGATTTGCATG
                        GATGAGGATGGGAATGAGAAGAGGCCCGGGGACGTCTGGACCTTGCCAGACCAGTGCCAC
                        ACCGTGACTTGCCAGCCAGATGGCCAGACCTTGCTGAAGACTCATCGGGTCAACTGTGAC
                        CGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAGTCCCCTGTTAAAGTGGAAGAGACCTGT
                        GGCTGCCGCTGGACCTGCCCCTGCGTGTGCACAGGCAGCTCCACTCGGCACATCGTGACC
                        TTTGATGGGCAGAATTTCAAGCTGACTGGCAGCTGTTCTTATGTCCTATTTCAAAACAAG
                        GAGCAGGACCTGGAGGTGATTCTCCATAATGGTGCCTGCAGCCCTGGAGCAAGGCAGGGC
                        TGCATGAAATCCATCGAGGTGAAGCACAGTGCCCTCTCCGTCGAGCTGCACAGTGACATG
                        GAGGTGACGGTGAATGGGAGACTGGTCTCTGTTCCTTACGTGGGTGGGAACATGGAAGTC
                        AACGTTTATGGTGCCATCATGCATGAGGTCAGATTCAATCACCTTGGTCACATCTTCACA
                        TTCACTCCACAAAACAATGAGTTCCAACTGCAGCTCAGCCCCAAGACTTTTGCTTCAAAG
                        ACGTATGGTCTGTGTGGGATCTGTGATGAGAACGGAGCCAATGACTTCATGCTGAGGGAT
                        GGCACAGTCACCACAGACTGGAAAACACTTGTTCAGGAATGGACTGTGCAGCGGCCAGGG
                        CAGACGTGCCAGCCCATCCTGGAGGAGCAGTGTCTTGTCCCCGACAGCTCCCACTGCCAG
                        GTCCTCCTCTTACCACTGTTTGCTGAATGCCACAAGGTCCTGGCTCCAGCCACATTCTAT
                        GCCATCTGCCAGCAGGACAGTTGCCACCAGGAGCAAGTGTGTGAGGTGATCGCCTCTTAT
                        GCCCACCTCTGTCGGACCAACGGGGTCTGCGTTGACTGGAGGACACCTGATTTCTGTGCT
                        ATGTCATGCCCACCATCTCTGGTCTACAACCACTGTGAGCATGGCTGTCCCCGGCACTGT
                        GATGGCAACGTGAGCTCCTGTGGGGACCATCCCTCCGAAGGCTGTTTCTGCCCTCCAGAT
                        AAAGTCATGTTGGAAGGCAGCTGTGTCCCTGAAGAGGCCTGCACTCAGTGCATTGGTGAG
                        GATGGAGTCCAGCACCAGTTCCTGGAAGCCTGGGTCCCGGACCACCAGCCCTGTCAGATC
                        TGCACATGCCTCAGCGGGCGGAAGGTCAACTGCACAACGCAGCCCTGCCCCACGGCCAAA
                        GCTCCCACGTGTGGCCTGTGTGAAGTAGCCCGCCTCCGCCAGAATGCAGACCAGTGCTGC
                        CCCGAGTATGAGTGTGTGTGTGACCCAGTGAGCTGTGACCTGCCCCCAGTGCCTCACTGT
                        GAACGTGGCCTCCAGCCCACACTGACCAACCCTGGCGAGTGCAGACCCAACTTCACCTGC
                        GCCTGCAGGAAGGAGGAGTGCAAAAGAGTGTCCCCACCCTCCTGCCCCCCGCACCGTTTG
                        CCCACCCTTCGGAAGACCCAGTGCTGTGATGAGTATGAGTGTGCCTGCAACTGTGTCAAC
                        TCCACAGTGAGCTGTCCCCTTGGGTACTTGGCCTCAACCGCCACCAATGACTGTGGCTGT
                        ACCACAACCACCTGCCTTCCCGACAAGGTGTGTGTCCACCGAAGCACCATCTACCCTGTG
                        GGCCAGTTCTGGGAGGAGGGCTGCGATGTGTGCACCTGCACCGACATGGAGGATGCCGTG
                        ATGGGCCTCCGCGTGGCCCAGTGCTCCCAGAAGCCCTGTGAGGACAGCTGTCGGTCGGGC
                        TTCACTTACGTTCTGCATGAAGGCGAGTGCTGTGGAAGGTGCCTGCCATCTGCCTGTGAG
                        GTGGTGACTGGCTCACCGCGGGGGGACTCCCAGTCTTCCTGGAAGAGTGTCGGCTCCCAG
                        TGGGCCTCCCCGGAGAACCCCTGCCTCATCAATGAGTGTGTCCGAGTGAAGGAGGAGGTC
                        TTTATACAACAAAGGAACGTCTCCTGCCCCCAGCTGGAGGTCCCTGTCTGCCCCTCGGGC
                        TTTCAGCTGAGCTGTAAGACCTCAGCGTGCTGCCCAAGCTGTCGCTGTGAGCGCATGGAG
                        GCCTGCATGCTCAATGGCACTGTCATTGGGCCCGGGAAGACTGTGATGATCGATGTGTGC
                        ACGACCTGCCGCTGCATGGTGCAGGTGGGGGTCATCTCTGGATTCAAGCTGGAGTGCAGG
                        AAGACCACCTGCAACCCCTGCCCCCTGGGTTACAAGGAAGAAAATAACACAGGTGAATGT
                        TGTGGGAGATGTTTGCCTACGGCTTGCACCATTCAGCTAAGAGGAGGACAGATCATGACA
                        CTGAAGCGTGATGAGACGCTCCAGGATGGCTGTGATACTCACTTCTGCAAGGTCAATGAG
                        AGAGGAGAGTACTTCTGGGAGAAGAGGGTCACAGGCTGCCCACCCTTTGATGAACACAAG
                        TGTCTGGCTGAGGGAGGTAAAATTATGAAAATTCCAGGCACCTGCTGTGACACATGTGAG
                        GAGCCTGAGTGCAACGACATCACTGCCAGGCTGCAGTATGTCAAGGTGGGAAGCTGTAAG
                        TCTGAAGTAGAGGTGGATATCCACTACTGCCAGGGCAAATGTGCCAGCAAAGCCATGTAC
                        TCCATTGACATCAACGATGTGCAGGACCAGTGCTCCTGCTGCTCTCCGACACGGACGGAG
                        CCCATGCAGGTGGCCCTGCACTGCACCAATGGCTCTGTTGTGTACCATGAGGTTCTCAAT
                        GCCATGGAGTGCAAATGCTCCCCCAGGAAGTGCAGCAAGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00093</identifier>
                            <name>VWC</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00092</identifier>
                            <name>VWA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00094</identifier>
                            <name>VWD</name>
                        </pfam>
                        <pfam>
                            <identifier>PF08742</identifier>
                            <name>DUF1787</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01826</identifier>
                            <name>TIL</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix (sensu Metazoa)</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell adhesion</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0002117</id>
                <name>Phytanoyl-CoA dioxygenase, peroxisomal</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Chen C, Wang Q, Fang X, Xu Q, Chi C, Gu J: Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII. J Biol Chem. 2001 Dec 7;276(49):46340-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11574539</references>
                <known-action>unknown</known-action>
                <polypeptide id="O14832" source="Swiss-Prot">
                    <name>Phytanoyl-CoA dioxygenase, peroxisomal</name>
                    <general-function/>
                    <specific-function>Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA</specific-function>
                    <gene-name>PHYH</gene-name>
                    <locus>10pter-p11.2</locus>
                    <cellular-location>Peroxisome</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.65</theoretical-pi>
                    <molecular-weight>38539.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8940</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PHYH</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PHYH</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF023462</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>2564671</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O14832</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAHX_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 1.14.11.18</synonym>
                        <synonym>PhyH</synonym>
                        <synonym>Phytanic acid oxidase</synonym>
                        <synonym>Phytanoyl-CoA alpha-hydroxylase</synonym>
                        <synonym>Phytanoyl-CoA dioxygenase, peroxisomal precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Phytanoyl-CoA dioxygenase, peroxisomal
                        MEQLRAAARLQIVLGHLGRPSAGAVVAHPTSGTISSASFHPQQFQYTLDNNVLTLEQRKF
                        YEENGFLVIKNLVPDADIQRFRNEFEKICRKEVKPLGLTVMRDVTISKSEYAPSEKMITK
                        VQDFQEDKELFRYCTLPEILKYVECFTGPNIMAMHTMLINKPPDSGKKTSRHPLHQDLHY
                        FPFRPSDLIVCAWTAMEHISRNNGCLVVLPGTHKGSLKPHDYPKWEGGVNKMFHGIQDYE
                        ENKARVHLVMEKGDTVFFHPLLIHGSGQNKTQGFRKAISCHFASADCHYIDVKGTSQENI
                        EKEVVGIAHKFFGAENSVNLKDIWMFRARLVKGERTNL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1017 bp
                        ATGGAGCAGCTTCGCGCCGCCGCCCGTCTGCAGATTGTTCTGGGCCACCTCGGCCGCCCC
                        TCGGCCGGGGCTGTCGTAGCTCATCCCACTTCAGGGACTATTTCCTCTGCCAGTTTCCAT
                        CCTCAACAATTCCAGTATACTCTGGATAATAATGTTCTAACCCTGGAACAGAGAAAATTT
                        TATGAAGAAAATGGGTTTCTAGTAATCAAAAATCTTGTACCTGATGCCGATATTCAACGC
                        TTTCGGAATGAGTTTGAAAAAATCTGCAGAAAGGAGGTGAAACCATTAGGATTAACAGTA
                        ATGAGAGATGTGACCATTTCGAAATCCGAATATGCTCCAAGTGAGAAGATGATCACGAAG
                        GTCCAGGATTTCCAGGAAGATAAGGAGCTCTTCAGATACTGCACTCTCCCCGAGATTCTG
                        AAATATGTGGAGTGCTTCACTGGACCTAATATTATGGCCATGCACACAATGTTGATAAAC
                        AAACCTCCAGATTCTGGCAAGAAGACGTCCCGTCACCCCCTGCACCAGGACCTGCACTAT
                        TTCCCCTTCAGGCCCAGCGATCTCATCGTTTGCGCCTGGACGGCGATGGAGCACATCAGC
                        CGGAACAACGGCTGTCTGGTTGTGCTCCCAGGCACGCACAAGGGCTCCCTGAAGCCCCAC
                        GATTACCCCAAGTGGGAGGGGGGAGTTAACAAAATGTTCCACGGGATCCAGGACTACGAG
                        GAAAACAAGGCCCGGGTGCACCTGGTGATGGAGAAGGGCGACACTGTTTTCTTCCATCCT
                        TTGCTCATCCACGGATCTGGTCAGAATAAAACCCAGGGATTCCGGAAGGCAATTTCCTGC
                        CATTTCGCCAGTGCCGATTGCCACTACATTGACGTGAAGGGCACCAGTCAAGAAAACATC
                        GAGAAGGAAGTTGTAGGAATAGCACATAAATTCTTTGGAGCTGAAAATAGCGTGAACTTG
                        AAGGATATTTGGATGTTTCGAGCTCGACTTGTGAAAGGAGAAAGAACCAATCTTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF05721</identifier>
                            <name>PhyH</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0002118</id>
                <name>Asialoglycoprotein receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K: The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005 Jun;3(6):1257-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15946216</references>
                <known-action>unknown</known-action>
                <polypeptide id="P07307" source="Swiss-Prot">
                    <name>Asialoglycoprotein receptor 2</name>
                    <general-function/>
                    <specific-function>Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface</specific-function>
                    <gene-name>ASGR2</gene-name>
                    <locus>17p</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>59-79</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.34</theoretical-pi>
                    <molecular-weight>35192.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:743</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>ASGR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>ASGR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M11025</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>179081</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P07307</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>ASGR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>ASGP-R 2</synonym>
                        <synonym>ASGPR 2</synonym>
                        <synonym>Hepatic lectin H2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Asialoglycoprotein receptor 2
                        MAKDFQDIQQLSSEENDHPFHQGEGPGTRRLNPRRGNPFLKGPPPAQPLAQRLCSMVCFS
                        LLALSFNILLLVVICVTGSQSEGHRGAQLQAELRSLKEAFSNFSSSTLTEVQAISTHGGS
                        VGDKITSLGAKLEKQQQDLKADHDALLFHLKHFPVDLRFVACQMELLHSNGSQRTCCPVN
                        WVEHQGSCYWFSHSGKAWAEAEKYCQLENAHLVVINSWEEQKFIVQHTNPFNTWIGLTDS
                        DGSWKWVDGTDYRHNYKNWAVTQPDNWHGHELGGSEDCVEVQPDGRWNDDFCLQVYRWVC
                        EKRRNATGEVA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;936 bp
                        ATGGCCAAGGACTTTCAAGATATCCAGCAGCTGAGCTCGGAGGAAAATGACCATCCTTTC
                        CATCAAGGTGAGGGGCCAGGCACTCGCAGGCTGAATCCCAGGAGAGGAAATCCATTTTTG
                        AAAGGGCCACCTCCTGCCCAGCCCCTGGCACAGCGTCTCTGCTCCATGGTCTGCTTCAGT
                        CTGCTTGCCCTGAGCTTCAACATCCTGCTGCTGGTGGTCATCTGTGTGACTGGGTCCCAA
                        AGTGAGGGTCACAGAGGTGCACAGCTGCAAGCCGAGCTGCGGAGCCTGAAGGAAGCTTTC
                        AGCAACTTCTCCTCGAGCACCCTGACGGAGGTCCAGGCAATCAGCACCCACGGAGGCAGC
                        GTGGGTGACAAGATCACATCCCTAGGAGCCAAGCTGGAGAAACAGCAGCAGGACCTGAAA
                        GCAGATCACGATGCCCTGCTCTTCCATCTGAAGCACTTCCCCGTGGACCTGCGCTTCGTG
                        GCCTGCCAGATGGAGCTCCTCCACAGCAACGGCTCCCAAAGGACCTGCTGCCCCGTCAAC
                        TGGGTGGAGCACCAAGGCAGCTGCTACTGGTTCTCTCACTCCGGGAAGGCCTGGGCTGAG
                        GCGGAGAAGTACTGCCAGCTGGAGAACGCACACCTGGTGGTCATCAACTCCTGGGAGGAG
                        CAGAAATTCATTGTACAACACACGAACCCCTTCAATACCTGGATAGGTCTCACGGACAGT
                        GATGGCTCTTGGAAATGGGTGGATGGCACAGACTATAGGCACAACTACAAGAACTGGGCT
                        GTCACTCAGCCAGATAATTGGCACGGGCACGAGCTGGGTGGAAGTGAAGACTGTGTTGAA
                        GTCCAGCCGGATGGCCGCTGGAACGATGACTTCTGCCTGCAGGTGTACCGCTGGGTGTGT
                        GAGAAAAGGCGGAATGCCACCGGCGAGGTGGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00059</identifier>
                            <name>Lectin_C</name>
                        </pfam>
                        <pfam>
                            <identifier>PF03954</identifier>
                            <name>Lectin_N</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>carbohydrate binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>sugar binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0001098</id>
                <name>78 kDa glucose-regulated protein</name>
                <organism>Human</organism>
                <actions>
                    <action>chaperone</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9607108</references>
                <known-action>unknown</known-action>
                <polypeptide id="P11021" source="Swiss-Prot">
                    <name>78 kDa glucose-regulated protein</name>
                    <general-function>Posttranslational modification, protein turnover, chaperones</general-function>
                    <specific-function>Probably plays a role in facilitating the assembly of multimeric protein complexes inside the ER</specific-function>
                    <gene-name>HSPA5</gene-name>
                    <locus>9q33-q34.1</locus>
                    <cellular-location>Endoplasmic reticulum; endoplasmic reticulum lumen. Melanosome. Note=Identified by mass spectrometry</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.8</theoretical-pi>
                    <molecular-weight>72334.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5238</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>HSPA5</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>HSPA5</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M19645</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>386758</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P11021</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GRP78_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>78 kDa glucose-regulated protein precursor</synonym>
                        <synonym>BiP</synonym>
                        <synonym>Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78</synonym>
                        <synonym>GRP 78</synonym>
                        <synonym>Heat shock 70 kDa protein 5</synonym>
                        <synonym>Immunoglobulin heavy chain-binding protein</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;78 kDa glucose-regulated protein precursor
                        MKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNR
                        ITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVV
                        EKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQ
                        RQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNG
                        VFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALS
                        SQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIV
                        LVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVC
                        PLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLG
                        TFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIER
                        MVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEE
                        KIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1962 bp
                        ATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAG
                        GAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACTTGGGGACCACCTACTCC
                        TGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGC
                        ATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCC
                        AAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCTCATCGGC
                        CGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTT
                        GAAAAGAAAACTAAACCATACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTT
                        GCTCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCTTAT
                        TTGGGAAAGAAGGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAATGATGCCCAA
                        CGCCAAGCAACCAAAGACGCTGGAACTATTGCTGGCCTAAATGTTATGAGGATCATCAAC
                        GAGCCTACGGCAGCTGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGGAGAAGAACATC
                        CTGGTGTTTGACCTGGGTGGCGGAACCTTCGATGTGTCTCTTCTCACCATTGACAATGGT
                        GTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTTGACCAG
                        CGTGTCATGGAACACTTCATCAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAG
                        GACAATAGAGCTGTGCAGAAACTCCGGCGCGAGGTAGAAAAGGCCAAGGCCCTGTCTTCT
                        CAGCATCAAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAGACC
                        CTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACTATGAAGCCC
                        GTCCAGAAAGTGTTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAAATTGTTCTT
                        GTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAGAGTTCTTCAATGGC
                        AAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAGCGTATGGTGCTGCTGTCCAG
                        GCTGGTGTGCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTCATGTATGTCCC
                        CTTACACTTGGTATTGAAACTGTAGGAGGTGTCATGACCAAACTGATTCCAAGTAATACA
                        GTGGTGCCTACCAAGAACTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACTGTT
                        ACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATCATCTTCTGGGTACA
                        TTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCACAGATTGAAGTCACCTTT
                        GAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTGAAGACAAGGGTACAGGGAACAAA
                        AATAAGATCACAATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGGATG
                        GTTAATGATGCTGAGAAGTTTGCTGAGGAAGACAAAAAGCTGAAGGAGCGCATTGATACT
                        AGAAATGAGTTGGAAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAAAAG
                        CTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAAAAG
                        ATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAGAAG
                        GAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACTCTATGGAAGTGCAGGCCCTCCC
                        CCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00012</identifier>
                            <name>HSP70</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0002109</id>
                <name>Calreticulin</name>
                <organism>Human</organism>
                <actions>
                    <action>chaperone</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9525969&#13;
                    # Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2007 Sep 26;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17899080&#13;
                    # Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9607108&#13;
                    # Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9607108</references>
                <known-action>unknown</known-action>
                <polypeptide id="P27797" source="Swiss-Prot">
                    <name>Calreticulin</name>
                    <general-function/>
                    <specific-function>Molecular calcium binding chaperone promoting folding, oligomeric assembly and quality control in the ER via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export</specific-function>
                    <gene-name>CALR</gene-name>
                    <locus>19p13.3-p13.2</locus>
                    <cellular-location>Endoplasmic reticulum</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.04</theoretical-pi>
                    <molecular-weight>48142.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1455</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CALR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CALR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M32294</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>337487</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P27797</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CALR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Calregulin</synonym>
                        <synonym>Calreticulin precursor</synonym>
                        <synonym>CRP55</synonym>
                        <synonym>ERp60</synonym>
                        <synonym>grp60</synonym>
                        <synonym>HACBP</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Calreticulin
                        MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE
                        EKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT
                        DMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN
                        TYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE
                        HIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS
                        PDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK
                        QDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1254 bp
                        ATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCCGCC
                        GTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC
                        AAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG
                        GAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT
                        TTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG
                        CAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA
                        GACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC
                        ACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC
                        ATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC
                        ACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG
                        GACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT
                        GAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG
                        CATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG
                        TGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC
                        GACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT
                        CCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG
                        GTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG
                        GAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA
                        CAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG
                        GAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC
                        AAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00262</identifier>
                            <name>Calreticulin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane-bound organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular membrane-bound organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>endoplasmic reticulum</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>unfolded protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein folding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0001011</id>
                <name>Calnexin</name>
                <organism>Human</organism>
                <actions>
                    <action>chaperone</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9525969&#13;
                    # Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, Grez M, Seifried E, Tonn T: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost. 2004 Jul;92(1):23-35. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15213841&#13;
                    # Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2007 Sep 26;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17899080&#13;
                    # Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9607108</references>
                <known-action>unknown</known-action>
                <polypeptide id="P27824" source="Swiss-Prot">
                    <name>Calnexin</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins</specific-function>
                    <gene-name>CANX</gene-name>
                    <locus>5q35</locus>
                    <cellular-location>Endoplasmic reticulum; endoplasmic reticulum membrane; single-pass type I membrane protein. Melanoso</cellular-location>
                    <transmembrane-regions>482-502</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.21</theoretical-pi>
                    <molecular-weight>67569.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1473</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CANX</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CANX</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L10284</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>186523</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P27824</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CALX_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Calnexin precursor</synonym>
                        <synonym>IP90</synonym>
                        <synonym>Major histocompatibility complex class I antigen- binding protein p88</synonym>
                        <synonym>p90</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Calnexin precursor
                        MEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY
                        KAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL
                        VLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH
                        DKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL
                        ILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK
                        PDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC
                        ESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS
                        AIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER
                        PWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE
                        EEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1779 bp
                        ATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT
                        CATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA
                        GAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC
                        AAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG
                        TCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT
                        GATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT
                        GTGTTGATGTCTCGGGCCAAGCATCATGCGATCTCTGCTAAACTGAACAAGCCCTTCCTG
                        TTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT
                        GGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT
                        GACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG
                        CACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG
                        AGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA
                        ATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA
                        AATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA
                        GACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG
                        CCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC
                        GAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG
                        GATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT
                        GAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA
                        GGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG
                        AAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT
                        GCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT
                        TGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT
                        GCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC
                        CCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC
                        TTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT
                        CAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG
                        GAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT
                        GGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG
                        AACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00262</identifier>
                            <name>Calreticulin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="9">
                <id>BE0002119</id>
                <name>Protein ERGIC-53</name>
                <organism>Human</organism>
                <actions>
                    <action>chaperone</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Cunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ: LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost. 2003 Nov;1(11):2360-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14629470&#13;
                    # Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004 May 1;103(9):3412-9. Epub 2004 Jan 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14726380</references>
                <known-action>unknown</known-action>
                <polypeptide id="P49257" source="Swiss-Prot">
                    <name>Protein ERGIC-53</name>
                    <general-function/>
                    <specific-function>Mannose-specific lectin. May recognize sugar residues of glycoproteins, glycolipids, or glycosylphosphatidyl inositol anchors and may be involved in the sorting or recycling of proteins, lipids, or both. The LMAN1-MCFD2 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins</specific-function>
                    <gene-name>LMAN1</gene-name>
                    <locus>18q21.3-q22</locus>
                    <cellular-location>Endoplasmic reticulum-Golgi intermediate compartment</cellular-location>
                    <transmembrane-regions>478-498</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.76</theoretical-pi>
                    <molecular-weight>57550.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6631</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LMAN1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LMAN1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X71661</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>433938</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P49257</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LMAN1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>ER-Golgi intermediate compartment 53 kDa protein</synonym>
                        <synonym>ERGIC-53 protein precursor</synonym>
                        <synonym>Gp58</synonym>
                        <synonym>Intracellular mannose- specific lectin MR60</synonym>
                        <synonym>Lectin, mannose-binding 1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;ERGIC-53 protein
                        MAGSRQRGLRARVRPLFCALLLSLGRFVRGDGVGGDPAVALPHRRFEYKYSFKGPHLVQS
                        DGTVPFWAHAGNAIPSSDQIRVAPSLKSQRGSVWTKTKAAFENWEVEVTFRVTGRGRIGA
                        DGLAIWYAENQGLEGPVFGSADLWNGVGIFFDSFDNDGKKNNPAIVIIGNNGQIHYDHQN
                        DGASQALASCQRDFRNKPYPVRAKITYYQNTLTVMINNGFTPDKNDYEFCAKVENMIIPA
                        QGHFGISAATGGLADDHDVLSFLTFQLTEPGKEPPTPDKEISEKEKEKYQEEFEHFQQEL
                        DKKKEEFQKGHPDLQGQPAEEIFESVGDRELRQVFEGQNRIHLEIKQLNRQLDMILDEQR
                        RYVSSLTEEISKRGAGMPGQHGQITQQELDTVVKTQHEILRQVNEMKNSMSETVRLVSGM
                        QHPGSAGGVYETTQHFIDIKEHLHIVKRDIDNLVQRNMPSNEKPKCPELPPFPSCLSTVH
                        FIIFVVVQTVLFIGYIMYRSQQEAAAKKFF</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1533 bp
                        ATGGCGGGATCCAGGCAAAGGGGTCTCCGGGCCAGAGTTCGGCCGCTGTTCTGCGCCTTG
                        CTGCTGTCACTCGGTCGCTTCGTCCGGGGCGACGGCGTGGGAGGAGACCCCGCGGTCGCG
                        TTGCCACATCGCCGTTTCGAGTACAAATACAGCTTCAAGGGGCCGCACCTGGTGCAGAGC
                        GACGGGACCGTGCCCTTCTGGGCCCACGCGGGGAATGCTATTCCAAGTTCAGATCAAATT
                        CGAGTAGCACCATCTTTAAAAAGCCAAAGAGGCTCAGTGTGGACAAAGACAAAAGCGGCC
                        TTTGAGAACTGGGAAGTTGAGGTGACATTTCGAGTGACTGGAAGAGGTCGAATTGGAGCT
                        GATGGCCTAGCAATTTGGTATGCAGAAAATCAAGGCTTGGAGGGCCCTGTGTTTGGATCA
                        GCTGATCTGTGGAATGGTGTTGGAATATTTTTTGATACTTTTGACAATGATGGAAAGAAA
                        AATAATCCTGCTATAGTAATTATAGGCAACAATGGACAAATCCATTATGACCATCAAAAT
                        GACGGGGCTAGTCAAGCTTTGGCAAGTTGCCAGAGGGACTTCCGCAACAAACCCTATCCT
                        GTCCGAGCAAAGATTACCTATTACCAGAACACACTGACAGTAATGATCAATAATGGCTTT
                        ACACCAGATAAAAATGATTATGAATTTTGTGCCAAAGTGGAAAATATGATTATCCCTGCA
                        CAAGGGCATTTTGGAATATCTGCTGCAACTGGAGGTCTTGCAGATGACCATGATGTCCTT
                        TCTTTTCTGACTTTCCAGTTGACTGAACCTGGAAAAGAGCCGCCCACACCAGATAAAGAA
                        ATTTCGGAAAAGGAAAAAGAAAAGTATCAGGAGGAATTTGAGCACTTTCAACAAGAATTG
                        GATAAAAAAAAAGAGGAATTCCAGAAGGGCCACCCCGACCTCCAAGGGCAGCCTGCGGAG
                        GAAATATTTGAGAGTGTAGGAGATCGAGAGCTAAGACAAGTCTTTGAAGGACAGAATCGT
                        ATTCATCTTGAAATCAAGCAGCTGAACCGGCAGTTAGATATGATTCTTGATGAACAGAGA
                        AGATATGTCTCTTCCTTAACAGAGGAAATCTCTAAAAGAGGAGCAGGAATGCCTGGGCAG
                        CATGGGCAGATTACTCAACAAGAACTGGATACTGTTGTGAAAACTCAGCATGAGATTCTG
                        AGACAAGTAAATGAAATGAAAAATTCCATGAGTGAAACCGTCAGACTGGTCAGTGGAATG
                        CAGCACCCTGGCTCTGCTGGAGGCGTCTATGAGACAACACAGCACTTCATTGACATCAAA
                        GAGCACCTGCACATAGTAAAGAGGGACATAGATAACTTAGTGCAGCGAAATATGCCATCA
                        AATGAAAAGCCGAAATGCCCAGAACTACCACCATTTCCATCATGTTTGTCTACGGTCCAC
                        TTCATTATATTTGTTGTGGTGCAAACTGTATTATTCATTGGTTATATCATGTATAGGTCT
                        CAGCAAGAAGCAGCTGCCAAAAAATTCTTTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF03388</identifier>
                            <name>Lectin_leg-like</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="10">
                <id>BE0002110</id>
                <name>Prolow-density lipoprotein receptor-related protein 1</name>
                <organism>Human</organism>
                <actions>
                    <action>modulator</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Franchini M, Montagnana M: Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med. 2011 Jun;49(6):967-70. Epub 2011 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21391865</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q07954" source="Swiss-Prot">
                    <name>Prolow-density lipoprotein receptor-related protein 1</name>
                    <general-function/>
                    <specific-function>Required for early embryonic development. Involved in the plasma clearance of chylomicron remnants and activated alpha 2-macroglobulin, as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission</specific-function>
                    <gene-name>LRP1</gene-name>
                    <locus>12q13-q14</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>4420-4444</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.02</theoretical-pi>
                    <molecular-weight>504578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6692</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LRP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LRP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X13916</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>34339</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q07954</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LRP1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>A2MR</synonym>
                        <synonym>Alpha-2-macroglobulin receptor</synonym>
                        <synonym>APOER</synonym>
                        <synonym>Apolipoprotein E receptor</synonym>
                        <synonym>CD91 antigen</synonym>
                        <synonym>Low-density lipoprotein receptor-related protein 1 precursor</synonym>
                        <synonym>LRP</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low-density lipoprotein receptor-related protein 1
                        MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA
                        PEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC
                        QHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL
                        LQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE
                        TVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI
                        DDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK
                        LVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE
                        NYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN
                        DQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG
                        MDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG
                        IHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG
                        WMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY
                        DRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT
                        LLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV
                        TCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF
                        KCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD
                        CGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF
                        KCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW
                        RCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC
                        ESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP
                        GEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES
                        CRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK
                        IYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT
                        LLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT
                        VDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT
                        LAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT
                        VSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL
                        DYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN
                        KKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG
                        QKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW
                        WADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL
                        CLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG
                        TSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY
                        WTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG
                        TERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS
                        VSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA
                        VANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL
                        NAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE
                        NVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD
                        ECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK
                        IERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI
                        PQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV
                        NSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS
                        NMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS
                        ATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY
                        FACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG
                        DGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD
                        REFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG
                        ENDCHDQSDEAPKNPHCTSPEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH
                        INECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH
                        GSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV
                        ALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD
                        KGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR
                        SVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF
                        EDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG
                        CSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG
                        DHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC
                        TNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV
                        DGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ
                        FRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC
                        ADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ
                        CNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD
                        NCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP
                        KLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN
                        TKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV
                        RIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP
                        RGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW
                        GNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI
                        VAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH
                        QHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC
                        NLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT
                        GFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM
                        AADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH
                        CSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV
                        VFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT
                        NFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;13635 bp
                        ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT
                        ATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT
                        ATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC
                        CCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG
                        GGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC
                        GGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC
                        CAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG
                        CTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC
                        AGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC
                        CTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG
                        CTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT
                        ACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG
                        ACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC
                        ATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC
                        CACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC
                        GATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG
                        GAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT
                        GACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG
                        CTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT
                        GTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC
                        CGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG
                        AATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC
                        CGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT
                        GCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC
                        GACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG
                        GCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG
                        AAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC
                        ATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC
                        CCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC
                        TACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC
                        ATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC
                        GATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG
                        ACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG
                        TGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG
                        AGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG
                        CCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC
                        GACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT
                        GAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT
                        CGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC
                        CTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG
                        CAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC
                        ACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC
                        ACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC
                        TGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG
                        GACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC
                        AAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT
                        GGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG
                        TTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC
                        TGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT
                        CAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT
                        GACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC
                        AAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC
                        GGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT
                        GGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG
                        CGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG
                        ACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC
                        AAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC
                        GAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG
                        CCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG
                        CTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT
                        GGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC
                        TGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC
                        AAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC
                        TGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG
                        CGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC
                        GCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG
                        ATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG
                        TATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG
                        GTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC
                        CTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC
                        CTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG
                        GCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC
                        GTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA
                        GCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC
                        CCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA
                        CTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC
                        CAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT
                        GAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC
                        GTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG
                        TTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT
                        CCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA
                        GACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG
                        CGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC
                        CACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT
                        AAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC
                        CTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT
                        GGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC
                        CAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC
                        TCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT
                        GCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG
                        TGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC
                        GTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC
                        CAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC
                        TGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG
                        AGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA
                        ATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG
                        ACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC
                        ATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG
                        ACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC
                        TGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC
                        GTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG
                        TACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC
                        ACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC
                        TACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC
                        CTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA
                        GTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC
                        AAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC
                        CAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG
                        GTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC
                        GCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC
                        CTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC
                        AATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC
                        TTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC
                        CACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA
                        AACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA
                        AGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC
                        GAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC
                        GAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG
                        GCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT
                        GGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG
                        ATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC
                        CACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG
                        GCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC
                        CCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT
                        CCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT
                        GTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG
                        AATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC
                        AGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC
                        TGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC
                        AACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC
                        AACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC
                        TCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT
                        GCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC
                        GAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG
                        GACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC
                        TTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC
                        TGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG
                        TGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG
                        GATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC
                        TGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT
                        GCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC
                        CGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC
                        CGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC
                        AGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC
                        GAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCCA
                        GAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG
                        GCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC
                        ATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG
                        ATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGATGACGGCCGGACGTGT
                        GCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACCCAT
                        GGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC
                        TGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC
                        AAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT
                        GCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC
                        AGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC
                        CTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC
                        AAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC
                        AGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC
                        TGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC
                        AGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT
                        GAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC
                        TCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT
                        GAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC
                        ACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC
                        TTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC
                        TGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC
                        TTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA
                        TGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG
                        GACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG
                        TGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG
                        GACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC
                        ACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA
                        GATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC
                        TCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG
                        GATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC
                        TGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT
                        GGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG
                        TTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT
                        TGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC
                        TCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC
                        GCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC
                        AAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC
                        GGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG
                        TGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG
                        GACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC
                        TTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC
                        AACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC
                        TGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC
                        TGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC
                        AAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC
                        ACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC
                        GGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC
                        ACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC
                        AAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC
                        CTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC
                        CGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC
                        ACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC
                        CACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC
                        AGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT
                        GTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT
                        GACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG
                        GGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG
                        CAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC
                        TGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT
                        GTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT
                        TACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC
                        AGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT
                        CAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC
                        CTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC
                        ACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT
                        AACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC
                        CGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT
                        CGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG
                        GGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC
                        ACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC
                        GACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG
                        GCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG
                        GTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT
                        GTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC
                        TGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA
                        CCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT
                        ATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG
                        GTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC
                        AACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG
                        CCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC
                        AACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC
                        CTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG
                        GACCCCTTGGCATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00057</identifier>
                            <name>Ldl_recept_a</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00058</identifier>
                            <name>Ldl_recept_b</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="11">
                <id>BE0002120</id>
                <name>Multiple coagulation factor deficiency protein 2</name>
                <organism>Human</organism>
                <actions>
                    <action>modulator</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # :   "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15886209</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q8NI22" source="Swiss-Prot">
                    <name>Multiple coagulation factor deficiency protein 2</name>
                    <general-function/>
                    <specific-function>The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins</specific-function>
                    <gene-name>MCFD2</gene-name>
                    <locus>2p21</locus>
                    <cellular-location>Endoplasmic reticulum-Golgi intermediate compartment</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.25</theoretical-pi>
                    <molecular-weight>16391.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:18451</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>MCFD2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>MCFD2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF475284</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>20799383</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q8NI22</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>MCFD2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Multiple coagulation factor deficiency protein 2 precursor</synonym>
                        <synonym>Neural stem cell-derived neuronal survival protein</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Multiple coagulation factor deficiency protein 2
                        MTMRSLLRTPFLCGLLWAFCAPGARAEEPAASFSQPGSMGLDKNTVHDQEHIMEHLEGVI
                        NKPEAEMSPQELQLHYFKMHDYDGNNLLDGLELSTAITHVHKEEGSEQAPLMSEDELINI
                        IDGVLRDDDKNNDGYIDYAEFAKSLQ</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;441 bp
                        ATGACCATGAGATCCCTGCTCAGAACCCCCTTCCTGTGTGGCCTGCTCTGGGCCTTTTGT
                        GCCCCAGGCGCCAGGGCTGAGGAGCCTGCAGCCAGCTTCTCCCAACCCGGCAGCATGGGC
                        CTGGATAAGAACACAGTGCACGACCAAGAGCATATCATGGAGCATCTAGAAGGTGTCATC
                        AACAAACCAGAGGCGGAGATGTCGCCACAAGAATTGCAGCTCCATTACTTCAAAATGCAT
                        GATTATGATGGCAATAATTTGCTTGATGGCTTAGAACTCTCCACAGCCATCACTCATGTC
                        CATAAGGAGGAAGGGAGTGAACAGGCACCACTAATGAGTGAAGATGAACTGATTAACATA
                        ATAGATGGTGTTTTGAGAGATGATGACAAGAACAATGATGGATACATTGACTATGCTGAA
                        TTTGCAAAATCACTGCAGTAG</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme position="12">
                <id>BE0000048</id>
                <name>Prothrombin</name>
                <organism>Human</organism>
                <actions>
                    <action>activator</action>
                </actions>
                <references># Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL: Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000 Mar 1;95(5):1694-702. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10688826&#13;
                    # Ratnoff OD, Lewis JH: Heckathorn's disease: variable functional dificiency of antihemophilic factor (factor VIII). Blood. 1975 Aug;46(2):161-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1139038&#13;
                    # Anderson DM, Shelley S, Crick N, Buraglio M: No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002 Dec;42(12):1358-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12463731&#13;
                    # Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B: The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion. 1990 Sep;30(7):591-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2402772&#13;
                    # Lazarchick J, Ashby MA, Lazarchick JJ, Sens DA: Mechanism of factor VIII inactivation by human antibodies. IV. Antibody binding prevents factor VIII proteolysis by thrombin. Ann Clin Lab Sci. 1986 Nov-Dec;16(6):497-501. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3099625</references>
                <known-action>unknown</known-action>
                <polypeptide id="P00734" source="Swiss-Prot">
                    <name>Prothrombin</name>
                    <general-function>Involved in blood clotting cascade</general-function>
                    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C</specific-function>
                    <gene-name>F2</gene-name>
                    <locus>11p11-q12</locus>
                    <cellular-location>Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.7</theoretical-pi>
                    <molecular-weight>70037.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3535</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M17262</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339641</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00734</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>THRB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Activated Factor II [IIa]</synonym>
                        <synonym>Coagulation factor II</synonym>
                        <synonym>EC 3.4.21.5</synonym>
                        <synonym>Prothrombin precursor</synonym>
                        <synonym>Thrombin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prothrombin precursor
                        MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
                        VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
                        NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
                        CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
                        QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
                        DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
                        DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
                        DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
                        VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
                        RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
                        GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1869 bp
                        ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
                        CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
                        GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC
                        GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
                        GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
                        GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
                        AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
                        GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
                        GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
                        TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
                        GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
                        TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
                        CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
                        TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
                        GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
                        GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
                        CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
                        CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
                        GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
                        CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
                        GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
                        GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG
                        ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
                        CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
                        GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
                        GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
                        AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
                        CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
                        GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
                        CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
                        GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
                        GGAGAGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>thrombin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
            <enzyme position="13">
                <id>BE0000380</id>
                <name>Vitamin K-dependent protein C</name>
                <organism>Human</organism>
                <actions>
                    <action>inactivator</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Bereczky Z, Kovacs KB, Muszbek L: Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med. 2010 Dec;48 Suppl 1:S53-66. Epub 2010 Nov 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21054189</references>
                <known-action>unknown</known-action>
                <polypeptide id="P04070" source="Swiss-Prot">
                    <name>Vitamin K-dependent protein C</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids</specific-function>
                    <gene-name>PROC</gene-name>
                    <locus>2q13-q14</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.23</theoretical-pi>
                    <molecular-weight>52072.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9451</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PROC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PROC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M11228</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>190334</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P04070</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PROC_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Anticoagulant protein C</synonym>
                        <synonym>Autoprothrombin IIA</synonym>
                        <synonym>Blood coagulation factor XIV</synonym>
                        <synonym>EC 3.4.21.69</synonym>
                        <synonym>Vitamin K-dependent protein C precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Vitamin K-dependent protein C precursor
                        MWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECI
                        EEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSC
                        DCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVK
                        FPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGA
                        VLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDI
                        ALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVL
                        NFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLV
                        SWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1386 bp
                        ATGTGGCAGCTCACAAGCCTCCTGCTGTTCGTGGCCACCTGGGGAATTTCCGGCACACCA
                        GCTCCTCTTGACTCAGTGTTCTCCAGCAGCGAGCGTGCCCACCAGGTGCTGCGGATCCGC
                        AAACGTGCCAACTCCTTCCTGGAGGAGCTCCGTCACAGCAGCCTGGAGCGGGAGTGCATA
                        GAGGAGATCTGTGACTTCGAGGAGGCCAAGGAAATTTTCCAAAATGTGGATGACACACTG
                        GCCTTCTGGTCCAAGCACGTCGACGGTGACCAGTGCTTGGTCTTGCCCTTGGAGCACCCG
                        TGCGCCAGCCTGTGCTGCGGGCACGGCACGTGCATCGACGGCATCGGCAGCTTCAGCTGC
                        GACTGCCGCAGCGGCTGGGAGGGCCGCTTCTGCCAGCGCGAGGTGAGCTTCCTCAATTGC
                        TCTCTGGACAACGGCGGCTGCACGCATTACTGCCTAGAGGAGGTGGGCTGGCGGCGCTGT
                        AGCTGTGCGCCTGGCTACAAGCTGGGGGACGACCTCCTGCAGTGTCACCCCGCAGTGAAG
                        TTCCCTTGTGGGAGGCCCTGGAAGCGGATGGAGAAGAAGCGCAGTCACCTGAAACGAGAC
                        ACAGAAGACCAAGAAGACCAAGTAGATCCGCGGCTCATTGATGGGAAGATGACCAGGCGG
                        GGAGACAGCCCCTGGCAGGTGGTCCTGCTGGACTCAAAGAAGAAGCTGGCCTGCGGGGCA
                        GTGCTCATCCACCCCTCCTGGGTGCTGACAGCGGCCCACTGCATGGATGAGTCCAAGAAG
                        CTCCTTGTCAGGCTTGGAGAGTATGACCTGCGGCGCTGGGAGAAGTGGGAGCTGGACCTG
                        GACATCAAGGAGGTCTTCGTCCACCCCAACTACAGCAAGAGCACCACCGACAATGACATC
                        GCACTGCTGCACCTGGCCCAGCCCGCCACCCTCTCGCAGACCATAGTGCCCATCTGCCTC
                        CCGGACAGCGGCCTTGCAGAGCGCGAGCTCAATCAGGCCGGCCAGGAGACCCTCGTGACG
                        GGCTGGGGCTACCACAGCAGCCGAGAGAAGGAGGCCAAGAGAAACCGCACCTTCGTCCTC
                        AACTTCATCAAGATTCCCGTGGTCCCGCACAATGAGTGCAGCGAGGTCATGAGCAACATG
                        GTGTCTGAGAACATGCTGTGTGCGGGCATCCTCGGGGACCGGCAGGATGCCTGCGAGGGC
                        GACAGTGGGGGGCCCATGGTCGCCTCCTTCCACGGCACCTGGTTCCTGGTGGGCCTGGTG
                        AGCTGGGGTGAGGGCTGTGGGCTCCTTCACAACTACGGCGTTTACACCAAAGTCAGCCGC
                        TACCTCGACTGGATCCATGGGCACATCAGAGACAAGGAAGCCCCCCAGAAGAGCTGGGCA
                        CCTTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-06-19">
        <drugbank-id primary="true">DB00026</drugbank-id>
        <drugbank-id>BIOD00060</drugbank-id>
        <drugbank-id>BTD00060</drugbank-id>
        <name>Anakinra</name>
        <description>Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference  between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001. </description>
        <cas-number>143090-92-0</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352&#13;
            # Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):281-2.&#13;
            "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17947302&#13;
            # FDA label </general-references>
        <synthesis-reference/>
        <indication>For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). </indication>
        <pharmacodynamics>Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.</pharmacodynamics>
        <mechanism-of-action>Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.</mechanism-of-action>
        <toxicity>Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence &gt;10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis. </toxicity>
        <metabolism/>
        <absorption>When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. &#13;
            Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours;&#13;
            Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL. &#13;
        </absorption>
        <half-life>Healthy subjects = 4 - 6 hours;&#13;
            NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours). </half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>Clearance is variable and increases with increasing creatinine clearance and body weight. However, gender and age were not significant factors. </clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">ICIL-1RA</synonym>
            <synonym language="" coder="">IL-1ra</synonym>
            <synonym language="" coder="">IL-1RN</synonym>
            <synonym language="" coder="">IL1 inhibitor</synonym>
            <synonym language="" coder="">Interleukin-1 receptor antagonist protein precursor</synonym>
            <synonym language="" coder="">IRAP</synonym>
        </synonyms>
        <products>
            <product>
                <name>Kineret</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02245913</dpd-id>
                <started-marketing-on>2002-05-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>150 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kineret</name>
                <ndc-id>66658-234_5888e955-91e4-4c46-95bb-46e7ba8d0aa1</ndc-id>
                <ndc-product-code>66658-234</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-12-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 mg/.67mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103950</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Kineret</name>
                <ingredients>Anakinra</ingredients>
            </mixture>
            <mixture>
                <name>Kineret</name>
                <ingredients>Anakinra</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Amgen Inc.</name>
                <url>http://www.amgen.com</url>
            </packager>
            <packager>
                <name>BioVitrum AB</name>
                <url>http://www.biovitrum.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Kineret 100 mg/0.67 ml syr</description>
                <cost currency="USD">61.8</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Kineret 1 Box = 7 Syringes, 4.69ml Box</description>
                <cost currency="USD">449.9</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antirheumatic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>100 mg/.67mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>150 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L04AC03">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L04">IMMUNOSUPPRESSANTS</level>
                <level code="L04A">IMMUNOSUPPRESSANTS</level>
                <level code="L04AC">Interleukin inhibitors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>92:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1341322</number>
                <country>Canada</country>
                <approved>2001-11-27</approved>
                <expires>2018-11-27</expires>
            </patent>
            <patent>
                <number>2141953</number>
                <country>Canada</country>
                <approved>2008-04-08</approved>
                <expires>2013-09-17</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB01281</drugbank-id>
                <name>Abatacept</name>
                <description>Anakinra may enhance the adverse/toxic effect of Abatacept.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00051</drugbank-id>
                <name>Adalimumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06168</drugbank-id>
                <name>Canakinumab</name>
                <description>Interleukin-1 Receptor Antagonist may enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08904</drugbank-id>
                <name>Certolizumab pegol</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06643</drugbank-id>
                <name>Denosumab</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00005</drugbank-id>
                <name>Etanercept</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06674</drugbank-id>
                <name>golimumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00065</drugbank-id>
                <name>Infliximab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01097</drugbank-id>
                <name>Leflunomide</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00480</drugbank-id>
                <name>Lenalidomide</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00108</drugbank-id>
                <name>Natalizumab</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00337</drugbank-id>
                <name>Pimecrolimus</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08910</drugbank-id>
                <name>Pomalidomide</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01656</drugbank-id>
                <name>Roflumilast</name>
                <description>May enhance the immunosuppressive effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06688</drugbank-id>
                <name>Sipuleucel-T</name>
                <description>Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01041</drugbank-id>
                <name>Thalidomide</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08895</drugbank-id>
                <name>Tofacitinib</name>
                <description>Anakinra may enhance the adverse/toxic effect of Tofacitinib.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00072</drugbank-id>
                <name>Trastuzumab</name>
                <description>May enhance the neutropenic effect of Immunosuppressants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00026 sequence
                MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLG
                IHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGW
                FLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.412</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.46</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>17257.6000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C759H1186N208O232S10</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12604</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D02934</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>66658-234-28</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M55646</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10799</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P18510</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Anakinra</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/anakinra.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/anakinra.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000565</id>
                <name>Interleukin-1 receptor type 1</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Tang YH, Zhang SP, Liang Y, Deng CQ: [Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats] Zhong Xi Yi Jie He Xue Bao. 2007 May;5(3):328-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17498496&#13;
                    # Dayer JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii3-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12817089&#13;
                    # Vamvakopoulos J, Green C, Metcalfe S: Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol. 2002 Oct;32(10):2988-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12355453&#13;
                    # Do H, Vasilescu A, Carpentier W, Meyer L, Diop G, Hirtzig T, Coulonges C, Labib T, Spadoni JL, Therwath A, Lathrop M, Matsuda F, Zagury JF: Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis. 2006 Dec 1;194(11):1492-504. Epub 2006 Oct 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17083033&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352&#13;
                    # So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17352828&#13;
                    # Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H: Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw. 1999 Mar;10(1):37-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10210771</references>
                <known-action>yes</known-action>
                <polypeptide id="P14778" source="Swiss-Prot">
                    <name>Interleukin-1 receptor type 1</name>
                    <general-function>Involved in transmembrane receptor activity</general-function>
                    <specific-function>Receptor for interleukin-1 alpha (IL-1A), beta (IL-1B), and interleukin-1 receptor antagonist protein (IL-1RA). Binding to the agonist leads to the activation of NF-kappa-B. Signaling involves formation of a ternary complex containing IL1RAP, TOLLIP, MYD88, and IRAK1 or IRAK2</specific-function>
                    <gene-name>IL1R1</gene-name>
                    <locus>2q12</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>337-356</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.89</theoretical-pi>
                    <molecular-weight>65403.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5993</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL1R1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL1R1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16896</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33801</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P14778</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL1R1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD121a antigen</synonym>
                        <synonym>IL-1R- alpha</synonym>
                        <synonym>IL-1R-1</synonym>
                        <synonym>IL-1RT1</synonym>
                        <synonym>Interleukin-1 receptor type I precursor</synonym>
                        <synonym>p80</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interleukin-1 receptor type I precursor
                        MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKD
                        DSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNL
                        CYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDR
                        LIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDL
                        GSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISE
                        IESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFK
                        IDIVLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCG
                        YKLFIYGRDDYVGEDIVEVINENVKKSRRLIIILVRETSGFSWLGGSSEEQIAMYNALVQ
                        DGIKVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPV
                        QRRSPSSKHQLLSPATKEKLQREAHVPLG</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1710 bp
                        ATGAAAGTGTTACTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTGGAGGCT
                        GATAAATGCAAGGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGAT
                        GTTCGTCCCTGTCCTCTTAACCCAAATGAACACAAAGGCACTATAACTTGGTATAAAGAT
                        GACAGCAAGACACCTGTATCTACAGAACAAGCCTCCAGGATTCATCAACACAAAGAGAAA
                        CTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTATTGCGTGGTAAGAAAT
                        TCATCTTACTGCCTCAGAATTAAAATAAGTGCAAAATTTGTGGAGAATGAGCCTAACTTA
                        TGTTATAATGCACAAGCCATATTTAAGCAGAAACTACCCGTTGCAGGAGACGGAGGACTT
                        GTGTGCCCTTATATGGAGTTTTTTAAAAATGAAAATAATGAGTTACCTAAATTACAGTGG
                        TATAAGGATTGCAAACCTCTACTTCTTGACAATATACACTTTAGTGGAGTCAAAGATAGG
                        CTCATCGTGATGAATGTGGCTGAAAAGCATAGAGGGAACTATACTTGTCATGCATCCTAC
                        ACATACTTGGGCAAGCAATATCCTATTACCCGGGTAATAGAATTTATTACTCTAGAGGAA
                        AACAAACCCACAAGGCCTGTGATTGTGAGCCCAGCTAATGAGACAATGGAAGTAGACTTG
                        GGATCCCAGATACAATTGATCTGTAATGTCACCGGCCAGTTGAGTGACATTGCTTACTGG
                        AAGTGGAATGGGTCAGTAATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGT
                        GTGGAAAATCCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCGGAA
                        ATTGAAAGTAGATTTTATAAACATCCATTTACCTGTTTTGCCAAGAATACACATGGTATA
                        GATGCAGCATATATCCAGTTAATATATCCAGTCACTAATTTCCAGAAGCACATGATTGGT
                        ATATGTGTCACGTTGACAGTCATAATTGTGTGTTCTGTTTTCATCTATAAAATCTTCAAG
                        ATTGACATTGTGCTTTGGTACAGGGATTCCTGCTATGATTTTCTCCCAATAAAAGCTTCA
                        GATGGAAAGACCTATGACGCATATATACTGTATCCAAAGACTGTTGGGGAAGGGTCTACC
                        TCTGACTGTGATATTTTTGTGTTTAAAGTCTTGCCTGAGGTCTTGGAAAAACAGTGTGGA
                        TATAAGCTGTTCATTTATGGAAGGGATGACTACGTTGGGGAAGACATTGTTGAGGTCATT
                        AATGAAAACGTAAAGAAAAGCAGAAGACTGATTATCATTTTAGTCAGAGAAACATCAGGC
                        TTCAGCTGGCTGGGTGGTTCATCTGAAGAGCAAATAGCCATGTATAATGCTCTTGTTCAG
                        GATGGAATTAAAGTTGTCCTGCTTGAGCTGGAGAAAATCCAAGACTATGAGAAAATGCCA
                        GAATCGATTAAATTCATTAAGCAGAAACATGGGGCTATCCGCTGGTCAGGGGACTTTACA
                        CAGGGACCACAGTCTGCAAAGACAAGGTTCTGGAAGAATGTCAGGTACCACATGCCAGTC
                        CAGCGACGGTCACCTTCATCTAAACACCAGTTACTGTCACCAGCCACTAAGGAGAAACTG
                        CAAAGAGAGGCTCACGTGCCTCTCGGGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01582</identifier>
                            <name>TIR</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>interleukin-1 receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>interleukin-1, Type I, activating receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>interleukin receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-07-31">
        <drugbank-id primary="true">DB00027</drugbank-id>
        <drugbank-id>BIOD00036</drugbank-id>
        <drugbank-id>BTD00036</drugbank-id>
        <name>Gramicidin D</name>
        <description>Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively gramicidin D.  Gramcidins are 15 residue peptides with alternating D and L amino acids.  The peptides assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix. The helix itself is not long enough to span the membrane but it dimerizes to form the elongated channel needed to span the whole membrane. Gramicidin D is used primarily as a topical antibiotic and is one of the three constituents of consumer antibiotic polysporin ophthalmic solution.</description>
        <cas-number>1405-97-6</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Ketchem RR, Lee KC, Huo S, Cross TA: Macromolecular structural elucidation with solid-state NMR-derived orientational constraints. J Biomol NMR. 1996 Jul;8(1):1-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8810522&#13;
            # Townsley LE, Tucker WA, Sham S, Hinton JF: Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11570868&#13;
            # Burkhart BM, Gassman RM, Langs DA, Pangborn WA, Duax WL, Pletnev V: Gramicidin D conformation, dynamics and membrane ion transport. Biopolymers. 1999;51(2):129-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10397797</general-references>
        <synthesis-reference>U.S.Patent 2,534,541.</synthesis-reference>
        <indication>For treatment of skin lesions, surface wounds and eye infections</indication>
        <pharmacodynamics>Gramicidin is particularly effective against gram-positive bacteria. Because the drug is highly hemolytic, it cannot be administered internally and so is used only on the skin as a lotion or ointment. It is used primarily in the treatment of infected surface wounds, and in eye, nose, and throat infections. It is normally given with two other antibiotics (neomycin and polymixin B) as an ophthalmic solution</pharmacodynamics>
        <mechanism-of-action>Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization (it acts as a channel). This leads to (i) loss of intracellular solutes (e.g., K+ and amino acids); (ii) dissipation of the transmembrane potential; (iii) inhibition of respiration; (iv) a reduction in ATP pools; and (v) inhibition of DNA, RNA, and protein synthesis, which leads to cell death.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Gramicidin</synonym>
            <synonym language="" coder="">Gramicidin A</synonym>
            <synonym language="" coder="">Gramicidin B</synonym>
            <synonym language="" coder="">Gramicidin C</synonym>
            <synonym language="" coder="">Gramicidine</synonym>
        </synonyms>
        <products>
            <product>
                <name>Ak Spor Liq</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00635065</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>liquid</dosage-form>
                <strength>10000 unit</strength>
                <route>ophthalmic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02311844</dpd-id>
                <started-marketing-on>2009-12-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02208288</dpd-id>
                <started-marketing-on>1998-11-03</started-marketing-on>
                <ended-marketing-on>2005-08-05</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02372029</dpd-id>
                <started-marketing-on>2012-03-22</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream for Kids</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02315033</dpd-id>
                <started-marketing-on>2009-07-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream for Kids</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02317974</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream Plus Pain Relief</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02317834</dpd-id>
                <started-marketing-on>2009-12-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream Plus Pain Relief</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02372045</dpd-id>
                <started-marketing-on>2012-04-09</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>40 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Cream Plus Pain Relief for Kids</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02377187</dpd-id>
                <started-marketing-on>2012-07-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>40 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Antibiotic Plus Pain Relief Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02304457</dpd-id>
                <started-marketing-on>2009-07-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kenacomb Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01999850</dpd-id>
                <started-marketing-on>1965-12-31</started-marketing-on>
                <ended-marketing-on>2004-08-05</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kenacomb Mild Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01999842</dpd-id>
                <started-marketing-on>1968-12-31</started-marketing-on>
                <ended-marketing-on>2004-08-05</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>.25 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kenacomb Mild Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01999834</dpd-id>
                <started-marketing-on>1968-12-31</started-marketing-on>
                <ended-marketing-on>2004-08-05</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>.25 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kenacomb Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01999826</dpd-id>
                <started-marketing-on>1996-07-31</started-marketing-on>
                <ended-marketing-on>2004-08-05</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Kenacomb Ont</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00245267</dpd-id>
                <started-marketing-on>1965-12-31</started-marketing-on>
                <ended-marketing-on>1997-08-14</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lidecomb Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00492442</dpd-id>
                <started-marketing-on>1980-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-25</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>0.5 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lidosporin Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230842</dpd-id>
                <started-marketing-on>1998-07-08</started-marketing-on>
                <ended-marketing-on>2000-11-27</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lidosporin Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01966006</dpd-id>
                <started-marketing-on>1971-12-31</started-marketing-on>
                <ended-marketing-on>2000-08-03</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Mecomb Crm 0.1%</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00464554</dpd-id>
                <started-marketing-on>1979-12-31</started-marketing-on>
                <ended-marketing-on>2003-07-17</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Neocidin</name>
                <ndc-id>0904-3016_b7aa0bae-255b-4792-a963-6606370a175f</ndc-id>
                <ndc-product-code>0904-3016</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2004-06-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution/ drops</dosage-form>
                <strength>1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL</strength>
                <route>ophthalmic</route>
                <fda-application-number>ANDA064047</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ndc-id>54569-1188_dfc13b9e-15f1-40dd-bc59-b1eb48ee5dac</ndc-id>
                <ndc-product-code>54569-1188</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1996-01-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution/ drops</dosage-form>
                <strength>1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL</strength>
                <route>ophthalmic</route>
                <fda-application-number>ANDA064047</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ndc-id>24208-790_e0a6cfdc-12c3-471f-ad46-ad2868caf94b</ndc-id>
                <ndc-product-code>24208-790</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1996-01-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution/ drops</dosage-form>
                <strength>1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL</strength>
                <route>ophthalmic</route>
                <fda-application-number>ANDA064047</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ndc-id>55045-1194_07080003-b495-447a-bb9d-0efbe866e37a</ndc-id>
                <ndc-product-code>55045-1194</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1996-01-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution/ drops</dosage-form>
                <strength>1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL</strength>
                <route>ophthalmic</route>
                <fda-application-number>ANDA064047</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ndc-id>21695-528_65edc059-0806-4625-b583-0e36f04cf085</ndc-id>
                <ndc-product-code>21695-528</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1996-01-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution/ drops</dosage-form>
                <strength>1.75; 10000; .025 mg/mL; mg/mL; mg/mL</strength>
                <route>ophthalmic</route>
                <fda-application-number>ANDA064047</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ndc-id>54868-6253_96b4ed40-9853-4ac2-8b3a-4548355d1c40</ndc-id>
                <ndc-product-code>54868-6253</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-04-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution/ drops</dosage-form>
                <strength>1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL</strength>
                <route>ophthalmic</route>
                <fda-application-number>ANDA064047</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Neosporin</name>
                <ndc-id>61570-045_b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2</ndc-id>
                <ndc-product-code>61570-045</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1955-04-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>1.75; 10000; .025 mg/mL; [iU]/mL; mg/mL</strength>
                <route>ophthalmic</route>
                <fda-application-number>ANDA060582</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Neosporin Antibiotic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00666203</dpd-id>
                <started-marketing-on>1986-12-31</started-marketing-on>
                <ended-marketing-on>2007-12-19</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Neosporin Eye-ear Solution</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00694371</dpd-id>
                <started-marketing-on>1987-12-31</started-marketing-on>
                <ended-marketing-on>2006-11-21</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>10000 unit</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Optimyxin Oto/opht Gtte</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00701785</dpd-id>
                <started-marketing-on>1989-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>drops</dosage-form>
                <strength>10000 unit</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Optimyxin Plus Oto-opht Gtte</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00807435</dpd-id>
                <started-marketing-on>1989-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>drops</dosage-form>
                <strength>10000 unit</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Original Antibiotic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401002</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Original Antibiotic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02317656</dpd-id>
                <started-marketing-on>2010-10-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polycidin Eye, Ear Drops</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02229903</dpd-id>
                <started-marketing-on>1997-01-30</started-marketing-on>
                <ended-marketing-on>2002-09-10</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>10000 unit</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Antibiotic Burn Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230843</dpd-id>
                <started-marketing-on>1998-07-08</started-marketing-on>
                <ended-marketing-on>1999-06-18</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Antibiotic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230844</dpd-id>
                <started-marketing-on>1997-08-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Burn Formula Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00068535</dpd-id>
                <started-marketing-on>1991-12-31</started-marketing-on>
                <ended-marketing-on>2000-08-03</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00035335</dpd-id>
                <started-marketing-on>1971-12-31</started-marketing-on>
                <ended-marketing-on>2000-08-03</ended-marketing-on>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Eye and Ear Drops Sterile</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00035343</dpd-id>
                <started-marketing-on>1971-12-31</started-marketing-on>
                <ended-marketing-on>2000-08-03</ended-marketing-on>
                <dosage-form>drops</dosage-form>
                <strength>10000 unit</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Eye and Ear Drops Sterile</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239156</dpd-id>
                <started-marketing-on>2000-02-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>drops</dosage-form>
                <strength>10000 unit</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin for Kids</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02248189</dpd-id>
                <started-marketing-on>2004-04-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Plus Pain Relief</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239201</dpd-id>
                <started-marketing-on>1999-06-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>50 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Triple Antibiotic Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02194104</dpd-id>
                <started-marketing-on>1996-12-31</started-marketing-on>
                <ended-marketing-on>2000-08-03</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>500 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polysporin Triple Antibiotic Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230847</dpd-id>
                <started-marketing-on>1998-07-08</started-marketing-on>
                <ended-marketing-on>1999-08-13</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>500 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Polytopic Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00422908</dpd-id>
                <started-marketing-on>1997-01-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>10000 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ratio-triacomb</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00550507</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sandoz Opticort</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02247920</dpd-id>
                <started-marketing-on>2004-01-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>0.5 mg</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sofracort Ear/eye Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00173606</dpd-id>
                <started-marketing-on>1966-12-31</started-marketing-on>
                <ended-marketing-on>1996-09-09</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>.5 mg</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sofracort Sterile Ear/eye Drops</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01987712</dpd-id>
                <started-marketing-on>1966-12-31</started-marketing-on>
                <ended-marketing-on>2004-07-30</ended-marketing-on>
                <dosage-form>drops</dosage-form>
                <strength>.5 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sofracort Sterile Ear/eye Drops</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02224623</dpd-id>
                <started-marketing-on>2002-07-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>drops</dosage-form>
                <strength>0.5 mg</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sofracort Sterile Ear/eye Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02224631</dpd-id>
                <started-marketing-on>1999-10-25</started-marketing-on>
                <ended-marketing-on>2006-07-28</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>0.5 mg</strength>
                <route>ophthalmic; otic</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sofracort Sterile Ear/eye Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01987720</dpd-id>
                <started-marketing-on>1966-12-31</started-marketing-on>
                <ended-marketing-on>2001-07-20</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>.5 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Soframycin Nasal Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01987690</dpd-id>
                <started-marketing-on>1994-12-31</started-marketing-on>
                <ended-marketing-on>1998-08-12</ended-marketing-on>
                <dosage-form>spray</dosage-form>
                <strength>2.5 mg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Soframycin Nasal Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02224860</dpd-id>
                <started-marketing-on>2001-05-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray</dosage-form>
                <strength>2.5 mg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Soframycin Nasal Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00173584</dpd-id>
                <started-marketing-on>1959-12-31</started-marketing-on>
                <ended-marketing-on>1996-09-09</ended-marketing-on>
                <dosage-form>spray</dosage-form>
                <strength>2.5 mg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Soframycin Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00026972</dpd-id>
                <started-marketing-on>1961-12-31</started-marketing-on>
                <ended-marketing-on>1997-08-05</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>.05 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Soframycin Skin Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01987674</dpd-id>
                <started-marketing-on>1995-12-31</started-marketing-on>
                <ended-marketing-on>2000-07-28</ended-marketing-on>
                <dosage-form>ointment</dosage-form>
                <strength>50 mcg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Soframycin Skin Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02224879</dpd-id>
                <started-marketing-on>2001-05-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>ointment</dosage-form>
                <strength>50 mcg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Theraderm Cream</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02022818</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Triple Antibiotic Ointment</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02088339</dpd-id>
                <started-marketing-on>1994-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>ointment</dosage-form>
                <strength>500 unit</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Viaderm Kc Crm</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00717002</dpd-id>
                <started-marketing-on>1983-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>cream</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Viaderm Kc Ont</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00717029</dpd-id>
                <started-marketing-on>1983-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>ointment</dosage-form>
                <strength>1 mg</strength>
                <route>topical</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Sofradex</name>
                <company>Sanofi</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Neocidin</name>
                <ingredients>Neomycin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ingredients>Neomycin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ingredients>Neomycin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ingredients>Neomycin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ingredients>Neomycin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
                <ingredients>Neomycin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Neosporin</name>
                <ingredients>Neomycin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Optimyxin Oto/opht Gtte</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Optimyxin Plus Oto-opht Gtte</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Ratio-triacomb</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Ak Spor Liq</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Theraderm Cream</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Triple Antibiotic Ointment</name>
                <ingredients>Bacitracin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Sofracort Sterile Ear/eye Drops</name>
                <ingredients>Dexamethasone + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Soframycin Nasal Spray</name>
                <ingredients>Phenylephrine + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Soframycin Skin Ointment</name>
                <ingredients>Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Antibiotic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Polytopic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Eye and Ear Drops Sterile</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Plus Pain Relief</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Sandoz Opticort</name>
                <ingredients>Dexamethasone + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin for Kids</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Plus Pain Relief Cream</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream for Kids</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Original Antibiotic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream Plus Pain Relief</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream Plus Pain Relief</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream Plus Pain Relief for Kids</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Viaderm Kc Crm</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Viaderm Kc Ont</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Eye and Ear Drops Sterile</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Lidosporin Cream</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Burn Formula Cream</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Kenacomb Ont</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Sofracort Sterile Ear/eye Drops</name>
                <ingredients>Dexamethasone + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Soframycin Nasal Spray</name>
                <ingredients>Phenylephrine + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Kenacomb Mild Cream</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Sofracort Sterile Ear/eye Ointment</name>
                <ingredients>Dexamethasone + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Kenacomb Cream</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Soframycin Skin Ointment</name>
                <ingredients>Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Kenacomb Mild Ointment</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Triple Antibiotic Ointment</name>
                <ingredients>Bacitracin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Kenacomb Ointment</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Sofracort Ear/eye Ointment</name>
                <ingredients>Dexamethasone + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Soframycin Nasal Spray</name>
                <ingredients>Phenylephrine + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Mecomb Crm 0.1%</name>
                <ingredients>Triamcinolone + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Sofracort Sterile Ear/eye Ointment</name>
                <ingredients>Dexamethasone + Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Lidecomb Cream</name>
                <ingredients>Fluocinonide + Nystatin + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Polycidin Eye, Ear Drops</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Antibiotic Burn Cream</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Polysporin Triple Antibiotic Ointment</name>
                <ingredients>Bacitracin + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Lidosporin Cream</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Neosporin Antibiotic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Neosporin Eye-ear Solution</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D + Neomycin</ingredients>
            </mixture>
            <mixture>
                <name>Soframycin Ointment</name>
                <ingredients>Gramicidin D + Framycetin</ingredients>
            </mixture>
            <mixture>
                <name>Antibiotic Cream for Kids</name>
                <ingredients>Lidocaine + Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
            <mixture>
                <name>Original Antibiotic Cream</name>
                <ingredients>Polymyxin B Sulfate + Gramicidin D</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Johnson &amp; Johnson Healthcare</name>
                <url>http://www.jnjcanada.com</url>
            </packager>
            <packager>
                <name>Monarch Pharmacy</name>
                <url>http://www.monarch-pharmacy.co.uk</url>
            </packager>
            <packager>
                <name>Professional Co.</name>
                <url/>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Neosporin gu irr 40 mg/ml amp</description>
                <cost currency="USD">23.12</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Gramicidin d powder</description>
                <cost currency="USD">240.0</cost>
                <unit>g</unit>
            </price>
            <price>
                <description>Neosporin + pain relief cream</description>
                <cost currency="USD">0.32</cost>
                <unit>g</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Anti-Bacterial Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-Infective Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Antibiotics</category>
                <mesh-id/>
            </category>
            <category>
                <category>Antibiotics, Topical</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Pseudomonas aeruginosa</affected-organism>
            <affected-organism>Streptococcus pneumoniae</affected-organism>
            <affected-organism>Streptococcus agalactiae</affected-organism>
            <affected-organism>Neisseria meningitidis</affected-organism>
            <affected-organism>Haemophilus influenzae</affected-organism>
            <affected-organism>Neisseria gonorrhoeae</affected-organism>
            <affected-organism>Escherichia coli</affected-organism>
            <affected-organism>Staphylococcus aureus</affected-organism>
            <affected-organism>Klebsiella</affected-organism>
            <affected-organism>Enterobacter</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid</form>
                <route>ophthalmic</route>
                <strength>10000 unit</strength>
            </dosage>
            <dosage>
                <form>Cream</form>
                <route>topical</route>
                <strength>40 mg</strength>
            </dosage>
            <dosage>
                <form>Cream</form>
                <route>topical</route>
                <strength>.25 mg</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>topical</route>
                <strength>.25 mg</strength>
            </dosage>
            <dosage>
                <form>Cream</form>
                <route>topical</route>
                <strength>0.5 mg</strength>
            </dosage>
            <dosage>
                <form>Solution/ drops</form>
                <route>ophthalmic</route>
                <strength>1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL</strength>
            </dosage>
            <dosage>
                <form>Solution/ drops</form>
                <route>ophthalmic</route>
                <strength>1.75; 10000; .025 mg/mL; mg/mL; mg/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>ophthalmic</route>
                <strength>1.75; 10000; .025 mg/mL; [iU]/mL; mg/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>ophthalmic; otic</route>
                <strength>10000 unit</strength>
            </dosage>
            <dosage>
                <form>Drops</form>
                <route>ophthalmic; otic</route>
                <strength>10000 unit</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>ophthalmic; otic</route>
                <strength>10000 unit</strength>
            </dosage>
            <dosage>
                <form>Cream</form>
                <route>topical</route>
                <strength>10000 unit</strength>
            </dosage>
            <dosage>
                <form>Cream</form>
                <route>topical</route>
                <strength>50 mg</strength>
            </dosage>
            <dosage>
                <form>Cream</form>
                <route>topical</route>
                <strength>1 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>ophthalmic; otic</route>
                <strength>0.5 mg</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>ophthalmic; otic</route>
                <strength>.5 mg</strength>
            </dosage>
            <dosage>
                <form>Drops</form>
                <route>ophthalmic; otic</route>
                <strength>0.5 mg</strength>
            </dosage>
            <dosage>
                <form>Drops</form>
                <route>topical</route>
                <strength>.5 mg</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>ophthalmic; otic</route>
                <strength>0.5 mg</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>topical</route>
                <strength>.5 mg</strength>
            </dosage>
            <dosage>
                <form>Spray</form>
                <route>nasal</route>
                <strength>2.5 mg</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>topical</route>
                <strength>.05 mg</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>topical</route>
                <strength>50 mcg</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>topical</route>
                <strength>500 unit</strength>
            </dosage>
            <dosage>
                <form>Ointment</form>
                <route>topical</route>
                <strength>1 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="R02AB30">
                <level code="R">RESPIRATORY SYSTEM</level>
                <level code="R02">THROAT PREPARATIONS</level>
                <level code="R02A">THROAT PREPARATIONS</level>
                <level code="R02AB">Antibiotics</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences/>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>229 °C</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>1882.2947</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C99H140N20O17</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>8523</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D04369</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA449808</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Gramicidin_D</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links/>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets/>
        <enzymes/>
        <carriers/>
        <transporters>
            <transporter position="1">
                <id>BE0001032</id>
                <name>Multidrug resistance protein 1</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14985103</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08183" source="Swiss-Prot">
                    <name>Multidrug resistance protein 1</name>
                    <general-function>Defense mechanisms and drug export</general-function>
                    <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells</specific-function>
                    <gene-name>ABCB1</gene-name>
                    <locus>7q21.1</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>52-72
                        120-140
                        189-209
                        216-236
                        297-317
                        326-346
                        711-731
                        757-777
                        833-853
                        854-874
                        937-957
                        974-994</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.44</theoretical-pi>
                    <molecular-weight>141464.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:40</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>ABCB1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>ABCB1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M14758</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>307180</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08183</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>MDR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>ATP-binding cassette sub-family B member 1</synonym>
                        <synonym>CD243 antigen</synonym>
                        <synonym>EC 3.6.3.44</synonym>
                        <synonym>P-glycoprotein 1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Multidrug resistance protein 1
                        MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
                        HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
                        IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
                        KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
                        DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
                        AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
                        AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
                        QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
                        ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
                        IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
                        FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
                        SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
                        NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
                        GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
                        ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGAGKIATEA
                        IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
                        AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
                        YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
                        QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
                        SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
                        EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
                        LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;3843 bp
                        ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
                        AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
                        CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
                        CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
                        AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
                        ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
                        ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
                        GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
                        GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCT
                        AAGATTAATGAAGTTATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
                        TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
                        ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
                        GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
                        ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
                        TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
                        GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
                        GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
                        GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
                        GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
                        AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
                        TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGCCTGAACCTGAAGGTGCAGAGTGGG
                        CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
                        CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
                        ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
                        GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
                        GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
                        GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
                        ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
                        TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
                        ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
                        TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
                        ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
                        GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
                        AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
                        AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
                        ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
                        AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
                        AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
                        GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
                        GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
                        GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
                        GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
                        GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
                        CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
                        GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTGCTGGGAAGATCGCTACTGAAGCA
                        ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
                        GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
                        ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
                        GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
                        GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
                        GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
                        TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
                        GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
                        AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
                        CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
                        ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
                        ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
                        TCACAGGAAGAGATCGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
                        CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
                        AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
                        GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
                        GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
                        GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
                        CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
                        TGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00005</identifier>
                            <name>ABC_tran</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00664</identifier>
                            <name>ABC_membrane</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATPase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATPase activity, coupled to transmembrane movement of substances</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity, acting on acid anhydrides</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>pyrophosphatase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleoside-triphosphatase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </transporter>
        </transporters>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-23">
        <drugbank-id primary="true">DB00028</drugbank-id>
        <drugbank-id>BIOD00091</drugbank-id>
        <drugbank-id>BTD00091</drugbank-id>
        <name>Intravenous Immunoglobulin</name>
        <description>Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.</description>
        <cas-number>9007-83-4</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. Epub 2010 Dec 9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20970960&#13;
            # Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
            # Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16998749&#13;
            # Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12032582&#13;
            # http://www.path.cam.ac.uk/~mrc7/lecturenotes/handout1a.pdf</general-references>
        <synthesis-reference>Wolfgang Stephan, "Production of intravenously applicable native human immune globulin having a normal half-life." U.S. Patent US4082734, issued July, 1970.</synthesis-reference>
        <indication>IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.</indication>
        <pharmacodynamics>Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.</pharmacodynamics>
        <mechanism-of-action>IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>&gt;20 hours (mammalian reticulocytes, in vitro).</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Ig alpha-2 chain C region</synonym>
            <synonym language="" coder="">immune globulin</synonym>
            <synonym language="" coder="">Immunoglobulin G</synonym>
        </synonyms>
        <products>
            <product>
                <name>Gamastan</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00083259</dpd-id>
                <started-marketing-on>1951-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-25</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>16.5 %</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gamastan S/d</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230579</dpd-id>
                <started-marketing-on>2004-03-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>18 %</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gamimune N 10%  (iv)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02229695</dpd-id>
                <started-marketing-on>2000-05-16</started-marketing-on>
                <ended-marketing-on>2006-08-03</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>100 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gamimune N 5%  (iv)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02178842</dpd-id>
                <started-marketing-on>1997-01-17</started-marketing-on>
                <ended-marketing-on>2006-08-03</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gamimune N Inj 5%  (iv)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00559261</dpd-id>
                <started-marketing-on>1986-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-25</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gammagard Liquid</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02279444</dpd-id>
                <started-marketing-on>2007-08-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 %</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gammagard S/d</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231470</dpd-id>
                <started-marketing-on>1997-08-22</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>5 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gammagard S/d</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231471</dpd-id>
                <started-marketing-on>1997-08-22</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>10 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gammagard S/d</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231469</dpd-id>
                <started-marketing-on>1997-08-22</started-marketing-on>
                <ended-marketing-on>2015-05-12</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>2.5 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gammagard S/d  (iv)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231468</dpd-id>
                <started-marketing-on>1997-08-22</started-marketing-on>
                <ended-marketing-on>2013-11-04</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.5 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gammar Inj 165mg/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01915312</dpd-id>
                <started-marketing-on>1991-12-31</started-marketing-on>
                <ended-marketing-on>1999-12-15</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>165 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Gamunex</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02247724</dpd-id>
                <started-marketing-on>2003-10-22</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 g</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Hizentra</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02370352</dpd-id>
                <started-marketing-on>2011-10-13</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Hyperrho S/d Full Dose</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02379457</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>1500 unit</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Hyperrho S/d Full Dose</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243524</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>1500 unit</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Igivnex</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02277921</dpd-id>
                <started-marketing-on>2006-05-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 g</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Immune Globulin Intravenous (human) 5%</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02185342</dpd-id>
                <started-marketing-on>1996-12-31</started-marketing-on>
                <ended-marketing-on>1998-09-28</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Immune Globulin Intravenous (human), 10%</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230920</dpd-id>
                <started-marketing-on>2000-07-31</started-marketing-on>
                <ended-marketing-on>2006-08-03</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>10 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Immune Globulin Intravenous (human), 5%</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230919</dpd-id>
                <started-marketing-on>1997-11-03</started-marketing-on>
                <ended-marketing-on>2006-08-03</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>5 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Immune Serum Globulin (human)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230647</dpd-id>
                <started-marketing-on>1997-04-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>18 %</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Iveegam Immuno 5000mg  (iv)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01959301</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>2008-12-23</ended-marketing-on>
                <dosage-form>kit; liquid; powder for solution</dosage-form>
                <strength>5 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Octagam 10%</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02380145</dpd-id>
                <started-marketing-on>2013-04-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Octagam 5%</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02267713</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Privigen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02304619</dpd-id>
                <started-marketing-on>2009-01-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 %</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Sandoglobulin Nf Liquid</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02287994</dpd-id>
                <started-marketing-on>2007-06-28</started-marketing-on>
                <ended-marketing-on>2010-04-20</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>120 g</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Vivaglobin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02282518</dpd-id>
                <started-marketing-on>2007-03-01</started-marketing-on>
                <ended-marketing-on>2015-04-02</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>160 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Civacir</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Flebogamma</name>
                <company>Instituto Grifols SA</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Gamastan S/d</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Immune Serum Globulin (human)</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gammagard S/d</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gammagard S/d</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gamunex</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Igivnex</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gammagard Liquid</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Privigen</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Hizentra</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Octagam 10%</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gammar Inj 165mg/ml</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Iveegam Immuno 5000mg  (iv)</name>
                <ingredients>Intravenous Immunoglobulin + Water</ingredients>
            </mixture>
            <mixture>
                <name>Immune Globulin Intravenous (human) 5%</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gamimune N 5%  (iv)</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gamastan</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gamimune N 10%  (iv)</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Immune Globulin Intravenous (human), 5%</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Immune Globulin Intravenous (human), 10%</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gammagard S/d  (iv)</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gammagard S/d</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Gamimune N Inj 5%  (iv)</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Vivaglobin</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Sandoglobulin Nf Liquid</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Hyperrho S/d Full Dose</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Octagam 5%</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
            <mixture>
                <name>Hyperrho S/d Full Dose</name>
                <ingredients>Intravenous Immunoglobulin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Alpha Therapeutic Corp.</name>
                <url/>
            </packager>
            <packager>
                <name>American Red Cross</name>
                <url>http://www.redcross.org</url>
            </packager>
            <packager>
                <name>Baxter International Inc.</name>
                <url>http://www.baxter.com</url>
            </packager>
            <packager>
                <name>Biotest Pharmaceuticals</name>
                <url>http://www.biotestpharma.com</url>
            </packager>
            <packager>
                <name>Cangene Corp.</name>
                <url>http://www.cangene.com</url>
            </packager>
            <packager>
                <name>CSL Behring LLC</name>
                <url>http://www.cslbehring.com</url>
            </packager>
            <packager>
                <name>Grifols SA</name>
                <url>http://www.grifols.com</url>
            </packager>
            <packager>
                <name>Massachusetts Public Health</name>
                <url>http://www.mphaweb.org</url>
            </packager>
            <packager>
                <name>Massbiologics</name>
                <url>http://www.massbio.org</url>
            </packager>
            <packager>
                <name>Medimmune Inc.</name>
                <url>http://www.medimmune.com</url>
            </packager>
            <packager>
                <name>Novartis AG</name>
                <url>http://www.novartis.com</url>
            </packager>
            <packager>
                <name>Octapharma USA</name>
                <url>http://www.octapharma.com</url>
            </packager>
            <packager>
                <name>Talecris Biotherapeutics</name>
                <url>http://www.talecris.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Flebogamma 5% vial</description>
                <cost currency="USD">4.84</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Flebogamma dif 5% vial</description>
                <cost currency="USD">4.84</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Immune globulin vial</description>
                <cost currency="USD">9.34</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Gamunex 10% vial</description>
                <cost currency="USD">11.6</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Gammagard liquid 10% vial</description>
                <cost currency="USD">13.79</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Gamastan s-d vial</description>
                <cost currency="USD">24.44</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Hizentra 1 gram/5 ml vial</description>
                <cost currency="USD">30.24</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Hizentra 2 gram/10 ml vial</description>
                <cost currency="USD">30.24</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Hizentra 4 gram/20 ml vial</description>
                <cost currency="USD">30.24</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Hyperhep b s-d vial</description>
                <cost currency="USD">165.04</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Nabi-hb vial</description>
                <cost currency="USD">176.34</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Hyperrab s-d vial</description>
                <cost currency="USD">224.07</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Hypertet s-d 250 unit syringe</description>
                <cost currency="USD">324.23</cost>
                <unit>syringe</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunologic Factors</category>
                <mesh-id/>
            </category>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-Infective Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
            <affected-organism>Bacteria and protozoa</affected-organism>
            <affected-organism>Various viruses</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular</route>
                <strength>16.5 %</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular</route>
                <strength>18 %</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>50 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>10 %</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>10 g</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>2.5 g</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>5 g</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>0.5 g</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular</route>
                <strength>165 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>10 g</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>200 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular</route>
                <strength>1500 unit</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intravenous</route>
                <strength>50 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>10 g</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>5 g</strength>
            </dosage>
            <dosage>
                <form>Kit; liquid; powder for solution</form>
                <route>intravenous</route>
                <strength>5 g</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>100 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>120 g</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>160 mg</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes>
            <ahfs-code>80:04.00</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00304</drugbank-id>
                <name>Desogestrel</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01395</drugbank-id>
                <name>Drospirenone</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00783</drugbank-id>
                <name>Estradiol</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04574</drugbank-id>
                <name>Estropipate</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00977</drugbank-id>
                <name>Ethinyl Estradiol</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00823</drugbank-id>
                <name>Ethynodiol</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01357</drugbank-id>
                <name>Mestranol</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00957</drugbank-id>
                <name>Norgestimate</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00592</drugbank-id>
                <name>Piperazine</name>
                <description>Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;IGG1
                PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGV
                PDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVT
                LFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS
                YLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTV
                SGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKL
                SSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
                LVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
                KPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYV
                DGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKA
                KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
                SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL</sequence>
            <sequence format="FASTA">&gt;IgA2
                ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPS
                RFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPP
                SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
                LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKAS
                GYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSS
                LRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVV
                ACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVT
                CHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASG
                ATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTA
                NITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYL
                TWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPT
                HVNVSVVMAEVDGTCY</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
                <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.331</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.13</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>142682.3000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C6332H9826N1692O1980S42</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>7773</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>15161</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>67467-843-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00221</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164754884</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01877</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/baygam.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/immune-globulin-human.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000710</id>
                <name>High affinity immunoglobulin gamma Fc receptor I</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
                    # Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760</references>
                <known-action>yes</known-action>
                <polypeptide id="P12314" source="Swiss-Prot">
                    <name>High affinity immunoglobulin gamma Fc receptor I</name>
                    <general-function>Involved in receptor signaling protein activity</general-function>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. High affinity receptor</specific-function>
                    <gene-name>FCGR1A</gene-name>
                    <locus>1q21.2-q21.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>293-313</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.08</theoretical-pi>
                    <molecular-weight>42632.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3613</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X14356</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31332</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12314</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCGR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD64 antigen</synonym>
                        <synonym>Fc-gamma RI</synonym>
                        <synonym>FcRI</synonym>
                        <synonym>High affinity immunoglobulin gamma Fc receptor I precursor</synonym>
                        <synonym>IgG Fc receptor I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin gamma Fc receptor I precursor
                        MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
                        TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
                        ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
                        ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
                        TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
                        IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
                        LQEGVHRKEPQGAT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1125 bp
                        ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
                        AAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
                        TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
                        ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
                        GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
                        CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
                        GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
                        GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
                        AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
                        ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
                        CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
                        CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
                        ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
                        GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
                        CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
                        ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
                        AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC
                        CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
                        CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0004684</id>
                <name>High affinity immunoglobulin gamma Fc receptor IB</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
                    # Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760</references>
                <known-action>yes</known-action>
                <polypeptide id="Q92637" source="Swiss-Prot">
                    <name>High affinity immunoglobulin gamma Fc receptor IB</name>
                    <general-function>Involved in interferon-gamma-mediated signaling pathway</general-function>
                    <specific-function>May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.</specific-function>
                    <gene-name>FCGR1B</gene-name>
                    <locus/>
                    <cellular-location/>
                    <transmembrane-regions/>
                    <signal-regions/>
                    <theoretical-pi/>
                    <molecular-weight>32231.795</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q92637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCGRB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin gamma Fc receptor IB
                        MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
                        TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFMEGEPL
                        ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
                        ISQYTVKGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWNLEISLDSGHE
                        KKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT</amino-acid-sequence>
                    <gene-sequence format="FASTA"/>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0002098</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
                    # Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760</references>
                <known-action>yes</known-action>
                <polypeptide id="P12318" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens</specific-function>
                    <gene-name>FCGR2A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.78</theoretical-pi>
                    <molecular-weight>34990.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3616</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31932</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182474</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-a</synonym>
                        <synonym>Fc-gamma-RIIa</synonym>
                        <synonym>FcRII-a</synonym>
                        <synonym>IgG Fc receptor II-a</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-a precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-a
                        MAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
                        TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
                        SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS
                        HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
                        CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
                        KNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;954 bp
                        ATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
                        CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
                        GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
                        ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
                        CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
                        GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
                        TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
                        CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
                        AAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
                        CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
                        GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
                        GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
                        TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
                        CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
                        TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
                        AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0002099</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
                    # Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760</references>
                <known-action>yes</known-action>
                <polypeptide id="P31994" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis</specific-function>
                    <gene-name>FCGR2B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.12</theoretical-pi>
                    <molecular-weight>34044.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3618</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U87560</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4099445</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31994</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-b</synonym>
                        <synonym>Fc-gamma-RIIb</synonym>
                        <synonym>FcRII-b</synonym>
                        <synonym>IgG Fc receptor II-b</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-b precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-b
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
                        LEEPDDQNRI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;930 bp
                        ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG
                        TGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG
                        GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
                        CTGGAAGAGCCTGATGACCAGAACCGTATT</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0002100</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
                    # Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760</references>
                <known-action>yes</known-action>
                <polypeptide id="P31995" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells</specific-function>
                    <gene-name>FCGR2C</gene-name>
                    <locus>1q23.3</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>224-246</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.9</theoretical-pi>
                    <molecular-weight>35578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:15626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X17652</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>32074</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31995</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2C_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-c</synonym>
                        <synonym>Fc-gamma-RIIc</synonym>
                        <synonym>FcRII-c</synonym>
                        <synonym>IgG Fc receptor II-c</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-c precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-c
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
                        APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;972 bp
                        ATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
                        AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
                        GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
                        GCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC
                        AGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0002097</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
                    # Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760</references>
                <known-action>yes</known-action>
                <polypeptide id="P08637" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis</specific-function>
                    <gene-name>FCGR3A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>209-229</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.21</theoretical-pi>
                    <molecular-weight>29089.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3619</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X52645</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31324</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16a antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-alpha</synonym>
                        <synonym>Fc-gamma RIIIa</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIa</synonym>
                        <synonym>IgG Fc receptor III-2</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-A
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
                        VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
                        KDHKFKWRKDPQDK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;765 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA
                        AAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG
                        AAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0000901</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465&#13;
                    # Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760</references>
                <known-action>yes</known-action>
                <polypeptide id="O75015" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils</specific-function>
                    <gene-name>FCGR3B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.71</theoretical-pi>
                    <molecular-weight>26216.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3620</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16863</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31322</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O75015</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16b antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-beta</synonym>
                        <synonym>Fc-gamma RIIIb</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIb</synonym>
                        <synonym>IgG Fc receptor III-1</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-B precursor
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
                        VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
                        AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0003455</id>
                <name>Complement C3</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760&#13;
                    # Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465</references>
                <known-action>yes</known-action>
                <polypeptide id="P01024" source="Swiss-Prot">
                    <name>Complement C3</name>
                    <general-function/>
                    <specific-function>Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes</specific-function>
                    <gene-name>C3</gene-name>
                    <locus/>
                    <cellular-location>Secreted</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.34</theoretical-pi>
                    <molecular-weight>187150.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C3</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AY513239</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01024</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO3_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C3 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C3
                        MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVH
                        DFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKV
                        VLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSL
                        SSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTE
                        KFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEV
                        VLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKT
                        PKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPL
                        SITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMD
                        RAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGA
                        SGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDK
                        GVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAEL
                        QCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEAC
                        KKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKE
                        PPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVV
                        RNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVI
                        VPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKE
                        DIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTP
                        TVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTA
                        YVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKD
                        MALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMG
                        RLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQR
                        YYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLR
                        SEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDA
                        KNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSD
                        RNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDG
                        KLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDE
                        YIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSY
                        IIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN</amino-acid-sequence>
                    <gene-sequence format="FASTA"/>
                    <pfams>
                        <pfam>
                            <identifier>PF00207</identifier>
                            <name>A2M</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07678</identifier>
                            <name>A2M_comp</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01835</identifier>
                            <name>A2M_N</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07703</identifier>
                            <name>A2M_N_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07677</identifier>
                            <name>A2M_recep</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01821</identifier>
                            <name>ANATO</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01759</identifier>
                            <name>NTR</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inflammatory response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="11">
                <id>BE0004685</id>
                <name>Complement C4-A</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760&#13;
                    # Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465</references>
                <known-action>yes</known-action>
                <polypeptide id="P0C0L4" source="Swiss-Prot">
                    <name>Complement C4-A</name>
                    <general-function>Involved in regulation of complement activation</general-function>
                    <specific-function>Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.</specific-function>
                    <gene-name>C4A</gene-name>
                    <locus/>
                    <cellular-location/>
                    <transmembrane-regions/>
                    <signal-regions/>
                    <theoretical-pi/>
                    <molecular-weight>192783.805</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P0C0L4</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO4A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C4-A
                        MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN
                        PSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS
                        LSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN
                        SHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN
                        FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE
                        SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW
                        YFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD
                        IQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS
                        RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS
                        FYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA
                        LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW
                        TLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA
                        ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE
                        NWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP
                        MSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS
                        VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI
                        PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP
                        TLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTA
                        FVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVA
                        LTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL
                        TLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL
                        WIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH
                        TTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV
                        LRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP
                        LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD
                        LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY
                        NPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY
                        PRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG
                        KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ
                        GCQV</amino-acid-sequence>
                    <gene-sequence format="FASTA"/>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="12">
                <id>BE0004686</id>
                <name>Complement C4-B</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760&#13;
                    # Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465</references>
                <known-action>yes</known-action>
                <polypeptide id="P0C0L5" source="Swiss-Prot">
                    <name>Complement C4-B</name>
                    <general-function>Involved in regulation of complement activation</general-function>
                    <specific-function>Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.</specific-function>
                    <gene-name>C4B</gene-name>
                    <locus/>
                    <cellular-location/>
                    <transmembrane-regions/>
                    <signal-regions/>
                    <theoretical-pi/>
                    <molecular-weight>192749.785</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P0C0L5</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO4B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C4-B
                        MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN
                        PSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS
                        LSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN
                        SHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN
                        FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE
                        SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW
                        YFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD
                        IQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS
                        RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS
                        FYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA
                        LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW
                        TLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA
                        ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE
                        NWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP
                        MSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS
                        VVPTAATAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI
                        PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP
                        TLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRGSSTWLTA
                        FVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDLSPVIHRSMQGGLVGNDETVA
                        LTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL
                        TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL
                        WIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH
                        TTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV
                        LRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP
                        LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD
                        LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY
                        NPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY
                        PRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG
                        KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ
                        GCQV</amino-acid-sequence>
                    <gene-sequence format="FASTA"/>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="12">
                <id>BE0000855</id>
                <name>Complement C5</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20441428&#13;
                    # Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351760&#13;
                    # Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465</references>
                <known-action>yes</known-action>
                <polypeptide id="P01031" source="Swiss-Prot">
                    <name>Complement C5</name>
                    <general-function>Involved in endopeptidase inhibitor activity</general-function>
                    <specific-function>Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis)</specific-function>
                    <gene-name>C5</gene-name>
                    <locus>9q33-q34</locus>
                    <cellular-location/>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.49</theoretical-pi>
                    <molecular-weight>188333.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1331</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C5</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C5</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M57729</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>179983</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01031</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO5_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C5 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C5 precursor [Contains: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' chain]
                        MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYP
                        DKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPIT
                        YDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHI
                        GIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGY
                        KNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVT
                        FDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATP
                        LFLKPGIPYPIKVQVKDSLDQLVGGVPVILNAQTIDVNQETSDLDPSKSVTRVDDGVASF
                        VLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGE
                        HLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRL
                        LVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWV
                        ALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANAD
                        DSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISL
                        GPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLV
                        PRRKQLQFALPDSLTTWEIQGIGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQ
                        LKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTV
                        LPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFP
                        YRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFY
                        VFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTA
                        FALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEAREN
                        SLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDK
                        THPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLN
                        LKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHK
                        GALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLK
                        IDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLK
                        ALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHR
                        PDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYA
                        YKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIM
                        GKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;5031 bp
                        ATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAG
                        CAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTG
                        ATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCT
                        GATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAA
                        AACTCTGCAATCTTAACAATACAACCAAAACAATTGCCTGGAGGACAAAACCCAGTTTCT
                        TATGTGTATTTGGAAGTTGTATCAAAGCATTTTTCAAAATCAAAAAGAATGCCAATAACC
                        TATGACAATGGATTTCTCTTCATTCATACAGACAAACCTGTTTATACTCCAGACCAGTCA
                        GTAAAAGTTAGAGTTTATTCGTTGAATGACGACTTGAAGCCAGCCAAAAGAGAAACTGTC
                        TTAACCTTCATAGATCCTGAAGGATCAGAAGTTGACATGGTAGAAGAAATTGATCATATT
                        GGAATTATCTCTTTTCCTGACTTCAAGATTCCGTCTAATCCTAGATATGGTATGTGGACG
                        ATCAAGGCTAAATATAAAGAGGACTTTTCAACAACTGGAACCGCATATTTTGAAGTTAAA
                        GAATATGTCTTGCCACATTTTTCTGTCTCAATCGAGCCAGAATATAATTTCATTGGTTAC
                        AAGAACTTTAAGAATTTTGAAATTACTATAAAAGCAAGATATTTTTATAATAAAGTAGTC
                        ACTGAGGCTGACGTTTATATCACATTTGGAATAAGAGAAGACTTAAAAGATGATCAAAAA
                        GAAATGATGCAAACAGCAATGCAAAACACAATGTTGATAAATGGAATTGCTCAAGTCACA
                        TTTGATTCTGAAACAGCAGTCAAAGAACTGTCATACTACAGTTTAGAAGATTTAAACAAC
                        AAGTACCTTTATATTGCTGTAACAGTCATAGAGTCTACAGGTGGATTTTCTGAAGAGGCA
                        GAAATACCTGGCATCAAATATGTCCTCTCTCCCTACAAACTGAATTTGGTTGCTACTCCT
                        CTTTTCCTGAAGCCTGGGATTCCATATCCCATCAAGGTGCAGGTTAAAGATTCGCTTGAC
                        CAGTTGGTAGGAGGAGTCCCAGTAATACTGAATGCACAAACAATTGATGTAAACCAAGAG
                        ACATCTGACTTGGATCCAAGCAAAAGTGTAACACGTGTTGATGATGGAGTAGCTTCCTTT
                        GTGCTTAATCTCCCATCTGGAGTGACGGTGCTGGAGTTTAATGTCAAAACTGATGCTCCA
                        GATCTTCCAGAAGAAAATCAGGCCAGGGAAGGTTACCGAGCAATAGCATACTCATCTCTC
                        AGCCAAAGTTACCTTTATATTGATTGGACTGATAACCATAAGGCTTTGCTAGTGGGAGAA
                        CATCTGAATATTATTGTTACCCCCAAAAGCCCATATATTGACAAAATAACTCACTATAAT
                        TACTTGATTTTATCCAAGGGCAAAATTATCCATTTTGGCACGAGGGAGAAATTTTCAGAT
                        GCATCTTATCAAAGTATAAACATTCCAGTAACACAGAACATGGTTCCTTCATCCCGACTT
                        CTGGTCTATTATATCGTCACAGGAGAACAGACAGCAGAATTAGTGTCTGATTCAGTCTGG
                        TTAAATATTGAAGAAAAATGTGGCAACCAGCTCCAGGTTCATCTGTCTCCTGATGCAGAT
                        GCATATTCTCCAGGCCAAACTGTGTCTCTTAATATGGCAACTGGAATGGATTCCTGGGTG
                        GCATTAGCAGCAGTGGACAGTGCTGTGTATGGAGTCCAAAGAGGAGCCAAAAAGCCCTTG
                        GAAAGAGTATTTCAATTCTTAGAGAAGAGTGATCTGGGCTGTGGGGCAGGTGGTGGCCTC
                        AACAATGCCAATGTGTTCCACCTAGCTGGACTTACCTTCCTCACTAATGCAAATGCAGAT
                        GACTCCCAAGAAAATGATGAACCTTGTAAAGAAATTCTCAGGCCAAGAAGAACGCTGCAA
                        AAGAAGATAGAAGAAATAGCTGCTAAATATAAACATTCAGTAGTGAAGAAATGTTGTTAC
                        GATGGAGCCTGCGTTAATAATGATGAAACCTGTGAGCAGCGAGCTGCACGGATTAGTTTA
                        GGGCCAAGATGCATCAAAGCTTTCACTGAATGTTGTGTCGTCGCAAGCCAGCTCCGTGCT
                        AATATCTCTCATAAAGACATGCAATTGGGAAGGCTACACATGAAGACCCTGTTACCAGTA
                        AGCAAGCCAGAAATTCGGAGTTATTTTCCAGAAAGCTGGTTGTGGGAAGTTCATCTTGTT
                        CCCAGAAGAAAACAGTTGCAGTTTGCCCTACCTGATTCTCTAACCACCTGGGAAATTCAA
                        GGCATTGGCATTTCAAACACTGGTATATGTGTTGCTGATACTGTCAAGGCAAAGGTGTTC
                        AAAGATGTCTTCCTGGAAATGAATATACCATATTCTGTTGTACGAGGAGAACAGATCCAA
                        TTGAAAGGAACTGTTTACAACTATAGGACTTCTGGGATGCAGTTCTGTGTTAAAATGTCT
                        GCTGTGGAGGGAATCTGCACTTCGGAAAGCCCAGTCATTGATCATCAGGGCACAAAGTCC
                        TCCAAATGTGTGCGCCAGAAAGTAGAGGGCTCCTCCAGTCACTTGGTGACATTCACTGTG
                        CTTCCTCTGGAAATTGGCCTTCACAACATCAATTTTTCACTGGAGACTTGGTTTGGAAAA
                        GAAATCTTAGTAAAAACATTACGAGTGGTGCCAGAAGGTGTCAAAAGGGAAAGCTATTCT
                        GGTGTTACTTTGGATCCTAGGGGTATTTATGGTACCATTAGCAGACGAAAGGAGTTCCCA
                        TACAGGATACCCTTAGATTTGGTCCCCAAAACAGAAATCAAAAGGATTTTGAGTGTAAAA
                        GGACTGCTTGTAGGTGAGATCTTGTCTGCAGTTCTAAGTCAGGAAGGCATCAATATCCTA
                        ACCCACCTCCCCAAAGGGAGTGCAGAGGCGGAGCTGATGAGCGTTGTCCCAGTATTCTAT
                        GTTTTTCACTACCTGGAAACAGGAAATCATTGGAACATTTTTCATTCTGACCCATTAATT
                        GAAAAGCAGAAACTGAAGAAAAAATTAAAAGAAGGGATGTTGAGCATTATGTCCTACAGA
                        AATGCTGACTACTCTTACAGTGTGTGGAAGGGTGGAAGTGCTAGCACTTGGTTAACAGCT
                        TTTGCTTTAAGAGTACTTGGACAAGTAAATAAATACGTAGAGCAGAACCAAAATTCAATT
                        TGTAATTCTTTATTGTGGCTAGTTGAGAATTATCAATTAGATAATGGATCTTTCAAGGAA
                        AATTCACAGTATCAACCAATAAAATTACAGGGTACCTTGCCTGTTGAAGCCCGAGAGAAC
                        AGCTTATATCTTACAGCCTTTACTGTGATTGGAATTAGAAAGGCTTTCGATATATGCCCC
                        CTGGTGAAAATCGACACAGCTCTAATTAAAGCTGACAACTTTCTGCTTGAAAATACACTG
                        CCAGCCCAGAGCACCTTTACATTGGCCATTTCTGCGTATGCTCTTTCCCTGGGAGATAAA
                        ACTCACCCACAGTTTCGTTCAATTGTTTCAGCTTTGAAGAGAGAAGCTTTGGTTAAAGGT
                        AATCCACCCATTTATCGTTTTTGGAAAGACAATCTTCAGCATAAAGACAGCTCTGTACCT
                        AACACTGGTACGGCACGTATGGTAGAAACAACTGCCTATGCTTTACTCACCAGTCTGAAC
                        TTGAAAGATATAAATTATGTTAACCCAGTCATCAAATGGCTATCAGAAGAGCAGAGGTAT
                        GGAGGTGGCTTTTATTCAACCCAGGACACCATCAATGCCATTGAGGGCCTGACGGAATAT
                        TCACTCCTGGTTAAACAACTCCGCTTGAGTATGGACATCGATGTTTCTTACAAGCATAAA
                        GGTGCCTTACATAATTATAAAATGACAGACAAGAATTTCCTTGGGAGGCCAGTAGAGGTG
                        CTTCTCAATGATGACCTCATTGTCAGTACAGGATTTGGCAGTGGCTTGGCTACAGTACAT
                        GTAACAACTGTAGTTCACAAAACCAGTACCTCTGAGGAAGTTTGCAGCTTTTATTTGAAA
                        ATCGATACTCAGGATATTGAAGCATCCCACTACAGAGGCTACGGAAACTCTGATTACAAA
                        CGCATAGTAGCATGTGCCAGCTACAAGCCCAGCAGGGAAGAATCATCATCTGGATCCTCT
                        CATGCGGTGATGGACATCTCCTTGCCTACTGGAATCAGTGCAAATGAAGAAGACTTAAAA
                        GCCCTTGTGGAAGGGGTGGATCAACTATTCACTGATTACCAAATCAAAGATGGACATGTT
                        ATTCTGCAACTGAATTCGATTCCCTCCAGTGATTTCCTTTGTGTACGATTCCGGATATTT
                        GAACTCTTTGAAGTTGGGTTTCTCAGTCCTGCCACTTTCACAGTTTACGAATACCACAGA
                        CCAGATAAACAGTGTACCATGTTTTATAGCACTTCCAATATCAAAATTCAGAAAGTCTGT
                        GAAGGAGCCGCGTGCAAGTGTGTAGAAGCTGATTGTGGGCAAATGCAGGAAGAATTGGAT
                        CTGACAATCTCTGCAGAGACAAGAAAACAAACAGCATGTAAACCAGAGATTGCATATGCT
                        TATAAAGTTAGCATCACATCCATCACTGTAGAAAATGTTTTTGTCAAGTACAAGGCAACC
                        CTTCTGGATATCTACAAAACTGGGGAAGCTGTTGCTGAGAAAGACTCTGAGATTACCTTC
                        ATTAAAAAGGTAACCTGTACTAACGCTGAGCTGGTAAAAGGAAGACAGTACTTAATTATG
                        GGTAAAGAAGCCCTCCAGATAAAATACAATTTCAGTTTCAGGTACATCTACCCTTTAGAT
                        TCCTTGACCTGGATTGAATACTGGCCTAGAGACACAACATGTTCATCGTGTCAAGCATTT
                        TTAGCTAATTTAGATGAATTTGCCGAAGATATCTTTTTAAATGGATGCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00207</identifier>
                            <name>A2M</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07678</identifier>
                            <name>A2M_comp</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01835</identifier>
                            <name>A2M_N</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07703</identifier>
                            <name>A2M_N_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07677</identifier>
                            <name>A2M_recep</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01821</identifier>
                            <name>ANATO</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01759</identifier>
                            <name>NTR</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inflammatory response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2010-09-29">
        <drugbank-id primary="true">DB00029</drugbank-id>
        <drugbank-id>BIOD00102</drugbank-id>
        <drugbank-id>BTD00102</drugbank-id>
        <name>Anistreplase</name>
        <description>Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.</description>
        <cas-number>81669-57-0</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction</indication>
        <pharmacodynamics>Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.</pharmacodynamics>
        <mechanism-of-action>Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">t- PA</synonym>
            <synonym language="" coder="">t-plasminogen activator</synonym>
            <synonym language="" coder="">Tissue-type plasminogen activator precursor</synonym>
            <synonym language="" coder="">tPA</synonym>
        </synonyms>
        <products>
            <product>
                <name>Eminase 30 Units</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02229390</dpd-id>
                <started-marketing-on>1997-12-15</started-marketing-on>
                <ended-marketing-on>2009-02-23</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>30 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Eminase</name>
                <company>Wulfing Pharma GmbH</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Eminase 30 Units</name>
                <ingredients>Anistreplase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Haupt Pharma</name>
                <url>http://haupt-pharma.de</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices/>
        <categories>
            <category>
                <category>Fibrinolytic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Thrombolytic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>30 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AD03">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AD">Enzymes</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:12.20</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00233</drugbank-id>
                <name>Aminosalicylic Acid</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00261</drugbank-id>
                <name>Anagrelide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06605</drugbank-id>
                <name>Apixaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06692</drugbank-id>
                <name>Aprotinin</name>
                <description>Aprotinin may diminish the therapeutic effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00278</drugbank-id>
                <name>Argatroban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01294</drugbank-id>
                <name>Bismuth Subsalicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00006</drugbank-id>
                <name>Bivalirudin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06441</drugbank-id>
                <name>Cangrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01166</drugbank-id>
                <name>Cilostazol</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00215</drugbank-id>
                <name>Citalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00758</drugbank-id>
                <name>Clopidogrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06695</drugbank-id>
                <name>Dabigatran etexilate</name>
                <description>May enhance the anticoagulant effect of Dabigatran etexilate.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06754</drugbank-id>
                <name>Danaparoid</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06700</drugbank-id>
                <name>Desvenlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00586</drugbank-id>
                <name>Diclofenac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00861</drugbank-id>
                <name>Diflunisal</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01551</drugbank-id>
                <name>Dihydrocodeine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00975</drugbank-id>
                <name>Dipyridamole</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00476</drugbank-id>
                <name>Duloxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09075</drugbank-id>
                <name>Edoxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01240</drugbank-id>
                <name>Epoprostenol</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00063</drugbank-id>
                <name>Eptifibatide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01175</drugbank-id>
                <name>Escitalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00749</drugbank-id>
                <name>Etodolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00573</drugbank-id>
                <name>Fenoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08976</drugbank-id>
                <name>Floctafenine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00472</drugbank-id>
                <name>Fluoxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00712</drugbank-id>
                <name>Flurbiprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01050</drugbank-id>
                <name>Ibuprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01088</drugbank-id>
                <name>Iloprost</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00328</drugbank-id>
                <name>Indomethacin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01009</drugbank-id>
                <name>Ketoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00465</drugbank-id>
                <name>Ketorolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08918</drugbank-id>
                <name>Levomilnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01397</drugbank-id>
                <name>Magnesium salicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00784</drugbank-id>
                <name>Mefenamic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00814</drugbank-id>
                <name>Meloxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04896</drugbank-id>
                <name>Milnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00461</drugbank-id>
                <name>Nabumetone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08813</drugbank-id>
                <name>Nadroparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00788</drugbank-id>
                <name>Naproxen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00991</drugbank-id>
                <name>Oxaprozin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00715</drugbank-id>
                <name>Paroxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00554</drugbank-id>
                <name>Piroxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06209</drugbank-id>
                <name>Prasugrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06228</drugbank-id>
                <name>Rivaroxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01399</drugbank-id>
                <name>Salsalate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01104</drugbank-id>
                <name>Sertraline</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00605</drugbank-id>
                <name>Sulindac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01600</drugbank-id>
                <name>Tiaprofenic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08816</drugbank-id>
                <name>Ticagrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00208</drugbank-id>
                <name>Ticlopidine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06822</drugbank-id>
                <name>Tinzaparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00775</drugbank-id>
                <name>Tirofiban</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00500</drugbank-id>
                <name>Tolmetin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00285</drugbank-id>
                <name>Venlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06684</drugbank-id>
                <name>Vilazodone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09030</drugbank-id>
                <name>Vorapaxar</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09068</drugbank-id>
                <name>Vortioxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00029 sequence
                SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG
                TCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA
                LAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC
                YFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK
                PWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS
                PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH
                KEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL
                SPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG
                PLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>60 °C</value>
                <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.516</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.61</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>59042.3000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C2569H3928N746O781S40</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>1199</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>L00153</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164769075</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P00750</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Anistreplase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links/>
        <pathways>
            <pathway>
                <smpdb-id>SMP00281</smpdb-id>
                <name>Anistreplase Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00029</drugbank-id>
                        <name>Anistreplase</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000211</id>
                <name>Plasminogen</name>
                <organism>Human</organism>
                <actions>
                    <action>activator</action>
                </actions>
                <references># Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235
                    # Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656
                    # Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00747" source="Swiss-Prot">
                    <name>Plasminogen</name>
                    <general-function>Involved in plasmin activity</general-function>
                    <specific-function>Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo</specific-function>
                    <gene-name>PLG</gene-name>
                    <locus>6q26</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.25</theoretical-pi>
                    <molecular-weight>90569.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9071</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X05199</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>387026</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PLMN_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.7</synonym>
                        <synonym>Plasminogen precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen precursor
                        MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
                        CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
                        GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
                        CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
                        LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
                        AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
                        QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
                        LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
                        CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
                        PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
                        RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
                        PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
                        LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
                        GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2433 bp
                        ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
                        CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
                        CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
                        TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
                        AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
                        TCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT
                        GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
                        ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
                        GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
                        TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
                        ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
                        CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
                        CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC
                        CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
                        GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
                        GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT
                        GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
                        CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
                        CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
                        GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
                        TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
                        CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
                        GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
                        GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC
                        TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
                        CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
                        AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
                        CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
                        GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
                        GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
                        AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
                        GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
                        CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
                        CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
                        GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
                        ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
                        CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
                        TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
                        GGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
                        GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
                        ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00024</identifier>
                            <name>PAN_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>plasmin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000538</id>
                <name>Fibrinogen alpha chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>yes</known-action>
                <polypeptide id="P02671" source="Swiss-Prot">
                    <name>Fibrinogen alpha chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation</specific-function>
                    <gene-name>FGA</gene-name>
                    <locus>4q28</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.87</theoretical-pi>
                    <molecular-weight>94974.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3661</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF361104</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>13591824</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02671</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FIBA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Fibrinogen alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]
                        MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
                        NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
                        NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
                        RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
                        LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
                        GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
                        NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
                        SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
                        EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
                        VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
                        YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
                        VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
                        GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
                        NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
                        VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2601 bp
                        ATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA
                        GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
                        GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
                        AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
                        TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
                        GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
                        AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
                        CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
                        GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
                        CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
                        CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
                        TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
                        CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
                        TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
                        TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
                        GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
                        TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
                        ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
                        AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
                        GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
                        GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
                        AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
                        GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
                        TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
                        GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
                        TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
                        GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
                        GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
                        AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
                        AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
                        TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
                        AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
                        TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
                        GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
                        GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
                        GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
                        GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
                        CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
                        ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
                        AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
                        GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
                        TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
                        GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
                        AGGCCCCTTGTGACCCAATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00147</identifier>
                            <name>Fibrinogen_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0000717</id>
                <name>Urokinase plasminogen activator surface receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q03405" source="Swiss-Prot">
                    <name>Urokinase plasminogen activator surface receptor</name>
                    <general-function>Involved in U-plasminogen activator receptor activity</general-function>
                    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form</specific-function>
                    <gene-name>PLAUR</gene-name>
                    <locus>19q13</locus>
                    <cellular-location>Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.64</theoretical-pi>
                    <molecular-weight>36978.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9053</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X51675</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>37605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q03405</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>UPAR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD87 antigen</synonym>
                        <synonym>Monocyte activation antigen Mo3</synonym>
                        <synonym>U- PAR</synonym>
                        <synonym>uPAR</synonym>
                        <synonym>Urokinase plasminogen activator surface receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Urokinase plasminogen activator surface receptor precursor
                        MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
                        ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
                        GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
                        FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
                        MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
                        QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1008 bp
                        ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
                        TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
                        CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
                        GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
                        ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
                        GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
                        GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
                        GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
                        AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
                        TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
                        GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
                        GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
                        ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA
                        AGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG
                        AACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC
                        CAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC
                        CTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00021</identifier>
                            <name>UPAR_LY6</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>U-plasminogen activator receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0000240</id>
                <name>Plasminogen activator inhibitor 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05121" source="Swiss-Prot">
                    <name>Plasminogen activator inhibitor 1</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis</specific-function>
                    <gene-name>SERPINE1</gene-name>
                    <locus>7q21.3-q22</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.22</theoretical-pi>
                    <molecular-weight>45061.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8583</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04429</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>35272</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05121</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAI1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Endothelial plasminogen activator inhibitor</synonym>
                        <synonym>PAI</synonym>
                        <synonym>PAI-1</synonym>
                        <synonym>Plasminogen activator inhibitor 1 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen activator inhibitor 1 precursor
                        MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
                        GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
                        FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
                        DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
                        GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
                        FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
                        STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1209 bp
                        ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
                        GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
                        AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
                        GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
                        ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
                        CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC
                        TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
                        CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
                        GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
                        GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
                        CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
                        TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
                        GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
                        GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
                        CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
                        TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
                        ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
                        GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
                        TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
                        TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
                        GAACCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-06-27">
        <drugbank-id primary="true">DB00030</drugbank-id>
        <drugbank-id>BIOD00105</drugbank-id>
        <drugbank-id>BTD00105</drugbank-id>
        <drugbank-id>DB01383</drugbank-id>
        <name>Insulin Regular</name>
        <description>Insulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use. </description>
        <cas-number>11061-68-0</cas-number>
        <groups>
            <group>approved</group>
            <group>experimental</group>
            <group>investigational</group>
        </groups>
        <general-references># Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A: Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):210-3. doi: 10.1055/s-0033-1334905. Epub 2013 Mar 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23512415</general-references>
        <synthesis-reference>Humulin is synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been genetically altered to produce human insulin.</synthesis-reference>
        <indication>Indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. </indication>
        <pharmacodynamics>Insulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action. </pharmacodynamics>
        <mechanism-of-action>The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.&#13;
            Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.</mechanism-of-action>
        <toxicity>Hypoglycemia is one of the most frequent adverse events experienced by insulin users. </toxicity>
        <metabolism>Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.</metabolism>
        <absorption>Insulin is generally well absorbed. </absorption>
        <half-life/>
        <protein-binding>5% protein bound </protein-binding>
        <route-of-elimination/>
        <volume-of-distribution>0.15 L/kg </volume-of-distribution>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Insulin human </synonym>
        </synonyms>
        <products>
            <product>
                <name>Afrezza</name>
                <ndc-id>0024-5874_f222a734-081c-4098-a973-a3274e29e7ac</ndc-id>
                <ndc-product-code>0024-5874</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2014-07-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder, metered</dosage-form>
                <strength>4 1</strength>
                <route>respiratory (inhalation)</route>
                <fda-application-number>NDA022472</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog 70/30</name>
                <ndc-id>54868-2746_3457b3b5-976d-4240-bfad-e448294ec9cb</ndc-id>
                <ndc-product-code>54868-2746</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1994-12-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019717</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin 70/30</name>
                <ndc-id>0002-8715_003856b7-9100-4b23-bedb-3045b2e6f405</ndc-id>
                <ndc-product-code>0002-8715</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1989-06-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019717</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin 70/30</name>
                <ndc-id>0002-8770_003856b7-9100-4b23-bedb-3045b2e6f405</ndc-id>
                <ndc-product-code>0002-8770</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1999-02-01</started-marketing-on>
                <ended-marketing-on>2015-10-31</ended-marketing-on>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019717</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin 70/30</name>
                <ndc-id>0002-8803_003856b7-9100-4b23-bedb-3045b2e6f405</ndc-id>
                <ndc-product-code>0002-8803</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-11-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019717</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin 70/30 70/30</name>
                <ndc-id>52125-415_4db2dc6a-a89e-497b-bc23-4f3d57e899f4</ndc-id>
                <ndc-product-code>52125-415</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-06-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019717</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin 70/30 70/30</name>
                <ndc-id>52125-415_b1b49436-6e5c-4b36-8982-989d622f35ed</ndc-id>
                <ndc-product-code>52125-415</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-09-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019717</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin N</name>
                <ndc-id>0002-8730_ea9b211f-abbc-4a62-867a-596a24a5b419</ndc-id>
                <ndc-product-code>0002-8730</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1999-02-01</started-marketing-on>
                <ended-marketing-on>2015-10-31</ended-marketing-on>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA018781</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin N</name>
                <ndc-id>0002-8805_ea9b211f-abbc-4a62-867a-596a24a5b419</ndc-id>
                <ndc-product-code>0002-8805</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-11-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA018781</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin N</name>
                <ndc-id>54868-1429_2232ce07-e218-4907-8f20-1e8fe3277dde</ndc-id>
                <ndc-product-code>54868-1429</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1994-10-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA018781</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin R</name>
                <ndc-id>0002-8215_08827443-2aa4-4cd9-9657-64a52085fd83</ndc-id>
                <ndc-product-code>0002-8215</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1983-06-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>parenteral</route>
                <fda-application-number>NDA018780</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin R</name>
                <ndc-id>54868-3619_5ace7bf4-ae3d-4cc5-b5b6-a171d26d82a2</ndc-id>
                <ndc-product-code>54868-3619</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-07-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA018780</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humulin R U-500</name>
                <ndc-id>0002-8501_56852e9d-9832-4a7e-a19f-7ae855017bd6</ndc-id>
                <ndc-product-code>0002-8501</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1997-01-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>500 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA018780</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin 70/30</name>
                <ndc-id>0169-1837_6748f022-4f9d-42ea-9f82-e39abad34324</ndc-id>
                <ndc-product-code>0169-1837</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-06-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [USP'U]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019991</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin 70/30</name>
                <ndc-id>54569-2918_8e7cb87c-79c5-46d0-88b7-5ccb6b66dd87</ndc-id>
                <ndc-product-code>54569-2918</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-06-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [USP'U]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019991</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin 70/30</name>
                <ndc-id>54868-3474_f8f7bdaf-47bb-43bc-8696-a6b844e21933</ndc-id>
                <ndc-product-code>54868-3474</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-01-11</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [USP'U]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019991</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin 70/30</name>
                <ndc-id>64725-1837_05dc7def-3137-4c5c-8d43-2baf9d7888df</ndc-id>
                <ndc-product-code>64725-1837</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-06-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [USP'U]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019991</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin N</name>
                <ndc-id>0169-1834_5ddfd50a-7a65-4658-85d6-500ae7aae946</ndc-id>
                <ndc-product-code>0169-1834</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-07-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019959</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin N</name>
                <ndc-id>64725-1834_88240c8b-10c5-43b4-8a36-020380cea930</ndc-id>
                <ndc-product-code>64725-1834</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-07-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019959</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin R</name>
                <ndc-id>0169-1833_6ede8238-f902-478d-8cee-997855045083</ndc-id>
                <ndc-product-code>0169-1833</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-06-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019938</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin R</name>
                <ndc-id>64725-1833_a2c745d7-1b63-4064-b6a1-e18e43b318ad</ndc-id>
                <ndc-product-code>64725-1833</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1991-06-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019938</fda-application-number>
                <generic>false</generic>
                <over-the-counter>true</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin70/30 70/30</name>
                <ndc-id>52125-414_4c714861-6964-4ecf-bf7e-2f353c9226c2</ndc-id>
                <ndc-product-code>52125-414</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2014-07-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [USP'U]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019991</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Novolin70/30 70/30</name>
                <ndc-id>52125-414_ea917f6b-3e25-4236-93ae-9376d5282b27</ndc-id>
                <ndc-product-code>52125-414</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-06-13</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [USP'U]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA019991</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Humulin R</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin R U-500</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin N</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin N</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Afrezza</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin R</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin N</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin70/30 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin70/30 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin 70/30 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin 70/30 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin N</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humalog 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Humulin R</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin R</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin N</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
            <mixture>
                <name>Novolin 70/30</name>
                <ingredients>Insulin Regular</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>A-S Medication Solutions LLC</name>
                <url>http://orders.a-smeds.com</url>
            </packager>
            <packager>
                <name>DispenseXpress Inc.</name>
                <url/>
            </packager>
            <packager>
                <name>Eli Lilly &amp; Co.</name>
                <url>http://www.lilly.com</url>
            </packager>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>Intervet International</name>
                <url>http://www.intervet.ca</url>
            </packager>
            <packager>
                <name>Novo Nordisk Inc.</name>
                <url>http://www.novonordisk.com</url>
            </packager>
            <packager>
                <name>Pfizer Inc.</name>
                <url>http://www.pfizer.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Novo nordisk inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Novolin Ge Nph 100 unit/ml</description>
                <cost currency="USD">2.14</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Novolin Ge Toronto 100 unit/ml</description>
                <cost currency="USD">2.14</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Humulin N 100 unit/ml</description>
                <cost currency="USD">2.29</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Humulin R 100 unit/ml</description>
                <cost currency="USD">2.29</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Novolin Ge Nph Penfill 100 unit/ml Cartridge</description>
                <cost currency="USD">2.78</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Novolin Ge Toronto Penfill 100 unit/ml Cartridge</description>
                <cost currency="USD">2.8</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Humulin N Cartridge 100 unit/ml Cartridge</description>
                <cost currency="USD">2.99</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Humulin R Cartridge 100 unit/ml Cartridge</description>
                <cost currency="USD">2.99</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>NovoLIN R InnoLet 100 unit/ml Solution 3ml Cartridge</description>
                <cost currency="USD">24.17</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Novolin r 100 unit/ml cartridg</description>
                <cost currency="USD">33.33</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>NovoLIN R 100 unit/ml Solution 10ml Vial</description>
                <cost currency="USD">73.19</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>NovoLIN R PenFill 100 unit/ml Solution Five 3ml Cartridges Per Box = 15ml</description>
                <cost currency="USD">162.26</cost>
                <unit>cartridge</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antidiabetic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder, metered</form>
                <route>respiratory (inhalation)</route>
                <strength>4 1</strength>
            </dosage>
            <dosage>
                <form>Injection, suspension</form>
                <route>subcutaneous</route>
                <strength>100 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>parenteral</route>
                <strength>100 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>500 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, suspension</form>
                <route>subcutaneous</route>
                <strength>100 [USP'U]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>100 [iU]/mL</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes>
            <ahfs-code>68:20.08</ahfs-code>
            <ahfs-code>92:02.00*</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00414</drugbank-id>
                <name>Acetohexamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06203</drugbank-id>
                <name>Alogliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01238</drugbank-id>
                <name>Aripiprazole</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01169</drugbank-id>
                <name>Arsenic trioxide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09009</drugbank-id>
                <name>Articaine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06216</drugbank-id>
                <name>Asenapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01072</drugbank-id>
                <name>Atazanavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00436</drugbank-id>
                <name>Bendroflumethiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00443</drugbank-id>
                <name>Betamethasone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09128</drugbank-id>
                <name>Brexpiprazole</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00887</drugbank-id>
                <name>Bumetanide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06719</drugbank-id>
                <name>Buserelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08907</drugbank-id>
                <name>Canagliflozin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09063</drugbank-id>
                <name>Ceritinib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00880</drugbank-id>
                <name>Chlorothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00672</drugbank-id>
                <name>Chlorpropamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00310</drugbank-id>
                <name>Chlorthalidone</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01285</drugbank-id>
                <name>Corticotropin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01380</drugbank-id>
                <name>Cortisone acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04839</drugbank-id>
                <name>Cyproterone acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08912</drugbank-id>
                <name>Dabrafenib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01406</drugbank-id>
                <name>Danazol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01264</drugbank-id>
                <name>Darunavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00304</drugbank-id>
                <name>Desogestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01234</drugbank-id>
                <name>Dexamethasone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01119</drugbank-id>
                <name>Diazoxide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09123</drugbank-id>
                <name>Dienogest</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB02901</drugbank-id>
                <name>Dihydrotestosterone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00280</drugbank-id>
                <name>Disopyramide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01395</drugbank-id>
                <name>Drospirenone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00668</drugbank-id>
                <name>Epinephrine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00783</drugbank-id>
                <name>Estradiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04574</drugbank-id>
                <name>Estropipate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00903</drugbank-id>
                <name>Ethacrynic acid</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00977</drugbank-id>
                <name>Ethinyl Estradiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00823</drugbank-id>
                <name>Ethynodiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00294</drugbank-id>
                <name>Etonogestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01590</drugbank-id>
                <name>Everolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00687</drugbank-id>
                <name>Fludrocortisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01319</drugbank-id>
                <name>Fosamprenavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00695</drugbank-id>
                <name>Furosemide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01120</drugbank-id>
                <name>Gliclazide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00222</drugbank-id>
                <name>Glimepiride</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01067</drugbank-id>
                <name>Glipizide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01251</drugbank-id>
                <name>Gliquidone</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01016</drugbank-id>
                <name>Glyburide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00014</drugbank-id>
                <name>Goserelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06788</drugbank-id>
                <name>Histrelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00999</drugbank-id>
                <name>Hydrochlorothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00741</drugbank-id>
                <name>Hydrocortisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06789</drugbank-id>
                <name>Hydroxyprogesterone caproate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04946</drugbank-id>
                <name>Iloperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00808</drugbank-id>
                <name>Indapamide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00224</drugbank-id>
                <name>Indinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB05278</drugbank-id>
                <name>inhaled insulin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01306</drugbank-id>
                <name>Insulin Aspart</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01307</drugbank-id>
                <name>Insulin Detemir</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00047</drugbank-id>
                <name>Insulin Glargine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01309</drugbank-id>
                <name>Insulin Glulisine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00046</drugbank-id>
                <name>Insulin Lispro</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08914</drugbank-id>
                <name>Insulin, isophane</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06791</drugbank-id>
                <name>Lanreotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00007</drugbank-id>
                <name>Leuprolide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00367</drugbank-id>
                <name>Levonorgestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08882</drugbank-id>
                <name>Linagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00166</drugbank-id>
                <name>Lipoic Acid</name>
                <description>May enhance the hypoglycemic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06655</drugbank-id>
                <name>Liraglutide</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01601</drugbank-id>
                <name>Lopinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08815</drugbank-id>
                <name>Lurasidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01277</drugbank-id>
                <name>Mecasermin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00603</drugbank-id>
                <name>Medroxyprogesterone Acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00351</drugbank-id>
                <name>Megestrol acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01357</drugbank-id>
                <name>Mestranol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00331</drugbank-id>
                <name>Metformin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01403</drugbank-id>
                <name>Methotrimeprazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00232</drugbank-id>
                <name>Methyclothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00959</drugbank-id>
                <name>Methylprednisolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00524</drugbank-id>
                <name>Metolazone</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09046</drugbank-id>
                <name>Metreleptin</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00834</drugbank-id>
                <name>Mifepristone</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00731</drugbank-id>
                <name>Nateglinide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00220</drugbank-id>
                <name>Nelfinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00627</drugbank-id>
                <name>Niacin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04868</drugbank-id>
                <name>Nilotinib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00717</drugbank-id>
                <name>Norethindrone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00957</drugbank-id>
                <name>Norgestimate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00104</drugbank-id>
                <name>Octreotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00334</drugbank-id>
                <name>Olanzapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00621</drugbank-id>
                <name>Oxandrolone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01267</drugbank-id>
                <name>Paliperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06663</drugbank-id>
                <name>Pasireotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00082</drugbank-id>
                <name>Pegvisomant</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00738</drugbank-id>
                <name>Pentamidine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01132</drugbank-id>
                <name>Pioglitazone</name>
                <description>May enhance the adverse/toxic effect of Insulin. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00592</drugbank-id>
                <name>Piperazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01621</drugbank-id>
                <name>Pipotiazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01278</drugbank-id>
                <name>Pramlintide</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00860</drugbank-id>
                <name>Prednisolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00635</drugbank-id>
                <name>Prednisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00396</drugbank-id>
                <name>Progesterone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01224</drugbank-id>
                <name>Quetiapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00468</drugbank-id>
                <name>Quinine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00912</drugbank-id>
                <name>Repaglinide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00503</drugbank-id>
                <name>Ritonavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00412</drugbank-id>
                <name>Rosiglitazone</name>
                <description>Insulin may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01232</drugbank-id>
                <name>Saquinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06335</drugbank-id>
                <name>Saxagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00877</drugbank-id>
                <name>Sirolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00359</drugbank-id>
                <name>Sulfadiazine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01015</drugbank-id>
                <name>Sulfamethoxazole</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00263</drugbank-id>
                <name>Sulfisoxazole</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01268</drugbank-id>
                <name>Sunitinib</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00864</drugbank-id>
                <name>Tacrolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06287</drugbank-id>
                <name>Temsirolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00624</drugbank-id>
                <name>Testosterone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00932</drugbank-id>
                <name>Tipranavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00839</drugbank-id>
                <name>Tolazamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01124</drugbank-id>
                <name>Tolbutamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00214</drugbank-id>
                <name>Torasemide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00620</drugbank-id>
                <name>Triamcinolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06825</drugbank-id>
                <name>Triptorelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04876</drugbank-id>
                <name>Vildagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB02546</drugbank-id>
                <name>Vorinostat</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00246</drugbank-id>
                <name>Ziprasidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;A chain
                GIVEQCCTSICSLYQLENYCN</sequence>
            <sequence format="FASTA">&gt;B chain
                FVNQHLCGSHLVEALYLVCGERGFFYTPKT</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>81 °C</value>
                <source>Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>0.218</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.39</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>5808 Daltons </value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C257H383N65O77S6</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>ChEBI</resource>
                <identifier>5931</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C00723</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D03230</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0002-8215-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>AY137503</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164744571</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>Q8HXV2</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Insulin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/novolog.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/pro/humulin-r.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000033</id>
                <name>Insulin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12970169&#13;
                    # Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem (Tokyo). 2002 Jun;131(6):855-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12038982&#13;
                    # Bell DS: Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs. 2007;67(13):1813-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17722952&#13;
                    # Tanti JF, Jager J: Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009 Dec;9(6):753-62. Epub 2009 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19683471&#13;
                    # Chiu SL, Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010 Mar 15;5:7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20230616&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P06213" source="Swiss-Prot">
                    <name>Insulin receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1</specific-function>
                    <gene-name>INSR</gene-name>
                    <locus>19p13.3-p13.2</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>957-979</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.18</theoretical-pi>
                    <molecular-weight>156308.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6091</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>INSR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>INSR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M10051</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>307070</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P06213</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INSR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD220 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>Insulin receptor precursor</synonym>
                        <synonym>IR</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin receptor precursor
                        MGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
                        QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
                        VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
                        ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
                        GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
                        CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
                        TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
                        EIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
                        RNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
                        NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
                        DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
                        RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
                        KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
                        PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
                        SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
                        SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
                        PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
                        EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
                        FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
                        AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
                        RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
                        CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
                        FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
                        PS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4149 bp
                        ATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
                        CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
                        CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
                        CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
                        CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
                        GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
                        GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
                        CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
                        TCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG
                        GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
                        ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
                        ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
                        GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
                        GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
                        GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
                        TGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
                        ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
                        CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
                        ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
                        CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
                        TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
                        GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
                        TGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
                        CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
                        AGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT
                        AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
                        CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
                        AATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
                        ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
                        CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
                        GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
                        AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
                        AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
                        AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
                        CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
                        GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
                        AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
                        TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
                        CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
                        CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
                        GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
                        GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
                        AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
                        ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
                        ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
                        TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
                        TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
                        TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
                        CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
                        AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
                        AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
                        GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
                        AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
                        GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
                        TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
                        GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
                        GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
                        GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
                        GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
                        ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
                        CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
                        TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
                        TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
                        TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
                        CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
                        GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
                        TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
                        GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
                        TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
                        CCTTCCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000858</id>
                <name>Insulin-like growth factor 1 receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08069" source="Swiss-Prot">
                    <name>Insulin-like growth factor 1 receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade</specific-function>
                    <gene-name>IGF1R</gene-name>
                    <locus>15q26.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>936-959</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.54</theoretical-pi>
                    <molecular-weight>154795.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5465</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IGF1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IGF1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04434</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>804990</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08069</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IGF1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD221 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>IGF-I receptor</synonym>
                        <synonym>Insulin-like growth factor 1 receptor precursor</synonym>
                        <synonym>Insulin-like growth factor I receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin-like growth factor 1 receptor precursor
                        MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
                        ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
                        EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
                        LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
                        APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
                        GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
                        LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
                        YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
                        NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
                        QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
                        ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
                        NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
                        VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
                        RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
                        EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
                        YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
                        KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
                        VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
                        LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
                        CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
                        VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
                        EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
                        SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4104 bp
                        ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
                        GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
                        AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
                        ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
                        ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
                        CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
                        GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
                        ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
                        CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
                        CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
                        TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
                        AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
                        GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
                        GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
                        TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
                        GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
                        TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
                        ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
                        CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
                        ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
                        TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
                        TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
                        ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
                        CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
                        AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
                        TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
                        ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
                        CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
                        GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
                        GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
                        ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
                        TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
                        CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
                        AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
                        GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
                        GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
                        GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
                        GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
                        GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
                        AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
                        ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
                        GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
                        GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
                        TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
                        TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
                        TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
                        TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
                        CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
                        AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
                        TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
                        ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
                        GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
                        ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
                        CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
                        CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
                        AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
                        GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
                        TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
                        TATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
                        CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
                        GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
                        GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
                        CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
                        GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
                        TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
                        GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
                        TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
                        GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
                        CTGCCCCAGTCTTCGACCTGCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0002123</id>
                <name>Retinoblastoma-associated protein</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P06400" source="Swiss-Prot">
                    <name>Retinoblastoma-associated protein</name>
                    <general-function/>
                    <specific-function>Key regulator of entry into cell division that acts as a tumor suppressor. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Also acts as a transcription repressor of E2F target genes by recruiting chromatin-modifying enzymes to promoters. Inhibits the intrinsic kinase activity of TAF1. Forms a complex with adenovirus E1A and with SV40 large T antigen. May bind and modulate functionally certain cellular proteins with which T and E1A compete for pocket binding</specific-function>
                    <gene-name>RB1</gene-name>
                    <locus>13q14.2</locus>
                    <cellular-location>Nucleus</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.04</theoretical-pi>
                    <molecular-weight>106161.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9884</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>RB1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>RB1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M15400</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>190959</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P06400</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>RB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>P105-RB</synonym>
                        <synonym>PP110</synonym>
                        <synonym>RB</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Retinoblastoma-associated protein
                        MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTAL
                        CQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTEL
                        QKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSS
                        ISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYK
                        TAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFM
                        NSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKS
                        NLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVK
                        DIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDN
                        IFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEG
                        NLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNH
                        TAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYL
                        RLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLK
                        FKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLS
                        PIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFG
                        TSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQK
                        LAEMTSTRTRMQKQKMNDSMDTSNKEEK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2787 bp
                        ATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCC
                        CCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAG
                        GACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA
                        TGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAA
                        GTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGA
                        ATCTGTATCTTTATTGCACGAGTTGACCTAGATGAGATGTCGTTCACTTTACTGAGCTAC
                        AGAAAAACATACGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACC
                        AGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAGTATGATGTATTGTTTGCA
                        CTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCG
                        ATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTA
                        GCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTA
                        TGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTGCTCAAAGAACCATATAAA
                        ACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGT
                        GCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATTGAAGTTCTCTGTAAAGAA
                        CATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATG
                        AATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTTGAAAATCTTTCTAAACGA
                        TACGAAGAAATTTATCTTAAAAATAAAGATCTAGATCGAAGATTATTTTTGGATCATGAT
                        AAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAGAGAACACCACGAAAAAGT
                        AACCTTGATGAAGAGGTGAATATAATTCCTCCACACACTCCAGTTAGGACTGTTATGAAC
                        ACTATCCAACAATTAATGATGATTTTAAATTCTGCAAGTGATCAACCTTCAGAAAATCTG
                        ATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAG
                        GATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTGGGACAGGGTTGTGTCGAA
                        ATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATG
                        CTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGCAAACTTCTGAATGACAAC
                        ATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGA
                        AGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTCCCATGGATTCTGAATGTG
                        CTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGC
                        AACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAACATCGAATCATGGAATCC
                        CTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAA
                        GGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTTCCTCTCCAGAATAATCAC
                        ACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACG
                        CGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCAGCCTTCCAGACCCAGAAG
                        CCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTC
                        CGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCAGAATTAGAACATATCATC
                        TGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTG
                        GACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTGAAGAATATAGACCTTAAA
                        TTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAA
                        CGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTATTCTATAACTCGGTCTTC
                        ATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCA
                        CCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGTTCACCCTTACGGATTCCT
                        GGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCA
                        ACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCAATTGGTGAATCATTCGGG
                        ACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAA
                        AGAAGTGCTGAAGGAAGCAACCCTCCTAAACCACTGAAAAAACTACGCTTTGATATTGAA
                        GGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAA
                        CTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAGAAAATGAATGATAGCATG
                        GATACCTCAAACAAGGAAGAGAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01858</identifier>
                            <name>RB_A</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01857</identifier>
                            <name>RB_B</name>
                        </pfam>
                        <pfam>
                            <identifier>PF08934</identifier>
                            <name>Rb_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0000941</id>
                <name>Cathepsin D</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P07339" source="Swiss-Prot">
                    <name>Cathepsin D</name>
                    <general-function>Involved in aspartic-type endopeptidase activity</general-function>
                    <specific-function>Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease</specific-function>
                    <gene-name>CTSD</gene-name>
                    <locus>11p15.5</locus>
                    <cellular-location>Lysosome. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to s</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.5</theoretical-pi>
                    <molecular-weight>44553.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2529</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CTSD</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CTSD</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M11233</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>181180</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P07339</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CATD_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Cathepsin D precursor</synonym>
                        <synonym>EC 3.4.23.5</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cathepsin D precursor
                        MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVP
                        AVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIH
                        HKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG
                        EATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQ
                        PGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSL
                        MVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQ
                        AGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1239 bp
                        ATGCAGCCCTCCAGCCTTCTGCCGCTCGCCCTCTGCCTGCTGGCTGCACCCGCCTCCGCG
                        CTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTCGGAGGTTGGG
                        GGCTCTGTGGAGGACCTGATTGCCAAAGGCCCCGTCTCAAAGTACTCCCAGGCGGTGCCA
                        GCCGTGACCGAGGGGCCCATTCCCGAGGTGCTCAAGAACTACATGGACGCCCAGTACTAC
                        GGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCACAGTCGTCTTCGACACGGGCTCC
                        TCCAACCTGTGGGTCCCCTCCATCCACTGCAAACTGCTGGACATCGCTTGCTGGATCCAC
                        CACAAGTACAACAGCGACAAGTCCAGCACCTACGTGAAGAATGGTACCTCGTTTGACATC
                        CACTATGGCTCGGGCAGCCTCTCCGGGTACCTGAGCCAGGACACTGTGTCGGTGCCCTGC
                        CAGTCAGCGTCGTCAGCCTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGG
                        GAGGCCACCAAGCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGC
                        ATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAG
                        CAGAAGCTGGTGGACCAGAACATCTTCTCCTTCTACCTGAGCAGGGACCCAGATGCGCAG
                        CCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCC
                        TACCTGAATGTCACCCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCC
                        AGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATTGTGGACACAGGCACTTCCCTC
                        ATGGTGGGCCCGGTGGATGAGGTGCGCGAGCTGCAGAAGGCCATCGGGGCCGTGCCGCTG
                        ATTCAGGGCGAGTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTG
                        AAGCTGGGAGGCAAAGGCTACAAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTCGCAG
                        GCCGGGAAGACCCTCTGCCTGAGCGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGG
                        CCACTCTGGATCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGAC
                        AACAACAGGGTGGGCTTCGCCGAGGCTGCCCGCCTCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07966</identifier>
                            <name>A1_Propeptide</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00026</identifier>
                            <name>Asp</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>pepsin A activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>aspartic-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0001183</id>
                <name>Insulin-degrading enzyme</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P14735" source="Swiss-Prot">
                    <name>Insulin-degrading enzyme</name>
                    <general-function>Posttranslational modification, protein turnover, chaperones</general-function>
                    <specific-function>May play a role in the cellular processing of insulin. May be involved in intercellular peptide signaling</specific-function>
                    <gene-name>IDE</gene-name>
                    <locus>10q23-q25</locus>
                    <cellular-location>Cytoplasm</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.74</theoretical-pi>
                    <molecular-weight>118023.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5381</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IDE</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IDE</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M21188</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>184556</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P14735</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IDE_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.24.56</synonym>
                        <synonym>Insulin protease</synonym>
                        <synonym>Insulinase</synonym>
                        <synonym>Insulysin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin-degrading enzyme
                        MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPED
                        KREYRGLELANGIKVLLMSDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKK
                        YPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKD
                        REVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQE
                        LLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQ
                        LYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLV
                        GGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAV
                        AFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAI
                        VSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPL
                        EKEATPYPALIKDTVMSKLWFKQDDKKKKPKACLNFEFFSPFAYVDPLHCNMAYLYLELL
                        KDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFE
                        IIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLL
                        SRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQ
                        QRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRA
                        NGIQSLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKL
                        SAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLA
                        REMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;3060 bp
                        ATGCGGTACCGGCTAGCGTGGCTTCTGCACCCCGCACTGCCCAGCACCTTCCGCTCAGTC
                        CTCGGCGCCCGCCTGCCGCCTCCGGAGCGCCTGTGTGGTTTCCAAAAAAAGACTTACAGC
                        AAAATGAATAATCCAGCCATCAAGAGAATAGGAAATCACATTACCAAGTCTCCTGAAGAC
                        AAGCGAGAATATCGAGGGCTAGAGCTGGCCAATGGTATCAAAGTACTTCTTATGAGTGAT
                        CCCACCACGGATAAGTCATCAGCAGCACTTGATGTGCACATAGGTTCATTGTCGGATCCT
                        CCAAATATTGCTGGCTTAAGTCATTTTTGTGAACATATGCTTTTTTTGGGAACAAAGAAA
                        TACCCTAAAGAAAATGAATACAGCCAGTTTCTCAGTGAGCATGCAGGAAGTTCAAATGCC
                        TTTACTAGTGGAGAGCATACCAATTACTATTTTGATGTTTCTCATGAACACCTAGAAGGT
                        GCCCTAGACAGGTTTGCACAGTTTTTTCTGTGCCCCTTGTTCGATGAAAGTTGCAAAGAC
                        AGAGAGGTGAATGCAGTTGATTCAGAACATGAGAAGAATGTGATGAATGATGCCTGGAGA
                        CTCTTTCAATTGGAAAAAGCTACAGGGAATCCTAAACACCCCTTCAGTAAATTTGGGACA
                        GGTAACAAATATACTCTGGAGACTAGACCAAACCAAGAAGGCATTGATGTAAGACAAGAG
                        CTACTGAAATTCCATTCTGCTTACTATTCATCCAACTTAATGGCTGTTTGTGTTTTAGGT
                        CGAGAATCTTTAGATGACTTGACTAATCTGGTGGTAAAGTTATTTTCTGAAGTAGAGAAC
                        AAAAATGTTCCATTGCCAGAATTTCCTGAACACCCTTTCCAAGAAGAACATCTTAAACAA
                        CTTTACAAAATAGTACCCATTAAAGATATTAGGAATCTCTATGTGACATTTCCCATACCT
                        GACCTTCAGAAATACTACAAATCAAATCCTGGTCATTATCTTGGTCATCTCATTGGGCAT
                        GAAGGTCCTGGAAGTCTGTTATCAGAACTTAAGTCAAAGGGCTGGGTTAATACTCTTGTT
                        GGTGGGCAGAAGGAAGGAGCCCGAGGTTTTATGTTTTTTATCATTAATGTGGACTTGACC
                        GAGGAAGGATTATTACATGTTGAAGATATAATTTTGCACATGTTTCAATACATTCAGAAG
                        TTACGTGCAGAAGGACCTCAAGAATGGGTTTTCCAAGAGTGCAAGGACTTGAATGCTGTT
                        GCTTTTAGGTTTAAAGACAAAGAGAGGCCACGGGGCTATACATCTAAGATTGCAGGAATA
                        TTGCATTATTATCCCCTAGAAGAGGTGCTCACAGCGGAATATTTACTGGAAGAATTTAGA
                        CCTGACTTAATAGAGATGGTTCTCGATAAACTCAGACCAGAAAATGTCCGGGTTGCCATA
                        GTTTCTAAATCTTTTGAAGGAAAAACTGATCGCACAGAAGAGTGGTATGGAACCCAGTAC
                        AAACAAGAAGCTATACCGGATGAAGTCATCAAGAAATGGCAAAATGCTGACCTGAATGGG
                        AAATTTAAACTTCCTACAAAGAATGAATTTATTCCTACGAATTTTGAGATTTTACCGTTA
                        GAAAAAGAGGCGACACCATACCCTGCTCTTATTAAGGATACAGTCATGAGCAAACTTTGG
                        TTCAAACAAGATGATAAGAAAAAAAAGCCGAAGGCTTGTCTCAACTTTGAATTTTTCAGC
                        CCATTTGCTTATGTGGACCCCTTGCACTGTAACATGGCCTATTTGTACCTTGAGCTCCTC
                        AAAGACTCACTCAACGAGTATGCATATGCAGCAGAGCTAGCAGGCTTGAGCTATGATCTC
                        CAAAATACCATCTATGGGATGTATCTTTCAGTGAAAGGTTACAATGACAAGCAGCCAATT
                        TTACTAAAGAAGATTATTGAGAAAATGGCTACCTTTGAGATTGATGAAAAAAGATTTGAA
                        ATTATCAAAGAAGCATATATGCGATCTCTTAACAATTTCCGGGCTGAACAGCCTCACCAG
                        CATGCCATGTACTACCTCCGCTTGCTGATGACTGAAGTGGCCTGGACTAAAGATGAGTTA
                        AAAGAAGCTCTGGATGATGTAACCCTTCCTCGCCTTAAGGCCTTCATACCTCAGCTCCTG
                        TCACGGCTGCACATTGAAGCCCTTCTCCATGGAAACATAACAAAGCAGGCTGCATTAGGA
                        ATTATGCAGATGGTTGAAGACACCCTCATTGAACATGCTCATACCAAACCTCTCCTTCCA
                        AGTCAGCTGGTTCGGTATAGAGAAGTTCAGCTCCCTGACAGAGGATGGTTTGTTTATCAG
                        CAGAGAAATGAAGTTCACAATAACTGTGGCATCGAGATATACTACCAAACAGACATGCAA
                        AGCACCTCAGAGAATATGTTTCTGGAGCTCTTCTGTCAGATTATCTCGGAACCTTGCTTC
                        AACACCCTGCGCACCAAGGAGCAGTTGGGCTATATCGTCTTCAGCGGGCCACGTCGAGCT
                        AATGGCATACAGAGCTTGAGATTCATCATCCAGTCAGAAAAGCCACCTCACTACCTAGAA
                        AGCAGAGTGGAAGCTTTCTTAATTACCATGGAAAAGTCCATAGAGGACATGACAGAAGAG
                        GCCTTCCAAAAACACATTCAGGCATTAGCAATTCGTCGACTAGACAAACCAAAGAAGCTA
                        TCTGCTGAGTGTGCTAAATACTGGGGAGAAATCATCTCCCAGCAATATAATTTTGACAGA
                        GATAACACTGAGGTTGCATATTTAAAGACACTTACCAAGGAAGATATCATCAAATTCTAC
                        AAGGAAATGTTGGCAGTAGATGCTCCAAGGAGACATAAGGTATCCGTCCATGTTCTTGCC
                        AGGGAAATGGATTCTTGTCCTGTTGTTGGAGAGTTCCCATGTCAAAATGACATAAATTTG
                        TCACAAGCACCAGCCTTGCCACAACCTGAAGTGATTCAGAACATGACCGAATTCAAGCGT
                        GGTCTGCCACTGTTTCCCCTTGTGAAACCACATATTAACTTCATGGCTGCAAAACTCTGA
                    </gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00675</identifier>
                            <name>Peptidase_M16</name>
                        </pfam>
                        <pfam>
                            <identifier>PF05193</identifier>
                            <name>Peptidase_M16_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>metalloendopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0002124</id>
                <name>Neuroendocrine convertase 2</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P16519" source="Swiss-Prot">
                    <name>Neuroendocrine convertase 2</name>
                    <general-function>Posttranslational modification, protein turnover, chaperones</general-function>
                    <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues</specific-function>
                    <gene-name>PCSK2</gene-name>
                    <locus>20p11.2</locus>
                    <cellular-location>Cytoplasmic vesicle</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.47</theoretical-pi>
                    <molecular-weight>70566.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8744</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PCSK2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PCSK2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J05252</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>189652</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P16519</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>NEC2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.94</synonym>
                        <synonym>KEX2-like endoprotease 2</synonym>
                        <synonym>NEC 2</synonym>
                        <synonym>Neuroendocrine convertase 2 precursor</synonym>
                        <synonym>PC2</synonym>
                        <synonym>Prohormone convertase 2</synonym>
                        <synonym>Proprotein convertase 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Neuroendocrine convertase 2
                        MKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKL
                        PFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDIN
                        MNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN
                        YNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRM
                        LDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK
                        GSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK
                        RNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN
                        QLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP
                        STGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP
                        RDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYI
                        DQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1917 bp
                        ATGAAGGGTGGTTGTGTCTCCCAGTGGAAGGCGGCCGCCGGGTTCCTCTTCTGTGTCATG
                        GTTTTTGCATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCATAAA
                        GGGGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAAGCTT
                        CCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCCAAGAGAAGA
                        CGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCCAGGGTAAAGATGGCTTTGCAG
                        CAGGAAGGATTTGACCGAAAAAAGCGAGGTTACAGAGACATCAATGAGATCGACATCAAC
                        ATGAACGATCCTCTTTTTACAAAGCAGTGGTATCTGATCAATACTGGGCAAGCTGATGGC
                        ACTCCTGGCCTTGATTTGAATGTGGCTGAAGCCTGGGAGCTGGGATACACAGGGAAAGGT
                        GTTACCATTGGAATTATGGATGATGGGATTGACTATCTCCACCCGGACCTGGCCTCCAAC
                        TATAATGCCGAAGCAAGTTACGACTTCAGCAGCAACGACCCCTATCCTTACCCTCGGTAC
                        ACAGATGACTGGTTTAACAGCCACGGGACCCGATGTGCAGGAGAAGTTTCTGCTGCCGCC
                        AACAACAATATCTGTGGAGTTGGAGTAGCATACAACTCCAAGGTTGCAGGCATCCGGATG
                        CTGGACCAGCCATTCATGACAGACATCATCGAGGCCTCCTCCATCAGTCATATGCCACAG
                        CTGATTGACATCTACAGCGCCAGCTGGGGCCCCACAGACAACGGCAAGACAGTGGATGGG
                        CCCCGGGACGTCACGCTGCAGGCCATGGCCGATGGCGTGAACAAGGGCCGCGGCGGCAAA
                        GGCAGCATCTACGTGTGGGCCTCCGGGGACGGCGGCAGCTATGACGACTGCAACTGCGAC
                        GGCTACGCCTCCAGCATGTGGACCATCTCCATCAACTCAGCCATCAACGACGGCAGGACT
                        GCCCTGTACGACGAGAGCTGCTCTTCCACCTTGGCTTCCACCTTCAGCAACGGGAGGAAA
                        AGGAACCCCGAGGCCGGTGTGGCAACCACAGATTTGTACGGCAACTGCACTCTGAGGCAT
                        TCTGGGACATCTGCAGCTGCCCCCGAGGCAGCTGGTGTGTTTGCACTGGCTCTGGAGGCT
                        AACCTGGGTCTGACCTGGCGGGACATGCAGCATCTGACTGTGCTCACCTCCAAACGGAAC
                        CAGCTTCACGACGAGGTCCATCAGTGGCGGCGCAATGGGGTCGGCCTGGAATTTAATCAC
                        CTCTTTGGCTACGGGGTCCTTGATGCAGGTGCCATGGTGAAAATGGCTAAAGACTGGAAA
                        ACCGTGCCTGAGAGATTCCACTGTGTGGGAGGCTCCGTGCAGGACCCTGAGAAAATACCA
                        TCCACTGGCAAGTTGGTGCTGACACTCACAACCGACGCCTGTGAGGGGAAGGAAAATTTT
                        GTCCGCTACCTGGAGCATGTCCAGGCTGTCATCACGGTCAACGCAACCAGAAGAGGAGAC
                        CTGAACATCAACATGACTTCCCCTATGGGCACCAAGTCCATTTTGCTGAGCCGGCGTCCA
                        AGGGATGACGACTCCAAGGTGGGCTTTGACAAGTGGCCTTTCATGACCACTCACACGTGG
                        GGGGAAGACGCCCGAGGCACCTGGACCCTGGAGCTGGGATTTGTCGGCAGCGCCCCGCAG
                        AAGGGGGTGCTGAAGGAGTGGACCCTGATGCTGCATGGCACTCAGAGTGCCCCGTACATC
                        GACCAGGTGGTGCGGGATTACCAGTCCAAGTTGGCCATGTCCAAGAAAGAGGAGCTGGAG
                        GAAGAGCTGGACGAAGCCGTGGAGAGAAGCCTGAAAAGCATCCTTAACAAGAACTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00082</identifier>
                            <name>Peptidase_S8</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01483</identifier>
                            <name>P_proprotein</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>subtilase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0001123</id>
                <name>Carboxypeptidase E</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P16870" source="Swiss-Prot">
                    <name>Carboxypeptidase E</name>
                    <general-function>Amino acid transport and metabolism</general-function>
                    <specific-function>Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin</specific-function>
                    <gene-name>CPE</gene-name>
                    <locus>4q32.3</locus>
                    <cellular-location>Secreted protein. Note=Secretory granules of pancreatic islets, adrenal gland, pituitary and brain</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.78</theoretical-pi>
                    <molecular-weight>53151.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2303</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CPE</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CPE</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X51405</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29667</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P16870</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CBPE_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Carboxypeptidase E precursor</synonym>
                        <synonym>Carboxypeptidase H</synonym>
                        <synonym>CPE</synonym>
                        <synonym>CPH</synonym>
                        <synonym>EC 3.4.17.10</synonym>
                        <synonym>Enkephalin convertase</synonym>
                        <synonym>Prohormone-processing carboxypeptidase</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Carboxypeptidase E precursor
                        MAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR
                        EALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG
                        RELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS
                        NAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP
                        FVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC
                        RKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED
                        NKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK
                        LTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1431 bp
                        ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG
                        TGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC
                        CGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC
                        GAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG
                        CGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT
                        GAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA
                        CGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG
                        ACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT
                        GGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC
                        AATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG
                        AATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT
                        CAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT
                        TTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG
                        ACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC
                        TTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT
                        CGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC
                        AGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC
                        GTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT
                        AACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC
                        CGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC
                        GATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA
                        CTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC
                        CCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG
                        GAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00246</identifier>
                            <name>Peptidase_M14</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>exopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>carboxypeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>metallocarboxypeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>carboxypeptidase A activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0002125</id>
                <name>Neuroendocrine convertase 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P29120" source="Swiss-Prot">
                    <name>Neuroendocrine convertase 1</name>
                    <general-function>Posttranslational modification, protein turnover, chaperones</general-function>
                    <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin and insulin</specific-function>
                    <gene-name>PCSK1</gene-name>
                    <locus>5q15-q21</locus>
                    <cellular-location>Cytoplasmic vesicle</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.84</theoretical-pi>
                    <molecular-weight>84152.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8743</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PCSK1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PCSK1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X64810</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>35318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P29120</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>NEC1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.93</synonym>
                        <synonym>NEC 1</synonym>
                        <synonym>Neuroendocrine convertase 1 precursor</synonym>
                        <synonym>PC1</synonym>
                        <synonym>Prohormone convertase 1</synonym>
                        <synonym>Proprotein convertase 1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Neuroendocrine convertase 1
                        MERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQ
                        IGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNL
                        FNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYAN
                        YDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRM
                        LDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKG
                        SIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDY
                        TDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPL
                        ANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALK
                        ANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERE
                        RDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEH
                        MKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEE
                        GAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSL
                        YNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2262 bp
                        ATGGAGCGAAGAGCCTGGAGTCTGCAGTGCACTGCTTTCGTCCTCTTTTGCGCTTGGTGT
                        GCACTGAACAGTGCAAAAGCGAAAAGGCAATTTGTCAATGAATGGGCAGCGGAGATCCCC
                        GGGGGCCCGGAAGCAGCCTCGGCCATCGCCGAGGAGCTGGGCTATGACCTTTTGGGTCAG
                        ATTGGTTCACTTGAAAATCACTACTTATTCAAACATAAAAACCACCCCAGAAGGTCTCGA
                        AGGAGTGCCTTTCATATCACTAAGAGATTATCTGATGATGATCGTGTGATATGGGCTGAA
                        CAACAGTATGAAAAAGAAAGAAGTAAACGTTCAGCTCTAAGGGACTCAGCACTAAATCTC
                        TTCAATGATCCCATGTGGAATCAGCAATGGTACTTGCAAGATACCAGGATGACGGCAGCC
                        CTGCCCAAGCTGGACCTTCATGTGATACCTGTTTGGCAAAAAGGCATTACGGGCAAAGGA
                        GTTGTTATCACCGTACTGGATGATGGTTTGGAGTGGAATCACACGGACATTTATGCCAAC
                        TATGATCCAGAGGCTAGCTATGATTTTAATGATAATGACCATGATCCATTTCCCCGATAT
                        GATCCCACAAACGAGAACAAACACGGGACCAGATGTGCAGGAGAAATTGCCATGCAAGCA
                        AATAATCACAAATGCGGGGTTGGAGTTGCATACAATTCCAAAGTTGGAGGCATAAGAATG
                        CTGGATGGCATTGTGACGGATGCTATTGAGGCCAGTTCAATTGGATTCAATCCTGGACAC
                        GTGGATATTTACAGTGCAAGCTGGGGCCCTAATGATGATGGGAAAACTGTGGAGGGGCCT
                        GGCCGGCTAGCCCAGAAGGCTTTTGAATATGGTGTCAAACAGGGGAGACAGGGGAAGGGG
                        TCCATCTTCGTCTGGGCTTCGGGAAACGGGGGGCGTCAGGGAGATAATTGTGACTGTGAT
                        GGCTACACAGACAGCATCTACACCATCTCCATCAGCAGTGCCTCCCAGCAAGGCCTATCC
                        CCCTGGTACGCTGAGAAGTGCTCCTCCACACTGGCCACCTCTTACAGCGGCGGAGATTAC
                        ACCGACCAGAGAATCACGAGCGCTGACCTGCACAATGACTGCACGGAGACGCACACAGGC
                        ACCTCGGCCTCTGCACCTCTGGCTGCTGGCATCTTCGCTCTGGCCCTGGAAGCAAACCCA
                        AATCTCACCTGGCGAGATATGCAGCACCTGGTTGTCTGGACCTCTGAGTATGACCCGCTG
                        GCCAATAACCCTGGATGGAAAAAGAATGGAGCAGGCTTGATGGTGAATAGTCGATTTGGA
                        TTTGGCTTGCTAAATGCCAAAGCTCTGGTGGATTTAGCTGACCCCAGGACCTGGAGGAGC
                        GTGCCTGAGAAGAAAGAGTGTGTTGTAAAGGACAATGACTTTGAGCCCAGAGCCCTGAAA
                        GCTAATGGAGAAGTTATCATTGAAATTCCAACAAGAGCTTGTGAAGGACAAGAAAATGCT
                        ATCAAGTCCCTGGAGCATGTACAATTTGAAGCAACAATTGAATATTCCCGAAGAGGAGAC
                        CTTCATGTCACACTTACTTCTGCTGCTGGAACTAGCACTGTGCTCTTGGCTGAAAGAGAA
                        CGGGATACATCTCCTAATGGCTTTAAGAACTGGGACTTCATGTCTGTTCACACATGGGGA
                        GAGAACCCTATAGGTACTTGGACTTTGAGAATTACAGACATGTCTGGAAGAATTCAAAAT
                        GAAGGAAGAATTGTGAACTGGAAGCTGATTTTGCACGGGACCTCTTCTCAGCCAGAGCAT
                        ATGAAGCAGCCTCGTGTGTACACGTCCTACAACACTGTTCAGAATGACAGAAGAGGGGTG
                        GAGAAGATGGTGGATCCAGGGGAGGAGCAGCCCACACAAGAGAACCCTAAGGAGAACACC
                        CTGGTGTCCAAAAGCCCCAGCAGCAGCAGCGTAGGGGGCCGGAGGGATGAGTTGGAGGAG
                        GGAGCCCCTTCCCAGGCCATGCTGCGACTCCTGCAAAGTGCTTTCAGTAAAAACTCACCG
                        CCAAAGCAATCACCAAAGAAGTCCCCAAGTGCAAAGCTCAACATCCCTTATGAAAACTTC
                        TACGAAGCCCTGGAAAAGCTGAACAAACCTTCCCAGCTTAAAGACTCTGAAGACAGTCTG
                        TATAATGACTATGTTGATGTTTTTTATAACACTAAACCTTACAAGCACAGAGACGACCGG
                        CTGCTTCAAGCTCTGGTGGACATTCTGAATGAGGAAAATTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00082</identifier>
                            <name>Peptidase_S8</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01483</identifier>
                            <name>P_proprotein</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>subtilase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="9">
                <id>BE0001147</id>
                <name>Protein NOV homolog</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P48745" source="Swiss-Prot">
                    <name>Protein NOV homolog</name>
                    <general-function>Involved in insulin-like growth factor binding</general-function>
                    <specific-function>Immediate-early protein likely to play a role in cell growth regulation</specific-function>
                    <gene-name>NOV</gene-name>
                    <locus>8q24.1</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.74</theoretical-pi>
                    <molecular-weight>39162.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:7885</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>NOV</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>NOV</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X78351</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>825696</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P48745</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>NOV_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Nephroblastoma overexpressed gene protein homolog</synonym>
                        <synonym>NovH</synonym>
                        <synonym>Protein NOV homolog precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Protein NOV homolog precursor
                        MQSVQSTSFCLRKQCLCLTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDG
                        CSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEGDNCVFDGVIYRSG
                        EKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDS
                        LGGLTLAAYRPEATLGVEVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQ
                        TRLCMVRPCEQEPEQPTDKKGKKCLRTKKSLKAIHLQFKNCTSLHTYKPRFCGVCSDGRC
                        CTPHNTKTIQAEFQCSPGQIVKKPVMVIGTCTCHTNCPKNNEAFLQELELKTTRGKM</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1074 bp
                        ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTC
                        CTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCG
                        GGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGC
                        TGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCA
                        TGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGC
                        ATCTGCACGGCGGTAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGA
                        GAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAGATGGGCAGATTGGCTGT
                        GTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAA
                        GTTGAGGTGCCTGGAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCA
                        CTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCCTAGGAGTAGAAGTCTCT
                        GACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGT
                        GGTATGGGGTTCTCCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAG
                        ACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGCAGCCAACAGATAAGAAA
                        GGAAAAAAGTGTCTCCGCACCAAGAAGTCACTCAAAGCCATCCACCTGCAGTTCAAGAAC
                        TGCACCAGCCTGCACACCTACAAGCCCAGGTTCTGTGGGGTCTGCAGTGATGGCCGCTGC
                        TGCACTCCCCACAATACCAAAACCATCCAGGCAGAGTTTCAGTGCTCCCCAGGGCAAATA
                        GTCAAGAAGCCAGTGATGGTCATTGGGACCTGCACCTGTCACACCAACTGTCCTAAGAAC
                        AATGAGGCCTTCCTCCAGGAGCTGGAGCTGAAGACTACCAGAGGGAAAATGTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00093</identifier>
                            <name>VWC</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00219</identifier>
                            <name>IGFBP</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00007</identifier>
                            <name>Cys_knot</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00090</identifier>
                            <name>TSP_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>growth factor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>insulin-like growth factor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of biological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of growth</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of cell growth</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="10">
                <id>BE0000942</id>
                <name>Low-density lipoprotein receptor-related protein 2</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P98164" source="Swiss-Prot">
                    <name>Low-density lipoprotein receptor-related protein 2</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release</specific-function>
                    <gene-name>LRP2</gene-name>
                    <locus>2q24-q31</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>4424-4446</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.68</theoretical-pi>
                    <molecular-weight>521933.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6694</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LRP2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LRP2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U33837</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>1809240</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P98164</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LRP2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Glycoprotein 330</synonym>
                        <synonym>gp330</synonym>
                        <synonym>Low-density lipoprotein receptor-related protein 2 precursor</synonym>
                        <synonym>Megalin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low-density lipoprotein receptor-related protein 2 precursor
                        MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI
                        GCAVVTCQQGYFKCQSEGQCIPSSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC
                        IPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT
                        EICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV
                        CDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN
                        TSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ
                        KCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES
                        QNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK
                        IYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER
                        AFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL
                        IPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT
                        NPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR
                        GIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA
                        NRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL
                        FFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD
                        GLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL
                        KSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE
                        PPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI
                        PAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE
                        KNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC
                        IGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS
                        DEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL
                        GHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL
                        LANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV
                        ASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR
                        RVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD
                        PRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD
                        YMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM
                        YNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC
                        LRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE
                        IHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL
                        IANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH
                        LECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY
                        EVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL
                        FSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV
                        DVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY
                        FTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL
                        DCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP
                        YGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE
                        VNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS
                        LHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV
                        IASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY
                        LYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL
                        TGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI
                        NTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC
                        GASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC
                        DYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR
                        TCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH
                        WYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR
                        HQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC
                        GYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG
                        SDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS
                        GCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP
                        GYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR
                        LYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN
                        GGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII
                        STKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI
                        YWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC
                        LIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD
                        GSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ
                        CANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC
                        GDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH
                        PVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH
                        YNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA
                        YCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH
                        EVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL
                        GCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH
                        CRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD
                        EEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY
                        VMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF
                        WTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD
                        GTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI
                        FHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP
                        CRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL
                        AIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI
                        DRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE
                        IVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP
                        AKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;13968 bp
                        ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA
                        GCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC
                        ATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT
                        GGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC
                        ATCCCCAGCTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT
                        CAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT
                        ATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT
                        GACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC
                        AGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT
                        GAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT
                        GTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGATGAACATGCTTGCAACTATCCG
                        ACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT
                        TGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT
                        CATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC
                        TCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC
                        ACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG
                        TGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC
                        AATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG
                        AAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG
                        CGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT
                        GGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT
                        CAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG
                        ACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG
                        GTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA
                        ATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT
                        CGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT
                        GTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG
                        GCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT
                        GGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC
                        ATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC
                        ATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA
                        AAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG
                        GCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC
                        AATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTTCTCAGCCACAGAACA
                        GATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT
                        GAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT
                        GGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT
                        TCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG
                        TCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT
                        AACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG
                        ACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA
                        GTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA
                        TTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC
                        CTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT
                        GCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT
                        GGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC
                        ATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG
                        AAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG
                        AAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT
                        AACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC
                        CCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA
                        CCACCCACGGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC
                        AATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT
                        GGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT
                        CCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC
                        TGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG
                        TGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA
                        AAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA
                        TGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG
                        GTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT
                        ATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCG
                        GGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT
                        GGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT
                        GATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC
                        GGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT
                        GATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT
                        GGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT
                        GGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT
                        ACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA
                        CTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT
                        AGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG
                        TTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG
                        GCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA
                        TTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC
                        TTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA
                        AGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT
                        CGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG
                        AGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT
                        CCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG
                        CGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC
                        TGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT
                        TACATGGACTTTTGCGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG
                        ATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT
                        GCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG
                        TATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC
                        GTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT
                        CATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC
                        TTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC
                        CTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT
                        TTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA
                        ATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG
                        GGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT
                        AGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG
                        ATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT
                        GCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC
                        GCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC
                        CTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA
                        GGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGGATGATCCTGGTACACCAGCTT
                        TCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT
                        GAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT
                        GTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT
                        GGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG
                        TTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA
                        TATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG
                        TCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG
                        GATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT
                        GATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT
                        GGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT
                        TTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC
                        CGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG
                        AACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT
                        GACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA
                        GTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG
                        ATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT
                        TATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC
                        TTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC
                        AACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG
                        GTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG
                        CCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG
                        AATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC
                        TTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT
                        GTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC
                        TCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC
                        ATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT
                        TATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC
                        ACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC
                        CTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC
                        TTCCGGGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT
                        GAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG
                        ACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC
                        TATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA
                        TATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC
                        AACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG
                        GGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG
                        GGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT
                        GGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT
                        AATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC
                        TGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT
                        GATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC
                        AATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC
                        AATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC
                        ACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT
                        TTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC
                        ACTCACACATGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT
                        TGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT
                        CACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA
                        AGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG
                        CACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT
                        CCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC
                        GGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT
                        GGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC
                        TATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG
                        AACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA
                        TCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC
                        AAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT
                        TTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT
                        GGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT
                        TACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT
                        TTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA
                        GGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT
                        CTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC
                        CTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA
                        TTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC
                        AAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT
                        TCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT
                        GGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT
                        GATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG
                        GGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC
                        TCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC
                        TGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC
                        ACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT
                        TATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT
                        AGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT
                        AGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC
                        CTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT
                        CAACTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT
                        AACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT
                        GGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC
                        AGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT
                        GGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG
                        TGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG
                        GATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT
                        CGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT
                        GGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC
                        TTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT
                        GGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT
                        CCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT
                        GGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA
                        GAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT
                        TACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT
                        GAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC
                        GCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA
                        TACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA
                        TGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT
                        GTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT
                        GAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT
                        AGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC
                        ATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG
                        GGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC
                        CAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT
                        GACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC
                        TGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT
                        GACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC
                        AATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT
                        GAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT
                        GTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC
                        CCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC
                        GTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT
                        GTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT
                        TCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC
                        TGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC
                        AACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC
                        AATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT
                        GGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT
                        GAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT
                        GGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC
                        TTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC
                        CTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA
                        GAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA
                        TGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG
                        TGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA
                        GGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG
                        GCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG
                        CTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA
                        TCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT
                        GACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA
                        TTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG
                        GTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG
                        ATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG
                        AATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG
                        ATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT
                        GCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC
                        ACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00057</identifier>
                            <name>Ldl_recept_a</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00058</identifier>
                            <name>Ldl_recept_b</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07974</identifier>
                            <name>EGF_2</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="11">
                <id>BE0002126</id>
                <name>Insulin-like growth factor-binding protein 7</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q16270" source="Swiss-Prot">
                    <name>Insulin-like growth factor-binding protein 7</name>
                    <general-function/>
                    <specific-function>Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production</specific-function>
                    <gene-name>IGFBP7</gene-name>
                    <locus>4q12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.94</theoretical-pi>
                    <molecular-weight>29131.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5476</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IGFBP7</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IGFBP7</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L19182</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>307151</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q16270</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IBP7_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IBP- 7</synonym>
                        <synonym>IGF-binding protein 7</synonym>
                        <synonym>IGFBP-7</synonym>
                        <synonym>IGFBP-rP1</synonym>
                        <synonym>Insulin-like growth factor-binding protein 7 precursor</synonym>
                        <synonym>MAC25 protein</synonym>
                        <synonym>PGI2-stimulating factor</synonym>
                        <synonym>Prostacyclin-stimulating factor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin-like growth factor-binding protein 7
                        MERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCC
                        PMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVC
                        GSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLS
                        CEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSK
                        EDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;834 bp
                        ATGGAGCGCGCGTCGCTGCGCGCCCTGCTCTTCGGCCCCGCTGGGCTGCTGCTCCTGCTC
                        CTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGC
                        CCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGC
                        CCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTAC
                        TGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAGAGGCGGAGGGGTAAAGCCGGGGCA
                        GCAGCCGGCGGTCCGGGTGTAAGCGGCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGC
                        GGCAGCGACGGCACCACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCC
                        GAGAGCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCAAGGTCCT
                        TCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTGCCCAGGTGTACTTGAGC
                        TGTGAGGTCATCGGAATCCCGACACCTGTCCTCATCTGGAACAAGGTAAAAAGGGGTCAC
                        TATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACC
                        CGGGGTGGCCCAGAAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAG
                        GAAGATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTCAGCATCA
                        GCAAAAATTACAGTGGTTGATGCCTTACATGAAATAGCCAGTGAAAAAAGGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07679</identifier>
                            <name>I-set</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07648</identifier>
                            <name>Kazal_2</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>growth factor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>insulin-like growth factor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of biological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of growth</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of cell growth</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="12">
                <id>BE0002127</id>
                <name>Synaptotagmin-like protein 4</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q96C24" source="Swiss-Prot">
                    <name>Synaptotagmin-like protein 4</name>
                    <general-function/>
                    <specific-function>Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner</specific-function>
                    <gene-name>SYTL4</gene-name>
                    <locus>-</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.42</theoretical-pi>
                    <molecular-weight>76010.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:15588</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SYTL4</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SYTL4</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AK094110</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>21753104</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q96C24</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>SYTL4_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Exophilin-2</synonym>
                        <synonym>Granuphilin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Synaptotagmin-like protein 4
                        MSELLDLSFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSQHYSD
                        RTCARCQESLGRLSPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFY
                        DQKVNRFAYRTGSEIIRMSLRHKPAVSKRETVGQSLLHQTQMGDIWPGRKIIQERQKEPS
                        VLFEVPKLKSGKSALEAESESLDSFTADSDSTSRRDSLDKSGLFPEWKKMSAPKSQVEKE
                        TQPGGQNVVFVDEGEMIFKKNTRKILRPSEYTKSVIDLRPEDVVHESGSLGDRSKSVPGL
                        NVDMEEEEEEEDIDHLVKLHRQKLARSSMQSGSSMSTIGSMMSIYSEAGDFGNIFVTGRI
                        AFSLKYEQQTQSLVVHVKECHQLAYADEAKKRSNPYVKTYLLPDKSRQGKRKTSIKRDTV
                        NPLYDETLRYEIPESLLAQRTLQFSVWHHGRFGRNTFLGEAEIQMDSWKLDKKLDHCLPL
                        HGKISAESPTGLPSHKGELVVSLKYIPASKTPVGGDRKKSKGGEGGELQVWIKEAKNLTA
                        AKAGGTSDSFVKGYLLPMRNKASKRKTPVMKKTLNPHYNHTFVYNGVRLEDLQHMCLELT
                        VWDREPLASNDFLGGVRLGVGTGISNGEVVDWMDSTGEEVSLWQKMRQYPGSWAEGTLQL
                        RSSMAKQKLGL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2016 bp
                        ATGTCGGAGTTACTGGACCTTTCTTTTCTGTCTGAGGAGGAAAAGGATTTGATTCTCAGT
                        GTTCTACAGCGAGATGAAGAGGTCCGGAAAGCAGATGAGAAAAGGATTAGGCGACTAAAG
                        AATGAGTTACTGGAGATAAAAAGGAAAGGGGCCAAGAGGGGCAGCCAACACTACAGTGAT
                        CGGACCTGTGCCCGGTGCCAGGAGAGCCTGGGCCGTTTGAGTCCCAAAACCAATACTTGT
                        CGGGGTTGTAATCACCTGGTGTGTCGGGACTGCCGCATACAGGAAAGCAATGGTACCTGG
                        AGGTGCAAGGTGTGCGCCAAGGAAATAGAGTTGAAGAAAGCAACTGGGGACTGGTTTTAT
                        GACCAGAAAGTGAATCGCTTTGCTTACCGCACAGGTAGTGAGATAATCAGGATGTCCCTG
                        CGCCACAAACCTGCAGTGAGTAAAAGAGAGACAGTGGGACAGTCCCTCCTTCATCAGGCA
                        CAGATGGGTGACATCTGGCCAGGAAGAAAGATCATTCAGGAGCGGCAGAAGGAGCCCAGT
                        GTGCTATTTGAAGTGCCAAAGCTGAAAAGTGGAAAGAGTGCATTGGAAGCTGAGAGTGAG
                        AGTCTGGATAGCTTCACAGCTGACTCGGATAGCACCTCCAGGAGAGACTCTCTGGATAAA
                        TCTGGCCTCTTTCCAGAATGGAAGAAGATGTCTGCTCCCAAATCTCAAGTAGAAAAGGAA
                        ACTCAGCCTGGAGGTCAAAATGTGGTATTTGTGGATGAGGGTGAGATGATATTTAAGAAG
                        AACACCAGAAAAATCCTCAGGCCTTCAGAGTACACTAAATCTGTGATAGATCTTCGCCCA
                        GAAGATGTGGTACATGAAGGTGGCTCCTTGGGAGACAGAAGCAAATCCGTCCCAGGCCTC
                        AATGTGGATATGGAAGAGGAAGAAGAAGAAGAAGACATTGACCACCTAGTGAAGTTACAT
                        CGCCAGAAGCTAGCCAGAAGCAGCATGCAAAGTGGCTCCTCCATGAGTACGATCGGCAGC
                        ATGATGAGCATCTACAGTGAAGCTGGTGATTTCGGGAACATCTTTGTGACTGGCAGGATT
                        GCCTTTTCCCTGAAGTATGAGCAGCAAACCCAGAGTCTGGTTGTCCATGTGAAGGAGTGC
                        CATCAGCTGGCCTATGCTGATGAAGCCAAGAAGCGCTCTAACCCATATGTGAAGACTTAC
                        CTTCTGCCTGACAAGTCCCGCCAAGGAAAAAGAAAAACCAGCATCAAGCGGGACACTGTT
                        AATCCACTATATGATGAGACGCTGAGGTATGAGATCCCAGAATCTCTCCTGGCCCAGAGG
                        ACCCTGCAGTTCTCAGTTTGGCATCATGGTCGTTTTGGCAGAAACACTTTCCTTGGAGAG
                        GCAGAGATCCAGATGGATTCCTGGAAGCTTGATAAGAAACTGGATCATTGCCTCCCTTTA
                        CATGGAAAGATCAGTGCTGAGTCCCCGACTGGCTTGCCATCACACAAAGGCGAGTTGGTG
                        GTTTCATTGAAATACATCCCAGCCTCCAAAACCCCTGTTGGAGGTGACCGGAAAAAGAGT
                        AAAGGTGGGGAAGGGGGAGAGCTCCAGGTGTGGATCAAAGAAGCCAAGAACTTGACGGCT
                        GCCAAAGCAGGAGGGACTTCAGACAGCTTTGTCAAGGGATACCTCCTTCCCATGAGGAAC
                        AAGGCCAGTAAACGTAAAACTCCTGTGATGAAGAAGACCCTGAATCCTCACTACAACCAT
                        ACATTTGTCTACAATGGTGTGAGGCTGGAAGATCTACAGCATATGTGCCTGGAACTGACT
                        GTGTGGGACCGGGAGCCCCTGGCCAGCAATGACTTCCTGGGAGGGGTCAGGCTGGGTGTT
                        GGCACTGGGATCAGTAATGGGGAAGTGGTGGACTGGATGGACTCGACTGGGGAAGAAGTG
                        AGCCTGTGGCAGAAGATGCGACAGTACCCAGGGTCTTGGGCAGAAGGGACTCTGCAGCTC
                        CGTTCCTCAATGGCCAAGCAGAAGCTGGGTTTATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00168</identifier>
                            <name>C2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02318</identifier>
                            <name>RPH3A_effector</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>protein complex</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasmic vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasmic membrane-bound vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>coated vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>clathrin-coated vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>synaptic vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>ubiquitin ligase complex</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ligase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transition metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transporter activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ligase activity, forming carbon-nitrogen bonds</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>acid-amino acid ligase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ubiquitin-protein ligase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>GTPase binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>zinc ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>small GTPase binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>Rab GTPase binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>intracellular protein transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ubiquitin cycle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein ubiquitination</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme>
                <id>BE0002433</id>
                <name>Cytochrome P450 1A2</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Flockhart DA. "Drug Interactions: Cytochrome P450 Drug Interaction Table":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05177" source="Swiss-Prot">
                    <name>Cytochrome P450 1A2</name>
                    <general-function>Involved in monooxygenase activity</general-function>
                    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen</specific-function>
                    <gene-name>CYP1A2</gene-name>
                    <locus>15q24</locus>
                    <cellular-location>Endoplasmic reticulum</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.43</theoretical-pi>
                    <molecular-weight>58295.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CYP1A2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>Z00036</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05177</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CP1A2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CYPIA2</synonym>
                        <synonym>EC 1.14.14.1</synonym>
                        <synonym>P(3)450</synonym>
                        <synonym>P450 4</synonym>
                        <synonym>P450-P3</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytochrome P450 1A2
                        MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
                        PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
                        QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
                        AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
                        ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
                        LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
                        DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
                        WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
                        FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
                        TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
                        AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
                        CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
                        GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
                        CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
                        CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
                        CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
                        CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
                        GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
                        GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
                        AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
                        ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
                        CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
                        CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
                        CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
                        ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
                        AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
                        GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
                        TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
                        ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
                        TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
                        AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
                        GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
                        TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
                        CACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00067</identifier>
                            <name>p450</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>transition metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>iron ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tetrapyrrole binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>heme binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>monooxygenase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>generation of precursor metabolites and energy</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>electron transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2010-09-29">
        <drugbank-id primary="true">DB00031</drugbank-id>
        <drugbank-id>BIOD00019</drugbank-id>
        <drugbank-id>BTD00019</drugbank-id>
        <name>Tenecteplase</name>
        <description>Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.</description>
        <cas-number>191588-94-0</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Gurbel PA, Hayes K, Bliden KP, Yoho J, Tantry US: The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis. 2005 Jan;16(1):1-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15650539
            # Melzer C, Richter C, Rogalla P, Borges AC, Theres H, Baumann G, Laule M: Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis. 2004 Aug;18(1):47-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15744554
            # Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E: Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. Am Heart J. 2005 Jul;150(1):79-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16084152
            # De Luca G, Suryapranata H, Chiariello M: Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary. Evid Based Cardiovasc Med. 2005 Dec;9(4):284-7. Epub 2005 Nov 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16380055
            # : Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16488800</general-references>
        <synthesis-reference/>
        <indication>For treatment of myocardial infarction and lysis of intracoronary emboli</indication>
        <pharmacodynamics>Tenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.</pharmacodynamics>
        <mechanism-of-action>Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>1.9 hours (mammalian reticulocytes, in vitro)&#13;
&gt;20 hours (yeast, in vivo)&#13;
&gt;10 hours (Escherichia coli, in vivo)</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>* 99 - 119 mL/min [acute myocardial infarction patients]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">t- PA</synonym>
            <synonym language="" coder="">t-plasminogen activator</synonym>
            <synonym language="" coder="">Tissue-type plasminogen activator precursor</synonym>
            <synonym language="" coder="">tPA</synonym>
        </synonyms>
        <products>
            <product>
                <name>Tnkase</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02244826</dpd-id>
                <started-marketing-on>2001-10-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>50 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Tnkase</name>
                <ingredients>Tenecteplase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>F Hoffmann-La Roche Ltd.</name>
                <url>http://www.roche.com</url>
            </packager>
            <packager>
                <name>Genentech Inc.</name>
                <url>http://www.gene.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Tnkase 50 mg kit</description>
                <cost currency="USD">3238.76</cost>
                <unit>kit</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Fibrinolytic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Thrombolytic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>50 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AD11">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AD">Enzymes</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:12.20</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1341432</number>
                <country>Canada</country>
                <approved>2003-06-17</approved>
                <expires>2020-06-17</expires>
            </patent>
            <patent>
                <number>2129660</number>
                <country>Canada</country>
                <approved>2005-06-28</approved>
                <expires>2013-05-28</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00233</drugbank-id>
                <name>Aminosalicylic Acid</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00261</drugbank-id>
                <name>Anagrelide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06605</drugbank-id>
                <name>Apixaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06692</drugbank-id>
                <name>Aprotinin</name>
                <description>May diminish the therapeutic effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00278</drugbank-id>
                <name>Argatroban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01294</drugbank-id>
                <name>Bismuth Subsalicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00006</drugbank-id>
                <name>Bivalirudin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06441</drugbank-id>
                <name>Cangrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01166</drugbank-id>
                <name>Cilostazol</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00215</drugbank-id>
                <name>Citalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04272</drugbank-id>
                <name>Citric Acid</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00758</drugbank-id>
                <name>Clopidogrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06695</drugbank-id>
                <name>Dabigatran etexilate</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran etexilate.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06754</drugbank-id>
                <name>Danaparoid</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06700</drugbank-id>
                <name>Desvenlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00586</drugbank-id>
                <name>Diclofenac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00266</drugbank-id>
                <name>Dicoumarol</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00861</drugbank-id>
                <name>Diflunisal</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01551</drugbank-id>
                <name>Dihydrocodeine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00975</drugbank-id>
                <name>Dipyridamole</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00476</drugbank-id>
                <name>Duloxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09075</drugbank-id>
                <name>Edoxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01240</drugbank-id>
                <name>Epoprostenol</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00063</drugbank-id>
                <name>Eptifibatide</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01175</drugbank-id>
                <name>Escitalopram</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08794</drugbank-id>
                <name>Ethyl biscoumacetate</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00749</drugbank-id>
                <name>Etodolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00573</drugbank-id>
                <name>Fenoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08976</drugbank-id>
                <name>Floctafenine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00472</drugbank-id>
                <name>Fluoxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00712</drugbank-id>
                <name>Flurbiprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01050</drugbank-id>
                <name>Ibuprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01088</drugbank-id>
                <name>Iloprost</name>
                <description>May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00328</drugbank-id>
                <name>Indomethacin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01009</drugbank-id>
                <name>Ketoprofen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00465</drugbank-id>
                <name>Ketorolac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08918</drugbank-id>
                <name>Levomilnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01397</drugbank-id>
                <name>Magnesium salicylate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00784</drugbank-id>
                <name>Mefenamic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00814</drugbank-id>
                <name>Meloxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04896</drugbank-id>
                <name>Milnacipran</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00461</drugbank-id>
                <name>Nabumetone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08813</drugbank-id>
                <name>Nadroparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00788</drugbank-id>
                <name>Naproxen</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00991</drugbank-id>
                <name>Oxaprozin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00715</drugbank-id>
                <name>Paroxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00498</drugbank-id>
                <name>Phenindione</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00946</drugbank-id>
                <name>Phenprocoumon</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00554</drugbank-id>
                <name>Piroxicam</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06209</drugbank-id>
                <name>Prasugrel</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06228</drugbank-id>
                <name>Rivaroxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01399</drugbank-id>
                <name>Salsalate</name>
                <description>Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01104</drugbank-id>
                <name>Sertraline</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00605</drugbank-id>
                <name>Sulindac</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06271</drugbank-id>
                <name>Sulodexide</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01600</drugbank-id>
                <name>Tiaprofenic acid</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08816</drugbank-id>
                <name>Ticagrelor</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00208</drugbank-id>
                <name>Ticlopidine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06822</drugbank-id>
                <name>Tinzaparin</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00775</drugbank-id>
                <name>Tirofiban</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00500</drugbank-id>
                <name>Tolmetin</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00285</drugbank-id>
                <name>Venlafaxine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06684</drugbank-id>
                <name>Vilazodone</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09030</drugbank-id>
                <name>Vorapaxar</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09068</drugbank-id>
                <name>Vortioxetine</name>
                <description>Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00031 sequence
                SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG
                TCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTQWNSSA
                LAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC
                YFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK
                PWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAAAAKHRRS
                PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH
                KEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL
                SPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG
                PLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>60 °C</value>
                <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.528</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.61</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>58951.2000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C2561H3919N747O781S40</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12468</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D06070</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>50242-038-61</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>L00153</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164776757</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P00750</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Tenecteplase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/tenecteplase.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/mtm/tenecteplase.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00283</smpdb-id>
                <name>Tenecteplase Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00031</drugbank-id>
                        <name>Tenecteplase</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000211</id>
                <name>Plasminogen</name>
                <organism>Human</organism>
                <actions>
                    <action>activator</action>
                </actions>
                <references># Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235
                    # Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656
                    # Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00747" source="Swiss-Prot">
                    <name>Plasminogen</name>
                    <general-function>Involved in plasmin activity</general-function>
                    <specific-function>Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo</specific-function>
                    <gene-name>PLG</gene-name>
                    <locus>6q26</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.25</theoretical-pi>
                    <molecular-weight>90569.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9071</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X05199</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>387026</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PLMN_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.7</synonym>
                        <synonym>Plasminogen precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen precursor
                        MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
                        CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
                        GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
                        CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
                        LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
                        AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
                        QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
                        LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
                        CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
                        PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
                        RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
                        PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
                        LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
                        GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2433 bp
                        ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
                        CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
                        CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
                        TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
                        AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
                        TCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT
                        GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
                        ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
                        GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
                        TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
                        ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
                        CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
                        CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC
                        CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
                        GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
                        GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT
                        GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
                        CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
                        CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
                        GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
                        TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
                        CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
                        GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
                        GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC
                        TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
                        CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
                        AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
                        CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
                        GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
                        GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
                        AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
                        GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
                        CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
                        CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
                        GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
                        ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
                        CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
                        TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
                        GGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
                        GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
                        ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00024</identifier>
                            <name>PAN_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>plasmin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000538</id>
                <name>Fibrinogen alpha chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656
                    # Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235
                    # Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
                <known-action>yes</known-action>
                <polypeptide id="P02671" source="Swiss-Prot">
                    <name>Fibrinogen alpha chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation</specific-function>
                    <gene-name>FGA</gene-name>
                    <locus>4q28</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.87</theoretical-pi>
                    <molecular-weight>94974.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3661</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF361104</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>13591824</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02671</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FIBA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Fibrinogen alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]
                        MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
                        NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
                        NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
                        RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
                        LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
                        GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
                        NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
                        SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
                        EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
                        VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
                        YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
                        VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
                        GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
                        NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
                        VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2601 bp
                        ATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA
                        GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
                        GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
                        AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
                        TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
                        GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
                        AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
                        CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
                        GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
                        CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
                        CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
                        TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
                        CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
                        TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
                        TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
                        GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
                        TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
                        ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
                        AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
                        GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
                        GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
                        AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
                        GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
                        TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
                        GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
                        TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
                        GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
                        GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
                        AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
                        AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
                        TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
                        AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
                        TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
                        GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
                        GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
                        GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
                        GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
                        CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
                        ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
                        AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
                        GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
                        TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
                        GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
                        AGGCCCCTTGTGACCCAATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00147</identifier>
                            <name>Fibrinogen_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0000717</id>
                <name>Urokinase plasminogen activator surface receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Maupas-Schwalm F, Auge N, Robinet C, Cambus JP, Parsons SJ, Salvayre R, Negre-Salvayre A: The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator. FASEB J. 2004 Sep;18(12):1398-400. Epub 2004 Jul 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15231724
                    # Bankl HC, Samorapoompichit P, Pikula B, Latinovic L, Bankl H, Lechner K, Valent P: Characterization of human prostate mast cells and their increase in periprostatic vein thrombosis. Am J Clin Pathol. 2001 Jul;116(1):97-106. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11447759
                    # Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ: Spitz naevi may express components of the plasminogen activation system. J Pathol. 2002 Sep;198(1):92-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12210068</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q03405" source="Swiss-Prot">
                    <name>Urokinase plasminogen activator surface receptor</name>
                    <general-function>Involved in U-plasminogen activator receptor activity</general-function>
                    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form</specific-function>
                    <gene-name>PLAUR</gene-name>
                    <locus>19q13</locus>
                    <cellular-location>Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.64</theoretical-pi>
                    <molecular-weight>36978.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9053</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLAUR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X51675</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>37605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q03405</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>UPAR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD87 antigen</synonym>
                        <synonym>Monocyte activation antigen Mo3</synonym>
                        <synonym>U- PAR</synonym>
                        <synonym>uPAR</synonym>
                        <synonym>Urokinase plasminogen activator surface receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Urokinase plasminogen activator surface receptor precursor
                        MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
                        ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
                        GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
                        FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
                        MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
                        QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1008 bp
                        ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
                        TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
                        CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
                        GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
                        ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
                        GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
                        GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
                        GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
                        AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
                        TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
                        GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
                        GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
                        ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA
                        AGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG
                        AACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC
                        CAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC
                        CTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00021</identifier>
                            <name>UPAR_LY6</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>U-plasminogen activator receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0000240</id>
                <name>Plasminogen activator inhibitor 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Lindberg P, Kinnby B, Lecander I, Lang NP, Matsson L: Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation. Arch Oral Biol. 2001 Jan;46(1):23-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11163592
                    # Hattori M, Azami Y: Searching for preventive measures of cardiovascular events in aged Japanese taxi drivers--the daily rhythm of cardiovascular risk factors during a night duty day. J Hum Ergol (Tokyo). 2001 Dec;30(1-2):321-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14564902
                    # Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05121" source="Swiss-Prot">
                    <name>Plasminogen activator inhibitor 1</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis</specific-function>
                    <gene-name>SERPINE1</gene-name>
                    <locus>7q21.3-q22</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.22</theoretical-pi>
                    <molecular-weight>45061.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8583</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINE1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04429</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>35272</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05121</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAI1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Endothelial plasminogen activator inhibitor</synonym>
                        <synonym>PAI</synonym>
                        <synonym>PAI-1</synonym>
                        <synonym>Plasminogen activator inhibitor 1 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen activator inhibitor 1 precursor
                        MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
                        GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
                        FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
                        DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
                        GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
                        FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
                        STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1209 bp
                        ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
                        GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
                        AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
                        GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
                        ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
                        CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC
                        TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
                        CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
                        GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
                        GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
                        CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
                        TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
                        GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
                        GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
                        CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
                        TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
                        ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
                        GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
                        TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
                        TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
                        GAACCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0000969</id>
                <name>Plasminogen activator inhibitor 2</name>
                <organism>Human</organism>
                <actions/>
                <references># Verkleij-Hagoort AC, Ursem NT, Hop WC, Geurts-Moespot A, Steegers EA, Sweep FC, Steegers-Theunissen RP: Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid. Eur J Obstet Gynecol Reprod Biol. 2006 Nov 30;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17141398
                    # Bremer HA, Brommer EJ, Wallenburg HC: Effects of labor and delivery on fibrinolysis. Eur J Obstet Gynecol Reprod Biol. 1994 Jun 30;55(3):163-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7958159
                    # Stump DC, Thienpont M, Collen D: Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem. 1986 Sep 25;261(27):12759-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3091604</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05120" source="Swiss-Prot">
                    <name>Plasminogen activator inhibitor 2</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell- derived PAI-1</specific-function>
                    <gene-name>SERPINB2</gene-name>
                    <locus>18q21.3</locus>
                    <cellular-location>Cytoplasm. Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.34</theoretical-pi>
                    <molecular-weight>46597.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8584</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SERPINB2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SERPINB2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J02685</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>189545</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05120</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PAI2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Monocyte Arg-serpin</synonym>
                        <synonym>PAI-2</synonym>
                        <synonym>Placental plasminogen activator inhibitor</synonym>
                        <synonym>Plasminogen activator inhibitor 2 precursor</synonym>
                        <synonym>Urokinase inhibitor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Plasminogen activator inhibitor 2 precursor
                        MEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF
                        NEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN
                        YLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK
                        IPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK
                        LNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM
                        AEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV
                        DVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1248 bp
                        ATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA
                        AAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC
                        ATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT
                        AATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG
                        TTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA
                        GATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGGAT
                        TATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA
                        TATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA
                        TGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA
                        ATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT
                        GCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT
                        CCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG
                        CTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA
                        GATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG
                        CTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG
                        GCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC
                        AGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC
                        TCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG
                        GATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA
                        ACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCGTTTCTTTTTCTTATTATGCAT
                        AAGATAACCAAGTGCATTTTATTTTTCGGCAGATTTTGCTCACCCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00079</identifier>
                            <name>Serpin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0002104</id>
                <name>Tetranectin</name>
                <organism>Human</organism>
                <actions/>
                <references># Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE: Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem. 2003 Apr;270(8):1850-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12694198
                    # Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis J: Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. J Rheumatol. 1997 Feb;24(2):262-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9034981
                    # Vuckovic B, Deric M: [Lipoprotein(a): a link between thrombogenesis and atherogenesis] Med Pregl. 2007 Jan-Feb;60(1-2):37-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17853709</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05452" source="Swiss-Prot">
                    <name>Tetranectin</name>
                    <general-function/>
                    <specific-function>Tetranectin binds to plasminogen and to isolated kringle 4. May be involved in the packaging of molecules destined for exocytosis</specific-function>
                    <gene-name>CLEC3B</gene-name>
                    <locus>3p22-p21.3</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.36</theoretical-pi>
                    <molecular-weight>22567.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11891</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CLEC3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CLEC3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X64559</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>37409</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05452</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TETN_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>C-type lectin domain family 3 member B</synonym>
                        <synonym>Plasminogen kringle 4-binding protein</synonym>
                        <synonym>Tetranectin precursor</synonym>
                        <synonym>TN</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tetranectin
                        MELWGAYLLLCLFSLLTQVTTEPPTQKPKKIVNAKKDVVNTKMFEELKSRLDTLAQEVAL
                        LKEQQALQTVCLKGTKVHMKCFLAFTQTKTFHEASEDCISRGGTLSTPQTGSENDALYEY
                        LRQSVGNEAEIWLGLNDMAAEGTWVDMTGARIAYKNWETEITAQPDGGKTENCAVLSGAA
                        NGKWFDKRCRDQLPYICQFGIV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;609 bp
                        ATGGAGCTCTGGGGGGCCTACCTCCTCCTCTGCCTCTTCTCCCTCCTGACCCAGGTCACC
                        ACCGAGCCACCAACCCAGAAGCCCAAGAAGATTGTAAATGCCAAGAAAGATGTTGTGAAC
                        ACAAAGATGTTTGAGGAGCTCAAGAGCCGTCTGGACACCCTGGCCCAGGAGGTGGCCCTG
                        CTGAAGGAGCAGCAGGCCCTGCAGACGGTCTGCCTGAAGGGGACCAAGGTGCACATGAAA
                        TGCTTTCTGGCCTTCACCCAGACGAAGACCTTCCACGAGGCCAGCGAGGACTGCATCTCG
                        CGCGGGGGCACCCTGAGCACCCCTCAGACTGGCTCGGAGAACGACGCCCTGTATGAGTAC
                        CTGCGCCAGAGCGTGGGCAACGAGGCCGAGATCTGGCTGGGCCTCAACGACATGGCGGCC
                        GAGGGCACCTGGGTGGACATGACCGGCGCCCGCATCGCCTACAAGAACTGGGAGACTGAG
                        ATCACCGCGCAACCCGATGGCGGCAAGACCGAGAACTGCGCGGTCCTGTCAGGCGCGGCC
                        AACGGCAAGTGGTTCGACAAGCGCTGCCGCGATCAGCTGCCCTACATCTGCCAGTTCGGG
                        ATCGTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00059</identifier>
                            <name>Lectin_C</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>carbohydrate binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>sugar binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0002105</id>
                <name>Keratin, type II cytoskeletal 8</name>
                <organism>Human</organism>
                <actions/>
                <references># Kralovich KR, Li L, Hembrough TA, Webb DJ, Karns LR, Gonias SL: Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J Protein Chem. 1998 Nov;17(8):845-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9988531
                    # Hembrough TA, Kralovich KR, Li L, Gonias SL: Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J. 1996 Aug 1;317 ( Pt 3):763-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8760360
                    # Hembrough TA, Li L, Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem. 1996 Oct 11;271(41):25684-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8810346</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05787" source="Swiss-Prot">
                    <name>Keratin, type II cytoskeletal 8</name>
                    <general-function>Cell cycle control, cell division, chromosome partitioning</general-function>
                    <specific-function>Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle</specific-function>
                    <gene-name>KRT8</gene-name>
                    <locus>12q13</locus>
                    <cellular-location/>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.26</theoretical-pi>
                    <molecular-weight>53705.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6446</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>KRT8</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>KRT8</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M34482</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>181573</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05787</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>K2C8_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CK-8</synonym>
                        <synonym>Cytokeratin-8</synonym>
                        <synonym>K8</synonym>
                        <synonym>Keratin-8</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Keratin, type II cytoskeletal 8
                        MSIRVTQKSYKVSTSGPRAFSSRSYTSGPGSRISSSSFSRVGSSNFRGGLGGGYGGASGM
                        GGITAVTVNQSLLSPLVLEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLE
                        TKWSLLQQQKTARSNMDNMFESYINNLRRQLETLGQEKLKLEAELGNMQGLVEDFKNKYE
                        DEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQLYEEEIRELQSQIS
                        DTSVVLSMDNSRSLDMDSIIAEVKAQYEDIANRSRAEAESMYQIKYEELQSLAGKHGDDL
                        RRTKTEISEMNRNISRLQAEIEGLKGQRASLEAAIADAEQRGELAIKDANAKLSELEAAL
                        QRAKQDMARQLREYQELMNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYA
                        GGLSSAYGGLTSPGLSYSLGSSFGSGAGSSSFSRTSSSRAVVVKKIETRDGKLVSESSDV
                        LPK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1449 bp
                        ATGTCCATCAGGGTGACCCAGAAGTCCTACAAGGTGTCCACCTCTGGCCCCCGGGCCTTC
                        AGCAGCCGCTCCTACACGAGTGGGCCCGGTTCCCGCATCAGCTCCTCGAGCTTCTCCCGA
                        GTGGGCAGCAGCAACTTTCGCGGTGGCCTGGGCGGCGGCTATGGTGGGGCCAGCGGCATG
                        GGAGGCATCACCGCAGTTACGGTCAACCAGAGCCTGCTGAGCCCCCTTGTCCTGGAGGTG
                        GACCCCAACATCCAGGCCGTGCGCACCCAGGAGAAGGAGCAGATCAAGACCCTCAACAAC
                        AAGTTTGCCTCCTTCATAGACAAGGTACGGTTCCTGGAGCAGCAGAACAAGATGCTGGAG
                        ACCAAGTGGAGCCTCCTGCAGCAGCAGAAGACGGCTCGAAGCAACATGGACAACATGTTC
                        GAGAGCTACATCAACAACCTTAGGCGGCAGCTGGAGACTCTGGGCCAGGAGAAGCTGAAG
                        CTGGAGGCGGAGCTTGGCAACATGCAGGGGCTGGTGGAGGACTTCAAGAACAAGTATGAG
                        GATGAGATCAATAAGCGTACAGAGATGGAGAACGAATTTGTCCTCATCAAGAAGGATGTG
                        GATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAG
                        ATCAACTTCCTCAGGCAGCTATATGAAGAGGAGATCCGGGAGCTGCAGTCCCAGATCTCG
                        GACACATCTGTGGTGCTGTCCATGGACAACAGCCGCTCCCTGGACATGGACAGCATCATT
                        GCTGAGGTCAAGGCACAGTACGAGGATATTGCCAACCGCAGCCGGGCTGAGGCTGAGAGC
                        ATGTACCAGATCAAGTATGAGGAGCTGCAGAGCCTGGCTGGGAAGCACGGGGATGACCTG
                        CGGCGCACAAAGACTGAGATCTCTGAGATGAACCGGAACATCAGCCGGCTCCAGGCTGAG
                        ATTGAGGGCCTCAAAGGCCAGAGGGCTTCCCTGGAGGCCGCCATTGCAGATGCCGAGCAG
                        CGTGGAGAGCTGGCCATTAAGGATGCCAACGCCAAGTTGTCCGAGCTGGAGGCCGCCCTG
                        CAGCGGGCCAAGCAGGACATGGCGCGGCAGCTGCGTGAGTACCAGGAGCTGATGAACGTC
                        AAGCTGGCCCTGGACATCGAGATCGCCACCTACAGGAAGCTGCTGGAGGGCGAGGAGAGC
                        CGGCTGGAGTCTGGGATGCAGAACATGAGTATTCATACGAAGACCACCGGCGGCTATGCA
                        GGTGGTCTGAGCTCGGCCTATGGGGGCTCACAAGCCGGCCTCAGCTACAGCCTGGGCTCC
                        AGCTTTGGCTCTGGCGCGGGCTCCAGCTCCTTCAGCCGCACCAGCTCCTCCAGGGCCGTG
                        GTTGTGAAGAAGATCGAGACACGTGATGGGAAGCTGGTGTCTGAGTCCTCTGACGTCCTG
                        CCCAAGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00038</identifier>
                            <name>Filament</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>structural molecule activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0001170</id>
                <name>Annexin A2</name>
                <organism>Human</organism>
                <actions/>
                <references># Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R: Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004 Jul;53(7):993-1000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15194650
                    # Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM: Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med. 1999 Apr-May;9(3-4):92-102. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10578524
                    # MacLeod TJ, Kwon M, Filipenko NR, Waisman DM: Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem. 2003 Jul 11;278(28):25577-84. Epub 2003 Apr 30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12730231</references>
                <known-action>unknown</known-action>
                <polypeptide id="P07355" source="Swiss-Prot">
                    <name>Annexin A2</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity</specific-function>
                    <gene-name>ANXA2</gene-name>
                    <locus>15q21-q22</locus>
                    <cellular-location>Secreted protein; extracellular space; extracellular matrix; basement membrane. Melanosome. Note=In </cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.91</theoretical-pi>
                    <molecular-weight>38604.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:537</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>ANXA2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>ANXA2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>D00017</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>219910</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P07355</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>ANXA2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Annexin II</synonym>
                        <synonym>Calpactin I heavy chain</synonym>
                        <synonym>Chromobindin-8</synonym>
                        <synonym>Lipocortin II</synonym>
                        <synonym>p36</synonym>
                        <synonym>PAP-IV</synonym>
                        <synonym>Placental anticoagulant protein IV</synonym>
                        <synonym>Protein I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Annexin A2
                        MSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL
                        TNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKG
                        LGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRA
                        EDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDM
                        LESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDM
                        LKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1020 bp
                        ATGTCTACTGTTCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCC
                        CCAAGTGCATATGGGTCTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTG
                        AACATTGAAACAGCCATCAAGACCAAAGGTGTGGATGAGGTCACCATTGTCAACATTTTG
                        ACCAACCGCAGCAATGCACAGAGACAGGATATTGCCTTCGCCTACCAGAGAAGGACCAAA
                        AAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTG
                        GGCCTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGG
                        CTGGGAACCGACGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTG
                        CAGGAAATTAACAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATT
                        TCGGACACATCTGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCA
                        GAGGATGGCTCTGTCATTGATTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGAC
                        GCTGGAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCGAGCGG
                        AGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATG
                        TTGGAAAGCATCAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTT
                        CAGTGCATTCAGAACAAGCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGC
                        AAGGGGACGCGAGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATG
                        TTGAAAATTAGGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAG
                        CAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGA
                    </gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00191</identifier>
                            <name>Annexin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>phospholipase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>phospholipid binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium-dependent phospholipid binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cytoskeletal protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>lipid binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="9">
                <id>BE0002109</id>
                <name>Calreticulin</name>
                <organism>Human</organism>
                <actions/>
                <references># Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9359841</references>
                <known-action>unknown</known-action>
                <polypeptide id="P27797" source="Swiss-Prot">
                    <name>Calreticulin</name>
                    <general-function/>
                    <specific-function>Molecular calcium binding chaperone promoting folding, oligomeric assembly and quality control in the ER via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export</specific-function>
                    <gene-name>CALR</gene-name>
                    <locus>19p13.3-p13.2</locus>
                    <cellular-location>Endoplasmic reticulum</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.04</theoretical-pi>
                    <molecular-weight>48142.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1455</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CALR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CALR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M32294</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>337487</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P27797</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CALR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Calregulin</synonym>
                        <synonym>Calreticulin precursor</synonym>
                        <synonym>CRP55</synonym>
                        <synonym>ERp60</synonym>
                        <synonym>grp60</synonym>
                        <synonym>HACBP</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Calreticulin
                        MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE
                        EKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT
                        DMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN
                        TYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE
                        HIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS
                        PDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK
                        QDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1254 bp
                        ATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCCGCC
                        GTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC
                        AAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG
                        GAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT
                        TTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG
                        CAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA
                        GACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC
                        ACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC
                        ATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC
                        ACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG
                        GACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT
                        GAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG
                        CATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG
                        TGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC
                        GACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT
                        CCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG
                        GTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG
                        GAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA
                        CAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG
                        GAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC
                        AAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00262</identifier>
                            <name>Calreticulin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane-bound organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular membrane-bound organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>endoplasmic reticulum</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>unfolded protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein folding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="10">
                <id>BE0001011</id>
                <name>Calnexin</name>
                <organism>Human</organism>
                <actions/>
                <references># Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9359841</references>
                <known-action>unknown</known-action>
                <polypeptide id="P27824" source="Swiss-Prot">
                    <name>Calnexin</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins</specific-function>
                    <gene-name>CANX</gene-name>
                    <locus>5q35</locus>
                    <cellular-location>Endoplasmic reticulum; endoplasmic reticulum membrane; single-pass type I membrane protein. Melanoso</cellular-location>
                    <transmembrane-regions>482-502</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.21</theoretical-pi>
                    <molecular-weight>67569.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1473</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CANX</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CANX</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L10284</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>186523</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P27824</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CALX_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Calnexin precursor</synonym>
                        <synonym>IP90</synonym>
                        <synonym>Major histocompatibility complex class I antigen- binding protein p88</synonym>
                        <synonym>p90</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Calnexin precursor
                        MEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY
                        KAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL
                        VLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH
                        DKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL
                        ILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK
                        PDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC
                        ESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS
                        AIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER
                        PWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE
                        EEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1779 bp
                        ATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT
                        CATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA
                        GAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC
                        AAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG
                        TCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT
                        GATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT
                        GTGTTGATGTCTCGGGCCAAGCATCATGCGATCTCTGCTAAACTGAACAAGCCCTTCCTG
                        TTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT
                        GGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT
                        GACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG
                        CACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG
                        AGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA
                        ATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA
                        AATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA
                        GACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG
                        CCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC
                        GAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG
                        GATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT
                        GAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA
                        GGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG
                        AAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT
                        GCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT
                        TGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT
                        GCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC
                        CCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC
                        TTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT
                        CAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG
                        GAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT
                        GGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG
                        AACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00262</identifier>
                            <name>Calreticulin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="11">
                <id>BE0002110</id>
                <name>Prolow-density lipoprotein receptor-related protein 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Moestrup SK, Nielsen S, Andreasen P, Jorgensen KE, Nykjaer A, Roigaard H, Gliemann J, Christensen EI: Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem. 1993 Aug 5;268(22):16564-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8344937
                    # Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA, et al.: Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992 Jul 25;267(21):14543-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1378833
                    # Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006 Jan 27;281(4):2120-7. Epub 2005 Nov 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16303771</references>
                <known-action>unknown</known-action>
                <polypeptide id="Q07954" source="Swiss-Prot">
                    <name>Prolow-density lipoprotein receptor-related protein 1</name>
                    <general-function/>
                    <specific-function>Required for early embryonic development. Involved in the plasma clearance of chylomicron remnants and activated alpha 2-macroglobulin, as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission</specific-function>
                    <gene-name>LRP1</gene-name>
                    <locus>12q13-q14</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>4420-4444</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.02</theoretical-pi>
                    <molecular-weight>504578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6692</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LRP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LRP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X13916</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>34339</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q07954</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LRP1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>A2MR</synonym>
                        <synonym>Alpha-2-macroglobulin receptor</synonym>
                        <synonym>APOER</synonym>
                        <synonym>Apolipoprotein E receptor</synonym>
                        <synonym>CD91 antigen</synonym>
                        <synonym>Low-density lipoprotein receptor-related protein 1 precursor</synonym>
                        <synonym>LRP</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low-density lipoprotein receptor-related protein 1
                        MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA
                        PEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC
                        QHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL
                        LQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE
                        TVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI
                        DDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK
                        LVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE
                        NYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN
                        DQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG
                        MDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG
                        IHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG
                        WMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY
                        DRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT
                        LLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV
                        TCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF
                        KCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD
                        CGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF
                        KCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW
                        RCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC
                        ESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP
                        GEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES
                        CRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK
                        IYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT
                        LLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT
                        VDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT
                        LAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT
                        VSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL
                        DYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN
                        KKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG
                        QKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW
                        WADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL
                        CLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG
                        TSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY
                        WTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG
                        TERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS
                        VSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA
                        VANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL
                        NAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE
                        NVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD
                        ECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK
                        IERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI
                        PQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV
                        NSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS
                        NMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS
                        ATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY
                        FACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG
                        DGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD
                        REFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG
                        ENDCHDQSDEAPKNPHCTSPEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH
                        INECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH
                        GSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV
                        ALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD
                        KGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR
                        SVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF
                        EDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG
                        CSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG
                        DHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC
                        TNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV
                        DGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ
                        FRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC
                        ADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ
                        CNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD
                        NCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP
                        KLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN
                        TKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV
                        RIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP
                        RGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW
                        GNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI
                        VAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH
                        QHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC
                        NLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT
                        GFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM
                        AADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH
                        CSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV
                        VFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT
                        NFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;13635 bp
                        ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT
                        ATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT
                        ATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC
                        CCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG
                        GGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC
                        GGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC
                        CAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG
                        CTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC
                        AGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC
                        CTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG
                        CTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT
                        ACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG
                        ACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC
                        ATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC
                        CACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC
                        GATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG
                        GAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT
                        GACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG
                        CTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT
                        GTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC
                        CGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG
                        AATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC
                        CGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT
                        GCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC
                        GACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG
                        GCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG
                        AAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC
                        ATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC
                        CCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC
                        TACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC
                        ATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC
                        GATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG
                        ACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG
                        TGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG
                        AGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG
                        CCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC
                        GACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT
                        GAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT
                        CGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC
                        CTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG
                        CAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC
                        ACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC
                        ACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC
                        TGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG
                        GACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC
                        AAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT
                        GGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG
                        TTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC
                        TGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT
                        CAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT
                        GACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC
                        AAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC
                        GGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT
                        GGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG
                        CGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG
                        ACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC
                        AAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC
                        GAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG
                        CCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG
                        CTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT
                        GGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC
                        TGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC
                        AAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC
                        TGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG
                        CGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC
                        GCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG
                        ATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG
                        TATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG
                        GTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC
                        CTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC
                        CTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG
                        GCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC
                        GTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA
                        GCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC
                        CCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA
                        CTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC
                        CAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT
                        GAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC
                        GTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG
                        TTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT
                        CCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA
                        GACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG
                        CGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC
                        CACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT
                        AAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC
                        CTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT
                        GGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC
                        CAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC
                        TCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT
                        GCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG
                        TGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC
                        GTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC
                        CAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC
                        TGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG
                        AGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA
                        ATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG
                        ACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC
                        ATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG
                        ACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC
                        TGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC
                        GTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG
                        TACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC
                        ACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC
                        TACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC
                        CTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA
                        GTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC
                        AAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC
                        CAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG
                        GTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC
                        GCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC
                        CTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC
                        AATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC
                        TTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC
                        CACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA
                        AACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA
                        AGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC
                        GAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC
                        GAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG
                        GCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT
                        GGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG
                        ATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC
                        CACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG
                        GCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC
                        CCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT
                        CCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT
                        GTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG
                        AATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC
                        AGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC
                        TGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC
                        AACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC
                        AACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC
                        TCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT
                        GCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC
                        GAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG
                        GACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC
                        TTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC
                        TGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG
                        TGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG
                        GATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC
                        TGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT
                        GCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC
                        CGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC
                        CGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC
                        AGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC
                        GAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCCA
                        GAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG
                        GCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC
                        ATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG
                        ATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGATGACGGCCGGACGTGT
                        GCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACCCAT
                        GGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC
                        TGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC
                        AAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT
                        GCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC
                        AGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC
                        CTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC
                        AAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC
                        AGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC
                        TGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC
                        AGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT
                        GAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC
                        TCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT
                        GAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC
                        ACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC
                        TTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC
                        TGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC
                        TTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA
                        TGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG
                        GACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG
                        TGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG
                        GACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC
                        ACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA
                        GATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC
                        TCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG
                        GATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC
                        TGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT
                        GGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG
                        TTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT
                        TGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC
                        TCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC
                        GCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC
                        AAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC
                        GGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG
                        TGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG
                        GACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC
                        TTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC
                        AACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC
                        TGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC
                        TGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC
                        AAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC
                        ACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC
                        GGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC
                        ACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC
                        AAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC
                        CTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC
                        CGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC
                        ACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC
                        CACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC
                        AGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT
                        GTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT
                        GACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG
                        GGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG
                        CAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC
                        TGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT
                        GTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT
                        TACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC
                        AGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT
                        CAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC
                        CTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC
                        ACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT
                        AACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC
                        CGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT
                        CGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG
                        GGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC
                        ACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC
                        GACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG
                        GCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG
                        GTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT
                        GTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC
                        TGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA
                        CCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT
                        ATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG
                        GTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC
                        AACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG
                        CCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC
                        AACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC
                        CTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG
                        GACCCCTTGGCATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00057</identifier>
                            <name>Ldl_recept_a</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00058</identifier>
                            <name>Ldl_recept_b</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-10-03">
        <drugbank-id primary="true">DB00032</drugbank-id>
        <drugbank-id>BIOD00018</drugbank-id>
        <drugbank-id>BTD00018</drugbank-id>
        <name>Menotropins</name>
        <description>Menotropins contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women.  It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.</description>
        <cas-number>61489-71-2</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For the treatment of female infertility</indication>
        <pharmacodynamics>Used to treat female infertility, Menotropins stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Menotropins bind to the LH/hCG/FSH receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.</pharmacodynamics>
        <mechanism-of-action>Being a combination drug, Menotropins bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also binds the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH, therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure. FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Menopur</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02283093</dpd-id>
                <started-marketing-on>2006-09-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>75 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Repronex</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02247790</dpd-id>
                <started-marketing-on>2003-08-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>75 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Repronex</name>
                <ingredients>Menotropins</ingredients>
            </mixture>
            <mixture>
                <name>Menopur</name>
                <ingredients>Menotropins</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Ferring Pharmaceuticals Inc.</name>
                <url>http://www.ferring.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Menopur 75 unit vial</description>
                <cost currency="USD">93.85</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Repronex 75 unit vial</description>
                <cost currency="USD">93.85</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Repronex 5 75 unit Solution 1 Box Contains Five 1ml Vials</description>
                <cost currency="USD">488.04</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Fertility Agents, Female</category>
                <mesh-id/>
            </category>
            <category>
                <category>Fertility Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>75 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>75 unit</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes>
            <ahfs-code>68:18.00</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;AlphaChain (LH)
                APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
                VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
            <sequence format="FASTA">&gt;BetaChain (LH)
                SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYR
                DVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLF
                L</sequence>
            <sequence format="FASTA">&gt;AlphaChain (FSH)
                APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
                VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
            <sequence format="FASTA">&gt;BetaChain (FSH)
                NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET
                VRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>55 °C</value>
                <source>Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.063</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.44</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>23390.3000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1014H1609N287O294S27</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>7369</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X00264</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164749406</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01229</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Menotropins</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/menotropins.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/menotropins.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000387</id>
                <name>Follicle-stimulating hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14680547&#13;
                    # Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7872378&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P23945" source="Swiss-Prot">
                    <name>Follicle-stimulating hormone receptor</name>
                    <general-function>Involved in follicle-stimulating hormone receptor activity</general-function>
                    <specific-function>Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase</specific-function>
                    <gene-name>FSHR</gene-name>
                    <locus>2p21-p16</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>367-387
                        399-421
                        444-465
                        486-508
                        529-550
                        574-597
                        609-630</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.19</theoretical-pi>
                    <molecular-weight>78296.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3969</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FSHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FSHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M65085</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182771</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>253</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>30</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P23945</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FSHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Follicle-stimulating hormone receptor precursor</synonym>
                        <synonym>Follitropin receptor</synonym>
                        <synonym>FSH-R</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Follicle-stimulating hormone receptor precursor
                        MALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV
                        IQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP
                        NLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN
                        GIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN
                        LKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE
                        VDYMTQTRGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM
                        GYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS
                        VDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK
                        VQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL
                        AFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP
                        LITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS
                        TVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2088 bp
                        ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT
                        CGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT
                        CCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC
                        ATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT
                        GATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT
                        AGAATTGAAAAGGCCAACAACCTGCTCTACATCACCCCTGAGGCCTTCCAGAACCTTCCC
                        AACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG
                        ATTCATTCTCTCCAAAAGGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT
                        GAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT
                        GGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGCAGTGAATCTA
                        AGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA
                        GTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT
                        CTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG
                        CTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC
                        TGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA
                        GTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC
                        AGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA
                        GTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG
                        GGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC
                        ATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT
                        ATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA
                        GTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA
                        GGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG
                        ACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG
                        GTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT
                        GCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG
                        GATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG
                        GCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC
                        ATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT
                        GACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC
                        CTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT
                        GCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG
                        CTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC
                        ACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT
                        GGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00560</identifier>
                            <name>LRR_1</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01462</identifier>
                            <name>LRRNT</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>follicle stimulating hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000134</id>
                <name>Lutropin-choriogonadotropic hormone receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14680547&#13;
                    # Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7872378</references>
                <known-action>yes</known-action>
                <polypeptide id="P22888" source="Swiss-Prot">
                    <name>Lutropin-choriogonadotropic hormone receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase</specific-function>
                    <gene-name>LHCGR</gene-name>
                    <locus>2p21</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>364-385
                        396-416
                        440-462
                        483-505
                        526-549
                        571-594
                        606-627</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>78617.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6585</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M73746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>903746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>254</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>30</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P22888</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LSHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>LH/CG-R</synonym>
                        <synonym>LHR</synonym>
                        <synonym>LSH- R</synonym>
                        <synonym>Luteinizing hormone receptor</synonym>
                        <synonym>Lutropin-choriogonadotropic hormone receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Lutropin-choriogonadotropic hormone receptor precursor
                        MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP
                        VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI
                        NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK
                        LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY
                        GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF
                        SKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD
                        FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS
                        QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL
                        RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF
                        IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT
                        VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT
                        SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2058 bp
                        ATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG
                        CTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC
                        CTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA
                        GTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG
                        ATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA
                        ATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT
                        CCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG
                        AAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC
                        ACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT
                        GGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG
                        GAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA
                        GGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA
                        GAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA
                        CAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT
                        AGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA
                        CAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC
                        TGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC
                        ATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG
                        GGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT
                        TTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA
                        GCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA
                        GGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC
                        ACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC
                        CAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT
                        CTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC
                        CCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT
                        GTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC
                        CCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC
                        TTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA
                        GTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT
                        TCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT
                        CTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA
                        GATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT
                        CAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT
                        CGCTACACAGAGTGTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>lutropin-choriogonadotropic hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00033</drugbank-id>
        <drugbank-id>BIOD00017</drugbank-id>
        <drugbank-id>BTD00017</drugbank-id>
        <name>Interferon gamma-1b</name>
        <description>Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. &#13;
            The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.</description>
        <cas-number>82115-62-6</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Kantoch M, Dobrowolska H, Jarzabek Z, Jankowski M, Sadowski W, Janicki P: [Distribution and characteristics of Poliovirus strains circulating in Poland in 1968-1972. Genetic variation of strains isolated in various secretion periods and clones isolated from vaccines] Med Dosw Mikrobiol. 1975;27(4):353-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/55526&#13;
            # Ormas P, Pompa G, Beretta C, Faustini R: [The effects of some polypeptides on the systemic blood pressure of sheep (author's transl)] Folia Vet Lat. 1975 Jan-Mar;5(1):45-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3458&#13;
            # Selitrennikoff CP, Sonneborn DR: Alkaline phosphatase of Blastocladiella emersonii: partial purification and characterization. J Bacteriol. 1977 Apr;130(1):249-56. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15978&#13;
            # Gray PW, Goeddel DV: Structure of the human immune interferon gene. Nature. 1982 Aug 26;298(5877):859-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6180322&#13;
            # Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE: Three-dimensional structure of recombinant human interferon-gamma. Science. 1991 May 3;252(5006):698-702. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1902591&#13;
            # Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11900986&#13;
            # Chesler DA, Reiss CS: The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002 Dec;13(6):441-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12401479&#13;
            # Dessein A, Kouriba B, Eboumbou C, Dessein H, Argiro L, Marquet S, Elwali NE, Rodrigues V, Li Y, Doumbo O, Chevillard C: Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. Immunol Rev. 2004 Oct;201:180-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15361241&#13;
            # Joseph AM, Kumar M, Mitra D: Nef: "necessary and enforcing factor" in HIV infection. Curr HIV Res. 2005 Jan;3(1):87-94. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15638726&#13;
            # Copeland KF: Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem. 2005 Dec;5(12):1093-101. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16375755&#13;
            # Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004 Feb;75(2):163-89. Epub 2003 Oct 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14525967</general-references>
        <synthesis-reference>Irwin A. Braude, "Production of human IFN-gamma (immune) interferon." U.S. Patent US4376821, issued December, 1975.</synthesis-reference>
        <indication>Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.</indication>
        <pharmacodynamics>IFN gamma stimulates expression of the immunoglobulin heavy chain C gamma 3 and C gamma 2a germline transcripts in B cells. Many components of the antigen presentation pathways are also up-regulated by interferon gamma. It is also a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of type I interferons. Interferon gamma may also help the body regulate the activity of fibroblasts. By directly blocking the multiplication of fibroblasts and inhibiting the production and action of TGF-b, a potent scar-inducing molecule, Interferon gamma-1b may prevent excessive scarring.</pharmacodynamics>
        <mechanism-of-action>Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">IFN-gamma</synonym>
            <synonym language="" coder="">Immune interferon</synonym>
            <synonym language="" coder="">Interferon gamma precursor</synonym>
        </synonyms>
        <products>
            <product>
                <name>Actimmune</name>
                <ndc-id>42238-111_bf71a33a-8d53-43f9-89c2-f39960eac1bc</ndc-id>
                <ndc-product-code>42238-111</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-12-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 ug/.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103836</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Actimmune</name>
                <ingredients>Interferon gamma-1b</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>InterMune Inc.</name>
                <url>http://www.intermune.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Actimmune 2 million unit vial</description>
                <cost currency="USD">344.4</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms/>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>100 ug/.5mL</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes/>
        <patents>
            <patent>
                <number>6936694</number>
                <country>United States</country>
                <approved>2005-08-30</approved>
                <expires>2022-08-30</expires>
            </patent>
            <patent>
                <number>6936695</number>
                <country>United States</country>
                <approved>2005-08-30</approved>
                <expires>2022-08-30</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00697</drugbank-id>
                <name>Tizanidine</name>
                <description>CYP1A2 Inhibitors (Weak) may increase the serum concentration of Tizanidine.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00495</drugbank-id>
                <name>Zidovudine</name>
                <description>Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00033 sequence
                CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLF
                KNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVM
                AELSPAAKTGKRKRSQMLFRGRRASQ</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C</value>
                <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.823</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>9.54</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>17145.6000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C761H1206N214O225S6</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X13274</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164746386</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01579</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Interferon_gamma-1b</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/interferon-gamma-1b.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000711</id>
                <name>Interferon gamma receptor 1</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Matsuda A, Ebihara N, Kumagai N, Fukuda K, Ebe K, Hirano K, Sotozono C, Tei M, Hasegawa K, Shimizu M, Tamari M, Namba K, Ohno S, Mizuki N, Ikezawa Z, Shirakawa T, Hamuro J, Kinoshita S: Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17251453
                    # Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-371. Epub 2007 Jul 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17618444
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P15260" source="Swiss-Prot">
                    <name>Interferon gamma receptor 1</name>
                    <general-function>Involved in cytokine binding</general-function>
                    <specific-function>Receptor for interferon gamma. Two receptors bind one interferon gamma dimer</specific-function>
                    <gene-name>IFNGR1</gene-name>
                    <locus>6q23-q24</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>246-266</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.56</theoretical-pi>
                    <molecular-weight>54405.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5439</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNGR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNGR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03143</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>306915</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P15260</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INGR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD119 antigen</synonym>
                        <synonym>CDw119</synonym>
                        <synonym>IFN-gamma-R1</synonym>
                        <synonym>Interferon-gamma receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-gamma receptor alpha chain precursor
                        MALLFLLPLVMQGVSRAEMGTADLGPSSVPTPTNVTIESYNMNPIVYWEYQIMPQVPVFT
                        VEVKNYGVKNSEWIDACINISHHYCNISDHVGDPSNSLWVRVKARVGQKESAYAKSEEFA
                        VCRDGKIGPPKLDIRKEEKQIMIDIFHPSVFVNGDEQEVDYDPETTCYIRVYNVYVRMNG
                        SEIQYKILTQKEDDCDEIQCQLAIPVSSLNSQYCVSAEGVLHVWGVTTEKSKEVCITIFN
                        SSIKGSLWIPVVAALLLFLVLSLVFICFYIKKINPLKEKSIILPKSLISVVRSATLETKP
                        ESKYVSLITSYQPFSLEKEVVCEEPLSPATVPGMHTEDNPGKVEHTEELSSITEVVTTEE
                        NIPDVVPGSHLTPIERESSSPLSSNQSEPGSIALNSYHSRNCSESDHSRNGFDTDSSCLE
                        SHSSLSDSEFPPNNKGEIKTEGQELITVIKAPTSFGYDKPHVLVDLLVDDSGKESLIGYR
                        PTEDSKEFS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1470 bp
                        ATGGCTCTCCTCTTTCTCCTACCCCTTGTCATGCAGGGTGTGAGCAGGGCTGAGATGGGC
                        ACCGCGGATCTGGGGCCGTCCTCAGTGCCTACACCAACTAATGTTACAATTGAATCCTAT
                        AACATGAACCCTATCGTATATTGGGAGTACCAGATCATGCCACAGGTCCCTGTTTTTACC
                        GTAGAGGTAAAGAACTATGGTGTTAAGAATTCAGAATGGATTGATGCCTGCATCAATATT
                        TCTCATCATTATTGTAATATTTCTGATCATGTTGGTGATCCATCAAATTCTCTTTGGGTC
                        AGAGTTAAAGCCAGGGTTGGACAAAAAGAATCTGCCTATGCAAAGTCAGAAGAATTTGCT
                        GTATGCCGAGATGGAAAAATTGGACCACCTAAACTGGATATCAGAAAGGAGGAGAAGCAA
                        ATCATGATTGACATATTTCACCCTTCAGTTTTTGTAAATGGAGACGAGCAGGAAGTCGAT
                        TATGATCCCGAAACTACCTGTTACATTAGGGTGTACAATGTGTATGTGAGAATGAACGGA
                        AGTGAGATCCAGTATAAAATACTCACGCAGAAGGAAGATGATTGTGACGAGATTCAGTGC
                        CAGTTAGCGATTCCAGTATCCTCACTGAATTCTCAGTACTGTGTTTCAGCAGAAGGAGTC
                        TTACATGTGTGGGGTGTTACAACTGAAAAGTCAAAAGAAGTTTGTATTACCATTTTCAAT
                        AGCAGTATAAAAGGTTCTCTTTGGATTCCAGTTGTTGCTGCTTTACTACTCTTTCTAGTG
                        CTTAGCCTGGTATTCATCTGTTTTTATATTAAGAAAATTAATCCATTGAAGGAAAAAAGC
                        ATAATATTACCCAAGTCCTTGATCTCTGTGGTAAGAAGTGCTACTTTAGAGACAAAACCT
                        GAATCAAAATATGTATCACTCATCACGTCATACCAGCCATTTTCCTTAGAAAAGGAGGTG
                        GTCTGTGAAGAGCCGTTGTCTCCAGCAACAGTTCCAGGCATGCATACCGAAGACAATCCA
                        GGAAAAGTGGAACATACAGAAGAACTTTCTAGTATAACAGAAGTGGTGACTACTGAAGAA
                        AATATTCCTGACGTGGTCCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCA
                        CCTTTAAGTAGTAACCAGTCTGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCCAGA
                        AATTGTTCTGAGAGTGATCACTCCAGAAATGGTTTTGATACTGATTCCAGCTGTCTGGAA
                        TCACATAGCTCCTTATCTGACTCAGAATTTCCCCCAAATAATAAAGGTGAAATAAAAACA
                        GAAGGACAAGAGCTCATAACCGTAATAAAAGCCCCCACCTCCTTTGGTTATGATAAACCA
                        CATGTGCTAGTGGATCTACTTGTGGATGATAGCGGTAAAGAGTCCTTGATTGGTTATAGA
                        CCAACAGAAGATTCCAAAGAATTTTCATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07140</identifier>
                            <name>IFNGR1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cytokine binding</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000467</id>
                <name>Interferon gamma receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, Ivashkiv LB: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007 Jan;26(1):67-78. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17239631
                    # Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-371. Epub 2007 Jul 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17618444
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P38484" source="Swiss-Prot">
                    <name>Interferon gamma receptor 2</name>
                    <general-function>Involved in interferon-gamma receptor activity</general-function>
                    <specific-function>Part of the receptor for interferon gamma. Required for signal transduction. This accessory factor is an integral part of the IFN-gamma signal transduction pathway and is likely to interact with GAF, JAK1, and/or JAK2</specific-function>
                    <gene-name>IFNGR2</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>248-268</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.35</theoretical-pi>
                    <molecular-weight>37835.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5440</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNGR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNGR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U05875</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>463550</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P38484</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INGR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>AF-1</synonym>
                        <synonym>Interferon-gamma receptor accessory factor 1</synonym>
                        <synonym>Interferon-gamma receptor beta chain precursor</synonym>
                        <synonym>Interferon-gamma transducer 1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-gamma receptor beta chain precursor
                        MRPTLLWSLLLLLGVFAAAAAAPPDPLSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRP
                        VVYRVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELG
                        ALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYW
                        EKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMAD
                        ASTELQQVILISVGTFSLLSVLAGACFFLVLKYRGLIKYWFHTPPSIPLQIEEYLKDPTQ
                        PILEALDKDSSPKDDVWDSVSIISFPEKEQEDVLQTL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1014 bp
                        ATGCGACCGACGCTGCTGTGGTCGCTGCTGCTGCTGCTCGGAGTCTTCGCCGCCGCCGCC
                        GCGGCCCCGCCAGACCCTCTTTCCCAGCTGCCCGCTCCTCAGCACCCGAAGATTCGCCTG
                        TACAACGCAGAGCAGGTCCTGAGTTGGGAGCCAGTGGCCCTGAGCAATAGCACGAGGCCT
                        GTTGTCTACCGAGTGCAGTTTAAATACACCGACAGTAAATGGTTCACGGCCGACATCATG
                        TCCATAGGGGTGAATTGTACACAGATCACAGCAACAGAGTGTGACTTCACTGCCGCCAGT
                        CCCTCAGCAGGCTTCCCAATGGATTTCAATGTCACTCTACGCCTTCGAGCTGAGCTGGGA
                        GCACTCCATTCTGCCTGGGTGACAATGCCTTGGTTTCAACACTATCGGAATGTGACTGTC
                        GGGCCTCCAGAAAACATTGAGGTGACCCCAGGAGAAGGCTCCCTCATCATCAGGTTCTCC
                        TCTCCCTTTGACATCGCTGATACCTCCACGGCCTTTTTTTGTTATTATGTCCATTACTGG
                        GAAAAAGGAGGAATCCAACAGGTCAAAGGCCCTTTCAGAAGCAACTCCATTTCATTGGAT
                        AACTTAAAACCCTCCAGAGTGTACTGTTTACAAGTCCAGGCACAACTGCTTTGGAACAAA
                        AGTAACATCTTTAGAGTCGGGCATTTAAGCAACATATCTTGCTACGAAACAATGGCAGAT
                        GCCTCCACTGAGCTTCAGCAAGTCATCCTGATCTCCGTGGGAACATTTTCGTTGCTGTCG
                        GTGCTGGCAGGAGCCTGTTTCTTCCTGGTCCTGAAATATAGAGGCCTGATTAAATACTGG
                        TTTCACACTCCACCAAGCATCCCATTACAGATAGAAGAGTATTTAAAAGACCCAACTCAG
                        CCCATCTTAGAGGCCTTGGACAAGGACAGCTCACCAAAGGATGACGTCTGGGACTCTGTG
                        TCCATTATCTCGTTTCCGGAAAAGGAGCAAGAAGATGTTCTCCAAACGCTTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-09-23">
        <drugbank-id primary="true">DB00034</drugbank-id>
        <drugbank-id>BIOD00012</drugbank-id>
        <drugbank-id>BIOD00095</drugbank-id>
        <drugbank-id>BTD00012</drugbank-id>
        <drugbank-id>BTD00095</drugbank-id>
        <drugbank-id>DB00037</drugbank-id>
        <name>Interferon Alfa-2a, Recombinant</name>
        <description>Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.&#13;
&#13;
        </description>
        <cas-number>77907-69-8</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.</indication>
        <pharmacodynamics>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacodynamics>
        <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
        <toxicity>Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; hyperthyroidism or hypothyroidism; transient ischemic attacks; leukopenia; neurotoxicity; peripheral neuropathy; and thrombocytopenia. Some lesser side effects that may not need medical attention include blurred vision, change in taste or metallic taste, cold sores or stomatitis, diarrhea, dizziness, dry mouth, dry skin or itching, flu-like syndrome, increased sweating, leg cramps, loss of appetite, nausea or vomiting, skin rash, unusual tiredness, weight loss, and partial loss of hair.</toxicity>
        <metabolism/>
        <absorption>Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.</absorption>
        <half-life>The IM half-life of interferon alfa-2a is 6 hours to 8 hours; the half-life for IV infusion is 3.7 hours to 8.5 hours (mean 5.1 hours).</half-life>
        <protein-binding/>
        <route-of-elimination>Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.</route-of-elimination>
        <volume-of-distribution>* 0.223 to 0.748 L/kg [healthy people]</volume-of-distribution>
        <clearance>* 2.14 - 3.62 mL/min/kg [healthy]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Interferon alfa-2a</synonym>
            <synonym language="" coder="">Interferon alpha-2a</synonym>
            <synonym language="" coder="">Oral interferon alfa</synonym>
            <synonym language="" coder="">rIFN-alpha-2a</synonym>
        </synonyms>
        <products>
            <product>
                <name>Roferon A Soln Inj 6 Million</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00812498</dpd-id>
                <started-marketing-on>1989-12-31</started-marketing-on>
                <ended-marketing-on>1997-08-26</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>6000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon A Sterile Pws 18m Unit/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01912003</dpd-id>
                <started-marketing-on>1991-12-31</started-marketing-on>
                <ended-marketing-on>1996-09-30</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>18000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon A Sterile Pws 3m Unit/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01911988</dpd-id>
                <started-marketing-on>1991-12-31</started-marketing-on>
                <ended-marketing-on>1996-09-30</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>3000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon A Sterile Pws 9m Unit/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01911996</dpd-id>
                <started-marketing-on>1991-12-31</started-marketing-on>
                <ended-marketing-on>1996-09-30</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>9000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a  Solution Inj. 9million I.U./0.9ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02019914</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>1997-08-26</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>9000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a Sol Inj 3million Iu/vial</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00812501</dpd-id>
                <started-marketing-on>1989-12-31</started-marketing-on>
                <ended-marketing-on>1997-08-25</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>3000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a Soln-liq Im Sc 4.5million I.u/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02217023</dpd-id>
                <started-marketing-on>1997-04-25</started-marketing-on>
                <ended-marketing-on>1999-11-02</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>4.5 m</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a Soln-liq Im Sc 9million I.U./ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02217058</dpd-id>
                <started-marketing-on>1997-04-29</started-marketing-on>
                <ended-marketing-on>2004-11-01</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>9 m</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a Solution 18 Million I.U./3ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02217066</dpd-id>
                <started-marketing-on>1997-01-15</started-marketing-on>
                <ended-marketing-on>2005-07-14</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>18 m</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a Solution 3 Million I.U./ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02217015</dpd-id>
                <started-marketing-on>1997-02-25</started-marketing-on>
                <ended-marketing-on>2005-07-14</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>3 m</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a Solution 6 Million I.U./ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02217031</dpd-id>
                <started-marketing-on>1997-02-24</started-marketing-on>
                <ended-marketing-on>2000-07-27</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>6 m</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Roferon-a Solution Inj 36000000unit/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00891002</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on>1997-06-18</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>36000000 unit</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Roferon A</name>
                <company>Hoffmann-La Roche Inc</company>
            </international-brand>
            <international-brand>
                <name>Veldona</name>
                <company>Amarillo Biosciences</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Roferon A Sterile Pws 3m Unit/vial</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon A Sterile Pws 18m Unit/vial</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon A Sterile Pws 9m Unit/vial</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a Solution Inj 36000000unit/ml</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a  Solution Inj. 9million I.U./0.9ml</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a Solution 3 Million I.U./ml</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a Soln-liq Im Sc 4.5million I.u/ml</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a Solution 6 Million I.U./ml</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a Soln-liq Im Sc 9million I.U./ml</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a Solution 18 Million I.U./3ml</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon A Soln Inj 6 Million</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Roferon-a Sol Inj 3million Iu/vial</name>
                <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>F Hoffmann La Roche Ltd.</name>
                <url>http://www.roche.com</url>
            </packager>
            <packager>
                <name>F Hoffmann-La Roche Ltd.</name>
                <url>http://www.roche.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices/>
        <categories/>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; subcutaneous</route>
                <strength>6000000 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>18000000 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>3000000 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>9000000 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>9000000 unit</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; subcutaneous</route>
                <strength>3000000 unit</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; subcutaneous</route>
                <strength>4.5 m</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>9 m</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>18 m</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>3 m</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>6 m</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>36000000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L03AB04">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AB">Interferons</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents>
            <patent>
                <number>2172664</number>
                <country>Canada</country>
                <approved>2000-10-03</approved>
                <expires>2016-03-26</expires>
            </patent>
        </patents>
        <food-interactions>
            <food-interaction>Avoid alcohol.</food-interaction>
        </food-interactions>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00034 sequence
                CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
                QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
                KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Water Solubility</kind>
                <value>100 mg/ml</value>
                <source/>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.336</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.99</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>19241.1000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C860H1353N227O255S9</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>1746</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0004-2015-09</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00207</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164779048</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01563</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/roferon.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/interferon-alfa-2a-solution.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000661</id>
                <name>Interferon alpha/beta receptor 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717&#13;
                    # Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. Epub 2008 Jan 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18230610</references>
                <known-action>yes</known-action>
                <polypeptide id="P17181" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 1</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves</specific-function>
                    <gene-name>IFNAR1</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>437-457</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.56</theoretical-pi>
                    <molecular-weight>63526.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5432</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03171</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>306914</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P17181</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>Interferon-alpha/beta receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor alpha chain precursor
                        MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
                        FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
                        TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
                        ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
                        NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
                        GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
                        VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
                        FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
                        YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
                        EDESESKTSEELQQDFV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1674 bp
                        ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG
                        TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
                        ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
                        TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
                        AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
                        AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
                        ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
                        GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
                        TTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
                        GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
                        AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
                        ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
                        AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
                        TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
                        CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
                        GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
                        GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
                        TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
                        GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
                        GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
                        GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
                        TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
                        GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
                        TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
                        TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
                        AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
                        GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
                        GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000385</id>
                <name>Interferon alpha/beta receptor 2</name>
                <organism>Human</organism>
                <actions/>
                <references># Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717&#13;
                    # Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. Epub 2008 Jan 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18230610</references>
                <known-action>yes</known-action>
                <polypeptide id="P48551" source="Swiss-Prot">
                    <name>Interferon alpha/beta receptor 2</name>
                    <general-function>Involved in interferon-alpha/beta receptor activity</general-function>
                    <specific-function>Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity</specific-function>
                    <gene-name>IFNAR2</gene-name>
                    <locus/>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>244-264</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.11</theoretical-pi>
                    <molecular-weight>57759.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5433</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IFNAR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L42243</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>995300</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P48551</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INAR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IFN-alpha-REC</synonym>
                        <synonym>IFN-R</synonym>
                        <synonym>Interferon alpha/beta receptor 2</synonym>
                        <synonym>Interferon-alpha/beta receptor beta chain precursor</synonym>
                        <synonym>Type I interferon receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interferon-alpha/beta receptor beta chain precursor
                        MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
                        IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
                        SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
                        HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
                        SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
                        MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
                        DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
                        ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
                        FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
                        ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
                        TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
                        ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
                        GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
                        AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
                        AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
                        ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
                        GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
                        CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
                        ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
                        ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
                        TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
                        ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
                        AATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT
                        ATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT
                        GAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT
                        GGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA
                        GACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG
                        CCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT
                        CCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA
                        ATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT
                        GACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG
                        GATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC
                        TTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC
                        ACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="small molecule" created="2005-06-13" updated="2013-09-16">
        <drugbank-id primary="true">DB00035</drugbank-id>
        <drugbank-id>BIOD00061</drugbank-id>
        <drugbank-id>BIOD00112</drugbank-id>
        <drugbank-id>BTD00061</drugbank-id>
        <drugbank-id>BTD00112</drugbank-id>
        <name>Desmopressin</name>
        <description>Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.</description>
        <cas-number>16679-58-6</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11380629&#13;
            # Sequence Information "Link":http://www.ecplaza.net/tradeleads/seller/5605163/desmopressin_acetate.html</general-references>
        <synthesis-reference>Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.</synthesis-reference>
        <indication>Oral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia. </indication>
        <pharmacodynamics>Desmopressin is a synthetic analogue of the natural antidiuretic hormone (ADH or vasopressin) that is produced by the hypothalamus and stored in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. It also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. The efficacy of desmopressin for managing bleeds in patients with hemophilia A or von Willebrand’s disease Type I arises from its ability to elicit dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and to a lesser extent, factor VIII-related antigen and ristocetin cofactor activities; these changes improve blood clotting. </pharmacodynamics>
        <mechanism-of-action>Desmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by  deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis. </mechanism-of-action>
        <toxicity>Overdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations. </toxicity>
        <metabolism>Metabolic fate unknown. Is not affected by liver microsomal cytochrome P450 enzymes. </metabolism>
        <absorption>Minimally absorbed from the GI tract (average absolute bioavailability = 0.08-0.16%). 10-20% absorbed from nasal mucosa. </absorption>
        <half-life>Oral t&lt;sub&gt;1/2&lt;/sub&gt;=1.5-2.5 hours. Intranasal t&lt;sub&gt;1/2&lt;/sub&gt;=3.3-3.5 hours. IV t&lt;sub&gt;1/2&lt;/sub&gt; is biphasic: initial t&lt;sub&gt;1/2&lt;/sub&gt;=7.8 minutes, terminal t&lt;sub&gt;1/2&lt;/sub&gt;=0.4-4 hours. </half-life>
        <protein-binding>50%</protein-binding>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description>This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.</description>
            <direct-parent>Cyclic peptides</direct-parent>
            <kingdom>Organic compounds</kingdom>
            <superclass>Organic acids and derivatives</superclass>
            <class>Carboxylic acids and derivatives</class>
            <subclass>Amino acids, peptides, and analogues</subclass>
            <alternative-parent>Alpha amino acid amides</alternative-parent>
            <alternative-parent>Azacyclic compounds</alternative-parent>
            <alternative-parent>Carbonyl compounds</alternative-parent>
            <alternative-parent>Carboximidamides</alternative-parent>
            <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
            <alternative-parent>Guanidines</alternative-parent>
            <alternative-parent>Hydrocarbon derivatives</alternative-parent>
            <alternative-parent>Imines</alternative-parent>
            <alternative-parent>Lactams</alternative-parent>
            <alternative-parent>Macrolactams</alternative-parent>
            <alternative-parent>N-acyl amines</alternative-parent>
            <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
            <alternative-parent>N-acylpyrrolidines</alternative-parent>
            <alternative-parent>Organic disulfides</alternative-parent>
            <alternative-parent>Phenols and derivatives</alternative-parent>
            <alternative-parent>Primary carboxylic acid amides</alternative-parent>
            <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
            <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
            <alternative-parent>Tertiary amines</alternative-parent>
            <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
            <substituent>Alpha-amino acid amide</substituent>
            <substituent>Amine</substituent>
            <substituent>Aromatic heteromonocyclic compound</substituent>
            <substituent>Azacycle</substituent>
            <substituent>Benzenoid</substituent>
            <substituent>Carbonyl group</substituent>
            <substituent>Carboxamide group</substituent>
            <substituent>Carboximidamide</substituent>
            <substituent>Carboxylic acid amide</substituent>
            <substituent>Cyclic alcohol</substituent>
            <substituent>Cyclic alpha peptide</substituent>
            <substituent>Fatty acyl</substituent>
            <substituent>Fatty amide</substituent>
            <substituent>Guanidine</substituent>
            <substituent>Hydrocarbon derivative</substituent>
            <substituent>Imine</substituent>
            <substituent>Lactam</substituent>
            <substituent>Macrolactam</substituent>
            <substituent>Monocyclic benzene moiety</substituent>
            <substituent>N-acyl-alpha amino acid or derivatives</substituent>
            <substituent>N-acyl-amine</substituent>
            <substituent>N-acylpyrrolidine</substituent>
            <substituent>N-substituted-alpha-amino acid</substituent>
            <substituent>Organic disulfide</substituent>
            <substituent>Organoheterocyclic compound</substituent>
            <substituent>Organonitrogen compound</substituent>
            <substituent>Organooxygen compound</substituent>
            <substituent>Phenol</substituent>
            <substituent>Primary carboxylic acid amide</substituent>
            <substituent>Pyrrolidine</substituent>
            <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
            <substituent>Pyrrolidine-2-carboxamide</substituent>
            <substituent>Secondary carboxylic acid amide</substituent>
            <substituent>Tertiary amine</substituent>
            <substituent>Tertiary carboxylic acid amide</substituent>
        </classification>
        <salts>
            <salt>
                <drugbank-id primary="true">DBSALT000044</drugbank-id>
                <name>Desmopressin acetate</name>
                <cas-number/>
                <inchikey>InChIKey=MLSVJHOYXJGGTR-IFHOVBQLSA-N</inchikey>
            </salt>
            <salt>
                <drugbank-id primary="true">DBSALT001154</drugbank-id>
                <name>Desmopressin acetate trihydrate</name>
                <cas-number/>
                <inchikey/>
            </salt>
        </salts>
        <synonyms>
            <synonym language="" coder="">1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin</synonym>
            <synonym language="" coder="">1-deamino-8-D-arginine vasopressin</synonym>
            <synonym language="" coder="">1-Desamino-8-D-arginine vasopressin</synonym>
            <synonym language="" coder="">DDAVP</synonym>
            <synonym language="Spanish" coder="INN">Desmopresina</synonym>
            <synonym language="" coder="">Desmopressin</synonym>
            <synonym language="French" coder="INN">Desmopressine</synonym>
            <synonym language="Latin" coder="INN">Desmopressinum</synonym>
            <synonym language="" coder="">Minirin</synonym>
            <synonym language="" coder="">Stimate</synonym>
        </synonyms>
        <products>
            <product>
                <name>Apo-desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02284030</dpd-id>
                <started-marketing-on>2007-01-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.1 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Apo-desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02284049</dpd-id>
                <started-marketing-on>2007-01-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.2 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>0075-0016_594ad44c-9c5d-47ad-b596-f667476a6b2f</ndc-id>
                <ndc-product-code>0075-0016</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-09-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>NDA019955</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>0075-0026_594ad44c-9c5d-47ad-b596-f667476a6b2f</ndc-id>
                <ndc-product-code>0075-0026</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-09-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>NDA019955</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>55566-2200_ebab4450-8a4b-49fc-8a2f-1e480a8b4f77</ndc-id>
                <ndc-product-code>55566-2200</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1984-03-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>NDA018938</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>55566-2300_ebab4450-8a4b-49fc-8a2f-1e480a8b4f77</ndc-id>
                <ndc-product-code>55566-2300</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1984-03-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>NDA018938</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>55566-2400_5a42e2bc-8ddf-4ae3-bec5-b5043a94fd7c</ndc-id>
                <ndc-product-code>55566-2400</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1978-02-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray</dosage-form>
                <strength>.1 ug/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA017922</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>55566-2500_8bc70011-b272-4f88-8707-85232a02f472</ndc-id>
                <ndc-product-code>55566-2500</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1978-02-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray</dosage-form>
                <strength>.1 ug/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA021333</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>55566-2600_f1879d97-af32-42a8-81f2-1374fea9592d</ndc-id>
                <ndc-product-code>55566-2600</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-09-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>NDA019955</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>0075-2451_5e30ba6d-ebb3-4950-b03a-7f1e946da982</ndc-id>
                <ndc-product-code>0075-2451</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1984-03-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>NDA018938</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>55566-2700_f1879d97-af32-42a8-81f2-1374fea9592d</ndc-id>
                <ndc-product-code>55566-2700</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-09-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>NDA019955</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp</name>
                <ndc-id>0075-2452_517c673f-db39-4b91-bd86-eb35db5bea7f</ndc-id>
                <ndc-product-code>0075-2452</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1978-02-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>.1 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA017922</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp Inj 4mcg/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00873993</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>liquid</dosage-form>
                <strength>4 mcg</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp Melt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02284995</dpd-id>
                <started-marketing-on>2006-11-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet (orally disintegrating)</dosage-form>
                <strength>60 mcg</strength>
                <route>sublingual</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp Melt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02285002</dpd-id>
                <started-marketing-on>2006-11-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet (orally disintegrating)</dosage-form>
                <strength>120 mcg</strength>
                <route>sublingual</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp Melt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02285010</dpd-id>
                <started-marketing-on>2009-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet (orally disintegrating)</dosage-form>
                <strength>240 mcg</strength>
                <route>sublingual</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp Rhinal Tube</name>
                <ndc-id>0075-2450_b1b1e14c-afba-44c1-a384-5aae6a624046</ndc-id>
                <ndc-product-code>0075-2450</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1978-02-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>.1 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA017922</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Ddavp Rhinyle</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00402516</dpd-id>
                <started-marketing-on>1992-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>0.1 mg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00836362</dpd-id>
                <started-marketing-on>1989-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>metered-dose aerosol</dosage-form>
                <strength>10 mcg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp Tablets 0.1mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00824305</dpd-id>
                <started-marketing-on>1995-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.1 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Ddavp Tablets 0.2mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00824143</dpd-id>
                <started-marketing-on>1995-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.2 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02346788</dpd-id>
                <started-marketing-on>2011-07-27</started-marketing-on>
                <ended-marketing-on>2014-06-25</ended-marketing-on>
                <dosage-form>tablet</dosage-form>
                <strength>0.1 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02346796</dpd-id>
                <started-marketing-on>2011-07-27</started-marketing-on>
                <ended-marketing-on>2014-06-25</ended-marketing-on>
                <dosage-form>tablet</dosage-form>
                <strength>0.2 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>62756-529_b844ffe0-0b30-4d3b-8a16-1a6da45d9e28</ndc-id>
                <ndc-product-code>62756-529</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-01-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>ANDA091280</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>62756-529_fe90dd4d-c54b-4fce-b5d0-b9f3fa69d2e3</ndc-id>
                <ndc-product-code>62756-529</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2014-02-20</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>ANDA091280</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0591-2464_c7c57f26-7675-44ad-93dd-ae9c757db230</ndc-id>
                <ndc-product-code>0591-2464</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-08-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0591-2465_c7c57f26-7675-44ad-93dd-ae9c757db230</ndc-id>
                <ndc-product-code>0591-2465</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-08-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>24208-342_426fba34-8d84-4a3b-81a3-025ab9de95bf</ndc-id>
                <ndc-product-code>24208-342</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1999-01-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>.1 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>ANDA074830</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68084-604_0f7ffbf3-8321-4c41-a4ba-7d2186e5cb7d</ndc-id>
                <ndc-product-code>68084-604</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2012-10-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68084-606_0f7ffbf3-8321-4c41-a4ba-7d2186e5cb7d</ndc-id>
                <ndc-product-code>68084-606</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2012-10-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68462-275_f0ae047c-4feb-4de2-876e-3d3e423c0c20</ndc-id>
                <ndc-product-code>68462-275</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-05-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA201831</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68462-276_f0ae047c-4feb-4de2-876e-3d3e423c0c20</ndc-id>
                <ndc-product-code>68462-276</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-05-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA201831</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0409-2265_72245812-5df9-43dd-bcc6-91ded8d829a4</ndc-id>
                <ndc-product-code>0409-2265</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-08-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>ANDA075220</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0409-2265_e2133b89-2a7d-4da7-a2ba-d2965275ae7e</ndc-id>
                <ndc-product-code>0409-2265</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-01-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>ANDA075220</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>60687-109_a13b1439-215c-4305-aa26-4fc8469e298e</ndc-id>
                <ndc-product-code>60687-109</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-09-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0703-5051_ff87d1d1-98e4-42d0-afba-34cd1a7f2b2e</ndc-id>
                <ndc-product-code>0703-5051</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1997-11-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>ANDA074888</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0703-5054_ff87d1d1-98e4-42d0-afba-34cd1a7f2b2e</ndc-id>
                <ndc-product-code>0703-5054</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1997-11-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>ANDA074888</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>54868-5602_983a15fb-e0d8-4e75-aa92-ade42e5e625a</ndc-id>
                <ndc-product-code>54868-5602</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-05-22</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>.1 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>ANDA074830</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>60687-120_a13b1439-215c-4305-aa26-4fc8469e298e</ndc-id>
                <ndc-product-code>60687-120</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-09-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>54868-1129_01172abb-07b0-4cc9-ab0c-8922c8993c44</ndc-id>
                <ndc-product-code>54868-1129</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2007-07-19</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077122</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0093-7316_d90fa9b3-6dbb-402e-856e-008d26134ffd</ndc-id>
                <ndc-product-code>0093-7316</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-01-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077122</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68001-233_fd8867bb-e8f2-44e3-8443-d82a38e8a01b</ndc-id>
                <ndc-product-code>68001-233</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2014-02-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0093-7317_d90fa9b3-6dbb-402e-856e-008d26134ffd</ndc-id>
                <ndc-product-code>0093-7317</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-01-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077122</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>50268-220_21174971-6cf2-c95c-1311-53db61b8fd62</ndc-id>
                <ndc-product-code>50268-220</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-07-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68001-234_fd8867bb-e8f2-44e3-8443-d82a38e8a01b</ndc-id>
                <ndc-product-code>68001-234</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2014-02-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>50268-221_21174971-6cf2-c95c-1311-53db61b8fd62</ndc-id>
                <ndc-product-code>50268-221</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-07-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>51079-446_4bb201e7-661f-4e39-97eb-09001b44b3bf</ndc-id>
                <ndc-product-code>51079-446</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2007-12-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077122</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>60505-0257_59ba7fff-787d-4ba7-4078-b335868ed697</ndc-id>
                <ndc-product-code>60505-0257</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-03-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077414</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>60505-0258_59ba7fff-787d-4ba7-4078-b335868ed697</ndc-id>
                <ndc-product-code>60505-0258</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-03-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077414</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68151-1281_7769db37-fb59-41a3-bce2-af11e382c104</ndc-id>
                <ndc-product-code>68151-1281</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-01-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077122</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>0615-7549_321617aa-3c20-4330-8c8c-7d964d5cab39</ndc-id>
                <ndc-product-code>0615-7549</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-01-17</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077122</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>55566-5020_dbfe4d67-5335-5333-debb-428f6f991de6</ndc-id>
                <ndc-product-code>55566-5020</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1999-08-10</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>.1 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA017922</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>55566-5030_90bd1e51-06c1-61ab-fc0e-32c4dbd3b7a7</ndc-id>
                <ndc-product-code>55566-5030</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1999-10-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>NDA018938</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>55566-5040_90bd1e51-06c1-61ab-fc0e-32c4dbd3b7a7</ndc-id>
                <ndc-product-code>55566-5040</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1999-10-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>4 ug/mL</strength>
                <route>intravenous</route>
                <fda-application-number>NDA018938</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>55566-5060_a3e1a3bc-b2d8-4947-87de-f1bb016fc8a3</ndc-id>
                <ndc-product-code>55566-5060</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2008-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>NDA021795</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>55566-5061_a3e1a3bc-b2d8-4947-87de-f1bb016fc8a3</ndc-id>
                <ndc-product-code>55566-5061</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2008-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>NDA021795</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>62756-161_7f3fe422-471d-4136-82ef-8a5c1c9451ef</ndc-id>
                <ndc-product-code>62756-161</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2012-04-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>.1 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>ANDA077212</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>63629-4816_33b4f5b2-d4ed-484b-a190-0b148c71a7ef</ndc-id>
                <ndc-product-code>63629-4816</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-08-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA076470</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>60505-0815_02785654-305c-82ab-08db-8ce8b0e42440</ndc-id>
                <ndc-product-code>60505-0815</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-01-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray</dosage-form>
                <strength>10 ug</strength>
                <route>nasal</route>
                <fda-application-number>ANDA076703</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>66993-025_73f4ef96-b08d-43ee-9ef2-fc99894c2c00</ndc-id>
                <ndc-product-code>66993-025</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2014-01-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray</dosage-form>
                <strength>10 ug/.1mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA021333</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>47335-788_65420316-3251-490b-a0ef-e4cfec5cc384</ndc-id>
                <ndc-product-code>47335-788</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-12-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>.1 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>ANDA078271</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68084-084_c1829c84-80f5-4513-af2e-fc7a0476a0ba</ndc-id>
                <ndc-product-code>68084-084</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2010-01-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.1 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077414</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Acetate</name>
                <ndc-id>68084-085_c1829c84-80f5-4513-af2e-fc7a0476a0ba</ndc-id>
                <ndc-product-code>68084-085</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2010-01-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>.2 mg</strength>
                <route>oral</route>
                <fda-application-number>ANDA077414</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Desmopressin Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02242465</dpd-id>
                <started-marketing-on>2000-08-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered dose</dosage-form>
                <strength>10 mcg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Desmopressin Tablets</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02257696</dpd-id>
                <started-marketing-on>2005-02-18</started-marketing-on>
                <ended-marketing-on>2012-08-03</ended-marketing-on>
                <dosage-form>tablet</dosage-form>
                <strength>0.1 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Desmopressin Tablets</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02257718</dpd-id>
                <started-marketing-on>2005-02-18</started-marketing-on>
                <ended-marketing-on>2012-08-03</ended-marketing-on>
                <dosage-form>tablet</dosage-form>
                <strength>0.2 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Minirin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02238598</dpd-id>
                <started-marketing-on>2000-08-21</started-marketing-on>
                <ended-marketing-on>2005-08-02</ended-marketing-on>
                <dosage-form>metered-dose aerosol</dosage-form>
                <strength>10 mcg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Minirin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246500</dpd-id>
                <started-marketing-on>2003-01-15</started-marketing-on>
                <ended-marketing-on>2015-07-22</ended-marketing-on>
                <dosage-form>tablet</dosage-form>
                <strength>0.1 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nocdurna</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02431076</dpd-id>
                <started-marketing-on>2014-11-17</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet (orally disintegrating)</dosage-form>
                <strength>50 mcg</strength>
                <route>sublingual</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nocdurna</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02397927</dpd-id>
                <started-marketing-on>2013-07-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet (orally disintegrating)</dosage-form>
                <strength>25 mcg</strength>
                <route>sublingual</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nu-desmopressin Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02336154</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>metered-dose pump</dosage-form>
                <strength>0.1 g</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Octostim Liq Inj. 15mcg/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02024179</dpd-id>
                <started-marketing-on>1995-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>liquid</dosage-form>
                <strength>15 mcg</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Octostim Spray</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02237860</dpd-id>
                <started-marketing-on>1998-12-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray</dosage-form>
                <strength>150 mcg</strength>
                <route>nasal</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>PMS-desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02304368</dpd-id>
                <started-marketing-on>2008-01-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.1 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>PMS-desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02304376</dpd-id>
                <started-marketing-on>2008-01-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.2 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Stimate</name>
                <ndc-id>0053-6871_288faa68-9d71-441c-8fd0-6b6aeda2070f</ndc-id>
                <ndc-product-code>0053-6871</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-09-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>spray, metered</dosage-form>
                <strength>1.5 mg/mL</strength>
                <route>nasal</route>
                <fda-application-number>NDA020355</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Teva-desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02287730</dpd-id>
                <started-marketing-on>2007-07-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.1 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Teva-desmopressin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02287749</dpd-id>
                <started-marketing-on>2007-07-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>tablet</dosage-form>
                <strength>0.2 mg</strength>
                <route>oral</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Adiuretin</name>
                <company>Ferring</company>
            </international-brand>
            <international-brand>
                <name>DesmoMelt</name>
                <company>Ferring</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Stimate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Rhinal Tube</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Acetate</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Inj 4mcg/ml</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Rhinyle</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Octostim Liq Inj. 15mcg/ml</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Tablets 0.1mg</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Tablets 0.2mg</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Octostim Spray</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Spray</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Apo-desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Apo-desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Melt</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Melt</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Melt</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Teva-desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Teva-desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>PMS-desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>PMS-desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Nocdurna</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Nocdurna</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Ddavp Spray</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Minirin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Minirin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Tablets</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin Tablets</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Desmopressin</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
            <mixture>
                <name>Nu-desmopressin Spray</name>
                <ingredients>Desmopressin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Amerisource Health Services Corp.</name>
                <url>http://www.amerisourcebergen.com</url>
            </packager>
            <packager>
                <name>Apotex Inc.</name>
                <url>http://www.apotex.com</url>
            </packager>
            <packager>
                <name>Arcola Laboratories</name>
                <url/>
            </packager>
            <packager>
                <name>Bachem Inc.</name>
                <url>http://www.bachem.com</url>
            </packager>
            <packager>
                <name>Barr Pharmaceuticals</name>
                <url/>
            </packager>
            <packager>
                <name>Bausch &amp; Lomb Inc.</name>
                <url>http://www.bausch.com</url>
            </packager>
            <packager>
                <name>CSL Behring LLC</name>
                <url>http://www.cslbehring.com</url>
            </packager>
            <packager>
                <name>Ferring Pharmaceuticals Inc.</name>
                <url>http://www.ferring.com</url>
            </packager>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>Kaiser Foundation Hospital</name>
                <url/>
            </packager>
            <packager>
                <name>Pharmacy Service Center</name>
                <url/>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Promex Medical Inc.</name>
                <url/>
            </packager>
            <packager>
                <name>Rechon Life Science AB</name>
                <url>http://www.rechon.com</url>
            </packager>
            <packager>
                <name>Sanofi-Aventis Inc.</name>
                <url>http://www.sanofi-aventis.com</url>
            </packager>
            <packager>
                <name>Sicor Pharmaceuticals</name>
                <url/>
            </packager>
            <packager>
                <name>Sun Pharmaceutical Industries Ltd.</name>
                <url>http://www.sunpharma.com</url>
            </packager>
            <packager>
                <name>Teva Pharmaceutical Industries Ltd.</name>
                <url>http://www.tevapharm.com</url>
            </packager>
            <packager>
                <name>UDL Laboratories</name>
                <url>http://www.udllabs.com</url>
            </packager>
            <packager>
                <name>Watson Pharmaceuticals</name>
                <url>http://www.watson.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Sanofi aventis us llc</manufacturer>
            <manufacturer generic="true">Bedford laboratories div ben venue laboratories inc</manufacturer>
            <manufacturer generic="true">Hospira inc</manufacturer>
            <manufacturer generic="true">Teva parenteral medicines inc</manufacturer>
            <manufacturer generic="false">Ferring pharmaceuticals inc</manufacturer>
            <manufacturer generic="true">Bausch and lomb pharmaceuticals inc</manufacturer>
            <manufacturer generic="false">Apotex inc richmond hill</manufacturer>
            <manufacturer generic="false">Csl behring llc</manufacturer>
            <manufacturer generic="true">Apotex inc etobicoke site</manufacturer>
            <manufacturer generic="true">Teva pharmaceuticals usa</manufacturer>
            <manufacturer generic="true">Watson laboratories inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Apo-Desmopressin 10 mcg/dose Metered Dose Spray</description>
                <cost currency="USD">1.48</cost>
                <unit>dose</unit>
            </price>
            <price>
                <description>Ddavp 0.1 mg Tablet</description>
                <cost currency="USD">1.49</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Apo-Desmopressin 0.2 mg Tablet</description>
                <cost currency="USD">1.67</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Novo-Desmopressin 0.2 mg Tablet</description>
                <cost currency="USD">1.67</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Pms-Desmopressin 0.2 mg Tablet</description>
                <cost currency="USD">1.67</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Ddavp 10 mcg/dose Metered Dose Spray</description>
                <cost currency="USD">2.13</cost>
                <unit>dose</unit>
            </price>
            <price>
                <description>Ddavp 0.2 mg Tablet</description>
                <cost currency="USD">2.98</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Desmopressin acetate 0.1 mg tablet</description>
                <cost currency="USD">3.08</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Desmopressin acetate 0.2 mg tablet</description>
                <cost currency="USD">4.44</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Ddavp 0.1 mg tablet</description>
                <cost currency="USD">4.47</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Ddavp 0.2 mg tablet</description>
                <cost currency="USD">6.43</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Desmopressin ac 4 mcg/ml vial</description>
                <cost currency="USD">7.08</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Desmopressin ac 4 mcg/ml amp</description>
                <cost currency="USD">7.28</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Ddavp 4 mcg/ml</description>
                <cost currency="USD">11.33</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Octostim 150 mcg/dose Metered Dose Spray</description>
                <cost currency="USD">17.39</cost>
                <unit>dose</unit>
            </price>
            <price>
                <description>Ddavp 0.1 mg/ml Solution</description>
                <cost currency="USD">21.26</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Desmopressin 0.1 mg/ml spray</description>
                <cost currency="USD">39.6</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Ddavp 4 mcg/ml ampul</description>
                <cost currency="USD">43.27</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Ddavp 0.01% nasal spray</description>
                <cost currency="USD">50.76</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Stimate 1.5 mg/ml nasal spray</description>
                <cost currency="USD">334.2</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Apo-Desmopressin 0.1 mg Tablet</description>
                <cost currency="USD">0.83</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Novo-Desmopressin 0.1 mg Tablet</description>
                <cost currency="USD">0.83</cost>
                <unit>tablet</unit>
            </price>
            <price>
                <description>Pms-Desmopressin 0.1 mg Tablet</description>
                <cost currency="USD">0.83</cost>
                <unit>tablet</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antidiuretic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Hemostatics</category>
                <mesh-id/>
            </category>
            <category>
                <category>Renal Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>4 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Spray</form>
                <route>nasal</route>
                <strength>.1 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Tablet</form>
                <route>oral</route>
                <strength>.1 mg</strength>
            </dosage>
            <dosage>
                <form>Tablet</form>
                <route>oral</route>
                <strength>.2 mg</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; intravenous; subcutaneous</route>
                <strength>4 mcg</strength>
            </dosage>
            <dosage>
                <form>Tablet (orally disintegrating)</form>
                <route>sublingual</route>
                <strength>120 mcg</strength>
            </dosage>
            <dosage>
                <form>Tablet (orally disintegrating)</form>
                <route>sublingual</route>
                <strength>240 mcg</strength>
            </dosage>
            <dosage>
                <form>Tablet (orally disintegrating)</form>
                <route>sublingual</route>
                <strength>60 mcg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>nasal</route>
                <strength>.1 mg/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>nasal</route>
                <strength>0.1 mg</strength>
            </dosage>
            <dosage>
                <form>Metered-dose aerosol</form>
                <route>nasal</route>
                <strength>10 mcg</strength>
            </dosage>
            <dosage>
                <form>Tablet</form>
                <route>oral</route>
                <strength>0.1 mg</strength>
            </dosage>
            <dosage>
                <form>Tablet</form>
                <route>oral</route>
                <strength>0.2 mg</strength>
            </dosage>
            <dosage>
                <form>Injection</form>
                <route>intravenous</route>
                <strength>4 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>4 ug/mL</strength>
            </dosage>
            <dosage>
                <form>Spray</form>
                <route>nasal</route>
                <strength>10 ug</strength>
            </dosage>
            <dosage>
                <form>Spray</form>
                <route>nasal</route>
                <strength>10 ug/.1mL</strength>
            </dosage>
            <dosage>
                <form>Spray, metered dose</form>
                <route>nasal</route>
                <strength>10 mcg</strength>
            </dosage>
            <dosage>
                <form>Tablet (orally disintegrating)</form>
                <route>sublingual</route>
                <strength>25 mcg</strength>
            </dosage>
            <dosage>
                <form>Tablet (orally disintegrating)</form>
                <route>sublingual</route>
                <strength>50 mcg</strength>
            </dosage>
            <dosage>
                <form>Metered-dose pump</form>
                <route>nasal</route>
                <strength>0.1 g</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intravenous; subcutaneous</route>
                <strength>15 mcg</strength>
            </dosage>
            <dosage>
                <form>Spray</form>
                <route>nasal</route>
                <strength>150 mcg</strength>
            </dosage>
            <dosage>
                <form>Spray, metered</form>
                <route>nasal</route>
                <strength>1.5 mg/mL</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="H01BA02">
                <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
                <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
                <level code="H01B">POSTERIOR PITUITARY LOBE HORMONES</level>
                <level code="H01BA">Vasopressin and analogues</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>68:28.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2484724</number>
                <country>Canada</country>
                <approved>2007-01-16</approved>
                <expires>2023-05-07</expires>
            </patent>
            <patent>
                <number>2486833</number>
                <country>Canada</country>
                <approved>2005-08-02</approved>
                <expires>2024-04-30</expires>
            </patent>
            <patent>
                <number>5500413</number>
                <country>United States</country>
                <approved>1993-06-29</approved>
                <expires>2013-06-29</expires>
            </patent>
            <patent>
                <number>7022340</number>
                <country>United States</country>
                <approved>2003-04-30</approved>
                <expires>2023-04-30</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00802</drugbank-id>
                <name>Alfentanil</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00321</drugbank-id>
                <name>Amitriptyline</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00543</drugbank-id>
                <name>Amoxapine</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00921</drugbank-id>
                <name>Buprenorphine</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00611</drugbank-id>
                <name>Butorphanol</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00564</drugbank-id>
                <name>Carbamazepine</name>
                <description>May enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00482</drugbank-id>
                <name>Celecoxib</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00477</drugbank-id>
                <name>Chlorpromazine</name>
                <description>May enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00215</drugbank-id>
                <name>Citalopram</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01242</drugbank-id>
                <name>Clomipramine</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00318</drugbank-id>
                <name>Codeine</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00618</drugbank-id>
                <name>Demeclocycline</name>
                <description>May diminish the therapeutic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01151</drugbank-id>
                <name>Desipramine</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00586</drugbank-id>
                <name>Diclofenac</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00861</drugbank-id>
                <name>Diflunisal</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01551</drugbank-id>
                <name>Dihydrocodeine</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01142</drugbank-id>
                <name>Doxepin</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01175</drugbank-id>
                <name>Escitalopram</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00749</drugbank-id>
                <name>Etodolac</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00573</drugbank-id>
                <name>Fenoprofen</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00813</drugbank-id>
                <name>Fentanyl</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08976</drugbank-id>
                <name>Floctafenine</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00472</drugbank-id>
                <name>Fluoxetine</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00712</drugbank-id>
                <name>Flurbiprofen</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00176</drugbank-id>
                <name>Fluvoxamine</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00956</drugbank-id>
                <name>Hydrocodone</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00327</drugbank-id>
                <name>Hydromorphone</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01050</drugbank-id>
                <name>Ibuprofen</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00458</drugbank-id>
                <name>Imipramine</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00328</drugbank-id>
                <name>Indomethacin</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01009</drugbank-id>
                <name>Ketoprofen</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00465</drugbank-id>
                <name>Ketorolac</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00555</drugbank-id>
                <name>Lamotrigine</name>
                <description>May enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00854</drugbank-id>
                <name>Levorphanol</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01356</drugbank-id>
                <name>Lithium</name>
                <description>May diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00784</drugbank-id>
                <name>Mefenamic acid</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00814</drugbank-id>
                <name>Meloxicam</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00333</drugbank-id>
                <name>Methadone</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00295</drugbank-id>
                <name>Morphine</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00461</drugbank-id>
                <name>Nabumetone</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00844</drugbank-id>
                <name>Nalbuphine</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00788</drugbank-id>
                <name>Naproxen</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00540</drugbank-id>
                <name>Nortriptyline</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00991</drugbank-id>
                <name>Oxaprozin</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00497</drugbank-id>
                <name>Oxycodone</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01192</drugbank-id>
                <name>Oxymorphone</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00715</drugbank-id>
                <name>Paroxetine</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00652</drugbank-id>
                <name>Pentazocine</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00454</drugbank-id>
                <name>Pethidine</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00554</drugbank-id>
                <name>Piroxicam</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00420</drugbank-id>
                <name>Promazine</name>
                <description>ChlorPromazine may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00344</drugbank-id>
                <name>Protriptyline</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00899</drugbank-id>
                <name>Remifentanil</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01104</drugbank-id>
                <name>Sertraline</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00708</drugbank-id>
                <name>Sufentanil</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00605</drugbank-id>
                <name>Sulindac</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06204</drugbank-id>
                <name>Tapentadol</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01600</drugbank-id>
                <name>Tiaprofenic acid</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00500</drugbank-id>
                <name>Tolmetin</name>
                <description>Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06212</drugbank-id>
                <name>Tolvaptan</name>
                <description>May diminish the therapeutic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00193</drugbank-id>
                <name>Tramadol</name>
                <description>Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00726</drugbank-id>
                <name>Trimipramine</name>
                <description>Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06684</drugbank-id>
                <name>Vilazodone</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09068</drugbank-id>
                <name>Vortioxetine</name>
                <description>Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.</description>
            </drug-interaction>
        </drug-interactions>
        <calculated-properties>
            <property>
                <kind>logP</kind>
                <value>-1</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>logS</kind>
                <value>-4</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>Water Solubility</kind>
                <value>1.10e-01 g/l</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>logP</kind>
                <value>-6.1</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>IUPAC Name</kind>
                <value>(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Traditional IUPAC Name</kind>
                <value>desmopressin</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>1069.217</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Monoisotopic Weight</kind>
                <value>1068.426954962</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>SMILES</kind>
                <value>NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C46H64N14O12S2</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>InChI</kind>
                <value>InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>InChIKey</kind>
                <value>InChIKey=NFLWUMRGJYTJIN-NXBWRCJVSA-N</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Polar Surface Area (PSA)</kind>
                <value>435.41</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Refractivity</kind>
                <value>279.78</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Polarizability</kind>
                <value>106.19</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Rotatable Bond Count</kind>
                <value>19</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>H Bond Acceptor Count</kind>
                <value>15</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>H Bond Donor Count</kind>
                <value>14</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>pKa (strongest acidic)</kind>
                <value>9.5</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>pKa (strongest basic)</kind>
                <value>11.77</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Physiological Charge</kind>
                <value>1</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Number of Rings</kind>
                <value>4</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Bioavailability</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Rule of Five</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Ghose Filter</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>MDDR-Like Rule</kind>
                <value>1</value>
                <source>ChemAxon</source>
            </property>
        </calculated-properties>
        <experimental-properties>
            <property>
                <kind>logP</kind>
                <value>-4.2</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>2155</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>19910</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>20181</identifier>
            </external-identifier>
            <external-identifier>
                <resource>ChEBI</resource>
                <identifier>4450</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C06944</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D00291</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>55566-5020-1</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA449237</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Desmopressin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/desmoprt.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/desmopressin.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000293</id>
                <name>Vasopressin V2 receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. Epub 2008 Aug 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18761325&#13;
                    # Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16333859&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P30518" source="Swiss-Prot">
                    <name>Vasopressin V2 receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase</specific-function>
                    <gene-name>AVPR2</gene-name>
                    <locus>Xq28</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>39-63
                        78-98
                        114-135
                        160-180
                        201-220
                        272-293
                        309-328</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.41</theoretical-pi>
                    <molecular-weight>40279.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:897</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>AVPR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>AVPR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U04357</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>28418</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>368</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>66</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P30518</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>V2R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Antidiuretic hormone receptor</synonym>
                        <synonym>AVPR V2</synonym>
                        <synonym>Renal-type arginine vasopressin receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Vasopressin V2 receptor
                        MLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLA
                        ALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQM
                        VGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQ
                        RNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGP
                        SERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEA
                        PLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTT
                        ASSSLAKDTSS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1116 bp
                        ATGCTCATGGCGTCCACCACTTCCGCTGTGCCTGGGCATCCCTCTCTGCCCAGCCTGCCC
                        AGCAACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCGGAG
                        CTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGGTGCTGGCG
                        GCCCTAGCTCGGCGGGGCCGGCGGGGCCACTGGGCACCCATACACGTCTTCATTGGCCAC
                        TTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTGCCCCAGCTGGCCTGGAAG
                        GCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTCGGGCCGTGAAGTATCTGCAGATG
                        GTGGGCATGTATGCCTCCTCCTACATGATCCTGGCCATGACGCTGGACCGCCACCGTGCC
                        ATCTGCCGTCCCATGCTGGCGTACCGCCATGGAAGTGGGGCTCACTGGAACCGGCCGGTG
                        CTAGTGGCTTGGGCCTTCTCGCTCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCCAG
                        CGCAACGTGGAAGGTGGCAGCGGGGTCACTGACTGCTGGGCCTGCTTTGCGGAGCCCTGG
                        GGCCGTCGCACCTATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGT
                        ATCGCCGCCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCA
                        TCAGAGAGGCCTGGGGGGCGCCGCAGGGGACGCCGGACAGGCAGCCCCGGTGAGGGAGCC
                        CACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTGTGGTCGTCTAT
                        GTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGCCGCGTGGGACCCGGAGGCA
                        CCTCTGGAAGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCCAGCCTCAACAGCTGCACC
                        AACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGTCCTCAGAGCTGCGAAGCTTGCTC
                        TGCTGTGCCCGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACC
                        GCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptide receptor activity, G-protein coupled</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasopressin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasopressin receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000165</id>
                <name>Vasopressin V1a receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10731046&#13;
                    # Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10594321&#13;
                    # Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8957254&#13;
                    # Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15613460</references>
                <known-action>yes</known-action>
                <polypeptide id="P37288" source="Swiss-Prot">
                    <name>Vasopressin V1a receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl- inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment</specific-function>
                    <gene-name>AVPR1A</gene-name>
                    <locus>12q14-q15</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>53-76
                        89-110
                        126-147
                        169-190
                        219-239
                        294-313
                        332-351</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.67</theoretical-pi>
                    <molecular-weight>46800.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:895</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>AVPR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>AVPR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L25615</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>667068</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>366</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>66</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P37288</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>V1AR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Antidiuretic hormone receptor 1a</synonym>
                        <synonym>AVPR V1a</synonym>
                        <synonym>V1aR</synonym>
                        <synonym>Vascular/hepatic-type arginine vasopressin receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Vasopressin V1a receptor
                        MRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV
                        TFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP
                        DWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV
                        LSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC
                        YNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY
                        IVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV
                        QSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1257 bp
                        ATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT
                        CTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC
                        CCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG
                        ACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG
                        CGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG
                        GCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC
                        GACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC
                        ATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG
                        CAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG
                        CTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC
                        CGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG
                        ACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC
                        TACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG
                        CAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG
                        TCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC
                        ATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC
                        GTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT
                        AGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT
                        CAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT
                        ATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG
                        TGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptide receptor activity, G-protein coupled</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasopressin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasopressin receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0000773</id>
                <name>Vasopressin V1b receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15613460&#13;
                    # Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14971638&#13;
                    # Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18655906</references>
                <known-action>yes</known-action>
                <polypeptide id="P47901" source="Swiss-Prot">
                    <name>Vasopressin V1b receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl- inositol-calcium second messenger system</specific-function>
                    <gene-name>AVPR1B</gene-name>
                    <locus>1q32</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>36-59
                        72-93
                        109-130
                        152-173
                        202-222
                        284-303
                        322-341</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.05</theoretical-pi>
                    <molecular-weight>46971.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:896</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>AVPR1B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>AVPR1B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>D31833</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>563982</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>367</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>66</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P47901</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>V1BR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Antidiuretic hormone receptor 1b</synonym>
                        <synonym>AVPR V1b</synonym>
                        <synonym>AVPR V3</synonym>
                        <synonym>V1bR</synonym>
                        <synonym>Vasopressin V3 receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Vasopressin V1b receptor
                        MDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLG
                        QLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFA
                        STYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQG
                        SGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVG
                        GGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSV
                        QMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQ
                        PRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAE
                        TIIF</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1275 bp
                        ATGGATTCTGGGCCTCTGTGGGATGCCAACCCCACCCCTCGGGGCACCCTCTCTGCCCCC
                        AATGCCACAACACCCTGGCTGGGCCGGGATGAGGAGCTGGCCAAGGTGGAGATCGGAGTC
                        CTGGCCACTGTCCTGGTGCTGGCGACCGGGGGCAACCTGGCTGTGCTGCTGACCCTGGGC
                        CAGCTGGGCCGCAAGCGCTCCCGCATGCACCTGTTCGTGCTGCACTTAGCCCTGACAGAC
                        CTGGCCGTGGCGCTCTTCCAGGTGCTGCCACAGCTGCTGTGGGACATCACCTACCGCTTC
                        CAGGGCCCCGACCTCCTGTGCAGGGCCGTCAAGTACCTGCAGGTGCTCAGCATGTTTGCC
                        TCCACCTACATGCTGCTGGCCATGACGCTGGACCGCTACCTGGCTGTCTGTCACCCCCTG
                        CGCAGCCTCCAGCAGCCAGGCCAGTCCACCTACCTGCTCATCGCTGCTCCCTGGCTGCTG
                        GCCGCCATCTTCAGCCTCCCTCAAGTCTTCATTTTTTCCCTGCGGGAGGTGATCCAGGGC
                        TCAGGGGTGCTGGACTGCTGGGCAGACTTCGGCTTCCCTTGGGGGCCACGGGCCTACCTC
                        ACCTGGACCACCCTGGCTATCTTCGTTCTGCCGGTGACCATGCTCACGGCCTGCTACAGC
                        CTCATCTGCCATGAGATCTGTAAAAACCTAAAAGTCAAGACACAGGCCTGGCGGGTGGGA
                        GGAGGGGGCTGGAGGACTTGGGACAGGCCCTCACCTTCCACCTTAGCTGCCACCACTCGG
                        GGGCTGCCATCTCGGGTCAGCAGCATCAACACCATCTCACGGGCCAAGATCCGAACAGTG
                        AAGATGACCTTTGTCATCGTGCTGGCCTACATCGCTTGCTGGGCTCCCTTCTTCAGTGTC
                        CAGATGTGGTCCGTGTGGGACAAGAATGCCCCTGATGAAGATTCCACCAATGTGGCTTTC
                        ACCATCTCTATGCTTTTGGGCAACCTCAACAGCTGCTGCAACCCCTGGATCTACATGGGC
                        TTCAACAGCCACCTGTTACCGCGGCCCCTGCGTCACCTTGCCTGCTGTGGGGGTCCCCAG
                        CCCAGGATGCGCCGGCGGCTCTCCGACGGCAGCCTCTCGAGCCGCCACACCACGCTGCTG
                        ACCCGCTCCAGCTGCCCGGCCACCCTCAGCCTCAGCCTCAGCCTAACCCTCAGTGGGAGG
                        CCCAGGCCTGAAGAGTCACCAAGGGACTTGGAGCTGGCAGATGGGGAAGGCACCGCTGAG
                        ACCATCATCTTTTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptide receptor activity, G-protein coupled</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasopressin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>vasopressin receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme position="4">
                <id>BE0000017</id>
                <name>Prostaglandin G/H synthase 1</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15644490</references>
                <known-action>unknown</known-action>
                <polypeptide id="P23219" source="Swiss-Prot">
                    <name>Prostaglandin G/H synthase 1</name>
                    <general-function>Involved in peroxidase activity</general-function>
                    <specific-function>May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells</specific-function>
                    <gene-name>PTGS1</gene-name>
                    <locus>9q32-q33.3</locus>
                    <cellular-location>Microsome; microsomal membrane; peripheral membrane protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.39</theoretical-pi>
                    <molecular-weight>68657.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9604</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PTGS1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PTGS1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31822</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>387018</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P23219</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PGH1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>COX-1</synonym>
                        <synonym>Cyclooxygenase- 1</synonym>
                        <synonym>EC 1.14.99.1</synonym>
                        <synonym>PGH synthase 1</synonym>
                        <synonym>PGHS-1</synonym>
                        <synonym>PHS 1</synonym>
                        <synonym>Prostaglandin G/H synthase 1 precursor</synonym>
                        <synonym>Prostaglandin H2 synthase 1</synonym>
                        <synonym>Prostaglandin-endoperoxide synthase 1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prostaglandin G/H synthase 1 precursor
                        MSRSLLLRFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR
                        TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS
                        NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF
                        LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ
                        YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY
                        ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF
                        DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA
                        LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL
                        VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS
                        PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1800 bp
                        ATGAGCCGGAGTCTCTTGCTCCGGTTCTTGCTGTTGCTGCTCCTGCTCCCGCCGCTCCCC
                        GTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC
                        CAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC
                        ACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA
                        CTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG
                        TTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCTCCTGGTACTCACAGTGCGCTCC
                        AACCTTATCCCCAGTCCCCCCACCTACAACTCTGCACATGACTACATCAGCTGGGAGTCT
                        TTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA
                        CCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC
                        CTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT
                        GCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC
                        AAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG
                        TATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG
                        TACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC
                        CAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT
                        GCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC
                        ACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC
                        AAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT
                        GACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCACGGAGTTC
                        AACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG
                        TACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC
                        CTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC
                        CACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG
                        CCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC
                        GTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG
                        GAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT
                        ATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT
                        CCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG
                        GCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT
                        GTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA
                    </gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF03098</identifier>
                            <name>An_peroxidase</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>antioxidant activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peroxidase activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
            <enzyme position="5">
                <id>BE0000262</id>
                <name>Prostaglandin G/H synthase 2</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15644490</references>
                <known-action>unknown</known-action>
                <polypeptide id="P35354" source="Swiss-Prot">
                    <name>Prostaglandin G/H synthase 2</name>
                    <general-function>Involved in peroxidase activity</general-function>
                    <specific-function>May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity</specific-function>
                    <gene-name>PTGS2</gene-name>
                    <locus>1q25.2-q25.3</locus>
                    <cellular-location>Microsome; microsomal membrane; peripheral membrane protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.41</theoretical-pi>
                    <molecular-weight>68997.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PTGS2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PTGS2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L15326</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>291988</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P35354</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PGH2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>COX-2</synonym>
                        <synonym>Cyclooxygenase- 2</synonym>
                        <synonym>EC 1.14.99.1</synonym>
                        <synonym>PGH synthase 2</synonym>
                        <synonym>PGHS-2</synonym>
                        <synonym>PHS II</synonym>
                        <synonym>Prostaglandin G/H synthase 2 precursor</synonym>
                        <synonym>Prostaglandin H2 synthase 2</synonym>
                        <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prostaglandin G/H synthase 2 precursor
                        MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
                        TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
                        GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
                        NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
                        QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
                        VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
                        NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
                        AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
                        YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
                        GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
                        STEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1815 bp
                        ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
                        TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
                        AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
                        ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
                        TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
                        TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
                        GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
                        GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
                        AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
                        AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
                        AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
                        GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
                        CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
                        TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
                        GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
                        GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
                        ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
                        TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
                        AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
                        TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
                        CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
                        GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCACTGACCAG
                        AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
                        TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
                        TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
                        GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
                        ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
                        GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
                        TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
                        GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
                        TCGACTGAACTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF03098</identifier>
                            <name>An_peroxidase</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>antioxidant activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peroxidase activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2010-09-14">
        <drugbank-id primary="true">DB00036</drugbank-id>
        <drugbank-id>BIOD00006</drugbank-id>
        <drugbank-id>BTD00006</drugbank-id>
        <name>Coagulation factor VIIa</name>
        <description>Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade.1 NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.</description>
        <cas-number>9001-25-6</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Blackshear PJ, Holloway PA, Alberti KG: Factors regulating amino acid release from extrasplanchnic tissues in the rat. Interactions of alanine and glutamine. Biochem J. 1975 Sep;150(3):379-87. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2155
            # Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004 Dec 15;104(13):3858-64. Epub 2004 Aug 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15328151
            # Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999 Nov 27;354(9193):1879. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10584732
            # O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 Jan 18;295(3):293-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16418464
            # Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005 Feb 24;352(8):777-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15728810</general-references>
        <synthesis-reference/>
        <indication>For treatment of hemorrhagic complications in hemophilia A and B</indication>
        <pharmacodynamics>Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.</pharmacodynamics>
        <mechanism-of-action>NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution>* 121 ± 30 mL/kg [adults]
            * 153 ± 29 mL/kg [children]
            * 280 to 290 mL/kg [congenital Factor VII deficiency]</volume-of-distribution>
        <clearance>* 33 - 37 mL/h x kg [healthy]
            * 1375 +/- 396 mL/hr [severe hemophilia A male children]
            * 57.3 +/- 9.5 mL/hr/kg [severe hemophilia A male children]
            * 2767 +/- 385 mL/hr [severe hemophilia A men]
            * 37.6 +/- 13.1 mL/hr/kg [severe hemophilia A men]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Coagulation factor VII precursor</synonym>
            <synonym language="" coder="">Eptacog alfa</synonym>
            <synonym language="" coder="">Proconvertin</synonym>
            <synonym language="" coder="">Serum prothrombin conversion accelerator</synonym>
            <synonym language="" coder="">SPCA</synonym>
        </synonyms>
        <products>
            <product>
                <name>Niastase</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239659</dpd-id>
                <started-marketing-on>1999-08-05</started-marketing-on>
                <ended-marketing-on>2013-07-22</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1.2 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239660</dpd-id>
                <started-marketing-on>1999-08-05</started-marketing-on>
                <ended-marketing-on>2013-07-22</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>2.4 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239661</dpd-id>
                <started-marketing-on>1999-08-05</started-marketing-on>
                <ended-marketing-on>2013-07-22</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>4.8 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02365669</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>8 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02417146</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>8 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02417103</dpd-id>
                <started-marketing-on>2015-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02417111</dpd-id>
                <started-marketing-on>2015-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>2 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02417138</dpd-id>
                <started-marketing-on>2015-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>5 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02347113</dpd-id>
                <started-marketing-on>2010-08-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02347121</dpd-id>
                <started-marketing-on>2010-08-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>2 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Niastase Rt</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02347148</dpd-id>
                <started-marketing-on>2010-08-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>5 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>NovoSeven</name>
                <company>Novo Nordisk</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
            <mixture>
                <name>Niastase Rt</name>
                <ingredients>Coagulation factor VIIa</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Novo Nordisk Inc.</name>
                <url>http://www.novonordisk.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Novoseven 1200 mcg vial</description>
                <cost currency="USD">1.64</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Novoseven 2400 mcg vial</description>
                <cost currency="USD">1.64</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Novoseven 4800 mcg vial</description>
                <cost currency="USD">1.64</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Coagulants</category>
                <mesh-id/>
            </category>
            <category>
                <category>Thrombotic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>1.2 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>2.4 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>4.8 mg</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intravenous</route>
                <strength>1 mg</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intravenous</route>
                <strength>2 mg</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intravenous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intravenous</route>
                <strength>8 mg</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00036 sequence
                ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS
                CKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL
                LADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG
                TLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
                HDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL
                NVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG
                IVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>58 °C</value>
                <source>Petersen, L.C. et al., Eur. J. Biochem 261: 124-129 (1999)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.311</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>6.09</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>45079.1000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1972H3076N560O597S28</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13301</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C03378</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D00172</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0169-7010-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M13232</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164748389</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P08709</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Factor_VII</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/novoseven.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000216</id>
                <name>Coagulation factor X</name>
                <organism>Human</organism>
                <actions/>
                <references># Malinvaud G: [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)] Transfusion (Paris). 1966;9(3):245-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5969560
                    # BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)] Pathol Biol (Paris). 1959 Dec;7:2477-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13801371
                    # HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13713641
                    # GAERTNER H, CAEN J: [FUNCTIONAL RELATION BETWEEN ERYTHROPLASTIN (ERYTHROCYTE COAGULANT FACTOR) AND PLASMA FACTORS: PROACCELERIN (V), PROCONVERTIN (VII) AND STUART FACTOR(X).] Acta Physiol Pol. 1964 Mar-Apr;15:237-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14227143
                    # DIDISHEIM P, LOEB J, BLATRIX C, SOULIER JP: Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med. 1959 Feb;53(2):322-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13621053</references>
                <known-action>unknown</known-action>
                <polypeptide id="P00742" source="Swiss-Prot">
                    <name>Coagulation factor X</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting</specific-function>
                    <gene-name>F10</gene-name>
                    <locus>13q34</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>7-26</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.74</theoretical-pi>
                    <molecular-weight>54732.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3528</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F10</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F10</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>K03194</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182841</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00742</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FA10_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Coagulation factor X precursor</synonym>
                        <synonym>EC 3.4.21.6</synonym>
                        <synonym>Stuart factor</synonym>
                        <synonym>Stuart- Prower factor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Coagulation factor X precursor
                        MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
                        TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN
                        CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR
                        KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE
                        CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE
                        AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI
                        VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG
                        GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE
                        VITSSPLK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1433 bp
                        CCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCA
                        ACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGAC
                        ACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTG
                        AGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAAGATGGCGACCAGTGTGAGA
                        CCAGTCCTTGCCAGAACCAGGGCAAATGTAAAGACGGCCTCGGGGAATACACCTGCACCT
                        GTTTAGAAGGATTCGAAGGCAAAAACTGTGAATTATTCACACGGAAGCTCTGCAGCCTGG
                        ACAACGGGGACTGTGACCAGTTCTGCCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCG
                        CCCGCGGGTACACCCTGGCTGACAACGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCT
                        GTGGGAAACAGACCCTGGAACGCAGGAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCG
                        GGGAGGCCCCTGACAGCATCACATGGAAGCCATATGATGCAGCCGACCTGGACCCCACCG
                        AGAACCCCTTCGACCTGCTTGACTTCAACCAGACGCAGCCTGAGAGGGGCGACAACAACC
                        TCACCAGGATCGTGGGAGGCCAGGAATGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGC
                        TCATCAATGAGGAAAACGAGGGTTTCTGTGGTGGAACTATTCTGAGCGAGTTCTACATCC
                        TAACGGCAGCCCACTGTCTCTACCAAGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGA
                        ACACGGAGCAGGAGGAGGGCGGTGAGGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACA
                        ACCGGTTCACAAAGGAGACCTATGACTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCA
                        TCACCTTCCGCATGAACGTGGCGCCTGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCA
                        CGCTGATGACGCAGAAGACGGGGATTGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCC
                        GGCAGTCCACCAGGCTCAAGATGCTGGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGC
                        TGTCCAGCAGCTTCATCATCACCCAGAACATGTTCTGTGCCGGCTACGACACCAAGCAGG
                        AGGATGCCTGCCAGGGGGACAGCGGGGGCCCGCACGTCACCCGCTTCAAGGACACCTACT
                        TCGTGACAGGCATCGTCAGCTGGGGAGAGAGCTGTGCCCGTAAGGGGAAGTACGGGATCT
                        ACACCAAGGTCACCGCCTTCCTCAAGTGGATCGACAGGTCCATGAAAACCAGGGGCTTGC
                        CCAAGGCCAAGAGCCATGCCCCGGAGGTCATAACGTCCTCTCCATTAAAGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002128</id>
                <name>Serine protease hepsin</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05981" source="Swiss-Prot">
                    <name>Serine protease hepsin</name>
                    <general-function/>
                    <specific-function>Plays an essential role in cell growth and maintenance of cell morphology</specific-function>
                    <gene-name>HPN</gene-name>
                    <locus>19q11-q13.2</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>24-44</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.66</theoretical-pi>
                    <molecular-weight>45012.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5155</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>HPN</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>HPN</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M18930</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>306886</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05981</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>HEPS_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 3.4.21.106</synonym>
                        <synonym>Transmembrane protease, serine 1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Serine protease hepsin
                        MAQKEGGRTVPCCSRPKVAALTAGTLLLLTAIGAASWAIVAVLLRSDQEPLYPVQVSSAD
                        ARLMVFDKTEGTWRLLCSSRSNARVAGLSCEEMGFLRALTHSELDVRTAGANGTSGFFCV
                        DEGRLPHTQRLLEVISVCDCPRGRFLAAICQDCGRRKLPVDRIVGGRDTSLGRWPWQVSL
                        RYDGAHLCGGSLLSGDWVLTAAHCFPERNRVLSRWRVFAGAVAQASPHGLQLGVQAVVYH
                        GGYLPFRDPNSEENSNDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGKICTVTGWGNTQ
                        YYGQQAGVLQEARVPIISNDVCNGADFYGNQIKPKMFCAGYPEGGIDACQGDSGGPFVCE
                        DSISRTPRWRLCGIVSWGTGCALAQKPGVYTKVSDFREWIFQAIKTHSEASGMVTQL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1254 bp
                        ATGGCGCAGAAGGAGGGTGGCCGGACTGTGCCATGCTGCTCCAGACCCAAGGTGGCAGCT
                        CTCACTGCGGGGACCCTGCTACTTCTGACAGCCATCGGGGCGGCATCCTGGGCCATTGTG
                        GCTGTTCTCCTCAGGAGTGACCAGGAGCCGCTGTACCCAGTGCAGGTCAGCTCTGCGGAC
                        GCTCGGCTCATGGTCTTTGACAAGACGGAAGGGACGTGGCGGCTGCTGTGCTCCTCGCGC
                        TCCAACGCCAGGGTAGCCGGACTCAGCTGCGAGGAGATGGGCTTCCTCAGGGCACTGACC
                        CACTCCGAGCTGGACGTGCGAACGGCGGGCGCCAATGGCACGTCGGGCTTCTTCTGTGTG
                        GACGAGGGGAGGCTGCCCCACACCCAGAGGCTGCTGGAGGTCATCTCCGTGTGTGATTGC
                        CCCAGAGGCCGTTTCTTGGCCGCCATCTGCCAAGACTGTGGCCGCAGGAAGCTGCCCGTG
                        GACCGCATCGTGGGAGGCCGGGACACCAGCTTGGGCCGGTGGCCGTGGCAAGTCAGCCTT
                        CGCTATGATGGAGCACACCTCTGTGGGGGATCCCTGCTCTCCGGGGACTGGGTGCTGACA
                        GCCGCCCACTGCTTCCCGGAGCGGAACCGGGTCCTGTCCCGATGGCGAGTGTTTGCCGGT
                        GCCGTGGCCCAGGCCTCTCCCCACGGTCTGCAGCTGGGGGTGCAGGCTGTGGTCTACCAC
                        GGGGGCTATCTTCCCTTTCGGGACCCCAACAGCGAGGAGAACAGCAACGATATTGCCCTG
                        GTCCACCTCTCCAGTCCCCTGCCCCTCACAGAATACATCCAGCCTGTGTGCCTCCCAGCT
                        GCCGGCCAGGCCCTGGTGGATGGCAAGATCTGTACCGTGACGGGCTGGGGCAACACGCAG
                        TACTATGGCCAACAGGCCGGGGTACTCCAGGAGGCTCGAGTCCCCATAATCAGCAATGAT
                        GTCTGCAATGGCGCTGACTTCTATGGAAACCAGATCAAGCCCAAGATGTTCTGTGCTGGC
                        TACCCCGAGGGTGGCATTGATGCCTGCCAGGGCGACAGCGGTGGTCCCTTTGTGTGTGAG
                        GACAGCATCTCTCGGACGCCACGTTGGCGGCTGTGTGGCATTGTGAGTTGGGGCACTGGC
                        TGTGCCCTGGCCCAGAAGCCAGGCGTCTACACCAAAGTCAGTGACTTCCGGGAGTGGATC
                        TTCCAGGCCATAAAGACTCACTCCGAAGCCAGCGGCATGGTGACCCAGCTCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF09272</identifier>
                            <name>Hepsin-SRCR</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>scavenger receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000967</id>
                <name>Tissue factor pathway inhibitor</name>
                <organism>Human</organism>
                <actions/>
                <references># Mine S, Yamazaki T, Miyata T, Hara S, Kato H: Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry. 2002 Jan 8;41(1):78-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11772005
                    # Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ Jr, Schwartz AL: Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem. 1995 Oct 20;270(42):24800-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7559599
                    # Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP: Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2149-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8700900
                    # Lee AY, Vlasuk GP: Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med. 2003 Oct;254(4):313-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12974870
                    # Hansen CB, Pyke C, Petersen LC, Rao LV: Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood. 2001 Mar 15;97(6):1712-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11238112</references>
                <known-action>unknown</known-action>
                <polypeptide id="P10646" source="Swiss-Prot">
                    <name>Tissue factor pathway inhibitor</name>
                    <general-function>Involved in serine-type endopeptidase inhibitor activity</general-function>
                    <specific-function>Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma</specific-function>
                    <gene-name>TFPI</gene-name>
                    <locus>2q32</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.31</theoretical-pi>
                    <molecular-weight>35015.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11760</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>TFPI</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>TFPI</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03225</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>180546</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P10646</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TFPI1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EPI</synonym>
                        <synonym>Extrinsic pathway inhibitor</synonym>
                        <synonym>LACI</synonym>
                        <synonym>Lipoprotein- associated coagulation inhibitor</synonym>
                        <synonym>TFPI</synonym>
                        <synonym>Tissue factor pathway inhibitor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tissue factor pathway inhibitor precursor
                        MIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADD
                        GPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQE
                        KPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPN
                        GFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIG
                        KCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIF
                        VKNM</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;915 bp
                        ATGATTTACACAATGAAGAAAGTACATGCACTTTGGGCTTCTGTATGCCTGCTGCTTAAT
                        CTTGCCCCTGCCCCTCTTAATGCTGATTCTGAGGAAGATGAAGAACACACAATTATCACA
                        GATACGGAGTTGCCACCACTGAAACTTATGCATTCATTTTGTGCATTCAAGGCGGATGAT
                        GGCCCATGTAAAGCAATCATGAAAAGATTTTTCTTCAATATTTTCACTCGACAGTGCGAA
                        GAATTTATATATGGGGGATGTGAAGGAAATCAGAATCGATTTGAAAGTCTGGAAGAGTGC
                        AAAAAAATGTGTACAAGAGATAATGCAAACAGGATTATAAAGACAACATTGCAACAAGAA
                        AAGCCAGATTTCTGCTTTTTGGAAGAAGATCCTGGAATATGTCGAGGTTATATTACCAGG
                        TATTTTTATAACAATCAGACAAAACAGTGTGAACGTTTCAAGTATGGTGGATGCCTGGGC
                        AATATGAACAATTTTGAGACACTGGAAGAATGCAAGAACATTTGTGAAGATGGTCCGAAT
                        GGTTTCCAGGTGGATAATTATGGAACCCAGCTCAATGCTGTGAATAACTCCCTGACTCCG
                        CAATCAACCAAGGTTCCCAGCCTTTTTGAATTTCACGGTCCCTCATGGTGTCTCACTCCA
                        GCAGACAGAGGATTGTGTCGTGCCAATGAGAACAGATTCTACTACAATTCAGTCATTGGG
                        AAATGCCGCCCATTTAAGTACAGTGGATGTGGGGGAAATGAAAACAATTTTACTTCCAAA
                        CAAGAATGTCTGAGGGCATGTAAAAAAGGTTTCATCCAAAGAATATCAAAAGGAGGCCTA
                        ATTAAAACCAAAAGAAAAAGAAAGAAGCAGAGAGTGAAAATAGCATATGAAGAAATTTTT
                        GTTAAAAATATGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00014</identifier>
                            <name>Kunitz_BPTI</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protease inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme regulator activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>enzyme inhibitor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000403</id>
                <name>Vitamin K-dependent gamma-carboxylase</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
                    # Bouwman CA, Van Dam E, Fase KM, Koppe JG, Seinen W, Thijssen HH, Vermeer C, Van den Berg M: Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats. Chemosphere. 1999 Feb;38(3):489-505. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10901669</references>
                <known-action>unknown</known-action>
                <polypeptide id="P38435" source="Swiss-Prot">
                    <name>Vitamin K-dependent gamma-carboxylase</name>
                    <general-function>Involved in gamma-glutamyl carboxylase activity</general-function>
                    <specific-function>Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium binding gamma-carboxyglutamate (Gla) residues with the concomitant convertion of the reduced hydroquinone form of vitamin K to vitamin K epoxide</specific-function>
                    <gene-name>GGCX</gene-name>
                    <locus>2p12</locus>
                    <cellular-location>Endoplasmic reticulum; endoplasmic reticulum membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>61-81
                        114-134
                        137-157
                        293-313
                        362-382</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.1</theoretical-pi>
                    <molecular-weight>87562.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4247</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GGCX</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GGCX</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M81592</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>184028</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P38435</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>VKGC_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 6.4.-.-</synonym>
                        <synonym>Gamma-glutamyl carboxylase</synonym>
                        <synonym>Vitamin K gamma glutamyl carboxylase</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Vitamin K-dependent gamma-carboxylase
                        MAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD
                        PASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT
                        IMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW
                        SVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP
                        FKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS
                        YVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH
                        QLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT
                        GELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR
                        IFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL
                        ENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM
                        YVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL
                        RRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV
                        TYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2277 bp
                        ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC
                        AAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT
                        GAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC
                        CCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC
                        CAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC
                        TTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC
                        ATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG
                        TTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC
                        TCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG
                        TCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT
                        GCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT
                        GCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC
                        TTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG
                        CTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG
                        TTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC
                        TACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG
                        TCCTACTGCCCCCAAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT
                        GTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT
                        CAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT
                        CATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC
                        ATGATGGTGCACTCCCGTTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT
                        GGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT
                        GCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC
                        ACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG
                        ATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC
                        TGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG
                        AGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG
                        GAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG
                        ACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG
                        TTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG
                        TACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA
                        TTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT
                        CTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT
                        AGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA
                        TTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT
                        ATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG
                        ACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT
                        TCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF05090</identifier>
                            <name>VKG_Carbox</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>gamma-glutamyl carboxylase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>lyase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>carbon-carbon lyase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>carboxy-lyase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>peptidyl-amino acid modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>peptidyl-glutamic acid modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>peptidyl-glutamic acid carboxylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000333</id>
                <name>Coagulation factor VII</name>
                <organism>Human</organism>
                <actions/>
                <references># Perera L, Darden TA, Pedersen LG: Probing the structural changes in the light chain of human coagulation factor VIIa due to tissue factor association. Biophys J. 1999 Jul;77(1):99-113. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10388743
                    # Shapiro A: Inhibitor treatment: state of the art. Semin Hematol. 2001 Oct;38(4 Suppl 12):26-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11735107
                    # Shapiro A: Inhibitor treatment: state of the art. Dis Mon. 2003 Jan;49(1):22-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12525826
                    # Siddiqui MA, Scott LJ: Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs. 2005;65(8):1161-77. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15907148
                    # Rizoli SB, Chughtai T: The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert Opin Biol Ther. 2006 Jan;6(1):73-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16370916</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08709" source="Swiss-Prot">
                    <name>Coagulation factor VII</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium</specific-function>
                    <gene-name>F7</gene-name>
                    <locus>13q34</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.23</theoretical-pi>
                    <molecular-weight>51594.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3544</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F7</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F7</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M13232</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182801</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08709</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FA7_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Coagulation factor VII precursor</synonym>
                        <synonym>EC 3.4.21.21</synonym>
                        <synonym>Eptacog alfa</synonym>
                        <synonym>Proconvertin</synonym>
                        <synonym>Serum prothrombin conversion accelerator</synonym>
                        <synonym>SPCA</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Coagulation factor VII precursor
                        MVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRR
                        ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS
                        CKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL
                        LADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG
                        TLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
                        HDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL
                        NVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG
                        IVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1401 bp
                        ATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCT
                        GCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGG
                        CCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGC
                        GCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAG
                        CAGTGCTCCTTCGAGGAGGCCCGGGAGATCTTCAAGGACGCGGAGAGGACGAAGCTGTTC
                        TGGATTTCTTACAGTGATGGGGACCAGTGTGCCTCAAGTCCATGCCAGAATGGGGGCTCC
                        TGCAAGGACCAGCTCCAGTCCTATATCTGCTTCTGCCTCCCTGCCTTCGAGGGCCGGAAC
                        TGTGAGACGCACAAGGATGACCAGCTGATCTGTGTGAACGAGAACGGCGGCTGTGAGCAG
                        TACTGCAGTGACCACACGGGCACCAAGCGCTCCTGTCGGTGCCACGAGGGGTACTCTCTG
                        CTGGCAGACGGGGTGTCCTGCACACCCACAGTTGAATATCCATGTGGAAAAATACCTATT
                        CTAGAAAAAAGAAATGCCAGCAAACCCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCC
                        AAAGGGGAGTGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGG
                        ACCCTGATCAACACCATCTGGGTGGTCTCCGCGGCCCACTGTTTCGACAAAATCAAGAAC
                        TGGAGGAACCTGATCGCGGTGCTGGGCGAGCACGACCTCAGCGAGCACGACGGGGATGAG
                        CAGAGCCGGCGGGTGGCGCAGGTCATCATCCCCAGCACGTACGTCCCGGGCACCACCAAC
                        CACGACATCGCGCTGCTCCGCCTGCACCAGCCCGTGGTCCTCACTGACCATGTGGTGCCC
                        CTCTGCCTGCCCGAACGGACGTTCTCTGAGAGGACGCTGGCCTTCGTGCGCTTCTCATTG
                        GTCAGCGGCTGGGGCCAGCTGCTGGACCGTGGCGCCACGGCCCTGGAGCTCATGGTGCTC
                        AACGTGCCCCGGCTGATGACCCAGGACTGCCTGCAGCAGTCACGGAAGGTGGGAGACTCC
                        CCAAATATCACGGAGTACATGTTCTGTGCCGGCTACTCGGATGGCAGCAAGGACTCCTGC
                        AAGGGGGACAGTGGAGGCCCACATGCCACCCACTACCGGGGCACGTGGTACCTGACGGGC
                        ATCGTCAGCTGGGGCCAGGGCTGCGCAACCGTGGGCCACTTTGGGGTGTACACCAGGGTC
                        TCCCAGTACATCGAGTGGCTGCAAAAGCTCATGCGCTCAGAGCCACGCCCAGGAGTCCTC
                        CTGCGAGCCCCATTTCCCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0001178</id>
                <name>Tissue factor</name>
                <organism>Human</organism>
                <actions/>
                <references># HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13713641
                    # Rogers KS, Barton CL, Benson PA, Green RA: Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma. Am J Vet Res. 1992 Apr;53(4):580-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1586032
                    # Christensen NJ: Measurements of some blood clotting factors using a centrifugal analyser (Multistat III). Scand J Clin Lab Invest. 1983 Oct;43(6):521-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6658368</references>
                <known-action>unknown</known-action>
                <polypeptide id="P13726" source="Swiss-Prot">
                    <name>Tissue factor</name>
                    <general-function/>
                    <specific-function>Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade</specific-function>
                    <gene-name>F3</gene-name>
                    <locus>1p22-p21</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>252-274</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.09</theoretical-pi>
                    <molecular-weight>33068.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3541</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F3</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F3</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M16553</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339504</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P13726</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TF_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD142 antigen</synonym>
                        <synonym>Coagulation factor III</synonym>
                        <synonym>TF</synonym>
                        <synonym>Thromboplastin</synonym>
                        <synonym>Tissue factor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tissue factor precursor
                        METPAWPRVPRPETAVARTLLLGWVFAQVAGASGTTNTVAAYNLTWKSTNFKTILEWEPK
                        PVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGS
                        AGEPLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFG
                        KDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVE
                        CMGQEKGEFREIFYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;888 bp
                        ATGGAGACCCCTGCCTGGCCCCGGGTCCCGCGCCCCGAGACCGCCGTCGCTCGGACGCTC
                        CTGCTCGGCTGGGTCTTCGCCCAGGTGGCCGGCGCTTCAGGCACTACAAATACTGTGGCA
                        GCATATAATTTAACTTGGAAATCAACTAATTTCAAGACAATTTTGGAGTGGGAACCCAAA
                        CCCGTCAATCAAGTCTACACTGTTCAAATAAGCACTAAGTCAGGAGATTGGAAAAGCAAA
                        TGCTTTTACACAACAGACACAGAGTGTGACCTCACCGACGAGATTGTGAAGGATGTGAAG
                        CAGACGTACTTGGCACGGGTCTTCTCCTACCCGGCAGGGAATGTGGAGAGCACCGGTTCT
                        GCTGGGGAGCCTCTGTATGAGAACTCCCCAGAGTTCACACCTTACCTGGAGACAAACCTC
                        GGACAGCCAACAATTCAGAGTTTTGAACAGGTGGGAACAAAAGTGAATGTGACCGTAGAA
                        GATGAACGGACTTTAGTCAGAAGGAACAACACTTTCCTAAGCCTCCGGGATGTTTTTGGC
                        AAGGACTTAATTTATACACTTTATTATTGGAAATCTTCAAGTTCAGGAAAGAAAACAGCC
                        AAAACAAACACTAATGAGTTTTTGATTGATGTGGATAAAGGAGAAAACTACTGTTTCAGT
                        GTTCAAGCAGTGATTCCCTCCCGAACAGTTAACCGGAAGAGTACAGACAGCCCGGTAGAG
                        TGTATGGGCCAGGAGAAAGGGGAATTCAGAGAAATATTCTACATCATTGGAGCTGTGGCA
                        TTTGTGGTCATCATCCTTGTCATCATCCTGGCTATATCTCTACACAAGTGTAGAAAGGCA
                        GGAGTGGGGCAGAGCTGGAAGGAGAACTCCCCACTGAATGTTTCATAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01108</identifier>
                            <name>Tissue_fac</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2010-09-29">
        <drugbank-id primary="true">DB00038</drugbank-id>
        <drugbank-id>BIOD00021</drugbank-id>
        <drugbank-id>BTD00021</drugbank-id>
        <name>Oprelvekin</name>
        <description>Oprelvekin, the active ingredient in Neumega® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.&#13;
&#13;
            The primary hematopoietic activity of Neumega® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega® has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega® improved platelet nadirs and accelerated platelet recoveries compared to controls.&#13;
&#13;
            In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.</description>
        <cas-number>145941-26-0</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>Increases reduced platelet levels due to chemotherapy</indication>
        <pharmacodynamics>Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Oprelvekin is stimulation of megakaryocytopoiesis and thrombopoiesis. Oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis</pharmacodynamics>
        <mechanism-of-action>Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption>Absolute bioavailability is over 80%.</absorption>
        <half-life>6.9 +/- 1.7 hrs</half-life>
        <protein-binding/>
        <route-of-elimination>The kidney is the primary route of elimination. The amount of intact Neumega in urine was low, indicating that the molecule was metabolized before excretion.</route-of-elimination>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Adipogenesis inhibitory factor</synonym>
            <synonym language="" coder="">AGIF</synonym>
            <synonym language="" coder="">IL-11</synonym>
            <synonym language="" coder="">Interleukin-11 precursor</synonym>
        </synonyms>
        <products/>
        <international-brands/>
        <mixtures/>
        <packagers>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Wyeth Pharmaceuticals</name>
                <url>http://www.wyeth.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Neumega 5 mg vial</description>
                <cost currency="USD">352.9</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antineoplastic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Coagulants</category>
                <mesh-id/>
            </category>
            <category>
                <category>Thrombotic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages/>
        <atc-codes>
            <atc-code code="L03AC02">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AC">Interleukins</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00038 sequence
                GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSA
                GALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQL
                LMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.070</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>11.16</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>19047.2000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C854H1411N253O235S2</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>58394-004-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M57765</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164747991</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P20809</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Oprelvekin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/oprelvek.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/oprelvekin.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000416</id>
                <name>Interleukin-11 receptor subunit alpha</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Nandurkar HH, Robb L, Begley CG: The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor. Stem Cells. 1998;16 Suppl 2:53-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11012177
                    # Li R, Hartley L, Robb L: Cloning of rat interleukin 11 and interleukin 11 receptor alpha chain and analysis of their expression in rat uterus in the peri-implantation period. Reproduction. 2001 Oct;122(4):593-600. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11570967
                    # Nandurkar HH, Hilton DJ, Nathan P, Willson T, Nicola N, Begley CG: The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor. Oncogene. 1996 Feb 1;12(3):585-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8637716
                    # Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996 Jun 1;183(6):2581-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8676079
                    # Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley CG: Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood. 1997 Sep 15;90(6):2148-59. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9310465
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="Q14626" source="Swiss-Prot">
                    <name>Interleukin-11 receptor subunit alpha</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>Receptor for interleukin-11. The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells</specific-function>
                    <gene-name>IL11RA</gene-name>
                    <locus>9p13</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>371-391</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.91</theoretical-pi>
                    <molecular-weight>45223.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5967</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL11RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL11RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>Z38102</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>995654</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q14626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>I11RA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>IL- 11RA</synonym>
                        <synonym>IL-11R-alpha</synonym>
                        <synonym>Interleukin-11 receptor alpha chain precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interleukin-11 receptor alpha chain precursor
                        MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWF
                        RDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSC
                        QAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARC
                        VVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASW
                        TYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLD
                        AGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHR
                        DSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAP
                        NL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1269 bp
                        ATGAGCAGCAGCTGCTCAGGGCTGAGCAGGGTCCTGGTGGCCGTGGCTACAGCCCTGGTG
                        TCTGCCTCCTCCCCCTGCCCCCAGGCCTGGGGCCCCCCAGGGGTCCAGTATGGGCAGCCA
                        GGCAGGTCCGTGAAGCTGTGTTGTCCTGGAGTGACTGCCGGGGACCCAGTGTCCTGGTTT
                        CGGGATGGGGAGCCAAAGCTGCTCCAGGGACCTGACTCTGGGCTAGGGCATGAACTGGTC
                        CTGGCCCAGGCAGACAGCACTGATGAGGGCACCTACATCTGCCAGACCCTGGATGGTGCA
                        CTTGGGGGCACAGTGACCCTGCAGCTGGGCTACCCTCCAGCCCGCCCTGTTGTCTCCTGC
                        CAAGCAGCCGACTATGAGAACTTCTCTTGCACTTGGAGTCCCAGCCAGATCAGCGGTTTA
                        CCCACCCGCTACCTCACCTCCTACAGGAAGAAGACAGTCCTAGGAGCTGATAGCCAGAGG
                        AGGAGTCCATCCACAGGGCCCTGGCCATGCCCACAGGATCCCCTAGGGGCTGCCCGCTGT
                        GTTGTCCACGGGGCTGAGTTCTGGAGCCAGTACCGGATTAATGTGACTGAGGTGAACCCA
                        CTGGGTGCCAGCACACGCCTGCTGGATGTGAGCTTGCAGAGCATCTTGCGCCCTGACCCA
                        CCCCAGGGCCTGCGGGTAGAGTCAGTACCAGGTTACCCCCGACGCCTGCGAGCCAGCTGG
                        ACATACCCTGCCTCCTGGCCGTGCCAGCCCCACTTCCTGCTCAAGTTCCGTTTGCAGTAC
                        CGTCCGGCGCAGCATCCAGCCTGGTCCACGGTGGAGCCAGCTGGACTGGAGGAGGTGATC
                        ACAGATGCTGTGGCTGGGCTGCCCCATGCTGTACGAGTCAGTGCCCGGGACTTTCTAGAT
                        GCTGGCACCTGGAGCACCTGGAGCCCGGAGGCCTGGGGAACTCCGAGCACTGGGACCATA
                        CCAAAGGAGATACCAGCATGGGGCCAGCTACACACGCAGCCAGAGGTGGAGCCTCAGGTG
                        GACAGCCCTGCTCCTCCAAGGCCCTCCCTCCAACCACACCCTCGGCTACTTGATCACAGG
                        GACTCTGTGGAGCAGGTAGCTGTGCTGGCGTCTTTGGGAATCCTTTCTTTCCTGGGACTG
                        GTGGCTGGGGCCCTGGCACTGGGGCTCTGGCTGAGGCTGAGACGGGGTGGGAAGGATGGA
                        TCCCCAAAGCCTGGGTTCTTGGCCTCAGTGATTCCAGTGGACAGGCGTCCAGGAGCTCCA
                        AACCTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-12-01">
        <drugbank-id primary="true">DB00039</drugbank-id>
        <drugbank-id>BIOD00042</drugbank-id>
        <drugbank-id>BTD00042</drugbank-id>
        <name>Palifermin</name>
        <description>Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.</description>
        <cas-number>162394-19-6</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references>#Lexicomp [Internet]. Palifermin. 2014 [cited 1 December 2014]. Available from: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7429#f_interactions</general-references>
        <synthesis-reference/>
        <indication>For treatment of oral mucositis associated with chemotherapy and radiation therapy.</indication>
        <pharmacodynamics>Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.</pharmacodynamics>
        <mechanism-of-action>Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>Elimination half-life: 4.5 hours (range: 3.3-5.7 hours)</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">FGF-7</synonym>
            <synonym language="" coder="">Fibroblast growth factor- 7</synonym>
            <synonym language="" coder="">HBGF-7</synonym>
            <synonym language="" coder="">Keratinocyte growth factor precursor</synonym>
            <synonym language="" coder="">KGF</synonym>
        </synonyms>
        <products>
            <product>
                <name>Kepivance</name>
                <ndc-id>66658-112_1cf1e381-844f-4c03-8c6f-581b0b79b3bf</ndc-id>
                <ndc-product-code>66658-112</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-12-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>6.25 mg/1.2mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA125103</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Kepivance</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02274221</dpd-id>
                <started-marketing-on>2006-03-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>6.25 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Kepivance</name>
                <ingredients>Palifermin</ingredients>
            </mixture>
            <mixture>
                <name>Kepivance</name>
                <ingredients>Palifermin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Amgen Inc.</name>
                <url>http://www.amgen.com</url>
            </packager>
            <packager>
                <name>Baxter International Inc.</name>
                <url>http://www.baxter.com</url>
            </packager>
            <packager>
                <name>BioVitrum AB</name>
                <url>http://www.biovitrum.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Kepivance 6.25 mg vial</description>
                <cost currency="USD">1650.0</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Anti-Mucositis Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>intravenous</route>
                <strength>6.25 mg/1.2mL</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>6.25 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="V03AF08">
                <level code="V">VARIOUS</level>
                <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
                <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
                <level code="V03AF">Detoxifying agents for antineoplastic treatment</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>84:16.00</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>May increase the serum concentration of Palifermin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08813</drugbank-id>
                <name>Nadroparin</name>
                <description>Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06822</drugbank-id>
                <name>Tinzaparin</name>
                <description>Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Palifermin sequence
                SYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVE
                SEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPV
                RGKKTKKEQKTAHFLPMAIT</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.650</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>9.47</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>16192.7000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C721H1142N202O204S9</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>17147</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>55513-520-06</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M60828</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164744014</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P21781</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Palifermin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/kepivance.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/palifermin.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000748</id>
                <name>Fibroblast growth factor receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Beaven AW, Shea TC: Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs Today (Barc). 2007 Jul;43(7):461-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17728847&#13;
                    # Radtke ML, Kolesar JM: Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract. 2005 Sep;11(3):121-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16390600&#13;
                    # Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, Lin YC: Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):24-33. Epub 2006 Jul 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16854582&#13;
                    # Patrie KM, Kudla AJ, Olwin BB, Chiu IM: Conservation of ligand specificity between the mammalian and amphibian fibroblast growth factor receptors. J Biol Chem. 1995 Dec 1;270(48):29018-24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7499435&#13;
                    # Cardoso WV, Itoh A, Nogawa H, Mason I, Brody JS: FGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epithelium. Dev Dyn. 1997 Mar;208(3):398-405. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9056643&#13;
                    # Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10593896&#13;
                    # Zhu X, Lee K, Asa SL, Ezzat S: Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol. 2007 May;170(5):1618-28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17456767&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P21802" source="Swiss-Prot">
                    <name>Fibroblast growth factor receptor 2</name>
                    <general-function>Involved in protein kinase activity</general-function>
                    <specific-function>Receptor for acidic and basic fibroblast growth factors</specific-function>
                    <gene-name>FGFR2</gene-name>
                    <locus>10q26</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. Isoform 14:Secreted protein. Isoform 19:Secreted</cellular-location>
                    <transmembrane-regions>378-398</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.68</theoretical-pi>
                    <molecular-weight>92026.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3689</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGFR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGFR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X52832</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31374</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P21802</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FGFR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD332 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>FGFR-2</synonym>
                        <synonym>Fibroblast growth factor receptor 2 precursor</synonym>
                        <synonym>Keratinocyte growth factor receptor 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Fibroblast growth factor receptor 2 precursor
                        MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEV
                        RCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYF
                        MVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP
                        AGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSI
                        NHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSK
                        YGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL
                        PAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTK
                        RIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDK
                        LTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKM
                        IGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTF
                        KDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKT
                        TNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGH
                        RMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYS
                        PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2466 bp
                        ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTG
                        GCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACC
                        AAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCACCAGGGGAGTCGCTAGAGGTG
                        CGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGG
                        CCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGA
                        GACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTGGTACTTC
                        ATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCG
                        GAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAA
                        AAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTTTCGCTGCCCA
                        GCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAG
                        GAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGT
                        GTGGTCCCATCTGACAAGGGAAATTATACCTGTGTGGTGGAGAATGAATACGGGTCCATC
                        AATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCC
                        GGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTT
                        TACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGAAAAGAACGGCAGTAAA
                        TACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCGCCGGTGTTAACACCACG
                        GACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTTGAGGACGCTGGGGAATAT
                        ACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTCTGCATGGTTGACAGTTCTG
                        CCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATT
                        TACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATG
                        AAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCACAAGCTGACCAAA
                        CGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCC
                        AACACCCCGCTGGTGAGGATAACAACACGCCTCTCTTCAACGGCAGACACCCCCATGCTG
                        GCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGAGATAAG
                        CTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCA
                        GTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAA
                        GATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATG
                        ATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTC
                        TATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGG
                        CCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATGACCTTC
                        AAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAA
                        AAATGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATG
                        AAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACC
                        ACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATAC
                        ACTCATCAGAGTGATGTCTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGG
                        GGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACAC
                        AGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGG
                        CATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATT
                        CTCACTCTCACAACCAATGAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCA
                        CCTAGTTACCCTGACACAAGAAGTTCTTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCA
                        GACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAA
                        ACATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002129</id>
                <name>Neuropilin-1</name>
                <organism>Human</organism>
                <actions/>
                <references># Beer HD, Vindevoghel L, Gait MJ, Revest JM, Duan DR, Mason I, Dickson C, Werner S: Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem. 2000 May 26;275(21):16091-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10821861&#13;
                    # Friedl A, Chang Z, Tierney A, Rapraeger AC: Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am J Pathol. 1997 Apr;150(4):1443-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9094999&#13;
                    # Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL: Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry. 1999 Jan 5;38(1):160-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9890894</references>
                <known-action>unknown</known-action>
                <polypeptide id="O14786" source="Swiss-Prot">
                    <name>Neuropilin-1</name>
                    <general-function/>
                    <specific-function>The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. It may also induce apoptosis by sequestering VEGF-165. May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity</specific-function>
                    <gene-name>NRP1</gene-name>
                    <locus>10p12</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>857-879</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.71</theoretical-pi>
                    <molecular-weight>103121.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:8004</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>NRP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>NRP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF018956</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>2407641</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O14786</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>NRP1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD304 antigen</synonym>
                        <synonym>Neuropilin-1 precursor</synonym>
                        <synonym>Vascular endothelial cell growth factor 165 receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Neuropilin-1
                        MERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQA
                        PDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLF
                        IKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFAP
                        KMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSS
                        GILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTN
                        WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKI
                        DVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFE
                        VYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSY
                        INEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSF
                        EGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLV
                        DECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEFGWGSHKTF
                        CHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAH
                        CMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVI
                        FEGEIGKGNLGGIAVDDISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGD
                        KNISRKPGNVLKTLEPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSERNLSALENYN
                        FELVDGVKLKKDKLNTQSTYSEA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2772 bp
                        ATGGAGAGGGGGCTGCCGCTCCTCTGCGCCGTGCTCGCCCTCGTCCTCGCCCCGGCCGGC
                        GCTTTTCGCAACGATGAATGTGGCGATACTATAAAAATTGAAAGCCCCGGGTACCTTACA
                        TCTCCTGGTTATCCTCATTCTTATCACCCAAGTGAAAAATGCGAATGGCTGATTCAGGCT
                        CCGGACCCATACCAGAGAATTATGATCAACTTCAACCCTCACTTCGATTTGGAGGACAGA
                        GACTGCAAGTATGACTACGTGGAAGTCTTCGATGGAGAAAATGAAAATGGACATTTTAGG
                        GGAAAGTTCTGTGGAAAGATAGCCCCTCCTCCTGTTGTGTCTTCAGGGCCATTTCTTTTT
                        ATCAAATTTGTCTCTGACTACGAAACACATGGTGCAGGATTTTCCATACGTTATGAAATT
                        TTCAAGAGAGGTCCTGAATGTTCCCAGAACTACACAACACCTAGTGGAGTGATAAAGTCC
                        CCCGGATTCCCTGAAAAATATCCCAACAGCCTTGAATGCACTTATATTGTCTTTGCGCCA
                        AAGATGTCAGAGATTATCCTGGAATTTGAAAGCTTTGACCTGGAGCCTGACTCAAATCCT
                        CCAGGGGGGATGTTCTGTCGCTACGACCGGCTAGAAATCTGGGATGGATTCCCTGATGTT
                        GGCCCTCACATTGGGCGTTACTGTGGACAGAAAACACCAGGTCGAATCCGATCCTCATCG
                        GGCATTCTCTCCATGGTTTTTTACACCGACAGCGCGATAGCAAAAGAAGGTTTCTCAGCA
                        AACTACAGTGTCTTGCAGAGCAGTGTCTCAGAAGATTTCAAATGTATGGAAGCTCTGGGC
                        ATGGAATCAGGAGAAATTCATTCTGACCAGATCACAGCTTCTTCCCAGTATAGCACCAAC
                        TGGTCTGCAGAGCGCTCCCGCCTGAACTACCCTGAGAATGGGTGGACTCCCGGAGAGGAT
                        TCCTACCGAGAGTGGATACAGGTAGACTTGGGCCTTCTGCGCTTTGTCACGGCTGTCGGG
                        ACACAGGGCGCCATTTCAAAAGAAACCAAGAAGAAATATTATGTCAAGACTTACAAGATC
                        GACGTTAGCTCCAACGGGGAAGACTGGATCACCATAAAAGAAGGAAACAAACCTGTTCTC
                        TTTCAGGGAAACACCAACCCCACAGATGTTGTGGTTGCAGTATTCCCCAAACCACTGATA
                        ACTCGATTTGTCCGAATCAAGCCTGCAACTTGGGAAACTGGCATATCTATGAGATTTGAA
                        GTATACGGTTGCAAGATAACAGATTATCCTTGCTCTGGAATGTTGGGTATGGTGTCTGGA
                        CTTATTTCTGACTCCCAGATCACATCATCCAACCAAGGAGACAGAAACTGGATGCCTGAA
                        AACATCCGCCTGGTAACCAGTCGCTCTGGCTGGGCACTTCCACCCGCACCTCATTCCTAC
                        ATCAATGAGTGGCTCCAAATAGACCTGGGGGAGGAGAAGATCGTGAGGGGCATCATCATT
                        CAGGGTGGGAAGCACCGAGAGAACAAGGTGTTCATGAGGAAGTTCAAGATCGGGTACAGC
                        AACAACGGCTCGGACTGGAAGATGATCATGGATGACAGCAAACGCAAGGCGAAGTCTTTT
                        GAGGGCAACAACAACTATGATACACCTGAGCTGCGGACTTTTCCAGCTCTCTCCACGCGA
                        TTCATCAGGATCTACCCCGAGAGAGCCACTCATGGCGGACTGGGGCTCAGAATGGAGCTG
                        CTGGGCTGTGAAGTGGAAGCCCCTACAGCTGGACCGACCACTCCCAACGGGAACTTGGTG
                        GATGAATGTGATGACGACCAGGCCAACTGCCACAGTGGAACAGGTGATGACTTCCAGCTC
                        ACAGGTGGCACCACTGTGCTGGCCACAGAAAAGCCCACGGTCATAGACAGCACCATACAA
                        TCAGAGTTTCCAACATATGGTTTTAACTGTGAATTTGGCTGGGGCTCTCACAAGACCTTC
                        TGCCACTGGGAACATGACAATCACGTGCAGCTCAAGTGGAGTGTGTTGACCAGCAAGACG
                        GGACCCATTCAGGATCACACAGGAGATGGCAACTTCATCTATTCCCAAGCTGACGAAAAT
                        CAGAAGGGCAAAGTGGCTCGCCTGGTGAGCCCTGTGGTTTATTCCCAGAACTCTGCCCAC
                        TGCATGACCTTCTGGTATCACATGTCTGGGTCCCACGTCGGCACACTCAGGGTCAAACTG
                        CGCTACCAGAAGCCAGAGGAGTACGATCAGCTGGTCTGGATGGCCATTGGACACCAAGGT
                        GACCACTGGAAGGAAGGGCGTGTCTTGCTCCACAAGTCTCTGAAACTTTATCAGGTGATT
                        TTCGAGGGCGAAATCGGAAAAGGAAACCTTGGTGGGATTGCTGTGGATGACATTAGTATT
                        AATAACCACATTTCACAAGAAGATTGTGCAAAACCAGCAGACCTGGATAAAAAGAACCCA
                        GAAATTAAAATTGATGAAACAGGGAGCACGCCAGGATACGAAGGTGAAGGAGAAGGTGAC
                        AAGAACATCTCCAGGAAGCCAGGCAATGTGTTGAAGACCTTAGAACCCATCCTCATCACC
                        ATCATAGCCATGAGCGCCCTGGGGGTCCTCCTGGGGGCTGTCTGTGGGGTCGTGCTGTAC
                        TGTGCCTGTTGGCATAATGGGATGTCAGAAAGAAACTTGTCTGCCCTGGAGAACTATAAC
                        TTTGAACTTGTGGATGGTGTGAAGTTGAAAAAAGACAAACTGAATACACAGAGTACTTAT
                        TCGGAGGCATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00754</identifier>
                            <name>F5_F8_type_C</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00629</identifier>
                            <name>MAM</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell adhesion</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002131</id>
                <name>Fibroblast growth factor receptor 1</name>
                <organism>Human</organism>
                <actions/>
                <references># Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D: Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem. 2002 Jan 25;277(4):2444-53. Epub 2001 Nov 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11714710&#13;
                    # Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2000 Nov 10;275(45):34881-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10950949&#13;
                    # Matsubara A, Yasumoto H, Usui T: Hormone Refractory Prostate Cancer and Fibroblast Growth Factor Receptor. Breast Cancer. 1999 Oct 25;6(4):320-324. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11091737&#13;
                    # Lu W, Luo Y, Kan M, McKeehan WL: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 1999 Apr 30;274(18):12827-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10212269&#13;
                    # Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL: Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry. 1999 Jan 5;38(1):160-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9890894</references>
                <known-action>unknown</known-action>
                <polypeptide id="P11362" source="Swiss-Prot">
                    <name>Fibroblast growth factor receptor 1</name>
                    <general-function/>
                    <specific-function>Receptor for basic fibroblast growth factor. A shorter form of the receptor could be a receptor for FGF1 (aFGF)</specific-function>
                    <gene-name>FGFR1</gene-name>
                    <locus>8p11.2-p11.1</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>377-397</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.14</theoretical-pi>
                    <molecular-weight>91869.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3688</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGFR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGFR1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X51803</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31368</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P11362</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FGFR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Basic fibroblast growth factor receptor 1 precursor</synonym>
                        <synonym>bFGF-R</synonym>
                        <synonym>c-fgr</synonym>
                        <synonym>CD331 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>FGFR-1</synonym>
                        <synonym>Fms-like tyrosine kinase 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Basic fibroblast growth factor receptor 1
                        MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDD
                        VQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSD
                        ALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPS
                        SGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSIN
                        HTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKI
                        GPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE
                        ALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKS
                        IPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVL
                        GKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGK
                        HKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDL
                        VSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNG
                        RLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMD
                        KPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSF
                        PDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2469 bp
                        ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACC
                        GCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTG
                        GAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGAT
                        GTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGC
                        ATCACAGGGGAGGAGGTGGAGGTGCAGGACTCCGTGCCCGCAGACTCCGGCCTCTATGCT
                        TGCGTAACCAGCAGCCCCTCGGGCAGTGACACCACCTACTTCTCCGTCAATGTTTCAGAT
                        GCTCTCCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAA
                        ACAGATAACACCAAACCAAACCGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAG
                        ATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCC
                        AGTGGGACCCCAAACCCCACACTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGAC
                        CACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTG
                        GTGCCCTCTGACAAGGGCAACTACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAAC
                        CACACATACCAGCTGGATGTCGTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGG
                        TTGCCCGCCAACAAAACAGTGGCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTAC
                        AGTGACCCGCAGCCGCACATCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATT
                        GGCCCAGACAACCTGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGAC
                        AAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGACGCAGGGGAGTATACG
                        TGCTTGGCGGGTAACTCTATCGGACTCTCCCATCACTCTGCATGGTTGACCGTTCTGGAA
                        GCCCTGGAAGAGAGGCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTAT
                        TGCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCTACAAGATGAAG
                        AGTGGTACCAAGAAGAGTGACTTCCACAGCCAGATGGCTGTGCACAAGCTGGCCAAGAGC
                        ATCCCTCTGCGCAGACAGGTAACAGTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGG
                        GTTCTTCTGGTTCGGCCATCACGGCTCTCCTCCAGTGGGACTCCCATGCTAGCAGGGGTC
                        TCTGAGTATGAGCTTCCCGAAGACCCTCGCTGGGAGCTGCCTCGGGACAGACTGGTCTTA
                        GGCAAACCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGAGGCTATCGGGCTG
                        GACAAGGACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTCGGACGCA
                        ACAGAGAAAGACTTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGATCGGGAAG
                        CATAAGAATATCATCAACCTGCTGGGGGCCTGCACGCAGGATGGTCCCTTGTATGTCATC
                        GTGGAGTATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGCCCCCAGGG
                        CTGGAATACTGCTACAACCCCAGCCACAACCCAGAGGAGCAGCTCTCCTCCAAGGACCTG
                        GTGTCCTGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCTGGCCTCCAAGAAGTGCATA
                        CACCGAGACCTGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAGATAGCA
                        GACTTTGGCCTCGCACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGC
                        CGACTGCCTGTGAAGTGGATGGCACCCGAGGCATTATTTGACCGGATCTACACCCACCAG
                        AGTGATGTGTGGTCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCA
                        TACCCCGGTGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGAC
                        AAGCCCAGTAACTGCACCAACGAGCTGTACATGATGATGCGGGACTGCTGGCATGCAGTG
                        CCCTCACAGAGACCCACCTTCAAGCAGCTGGTGGAAGACCTGGACCGCATCGTGGCCTTG
                        ACCTCCAACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTCCCCCAGCTTT
                        CCCGACACCCGGAGCTCTACGTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCG
                        CTGCCCGAGGAGCCCTGCCTGCCCCGACACCCAGCCCAGCTTGCCAATCGGGGACTCAAA
                        CGCCGCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07679</identifier>
                            <name>I-set</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0001203</id>
                <name>Fibroblast growth factor receptor 4</name>
                <organism>Human</organism>
                <actions/>
                <references># Imagawa W, Cunha GR, Young P, Nandi S: Keratinocyte growth factor and acidic fibroblast growth factor are mitogens for primary cultures of mammary epithelium. Biochem Biophys Res Commun. 1994 Nov 15;204(3):1165-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7526860&#13;
                    # Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2000 Nov 10;275(45):34881-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10950949&#13;
                    # Sannes PL, Khosla J, Li CM, Pagan I: Sulfation of extracellular matrices modifies growth factor effects on type II cells on laminin substrata. Am J Physiol. 1998 Oct;275(4 Pt 1):L701-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9755102&#13;
                    # Luo Y, Lu W, Mohamedali KA, Jang JH, Jones RB, Gabriel JL, Kan M, McKeehan WL: The glycine box: a determinant of specificity for fibroblast growth factor. Biochemistry. 1998 Nov 24;37(47):16506-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9843417&#13;
                    # Yamanaka T, Sakamoto A, Tanaka Y, Zhang Y, Hayashido Y, Toratani S, Akagawa Y, Okamoto T: Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament. In Vitro Cell Dev Biol Anim. 2000 Sep;36(8):548-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11149756</references>
                <known-action>unknown</known-action>
                <polypeptide id="P22455" source="Swiss-Prot">
                    <name>Fibroblast growth factor receptor 4</name>
                    <general-function>Involved in protein kinase activity</general-function>
                    <specific-function>Receptor for acidic fibroblast growth factor. Does not bind to basic fibroblast growth factor. Binds FGF19</specific-function>
                    <gene-name>FGFR4</gene-name>
                    <locus>5q35.1-qter</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>370-390</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.81</theoretical-pi>
                    <molecular-weight>87955.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3691</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGFR4</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGFR4</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X57205</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31372</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P22455</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FGFR4_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD334 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>FGFR-4</synonym>
                        <synonym>Fibroblast growth factor receptor 4 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Fibroblast growth factor receptor 4 precursor
                        MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRA
                        ERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDS
                        LTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTP
                        TIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLD
                        VLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFP
                        YVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTA
                        AAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSL
                        ESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQ
                        VVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVC
                        TQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGM
                        QYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEA
                        LFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYG
                        LMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDS
                        VFSHDPLPLGSSSFPFGSGVQT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2409 bp
                        ATGCGGCTGCTGCTGGCCCTGTTGGGGGTCCTGCTGAGTGTGCCTGGGCCTCCAGTCTTG
                        TCCCTGGAGGCCTCTGAGGAAGTGGAGCTTGAGCCCTGCCTGGCTCCCAGCCTGGAGCAG
                        CAAGAGCAGGAGCTGACAGTAGCCCTTGGGCAGCCTGTGCGTCTGTGCTGTGGGCGGGCT
                        GAGCGTGGTGGCCACTGGTACAAGGAGGGCAGTCGCCTGGCACCTGCTGGCCGTGTACGG
                        GGCTGGAGGGGCCGCCTAGAGATTGCCAGCTTCCTACCTGAGGATGCTGGCCGCTACCTC
                        TGCCTGGCACGAGGCTCCATGATCGTCCTGCAGAATCTCACCTTGATTACAGGTGACTCC
                        TTGACCTCCAGCAACGATGATGAGGACCCCAAGTCCCATAGGGACCCCTCGAATAGGCAC
                        AGTTACCCCCAGCAAGCACCCTACTGGACACACCCCCAGCGCATGGAGAAGAAACTGCAT
                        GCAGTACCTGCGGGGAACACCGTCAAGTTCCGCTGTCCAGCTGCAGGCAACCCCACGCCC
                        ACCATCCGCTGGCTTAAGGATGGACAGGCCTTTCATGGGGAGAACCGCATTGGAGGCATT
                        CGGCTGCGCCATCAGCACTGGAGTCTCGTGATGGAGAGCGTGGTGCCCTCGGACCGCGGC
                        ACATACACCTGCCTGGTAGAGAACGCTGTGGGCAGCATCCGCTATAACTACCTGCTAGAT
                        GTGCTGGAGCGGTCCCCGCACCGGCCCATCCTGCAGGCCGGGCTCCCGGCCAACACCACA
                        GCCGTGGTGGGCAGCGACGTGGAGCTGCTGTGCAAGGTGTACAGCGATGCCCAGCCCCAC
                        ATCCAGTGGCTGAAGCACATCGTCATCAACGGCAGCAGCTTCGGAGCCGTCGGTTTCCCC
                        TATGTGCAAGTCCTAAAGACTGCAGACATCAATAGCTCAGAGGTGGAGGTCCTGTACCTG
                        CGGAACGTGTCAGCCGAGGACGCAGGCGAGTACACCTGCCTCGCAGGCAATTCCATCGGC
                        CTCTCCTACCAGTCTGCCTGGCTCACGGTGCTGCCAGAGGAGGACCCCACATGGACCGCA
                        GCAGCGCCCGAGGCCAGGTATACGGACATCATCCTGTACGCGTCGGGCTCCCTGGCCTTG
                        GCTGTGCTCCTGCTGCTGGCCGGGCTGTATCGAGGGCAGGCGCTCCACGGCCGGCACCCC
                        CGCCCGCCCGCCACTGTGCAGAAGCTCTCCCGCTTCCCTCTGGCCCGACAGTTCTCCCTG
                        GAGTCAGGCTCTTCCGGCAAGTCAAGCTCATCCCTGGTACGAGGCGTGCGTCTCTCCTCC
                        AGCGGCCCCGCCTTGCTCGCCGGCCTCGTGAGTCTAGATCTACCTCTCGACCCACTATGG
                        GAGTTCCCCCGGGACAGGCTGGTGCTTGGGAAGCCCCTAGGCGAGGGCTGCTTTGGCCAG
                        GTAGTACGTGCAGAGGCCTTTGGCATGGACCCTGCCCGGCCTGACCAAGCCAGCACTGTG
                        GCCGTCAAGATGCTCAAAGACAACGCCTCTGACAAGGACCTGGCCGACCTGGTCTCGGAG
                        ATGGAGGTGATGAAGCTGATCGGCCGACACAAGAACATCATCAACCTGCTTGGTGTCTGC
                        ACCCAGGAAGGGCCCCTGTACGTGATCGTGGAGTGCGCCGCCAAGGGAAACCTGCGGGAG
                        TTCCTGCGGGCCCGGCGCCCCCCAGGCCCCGACCTCAGCCCCGACGGTCCTCGGAGCAGT
                        GAGGGGCCGCTCTCCTTCCCAGTCCTGGTCTCCTGCGCCTACCAGGTGGCCCGAGGCATG
                        CAGTATCTGGAGTCCCGGAAGTGTATCCACCGGGACCTGGCTGCCCGCAATGTGCTGGTG
                        ACTGAGGACAATGTGATGAAGATTGCTGACTTTGGGCTGGCCCGCGGCGTCCACCACATT
                        GACTACTATAAGAAAACCAGCAACGGCCGCCTGCCTGTGAAGTGGATGGCGCCCGAGGCC
                        TTGTTTGACCGGGTGTACACACACCAGAGTGACGTGTGGTCTTTTGGGATCCTGCTATGG
                        GAGATCTTCACCCTCGGGGGCTCCCCGTATCCTGGCATCCCGGTGGAGGAGCTGTTCTCG
                        CTGCTGCGGGAGGGACATCGGATGGACCGACCCCCACACTGCCCCCCAGAGCTGTACGGG
                        CTGATGCGTGAGTGCTGGCACGCAGCGCCCTCCCAGAGGCCTACCTTCAAGCAGCTGGTG
                        GAGGCGCTGGACAAGGTCCTGCTGGCCGTCTCTGAGGAGTACCTCGACCTCCGCCTGACC
                        TTCGGACCCTATTCCCCCTCTGGTGGGGACGCCAGCAGCACCTGCTCCTCCAGCGATTCT
                        GTCTTCAGCCACGACCCCCTGCCATTGGGATCCAGCTCCTTCCCCTTCGGGTCTGGGGTG
                        CAGACATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07679</identifier>
                            <name>I-set</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002133</id>
                <name>Fibroblast growth factor receptor 3</name>
                <organism>Human</organism>
                <actions/>
                <references># Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF: Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int. 2001 Jul;60(1):147-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11422746&#13;
                    # Yamanaka T, Sakamoto A, Tanaka Y, Zhang Y, Hayashido Y, Toratani S, Akagawa Y, Okamoto T: Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament. In Vitro Cell Dev Biol Anim. 2000 Sep;36(8):548-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11149756&#13;
                    # Beer HD, Vindevoghel L, Gait MJ, Revest JM, Duan DR, Mason I, Dickson C, Werner S: Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem. 2000 May 26;275(21):16091-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10821861&#13;
                    # Launay C, Fromentoux V, Thery C, Shi DL, Boucaut JC: Comparative analysis of the tissue distribution of three fibroblast growth factor receptor mRNAs during amphibian morphogenesis. Differentiation. 1994 Dec;58(2):101-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7890137&#13;
                    # Mummery CL, van Rooyen M, Bracke M, van den Eijnden-van Raaij J, van Zoelen EJ, Alitalo K: Fibroblast growth factor-mediated growth regulation and receptor expression in embryonal carcinoma and embryonic stem cells and human germ cell tumours. Biochem Biophys Res Commun. 1993 Feb 26;191(1):188-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7680555</references>
                <known-action>unknown</known-action>
                <polypeptide id="P22607" source="Swiss-Prot">
                    <name>Fibroblast growth factor receptor 3</name>
                    <general-function/>
                    <specific-function>Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1</specific-function>
                    <gene-name>FGFR3</gene-name>
                    <locus>4p16.3</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>376-396</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.73</theoretical-pi>
                    <molecular-weight>87710.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3690</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FGFR3</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FGFR3</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M58051</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182569</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P22607</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FGFR3_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD333 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>FGFR-3</synonym>
                        <synonym>Fibroblast growth factor receptor 3 precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Fibroblast growth factor receptor 3
                        MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS
                        CPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH
                        FSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG
                        NPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT
                        YTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
                        DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAE
                        EELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLK
                        RQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGE
                        GCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIIN
                        LLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
                        VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKW
                        MAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCT
                        HDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSS
                        SSSGDDSVFAHDLLPPAPPSSGGSRT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2421 bp
                        ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCC
                        TCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCGGGC
                        CCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCTGAGC
                        TGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG
                        CTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCC
                        CACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCAC
                        TTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGGAGGACGAG
                        GCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAGCGGATGGAC
                        AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCCAGCCGCTGGC
                        AACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGC
                        ATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAAAGCGTGGTGCCC
                        TCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
                        TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCG
                        GCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGAC
                        GCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAACGGCAGCAAGGTGGGCCCG
                        GACGGCACACCCTACGTTACCGTGCTCAAGACGGCGGGCGCTAACACCACCGACAAGGAG
                        CTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCCGGGGAGTACACCTGCCTG
                        GCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCTGGTGGTGCTGCCAGCCGAG
                        GAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATGCAGGCATCCTCAGCTACGGG
                        GTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGC
                        CCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAG
                        CGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATC
                        GCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCCAATGTCTCCGAGCTCGAGCTGCCT
                        GCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCTTGGGGAG
                        GGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCC
                        AAGCCTGTCACCGTAGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCG
                        GACCTGGTGTCTGAGATGGAGATGATGAAGATGATCGGGAAACACAAAAACATCATCAAC
                        CTGCTGGGCGCCTGCACGCAGGGCGGGCCCCTGTACGTGCTGGTGGAGTACGCGGCCAAG
                        GGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGCCCCCGGGCCTGGACTACTCCTTCGAC
                        ACCTGCAAGCCGCCCGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTACCAG
                        GTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGAAGTGCATCCACAGGGACCTGGCTGCC
                        CGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTGGCCCGG
                        GACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGG
                        ATGGCGCCTGAGGCCTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCCTTT
                        GGGGTCCTGCTCTGGGAGATCTTCACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTG
                        GAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACA
                        CACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACC
                        TTCAAGCAGCTGGTGGAGGACCTGGACCGTGTCCTTACCGTGACGTCCACCGACGAGTAC
                        CTGGACCTGTCGGCGCCTTTCGAGCAGTACTCCCCGGGTGGCCAGGACACCCCCAGCTCC
                        AGCTCCTCAGGGGACGACTCCGTGTTTGCCCACGACCTGCTGCCCCCGGCCCCACCCAGC
                        AGTGGGGGCTCGCGGACGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07679</identifier>
                            <name>I-set</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0001031</id>
                <name>Basement membrane-specific heparan sulfate proteoglycan core protein</name>
                <organism>Human</organism>
                <actions/>
                <references># Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10593896&#13;
                    # Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV: Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998 Oct 15;102(8):1599-608. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9788974&#13;
                    # Iwabuchi T, Goetinck PF: Syndecan-4 dependent FGF stimulation of mouse vibrissae growth. Mech Dev. 2006 Nov;123(11):831-41. Epub 2006 Aug 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16989989&#13;
                    # Asada N, Tanaka Y, Hayashido Y, Toratani S, Kan M, Kitamoto M, Nakanishi T, Kajiyama G, Chayama K, Okamoto T: Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines. In Vitro Cell Dev Biol Anim. 2003 Jul-Aug;39(7):321-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14753849</references>
                <known-action>unknown</known-action>
                <polypeptide id="P98160" source="Swiss-Prot">
                    <name>Basement membrane-specific heparan sulfate proteoglycan core protein</name>
                    <general-function>Involved in protein binding and cell adhesion</general-function>
                    <specific-function>This protein is an integral component of basement membranes. It is responsible for the fixed negative electrostatic charge and is involved in the charge-selective ultrafiltration properties. It serves as an attachment substrate for cells</specific-function>
                    <gene-name>HSPG2</gene-name>
                    <locus>1p36.1-p34</locus>
                    <cellular-location>Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.49</theoretical-pi>
                    <molecular-weight>468829.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5273</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>HSPG2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>HSPG2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X62515</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29470</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P98160</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PGBM_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Basement membrane-specific heparan sulfate proteoglycan core protein precursor</synonym>
                        <synonym>HSPG</synonym>
                        <synonym>Perlecan</synonym>
                        <synonym>PLC</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Basement membrane-specific heparan sulfate proteoglycan core protein precursor
                        MGWRAPGALLLALLLHGRLLAVTHGLRAYDGLSLPEDIETVTASQMRWTHSYLSDDEDML
                        ADSISGDDLGSGDLGSGDFQMVYFRALVNFTRSIEYSPQLEDAGSREFREVSEAVVDTLE
                        SEYLKIPGDQVVSVVFIKELDGWVFVELDVGSEGNADGAQIQEMLLRVISSGSVASYVTS
                        PQGFQFRRLGTVPQFPRACTEAEFACHSYNECVALEYRCDRRPDCRDMSDELNCEEPVLG
                        ISPTFSLLVETTSLPPRPETTIMRQPPVTHAPQPLLPGSVRPLPCGPQEAACRNGHCIPR
                        DYLCDGQEDCEDGSDELDCGPPPPCEPNEFPCGNGHCALKLWRCDGDFDCEDRTDEANCP
                        TKRPEEVCGPTQFRCVSTNMCIPASFHCDEESDCPDRSDEFGCMPPQVVTPPRESIQASR
                        GQTVTFTCVAIGVPTPIINWRLNWGHIPSHPRVTVTSEGGRGTLIIRDVKESDQGAYTCE
                        AMNARGMVFGIPDGVLELVPQRGPCPDGHFYLEHSAACLPCFCFGITSVCQSTRRFRDQI
                        RLRFDQPDDFKGVNVTMPAQPGTPPLSSTQLQIDPSLHEFQLVDLSRRFLVHDSFWALPE
                        QFLGNKVDSYGGSLRYNVRYELARGMLEPVQRPDVVLVGAGYRLLSRGHTPTQPGALNQR
                        QVQFSEEHWVHESGRPVQRAELLQVLQSLEAVLIQTVYNTKMASVGLSDIAMDTTVTHAT
                        SHGRAHSVEECRCPIGYSGLSCESCDAHFTRVPGGPYLGTCSGCSCNGHASSCDPVYGHC
                        LNCQHNTEGPQCNKCKAGFFGDAMKATATSCRPCPCPYIDASRRFSDTCFLDTDGQATCD
                        ACAPGYTGRRCESCAPGYEGNPIQPGGKCRPVNQEIVRCDERGSMGTSGEACRCKNNVVG
                        RLCNECADGSFHLSTRNPDGCLKCFCMGVSRHCTSSSWSRAQLHGASEEPGHFSLTNAAS
                        THTTNEGIFSPTPGELGFSSFHRLLSGPYFWSLPSRFLGDKVTSYGGELRFTVTQRSQPG
                        STPLHGQPLVVLQGNNIILEHHVAQEPSPGQPSTFIVPFREQAWQRPDGQPATREHLLMA
                        LAGIDTLLIRASYAQQPAESRVSGISMDVAVPEETGQDPALEVEQCSCPPGYRGPSCQDC
                        DTGYTRTPSGLYLGTCERCSCHGHSEACEPETGACQGCQHHTEGPRCEQCQPGYYGDAQR
                        GTPQDCQLCPCYGDPAAGQAAHTCFLDTDGHPTCDACSPGHSGRHCERCAPGYYGNPSQG
                        QPCQRDSQVPGPIGCNCDPQGSVSSQCDAAGQCQCKAQVEGLTCSHCRPHHFHLSASNPD
                        GCLPCFCMGITQQCASSAYTRHLISTHFAPGDFQGFALVNPQRNSRLTGEFTVEPVPEGA
                        QLSFGNFAQLGHESFYWQLPETYQGDKVAAYGGKLRYTLSYTAGPQGSPLSDPDVQITGN
                        NIMLVASQPALQGPERRSYEIMFREEFWRRPDGQPATREHLLMALADLDELLIRATFSSV
                        PLVASISAVSLEVAQPGPSNRPRALEVEECRCPPGYIGLSCQDCAPGYTRTGSGLYLGHC
                        ELCECNGHSDLCHPETGACSQCQHNAAGEFCELCAPGYYGDATAGTPEDCQPCACPLTNP
                        ENMFSRTCESLGAGGYRCTACEPGYTGQYCEQCGPGYVGNPSVQGGQCLPETNQAPLVVE
                        VHPARSIVPQGGSHSLRCQVSGSPPHYFYWSREDGRPVPSGTQQRHQGSELHFPSVQPSD
                        AGVYICTCRNLHQSNTSRAELLVTEAPSKPITVTVEEQRSQSVRPGADVTFICTAKSKSP
                        AYTLVWTRLHNGKLPTRAMDFNGILTIRNVQLSDAGTYVCTGSNMFAMDQGTATLHVQAS
                        GTLSAPVVSIHPPQLTVQPGQLAEFRCSATGSPTPTLEWTGGPGGQLPAKAQIHGGILRL
                        PAVEPTDQAQYLCRAHSSAGQQVARAVLHVHGGGGPRVQVSPERTQVHAGRTVRLYCRAA
                        GVPSATITWRKEGGSLPPQARSERTDIATLLIPAITTADAGFYLCVATSPAGTAQARIQV
                        VVLSASDASPPPVKIESSSPSVTEGQTLDLNCVVAGSAHAQVTWYRRGGSLPPHTQVHGS
                        RLRLPQVSPADSGEYVCRVENGSGPKEASITVSVLHGTHSGPSYTPVPGSTRPIRIEPSS
                        SHVAEGQTLDLNCVVPGQAHAQVTWHKRGGSLPARHQTHGSLLRLHQVTPADSGEYVCHV
                        VGTSGPLEASVLVTIEASVIPGPIPPVRIESSSSTVAEGQTLDLSCVVAGQAHAQVTWYK
                        RGGSLPARHQVRGSRLYIFQASPADAGQYVCRASNGMEASITVTVTGTQGANLAYPAGST
                        QPIRIEPSSSQVAEGQTLDLNCVVPGQSHAQVTWHKRGGSLPVRHQTHGSLLRLYQASPA
                        DSGEYVCRVLGSSVPLEASVLVTIEPAGSVPALGVTPTVRIESSSSQVAEGQTLDLNCLV
                        AGQAHAQVTWHKRGGSLPARHQVHGSRLRLLQVTPADSGEYVCRVVGSSGTQEASVLVTI
                        QQRLSGSHSQGVAYPVRIESSSASLANGHTLDLNCLVASQAPHTITWYKRGGSLPSRHQI
                        VGSRLRIPQVTPADSGEYVCHVSNGAGSRETSLIVTIQGSGSSHVPSVSPPIRIESSSPT
                        VVEGQTLDLNCVVARQPQAIITWYKRGGSLPSRHQTHGSHLRLHQMSVADSGEYVCRANN
                        NIDALEASIVISVSPSAGSPSAPGSSMPIRIESSSSHVAEGETLDLNCVVPGQAHAQVTW
                        HKRGGSLPSHHQTRGSRLRLHHVSPADSGEYVCRVMGSSGPLEASVLVTIEASGSSAVHV
                        PAPGGAPPIRIEPSSSRVAEGQTLDLKCVVPGQAHAQVTWHKRGGNLPARHQVHGPLLRL
                        NQVSPADSGEYSCQVTGSSGTLEASVLVTIEPSSPGPIPAPGLAQPIYIEASSSHVTEGQ
                        TLDLNCVVPGQAHAQVTWYKRGGSLPARHQTHGSQLRLHLVSPADSGEYVCRAASGPGPE
                        QEASFTVTVPPSEGSSYRLRSPVISIDPPSSTVQQGQDASFKCLIHDGAAPISLEWKTRN
                        QELEDNVHISPNGSIITIVGTRPSNHGTYRCVASNAYGVAQSVVNLSVHGPPTVSVLPEG
                        PVWVKVGKAVTLECVSAGEPRSSARWTRISSTPAKLEQRTYGLMDSHAVLQISSAKPSDA
                        GTYVCLAQNALGTAQKQVEVIVDTGAMAPGAPQVQAEEAELTVEAGHTATLRCSATGSPA
                        PTIHWSKLRSPLPWQHRLEGDTLIIPRVAQQDSGQYICNATSPAGHAEATIILHVESPPY
                        ATTVPEHASVQAGETVQLQCLAHGTPPLTFQWSRVGSSLPGRATARNELLHFERAAPEDS
                        GRYRCRVTNKVGSAEAFAQLLVQGPPGSLPATSIPAGSTPTVQVTPQLETKSIGASVEFH
                        CAVPSDRGTQLRWFKEGGQLPPGHSVQDGVLRIQNLDQSCQGTYICQAHGPWGKAQASAQ
                        LVIQALPSVLINIRTSVQTVVVGHAVEFECLALGDPKPQVTWSKVGGHLRPGIVQSGGVV
                        RIAHVELADAGQYRCTATNAAGTTQSHVLLLVQALPQISMPQEVRVPAGSAAVFPCIASG
                        YPTPDISWSKLDGSLPPDSRLENNMLMLPSVRPQDAGTYVCTATNRQGKVKAFAHLQVPE
                        RVVPYFTQTPYSFLPLPTIKDAYRKFEIKITFRPDSADGMLLYNGQKRVPGSPTNLANRQ
                        PDFISFGLVGGRPEFRFDAGSGMATIRHPTPLALGHFHTVTLLRSLTQGSLIVGDLAPVN
                        GTSQGKFQGLDLNEELYLGGYPDYGAIPKAGLSSGFIGCVRELRIQGEEIVFHDLNLTAH
                        GISHCPTCRDRPCQNGGQCHDSESSSYVCVCPAGFTGSRCEHSQALHCHPEACGPDATCV
                        NRPDGRGYTCRCHLGRSGLRCEEGVTVTTPSLSGAGSYLALPALTNTHHELRLDVEFKPL
                        APDGVLLFSGGKSGPVEDFVSLAMVGGHLEFRYELGSGLAVLRSAEPLALGRWHRVSAER
                        LNKDGSLRVNGGRPVLRSSPGKSQGLNLHTLLYLGGVEPSVPLSPATNMSAHFRGCVGEV
                        SVNGKRLDLTYSFLGSQGIGQCYDSSPCERQPCQHGATCMPAGEYEFQCLCRDGFKGDLC
                        EHEENPCQLREPCLHGGTCQGTRCLCLPGFSGPRCQQGSGHGIAESDWHLEGSGGNDAPG
                        QYGAYFHDDGFLAFPGHVFSRSLPEVPETIELEVRTSTASGLLLWQGVEVGEAGQGKDFI
                        SLGLQDGHLVFRYQLGSGEARLVSEDPINDGEWHRVTALREGRRGSIQVDGEELVSGRSP
                        GPNVAVNAKGSVYIGGAPDVATLTGGRFSSGITGCVKNLVLHSARPGAPPPQPLDLQHRA
                        QAGANTRPCPS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;13182 bp
                        ATGGGGTGGCGGGCGCCGGGCGCGCTGCTGCTGGCGCTGCTGCTGCACGGGCGGCTGCTG
                        GCGGTGACCCATGGGCTGAGGGCATACGATGGCTTGTCTCTGCCTGAGGACATAGAGACC
                        GTCACAGCAAGCCAAATGCGCTGGACACATTCGTACCTTTCTGATGATGAGGACATGCTG
                        GCTGACAGCATCTCAGGAGACGACCTGGGCAGTGGGGACCTGGGCAGCGGGGACTTCCAG
                        ATGGTTTATTTCCGAGCCCTGGTGAATTTCACTCGCTCCATCGAGTACAGCCCTCAGCTG
                        GAGGATGCAGGCTCCAGAGAGTTTCGAGAGGTGTCCGAGGCTGTGGTAGACACGCTGGAG
                        TCGGAGTACTTGAAAATTCCCGGAGACCAGGTTGTCAGTGTGGTGTTCATCAAGGAGCTG
                        GATGGCTGGGTTTTTGTGGAGCTGGATGTGGGCTCGGAAGGGAATGCGGATGGGGCTCAG
                        ATTCAGGAGATGCTGCTCAGGGTCATCTCCAGCGGCTCTGTGGCCTCCTACGTCACCTCT
                        CCCCAGGGATTCCAGTTCCGACGCCTGGGCACAGTGCCCCAGTTCCCAAGAGCCTGCACG
                        GAGGCCGAGTTTGCCTGCCACAGCTACAATGAGTGTGTGGCCCTGGAGTATCGCTGTGAC
                        CGGCGGCCCGACTGCAGGGACATGTCTGATGAGCTCAATTGTGAGGAGCCAGTCCTGGGT
                        ATCAGCCCCACATTCTCTCTCCTCGTGGAGACGACATCTTTACCGCCCCGGCCAGAGACA
                        ACCATCATGCGACAGCCACCAGTCACCCACGCTCCTCAGCCCCTGCTTCCCGGTTCCGTC
                        AGGCCCCTGCCCTGTGGGCCCCAGGAGGCCGCATGCCGCAATGGGCACTGCATCCCCAGA
                        GACTACCTCTGCGACGGACAGGAGGACTGCGAGGACGGCAGCGATGAGCTAGACTGTGGC
                        CCCCCGCCACCCTGTGAGCCCAACGAGTTCCCCTGCGGGAATGGACATTGTGCCCTCAAG
                        CTGTGGCGCTGCGATGGTGACTTTGACTGTGAGGACCGAACTGATGAAGCCAACTGCCCC
                        ACCAAGCGTCCTGAGGAAGTGTGCGGGCCCACACAGTTCCGATGCGTCTCTACCAACATG
                        TGCATCCCAGCCAGCTTCCACTGTGACGAGGAGAGCGACTGTCCTGACCGGAGCGACGAG
                        TTTGGCTGCATGCCCCCCCAGGTGGTGACACCTCCCCGGGAGTCCATCCAGGCTTCCCGG
                        GGCCAGACAGTGACCTTCACCTGCGTGGCCATTGGCGTCCCCGCCCCCTTTCTCATCAAT
                        TGGAGGCTCAACTGGGGCCACATCCCCTCTCAGCCCAGGGTGACAGTGACCAGCGAGGGT
                        GGCCGTGGCACACTGATCATCCGTGATGTGAAGGAGTCAGACCAGGGTGCCTACACCTGT
                        GAGGCCATGAACGCCCGGGGCATGGTGTTTGGCATTCCTGACGGTGTCCTTGAGCTCGTC
                        CCACAACGAGCAGGCCCCTGCCCTGACGGCCACTTCTACCTGGAGCACAGCGCCGCCTGC
                        CTGCCCTGCTTCTGCTTTGGCATCACCAGCGTGTGCCAGAGCACCCGCCGCTTCCGGGAC
                        CAGATCAGGCTGCGCTTTGACCAACCCGATGACTTCAAGGGTGTGAATGTGACAATGCCT
                        GCGCAGCCCGGCACGCCACCCCTCTCCTCCACGCAGCTGCAGATCGACCCATCCCTGCAC
                        GAGTTCCAGCTAGTCGACCTGTCCCGCCGCTTCCTCGTCCACGACTCCTTCTGGGCTCTG
                        CCTGAACAGTTCCTGGGCAACAAGGTGGACTCCTATGGCGGCTCCCTGCGTTACAACGTG
                        CGCTACGAGTTGGCCCGTGGCATGCTGGAGCCAGTGCAGCGGCCGGACGTGGTCCTCGTG
                        GGTGCCGGGTACCGCCTCCTCTCCCGAGGCCACACACCCACCCAACCTGGTGCTCTGAAC
                        CAGCGCCAGGTCCAGTTCTCTGAGGAGCACTGGGTCCATGAGTCTGGCCGGCCGGTGCAG
                        CGCGCGGAGCTGCTGCAGGTGCTGCAGAGCCTGGAGGCCGTGCTCATCCAGACCGTGTAC
                        AACACCAAGATGGCTAGCGTGGGACTTAGCGACATCGCCATGGATACCACCGTCACCCAT
                        GCCACCAGCCATGGCCGTGCCCACAGTGTGGAGGAGTGCAGATGCCCCATTGGCTATTCT
                        GGCTTGTCCTGCGAGAGCTGTGATGCCCACTTCACTCGGGTGCCTGGTGGGCCCTACCTG
                        GGCACCTGCTCTGGTTGCAGTTGCAATGGCCATGCCAGCTCCTGTGACCCTGTGTATGGC
                        CACTGCCTGAATTGCCAGCACAACACGGAGGGGCCACAGTGCAAGAAGTGCAAGGCTGGC
                        TTCTTTGGGGACGCCATGAAGGCCACGGCCACTTCCTGCCGGCCCTGCCCTTGCCCATAC
                        ATCGATGCCTCCCGCAGATTCTCAGACACTTGCTTCCTGGACACGGATGGCCAAGCCACA
                        TGTGACGCCTGTGCCCCAGGCTACACTGGCCGCCGCTGTGAGAGCTGTGCCCCCGGATAC
                        GAGGGCAACCCCATCCAGCCCGGCGGGAAGTGCAGGCCCGTCAACCAGGAGATTGTGCGC
                        TGTGACGAGCGTGGCAGCATGGGGACCTCCGGGGAGGCCTGCCGCTGTAAGAACAATGTG
                        GTGGGGCGCTTGTGCAATGAATGTGCTGACCGCTCTTTCCACCTGAGTACCCGAAACCCC
                        GATGGCTGCCTCAAGTGCTTCTGCATGGGTGTCAGTCGCCACTGCACCAGCTCTTCATGG
                        AGCCGTGCCCAGTTGCATGGGGCCTCTGAGGAGCCTGGTCACTTCAGCCTGACCAACGCC
                        GCAAGCACCCACACCACCAACGAGGGCATCTTCTCCCCCACGCCCGGGGAACTGGGATTC
                        TCCTCCTTCCACAGACTCTTATCTGGACCCTACTTCTGGAGCCTCCCTTCACGCTTCCTG
                        GGGGACAAGGTGACCTCCTATGGAGGAGAGCTGCGCTTCACAGTGACCCAGAGGTCCCAG
                        CCGGGCTCCACACCCCTGCACGGGCAGCCGTTGGTGGTGCTGCAAGGTAACAACATCATC
                        CTAGAGCACCATGTGGCCCAGGAGCCCAGCCCCGGCCAGCCCAGCACCTTCATTGTGCCT
                        TTCCGGGAGCAAGCATGGCAGCGGCCCGATGGGCAGCCAGCCACACGGGAGCACCTGCTG
                        ATGGCACTGGCAGGCATCGACACCCTCCTGATCCGAGCATCCTACGCCCAGCAGCCCGCT
                        GAGAGCAGGGTCTCTGGCATCAGCATGGACGTGGCTGTGCCCGAGGAAACCGGCCAGGAC
                        CCCGCGCTGGAAGTGGAACAGTGCTCCTGCCCACCCGGGTACCGTGGGCCGTCCTGCCAG
                        GACTGTGACACAGGCTACACACGCACGCCCAGTGGCCTCTACCTGGGTACCTGTGAACGC
                        TGCAGCTGCCATGGCCACTCAGAGGCCTGCGAGCCAGAAACAGGTGCCTGCCAGGGCTGC
                        CAGCATCACACGGAGGGCCCTCGGTGTGAGCAGTGCCAGCCAGGATACTACGGGGACGCC
                        CAGCGGGGGACACCACAGGACTGCCAGCTGTGCCCCTGCTACGGAGACCCTGCTGCCGGC
                        CAGGCTGCCCACACTTGTTTTCTGGACACAGACGGCCACCCCACCTGTGATGCGTGCTCC
                        CCAGGCCACAGTGGGCGTCACTGTGAGAGGTGCGCCCCTGGCTACTATGGCAACCCCAGC
                        CAGGGCCAGCCATGCCAGAGAGACAGCCAGGTGCCAGGGCCCATAGGCTGCAACTGTGAC
                        CCCCAAGGCAGCGTCAGCAGCCAGTGTGATGCTGCTGGTCAGTGCCAGTGCAAGGCCCAG
                        GTGGAAGGCCTCACTTGCAGCCACTGCCGGCCCCACCACTTCCACCTGAGTGCCAGCAAC
                        CCAGACGGCTGCCTGCCCTGCTTCTGTATGGGCATCACCCAGCAGTGCGCCAGCTCTGCC
                        TACACACGCCACCTGATCTCCACCCACTTTGCCCCTGGGGACTTCCAAGGCTTTGCCCTG
                        GTGAACCCACAGCGAAACAGCCGCCTGACAGGAGAATTCACTGTGGAACCCGTGCCCGAG
                        GGTGCCCAGCTCTCTTTTGGCAACTTTGCCCAACTCGGCCATGAGTCCTTCTACTGGCAG
                        CTGCCGGAGACATACCAGGGAGACAAGGTGGCGGCCTACGGTGGGAAGTTGCGATACACC
                        CTCTCCTACACAGCAGGCCCACAGGGCAGCCCACTCTCTGACCCCGATGTGCAGATCACG
                        GGCAACAACATCATGCTAGTGGCCTCCCAGCCAGCGCTGCAGGGCCCTGAGAGGAGGAGC
                        TACGAGATCATGTTCCGAGAGGAATTCTGGCGCCGGCCCGATGGGCAGCCGGCCACACGC
                        GAGCACCTCCTGATGGCACTGGCCGACCTGGATGAGCTCCTGATCCGGGCCACGTTCTCC
                        TCCGTGCCGCTGGTGGCCAGCATCAGCGCAGTCAGCCTGGAGGTCGCCCAGCCGGGGCCC
                        TCAAACAGACCCCGCGCCCTCGAGGTGGAGGAGTGCCGCTGCCCGCCAGGCTACATCGGT
                        CTGTCCTGCCAGGACTGTGCCCCCGGCTACACGCGCACCGGGAGTGGGCTCTACCTCGGC
                        CACTGCGAGCTATGTGAATGCAATGGCCACTCAGACCTGTGCCACCCAGAGACTGGGGCC
                        TGCTCGCAATGCCAGCACAACGCCGCAGGGGAGTTCTGCGAGCTTTGTGCCCCTGGCTAC
                        TACGGAGATGCCACAGCCGGGACGCCTGAGGACTGCCAGCCCTGTGCCTGCCCACTGACC
                        AACCCAGAGAACATGTTTTCCCGCACCTGTGAGAGCCTGGGAGCCGGCGGGTACCGCTGC
                        ACGGCCTGCGAACCCGGCTACACTGGCCAGTACTGTGAGCAGTGTGGCCCAGGTTACGTG
                        GGTAACCCCAGTGTGCAAGGGGGCCAGTGCCTGCCAGAGACAAACCAAGCCCCACTGGTG
                        GTCGAGGTCCATCCTGCTCGAAGCATAGTGCCCCAAGGTGGCTCCCACTCCCTGCGGTGT
                        CAGGTCAGTGGGAGGGGACCCCACTACTTCTATTGGTCCCGTGAGGATGGGCGGCCTGTG
                        CCCAGCGGCACCCAGCAGCGACATCAAGGCTCCGAGCTCCACTTCCCCAGCGTCCAGCCC
                        TCGGATGCTGGGGTCTACATTTGCACCTGCCGTAATCTCCACCGATCCAATACCAGCCGG
                        GCAGAGCTGCTGGTCACTGAGGCTCCAAGCAAGCCCATCACAGTGACTGTGGAGGAGCAG
                        CGGAGCCAGAGCGTGCGCCCCGGAGCTGACGTCACCTTCATCTGCACAGCCAAAAGCAAG
                        TCCCCAGCCTATACCCTGGTGTGGACCCGCCTGCACAACGGGAAACTGCCCACCCGAGCC
                        ATGGATTTCAATGGCATCCTGACCATTCGCAACGTCCAGCTGAGTGATGCAGGCACCTAC
                        GTGTGCACCGGCTCCAACATGTTTGCCATGGACCAGGGCACAGCCACTCTACATGTGCAG
                        GCCTCGGGCACCTTGTCCGCCCCCGTGGTCTCCATCCATCCGCCACAGCTCACAGTGCAG
                        CCCGGGCAACTGGCGGAGTTCCGCTGCAGCGCCACAGGGAGCCCCACGCCCACCCTCGAG
                        TGGACAGGGGGCCCCGGCGGCCAGCTCCCTGCGAAGGCACAAATCCACGGCGGCATCCTG
                        CGCCTGCCAGCTGTCGAGCCCACGGATCAGGCCCAGTACTTGTGCCGAGCCCACAGCAGC
                        GCTGGGCAGCAGGTGGCCAGGGCTGTGCTCCACGTGCATGGGGGCGGTGGGCCCAGAGTC
                        CAAGTGAGCCCAGAGAGGACCCAGGTCCACGCAGGCCGCACCGTCAGGCTGTACTGCAGG
                        GCTGCAGGCGTGCCTAGCGCCACCATCACCTGGAGGAAGGAAGGGGGCAGCCTCCCACCA
                        CAGGCCCGGTCAGAGCGCACAGACATCGCGACACTGCTCATCCCAGCCATCACGACTGCT
                        GACGCCGGCTTCTACCTCTGCGTGGCCACCAGCCCTGCAGGCACTGCCCAGGCCCGGATC
                        CAAGTGGTTGTCCTTTCAGCCTCAGATGCCAGCCAACCGCCGGTCAAGATTGAGTCCTCA
                        TCGCCTTCTGTGACAGAAGGGCAAACACTCGACCTCAACTGTGTGGTGGCAGGGTCAGCC
                        CATGCCCAGGTCACCTGGTACAGGCGAGGGGGTAGCCTGCCTCACCACACCCAGGTGCAC
                        GGCTCCCGTCTGCGGCTCCCCCAGGTCTCACCAGCTGATTCTGGAGAGTATGTGTGCCGT
                        GTGGAGAATGGATCGGGCCCCAAGGAGGCCTCCATTACTGTGTCTGTGCTCCACGGCACC
                        CATTCTGGCCCCAGCTACACCCCAGTGCCCGGCAGCACCCGGCCCATCCGCATCGAGCCC
                        TCCTCCTCACACGTGGCGGAAGGGCAGACCCTGGATCTGAACTGCGTGGTGCCCGGGCAG
                        GCCCACGCCCAGGTCACGTGGCACAAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGACC
                        CACGGCTCGCTGCTGCGGCTGCACCAGGTGACCCCGGCCGACTCAGGCGAGTATGTGTGC
                        CATGTGGTGGGCACCTCCGGCCCCCTAGAGGCCTCAGTCCTGGTCACCATCGAAGCCTCT
                        GTCATCCCTGGACCCATCCCACCTGTCAGGATCGAGTCTTCATCCTCCACAGTGGCCGAG
                        GGCCAGACCCTGGATCTGAGCTGCGTGGTGGCAGGGCAGGCCCACGCCCAGGTCACATGG
                        TACAAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGGTTCGTGGCTCCCGCCTGTACATC
                        TTCCAGGCCTCACCTGCCGATGCGGGACAGTACGTCTGCCGGGCCAGCAACGGCATGGAG
                        GCCTCCATCACGGTCACAGTAACTGGGACCCAGGGGGCCAACTTAGCCTACCCTGCCGGC
                        AGCACCCAGCCCATCCGCATCGAGCCCTCCTCCTCGCAAGTGGCGGAAGGGCAGACCCTG
                        GATCTGAACTGCGTGGTGCCCGGGCAGTCCCATGCCCAGGTCACGTGGCACAAGCGTGGG
                        GGCAGCCTCCCTGTCCGGCACCAGACCCACGGCTCCCTGCTGAGACTCTACCAAGCGTCC
                        CCCGCCGACTCGGGCGAGTACGTGTGCCGAGTGTTGGGCAGCTCCGTGCCTCTAGAGGCC
                        TCTGTCCTGGTCACCATTGAGCCTGCGGGCTCAGTGCCTGCACTTGGGGTCACCCCCACG
                        GTCCGGATCGAGTCATCGTCTTCGCAAGTGGCAGAGGGGCAGACCCTGGACCTGAACTGC
                        CTCGTTGCTGGTCAGGCCCATGCCCAGGTCACGTGGCACAAGCGCGGGGGCAGCCTCCCG
                        GCCCGGCACCAGGTGCATGGCTCGAGGCTACGCCTGCTCCAGGTGACCCCAGCTGATTCA
                        GGGGAGTACGTGTGCCGTGTGGTCGGCAGCTCAGGTACCCAGGAAGCCTCAGTCCTTGTC
                        ACCATCCAGCAGCGCCTTAGTGGCTCCCACTCCCAGGGTGTGGCGTACCCCGTCCGCATC
                        GAGTCCTCCTCAGCCTCCCTGGCCAATGGACACACCCTGGACCTCAACTGCCTGGTTGCC
                        AGCCAGGCTCCCCACACCATCACCTGGTATAAGCGTGGAGGCAGCTTACCCAGCCGGCAC
                        CAGATCGTGGGCTCCCGGCTGCGGATCCCTCAGGTGACTCCGGCAGACTCGGGCGAGTAC
                        GTGTGTCACGTCAGTAACGGTGCAGGCTCCCGGGAGACCTCGCTCATCGTCACCATCCAG
                        GGCAGCGGTTCCTCCCACGTGCCCAGAGTCTCCCCACCGATCAGGATCGAGTCGTCTTCC
                        CCCACGGTGGTGGAAGGGCAGACCTTGGATCTGAACTGCGTGGTCGCCAGGCAGCCCCAG
                        GCTATCATCACATGGTACAAGCGTGGGGGCAGCCTTCCCTCCCGACACCAGACCCATGGC
                        TCCCACCTGCGGTTGCACCAAATGTCTGTGGCTGACTCGGGCGAGTATGTGTGCCGGGCC
                        AACAACAACATCGATGCCCTGGAGGCCTCAATCGTCATCTCCGTCTCCCCTAGCGCCGGC
                        AGCCCCTCCGCCCCTGGCAGCTCCATGCCCATCAGAATTGAGTCATCCTCCTCACACGTG
                        GCCGAAGGGGAGACCCTGGATCTGAACTGCGTGGTCCCCGGGCAGGCCCATGCCCAGGTC
                        ACTTGGCACAAGCGTGGGGGCAGCCTCCCCAGTTACCATCAGACCCGCGGCTCACGGCTG
                        CGGCTGCACCATGTGTCCCCGGCCGACTCGGGTGAATACGTGTGCCGGGTGATGGGCAGC
                        TCTGGCCCCCTGGAGGCCTCAGTCCTCGTCACCATCGAAGCCTCTGGCTCAAGTGCTGTC
                        CACGTCCCCGCCCCAGGTGGAGCCCCACCCATCCGCATCGAGCCCTCCTCCTCCCGAGTG
                        GCAGAAGGGCAGACCCTGGATCTGAAGTGCGTGGTGCCCGGGCAGGCCCACGCCCAGGTC
                        ACGTGGCACAAGCGTGGAGGAAACCTCCCTGCCCGGCACCAGGTCCACGGCCCACTGCTG
                        AGGCTGAACCAGGTGTCCCCGGCTGACTCTGGCGAGTACTCGTGCCAAGTGACCGGAAGC
                        TCAGGCACCCTGGAGGCATCTGTCCTGGTCACAATTGAGCCCTCCAGCCCAGGACCCATT
                        CCTGCTCCAGGACTGGCCCAGCCCATCTACATCGAGGCCTCCTCTTCACACGTGACTGAA
                        GGGCAGACTCTGGATCTGAACTGTGTGGTGCCCGGGCAGGCCCATGCCCAGGTCACGTGG
                        TACAAGCGCGGGGGCAGCCTCCCCGCCCGGCACCAGACCCATGGCTCCCAGCTGCGGCTC
                        CACCACGTCTCCCCTGCCGACTCAGGCGAGTATGTGTGTCGTGCAGCCGGCGGCCCAGGC
                        CCTGAGCAAGAAGCCTCCTTCACAGTCACCGTCCCGCCCAGTGAGGGGTCTTCCTACCGC
                        CTTAGGAGCCCGGTCATCTCGATCGACCCGCCCAGCAGCACCGTGCAGCAGGGCCAGGAT
                        GCCAGCTTCAAGTGCCTCATCCATGACGGGGCAGCCCCCATCAGCCTCGAGTGGAAGACC
                        CGGAACCAGGAGCTGGAGGACAACGTCCACATCAGTCCCAATGGCTCCATCATCACCATC
                        GTGGGCACCCGGCCCAGCAACCACGGTACCTACCGCTGCGTGGCCTCCAATGCCTACGGT
                        GTGGCCCAGAGTGTGGTGAACCTCAGTGTGCACGGGCCCCCTACAGTGTCCGTGCTCCCC
                        GAGGGCCCCGTGTGGGTGAAAGTGGGAAAGGCCGTCACCCTGGAGTGTGTCAGTGCCGGG
                        GAGCCCCGCTCCTCTGCTCGTTGGACCCGGATCAGCAGCACCCCTGCCAAGTTGGAGCAG
                        CGGACATATGGGCTCATGGACAGCCACACGGTGCTGCAGATTTCATCAGCTAAACCATCA
                        GATGCGGGCACTTATGTGTGCCTTGCTCAGAATGCACTAGGCACAGCACAGAAGCAGGTG
                        GAGGTGATCGTGGACACGGGCGCCATGGCCCCAGGGGCCCCTCAGGTCCAAGCTGAAGAA
                        GCTGAGCTGACTGTGGAGGCTGGACACACGGCCACCTTGCGCTGCTCAGCCACAGGCAGC
                        CCCGCGCGCACCATCCACTGGTCCAAGCTGCGTTCCCCACTGCCCTGGCAGCACCGGCTG
                        GAAGGTGACACACTCATCATACCCCGGGTAGCCCAGCAGGACTCGGGCCAGTACATCTGC
                        AATGCCACTAGCCCTGCCGGGCACGCTGAGGCCACCATCATCCTGCACGTGGAGAGCCCA
                        CCATATGCCACCACGGTCCCAGAGCACGCTTCGGTGCAGGCAGGGGAGACGGTGCAGCTC
                        CAGTGCCTGGCTCACGGGACACCCCCACTCACCTTCCAGTGGAGCCGCGTGGGCAGCAGC
                        CTTCCTGGGAGGGCGACCGCCAGGAACGAGCTGCTGCACTTTGAGCGTGCAGCCCCTGAG
                        GACTCAGGCCGCTACCGCTGCCGGGTCACCAACAAGGTGGGCTCAGCCGAGGCCTTTGCC
                        CAGCTGCTCGTCCAAGGCCCTCCCGGCTCTCTCCCTGCCACCTCCATCCCAGCAGGGTCC
                        ACGCCCACCGTGCAGGTCACGCCTCAGCTAGAGACCAAGAGCATTGGGGCCAGCGTTGAG
                        TTCCATTGTGCTGTGCCCAGCGACCGGGGTACCCAGCTCCGTTGGTTCAAGGAAGGGGGT
                        CAGCTGCCTCCCGGTCACAGCGTGCAGGATGGGGTGCTCCGAATCCAGAACTTGGACCAG
                        AGCTGCCAAGGGACGTATATATGCCAGGCCCATGGACCTTGGGGGAAGGCCCAGGCCAGT
                        GCCCAGCTGGTTATCCAAGCCCTGCCCTCGGTGCTCATCAACATCCGGACCTCTGTGCAG
                        ACCGTGGTGGTTGGCCACGCCGTGGAGTTCGAATGCCTGGCACTGGGTGACCCCAAGCCT
                        CAGGTGACATGGAGCAAAGTTGGAGGGCACCTGCGGCCAGGCATTGTGCAGAGCGGAGGT
                        GTCGTCAGGATCGCCCACGTAGAGCTGGCTGATGCGGGACAGTATCGCTGCACTGCCACC
                        AACGCAGCTGGCACCACACAATCCCACGTCCTGCTGCTTGTGCAAGCCTTGCCCCAGATC
                        TCAATGCCCCAAGAAGTCCGTGTGCCTGCTGGTTCTGCAGCTGTCTTCCCCTGCATAGCC
                        TCAGGCTACCCCACTCCTGACATCAGCTGGAGCAAGCTGGATGGCAGCCTGCCACCTGAC
                        AGCCGCCTGGAGAACAACATGCTGATGCTGCCCTCAGTCCAACCCCAGGACGCAGGTACC
                        TACGTCTGCACCGCCACTAACCGCCAGGGCAAGGTCAAAGCCTTTGCCCACCTGCAGGTG
                        CCAGAGCGGGTGGTGCCCTACTTCACGCAGACCCCCTACTCCTTCCTACCGCTGCCCACC
                        ATCAAGGATGCCTACAGGAAGTTCGAGATCAAGATCACCTTCCGGCCTGACTCAGCCGAT
                        GGGATGCTGCTGTACAATGGGCAGAAGCGAGTCCCAGGGAGCCCCACCAACCTGGCCAAC
                        CGGCAGCCCGACTTCATCTCCTTCGGCCTCGTGGGGGGAAGGCCCGAGTTCCGGTTCGAT
                        GCAGGCTCAGGCATGGCCACCATCCGCCATCCCACACCACTGGCCCTGGGCCATTTCCAC
                        ACCGTGACCCTGCTGCGCAGCCTCACCCAGGGCTCCCTGATTGTGGGTGACCTGGCCCCG
                        GTCAACGGGACCTCCCAGGGCAAGTTCCAGGGCCTGGATCTGAACGAGGAACTCTACCTG
                        GGTGGCTATCCTGACTATGGTGCCATCCCCAAGGCGGGGCTGAGCAGCGGCTTCATAGGC
                        TGTGTCCGGGAGCTGCGCATCCAGGGCGAGGAGATCGTCTTCCATGACCTCAACCTCACG
                        GCGCACGGCATCTCCCACTGCCCCACCTGTCGGGACCGGCCCTGCCAGAATGGCGGTCAG
                        TGCCATGACTCTGAGAGCAGCAGCTATGTGTGCGTCTGCCCAGCTGGCTTCACCGGGAGC
                        CGCTGTGAGCACTCGCAGGCCCTGCACTGCCATCCAGAGGCCTGTGGGCCCGACGCCACC
                        TGTGTGAACCGGCCTGACGGTCGAGGCTACACCTGCCGCTGCCACCTGGGCCGCTCGGGG
                        TTGCGGTGTGAGGAAGGTGTGACAGTGACCACCCCCTCGCTGTCGGGTGCTGGCTCCTAC
                        CTGGCACTGCCCGCCCTCACCAACACACACCACGAGCTACGCCTGGACGTGGAGTTCAAG
                        CCACTCGCCCCTGACGGGGTCCTGCTGTTCAGCGGGGGGAAGAGCGGGCCTGTGGAGGAC
                        TTCGTGTCCCTGGCGATGGTGGGCGGCCACCTGGAGTTCCGCTATGAGTTGGGGTCAGGG
                        CTGGCCGTTCTGCGGACGGCCGAGCCGCTGGCCCTGGGCCGCTGGCACCGTGTGTCTGCA
                        GAGCGTCTCAACAAGGACGGCAGCCTGCGGGTGAATGGTGGACGCCCTGTGCTGCGCTCC
                        TCGCCCGGCAAGAGCCAGGGCCTCAACCTGCACACCCTGCTCTACCTGGGGGGTGTGGAG
                        CCTTCCGTGCCACTGTCCCCGGCCACCAACATGAGCGCTCACTTCCGCGGCTGTGTGGGC
                        GAGGTGTCAGTGAATGGCAAACGGCTGGACCTCACCTACAGTTTCCTAGGCAGCCAGGGC
                        ATCGGGCAATGCTATGACAGCTCCCCATGTGAGCGCCAGCCTTGCCAACATGGTGCCACG
                        TGCATGCCCGCTGGCGAGTATGAGTTCCAGTGCCTGTGTCGAGATGGAATCAAAGGAGAC
                        CTGTGTGAGCACGAGGAGAACCCCTGCCAGCTCCGTGAACCCTGTCTGCATGGGGGCACC
                        TGCCAGGGCACCCGCTGCCTCTGCCTCCCTGGCTTCTCTGGCCCACGCTGCCAACAAGGC
                        TCTGGACATGGCATAGCAGAGTCCGACTGGCATCTTGAAGGCAGCGGGGGCAATGATGCC
                        CCTGGGCAGTACGGAGCCTATTTCCACGATGATGGCTTCCTCGCCTTCCCTGGCCATGTC
                        TTCTCCAGGAGCCTGCCCGAGGTGCCCGAGACCATCGAGCTGGAGGTTCGGACCAGCACA
                        GCCAGTGGCCTCCTGCTCTGGCAGGGTGTGGAGGTGGGAGAGGCCGGCCAAGGCAAGGAC
                        TTCATCAGCCTCGGGCTTCAAGACGGGCACCTTGTCTTCAGGTACCAGCTGGGTAGTGGG
                        GAGGCCCGCCTGGTCTCTGAGGACCCCATCAATGACGGCGAGTGGCACCGGGTGACAGCA
                        CTGCGGGAGGGCCGCAGAGGTTCCATCCAAGTCGACGGTGAGGAGCTGGTCAGCGGCCGG
                        TCCCCAGGTCCCAACGTGGCAGTCAACGCCAAGGGCAGCATCTACATCGGCGGAGCCCCT
                        GACGTGGCCACGCTGACCGGGGGCAGATTCTCCTCGGGCATCACAGGCTGTGTCAAGAAC
                        CTGGTGCTGCACTCGGCCCGACCCGGCGCCCCGCCCCCACAGCCCCTGGACCTGCAGCAC
                        CGCGCCCAGGCCGGGGCCAACACACGCCCCTGCCCCTCGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07679</identifier>
                            <name>I-set</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07686</identifier>
                            <name>V-set</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00057</identifier>
                            <name>Ldl_recept_a</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02210</identifier>
                            <name>Laminin_G_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01390</identifier>
                            <name>SEA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00052</identifier>
                            <name>Laminin_B</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00053</identifier>
                            <name>Laminin_EGF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>structural molecule activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell adhesion</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-27">
        <drugbank-id primary="true">DB00040</drugbank-id>
        <drugbank-id>BIOD00057</drugbank-id>
        <drugbank-id>BTD00057</drugbank-id>
        <name>Glucagon recombinant</name>
        <description>29 residue peptide hormone. Glucagon is synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons</description>
        <cas-number>9007-92-5</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># White CM: A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999 May;39(5):442-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10234590</general-references>
        <synthesis-reference/>
        <indication>For treatment of severe hypoglycemia, also used in gastrointestinal imaging</indication>
        <pharmacodynamics>Used in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.</pharmacodynamics>
        <mechanism-of-action>Glucagon binds the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution>* 0.25 L/kg</volume-of-distribution>
        <clearance>* 13.5  mL/min/kg [Adults with IV 1 mg]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Glucagon</synonym>
            <synonym language="" coder="">Glucagone</synonym>
            <synonym language="" coder="">Glucagonum</synonym>
            <synonym language="" coder="">His-ser-gln-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-gln-asp-phe-val-gln-trp-leu-met-asn-thr</synonym>
            <synonym language="" coder="">His-ser-glu(NH2)-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-glu(NH2)-asp-phe-val-glu(NH2)-trp-leu-met-asp(NH2)-thr</synonym>
            <synonym language="" coder="">HSQGTFTSDYSKYLDSRRAQDFVQWLMNT</synonym>
        </synonyms>
        <products>
            <product>
                <name>Glucagen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02333619</dpd-id>
                <started-marketing-on>2010-01-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Glucagen Hypokit</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02333627</dpd-id>
                <started-marketing-on>2009-12-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Glucagon</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02243297</dpd-id>
                <started-marketing-on>2002-05-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Glucagon</name>
                <ndc-id>63323-596_a28fb798-125d-40fb-a8e4-c5423236cd8b</ndc-id>
                <ndc-product-code>63323-596</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-05-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>1 mg/mL</strength>
                <route>intramuscular; intravenous</route>
                <fda-application-number>NDA201849</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Glucagon Ampoule 666 1mg</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00015377</dpd-id>
                <started-marketing-on>1961-12-31</started-marketing-on>
                <ended-marketing-on>2002-05-27</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Glucagon</name>
                <ingredients>Glucagon recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Glucagon</name>
                <ingredients>Glucagon recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Glucagen</name>
                <ingredients>Glucagon recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Glucagen Hypokit</name>
                <ingredients>Glucagon recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Glucagon Ampoule 666 1mg</name>
                <ingredients>Glucagon recombinant</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Bedford Labs</name>
                <url>http://www.bedfordlabs.com</url>
            </packager>
            <packager>
                <name>Eli Lilly &amp; Co.</name>
                <url>http://www.lilly.com</url>
            </packager>
            <packager>
                <name>Novo Nordisk Inc.</name>
                <url>http://www.novonordisk.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Eli lilly and co</manufacturer>
            <manufacturer generic="false">Novo nordisk pharmaceuticals inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Glucagen 1 mg vial</description>
                <cost currency="USD">84.0</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Glucagon 1 mg/vial</description>
                <cost currency="USD">94.98</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Glucagon 1 mg emergency kit</description>
                <cost currency="USD">119.28</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Glucagen 1 mg hypokit</description>
                <cost currency="USD">120.36</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>GlucaGen HypoKit 1 mg Solution Box</description>
                <cost currency="USD">123.72</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Glucagon Emergency 1 mg Kit Box</description>
                <cost currency="USD">124.05</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Glucagon 1 mg kit</description>
                <cost currency="USD">128.34</cost>
                <unit>kit</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Hypoglycemic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intramuscular</route>
                <strength>1 mg</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>intramuscular; intravenous</route>
                <strength>1 mg/mL</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intramuscular; intravenous; subcutaneous</route>
                <strength>1 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; intravenous; subcutaneous</route>
                <strength>1 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="H04AA01">
                <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
                <level code="H04">PANCREATIC HORMONES</level>
                <level code="H04A">GLYCOGENOLYTIC HORMONES</level>
                <level code="H04AA">Glycogenolytic hormones</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>68:22.12</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>May enhance the anticoagulant effect of Vitamin K Antagonists.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08897</drugbank-id>
                <name>Aclidinium</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00321</drugbank-id>
                <name>Amitriptyline</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00543</drugbank-id>
                <name>Amoxapine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00572</drugbank-id>
                <name>Atropine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00972</drugbank-id>
                <name>Azelastine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00245</drugbank-id>
                <name>Benzatropine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00835</drugbank-id>
                <name>Brompheniramine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00748</drugbank-id>
                <name>Carbinoxamine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00341</drugbank-id>
                <name>Cetirizine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01114</drugbank-id>
                <name>Chlorphenamine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00477</drugbank-id>
                <name>Chlorpromazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00283</drugbank-id>
                <name>Clemastine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00771</drugbank-id>
                <name>Clidinium</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01242</drugbank-id>
                <name>Clomipramine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00318</drugbank-id>
                <name>Codeine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01176</drugbank-id>
                <name>Cyclizine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00924</drugbank-id>
                <name>Cyclobenzaprine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00979</drugbank-id>
                <name>Cyclopentolate</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00434</drugbank-id>
                <name>Cyproheptadine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00496</drugbank-id>
                <name>Darifenacin</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01151</drugbank-id>
                <name>Desipramine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00967</drugbank-id>
                <name>Desloratadine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00405</drugbank-id>
                <name>Dexbrompheniramine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00804</drugbank-id>
                <name>Dicyclomine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01501</drugbank-id>
                <name>Difenoxin</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00985</drugbank-id>
                <name>Dimenhydrinate</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01075</drugbank-id>
                <name>Diphenhydramine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01081</drugbank-id>
                <name>Diphenoxylate</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00280</drugbank-id>
                <name>Disopyramide</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01142</drugbank-id>
                <name>Doxepin</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00366</drugbank-id>
                <name>Doxylamine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00450</drugbank-id>
                <name>Droperidol</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01288</drugbank-id>
                <name>Fenoterol</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06702</drugbank-id>
                <name>Fesoterodine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00950</drugbank-id>
                <name>Fexofenadine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01148</drugbank-id>
                <name>Flavoxate</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00875</drugbank-id>
                <name>Flupentixol</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00623</drugbank-id>
                <name>Fluphenazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00588</drugbank-id>
                <name>Fluticasone Propionate</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00986</drugbank-id>
                <name>Glycopyrrolate</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00502</drugbank-id>
                <name>Haloperidol</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00557</drugbank-id>
                <name>Hydroxyzine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00424</drugbank-id>
                <name>Hyoscyamine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00458</drugbank-id>
                <name>Imipramine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00328</drugbank-id>
                <name>Indomethacin</name>
                <description>Indomethacin may diminish the therapeutic effect of Glucagon.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00332</drugbank-id>
                <name>Ipratropium bromide</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01247</drugbank-id>
                <name>Isocarboxazid</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01106</drugbank-id>
                <name>Levocabastine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06282</drugbank-id>
                <name>Levocetirizine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00455</drugbank-id>
                <name>Loratadine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00408</drugbank-id>
                <name>Loxapine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00934</drugbank-id>
                <name>Maprotiline</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00737</drugbank-id>
                <name>Meclizine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04843</drugbank-id>
                <name>Mepenzolate</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01403</drugbank-id>
                <name>Methotrimeprazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01171</drugbank-id>
                <name>Moclobemide</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00540</drugbank-id>
                <name>Nortriptyline</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00334</drugbank-id>
                <name>Olanzapine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00768</drugbank-id>
                <name>Olopatadine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01173</drugbank-id>
                <name>Orphenadrine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01062</drugbank-id>
                <name>Oxybutynin</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00850</drugbank-id>
                <name>Perphenazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00780</drugbank-id>
                <name>Phenelzine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01100</drugbank-id>
                <name>Pimozide</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06153</drugbank-id>
                <name>Pizotifen</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00433</drugbank-id>
                <name>Prochlorperazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00387</drugbank-id>
                <name>Procyclidine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00420</drugbank-id>
                <name>Promazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01069</drugbank-id>
                <name>Promethazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00782</drugbank-id>
                <name>Propantheline</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00344</drugbank-id>
                <name>Protriptyline</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01224</drugbank-id>
                <name>Quetiapine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00747</drugbank-id>
                <name>Scopolamine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01591</drugbank-id>
                <name>Solifenacin</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00679</drugbank-id>
                <name>Thioridazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01623</drugbank-id>
                <name>Thiothixene</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01409</drugbank-id>
                <name>Tiotropium</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01036</drugbank-id>
                <name>Tolterodine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00752</drugbank-id>
                <name>Tranylcypromine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00831</drugbank-id>
                <name>Trifluoperazine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00376</drugbank-id>
                <name>Trihexyphenidyl</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00662</drugbank-id>
                <name>Trimethobenzamide</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00726</drugbank-id>
                <name>Trimipramine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00427</drugbank-id>
                <name>Triprolidine</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00209</drugbank-id>
                <name>Trospium</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09076</drugbank-id>
                <name>Umeclidinium</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>May enhance the anticoagulant effect of Vitamin K Antagonists.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01624</drugbank-id>
                <name>Zuclopenthixol</name>
                <description>Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Glucagon for Injection Sequence 
                HSQGTFTSDYSKYLDSRRAQDFVQWLMNT</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-1.197</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>9.52</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>3767.1000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C165H249N49O51S1</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12072</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>11363</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C01501</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D00116</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0002-8031-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>AF529185</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164779052</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>Q8MJ25</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Glucagon_recombinant</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/gluca.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/glucagon.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000527</id>
                <name>Glucagon receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Katayama T, Shimamoto S, Oda H, Nakahara K, Kangawa K, Murakami N: Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70. Epub 2007 Apr 9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17462598&#13;
                    # Li P, Rogers T, Smiley D, DiMarchi RD, Zhang F: Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jul 1;63(Pt 7):599-601. Epub 2007 Jun 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17620721&#13;
                    # Li XC, Zhuo JL: Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise. Clin Sci (Lond). 2007 Aug;113(4):183-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17623014&#13;
                    # Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17534934&#13;
                    # Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E, Ahren B: Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia. 2007 Jul;50(7):1453-62. Epub 2007 May 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17479245&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352&#13;
                    # Menzel S, Stoffel M, Espinosa R 3rd, Fernald AA, Le Beau MM, Bell GI: Localization of the glucagon receptor gene to human chromosome band 17q25. Genomics. 1994 Mar 15;20(2):327-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8020989&#13;
                    # Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12529935&#13;
                    # Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al.: The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene. 1994 Mar 25;140(2):203-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8144028</references>
                <known-action>yes</known-action>
                <polypeptide id="P47871" source="Swiss-Prot">
                    <name>Glucagon receptor</name>
                    <general-function>Involved in glucagon receptor activity</general-function>
                    <specific-function>This is a receptor for glucagon which plays a central role in regulating the level of blood glucose by controlling the rate of hepatic glucose production and insulin secretion. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system</specific-function>
                    <gene-name>GCGR</gene-name>
                    <locus>17q25</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>143-166
                        174-193
                        226-249
                        264-285
                        304-326
                        351-369
                        382-404</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.83</theoretical-pi>
                    <molecular-weight>54009.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4192</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U03469</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>439690</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>251</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>29</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P47871</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GLR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GL-R</synonym>
                        <synonym>Glucagon receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Glucagon receptor precursor
                        MPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNR
                        TFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQ
                        CQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANL
                        FASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYC
                        WLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDN
                        MGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGV
                        HEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRL
                        GKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1434 bp
                        ATGCCCCCCTGCCAGCCACAGCGACCCCTGCTGCTGTTGCTGCTGCTGCTGGCCTGCCAG
                        CCACAGGTCCCCTCCGCTCAGGTGATGGACTTCCTGTTTGAGAAGTGGAAGCTCTACGGT
                        GACCAGTGTCACCACAACCTGAGCCTGCTGCCCCCTCCCACGGAGCTGGTGTGCAACAGA
                        ACCTTCGACAAGTATTCCTGCTGGCCGGACACCCCCGCCAATACCACGGCCAACATCTCC
                        TGCCCCTGGTACCTGCCTTGGCACCACAAAGTGCAACACCGCTTCGTGTTCAAGAGATGC
                        GGGCCCGACGGTCAGTGGGTGCGTGGACCCCGGGGGCAGCCTTGGCGTGATGCCTCCCAG
                        TGCCAGATGGATGGCGAGGAGATTGAGGTCCAGAAGGAGGTGGCCAAGATGTACAGCAGC
                        TTCCAGGTGATGTACACAGTGGGCTACAGCCTGTCCCTGGGGGCGCTGCTCCTCGCCTTG
                        GCCATCCTGGGGGGCCTCAGCAAGCTGCACTGCACCCGCAATGCCATCCACGCGAATCTG
                        TTTGCGTCCTTCGTGCTGAAAGCCAGCTCCGTGCTGGTCATTGATGGGCTGCTCAGGACC
                        CGCTACAGCCAGAAAATTGGCGACGACCTCAGTGTCAGCACCTGGCTCAGTGATGGAGCG
                        GTGGCTGGCTGCCGTGTGGCCGCGGTGTTCATGCAATATGGCATCGTGGCCAACTACTGC
                        TGGCTGCTGGTGGAGGGCCTGTACCTGCACAACCTGCTGGGCCTGGCCACCCTCCCCGAG
                        AGGAGCTTCTTCAGCCTCTACCTGGGCATCGGCTGGGGTGCCCCCATGCTGTTCGTCGTC
                        CCCTGGGCAGTGGTCAAGTGTCTGTTCGAGAACGTCCAGTGCTGGACCAGCAATGACAAC
                        ATGGGCTTCTGGTGGATCCTGCGGTTCCCCGTCTTCCTGGCCATCCTGATCAACTTCTTC
                        ATCTTCGTCCGCATCGTTCAGCTGCTCGTGGCCAAGCTGCGGGCACGGCAGATGCACCAC
                        ACAGACTACAAGTTCCGGCTGGCCAAGTCCACGCTGACCCTCATCCCTCTGCTGGGCGTC
                        CACGAAGTGGTCTTCGCCTTCGTGACGGACGAGCACGCCCAGGGCACCCTGCGCTCCGCC
                        AAGCTCTTCTTCGACCTCTTCCTCAGCTCCTTCCAGGGCCTGCTGGTGGCTGTCCTCTAC
                        TGCTTCCTCAACAAGGAGGTGCAGTCGGAGCTGCGGCGGCGTTGGCACCGCTGGCGCCTG
                        GGCAAAGTGCTATGGGAGGAGCGGAACACCAGCAACCACAGGGCCTCATCTTCGCCCGGC
                        CACGGCCCTCCCAGCAAGGAGCTGCAGTTTGGGAGGGGTGGTGGCAGCCAGGATTCATCT
                        GCGGAGACCCCCTTGGCTGGTGGCCTCCCTAGATTGGCTGAGAGCCCCTTCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00002</identifier>
                            <name>7tm_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02793</identifier>
                            <name>HRM</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>secretin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>glucagon receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002134</id>
                <name>Glucagon-like peptide 2 receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Boushey RP, Yusta B, Drucker DJ: Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001 Jan 15;61(2):687-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11212269&#13;
                    # Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A: Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1569-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9990065&#13;
                    # Estall JL, Koehler JA, Yusta B, Drucker DJ: The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation. J Biol Chem. 2005 Jun 10;280(23):22124-34. Epub 2005 Apr 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15817468&#13;
                    # Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12529935</references>
                <known-action>unknown</known-action>
                <polypeptide id="O95838" source="Swiss-Prot">
                    <name>Glucagon-like peptide 2 receptor</name>
                    <general-function/>
                    <specific-function>This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase</specific-function>
                    <gene-name>GLP2R</gene-name>
                    <locus>17p13.3</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>180-202
                        211-230
                        262-286
                        299-322
                        338-363
                        386-406
                        422-442</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.03</theoretical-pi>
                    <molecular-weight>63002.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4325</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GLP2R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GLP2R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF105367</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4324491</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>250</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>29</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O95838</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GLP2R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GLP-2 receptor</synonym>
                        <synonym>GLP-2-R</synonym>
                        <synonym>GLP-2R</synonym>
                        <synonym>Glucagon-like peptide 2 receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Glucagon-like peptide 2 receptor
                        MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVS
                        IKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPS
                        YLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQL
                        MYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYS
                        KRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLW
                        PRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLK
                        ILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFI
                        QLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKK
                        LSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTM
                        ANTMEEILEESEI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1662 bp
                        ATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGC
                        GTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCAC
                        AGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCC
                        ATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAA
                        CAGGCATGTCTGAGAGACTTACTCAAGGAACCTTCTGGCATATTTTGTAACGGGACATTT
                        GATCAGTACGTGTGTTGGCCTCATTCTTCTCCTGGAAATGTCTCTGTACCCTGCCCTTCA
                        TACTTACCTTGGTGGAGTGAAGAGAGCTCAGGAAGGGCCTACAGACACTGCTTGGCTCAG
                        GGGACTTGGCAGACGATAGAGAACGCCACGGATATTTGGCAGGATGACTCCGAATGCTCC
                        GAGAACCACAGCTTCAAGCAAAACGTGGACCGTTATGCCTTGCTGTCAACCTTGCAGCTG
                        ATGTACACCGTGGGATACTCCTTCTCTCTTATCTCCCTCTTCCTGGCTCTCACCCTCCTC
                        TTGTTTCTTCGAAAACTCCACTGCACGCGCAACTACATCCACATGAACTTGTTTGCTTCT
                        TTCATCCTGAGAACCCTGGCTGTACTGGTGAAGGACGTCGTCTTCTACAACTCTTACTCC
                        AAGAGGCCTGACAATGAGAATGGGTGGATGTCCTACCTGTCAGAGATGTCCACCTCCTGC
                        CGCTCAGTCCAGGTTCTCTTGCATTACTTTGTGGGTGCCAATTACTTATGGCTGCTGGTT
                        GAAGGCCTCTACCTCCACACGCTGCTGGAGCCCACAGTGCTTCCTGAGAGGCGGCTGTGG
                        CCCAGATACCTGCTGTTGGGTTGGGCCTTCCCTGTGCTATTTGTTGTACCCTGGGGTTTC
                        GCCCGTGCACACCTGGAGAACACAGGGTGCTGGACAACAAATGGGAATAAGAAAATCTGG
                        TGGATCATCCGAGGACCCATGATGCTCTGTGTAACAGTCAATTTCTTCATCTTCCTGAAA
                        ATTCTCAAGCTTCTCATTTCTAAGCTCAAAGCTCATCAAATGTGCTTCAGAGATTATAAA
                        TACAGATTGGCAAAATCAACACTGGTCCTCATTCCTTTATTGGGCGTTCATGAGATCCTC
                        TTCTCTTTCATCACTGATGATCAAGTTGAAGGATTTGCAAAACTTATACGACTTTTCATT
                        CAGTTGACACTGAGCTCCTTTCATGGGTTCCTGGTGGCCTTGCAGTATGGTTTTGCCAAT
                        GGAGAAGTGAAGGCTGAGCTGCGGAAATACTGGGTCCGCTTCTTGCTAGCCCGCCACTCA
                        GGCTGCAGAGCCTGTGTCCTGGGGAAGGACTTCCGGTTCCTAGGAAAATGTCCCAAGAAG
                        CTCTCGGAAGGAGATGGCGCTGAGAAGCTTCGGAAGCTGCAGCCCTCACTTAACAGTGGG
                        CGGCTCCTACATCTAGCCATGCGAGGTCTTGGGGAGCTGGGCGCCCAGCCCCAACAGGAC
                        CATGCACGCTGGCCCCGGGGCAGCAGCCTGTCCGAGTGCAGTGAGGGGGATGTCACCATG
                        GCCAACACCATGGAGGAGATTCTGGAAGAGAGTGAGATCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00002</identifier>
                            <name>7tm_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02793</identifier>
                            <name>HRM</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000857</id>
                <name>Glucagon-like peptide 1 receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Korner M, Stockli M, Waser B, Reubi JC: GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007 May;48(5):736-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17475961&#13;
                    # Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17498508&#13;
                    # Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17534934&#13;
                    # Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12529935</references>
                <known-action>unknown</known-action>
                <polypeptide id="P43220" source="Swiss-Prot">
                    <name>Glucagon-like peptide 1 receptor</name>
                    <general-function>Involved in peptide receptor activity, G-protein coupled</general-function>
                    <specific-function>This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase</specific-function>
                    <gene-name>GLP1R</gene-name>
                    <locus>6p21</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>146-168
                        177-196
                        228-252
                        265-288
                        304-329
                        352-372
                        388-408</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.19</theoretical-pi>
                    <molecular-weight>53060.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4324</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GLP1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GLP1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U01104</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>405082</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>249</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>29</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P43220</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GLP1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GLP-1 receptor</synonym>
                        <synonym>GLP-1-R</synonym>
                        <synonym>GLP-1R</synonym>
                        <synonym>Glucagon-like peptide 1 receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Glucagon-like peptide 1 receptor precursor
                        MAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSLTEDPPPATDL
                        FCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHVYRFCTAEGLWLQKDNSSLPW
                        RDLSECEESKRGERSSPEEQLLFLYIIYTVGYALSFSALVIASAILLGFRHLHCTRNYIH
                        LNLFASFILRALSVFIKDAALKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAAN
                        YYWLLVEGVYLYTLLAFSVFSEQWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRN
                        SNMNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKANLMCKTDIKCRLAKSTLTLIPLL
                        GTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERW
                        RLEHLHIQRDSSMKPLKCPTSSLSSGATAGSSMYTATCQASCS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1392 bp
                        ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCCGTGCTGCTGCTCGGGATGGTGGGCAGG
                        GCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGA
                        GAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTG
                        TTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTC
                        GTGAATGTCAGCTGCCCCTGGTACCTGCCCTGGGCCAGCAGTGTGCCGCAGGGCCACGTG
                        TACCGGTTCTGCACAGCTGAAGGCCTCTGGCTGCAGAAGGACAACTCCAGCCTGCCCTGG
                        AGGGACTTGTCGGAGTGCGAGGAGTCCAAGCGAGGGGAGAGAAGCTGGGGGGAGGAGCAG
                        CTCCTGTTCCTCTACATCATCTACACGGTGGCGTACGCACTCTCCTTCTCTGCTCTGGTT
                        ATCGCCTCTGCGATCCTCCTCGGCTTCAGACACCTGCACTGCACCAGGAACTACATCCAC
                        CTGAACCTGTTTGCATCCTTCATCCTGCGAGCATTGTCCGTCTTCATCAAGGACGCAGCC
                        CTGAAGTGGATGTATAGCACAGCCGCCCAGCAGCACCAGTGGGATGGGCTCCTCTCCTAC
                        CAGGACTCTCTGAGCTGCCGCCTGGTGTTTCTGCTCATGCAGTACTGTGTGGCGGCCAAT
                        TACTACTGGCTCTTGGTGGAGGGCGTGTACCTGTACACACTGCTGGCCTTCTCGGTCTTC
                        TCTGAGCAATGGATCTTCAGGCTCTACGTGAGCATAGGCTGGGGTGTTCCCCTGCTGTTT
                        GTTGTCCCCTGGGGCATTGTCAAGATCCTCTATGAGGACGAGGGCTGCTGGACCAGGAAC
                        TCCAACATGAACTACTGGCTCATTATCCGGCTGCCCATTCTCTTTGCCATTGGGGTGAAC
                        TTCCTCATCTTTGTTCGGGTCATCTGCATCGTGGTATCCAAACTGAAGGCCAATCTCATG
                        TGCAAGACAGACATCAAATGCAGACTTGCCAAGTCCACGCTGACACTCATCCCCCTGCTG
                        GGGACTCATGAGGTCATCTTTGCCTTTGTGATGGACGAGCACGCCCGGGGGACCCTGCGC
                        TTCATCAAGCTGTTTACAGAGCTCTCCTTCACCTCCTTCCAGGGGCTGATGGTGGCCATC
                        TTATACTGCTTTGTCAACAATGAGGTCCAGCTGGAATTTCGGAAGAGCTGGGAGCGCTGG
                        CGGCTTGAGCACTTGCACATCCAGAGGGACAGCAGCATGAAGCCCCTCAAGTGTCCCACC
                        AGCAGCCTGAGCAGTGGAGCCACGGCGGGCAGCAGCATGTACACAGCCACTTGCCAGGCC
                        TCCTGCAGCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00002</identifier>
                            <name>7tm_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02793</identifier>
                            <name>HRM</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptide receptor activity, G-protein coupled</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>secretin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>glucagon receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00041</drugbank-id>
        <drugbank-id>BIOD00082</drugbank-id>
        <drugbank-id>BTD00082</drugbank-id>
        <name>Aldesleukin</name>
        <description>Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.</description>
        <cas-number>85898-30-2</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference>Hans-Ake Fabricius, Roland Stahn, "Serum-free and mitogen-free T-cell growth factor and process for making same." U.S. Patent US4464355, issued May, 1971.</synthesis-reference>
        <indication>For treatment of adults with metastatic renal cell carcinoma.</indication>
        <pharmacodynamics>Used to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.</pharmacodynamics>
        <mechanism-of-action>Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>13 min-85 min</half-life>
        <protein-binding/>
        <route-of-elimination>The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.</route-of-elimination>
        <volume-of-distribution>0.18 l/kg</volume-of-distribution>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">IL-2</synonym>
            <synonym language="" coder="">Interleukin-2 precursor</synonym>
            <synonym language="" coder="">T-cell growth factor</synonym>
            <synonym language="" coder="">TCGF</synonym>
        </synonyms>
        <products>
            <product>
                <name>Proleukin</name>
                <ndc-id>0078-0495_d7232a34-b86b-47f3-b921-13a27fdf93a6</ndc-id>
                <ndc-product-code>0078-0495</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1992-05-06</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection</dosage-form>
                <strength>1.1 mg/mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA103293</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Proleukin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02130181</dpd-id>
                <started-marketing-on>1995-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>22000000 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Proleukin</name>
                <ndc-id>65483-116_b3294680-603d-42f9-a4c9-473213f6797a</ndc-id>
                <ndc-product-code>65483-116</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1992-05-05</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>1.1 mg/mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA103293</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Proleukin</name>
                <ingredients>Aldesleukin</ingredients>
            </mixture>
            <mixture>
                <name>Proleukin</name>
                <ingredients>Aldesleukin</ingredients>
            </mixture>
            <mixture>
                <name>Proleukin</name>
                <ingredients>Aldesleukin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Bayer Healthcare</name>
                <url>http://www.bayerhealthcare.com</url>
            </packager>
            <packager>
                <name>Chiron Corp.</name>
                <url>http://www.chiron.com</url>
            </packager>
            <packager>
                <name>Novartis AG</name>
                <url>http://www.novartis.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Prometheus Laboratories Inc.</name>
                <url>http://www.prometheuslabs.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Proleukin 22000000 unit Solution Vial</description>
                <cost currency="USD">976.66</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Proleukin 22 million unit vial</description>
                <cost currency="USD">1092.34</cost>
                <unit>each</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antineoplastic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-HIV Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection</form>
                <route>intravenous</route>
                <strength>1.1 mg/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>intravenous</route>
                <strength>1.1 mg/mL</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>22000000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L03AC01">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L03">IMMUNOSTIMULANTS</level>
                <level code="L03A">IMMUNOSTIMULANTS</level>
                <level code="L03AC">Interleukins</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>10:00.00</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00240</drugbank-id>
                <name>Alclometasone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00288</drugbank-id>
                <name>Amcinonide</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00394</drugbank-id>
                <name>Beclomethasone</name>
                <description>May diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00443</drugbank-id>
                <name>Betamethasone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01222</drugbank-id>
                <name>Budesonide</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00237</drugbank-id>
                <name>Butabarbital</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01353</drugbank-id>
                <name>Butethal</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB02300</drugbank-id>
                <name>Calcipotriol</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01013</drugbank-id>
                <name>Clobetasol propionate</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00838</drugbank-id>
                <name>Clocortolone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01285</drugbank-id>
                <name>Corticotropin</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01380</drugbank-id>
                <name>Cortisone acetate</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00547</drugbank-id>
                <name>Desoximetasone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01234</drugbank-id>
                <name>Dexamethasone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00271</drugbank-id>
                <name>Diatrizoate</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00223</drugbank-id>
                <name>Diflorasone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00476</drugbank-id>
                <name>Duloxetine</name>
                <description>Hypotensive Agents may enhance the orthostatic hypotensive effect of Duloxetine.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00965</drugbank-id>
                <name>Ethiodized oil</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00687</drugbank-id>
                <name>Fludrocortisone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00591</drugbank-id>
                <name>Fluocinolone Acetonide</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01047</drugbank-id>
                <name>Fluocinonide</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00324</drugbank-id>
                <name>Fluorometholone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00846</drugbank-id>
                <name>Flurandrenolide</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08906</drugbank-id>
                <name>Fluticasone furoate</name>
                <description>May diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06786</drugbank-id>
                <name>Halcinonide</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00596</drugbank-id>
                <name>Halobetasol Propionate</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01354</drugbank-id>
                <name>Heptabarbital</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01355</drugbank-id>
                <name>Hexobarbital</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00769</drugbank-id>
                <name>Hydrocortamate</name>
                <description>May diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00741</drugbank-id>
                <name>Hydrocortisone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00018</drugbank-id>
                <name>Interferon alfa-n3</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00069</drugbank-id>
                <name>Interferon alfacon-1</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04711</drugbank-id>
                <name>Iodipamide</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01249</drugbank-id>
                <name>Iodixanol</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01362</drugbank-id>
                <name>Iohexol</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08947</drugbank-id>
                <name>Iopamidol</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09156</drugbank-id>
                <name>Iopromide</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09134</drugbank-id>
                <name>Ioversol</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09135</drugbank-id>
                <name>Ioxilan</name>
                <description>May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01235</drugbank-id>
                <name>Levodopa</name>
                <description>Hypotensive Agents may enhance the orthostatic hypotensive effect of Levodopa.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04817</drugbank-id>
                <name>Metamizole</name>
                <description>May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00474</drugbank-id>
                <name>Methohexital</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00959</drugbank-id>
                <name>Methylprednisolone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00764</drugbank-id>
                <name>Mometasone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00008</drugbank-id>
                <name>Peginterferon alfa-2a</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00022</drugbank-id>
                <name>Peginterferon alfa-2b</name>
                <description>Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00312</drugbank-id>
                <name>Pentobarbital</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01130</drugbank-id>
                <name>Prednicarbate</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00860</drugbank-id>
                <name>Prednisolone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00635</drugbank-id>
                <name>Prednisone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00794</drugbank-id>
                <name>Primidone</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00896</drugbank-id>
                <name>Rimexolone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>Hypotensive Agents may enhance the hypotensive effect of Risperidone.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00418</drugbank-id>
                <name>Secobarbital</name>
                <description>May enhance the hypotensive effect of Hypotensive Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00620</drugbank-id>
                <name>Triamcinolone</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09082</drugbank-id>
                <name>Vilanterol</name>
                <description>Corticosteroids may diminish the antineoplastic effect of Aldesleukin.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Aldesleukin sequence
                MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL
                EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN
                RWITFCQSIISTLT</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.192</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.31</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>15314.8000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C690H1115N177O202S6</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>278</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0078-0495-61</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M11144</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA448081</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P60569</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Aldesleukin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/aldesleukin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/aldesleukin.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000651</id>
                <name>Interleukin-2 receptor subunit beta</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                    <action>modulator</action>
                </actions>
                <references># Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16477002&#13;
                    # Steppan S, Eckart MR, Bajsarowicz K, Sternberg LR, Greve JM, Cassell DJ: Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog. J Interferon Cytokine Res. 2006 Mar;26(3):171-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16542139&#13;
                    # Cornish GH, Sinclair LV, Cantrell DA: Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006 Jul 15;108(2):600-8. Epub 2006 Mar 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16569767&#13;
                    # Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML: Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep. 2006 May;15(5):1211-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16596189&#13;
                    # Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ: Airway inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol. 2006 Jun;41(6):577-83. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16617454&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P14784" source="Swiss-Prot">
                    <name>Interleukin-2 receptor subunit beta</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2</specific-function>
                    <gene-name>IL2RB</gene-name>
                    <locus>22q13|22q13.1</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>241-265</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.68</theoretical-pi>
                    <molecular-weight>61118.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6009</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL2RB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL2RB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M26062</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>307048</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P14784</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL2RB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD122 antigen</synonym>
                        <synonym>High affinity IL-2 receptor subunit beta</synonym>
                        <synonym>IL-2 receptor</synonym>
                        <synonym>Interleukin-2 receptor subunit beta precursor</synonym>
                        <synonym>P70-75</synonym>
                        <synonym>p75</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interleukin-2 receptor beta chain precursor
                        MAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ
                        VHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA
                        IQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE
                        APLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT
                        IPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV
                        QKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT
                        NQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT
                        FPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP
                        DLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ
                        ELQGQDPTHLV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1656 bp
                        ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT
                        ACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG
                        AGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA
                        GTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT
                        CAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA
                        GTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC
                        ATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT
                        GTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC
                        TTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG
                        GCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA
                        GACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG
                        AGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC
                        ATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA
                        GTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT
                        AACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC
                        CAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT
                        GAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG
                        GACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC
                        AACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG
                        TACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC
                        ACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC
                        TTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC
                        CCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA
                        GAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA
                        GACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC
                        CCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG
                        GAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA
                        GAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000658</id>
                <name>Interleukin-2 receptor subunit alpha</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                    <action>modulator</action>
                </actions>
                <references># Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007 Jan;27(1):1-18. Epub 2007 Jan 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17216565&#13;
                    # Recchia F, Cesta A, Rea S: Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy. J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):135-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16767920&#13;
                    # Waldmann TA: Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007 May 28;26(25):3699-703. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17530023&#13;
                    # Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW, Jin Z, Burke E, Deng M, Cadeiras M, Cortesini R, Itescu S, Marboe C, Mancini D, Suciu-Foca N: Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol. 2007 Jul;18(1):13-21. Epub 2007 Apr 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17584597&#13;
                    # Liu BY, Zhu P, Luo HB, Fu N: [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain] Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jul;26(7):971-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16864089&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352&#13;
                    # Ouyang Y, Kaminski NE: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch Toxicol. 1999 Feb;73(1):1-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10207608</references>
                <known-action>yes</known-action>
                <polypeptide id="P01589" source="Swiss-Prot">
                    <name>Interleukin-2 receptor subunit alpha</name>
                    <general-function>Involved in interleukin-2 receptor activity</general-function>
                    <specific-function>Receptor for interleukin-2</specific-function>
                    <gene-name>IL2RA</gene-name>
                    <locus>10p15-p14</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>241-259</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.49</theoretical-pi>
                    <molecular-weight>30819.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6008</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL2RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL2RA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X01057</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33813</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01589</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL2RA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD25 antigen</synonym>
                        <synonym>IL-2 receptor alpha subunit</synonym>
                        <synonym>IL-2-RA</synonym>
                        <synonym>IL2-RA</synonym>
                        <synonym>Interleukin-2 receptor alpha chain precursor</synonym>
                        <synonym>p55</synonym>
                        <synonym>TAC antigen</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Interleukin-2 receptor alpha chain precursor
                        MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS
                        GSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS
                        LPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP
                        QLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ
                        VAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;819 bp
                        ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG
                        GCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC
                        TACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC
                        GGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT
                        CAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA
                        CAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC
                        CTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT
                        CATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC
                        AGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC
                        CAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG
                        GCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT
                        CAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG
                        GTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC
                        TGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002102</id>
                <name>Cytokine receptor common subunit gamma</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16477002&#13;
                    # Shibata F, Toma T, Wada T, Inoue M, Tone Y, Ohta K, Kasahara Y, Sano F, Kimura M, Ikeno M, Koizumi S, Yachie A: Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol. 2007 Jul;79(1):81-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17598841&#13;
                    # Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, Mairena EC, Bacal F, Bocchi E, Guilherme L, Zheng XX, Liew FY, Higuchi ML, Kalil J, Cunha-Neto E: Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol. 2007 Aug-Sep;66(2-3):362-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17635814&#13;
                    # Blank RB, Lamb EW, Tocheva AS, Crow ET, Lim KC, McKerrow JH, Davies SJ: The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells. J Infect Dis. 2006 Dec 1;194(11):1609-16. Epub 2006 Oct 23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17083048&#13;
                    # Smyth CM, Ginn SL, Deakin CT, Logan GJ, Alexander IE: Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood. 2007 Jul 1;110(1):91-8. Epub 2007 Mar 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17363735</references>
                <known-action>yes</known-action>
                <polypeptide id="P31785" source="Swiss-Prot">
                    <name>Cytokine receptor common subunit gamma</name>
                    <general-function/>
                    <specific-function>Common subunit for the receptors for a variety of interleukins</specific-function>
                    <gene-name>IL2RG</gene-name>
                    <locus>Xq13.1</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>263-283</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.31</theoretical-pi>
                    <molecular-weight>42287.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6010</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IL2RG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IL2RG</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>D11086</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>219890</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31785</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IL2RG_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD132 antigen</synonym>
                        <synonym>Cytokine receptor common gamma chain precursor</synonym>
                        <synonym>Gamma-C</synonym>
                        <synonym>IL-2R gamma chain</synonym>
                        <synonym>Interleukin- 2 receptor gamma chain</synonym>
                        <synonym>p64</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytokine receptor common gamma chain
                        MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV
                        QCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK
                        EIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN
                        HCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW
                        SHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV
                        TEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP
                        PCYTLKPET</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1110 bp
                        ATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA
                        GTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC
                        TTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT
                        CAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC
                        CAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG
                        AAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG
                        GAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA
                        CAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA
                        ACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC
                        CACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA
                        TCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG
                        TTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG
                        AGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG
                        GAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT
                        TTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT
                        ACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT
                        CTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG
                        GCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC
                        CCATGTTACACCCTAAAGCCTGAAACCTGA</gene-sequence>
                    <pfams>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme position="1">
                <id>BE0000262</id>
                <name>Prostaglandin G/H synthase 2</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Pyeon D, Diaz FJ, Splitter GA: Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol. 2000 Jun;74(12):5740-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10823885&#13;
                    # Hamada T, Tsuchihashi S, Avanesyan A, Duarte S, Moore C, Busuttil RW, Coito AJ: Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol. 2008 Feb 1;180(3):1843-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18209082</references>
                <known-action>unknown</known-action>
                <polypeptide id="P35354" source="Swiss-Prot">
                    <name>Prostaglandin G/H synthase 2</name>
                    <general-function>Involved in peroxidase activity</general-function>
                    <specific-function>May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity</specific-function>
                    <gene-name>PTGS2</gene-name>
                    <locus>1q25.2-q25.3</locus>
                    <cellular-location>Microsome; microsomal membrane; peripheral membrane protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.41</theoretical-pi>
                    <molecular-weight>68997.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9605</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PTGS2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PTGS2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L15326</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>291988</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P35354</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PGH2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>COX-2</synonym>
                        <synonym>Cyclooxygenase- 2</synonym>
                        <synonym>EC 1.14.99.1</synonym>
                        <synonym>PGH synthase 2</synonym>
                        <synonym>PGHS-2</synonym>
                        <synonym>PHS II</synonym>
                        <synonym>Prostaglandin G/H synthase 2 precursor</synonym>
                        <synonym>Prostaglandin H2 synthase 2</synonym>
                        <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prostaglandin G/H synthase 2 precursor
                        MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
                        TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
                        GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
                        NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
                        QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
                        VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
                        NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
                        AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
                        YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
                        GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
                        STEL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1815 bp
                        ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
                        TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
                        AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
                        ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
                        TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
                        TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
                        GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
                        GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
                        AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
                        AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
                        AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
                        GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
                        CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
                        TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
                        GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
                        GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
                        ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
                        TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
                        AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
                        TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
                        CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
                        GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCACTGACCAG
                        AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
                        TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
                        TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
                        GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
                        ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
                        GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
                        TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
                        GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
                        TCGACTGAACTGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF03098</identifier>
                            <name>An_peroxidase</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>antioxidant activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peroxidase activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
            <enzyme position="2">
                <id>BE0000657</id>
                <name>Cytosolic phospholipase A2</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE: Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother. 1995 Nov;41(5):287-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8536274</references>
                <known-action>unknown</known-action>
                <polypeptide id="P47712" source="Swiss-Prot">
                    <name>Cytosolic phospholipase A2</name>
                    <general-function>Involved in phospholipase activity</general-function>
                    <specific-function>Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response</specific-function>
                    <gene-name>PLA2G4A</gene-name>
                    <locus>1q25</locus>
                    <cellular-location>Cytoplasm. Cytoplasmic vesicle. Translocates to membrane vesicles in a calcium-dependent fashion</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.03</theoretical-pi>
                    <molecular-weight>85212.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9035</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PLA2G4A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PLA2G4A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M72393</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>190007</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P47712</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PA24A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>cPLA2</synonym>
                        <synonym>EC 3.1.1.4</synonym>
                        <synonym>Phospholipase A2 group IVA</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytosolic phospholipase A2
                        MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRT
                        RHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEV
                        PFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEG
                        LHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSH
                        PDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIG
                        ETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYG
                        TFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEE
                        LENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFN
                        TREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDV
                        KSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMN
                        KLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYKAPGVPRETE
                        EEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRR
                        QNPSRCSVSLSNVEARRFFNKEFLSKPKA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2250 bp
                        ATGTCATTTATAGATCCTTACCAGCACATTATAGTGGAGCACCAGTATTCCCACAAGTTT
                        ACGGTAGTGGTGTTACGTGCCACCAAAGTGACAAAGGGGGCCTTTGGTGACATGCTTGAT
                        ACTCCAGATCCCTATGTGGAACTTTTTATCTCTACAACCCCTGACAGCAGGAAGAGAACA
                        AGACATTTCAATAATGACATAAACCCTGTGTGGAATGAGACCTTTGAATTTATTTTGGAT
                        CCTAATCAGGAAAATGTTTTGGAGATTACGTTAATGGATGCCAATTATGTCATGGATGAA
                        ACTCTAGGGACAGCAACATTTACTGTATCTTCTATGAAGGTGGGAGAAAAGAAAGAAGTT
                        CCTTTTATTTTCAACCAAGTCACTGAAATGGTTCTAGAAATGTCTCTTGAAGTTTGCTCA
                        TGCCCAGACCTACGATTTAGTATGGCTCTGTGTGATCAGGAGAAGACTTTCAGACAACAG
                        AGAAAAGAACACATAAGGGAGAGCATGAAGAAACTCTTGGGTCCAAAGAATAGTGAAGGA
                        TTGCATTCTGCACGTGATGTGCCTGTGGTAGCCATATTGGGTTCAGGTGGGGGTTTCCGA
                        GCCATGGTGGGATTCTCTGGTGTGATGAAGGCATTATACGAATCAGGAATTCTGGATTGT
                        GCTACCTACGTTGCTGGTCTTTCTGGCTCCACCTGGTATATGTCAACCTTGTATTCTCAC
                        CCTGATTTTCCAGAGAAAGGGCCAGAGGAGATTAATGAAGAACTAATGAAAAATGTTAGC
                        CACAATCCCCTTTTACTTCTCACACCACAGAAAGTTAAAAGATATGTTGAGTCTTTATGG
                        AAGAAGAAAAGCTCTGGACAACCTGTCACCTTTACTGATATCTTTGGGATGTTAATAGGA
                        GAAACACTAATTCATAATAGAATGAATACTACTCTGAGCAGTTTGAAGGAAAAAGTTAAT
                        ACTGCACAATGCCCTTTACCTCTTTTCACCTGTCTTCATGTCAAACCTGACGTTTCAGAG
                        CTGATGTTTGCAGATTGGGTTGAATTTAGTCCATACGAAATTGGCATGGCTAAATATGGT
                        ACTTTTATGGCTCCCGACTTATTTGGAAGCAAATTTTTTATGGGAACAGTCGTTAAGAAG
                        TATGAAGAAAACCCCTTGCATTTCTTAATGGGTGTCTGGGGCAGTGCCTTTTCCATATTG
                        TTCAACAGAGTTTTGGGCGTTTCTGGTTCACAAAGCAGAGGCTCCACAATGGAGGAAGAA
                        TTAGAAAATATTACCACAAAGCATATTGTGAGTAATGATAGCTCGGACAGTGATGATGAA
                        TCACACGAACCCAAAGGCACTGAAAATGAAGATGCTGGAAGTGACTATCAAAGTGATAAT
                        CAAGCAAGTTGGATTCATCGTATGATAATGGCCTTGGTGAGTGATTCAGCTTTATTCAAT
                        ACCAGAGAAGGACGTGCTGGGAAGGTACACAACTTCATGCTGGGCTTGAATCTCAATACA
                        TCTTATCCACTGTCTCCTTTGAGTGACTTTGCCACACAGGACTCCTTTGATGATGATGAA
                        CTGGATGCAGCTGTAGCAGATCCTGATGAATTTGAGCGAATATATGAGCCTCTGGATGTC
                        AAAAGTAAAAAGATTCATGTAGTGGACAGTGGGCTCACATTTAACCTGCCGTATCCCTTG
                        ATACTGAGACCTCAGAGAGGGGTTGATCTCATAATCTCCTTTGACTTTTCTGCAAGGCCA
                        AGTGACTCTAGTCCTCCGTTCAAGGAACTTCTACTTGCAGAAAAGTGGGCTAAAATGAAC
                        AAGCTCCCCTTTCCAAAGATTGATCCTTATGTGTTTGATCGGGAAGGGCTGAAGGAGTGC
                        TATGTCTTTAAACCCAAGAATCCTGATATGGAGAAAGATTGCCCAACCATCATCCACTTT
                        GTTCTGGCCAACATCAACTTCAGAAAGTACAAGGCTCCAGGTGTTCCAAGGGAAACTGAG
                        GAAGAGAAAGAAATCGCTGACTTTGATATTTTTGATGACCCAGAATCACCATTTTCAACC
                        TTCAATTTTCAATATCCAAATCAAGCATTCAAAAGACTACATGATCTTATGCACTTCAAT
                        ACTCTGAACAACATTGATGTGATAAAAGAAGCCATGGTTGAAAGCATTGAATATAGAAGA
                        CAGAATCCATCTCGTTGCTCTGTTTCCCTTAGTAATGTTGAGGCAAGAAGATTTTTCAAC
                        AAGGAGTTTCTAAGTAAACCCAAAGCATAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00168</identifier>
                            <name>C2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01735</identifier>
                            <name>PLA2_B</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>carboxylic ester hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>lipase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>phospholipase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity, acting on ester bonds</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>membrane lipid metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phospholipid metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phospholipid catabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>primary metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>lipid metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular lipid metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
            <enzyme position="3">
                <id>BE0002638</id>
                <name>Cytochrome P450 3A4</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10086330&#13;
                    # Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD: Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 2004 Mar;32(3):359-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14977871</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08684" source="Swiss-Prot">
                    <name>Cytochrome P450 3A4</name>
                    <general-function>Involved in monooxygenase activity</general-function>
                    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4- hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. The enzyme also hydroxylates etoposide</specific-function>
                    <gene-name>CYP3A4</gene-name>
                    <locus>7q21.1</locus>
                    <cellular-location>Endoplasmic reticulum</cellular-location>
                    <transmembrane-regions>2-22</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.25</theoretical-pi>
                    <molecular-weight>57344.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CYP3A4</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M18907</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08684</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CP3A4_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CYPIIIA4</synonym>
                        <synonym>EC 1.14.13.67</synonym>
                        <synonym>EC 1.14.13.97</synonym>
                        <synonym>NF-25</synonym>
                        <synonym>Nifedipine oxidase</synonym>
                        <synonym>P450-PCN1</synonym>
                        <synonym>Quinine 3-monooxygenase</synonym>
                        <synonym>Taurochenodeoxycholate 6-alpha- hydroxylase</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytochrome P450 3A4
                        MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
                        DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
                        AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
                        MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
                        FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
                        IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
                        NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
                        KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
                        GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1512 bp
                        ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
                        CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
                        CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
                        GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
                        GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
                        GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
                        GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
                        AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
                        AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
                        ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
                        GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
                        CTCTCAATAACAGTCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTG
                        TTTCCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGC
                        CTCGAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT
                        TCAAAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATT
                        ATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAA
                        CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCC
                        AATAAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTG
                        AATGAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT
                        GTTGAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCT
                        CTTCACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGC
                        AAGAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA
                        AACTGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTT
                        CAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGA
                        GGACTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTA
                        AGTGGAGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00067</identifier>
                            <name>p450</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>transition metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>iron ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tetrapyrrole binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>heme binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>monooxygenase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>generation of precursor metabolites and energy</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>electron transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
            <enzyme position="4">
                <id>BE0002204</id>
                <name>Xanthine dehydrogenase/oxidase</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Faggioni R, Allavena P, Cantoni L, Carelli M, Demitri MT, Delgado R, Gatti S, Gnocchi P, Isetta AM, Paganin C, et al.: Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):194-201. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8032542</references>
                <known-action>unknown</known-action>
                <polypeptide id="P47989" source="Swiss-Prot">
                    <name>Xanthine dehydrogenase/oxidase</name>
                    <general-function>Nucleotide transport and metabolism</general-function>
                    <specific-function>This enzyme can be converted from the dehydrogenase form (D) to the oxidase form (O) irreversibly by proteolysis or reversibly through the oxidation of sulfhydryl groups</specific-function>
                    <gene-name>XDH</gene-name>
                    <locus>2p23.1</locus>
                    <cellular-location>Peroxisome</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>7.7</theoretical-pi>
                    <molecular-weight>146426.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:12805</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>XDH</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>XDH</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>D11456</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>10336525</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P47989</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>XDH_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 1.17.1.4</synonym>
                        <synonym>EC 1.17.3.2</synonym>
                        <synonym>Xanthine oxidase</synonym>
                        <synonym>XD</synonym>
                        <synonym>XO</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase
                        MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDR
                        LQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGI
                        VMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCC
                        MNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQAS
                        TLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFG
                        AACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISD
                        LNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA
                        FKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKE
                        ELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLD
                        PTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRY
                        ENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDK
                        VTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDL
                        KKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKM
                        LGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGR
                        HPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGR
                        LCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKL
                        EGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGA
                        LLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAA
                        SVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLG
                        YSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAF
                        VQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAV
                        GEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVT
                        GVPENCKPWSVRV</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4002 bp
                        ATGACAGCAGACAAATTGGTTTTCTTTGTGAATGGCAGAAAGGTGGTGGAGAAAAATGCA
                        GATCCAGAGACAACCCTTTTGGCCTACCTGAGAAGAAAGTTGGGGCTGAGTGGAACCAAG
                        CTCGGCTGTGGAGAGGGGGGCTGCGGGGCTTGCACAGTGATGCTCTCCAAGTATGATCGT
                        CTGCAGAACAAGATCGTCCACTTTTCTGCCAATGCCTGCCTGGCCCCCATCTGCTCCTTG
                        CACCATGTTGCAGTGACAACTGTGGAAGGAATAGGAAGCACCAAGACGAGGCTGCATCCT
                        GTGCAGGAGAGAATTGCCAAAAGCCACGGCTCCCAGTGCGGGTTCTGCACCCCTGGCATC
                        GTCATGAGTATGTACACACTGCTCCGGAATCAGCCCGAGCCCACCATGGAGGAGATTGAG
                        AATGCCTTCCAAGGAAATCTGTGCCGCTGCACAGGCTACAGACCCATCCTCCAGGGCTTC
                        CGGACCTTTGCCAGGGATGGTGGATGCTGTGGAGGAGATGGGAATAATCCAAATTGCTGC
                        ATGAACCAGAAGAAAGACCACTCAGTCAGCCTCTCGCCATCTTTATTCAAACCAGAGGAG
                        TTCACGCCCCTGGATCCAACCCAGGAGCCCATTTTTCCCCCAGAGTTGCTGAGGCTGAAA
                        GACACTCCTCGGAAGCAGCTGCGATTTGAAGGGGAGCGTGTGACGTGGATACAGGCCTCA
                        ACCCTCAAGGAGCTGCTGGACCTCAAGGCTCAGCACCCTGACGCCAAGCTGGTCGTGGGG
                        AACACGGAGATTGGCATTGAGATGAAGTTCAAGAATATGCTGTTTCCTATGATTGTCTGC
                        CCAGCCTGGATCCCTGAGCTGAATTCGGTAGAACATGGACCCGACGGTATCTCCTTTGGA
                        GCTGCTTGCCCCCTGAGCATTGTGGAAAAAACCCTGGTGGATGCTGTTGCTAAGCTTCCT
                        GCCCAAAAGACAGAGGTGTTCAGAGGGGTCCTGGAGCAGCTGCGCTGGTTTGCTGGGAAG
                        CAAGTCAAGTCTGTGGCGTCCGTTGGAGGGAACATCATCACTGCCAGCCCCATCTCCGAC
                        CTCAACCCCGTGTTCATGGCCAGTGGGGCCAAGCTGACACTTGTGTCCAGAGGCACCAGG
                        AGAACTGTCCAGATGGACCACACCTTCTTCCCTGGCTACAGAAAGACCCTGCTGAGCCCG
                        GAGGAGATACTGCTCTCCATAGAGATCCCCTACAGCAGGGAGGGGGAGTATTTCTCAGCA
                        TTCAAGCAGGCCTCCCGGAGAGAAGATGACATTGCCAAGGTAACCAGTGGCATGAGAGTT
                        TTATTCAAGCCAGGAACCACAGAGGTACAGGAGCTGGCCCTTTGCTATGGTGGAATGGCC
                        AACAGAACCATCTCAGCCCTCAAGACCACTCAGAGGCAGCTTTCCAAGCTCTGGAAGGAG
                        GAGCTGCTGCAGGACGTGTGTGCAGGACTGGCAGAGGAGCTGCATCTGCCTCCCGATGCC
                        CCTGGTGGCATGGTGGACTTCCGGTGCACCCTCACCCTCAGCTTCTTCTTCAAGTTCTAC
                        CTGACAGTCCTTCAGAAGCTGGGCCAAGAGAACCTGGAAGACAAGTGTGGTAAACTGGAC
                        CCCACTTTCGCCAGTGCAACTTTACTGTTTCAGAAAGACCCCCCAGCCGATGTCCAGCTC
                        TTCCAAGAGGTGCCCAAGGGTCAGTCTGAGGAGGACATGGTGGGCCGGCCCCTGCCCCAC
                        CTGGCAGCGGACATGCAGGCCTCTGGTGAGGCCGTGTACTGTGACGACATTCCTCGCTAC
                        GAGAATGAGCTGTCTCTCCGGCTGGTCACCAGCACCCGGGCCCACGCCAAGATCAAGTCC
                        ATAGATACATCAGAAGCTAAGAAGGTTCCAGGGTTTGTTTGTTTCATTTCCGCTGATGAT
                        GTTCCTGGGAGTAACATAACTGGAATTTGTAATGATGAGACAGTCTTTGCGAAGGATAAG
                        GTTACTTGTGTTGGGCATATCATTGGTGCTGTGGTTGCTGACACCCCGGAACACACACAG
                        AGAGCTGCCCAAGGGGTGAAAATCACCTATGAAGAACTACCAGCCATTATCACAATTGAG
                        GATGCTATAAAGAACAACTCCTTTTATGGACCTGAGCTGAAGATCGAGAAAGGGGACCTA
                        AAGAAGGGGTTTTCCGAAGCAGATAATGTTGTGTCAGGGGAGATATACATCGGTGGCCAA
                        GAGCACTTCTACCTGGAGACTCACTGCACCATTGCTGTTCCAAAAGGCGAGGCAGGGGAG
                        ATGGAGCTCTTTGTGTCTACACAGAACACCATGAAGACCCAGAGCTTTGTTGCAAAAATG
                        TTGGGGGTTCCAGCAAACCGGATTGTGGTTCGAGTGAAGAGAATGGGAGGAGGCTTTGGA
                        GGCAAGGAGACCCGGAGCACTGTGGTGTCCACGGCAGTGGCCCTGGCTGCATATAAGACC
                        GGCCGCCCTGTGCGATGCATGCTGGACCGTGATGAGGACATGCTGATAACTGGTGGCAGA
                        CATCCCTTCCTGGCCAGATACAAGGTTGGCTTCATGAAGACTGGGACAGTTGTGGCTCTT
                        GAGGTGGACCACTTCAGCAATGTGGGGAACACCCAGGATCTCTCTCAGAGTATTATGGAA
                        CGAGCTTTATTCCACATGGACAACTGCTATAAAATCCCCAACATCCGGGGCACTGGGCGG
                        CTGTGCAAAACCAACCTTCCCTCCAACACGGCCTTCCGGGGCTTTGGGGGGCCCCAGGGG
                        ATGCTCATTGCCGAGTGCTGGATGAGTGAAGTTGCAGTGACCTGTGGGATGCCTGCAGAG
                        GAGGTGCGGAGAAAAAACCTGTACAAAGAAGGGGACCTGACACACTTCAACCAGAAGCTT
                        GAGGGTTTCACCTTGCCCAGATGCTGGGAAGAATGCCTAGCAAGCTCTCAGTATCATGCT
                        CGGAAGAGTGAGGTTGACAAGTTCAACAAGGAGAATTGTTGGAAAAAGAGAGGATTGTGC
                        ATAATTCCCACCAAGTTTGGAATAAGCTTCACAGTTCCTTTTCTGAATCAGGCAGGAGCC
                        CTACTTCATGTGTACACAGATGGCTCTGTGCTGCTGACCCACGGGGGGACTGAGATGGGC
                        CAAGGCCTTCATACCAAAATGGTCCAGGTGGCCAGTAGAGCTCTGAAAATCCCCACCTCT
                        AAGATTTATATCAGCGAGACAAGCACTAACACTGTGCCCAACACCTCTCCCACGGCTGCC
                        TCTGTCAGCGCTGACCTCAATGGACAGGCCGTCTATGCGGCTTGTCAGACCATCTTGAAA
                        AGGCTGGAACCCTACAAGAAGAAGAATCCCAGTGGCTCCTGGGAAGACTGGGTCACAGCT
                        GCCTACATGGACACAGTGAGCTTGTCTGCCACTGGGTTTTATAGAACACCCAATCTGGGC
                        TACAGCTTTGAGACTAACTCAGGGAACCCCTTCCACTACTTCAGCTATGGGGTGGCTTGC
                        TCTGAAGTAGAAATCGACTGCCTAACAGGAGATCATAAGAACCTCCGCACAGATATTGTC
                        ATGGATGTTGGCTCCAGTCTAAACCCTGCCATTGATATTGGACAGGTGGAAGGGGCATTT
                        GTCCAGGGCCTTGGCCTCTTCACCCTAGAGGAGCTACACTATTCCCCCGAGGGGAGCCTG
                        CACACCCGTGGCCCTAGCACCTACAAGATCCCGGCATTTGGCAGCATCCCCATTGAGTTC
                        AGGGTGTCCCTGCTCCGCGACTGCCCCAACAAGAAGGCCATCTATGCATCGAAGGCTGTT
                        GGAGAGCCGCCCCTCTTCCTGGCTGCTTCTATCTTCTTTGCCATCAAAGATGCCATCCGT
                        GCAGCTCGAGCTCAGCACACAGGTAATAACGTGAAGGAACTCTTCCGGCTAGACAGCCCT
                        GCCACCCCGGAGAAGATCCGCAATGCCTGCGTGGACAAGTTCACCACCCTGTGTGTCACT
                        GGTGTCCCAGAAAACTGCAAACCCTGGTCTGTGAGGGTCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00111</identifier>
                            <name>Fer2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01315</identifier>
                            <name>Ald_Xan_dh_C</name>
                        </pfam>
                        <pfam>
                            <identifier>PF02738</identifier>
                            <name>Ald_Xan_dh_C2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01799</identifier>
                            <name>Fer2_2</name>
                        </pfam>
                        <pfam>
                            <identifier>PF03450</identifier>
                            <name>CO_deh_flav_C</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00941</identifier>
                            <name>FAD_binding_5</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>transition metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>iron ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transporter activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>electron transporter activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>generation of precursor metabolites and energy</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>electron transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
            <enzyme position="5">
                <id>BE0003533</id>
                <name>Cytochrome P450 2E1</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10086330</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05181" source="Swiss-Prot">
                    <name>Cytochrome P450 2E1</name>
                    <general-function>Secondary metabolites biosynthesis, transport and catabolism</general-function>
                    <specific-function>Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms</specific-function>
                    <gene-name>CYP2E1</gene-name>
                    <locus>10q24.3-qter</locus>
                    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.22</theoretical-pi>
                    <molecular-weight>56848.4</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>GNC:2631</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>CYP2E1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J02625</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>181360</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05181</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CP2E1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>4-nitrophenol 2-hydroxylase</synonym>
                        <synonym>CYPIIE1</synonym>
                        <synonym>P450-J</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytochrome P450 2E1
                        MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
                        AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
                        TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
                        ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
                        EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
                        TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
                        ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
                        FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
                        IPPRYKLCVIPRS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1482 bp
                        CCCAGCGCACCATGTCTGCCCTCGGAGTGACCGTGGCCCTGCTGGTGTGGGCGGCCTTCC
                        TCCTGCTGGTGTCCATGTGGAGGCAGGTGCACAGCAGCTGGAATCTGCCCCCAGGTCCTT
                        TCCCGCTTCCCATCATCGGGAACCTCTTCCAGTTGGAATTGAAGAATATTCCCAAGTCCT
                        TCACCCGGTTGGCCCAGCGCTTCGGGCCGGTGTTCACGCTGTACGTGGGCTCGCAGCGCA
                        TGGTGGTGATGCACGGCTACAAGGCGGTGAAGGAAGCGCTGCTGGACTACAAGGACGAGT
                        TCTCGGGCAGAGGCGACCTCCCCGCGTTCCATGCGCACAGGGACAGGGGAATCATTTTTA
                        ATAATGGACCTACCTGGAAGGACATCCGGCGGTTTTCCCTGACCACCCTCCGGAACTATG
                        GGATGGGGAAACAGGGCAATGAGAGCCGGATCCAGAGGGAGGCCCACTTCCTGCTGGAAG
                        CACTCAGGAAGACCCAAGGCCAGCCTTTCGACCCCACCTTCCTCATCGGCTGCGCGCCCT
                        GCAACGTCATAGCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTC
                        TAAGGCTGATGTATTTGTTTAATGAGAACTTCCACCTACTCAGCACTCCCTGGCTCCAGC
                        TTTACAATAATTTTCCCAGCTTTCTACACTACTTGCCTGGAAGCCACAGAAAAGTCATAA
                        AAAATGTGGCTGAAGTAAAAGAGTATGTGTCTGAAAGGGTGAAGGAGCACCATCAATCTC
                        TGGACCCCAACTGTCCCCGGGACCTCACCGACTGCCTGCTCGTGGAAATGGAGAAGGAAA
                        AGCACAGTGCAGAGCGCTTGTACACAATGGACGGTATCACCGTGACTGTGGCCGACCTGT
                        TCTTTGCGGGGACAGAGACCACCAGCACAACTCTGAGATATGGGCTCCTGATTCTCATGA
                        AATACCCTGAGATCGAAGAGAAGCTCCATGAAGAAATTGACAGGGTGATTGGGCCAAGCC
                        GAATCCCTGCCATCAAGGATAGGCAAGAGATGCCCTACATGGATGCTGTGGTGCATGAGA
                        TTCAGCGGTTCATCACCCTCGTGCCCTCCAACCTGCCCCATGAAGCAACCCGAGACACCA
                        TTTTCAGAGGATACCTCATCCCCAAGGGCACAGTCGTAGTGCCAACTCTGGACTCTGTTT
                        TGTATGACAACCAAGAATTTCCTGATCCAGAAAAGTTTAAGCCAGAACACTTCCTGAATG
                        AAAATGGAAAGTTCAAGTACAGTGACTATTTCAAGCCATTTTCCACAGGAAAACGAGTGT
                        GTGCTGGAGAAGGCCTGGCTCGCATGGAGTTGTTTCTTTTGTTGTGTGCCATTTTGCAGC
                        ATTTTAATTTGAAGCCTCTCGTTGACCCAAAGGATATCGACCTCAGCCCTATACATATTG
                        GGTTTGGCTGTATCCCACCACGTTACAAACTCTGTGTCATTC</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00067</identifier>
                            <name>p450</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>transition metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>iron ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tetrapyrrole binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>heme binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>monooxygenase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>generation of precursor metabolites and energy</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>electron transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-09-22">
        <drugbank-id primary="true">DB00042</drugbank-id>
        <drugbank-id>BIOD00070</drugbank-id>
        <drugbank-id>BTD00070</drugbank-id>
        <name>Botulinum Toxin Type B</name>
        <description>Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.</description>
        <cas-number>93384-44-2</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15907915&#13;
            # Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10534247&#13;
            # Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15839401&#13;
            # Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15887434&#13;
            # Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15928517</general-references>
        <synthesis-reference/>
        <indication>For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.</indication>
        <pharmacodynamics>Botulinum Toxin Type B inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release.</pharmacodynamics>
        <mechanism-of-action>Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.</mechanism-of-action>
        <toxicity>One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.</toxicity>
        <metabolism/>
        <absorption>Though pharmacokinetic or ADME studies were not performed, Botulinum Toxin Type B is not expected to be present in the peripheral blood at measurable levels following IM injection at the recommended doses.</absorption>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Botulinum neurotoxin type B precursor</synonym>
            <synonym language="" coder="">BTX-B</synonym>
            <synonym language="" coder="">RimabotulinumtoxinB</synonym>
        </synonyms>
        <products>
            <product>
                <name>Myobloc</name>
                <ndc-id>10454-710_fe96358c-e490-47bd-b992-3783022b7aff</ndc-id>
                <ndc-product-code>10454-710</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-12-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>2500 [USP'U]/.5mL</strength>
                <route>intramuscular</route>
                <fda-application-number>BLA103846</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Myobloc</name>
                <ndc-id>10454-711_fe96358c-e490-47bd-b992-3783022b7aff</ndc-id>
                <ndc-product-code>10454-711</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-12-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>5000 [USP'U]/mL</strength>
                <route>intramuscular</route>
                <fda-application-number>BLA103846</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Myobloc</name>
                <ndc-id>10454-712_fe96358c-e490-47bd-b992-3783022b7aff</ndc-id>
                <ndc-product-code>10454-712</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-12-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>10000 [USP'U]/2mL</strength>
                <route>intramuscular</route>
                <fda-application-number>BLA103846</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Myobloc</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02252295</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>5000 unit</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Neurobloc</name>
                <company>Solstice Neurosciences</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Myobloc</name>
                <ingredients>Botulinum Toxin Type B</ingredients>
            </mixture>
            <mixture>
                <name>Myobloc</name>
                <ingredients>Botulinum Toxin Type B</ingredients>
            </mixture>
            <mixture>
                <name>Myobloc</name>
                <ingredients>Botulinum Toxin Type B</ingredients>
            </mixture>
            <mixture>
                <name>Myobloc</name>
                <ingredients>Botulinum Toxin Type B</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Solstice Neurosciences</name>
                <url>http://www.solsticeneuro.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Myobloc 2500 unit/0.5 ml vial</description>
                <cost currency="USD">299.4</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Myobloc 10000 unit/2ml Solution 2ml Vial</description>
                <cost currency="USD">1245.5</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antidystonic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>intramuscular</route>
                <strength>10000 [USP'U]/2mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intramuscular</route>
                <strength>2500 [USP'U]/.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>intramuscular</route>
                <strength>5000 [USP'U]/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular</route>
                <strength>5000 unit</strength>
            </dosage>
        </dosages>
        <atc-codes/>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB08897</drugbank-id>
                <name>Aclidinium</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00479</drugbank-id>
                <name>Amikacin</name>
                <description>Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00321</drugbank-id>
                <name>Amitriptyline</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00543</drugbank-id>
                <name>Amoxapine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00732</drugbank-id>
                <name>Atracurium besylate</name>
                <description>Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00572</drugbank-id>
                <name>Atropine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00972</drugbank-id>
                <name>Azelastine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00245</drugbank-id>
                <name>Benzatropine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00083</drugbank-id>
                <name>Botulinum Toxin Type A</name>
                <description>AbobotulinumtoxinA may enhance the adverse neuromuscular effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00835</drugbank-id>
                <name>Brompheniramine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00748</drugbank-id>
                <name>Carbinoxamine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00341</drugbank-id>
                <name>Cetirizine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01114</drugbank-id>
                <name>Chlorphenamine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00477</drugbank-id>
                <name>Chlorpromazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00565</drugbank-id>
                <name>Cisatracurium besylate</name>
                <description>Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00283</drugbank-id>
                <name>Clemastine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00771</drugbank-id>
                <name>Clidinium</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01242</drugbank-id>
                <name>Clomipramine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00318</drugbank-id>
                <name>Codeine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01176</drugbank-id>
                <name>Cyclizine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00924</drugbank-id>
                <name>Cyclobenzaprine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00979</drugbank-id>
                <name>Cyclopentolate</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00434</drugbank-id>
                <name>Cyproheptadine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00496</drugbank-id>
                <name>Darifenacin</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01151</drugbank-id>
                <name>Desipramine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00967</drugbank-id>
                <name>Desloratadine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00405</drugbank-id>
                <name>Dexbrompheniramine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00804</drugbank-id>
                <name>Dicyclomine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01501</drugbank-id>
                <name>Difenoxin</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00985</drugbank-id>
                <name>Dimenhydrinate</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01075</drugbank-id>
                <name>Diphenhydramine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01081</drugbank-id>
                <name>Diphenoxylate</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00280</drugbank-id>
                <name>Disopyramide</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01142</drugbank-id>
                <name>Doxepin</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00366</drugbank-id>
                <name>Doxylamine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00450</drugbank-id>
                <name>Droperidol</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01288</drugbank-id>
                <name>Fenoterol</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06702</drugbank-id>
                <name>Fesoterodine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00950</drugbank-id>
                <name>Fexofenadine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01148</drugbank-id>
                <name>Flavoxate</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00875</drugbank-id>
                <name>Flupentixol</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00623</drugbank-id>
                <name>Fluphenazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00588</drugbank-id>
                <name>Fluticasone Propionate</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00798</drugbank-id>
                <name>Gentamicin</name>
                <description>Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00986</drugbank-id>
                <name>Glycopyrrolate</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00502</drugbank-id>
                <name>Haloperidol</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00557</drugbank-id>
                <name>Hydroxyzine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00424</drugbank-id>
                <name>Hyoscyamine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00458</drugbank-id>
                <name>Imipramine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00332</drugbank-id>
                <name>Ipratropium bromide</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01247</drugbank-id>
                <name>Isocarboxazid</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01172</drugbank-id>
                <name>Kanamycin</name>
                <description>Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01106</drugbank-id>
                <name>Levocabastine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06282</drugbank-id>
                <name>Levocetirizine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00455</drugbank-id>
                <name>Loratadine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00408</drugbank-id>
                <name>Loxapine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00934</drugbank-id>
                <name>Maprotiline</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00737</drugbank-id>
                <name>Meclizine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04843</drugbank-id>
                <name>Mepenzolate</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01403</drugbank-id>
                <name>Methotrimeprazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01171</drugbank-id>
                <name>Moclobemide</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00994</drugbank-id>
                <name>Neomycin</name>
                <description>Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00540</drugbank-id>
                <name>Nortriptyline</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00334</drugbank-id>
                <name>Olanzapine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00768</drugbank-id>
                <name>Olopatadine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01173</drugbank-id>
                <name>Orphenadrine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01062</drugbank-id>
                <name>Oxybutynin</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01337</drugbank-id>
                <name>Pancuronium</name>
                <description>Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00850</drugbank-id>
                <name>Perphenazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00780</drugbank-id>
                <name>Phenelzine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01100</drugbank-id>
                <name>Pimozide</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06153</drugbank-id>
                <name>Pizotifen</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00433</drugbank-id>
                <name>Prochlorperazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00387</drugbank-id>
                <name>Procyclidine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00420</drugbank-id>
                <name>Promazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01069</drugbank-id>
                <name>Promethazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00782</drugbank-id>
                <name>Propantheline</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00344</drugbank-id>
                <name>Protriptyline</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01224</drugbank-id>
                <name>Quetiapine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00728</drugbank-id>
                <name>Rocuronium</name>
                <description>Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00747</drugbank-id>
                <name>Scopolamine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01591</drugbank-id>
                <name>Solifenacin</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01082</drugbank-id>
                <name>Streptomycin</name>
                <description>Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00202</drugbank-id>
                <name>Succinylcholine</name>
                <description>Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00679</drugbank-id>
                <name>Thioridazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01623</drugbank-id>
                <name>Thiothixene</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01409</drugbank-id>
                <name>Tiotropium</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00684</drugbank-id>
                <name>Tobramycin</name>
                <description>Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01036</drugbank-id>
                <name>Tolterodine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00752</drugbank-id>
                <name>Tranylcypromine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00831</drugbank-id>
                <name>Trifluoperazine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00376</drugbank-id>
                <name>Trihexyphenidyl</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00662</drugbank-id>
                <name>Trimethobenzamide</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00726</drugbank-id>
                <name>Trimipramine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00427</drugbank-id>
                <name>Triprolidine</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00209</drugbank-id>
                <name>Trospium</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09076</drugbank-id>
                <name>Umeclidinium</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01339</drugbank-id>
                <name>Vecuronium</name>
                <description>Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01624</drugbank-id>
                <name>Zuclopenthixol</name>
                <description>Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Botulinum neurotoxin type B - Clostridium botulinum
                MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
                KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
                DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
                FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
                GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
                DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
                IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA
                YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN
                YIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY
                LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND
                FVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
                PVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY
                KALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV
                SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL
                SIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK
                LTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS
                GWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING
                KLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY
                SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY
                IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD
                SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS
                KWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Molecular Weight</kind>
                <value>150804.0000</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12854</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D02735</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M81186</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164747061</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P10844</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Botulinum_toxin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/botulinumtoxin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/botulinum-toxin-type-b.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0002137</id>
                <name>Vesicle-associated membrane protein 2</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Liu W, Montana V, Chapman ER, Mohideen U, Parpura V: Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13621-5. Epub 2003 Oct 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14573702&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P63027" source="Swiss-Prot">
                    <name>Vesicle-associated membrane protein 2</name>
                    <general-function/>
                    <specific-function>Involved in the targeting and/or fusion of transport vesicles to their target membrane</specific-function>
                    <gene-name>VAMP2</gene-name>
                    <locus>17p13.1</locus>
                    <cellular-location>Cytoplasmic vesicle</cellular-location>
                    <transmembrane-regions>95-114</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.48</theoretical-pi>
                    <molecular-weight>12649.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:12643</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>VAMP2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>VAMP2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M36205</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>338632</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P63027</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>VAMP2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Synaptobrevin-2</synonym>
                        <synonym>VAMP-2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Vesicle-associated membrane protein 2
                        MSATAATAPPAAPAGEGGPPAPPPNLTSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKL
                        SELDDRADALQAGASQFETSAAKLKRKYWWKNLKMMIILGVICAIILIIIIVYFSS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;351 bp
                        ATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGGAGGGTGGTCCCCCT
                        GCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCAGCAGACCCAGGCCCAGGTGGAT
                        GAGGTGGTGGACATCATGAGGGTGAACGTGGACAAGGTCCTGGAGCGAGACCAGAAGCTG
                        TCGGAGCTGGACGACCGTGCAGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGC
                        GCAGCCAAGCTCAAGCGCAAATACTGGTGGAAAAACCTCAAGATGATGATCATCTTGGGA
                        GTGATTTGCGCCATCATCCTCATCATCATCATAGTTTACTTCAGCTCTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00957</identifier>
                            <name>Synaptobrevin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>vesicle-mediated transport</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0002136</id>
                <name>Vesicle-associated membrane protein 1</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P23763" source="Swiss-Prot">
                    <name>Vesicle-associated membrane protein 1</name>
                    <general-function/>
                    <specific-function>Involved in the targeting and/or fusion of transport vesicles to their target membrane</specific-function>
                    <gene-name>VAMP1</gene-name>
                    <locus>12p</locus>
                    <cellular-location>Cytoplasmic vesicle</cellular-location>
                    <transmembrane-regions>97-116</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.59</theoretical-pi>
                    <molecular-weight>12902.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:12642</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>VAMP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>VAMP1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M36200</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>338625</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P23763</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>VAMP1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Synaptobrevin-1</synonym>
                        <synonym>VAMP-1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Vesicle-associated membrane protein 1
                        MSAPAQPPAEGTEGTAPGGGPPGPPPNMTSNRRLQQTQAQVEEVVDIIRVNVDKVLERDQ
                        KLSELDDRADALQAGASQFESSAAKLKRKYWWKNCKMMIMLGAICAIIVVVIVIYFFT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;357 bp
                        ATGTCTGCTCCAGCTCAGCCACCTGCTGAAGGGACAGAAGGGACTGCCCCAGGTGGGGGT
                        CCCCCTGGCCCTCCTCCTAACATGACCAGTAACAGACGACTACAGCAAACCCAGGCACAA
                        GTGGAGGAGGTGGTGGACATCATACGTGTGAACGTGGACAAGGTCCTGGAGAGGGACCAG
                        AAGCTGTCAGAGCTGGATGACCGAGCTGATGCCTTGCAGGCAGGAGCATCACAATTTGAG
                        AGCAGTGCTGCCAAGCTAAAGAGGAAGTATTGGTGGAAAAACTGCAAGATGATGATCATG
                        CTGGGAGCCATCTGTGCCATCATCGTGGTAGTTATTGTAATCTACTTTTTTACTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00957</identifier>
                            <name>Synaptobrevin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>vesicle-mediated transport</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0002138</id>
                <name>Synaptotagmin-2</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J: [Mechanisms of action of botulinum toxins and neurotoxins] Ann Dermatol Venereol. 2009 May;136 Suppl 4:S73-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19576489</references>
                <known-action>yes</known-action>
                <polypeptide id="Q8N9I0" source="Swiss-Prot">
                    <name>Synaptotagmin-2</name>
                    <general-function/>
                    <specific-function>May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse. It binds acidic phospholipids with a specificity that requires the presence of both an acidic head group and a diacyl backbone</specific-function>
                    <gene-name>SYT2</gene-name>
                    <locus>1q32.1</locus>
                    <cellular-location>Cytoplasmic vesicle</cellular-location>
                    <transmembrane-regions>63-83</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.12</theoretical-pi>
                    <molecular-weight>46873.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11510</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>SYT2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>SYT2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AK090672</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>21748879</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q8N9I0</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>SYT2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Synaptotagmin II</synonym>
                        <synonym>SytII</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Synaptotagmin-2
                        MRNIFKRNQEPIVAPATTTATMPIGPVDNSTESGGAGESQEDMFAKLKEKLFNEINKIPL
                        PPWALIAIAVVAGLLLLTCCFCICKKCCCKKKKNKKEKGKGMKNAMNMKDMKGGQDDDDA
                        ETGLTEGEGEGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQAAELPALDMGGTSDPYVK
                        VFLLPDKKKKYETKVHRKTLNPAFNETFTFKVPYQELGGKTLVMAIYDFDRFSKHDIIGE
                        VKVPMNTVDLGQPIEEWRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVCILEAKNLKKM
                        DVGGLSDPYVKIHLMQNGKRLKKKKTTVKKKTLNPYFNESFSFEIPFEQIQKVQVVVTVL
                        DYDKLGKNEAIGKIFVGSNATGTELRHWSDMLANPRRPIAQWHSLKPEEEVDALLGKNK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1260 bp
                        ATGAGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGGCTCCTGCCACCACCACCGCC
                        ACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGGGAGAGTCAG
                        GAGGACATGTTTGCCAAACTGAAGGAGAAGTTATTCAATGAGATAAACAAGATTCCCTTA
                        CCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCTTCTCACCTGCTGC
                        TTCTGCATCTGCAAGAAATGCTGCTGCAAGAAGAAGAAGAACAAGAAGGAGAAGGGCAAA
                        GGCATGAAGAATGCCATGAACATGAAGGACATGAAAGGGGGTCAGGATGACGACGACGCA
                        GAGACAGGCCTGACTGAGGGGGAAGGTGAAGGGGAGGAGGAGAAAGAGCCAGAGAACCTG
                        GGCAAACTGCAGTTTTCCCTGGACTATGATTTTCAGGCTAATCAGCTTACTGTGGGCGTT
                        CTGCAGGCTGCTGAACTGCCTGCCCTGGACATGGGAGGCACCTCAGACCCTTATGTCAAG
                        GTCTTCCTCCTTCCTGACAAGAAGAAGAAATATGAGACCAAAGTCCATCGGAAGACACTG
                        AACCCTGCCTTCAATGAAACCTTCACCTTCAAGGTGCCATACCAGGAGCTTGGGGGCAAA
                        ACTCTGGTGATGGCCATCTATGACTTTGACCGCTTCTCCAAACATGACATCATTGGAGAG
                        GTAAAGGTGCCTATGAACACAGTGGACCTCGGCCAGCCCATTGAGGAGTGGAGAGACCTG
                        CAAGGCGGGGAAAAGGAGGAGCCGGAGAAGCTGGGCGACATCTGCACCTCCCTGCGCTAT
                        GTGCCCACGGCCGGGAAGCTCACTGTCTGCATCCTGGAGGCTAAGAACCTCAAGAAGATG
                        GACGTGGGCGGCCTTTCAGACCCGTACGTGAAGATCCACCTGATGCAGAATGGCAAGAGG
                        CTCAAGAAGAAGAAGACAACCGTGAAGAAGAAGACCCTGAACCCATACTTCAACGAGTCC
                        TTCAGCTTTGAGATCCCCTTCGAGCAGATTCAGAAAGTCCAGGTAGTGGTCACCGTGCTG
                        GACTATGACAAGCTGGGCAAGAACGAAGCCATAGGCAAGATCTTCGTGGGCAGCAATGCC
                        ACGGGCACAGAGCTGCGGCACTGGTCCGACATGCTGGCCAACCCCCGGAGGCCCATCGCC
                        CAGTGGCACTCGCTCAAGCCTGAGGAGGAGGTGGATGCACTCCTGGGCAAGAACAAGTAG
                    </gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00168</identifier>
                            <name>C2</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasmic vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasmic membrane-bound vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>coated vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>clathrin-coated vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>synaptic vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>organelle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>vesicle</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transporter activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-22">
        <drugbank-id primary="true">DB00043</drugbank-id>
        <drugbank-id>BIOD00081</drugbank-id>
        <drugbank-id>BTD00081</drugbank-id>
        <name>Omalizumab</name>
        <description>A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.</description>
        <cas-number>242138-07-4</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12672069</general-references>
        <synthesis-reference/>
        <indication>For treatment of asthma caused by allergies</indication>
        <pharmacodynamics>Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.</pharmacodynamics>
        <mechanism-of-action>Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.</mechanism-of-action>
        <toxicity/>
        <metabolism>Most likely removed by opsonization via the reticuloendothelial system.</metabolism>
        <absorption/>
        <half-life>26 days</half-life>
        <protein-binding/>
        <route-of-elimination>Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.</route-of-elimination>
        <volume-of-distribution>* 78 ± 32 mL/kg</volume-of-distribution>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Ig gamma-1 chain C region</synonym>
        </synonyms>
        <products>
            <product>
                <name>Xolair</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02260565</dpd-id>
                <started-marketing-on>2005-02-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>150 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Xolair</name>
                <ndc-id>50242-040_7fa51469-9f7e-4823-a160-93f04f2a55b4</ndc-id>
                <ndc-product-code>50242-040</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2003-06-20</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>202.5 mg/1.4mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA103976</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Xolair</name>
                <ingredients>Omalizumab</ingredients>
            </mixture>
            <mixture>
                <name>Xolair</name>
                <ingredients>Omalizumab</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Genentech Inc.</name>
                <url>http://www.gene.com</url>
            </packager>
            <packager>
                <name>Novartis AG</name>
                <url>http://www.novartis.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Xolair 150 mg vial</description>
                <cost currency="USD">715.42</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Anti-Allergic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-Asthmatic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>202.5 mg/1.4mL</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>150 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="R03DX05">
                <level code="R">RESPIRATORY SYSTEM</level>
                <level code="R03">DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
                <level code="R03D">OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
                <level code="R03DX">Other systemic drugs for obstructive airway diseases</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>48:92.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1340233</number>
                <country>Canada</country>
                <approved>1998-12-15</approved>
                <expires>2015-12-15</expires>
            </patent>
            <patent>
                <number>2113813</number>
                <country>Canada</country>
                <approved>2005-04-12</approved>
                <expires>2012-08-14</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB08879</drugbank-id>
                <name>Belimumab</name>
                <description>Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00408</drugbank-id>
                <name>Loxapine</name>
                <description>Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Omalizumab heavy chain
                EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNY
                ADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVS
                SGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
                SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV
                FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
                RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
                NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
                NVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
            <sequence format="FASTA">&gt;Omalizumab light chain
                DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLES
                GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVF
                IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
                STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
                <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.432</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.03</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>145058.2000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C6450H9916N1714O2023S38</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13365</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>50242-040-62</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00228</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164752253</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01857</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Omalizumab</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/xolair.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/omalizumab.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000015</id>
                <name>High affinity immunoglobulin epsilon receptor subunit alpha</name>
                <organism>Human</organism>
                <actions/>
                <references># Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S: Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15356552&#13;
                    # Mirkina I, Schweighoffer T, Kricek F: Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett. 2007 Apr 15;109(2):120-8. Epub 2007 Mar 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17368811</references>
                <known-action>yes</known-action>
                <polypeptide id="P12319" source="Swiss-Prot">
                    <name>High affinity immunoglobulin epsilon receptor subunit alpha</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines</specific-function>
                    <gene-name>FCER1A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>206-224</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.67</theoretical-pi>
                    <molecular-weight>29596.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3609</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCER1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCER1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X06948</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12319</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCERA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Fc-epsilon RI-alpha</synonym>
                        <synonym>FcERI</synonym>
                        <synonym>High affinity immunoglobulin epsilon receptor subunit alpha precursor</synonym>
                        <synonym>IgE Fc receptor, alpha-subunit</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin epsilon receptor alpha-subunit precursor
                        MAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS
                        STKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE
                        VVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV
                        WQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR
                        KGFRLLNPHPKPNPKNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;774 bp
                        ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCA
                        GATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGA
                        ATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGT
                        TCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATT
                        GTGAATGCCAAATTTGAAGACAGTGGAGAATACAAATGTCAGCACCAACAAGTTAATGAG
                        AGTGAACCTGTGTACCTGGAAGTCTTCAGTGACTGGCTGCTCCTTCAGGCCTCTGCTGAG
                        GTGGTGATGGAGGGCCAGCCCCTCTTCCTCAGGTGCCATGGTTGGAGGAACTGGGATGTG
                        TACAAGGTGATCTATTATAAGGATGGTGAAGCTCTCAAGTACTGGTATGAGAACCACAAC
                        ATCTCCATTACAAATGCCACAGTTGAAGACAGTGGAACCTACTACTGTACGGGCAAAGTG
                        TGGCAGCTGGACTATGAGTCTGAGCCCCTCAACATTACTGTAATAAAAGCTCCGCGTGAG
                        AAGTACTGGCTACAATTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGGACACA
                        GGATTATTTATCTCAACTCAGCAGCAGGTCACATTTCTCTTGAAGATTAAGAGAACCAGG
                        AAAGGCTTCAGACTTCTGAACCCACATCCTAAGCCAAACCCCAAAAACAACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002139</id>
                <name>High affinity immunoglobulin epsilon receptor subunit beta</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # DuBuske LM: IgE, allergic diseases, and omalizumab. Curr Pharm Des. 2006;12(30):3929-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17073688</references>
                <known-action>yes</known-action>
                <polypeptide id="Q01362" source="Swiss-Prot">
                    <name>High affinity immunoglobulin epsilon receptor subunit beta</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines</specific-function>
                    <gene-name>MS4A2</gene-name>
                    <locus>11q13</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>60-79
                        98-117
                        131-150
                        181-200</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.78</theoretical-pi>
                    <molecular-weight>26534.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:7316</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>MS4A2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>MS4A2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>D10583</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>219882</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>Q01362</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCERB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Fc epsilon receptor I beta-chain</synonym>
                        <synonym>FcERI</synonym>
                        <synonym>IgE Fc receptor subunit beta</synonym>
                        <synonym>Membrane-spanning 4-domains subfamily A member 2</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin epsilon receptor subunit beta
                        MDTESNRRANLALPQEPSSVPAFEVLEISPQEVSSGRLLKSASSPPLHTWLTVLKKEQEF
                        LGVTQILTAMICLCFGTVVCSVLDISHIEGDIFSSFKAGYPFWGAIFFSISGMLSIISER
                        RNATYLVRGSLGANTASSIAGGTGITILIINLKKSLAYIHIHSCQKFFETKCFMASFSTE
                        IVVMMLFLTILGLGSAVSLTICGAGEELKGNKVPEDRVYEELNIYSATYSELEDPGEMSP
                        PIDL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;735 bp
                        ATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTG
                        CCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAG
                        TCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTC
                        CTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGC
                        TCTGTACTTGATATTTCACACATTGAGGGAGACATTTTTTCATCATTTAAAGCAGGTTAT
                        CCATTCTGGGGAGCCATATTTTTTTCTATTTCTGGAATGTTGTCAATTATATCTGAAAGG
                        AGAAATGCAACATATCTGGTGAGAGGAAGCCTGGGAGCAAACACTGCCAGCAGCATAGCT
                        GGGGGAACGGGAATTACCATCCTGATCATCAACCTGAAGAAGAGCTTGGCCTATATCCAC
                        ATCCACAGTTGCCAGAAATTTTTTGAGACCAAGTGCTTTATGGCTTCCTTTTCCACTGAA
                        ATTGTAGTGATGATGCTGTTTCTCACCATTCTGGGACTTGGTAGTGCTGTGTCACTCACA
                        ATCTGTGGAGCTGGGGAAGAACTCAAAGGAAACAAGGTTCCAGAGGATCGTGTTTATGAA
                        GAATTAAACATATATTCAGCTACTTACAGTGAGTTGGAAGACCCAGGGGAAATGTCTCCT
                        CCCATTGATTTATAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF04103</identifier>
                            <name>CD20</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-11-10">
        <drugbank-id primary="true">DB00044</drugbank-id>
        <drugbank-id>BIOD00056</drugbank-id>
        <drugbank-id>BTD00056</drugbank-id>
        <name>Lutropin alfa</name>
        <description>Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule. In females, an acute rise of LH ("LH surge") triggers ovulation and the development of the corpus luteum. In males, it stimulates Leydig cell production of testosterone. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development.</description>
        <cas-number>152923-57-4</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Blanchard J: Gastrointestinal absorption. I. Mechanisms. Am J Pharm Sci Support Public Health. 1975 Sep-Oct;147(5):135-46. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3972&#13;
            # Louvet JP, Harman SM, Ross GT: Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats. Endocrinology. 1975 May;96(5):1179-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1122882&#13;
            # Nielsen MS, Barton SD, Hatasaka HH, Stanford JB: Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril. 2001 Aug;76(2):384-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11476792&#13;
            # Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20161981&#13;
            # Dhillon S, Keating GM: Lutropin alfa. Drugs. 2008;68(11):1529-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18627209&#13;
            #Lutropin Alfa. In DynaMed [database online]. EBSCO Information Services.&#13;
            http://search.ebscohost.com/login.aspx?direct=true&amp;site=DynaMed&amp;id=233015. Updated January 18, 2013. Accessed October 1, 2014.&#13;
            #Lexicomp. Lutropin alfa. N.p., 2014. Web. 11 Nov. 2014.&#13;
            #EMD Serono, A Division of EMD Inc., Canada. Lutropin Alfa. Mississauga, Ontario: N.p., 2012. </general-references>
        <synthesis-reference/>
        <indication>For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH &lt;1.2 international units [IU]/L)</indication>
        <pharmacodynamics>Used to facilitate female conception, lutropin alfa performs the same actions as luteinizing hormone (LH), which is normally produced in the pituitary gland. Lutropin is usually given in combination with follitropin alfa. Together they stimulate the development of a follicle to prepare the reproductive tract for implementation and pregnancy. Lutropin alfa also stimulates the theca cells to produce androgens and the secretion of estradiol by the follicles. Lutropin alfa and follitropin alfa are discontinued once ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation. hCG is then administered to complete follicular maturation and induce ovulation. In females, a LH surge about halfway through the menstrual cycle triggers the onset of ovulation. Lutropin alfa substitutes for endogenous LH and induces rupture of the preovulatory ovarian follicle and oocyte expulsion. Lutropin alfa induces and maintains the corpus luteum, which then secretes progesterone.</pharmacodynamics>
        <mechanism-of-action>Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes. </mechanism-of-action>
        <toxicity>Lutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus. </toxicity>
        <metabolism>&lt;5% of dose excreted renally as unchanged drug.</metabolism>
        <absorption>Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours </absorption>
        <half-life>Biphasic; terminal half-life is approximately 18 hours.</half-life>
        <protein-binding/>
        <route-of-elimination>Total body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally.</route-of-elimination>
        <volume-of-distribution>The steady state volume of distribution is around 10-14 L.</volume-of-distribution>
        <clearance>* 2 – 3 L/h [healthy female following subcutaneous administration]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">ICSH</synonym>
            <synonym language="" coder="">Insterstiial cell-stimulating hormone</synonym>
            <synonym language="" coder="">LH</synonym>
            <synonym language="" coder="">LH-B</synonym>
            <synonym language="" coder="">LSH- beta</synonym>
            <synonym language="" coder="">LSH-B</synonym>
            <synonym language="" coder="">Luteinizing hormone</synonym>
            <synonym language="" coder="">Luteinizing hormone beta subunit</synonym>
            <synonym language="" coder="">Lutrophin</synonym>
            <synonym language="" coder="">Lutropin alpha</synonym>
            <synonym language="" coder="">Lutropin beta chain precursor</synonym>
        </synonyms>
        <products>
            <product>
                <name>Humegon Inj 75 I.U.</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>01958992</dpd-id>
                <started-marketing-on>1993-12-31</started-marketing-on>
                <ended-marketing-on>2006-08-17</ended-marketing-on>
                <dosage-form>liquid; powder for solution</dosage-form>
                <strength>.9 %</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Luveris</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02269066</dpd-id>
                <started-marketing-on>2005-06-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>75 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pergonal 75 I.U.</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00254916</dpd-id>
                <started-marketing-on>1979-12-31</started-marketing-on>
                <ended-marketing-on>2007-05-07</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>75 unit</strength>
                <route>intramuscular</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Pergoveris</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02445301</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>150 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Luveris</name>
                <ingredients>Lutropin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Pergoveris</name>
                <ingredients>Follitropin Alpha + Lutropin alfa</ingredients>
            </mixture>
            <mixture>
                <name>Humegon Inj 75 I.U.</name>
                <ingredients>Sodium Chloride + Lutropin alfa + Urofollitropin</ingredients>
            </mixture>
            <mixture>
                <name>Pergonal 75 I.U.</name>
                <ingredients>Lutropin alfa + Urofollitropin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>EMD Canada Inc.</name>
                <url>http://www.emdcanada.com</url>
            </packager>
            <packager>
                <name>Merck Serono SPA</name>
                <url>http://www.merckserono.net</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Emd serono inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Luveris 75 unit vial</description>
                <cost currency="USD">38.88</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Fertility Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid; powder for solution</form>
                <route>intramuscular</route>
                <strength>.9 %</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>75 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular</route>
                <strength>75 unit</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>subcutaneous</route>
                <strength>150 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="G03GA07">
                <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
                <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
                <level code="G03G">GONADOTROPINS AND OTHER OVULATION STIMULANTS</level>
                <level code="G03GA">Gonadotropins</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>68:18.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>5767251</number>
                <country>United States</country>
                <approved>1995-06-16</approved>
                <expires>2015-06-16</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;Alpha Chain
                APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
                VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
            <sequence format="FASTA">&gt;Beta Chain (LH)
                SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYR
                DVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLF
                L</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>55 °C</value>
                <source>Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.063</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.44</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>30,000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1014H1609N287O294S27</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>15875</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>7347</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>44087-1375-1</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X00264</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164750539</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01229</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Lutropin_alfa</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/lutropin-alfa.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000134</id>
                <name>Lutropin-choriogonadotropic hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20161981&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P22888" source="Swiss-Prot">
                    <name>Lutropin-choriogonadotropic hormone receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase</specific-function>
                    <gene-name>LHCGR</gene-name>
                    <locus>2p21</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>364-385
                        396-416
                        440-462
                        483-505
                        526-549
                        571-594
                        606-627</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>78617.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6585</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M73746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>903746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>254</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>30</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P22888</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LSHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>LH/CG-R</synonym>
                        <synonym>LHR</synonym>
                        <synonym>LSH- R</synonym>
                        <synonym>Luteinizing hormone receptor</synonym>
                        <synonym>Lutropin-choriogonadotropic hormone receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Lutropin-choriogonadotropic hormone receptor precursor
                        MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP
                        VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI
                        NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK
                        LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY
                        GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF
                        SKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD
                        FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS
                        QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL
                        RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF
                        IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT
                        VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT
                        SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2058 bp
                        ATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG
                        CTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC
                        CTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA
                        GTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG
                        ATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA
                        ATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT
                        CCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG
                        AAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC
                        ACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT
                        GGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG
                        GAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA
                        GGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA
                        GAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA
                        CAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT
                        AGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA
                        CAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC
                        TGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC
                        ATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG
                        GGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT
                        TTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA
                        GCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA
                        GGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC
                        ACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC
                        CAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT
                        CTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC
                        CCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT
                        GTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC
                        CCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC
                        TTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA
                        GTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT
                        TCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT
                        CTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA
                        GATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT
                        CAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT
                        CGCTACACAGAGTGTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>lutropin-choriogonadotropic hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2014-01-27">
        <drugbank-id primary="true">DB00045</drugbank-id>
        <drugbank-id>BIOD00054</drugbank-id>
        <drugbank-id>BTD00054</drugbank-id>
        <name>OspA lipoprotein</name>
        <description>Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.</description>
        <cas-number/>
        <groups>
            <group>approved</group>
            <group>withdrawn</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For prophylactic treatment of Lyme Disease</indication>
        <pharmacodynamics>OspA lipoprotein is a single polypeptide chain of 270 amino acids. It is a vaccination used to prevent Lyme Disease.</pharmacodynamics>
        <mechanism-of-action>OspA lipoprotein, an outer surface protein of the bacteria Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. It is used as a vaccination against Lyme Disease, a disease carried by ticks.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>1.2 hours (mammalian reticulocytes, in vitro).</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Outer surface protein A precursor</synonym>
        </synonyms>
        <products/>
        <international-brands>
            <international-brand>
                <name>LYMErix</name>
                <company>SmithKline Beecham</company>
            </international-brand>
        </international-brands>
        <mixtures/>
        <packagers/>
        <manufacturers/>
        <prices/>
        <categories>
            <category>
                <category>Vaccines</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages/>
        <atc-codes/>
        <ahfs-codes/>
        <patents/>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt; OspA lipoprotein
                MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDGKYDLMATVDN
                VDLKGTSDKNNGSGILEGVKADKSKVKLTVADDLSKTTLEVLKEDGTVVSRKVTSKDKST
                TEAKFNEKGELSEKTMTRANGTTLEYSQMTNEDNAAKAVETLKNGIKFEGNLASGKTAVE
                IKEGTVTLKREIDKNGKVTVSLNDTASGSKKTASWQESTSTLTISANSKKTKDLVFLTNG
                TITVQNYDSAGTKLEGSAAEIKKLDELKNALR</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.652</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>6.72</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>27743.1000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1198H2012N322O422S2</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X16467</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164743058</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P14013</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links/>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0001164</id>
                <name>Toll-like receptor 2</name>
                <organism>Human</organism>
                <actions>
                    <action>other/unknown</action>
                </actions>
                <references># Welty DM, Snyder DS: Internalization of OspA in rsCD14 complex and aggregated forms. Mol Microbiol. 2003 Nov;50(3):835-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14617145</references>
                <known-action>yes</known-action>
                <polypeptide id="O60603" source="Swiss-Prot">
                    <name>Toll-like receptor 2</name>
                    <general-function>Involved in transmembrane receptor activity</general-function>
                    <specific-function>Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Acts via MyD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6</specific-function>
                    <gene-name>TLR2</gene-name>
                    <locus>4q32</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>589-609</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.59</theoretical-pi>
                    <molecular-weight>89839.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11848</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>TLR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>TLR2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF051152</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>3132528</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O60603</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TLR2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD282 antigen</synonym>
                        <synonym>Toll-like receptor 2 precursor</synonym>
                        <synonym>Toll/interleukin 1 receptor-like protein 4</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Toll-like receptor 2 precursor
                        MPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLS
                        NNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWF
                        KPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELE
                        IDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFS
                        ELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDN
                        DRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLK
                        SLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDI
                        SKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLK
                        ELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCE
                        FLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFL
                        LILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMV
                        QELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFS
                        HFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRA
                        AIKS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2355 bp
                        ATGCCACATACTTTGTGGATGGTGTGGGTCCTGGGGGTCATCATCAGCCTCTCCAAGGAA
                        GAATCCTCCAATCAGGCTTCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCA
                        GGATCTTTAAACTCCATTCCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCC
                        AACAACAGGATCACCTACATTAGCAACAGTGACCTACAGAGGTGTGTGAACCTCCAGGCT
                        CTGGTGCTGACATCCAATGGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGC
                        AGTCTTGAACATTTAGACTTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTC
                        AAGCCCCTTTCTTCTTTAACATTCTTAAACTTACTGGGAAATCCTTACAAAACCCTAGGG
                        GAAACATCTCTTTTTTCTCATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATATGGAC
                        ACCTTCACTAAGATTCAAAGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAG
                        ATTGATGCTTCAGATCTACAGAGCTATGAGCCAAAAAGTTTGAAGTCAATTCAGAATGTA
                        AGTCATCTGATCCTTCATATGAAGCAGCATATTTTACTGCTGGAGATTTTTGTAGATGTT
                        ACAAGTTCCGTGGAATGTTTGGAACTGCGAGATACTGATTTGGACACTTTCCATTTTTCA
                        GAACTATCCACTGGTGAAACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAA
                        ATCACCGATGAAAGTTTGTTTCAGGTTATGAAACTTTTGAATCAGATTTCTGGATTGTTA
                        GAATTAGAGTTTGATGACTGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAAT
                        GACAGAGTTATAGATCCAGGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCA
                        AGGTTTTACTTATTTTATGATCTGAGCACTTTATATTCACTTACAGAAAGAGTTAAAAGA
                        ATCACAGTAGAAAACAGTAAAGTTTTTCTGGTTCCTTGTTTACTTTCACAACATTTAAAA
                        TCATTAGAATACTTGGATCTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCA
                        GCCTGTGAGGATGCCTGGCCCTCTCTACAAACTTTAATTTTAAGGCAAAATCATTTGGCA
                        TCATTGGAAAAAACCGGAGAGACTTTGCTCACTCTGAAAAACTTGACTAACATTGATATC
                        AGTAAGAATAGTTTTCATTCTATGCCTGAAACTTGTCAGTGGCCAGAAAAGATGAAATAT
                        TTGAACTTATCCAGCACACGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAA
                        ATTTTAGATGTTAGCAACAACAATCTCAATTTATTTTCTTTGAATTTGCCGCAACTCAAA
                        GAACTTTATATTTCCAGAAATAAGTTGATGACTCTACCAGATGCCTCCCTCTTACCCATG
                        TTACTAGTATTGAAAATCAGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGAC
                        TCATTTCACACACTGAAGACTTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAA
                        TTCCTCTCCTTCACTCAGGAGCAGCAAGCACTGGCCAAAGTCTTGATTGATTGGCCAGCA
                        AATTACCTGTGTGACTCTCCATCCCATGTGCGTGGCCAGCAGGTTCAGGATGTCCGCCTC
                        TCGGTGTCGGAATGTCACAGGACAGCACTGGTGTCTGGCATGTGCTGTGCTCTGTTCCTG
                        CTGATCCTGCTCACGGGGGTCCTGTGCCACCGTTTCCATGGCCTGTGGTATATGAAAATG
                        ATGTGGGCCTGGCTCCAGGCCAAAAGGAAGCCCAGGAAAGCTCCCAGCAGGAACATCTGC
                        TATGATGCATTTGTTTCTTACAGTGAGCGGGATGCCTACTGGGTGGAGAACCTTATGGTC
                        CAGGAGCTGGAGAACTTCAATCCCCCCTTCAAGTTGTGTCTTCATAAGCGGGACTTCATT
                        CCTGGCAAGTGGATCATTGACAATATCATTGACTCCATTGAAAAGAGCCACAAAACTGTC
                        TTTGTGCTTTCTGAAAACTTTGTGAAGAGTGAGTGGTGCAAGTATGAACTGGACTTCTCC
                        CATTTCCGTCTTTTTGATGAGAACAATGATGCTGCCATTCTCATTCTTCTGGAGCCCATT
                        GAGAAAAAAGCCATTCCCCAGCGCTTCTGCAAGCTGCGGAAGATAATGAACACCAAGACC
                        TACCTGGAGTGGCCCATGGACGAGGCTCAGCGGGAAGGATTTTGGGTAAATCTGAGAGCT
                        GCGATAAAGTCCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00560</identifier>
                            <name>LRR_1</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01463</identifier>
                            <name>LRRCT</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01582</identifier>
                            <name>TIR</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-06-24">
        <drugbank-id primary="true">DB00046</drugbank-id>
        <drugbank-id>BIOD00065</drugbank-id>
        <drugbank-id>BTD00065</drugbank-id>
        <drugbank-id>DB01310</drugbank-id>
        <name>Insulin Lispro</name>
        <description>Insulin lispro is a recombinant human insulin analogue produced in a specialized laboratory strain of Escherischia coli. Plasmid DNA transfected into the bacteria encodes for an analogue of human insulin that has a lysine at residuce B28 and proline at B29; these residues are reversed in endogenous human insulin. Reversal of these amino acid residues produces a rapid-acting insulin analogue. FDA approved on 1996. </description>
        <cas-number>133107-64-9</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Miles HL, Acerini CL: Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs. 2008;10(3):163-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18454569&#13;
            # Zib I, Raskin P: Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006 Nov;8(6):611-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17026485</general-references>
        <synthesis-reference/>
        <indication>For the treatment of Type 1 or 2 diabetes mellitus. To be used in conjunction with an intermediate or long-acting insulin except when used in a continuous insulin infusion pump. </indication>
        <pharmacodynamics>Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin lispro is a rapid-acting insulin analogue used to mimic postprandial insulin spikes in diabetic individuals. The onset of action of insulin lispro is 10-15 minutes. Its activity peaks 60 minutes following subcutaneous injection and its duration of action is 4-5 hours. Compared to regular human insulin, insulin lispro  has a more rapid onset of action and a shorter duration of action. Insulin lispro is also shown to be equipotent to human insulin on a molar basis.  </pharmacodynamics>
        <mechanism-of-action>Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and &lt;i&gt;m&lt;/i&gt;-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties. </mechanism-of-action>
        <toxicity>Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Rare cases of lipoatrophy or lipohypertrophy reactions have been observed. </toxicity>
        <metabolism>Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.</metabolism>
        <absorption>Rapidly absorbed following subcutaneous administration. It is also absorbed more quickly than regular human insulin. Peak serum levels occur 30-90 minutes after injection in healthy subjects. Absorption also differs depending on the site of injection. After insulin lispro was administered in the abdomen, serum drug levels were higher and the duration of action was slightly shorter than after deltoid or thigh administration.&#13;
            Bioavailability, 0.1 - 0.2 unit/kg = 55% - 77%. </absorption>
        <half-life>SubQ administration = 1 hour</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution>When administered intravenously as bolus injections of 0.1 and 0.2 U/kg dose in two separate groups of healthy subjects, the mean volume of distribution of insulin lispro appeared to decrease with increase in dose (1.55 and 0.72 L/kg, respectively). </volume-of-distribution>
        <clearance>Clearance is dose dependent. When a dose of 0.1 unit/kg and 0.2 unit/kg were administered intravenously, the mean clearance was 21.0 mL/min/kg and 9.6 mL/min/kg respectively. </clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Insulin Lispro Recombinant </synonym>
        </synonyms>
        <products>
            <product>
                <name>Humalog</name>
                <ndc-id>0002-7510_30b67795-62b2-45cc-9bb1-d570d38207a7</ndc-id>
                <ndc-product-code>0002-7510</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1996-07-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>NDA020563</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog</name>
                <ndc-id>0002-7516_30b67795-62b2-45cc-9bb1-d570d38207a7</ndc-id>
                <ndc-product-code>0002-7516</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1998-02-20</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>NDA020563</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02229704</dpd-id>
                <started-marketing-on>1996-11-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Humalog</name>
                <ndc-id>54868-5108_199662a5-c92a-43ca-88ff-38e30bc6c3b9</ndc-id>
                <ndc-product-code>54868-5108</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-05-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020563</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog</name>
                <ndc-id>55045-3602_0b67b87e-09b2-4469-846e-52ea3f962018</ndc-id>
                <ndc-product-code>55045-3602</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1996-07-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020563</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog  (cartridge)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02229705</dpd-id>
                <started-marketing-on>1996-11-27</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Humalog  (kwikpen)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02403412</dpd-id>
                <started-marketing-on>2013-08-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Humalog 200 Units/ml Kwikpen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02439611</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>200 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Humalog Cartridge</name>
                <ndc-id>54868-5836_199662a5-c92a-43ca-88ff-38e30bc6c3b9</ndc-id>
                <ndc-product-code>54868-5836</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2007-12-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020563</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog KwikPen</name>
                <ndc-id>0002-7712_30b67795-62b2-45cc-9bb1-d570d38207a7</ndc-id>
                <ndc-product-code>0002-7712</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-05-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>200 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA205747</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog KwikPen</name>
                <ndc-id>0002-8799_30b67795-62b2-45cc-9bb1-d570d38207a7</ndc-id>
                <ndc-product-code>0002-8799</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2008-01-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>intravenous; subcutaneous</route>
                <fda-application-number>NDA020563</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog Mix50/50</name>
                <ndc-id>0002-7512_a9613057-f8d7-4566-aecf-89d4dc6cbb50</ndc-id>
                <ndc-product-code>0002-7512</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-02-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021018</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog Mix50/50 KwikPen</name>
                <ndc-id>0002-8798_a9613057-f8d7-4566-aecf-89d4dc6cbb50</ndc-id>
                <ndc-product-code>0002-8798</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-02-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021018</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog Mix75/25</name>
                <ndc-id>0002-7511_8a709ede-6322-4c32-84ae-1812f5d716f7</ndc-id>
                <ndc-product-code>0002-7511</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1999-12-22</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021017</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog Mix75/25</name>
                <ndc-id>54868-4381_d1df2bf7-621c-4b96-b2fb-1634fe9053e9</ndc-id>
                <ndc-product-code>54868-4381</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-02-22</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021017</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog Mix75/25 KwikPen</name>
                <ndc-id>0002-8797_8a709ede-6322-4c32-84ae-1812f5d716f7</ndc-id>
                <ndc-product-code>0002-8797</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2008-01-16</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, suspension</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021017</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog Pen</name>
                <ndc-id>54868-5899_199662a5-c92a-43ca-88ff-38e30bc6c3b9</ndc-id>
                <ndc-product-code>54868-5899</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2008-05-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020563</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Humalog Pen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02241283</dpd-id>
                <started-marketing-on>2000-01-10</started-marketing-on>
                <ended-marketing-on>2011-04-29</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>100 unit</strength>
                <route>intramuscular; intravenous; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Humalog</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Mix75/25</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Mix50/50</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog KwikPen</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Mix75/25 KwikPen</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Mix50/50 KwikPen</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog KwikPen</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Mix75/25</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Cartridge</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Pen</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog  (cartridge)</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog  (kwikpen)</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog Pen</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
            <mixture>
                <name>Humalog 200 Units/ml Kwikpen</name>
                <ingredients>Insulin Lispro</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Eli Lilly &amp; Co.</name>
                <url>http://www.lilly.com</url>
            </packager>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>Lilly Del Caribe Inc.</name>
                <url/>
            </packager>
            <packager>
                <name>Midwest IV and Home Care</name>
                <url>http://midwestmed.org/iv</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Eli lilly and co</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Humalog 100 unit/ml</description>
                <cost currency="USD">2.95</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Humalog 100 unit/ml Cartridge</description>
                <cost currency="USD">9.37</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Humalog mix 50/50 kwikpen</description>
                <cost currency="USD">11.83</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Humalog 100 unit/ml kwikpen</description>
                <cost currency="USD">15.4</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Humalog 100 unit/ml pen</description>
                <cost currency="USD">15.4</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Humalog mix 50-50 kwikpen</description>
                <cost currency="USD">15.4</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Humalog mix 50-50 pen</description>
                <cost currency="USD">15.4</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>HumaLOG 100 unit/ml Solution 10ml Vial</description>
                <cost currency="USD">124.36</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>HumaLOG 100 unit/ml Solution 1 Box = Five 3ml Cartridges = 15ml</description>
                <cost currency="USD">231.0</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>HumaLOG KwikPen 100 unit/ml Solution (1box = 5 Pens = 15ml)</description>
                <cost currency="USD">240.18</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>HumaLOG Mix 50/50 KwikPen 50-50% Suspension Five 3ml Pens Per Box = 15ml</description>
                <cost currency="USD">240.18</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>HumaLOG Mix 75/25 KwikPen 75-25% Suspension Five 3ml Pen Per Box = 15ml</description>
                <cost currency="USD">240.18</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>HumaLOG Mix 75/25 Pen 75-25% Suspension 15ml Box</description>
                <cost currency="USD">240.18</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>HumaLOG Pen (five 3ml Pens Per Box) 15ml Box</description>
                <cost currency="USD">240.18</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Hypoglycemic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Antidiabetic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>intravenous; subcutaneous</route>
                <strength>100 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>100 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intramuscular; intravenous; subcutaneous</route>
                <strength>100 unit</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>200 unit</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>200 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, suspension</form>
                <route>subcutaneous</route>
                <strength>100 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>intramuscular; intravenous; subcutaneous</route>
                <strength>100 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="A10AB04">
                <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
                <level code="A10">DRUGS USED IN DIABETES</level>
                <level code="A10A">INSULINS AND ANALOGUES</level>
                <level code="A10AB">Insulins and analogues for injection, fast-acting</level>
            </atc-code>
            <atc-code code="A10AC04">
                <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
                <level code="A10">DRUGS USED IN DIABETES</level>
                <level code="A10A">INSULINS AND ANALOGUES</level>
                <level code="A10AC">Insulins and analogues for injection, intermediate-acting</level>
            </atc-code>
            <atc-code code="A10AD04">
                <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
                <level code="A10">DRUGS USED IN DIABETES</level>
                <level code="A10A">INSULINS AND ANALOGUES</level>
                <level code="A10AD">Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>68:20.08</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2151560</number>
                <country>Canada</country>
                <approved>2000-05-09</approved>
                <expires>2015-06-12</expires>
            </patent>
            <patent>
                <number>2151564</number>
                <country>Canada</country>
                <approved>2003-02-11</approved>
                <expires>2015-06-12</expires>
            </patent>
            <patent>
                <number>5474978</number>
                <country>United States</country>
                <approved>1994-06-16</approved>
                <expires>2014-06-16</expires>
            </patent>
            <patent>
                <number>5514646</number>
                <country>United States</country>
                <approved>1993-05-07</approved>
                <expires>2013-05-07</expires>
            </patent>
        </patents>
        <food-interactions>
            <food-interaction>Inject subcutaneuosly 15 minutes before meal</food-interaction>
        </food-interactions>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00414</drugbank-id>
                <name>Acetohexamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06203</drugbank-id>
                <name>Alogliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01238</drugbank-id>
                <name>Aripiprazole</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01169</drugbank-id>
                <name>Arsenic trioxide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09009</drugbank-id>
                <name>Articaine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06216</drugbank-id>
                <name>Asenapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01072</drugbank-id>
                <name>Atazanavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00436</drugbank-id>
                <name>Bendroflumethiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00443</drugbank-id>
                <name>Betamethasone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09128</drugbank-id>
                <name>Brexpiprazole</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00887</drugbank-id>
                <name>Bumetanide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06719</drugbank-id>
                <name>Buserelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08907</drugbank-id>
                <name>Canagliflozin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09063</drugbank-id>
                <name>Ceritinib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00880</drugbank-id>
                <name>Chlorothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00672</drugbank-id>
                <name>Chlorpropamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00310</drugbank-id>
                <name>Chlorthalidone</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01285</drugbank-id>
                <name>Corticotropin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01380</drugbank-id>
                <name>Cortisone acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04839</drugbank-id>
                <name>Cyproterone acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08912</drugbank-id>
                <name>Dabrafenib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01406</drugbank-id>
                <name>Danazol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01264</drugbank-id>
                <name>Darunavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00304</drugbank-id>
                <name>Desogestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01234</drugbank-id>
                <name>Dexamethasone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01119</drugbank-id>
                <name>Diazoxide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09123</drugbank-id>
                <name>Dienogest</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB02901</drugbank-id>
                <name>Dihydrotestosterone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00280</drugbank-id>
                <name>Disopyramide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01395</drugbank-id>
                <name>Drospirenone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00668</drugbank-id>
                <name>Epinephrine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00783</drugbank-id>
                <name>Estradiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04574</drugbank-id>
                <name>Estropipate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00903</drugbank-id>
                <name>Ethacrynic acid</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00977</drugbank-id>
                <name>Ethinyl Estradiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00823</drugbank-id>
                <name>Ethynodiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00294</drugbank-id>
                <name>Etonogestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01590</drugbank-id>
                <name>Everolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00687</drugbank-id>
                <name>Fludrocortisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01319</drugbank-id>
                <name>Fosamprenavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00695</drugbank-id>
                <name>Furosemide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01120</drugbank-id>
                <name>Gliclazide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00222</drugbank-id>
                <name>Glimepiride</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01067</drugbank-id>
                <name>Glipizide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01251</drugbank-id>
                <name>Gliquidone</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01016</drugbank-id>
                <name>Glyburide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00014</drugbank-id>
                <name>Goserelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06788</drugbank-id>
                <name>Histrelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00999</drugbank-id>
                <name>Hydrochlorothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00741</drugbank-id>
                <name>Hydrocortisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06789</drugbank-id>
                <name>Hydroxyprogesterone caproate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04946</drugbank-id>
                <name>Iloperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00808</drugbank-id>
                <name>Indapamide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00224</drugbank-id>
                <name>Indinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB05278</drugbank-id>
                <name>inhaled insulin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01306</drugbank-id>
                <name>Insulin Aspart</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01307</drugbank-id>
                <name>Insulin Detemir</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00047</drugbank-id>
                <name>Insulin Glargine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01309</drugbank-id>
                <name>Insulin Glulisine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00030</drugbank-id>
                <name>Insulin Regular</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08914</drugbank-id>
                <name>Insulin, isophane</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06791</drugbank-id>
                <name>Lanreotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00007</drugbank-id>
                <name>Leuprolide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00367</drugbank-id>
                <name>Levonorgestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08882</drugbank-id>
                <name>Linagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00166</drugbank-id>
                <name>Lipoic Acid</name>
                <description>May enhance the hypoglycemic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06655</drugbank-id>
                <name>Liraglutide</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01601</drugbank-id>
                <name>Lopinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08815</drugbank-id>
                <name>Lurasidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01277</drugbank-id>
                <name>Mecasermin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00603</drugbank-id>
                <name>Medroxyprogesterone Acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00351</drugbank-id>
                <name>Megestrol acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01357</drugbank-id>
                <name>Mestranol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00331</drugbank-id>
                <name>Metformin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01403</drugbank-id>
                <name>Methotrimeprazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00232</drugbank-id>
                <name>Methyclothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00959</drugbank-id>
                <name>Methylprednisolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00524</drugbank-id>
                <name>Metolazone</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09046</drugbank-id>
                <name>Metreleptin</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00834</drugbank-id>
                <name>Mifepristone</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00731</drugbank-id>
                <name>Nateglinide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00220</drugbank-id>
                <name>Nelfinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00627</drugbank-id>
                <name>Niacin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04868</drugbank-id>
                <name>Nilotinib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00717</drugbank-id>
                <name>Norethindrone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00957</drugbank-id>
                <name>Norgestimate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00104</drugbank-id>
                <name>Octreotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00334</drugbank-id>
                <name>Olanzapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00621</drugbank-id>
                <name>Oxandrolone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01267</drugbank-id>
                <name>Paliperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06663</drugbank-id>
                <name>Pasireotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00082</drugbank-id>
                <name>Pegvisomant</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00738</drugbank-id>
                <name>Pentamidine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01132</drugbank-id>
                <name>Pioglitazone</name>
                <description>May enhance the adverse/toxic effect of Insulin. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00592</drugbank-id>
                <name>Piperazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01621</drugbank-id>
                <name>Pipotiazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01278</drugbank-id>
                <name>Pramlintide</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00860</drugbank-id>
                <name>Prednisolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00635</drugbank-id>
                <name>Prednisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00396</drugbank-id>
                <name>Progesterone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01224</drugbank-id>
                <name>Quetiapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00468</drugbank-id>
                <name>Quinine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00912</drugbank-id>
                <name>Repaglinide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00503</drugbank-id>
                <name>Ritonavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00412</drugbank-id>
                <name>Rosiglitazone</name>
                <description>Insulin may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01232</drugbank-id>
                <name>Saquinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06335</drugbank-id>
                <name>Saxagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00877</drugbank-id>
                <name>Sirolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00359</drugbank-id>
                <name>Sulfadiazine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01015</drugbank-id>
                <name>Sulfamethoxazole</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00263</drugbank-id>
                <name>Sulfisoxazole</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01268</drugbank-id>
                <name>Sunitinib</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00864</drugbank-id>
                <name>Tacrolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06287</drugbank-id>
                <name>Temsirolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00624</drugbank-id>
                <name>Testosterone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00932</drugbank-id>
                <name>Tipranavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00839</drugbank-id>
                <name>Tolazamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01124</drugbank-id>
                <name>Tolbutamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00214</drugbank-id>
                <name>Torasemide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00620</drugbank-id>
                <name>Triamcinolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06825</drugbank-id>
                <name>Triptorelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04876</drugbank-id>
                <name>Vildagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB02546</drugbank-id>
                <name>Vorinostat</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00246</drugbank-id>
                <name>Ziprasidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;A chain
                GIVEQCCTSICSLYQLENYCN</sequence>
            <sequence format="FASTA">&gt;B chain
                FVNQHLCGSHLVEALYLVCGERGFFYTKPT</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>81 °C</value>
                <source>Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>0.218</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.39</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>5808.0000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C257H387N65O76S6</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>11115</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D04477</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0002-7510-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164747059</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Insulin_lispro</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/insulinlispro.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/mtm/insulin-lispro.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000033</id>
                <name>Insulin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352&#13;
                    # Jehle PM, Fussgaenger RD, Kunze U, Dolderer M, Warchol W, Koop I: The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab. 1996 Jun;81(6):2319-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8964871&#13;
                    # Jehle PM, Fussganger RD, Seibold A, Luttke B, Bohm BO: Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. Int J Clin Pharmacol Ther. 1996 Nov;34(11):498-503. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8937933&#13;
                    # Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Apr 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20424816</references>
                <known-action>yes</known-action>
                <polypeptide id="P06213" source="Swiss-Prot">
                    <name>Insulin receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1</specific-function>
                    <gene-name>INSR</gene-name>
                    <locus>19p13.3-p13.2</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>957-979</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.18</theoretical-pi>
                    <molecular-weight>156308.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6091</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>INSR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>INSR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M10051</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>307070</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P06213</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INSR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD220 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>Insulin receptor precursor</synonym>
                        <synonym>IR</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin receptor precursor
                        MGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
                        QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
                        VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
                        ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
                        GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
                        CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
                        TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
                        EIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
                        RNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
                        NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
                        DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
                        RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
                        KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
                        PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
                        SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
                        SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
                        PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
                        EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
                        FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
                        AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
                        RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
                        CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
                        FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
                        PS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4149 bp
                        ATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
                        CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
                        CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
                        CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
                        CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
                        GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
                        GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
                        CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
                        TCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG
                        GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
                        ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
                        ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
                        GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
                        GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
                        GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
                        TGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
                        ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
                        CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
                        ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
                        CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
                        TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
                        GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
                        TGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
                        CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
                        AGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT
                        AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
                        CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
                        AATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
                        ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
                        CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
                        GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
                        AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
                        AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
                        AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
                        CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
                        GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
                        AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
                        TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
                        CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
                        CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
                        GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
                        GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
                        AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
                        ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
                        ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
                        TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
                        TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
                        TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
                        CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
                        AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
                        AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
                        GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
                        AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
                        GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
                        TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
                        GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
                        GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
                        GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
                        GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
                        ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
                        CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
                        TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
                        TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
                        TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
                        CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
                        GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
                        TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
                        GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
                        TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
                        CCTTCCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000858</id>
                <name>Insulin-like growth factor 1 receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Smith TJ: Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010 Jun;62(2):199-236. Epub 2010 Apr 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20392809</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08069" source="Swiss-Prot">
                    <name>Insulin-like growth factor 1 receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade</specific-function>
                    <gene-name>IGF1R</gene-name>
                    <locus>15q26.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>936-959</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.54</theoretical-pi>
                    <molecular-weight>154795.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5465</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IGF1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IGF1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04434</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>804990</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08069</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IGF1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD221 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>IGF-I receptor</synonym>
                        <synonym>Insulin-like growth factor 1 receptor precursor</synonym>
                        <synonym>Insulin-like growth factor I receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin-like growth factor 1 receptor precursor
                        MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
                        ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
                        EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
                        LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
                        APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
                        GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
                        LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
                        YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
                        NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
                        QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
                        ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
                        NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
                        VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
                        RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
                        EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
                        YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
                        KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
                        VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
                        LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
                        CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
                        VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
                        EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
                        SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4104 bp
                        ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
                        GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
                        AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
                        ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
                        ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
                        CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
                        GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
                        ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
                        CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
                        CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
                        TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
                        AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
                        GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
                        GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
                        TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
                        GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
                        TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
                        ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
                        CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
                        ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
                        TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
                        TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
                        ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
                        CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
                        AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
                        TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
                        ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
                        CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
                        GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
                        GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
                        ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
                        TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
                        CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
                        AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
                        GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
                        GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
                        GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
                        GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
                        GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
                        AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
                        ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
                        GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
                        GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
                        TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
                        TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
                        TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
                        TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
                        CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
                        AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
                        TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
                        ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
                        GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
                        ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
                        CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
                        CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
                        AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
                        GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
                        TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
                        TATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
                        CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
                        GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
                        GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
                        CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
                        GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
                        TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
                        GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
                        TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
                        GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
                        CTGCCCCAGTCTTCGACCTGCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme>
                <id>BE0002433</id>
                <name>Cytochrome P450 1A2</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Flockhart DA. "Drug Interactions: Cytochrome P450 Drug Interaction Table":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05177" source="Swiss-Prot">
                    <name>Cytochrome P450 1A2</name>
                    <general-function>Involved in monooxygenase activity</general-function>
                    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen</specific-function>
                    <gene-name>CYP1A2</gene-name>
                    <locus>15q24</locus>
                    <cellular-location>Endoplasmic reticulum</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.43</theoretical-pi>
                    <molecular-weight>58295.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CYP1A2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>Z00036</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05177</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CP1A2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CYPIA2</synonym>
                        <synonym>EC 1.14.14.1</synonym>
                        <synonym>P(3)450</synonym>
                        <synonym>P450 4</synonym>
                        <synonym>P450-P3</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytochrome P450 1A2
                        MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
                        PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
                        QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
                        AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
                        ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
                        LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
                        DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
                        WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
                        FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
                        TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
                        AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
                        CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
                        GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
                        CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
                        CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
                        CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
                        CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
                        GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
                        GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
                        AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
                        ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
                        CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
                        CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
                        CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
                        ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
                        AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
                        GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
                        TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
                        ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
                        TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
                        AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
                        GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
                        TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
                        CACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00067</identifier>
                            <name>p450</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>transition metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>iron ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tetrapyrrole binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>heme binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>monooxygenase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>generation of precursor metabolites and energy</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>electron transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-06-27">
        <drugbank-id primary="true">DB00047</drugbank-id>
        <drugbank-id>BIOD00045</drugbank-id>
        <drugbank-id>BTD00045</drugbank-id>
        <drugbank-id>DB01308</drugbank-id>
        <name>Insulin Glargine</name>
        <description>Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration. </description>
        <cas-number>160337-95-1</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Chatterjee S, Tringham JR, Davies MJ: Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Expert Opin Pharmacother. 2006 Jul;7(10):1357-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16805721&#13;
            # Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ: Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63(16):1743-78. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12904090&#13;
            # Home PD, Ashwell SG: An overview of insulin glargine. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S57-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12324987&#13;
            # Jones R: Insulin glargine (Aventis Pharma). IDrugs. 2000 Sep;3(9):1081-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16049868&#13;
            # Wang F, Carabino JM, Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12860485&#13;
            # Warren E, Weatherley-Jones E, Chilcott J, Beverley C: Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004 Nov;8(45):iii, 1-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15525480&#13;
            # Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008 Oct;10(5):333-49. doi: 10.1089/dia.2008.0023. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18715209</general-references>
        <synthesis-reference/>
        <indication>For the treatment of Type 1 or 2 diabetes mellitus in patients over 17 years old who require a long-acting (basal) insulin for the control of hyperglycemia. May be used in pediatric patients with Type 1 diabetes mellitus who require a long-acting (basal) insulin for glycemic control.  </indication>
        <pharmacodynamics>Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin glargine is a long-acting insulin analogue with a flat and predictable action profile. It is used to mimic the basal levels of insulin in diabetic individuals. The onset of action of insulin glargine is approximately 90 minutes and its duration of action is up to 24 hours. The action profile of insulin glargine is peakless. The significance of this finding is that insulin glargine has a lower chance of nocturnal hypoglycemia. </pharmacodynamics>
        <mechanism-of-action>Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body. </mechanism-of-action>
        <toxicity>Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Other adverse events that may occur include allergic reaction, injection site reaction, lipodystrophy, pruritis, and rash.</toxicity>
        <metabolism>Partly metabolized to two active metabolites with similar &lt;i&gt;in vitro&lt;/i&gt; activity to insulin: A21-Gly-insulin and A21-Gly-des-B30-Thr-insulin. </metabolism>
        <absorption>Because of the modifications to the A and B chain, the isoelectric point shifts towards a neutral pH and insulin glargine is more stable in acidic conditions than regular insulin. As insulin glargine is less soluble at neutral pH, once injected, forms microprecipitates. Slow release of insulin glargine from microprecipitates provides a relatively constant concentration of insulin over 24 hours. Onset of action is approximately 1.1 hours. </absorption>
        <half-life>Not reported in humans; 30 hours &lt;i&gt;in vitro&lt;/i&gt; in mammalian reticulocytes.</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Insulin Glargine (rDNA origin)</synonym>
        </synonyms>
        <products>
            <product>
                <name>Basaglar</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02444844</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Basaglar</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02444852</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02294338</dpd-id>
                <started-marketing-on>2007-09-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02251930</dpd-id>
                <started-marketing-on>2006-05-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>52125-416_0c92b3d0-8c26-42ff-8788-7e050db63038</ndc-id>
                <ndc-product-code>52125-416</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-11-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>52125-416_add8d95a-6943-4dc5-bc75-5d0c2d458aef</ndc-id>
                <ndc-product-code>52125-416</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2013-06-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02276410</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>55045-3685_71907ed5-ee95-471a-8d7d-f72dcbbdfb60</ndc-id>
                <ndc-product-code>55045-3685</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-09-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>54868-4626_929a6a1f-8668-425d-aec4-15793be80ea7</ndc-id>
                <ndc-product-code>54868-4626</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2002-06-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02280418</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>64725-2220_7d9b3b09-2b30-40a4-8b37-38d2e6af3abf</ndc-id>
                <ndc-product-code>64725-2220</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-09-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>54868-5765_929a6a1f-8668-425d-aec4-15793be80ea7</ndc-id>
                <ndc-product-code>54868-5765</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2007-04-04</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02245689</dpd-id>
                <started-marketing-on>2002-07-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>100 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>0088-2220_0dd5b537-70f4-45d3-8003-8ce600908e96</ndc-id>
                <ndc-product-code>0088-2220</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-09-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus</name>
                <ndc-id>54868-6231_929a6a1f-8668-425d-aec4-15793be80ea7</ndc-id>
                <ndc-product-code>54868-6231</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2011-02-07</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Lantus Solostar</name>
                <ndc-id>0088-2219_0dd5b537-70f4-45d3-8003-8ce600908e96</ndc-id>
                <ndc-product-code>0088-2219</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-09-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>100 [iU]/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021081</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Toujeo</name>
                <ndc-id>0024-5869_ab5b1a7c-6eaf-4a3c-8886-28dfed0e4e49</ndc-id>
                <ndc-product-code>0024-5869</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-02-25</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>300 U/mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA206538</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Toujeo Solostar</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02441829</dpd-id>
                <started-marketing-on>2015-07-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>300 unit</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Lantus OptiSet </name>
                <company/>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Toujeo</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus Solostar</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Toujeo Solostar</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Lantus</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Basaglar</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
            <mixture>
                <name>Basaglar</name>
                <ingredients>Insulin Glargine</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Gruppo Lepetit SPA</name>
                <url/>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Sanofi-Aventis Inc.</name>
                <url>http://www.sanofi-aventis.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Sanofi aventis us llc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Lantus 100 unit/ml cartridge</description>
                <cost currency="USD">14.35</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Lantus solostar 100 unit/ml</description>
                <cost currency="USD">14.35</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Lantus for OptiClik 100 unit/ml Solution 3ml Cartridge</description>
                <cost currency="USD">44.78</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Lantus 100 unit/ml Solution 10ml Vial</description>
                <cost currency="USD">111.88</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Lantus SoloStar 100 unit/ml Solution 1 Box = Five 3ml Syringes</description>
                <cost currency="USD">223.89</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Hypoglycemic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Antidiabetic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>100 unit</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>100 [iU]/mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>300 U/mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>300 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="A10AE04">
                <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
                <level code="A10">DRUGS USED IN DIABETES</level>
                <level code="A10A">INSULINS AND ANALOGUES</level>
                <level code="A10AE">Insulins and analogues for injection, long-acting</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>68:20.08</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>1339044</number>
                <country>Canada</country>
                <approved>1997-04-01</approved>
                <expires>2014-04-01</expires>
            </patent>
            <patent>
                <number>6100376</number>
                <country>United States</country>
                <approved>1992-11-06</approved>
                <expires>2009-11-06</expires>
            </patent>
            <patent>
                <number>7476652</number>
                <country>United States</country>
                <approved>2004-01-23</approved>
                <expires>2024-01-23</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00414</drugbank-id>
                <name>Acetohexamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06203</drugbank-id>
                <name>Alogliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01238</drugbank-id>
                <name>Aripiprazole</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01169</drugbank-id>
                <name>Arsenic trioxide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09009</drugbank-id>
                <name>Articaine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06216</drugbank-id>
                <name>Asenapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01072</drugbank-id>
                <name>Atazanavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00436</drugbank-id>
                <name>Bendroflumethiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00443</drugbank-id>
                <name>Betamethasone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09128</drugbank-id>
                <name>Brexpiprazole</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00887</drugbank-id>
                <name>Bumetanide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06719</drugbank-id>
                <name>Buserelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08907</drugbank-id>
                <name>Canagliflozin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09063</drugbank-id>
                <name>Ceritinib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00880</drugbank-id>
                <name>Chlorothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00672</drugbank-id>
                <name>Chlorpropamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00310</drugbank-id>
                <name>Chlorthalidone</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00363</drugbank-id>
                <name>Clozapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01285</drugbank-id>
                <name>Corticotropin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01380</drugbank-id>
                <name>Cortisone acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04839</drugbank-id>
                <name>Cyproterone acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08912</drugbank-id>
                <name>Dabrafenib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01406</drugbank-id>
                <name>Danazol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01264</drugbank-id>
                <name>Darunavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00304</drugbank-id>
                <name>Desogestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01234</drugbank-id>
                <name>Dexamethasone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01119</drugbank-id>
                <name>Diazoxide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09123</drugbank-id>
                <name>Dienogest</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB02901</drugbank-id>
                <name>Dihydrotestosterone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00280</drugbank-id>
                <name>Disopyramide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01395</drugbank-id>
                <name>Drospirenone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00668</drugbank-id>
                <name>Epinephrine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00783</drugbank-id>
                <name>Estradiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04574</drugbank-id>
                <name>Estropipate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00903</drugbank-id>
                <name>Ethacrynic acid</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00977</drugbank-id>
                <name>Ethinyl Estradiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00823</drugbank-id>
                <name>Ethynodiol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00294</drugbank-id>
                <name>Etonogestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01590</drugbank-id>
                <name>Everolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00687</drugbank-id>
                <name>Fludrocortisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01319</drugbank-id>
                <name>Fosamprenavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00695</drugbank-id>
                <name>Furosemide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01120</drugbank-id>
                <name>Gliclazide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00222</drugbank-id>
                <name>Glimepiride</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01067</drugbank-id>
                <name>Glipizide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01251</drugbank-id>
                <name>Gliquidone</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01016</drugbank-id>
                <name>Glyburide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00014</drugbank-id>
                <name>Goserelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06788</drugbank-id>
                <name>Histrelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00999</drugbank-id>
                <name>Hydrochlorothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00741</drugbank-id>
                <name>Hydrocortisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06789</drugbank-id>
                <name>Hydroxyprogesterone caproate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04946</drugbank-id>
                <name>Iloperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00808</drugbank-id>
                <name>Indapamide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00224</drugbank-id>
                <name>Indinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB05278</drugbank-id>
                <name>inhaled insulin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01306</drugbank-id>
                <name>Insulin Aspart</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01307</drugbank-id>
                <name>Insulin Detemir</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01309</drugbank-id>
                <name>Insulin Glulisine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00046</drugbank-id>
                <name>Insulin Lispro</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00030</drugbank-id>
                <name>Insulin Regular</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08914</drugbank-id>
                <name>Insulin, isophane</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06791</drugbank-id>
                <name>Lanreotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00007</drugbank-id>
                <name>Leuprolide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00367</drugbank-id>
                <name>Levonorgestrel</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08882</drugbank-id>
                <name>Linagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00166</drugbank-id>
                <name>Lipoic Acid</name>
                <description>May enhance the hypoglycemic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06655</drugbank-id>
                <name>Liraglutide</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01601</drugbank-id>
                <name>Lopinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08815</drugbank-id>
                <name>Lurasidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01277</drugbank-id>
                <name>Mecasermin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00603</drugbank-id>
                <name>Medroxyprogesterone Acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00351</drugbank-id>
                <name>Megestrol acetate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01357</drugbank-id>
                <name>Mestranol</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00331</drugbank-id>
                <name>Metformin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01403</drugbank-id>
                <name>Methotrimeprazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00232</drugbank-id>
                <name>Methyclothiazide</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00959</drugbank-id>
                <name>Methylprednisolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00524</drugbank-id>
                <name>Metolazone</name>
                <description>Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09046</drugbank-id>
                <name>Metreleptin</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00834</drugbank-id>
                <name>Mifepristone</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00731</drugbank-id>
                <name>Nateglinide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00220</drugbank-id>
                <name>Nelfinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00627</drugbank-id>
                <name>Niacin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04868</drugbank-id>
                <name>Nilotinib</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00717</drugbank-id>
                <name>Norethindrone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00957</drugbank-id>
                <name>Norgestimate</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00104</drugbank-id>
                <name>Octreotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00334</drugbank-id>
                <name>Olanzapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00621</drugbank-id>
                <name>Oxandrolone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01267</drugbank-id>
                <name>Paliperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06663</drugbank-id>
                <name>Pasireotide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00082</drugbank-id>
                <name>Pegvisomant</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00738</drugbank-id>
                <name>Pentamidine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01132</drugbank-id>
                <name>Pioglitazone</name>
                <description>May enhance the adverse/toxic effect of Insulin. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00592</drugbank-id>
                <name>Piperazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01621</drugbank-id>
                <name>Pipotiazine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01278</drugbank-id>
                <name>Pramlintide</name>
                <description>May enhance the hypoglycemic effect of Insulin.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00860</drugbank-id>
                <name>Prednisolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00635</drugbank-id>
                <name>Prednisone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00396</drugbank-id>
                <name>Progesterone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01224</drugbank-id>
                <name>Quetiapine</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00468</drugbank-id>
                <name>Quinine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00912</drugbank-id>
                <name>Repaglinide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00734</drugbank-id>
                <name>Risperidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00503</drugbank-id>
                <name>Ritonavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00412</drugbank-id>
                <name>Rosiglitazone</name>
                <description>Insulin may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01232</drugbank-id>
                <name>Saquinavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06335</drugbank-id>
                <name>Saxagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00877</drugbank-id>
                <name>Sirolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00359</drugbank-id>
                <name>Sulfadiazine</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01015</drugbank-id>
                <name>Sulfamethoxazole</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00263</drugbank-id>
                <name>Sulfisoxazole</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01268</drugbank-id>
                <name>Sunitinib</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00864</drugbank-id>
                <name>Tacrolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06287</drugbank-id>
                <name>Temsirolimus</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00624</drugbank-id>
                <name>Testosterone</name>
                <description>May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00932</drugbank-id>
                <name>Tipranavir</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00839</drugbank-id>
                <name>Tolazamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01124</drugbank-id>
                <name>Tolbutamide</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00214</drugbank-id>
                <name>Torasemide</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00620</drugbank-id>
                <name>Triamcinolone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06825</drugbank-id>
                <name>Triptorelin</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04876</drugbank-id>
                <name>Vildagliptin</name>
                <description>May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB02546</drugbank-id>
                <name>Vorinostat</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00246</drugbank-id>
                <name>Ziprasidone</name>
                <description>Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;A chain
                GIVEQCCTSICSLYQLENYCG</sequence>
            <sequence format="FASTA">&gt;B chain
                FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>81 °C</value>
                <source>Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>0.098</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>6.88</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>6063 Daltons </value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C267H404N72O78S6 </value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12724</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D03250</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0088-2220-60</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA449992</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Insulin_glargine</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/lantus.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/insulin-glargine-cartridge-systems.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions>
            <reaction>
                <sequence>1</sequence>
                <left-element>
                    <drugbank-id>DB00047</drugbank-id>
                    <name>Insulin Glargine</name>
                </left-element>
                <right-element>
                    <drugbank-id>DBMET00786</drugbank-id>
                    <name>A21-Gly-des-B30-Thr-insulin</name>
                </right-element>
                <enzymes/>
            </reaction>
            <reaction>
                <sequence>1</sequence>
                <left-element>
                    <drugbank-id>DB00047</drugbank-id>
                    <name>Insulin Glargine</name>
                </left-element>
                <right-element>
                    <drugbank-id>DBMET00787</drugbank-id>
                    <name>A21-Gly-insulin</name>
                </right-element>
                <enzymes/>
            </reaction>
        </reactions>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000033</id>
                <name>Insulin receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352&#13;
                    # Le Roith D: Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev. 2007 Nov;23(8):593-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17922476&#13;
                    # Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Apr 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20424816&#13;
                    # Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T: Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract. 2008 Sep;81(3):269-77. Epub 2008 Jun 27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18585815</references>
                <known-action>yes</known-action>
                <polypeptide id="P06213" source="Swiss-Prot">
                    <name>Insulin receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1</specific-function>
                    <gene-name>INSR</gene-name>
                    <locus>19p13.3-p13.2</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>957-979</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.18</theoretical-pi>
                    <molecular-weight>156308.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6091</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>INSR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>INSR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M10051</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>307070</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P06213</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>INSR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD220 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>Insulin receptor precursor</synonym>
                        <synonym>IR</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin receptor precursor
                        MGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
                        QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
                        VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
                        ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
                        GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
                        CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
                        TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
                        EIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
                        RNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
                        NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
                        DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
                        RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
                        KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
                        PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
                        SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
                        SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
                        PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
                        EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
                        FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
                        AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
                        RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
                        CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
                        FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
                        PS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4149 bp
                        ATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
                        CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
                        CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
                        CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
                        CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
                        GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
                        GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
                        CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
                        TCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG
                        GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
                        ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
                        ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
                        GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
                        GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
                        GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
                        TGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
                        ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
                        CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
                        ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
                        CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
                        TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
                        GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
                        TGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
                        CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
                        AGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT
                        AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
                        CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
                        AATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
                        ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
                        CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
                        GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
                        AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
                        AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
                        AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
                        CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
                        GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
                        AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
                        TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
                        CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
                        CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
                        GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
                        GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
                        AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
                        ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
                        ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
                        TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
                        TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
                        TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
                        CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
                        AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
                        AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
                        GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
                        AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
                        GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
                        TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
                        GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
                        GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
                        GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
                        GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
                        ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
                        CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
                        TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
                        TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
                        TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
                        CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
                        GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
                        TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
                        GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
                        TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
                        CCTTCCTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="1">
                <id>BE0000858</id>
                <name>Insulin-like growth factor 1 receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>agonist</action>
                </actions>
                <references># Smith TJ: Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010 Jun;62(2):199-236. Epub 2010 Apr 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20392809</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08069" source="Swiss-Prot">
                    <name>Insulin-like growth factor 1 receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade</specific-function>
                    <gene-name>IGF1R</gene-name>
                    <locus>15q26.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>936-959</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.54</theoretical-pi>
                    <molecular-weight>154795.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:5465</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>IGF1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>IGF1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04434</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>804990</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08069</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>IGF1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD221 antigen</synonym>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>IGF-I receptor</synonym>
                        <synonym>Insulin-like growth factor 1 receptor precursor</synonym>
                        <synonym>Insulin-like growth factor I receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Insulin-like growth factor 1 receptor precursor
                        MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
                        ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
                        EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
                        LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
                        APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
                        GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
                        LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
                        YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
                        NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
                        QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
                        ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
                        NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
                        VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
                        RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
                        EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
                        YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
                        KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
                        VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
                        LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
                        CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
                        VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
                        EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
                        SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4104 bp
                        ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
                        GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
                        AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
                        ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
                        ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
                        CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
                        GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
                        ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
                        CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
                        CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
                        TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
                        AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
                        GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
                        GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
                        TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
                        GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
                        TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
                        ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
                        CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
                        ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
                        TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
                        TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
                        ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
                        CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
                        AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
                        TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
                        ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
                        CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
                        GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
                        GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
                        ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
                        TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
                        CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
                        AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
                        GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
                        GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
                        GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
                        GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
                        GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
                        AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
                        ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
                        GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
                        GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
                        TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
                        TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
                        TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
                        TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
                        CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
                        AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
                        TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
                        ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
                        GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
                        ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
                        CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
                        CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
                        AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
                        GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
                        TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
                        TATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
                        CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
                        GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
                        GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
                        CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
                        GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
                        TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
                        GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
                        TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
                        GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
                        CTGCCCCAGTCTTCGACCTGCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme>
                <id>BE0002433</id>
                <name>Cytochrome P450 1A2</name>
                <organism>Human</organism>
                <actions>
                    <action>inducer</action>
                </actions>
                <references># Flockhart DA. "Drug Interactions: Cytochrome P450 Drug Interaction Table":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05177" source="Swiss-Prot">
                    <name>Cytochrome P450 1A2</name>
                    <general-function>Involved in monooxygenase activity</general-function>
                    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen</specific-function>
                    <gene-name>CYP1A2</gene-name>
                    <locus>15q24</locus>
                    <cellular-location>Endoplasmic reticulum</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.43</theoretical-pi>
                    <molecular-weight>58295.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>CYP1A2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>Z00036</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05177</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CP1A2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CYPIA2</synonym>
                        <synonym>EC 1.14.14.1</synonym>
                        <synonym>P(3)450</synonym>
                        <synonym>P450 4</synonym>
                        <synonym>P450-P3</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Cytochrome P450 1A2
                        MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
                        PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
                        QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
                        AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
                        ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
                        LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
                        DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
                        WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
                        FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1548 bp
                        ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
                        TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
                        AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
                        CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
                        GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
                        CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
                        CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
                        CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
                        CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
                        GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
                        GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
                        AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
                        ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
                        CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
                        CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
                        CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
                        ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
                        AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
                        GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
                        TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
                        ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
                        TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
                        AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
                        GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
                        TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
                        CACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00067</identifier>
                            <name>p450</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>transition metal ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>iron ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tetrapyrrole binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>heme binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>monooxygenase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>oxidoreductase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>generation of precursor metabolites and energy</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>electron transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-09-22">
        <drugbank-id primary="true">DB00048</drugbank-id>
        <drugbank-id>BIOD00010</drugbank-id>
        <drugbank-id>BTD00010</drugbank-id>
        <name>Collagenase clostridium histolyticum</name>
        <description>Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum that dismantles collagen. It is used as a powder-and-solvent injection kit for the treatment of Dupuytren's contracture, a condition where the fingers bend towards the palm and cannot be fully straightened, and Peyronie's disease, a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. BioSpecifics Technologies developed the preparation, which is manufactured and marketed by Auxilium Pharmaceuticals as Xiaflex in the US and by Sobi as Xiapex in Europe.</description>
        <cas-number>9001-12-1</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Norris DB, Trudgill PW: Multiple forms of cyclohexanone oxygenase from Nocardia globerula CL1. Eur J Biochem. 1976 Mar 16;63(1):193-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4312&#13;
            # Pajot P: Fluroescence of proteins in 6-M guanidine hydrochloride. A method for the quantitative determination of tryptophan. Eur J Biochem. 1976 Mar 16;63(1):263-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4317</general-references>
        <synthesis-reference>Hun-Chi Lin, Shau-Ping Lei, "Molecular cloning of the genes responsible for collagenase production from Clostridium histolyticum." U.S. Patent US5177017, issued December, 1972.</synthesis-reference>
        <indication>Used to promote debridement of necrotic tissue in the treatment of severe burns and dermal ulcers including decubitus ulcers.</indication>
        <pharmacodynamics>Used in the treatment of skin ulcers and sever burns, collagenase is able to digest collagen in necrotic tissue at physiological pH by hydrolyzing the peptide bonds of undenatured and denatured collagen. Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. The action of collagenase may remove substrates necessary for bacterial proliferation or may permit antibodies, leukocytes, and antibiotics better access to the infected area.</pharmacodynamics>
        <mechanism-of-action>Collagenase is a protease that is specific to collagen. The triple helical region of interstitial collagens is highly resistant to most cell proteinases. However, during remodeling of the connective tissue in such processes as wound healing and metastasis, collagen becomes susceptible to cleavage by collagenases. Collagenase cleaves all 3 alpha helical chains of native Types I, II and III collagens at a single locus by hydrolyzing the peptide bond following the Gly residue of the sequence: Gly 775-(Ile or Leu) 776-(Ala or Leu) 777 located approximately three-fourths of the chain length from each N-terminus</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Collagenase Santyl</name>
                <ndc-id>50484-010_02a922f5-5f34-4784-95ed-fd20dcfe5cfb</ndc-id>
                <ndc-product-code>50484-010</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2012-12-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>ointment</dosage-form>
                <strength>250 [arb'U]/g</strength>
                <route>topical</route>
                <fda-application-number>BLA101995</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Collagenase Santyl</name>
                <ndc-id>0064-5010_4a7d5058-59c6-410e-8dec-e30d05a072ca</ndc-id>
                <ndc-product-code>0064-5010</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-10-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>ointment</dosage-form>
                <strength>250 [arb'U]/g</strength>
                <route>topical</route>
                <fda-application-number>BLA101995</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Xiaflex</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02388316</dpd-id>
                <started-marketing-on>2012-11-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.9 mg</strength>
                <route>intralesional</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Cordase</name>
                <company/>
            </international-brand>
            <international-brand>
                <name>Santyl</name>
                <company>Advance Biofactures Corp</company>
            </international-brand>
            <international-brand>
                <name>Xiapex</name>
                <company>Sobi</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Collagenase Santyl</name>
                <ingredients>Collagenase clostridium histolyticum</ingredients>
            </mixture>
            <mixture>
                <name>Collagenase Santyl</name>
                <ingredients>Collagenase clostridium histolyticum</ingredients>
            </mixture>
            <mixture>
                <name>Xiaflex</name>
                <ingredients>Collagenase clostridium histolyticum</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Abbott Laboratories Ltd.</name>
                <url>http://www.abbott.com</url>
            </packager>
            <packager>
                <name>Advance Biofactures Corp.</name>
                <url/>
            </packager>
            <packager>
                <name>Auxilium Pharmaceuticals</name>
                <url>http://www.auxilium.com</url>
            </packager>
            <packager>
                <name>BASF Corp.</name>
                <url>http://BASF Corp.</url>
            </packager>
            <packager>
                <name>Dispensing Solutions</name>
                <url>http://www.drxdispensing.com</url>
            </packager>
            <packager>
                <name>Healthpoint Ltd.</name>
                <url>http://www.healthpoint.com</url>
            </packager>
            <packager>
                <name>Medisca Inc.</name>
                <url>http://www.medisca.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Santyl ointment</description>
                <cost currency="USD">4.13</cost>
                <unit>g</unit>
            </price>
            <price>
                <description>Santyl 250 unit/gm Ointment 15 gm Tube</description>
                <cost currency="USD">62.98</cost>
                <unit>tube</unit>
            </price>
            <price>
                <description>Collagenase powder</description>
                <cost currency="USD">2432.7</cost>
                <unit>g</unit>
            </price>
            <price>
                <description>Xiaflex 0.9 mg vial</description>
                <cost currency="USD">3900.0</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories/>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Ointment</form>
                <route>topical</route>
                <strength>250 [arb'U]/g</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intralesional</route>
                <strength>0.9 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="M09AB02">
                <level code="M">MUSCULO-SKELETAL SYSTEM</level>
                <level code="M09">OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</level>
                <level code="M09A">OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</level>
                <level code="M09AB">Enzymes</level>
            </atc-code>
            <atc-code code="D03BA02">
                <level code="D">DERMATOLOGICALS</level>
                <level code="D03">PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS</level>
                <level code="D03B">ENZYMES</level>
                <level code="D03BA">Proteolytic enzymes</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>84:92.00</ahfs-code>
        </ahfs-codes>
        <patents/>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04272</drugbank-id>
                <name>Citric Acid</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00266</drugbank-id>
                <name>Dicoumarol</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08794</drugbank-id>
                <name>Ethyl biscoumacetate</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00498</drugbank-id>
                <name>Phenindione</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00946</drugbank-id>
                <name>Phenprocoumon</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06271</drugbank-id>
                <name>Sulodexide</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt; Collagenase Sequence 
                MKRKCLSKRLMLAITMATIFTVNSTLPIYAAVDKNNATAAVQNESKRYTVSYLKTLNYYD
                LVDLLVKTEIENLPDLFQYSSDAKEFYGNKTRMSFIMDEIGRRAPQYTEIDHKGIPTLVE
                VVRAGFYLGFHNKELNEINKRSFKERVIPSILAIQKNPNFKLGTEVQDKIVSATGLLAGN
                ETAPPEVVNNFTPILQDCIKNIDRYALDDLKSKALFNVLAAPTYDITEYLRATKEKPENT
                PWYGKIDGFINELKKLALYGKINDNNSWIIDNGIYHIAPLGKLHSNNKIGIETLTEVMKV
                YPYLSMQHLQSADQIKRHYDSKDAEGNKIPLDKFKKEGKEKYCPKTYTFDDGKVIIKAGA
                RVEEEKVKRLYWASKEVNSQFFRVYGIDKPLEEGNPDDILTMVIYNSPEEYKLNSVLYGY
                DTNNGGMYIEPEGTFFTYEREAQESTYTLEELFRHEYTHYLQGRYAVPGQWGRTKLYDND
                RLTWYEEGGAELFAGSTRTSGILPRKSIVSNIHNTTRNNRYKLSDTVHSKYGASFEFYNY
                ACMFMDYMYNKDMGILNKLNDLAKNNDVDGYDNYIRDLSSNYALNDKYQDHMQERIDNYE
                NLTVPFVADDYLVRHAYKNPNEIYSEISEVAKLKDAKSEVKKSQYFSTFTLRGSYTGGAS
                KGKLEDQKAMNKFIDDSLKKLDTYSWSGYKTLTAYFTNYKVDSSNRVTYDVVFHGYLPNE
                GDSKNSLPYGKINGTYKGTEKEKIKFSSEGSFDPDGKIVSYEWDFGDGNKSNEENPEHSY
                DKVGTYTVKLKVTDDKGESSVSTTTAEIKDLSENKLPVIYMHVPKSGALNQKVVFYGKGT
                YDPDGSIAGYQWDFGDGSDFSSEQNPSHVYTKKGEYTVTLRVMDSSGQMSEKTMKIKITD
                PVYPIGTEKEPNNSKETASGPIVPGIPVSGTIENTSDQDYFYFDVITPGEVKIDINKLGY
                GGATWVVYDENNNAVSYATDDGQNLSGKFKADKPGRYYIHLYMFNGSYMPYRINIEGSVG
                R</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.714</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.58</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>112023.2000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C5028H7666N1300O1564S21</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>21378</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Compound</resource>
                <identifier>C00816</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA449107</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Collagenase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/collagenase.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/collagenase-ointment.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000025</id>
                <name>Collagen alpha-1(I) chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Egeblad M, Shen HC, Behonick DJ, Wilmes L, Eichten A, Korets LV, Kheradmand F, Werb Z, Coussens LM: Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn. 2007 Jun;236(6):1683-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17440987&#13;
                    # Lindsey ML, Yoshioka J, MacGillivray C, Muangman S, Gannon J, Verghese A, Aikawa M, Libby P, Krane SM, Lee RT: Effect of a cleavage-resistant collagen mutation on left ventricular remodeling. Circ Res. 2003 Aug 8;93(3):238-45. Epub 2003 Jul 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12855673&#13;
                    # Beare AH, O'Kane S, Krane SM, Ferguson MW: Severely impaired wound healing in the collagenase-resistant mouse. J Invest Dermatol. 2003 Jan;120(1):153-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12535212&#13;
                    # Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ: Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):646-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12101112&#13;
                    # Beare AH, Krane SM, Ferguson MW: Variable impairment of wound healing in the heterozygous collagenase-resistant mouse. Wound Repair Regen. 2005 Jan-Feb;13(1):27-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15659034</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02452" source="Swiss-Prot">
                    <name>Collagen alpha-1(I) chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Type I collagen is a member of group I collagen (fibrillar forming collagen)</specific-function>
                    <gene-name>COL1A1</gene-name>
                    <locus>17q21.33</locus>
                    <cellular-location/>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.56</theoretical-pi>
                    <molecular-weight>138885.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2197</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>COL1A1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>COL1A1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>Z74615</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>1418928</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02452</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO1A1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Alpha-1 type I collagen</synonym>
                        <synonym>Collagen alpha-1(I) chain precursor</synonym>
                        <synonym>I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Collagen alpha-1(I) chain precursor
                        MFSFVDLRLLLLLAATALLTHGQEEGQVEGQDEDIPPITCVQNGLRYHDRDVWKPEPCRI
                        CVCDNGKVLCDDVICDETKNCPGAEVPEGECCPVCPDGSESPTDQETTGVEGPKGDTGPR
                        GPRGPAGPPGRDGIPGQPGLPGPPGPPGPPGPPGLGGNFAPQLSYGYDEKSTGGISVPGP
                        MGPSGPRGLPGPPGAPGPQGFQGPPGEPGEPGASGPMGPRGPPGPPGKNGDDGEAGKPGR
                        PGERGPPGPQGARGLPGTAGLPGMKGHRGFSGLDGAKGDAGPAGPKGEPGSPGENGAPGQ
                        MGPRGLPGERGRPGAPGPAGARGNDGATGAAGPPGPTGPAGPPGFPGAVGAKGEAGPQGP
                        RGSEGPQGVRGEPGPPGPAGAAGPAGNPGADGQPGAKGANGAPGIAGAPGFPGARGPSGP
                        QGPGGPPGPKGNSGEPGAPGSKGDTGAKGEPGPVGVQGPPGPAGEEGKRGARGEPGPTGL
                        PGPPGERGGPGSRGFPGADGVAGPKGPAGERGSPGPAGPKGSPGEAGRPGEAGLPGAKGL
                        TGSPGSPGPDGKTGPPGPAGQDGRPGPPGPPGARGQAGVMGFPGPKGAAGEPGKAGERGV
                        PGPPGAVGPAGKDGEAGAQGPPGPAGPAGERGEQGPAGSPGFQGLPGPAGPPGEAGKPGE
                        QGVPGDLGAPGPSGARGERGFPGERGVQGPPGPAGPRGANGAPGNDGAKGDAGAPGAPGS
                        QGAPGLQGMPGERGAAGLPGPKGDRGDAGPKGADGSPGKDGVRGLTGPIGPPGPAGAPGD
                        KGESGPSGPAGPTGARGAPGDRGEPGPPGPAGFAGPPGADGQPGAKGEPGDAGAKGDAGP
                        PGPAGPAGPPGPIGNVGAPGAKGARGSAGPPGATGFPGAAGRVGPPGPSGNAGPPGPPGP
                        AGKEGGKGPRGETGPAGRPGEVGPPGPPGPAGEKGSPGADGPAGAPGTPGPQGIAGQRGV
                        VGLPGQRGERGFPGLPGPSGEPGKQGPSGASGERGPPGPMGPPGLAGPPGESGREGAPGA
                        EGSPGRDGSPGAKGDRGETGPAGPPGAPGAPGAPGPVGPAGKSGDRGETGPAGPAGPVGP
                        AGARGPAGPQGPRGDKGETGEQGDRGIKGHRGFSGLQGPPGPPGSPGEQGPSGASGPAGP
                        RGPPGSAGAPGKDGLNGLPGPIGPPGPRGRTGDAGPVGPPGPPGPPGPPGPPSAGFDFSF
                        LPQPPQEKAHDGGRYYRADDANVVRDRDLEVDTTLKSLSQQIENIRSPEGSRKNPARTCR
                        DLKMCHSDWKSGEYWIDPNQGCNLDAIKVFCNMETGETCVYPTQPSVAQKNWYISKNPKD
                        KRHVWFGESMTDGFQFEYGGQGSDPADVAIQLTFLRLMSTEASQNITYHCKNSVAYMDQQ
                        TGNLKKALLLKGSNEIEIRAEGNSRFTYSVTVDGCTSHTGAWGKTVIEYKTTKTSRLPII
                        DVAPLDVGAPDQEFGFDVGPVCFL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4395 bp
                        ATGTTCAGCTTTGTGGACCTCCGGCTCCTGCTCCTCTTAGCGGCCACCGCCCTCCTGACG
                        CACGGCCAAGAGGAAGGCCAAGTCGAGGGCCAAGACGAAGACATCCCACCAATCACCTGC
                        GTACAGAACGGCCTCAGGTACCATGACCGAGACGTGTGGAAACCCGAGCCCTGCCGGATC
                        TGCGTCTGCGACAACGGCAAGGTGTTGTGCGATGACGTGATCTGTGACGAGACCAAGAAC
                        TGCCCCGGCGCCGAAGTCCCCGAGGGCGAGTGCTGTCCCGTCTGCCCCGACGGCTCAGAG
                        TCACCCACCGACCAAGAAACCACCGGCGTCGAGGGACCCAAGGGAGACACTGGCCCCCGA
                        GGCCCAAGGGGACCCGCAGGCCCCCCTGGCCGAGATGGCATCCCTGGACAGCCTGGACTT
                        CCCGGACCCCCCGGACCCCCCGGACCTCCCGGACCCCCTGGCCTCGGAGGAAACTTTGCT
                        CCCCAGCTGTCTTATGGCTATGATGAGAAATCAACCGGAGGAATTTCCGTGCCTGGCCCC
                        ATGGGTCCCTCTGGTCCTCGTGGTCTCCCTGGCCCCCCTGGTGCACCTGGTCCCCAAGGC
                        TTCCAAGGTCCCCCTGGTGAGCCTGGCGAGCCTGGAGCTTCAGGTCCCATGGGTCCCCGA
                        GGTCCCCCAGGTCCCCCTGGAAAGAATGGAGATGATGGGGAAGCTGGAAAACCTGGTCGT
                        CCTGGTGAGCGTGGGCCTCCTGGGCCTCAGGGTGCTCGAGGATTGCCCGGAACAGCTGGC
                        CTCCCTGGAATGAAGGGACACAGAGGTTTCAGTGGTTTGGATGGTGCCAAGGGAGATGCT
                        GGTCCTGCTGGTCCTAAGGGTGAGCCTGGCAGCCCTGGTGAAAATGGAGCTCCTGGTCAG
                        ATGGGCCCCCGTGGCCTGCCTGGTGAGAGAGGTCGCCCTGGAGCCCCTGGCCCTGCTGGT
                        GCTCGTGGAAATGATGGTGCTACTGGTGCTGCCGGGCCCCCTGGTCCCACCGGCCCCGCT
                        GGTCCTCCTGGCTTCCCTGGTGCTGTTGGTGCTAAGGGTGAAGCTGGTCCCCAAGGGCCC
                        CGAGGCTCTGAAGGTCCCCAGGGTGTGCGTGGTGAGCCTGGCCCCCCTGGCCCTGCTGGT
                        GCTGCTGGCCCTGCTGGAAACCCTGGTGCTGATGGACAGCCTGGTGCTAAAGGTGCCAAT
                        GGTGCTCCTGGTATTGCTGGTGCTCCTGGCTTCCCTGGTGCCCGAGGCCCCTCTGGACCC
                        CAGGGCCCCGGCGGCCCTCCTGGTCCCAAGGGTAACAGCGGTGAACCTGGTGCTCCTGGC
                        AGCAAAGGAGACACTGGTGCTAAGGGAGAGCCTGGCCCTGTTGGTGTTCAAGGACCCCCT
                        GGCCCTGCTGGAGAGGAAGGAAAGCGAGGAGCTCGAGGTGAACCCGGACCCACTGGCCTG
                        CCCGGACCCCCTGGCGAGCGTGGTGGACCTGGTAGCCGTGGTTTCCCTGGCGCAGATGGT
                        GTTGCTGGTCCCAAGGGTCCCGCTGGTGAACGTGGTTCTCCTGGCCCCGCTGGCCCCAAA
                        GGATCTCCTGGTGAAGCTGGTCGTCCCGGTGAAGCTGGTCTGCCTGGTGCCAAGGGTCTG
                        ACTGGAAGCCCTGGCAGCCCTGGTCCTGATGGCAAAACTGGCCCCCCTGGTCCCGCCGGT
                        CAAGATGGTCGCCCCGGACCCCCAGGCCCACCTGGTGCCCGTGGTCAGGCTGGTGTGATG
                        GGATTCCCTGGACCTAAAGGTGCTGCTGGAGAGCCCGGCAAGGCTGGAGAGCGAGGTGTT
                        CCCGGACCCCCTGGCGCTGTCGGTCCTGCTGGCAAAGATGGAGAGGCTGGAGCTCAGGGA
                        CCCCCTGGCCCTGCTGGTCCCGCTGGCGAGAGAGGTGAACAAGGCCCTGCTGGCTCCCCC
                        GGATTCCAGGGTCTCCCTGGTCCTGCTGGTCCTCCAGGTGAAGCAGGCAAACCTGGTGAA
                        CAGGGTGTTCCTGGAGACCTTGGCGCCCCTGGCCCCTCTGGAGCAAGAGGCGAGAGAGGT
                        TTCCCTGGCGAGCGTGGTGTGCAAGGTCCCCCTGGTCCTGCTGGACCCCGAGGGGCCAAC
                        GGTGCTCCCGGCAACGATGGTGCTAAGGGTGATGCTGGTGCCCCTGGAGCTCCCGGTAGC
                        CAGGGCGCCCCTGGCCTTCAGGGAATGCCTGGTGAACGTGGTGCAGCTGGTCTTCCAGGG
                        CCTAAGGGTGACAGAGGTGATGCTGGTCCCAAAGGTGCTGATGGCTCTCCTGGCAAAGAT
                        GGCGTCCGTGGTCTGACCGGCCCCATTGGTCCTCCTGGCCCTGCTGGTGCCCCTGGTGAC
                        AAGGGTGAAAGTGGTCCCAGCGGCCCTGCTGGTCCCACTGGAGCTCGTGGTGCCCCCGGA
                        GACCGTGGTGAGCCTGGTCCCCCCGGCCCTGCTGGCTTTGCTGGCCCCCCTGGTGCTGAC
                        GGCCAACCTGGTGCTAAAGGCGAACCTGGTGATGCTGGTGCCAAAGGCGATGCTGGTCCC
                        CCTGGGCCTGCCGGACCCGCTGGACCCCCTGGCCCCATTGGTAATGTTGGTGCTCCTGGA
                        GCCAAAGGTGCTCGCGGCAGCGCTGGTCCCCCTGGTGCTACTGGTTTCCCTGGTGCTGCT
                        GGCCGAGTCGGTCCTCCTGGCCCCTCTGGAAATGCTGGACCCCCTGGCCCTCCTGGTCCT
                        GCTGGCAAAGAAGGCGGCAAAGGTCCCCGTGGTGAGACTGGCCCTGCTGGACGTCCTGGT
                        GAAGTTGGTCCCCCTGGTCCCCCTGGCCCTGCTGGCGAGAAAGGATCCCCTGGTGCTGAT
                        GGTCCTGCTGGTGCTCCTGGTACTCCCGGGCCTCAAGGTATTGCTGGACAGCGTGGTGTG
                        GTCGGCCTGCCTGGTCAGAGAGGAGAGAGAGGCTTCCCTGGTCTTCCTGGCCCCTCTGGT
                        GAACCTGGCAAACAAGGTCCCTCTGGAGCAAGTGGTGAACGTGGTCCCCCCGGTCCCATG
                        GGCCCCCCTGGATTGGCTGGACCCCCTGGTGAATCTGGACGTGAGGGGGCTCCTGCTGCC
                        GAAGGTTCCCCTGGACGAGACGGTTCTCCTGGCGCCAAGGGTGACCGTGGTGAGACCGGC
                        CCCGCTGGACCCCCTGGTGCTCCTGGTGCTCCTGGTGCCCCTGGCCCCGTTGGCCCTGCT
                        GGCAAGAGTGGTGATCGTGGTGAGACTGGTCCTGCTGGTCCCGCCGGTCCCGTCGGCCCC
                        GTCGGCGCCCGTGGCCCCGCCGGACCCCAAGGCCCCCGTGGTGACAAGGGTGAGACAGGC
                        GAACAGGGCGACAGAGGCATAAAGGGTCACCGTGGCTTCTCTGGCCTCCAGGGTCCCCCT
                        GGCCCTCCTGGCTCTCCTGGTGAACAAGGTCCCTCTGGAGCCTCTGGTCCTGCTGGTCCC
                        CGAGGTCCCCCTGGCTCTGCTGGTGCTCCTGGCAAAGATGGACTCAACGGTCTCCCTGGC
                        CCCATTGGGCCCCCTGGTCCTCGCGGTCGCACTGGTGATGCTGGTCCTGTTGGTCCCCCC
                        GGCCCTCCTGGACCTCCTGGTCCCCCTGGTCCTCCCAGCGCTGGTTTCGACTTCAGCTTC
                        CTGCCCCAGCCACCTCAAGAGAAGGCTCACGATGGTGGCCGCTACTACCGGGCTGATGAT
                        GCCAATGTGGTTCGTGACCGTGACCTCGAGGTGGACACCACCCTCAAGAGCCTGAGCCAG
                        CAGATCGAGAACATCCGGAGCCCAGAGGGAAGCCGCAAGAACCCCGCCCGCACCTGCCGT
                        GACCTCAAGATGTGCCACTCTGACTGGAAGAGTGGAGAGTACTGGATTGACCCCAACCAA
                        GGCTGCAACCTGGATGCCATCAAAGTCTTCTGCAACATGGAGACTGGTGAGACCTGCGTG
                        TACCCCACTCAGCCCAGTGTGGCCCAGAAGAACTGGTACATCAGCAAGAACCCCAAGGAC
                        AAGAGGCATGTCTGGTTCGGCGAGAGCATGACCGATGGATTCCAGTTCGAGTATGGCGGC
                        CAGGGCTCCGACCCTGCCGATGTGGCCATCCAGCTGACCTTCCTGCGCCTGATGTCCACC
                        GAGGCCTCCCAGAACATCACCTACCACTGCAAGAACAGCGTGGCCTACATGGACCAGCAG
                        ACTGGCAACCTCAAGAAGGCCCTGCTCCTCAAGGGCTCCAACGAGATCGAGATCCGCGCC
                        GAGGGCAACAGCCGCTTCACCTACAGCGTCACTGTCGATGGCTGCACGAGTCACACCGGA
                        GCCTGGGGCAAGACAGTGATTGAATACAAAACCACCAAGTCCTCCCGCCTGCCCATCATC
                        GATGTGGCCCCCTTGGACGTTGGTGCCCCAGACCAGGAATTCGGCTTCGACGTTGGCCCT
                        GTCTGCTTCCTGTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01410</identifier>
                            <name>COLFI</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00093</identifier>
                            <name>VWC</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix (sensu Metazoa)</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>collagen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>extracellular matrix structural constituent</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>structural molecule activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002140</id>
                <name>Collagen alpha-1(II) chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ: Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003 Nov;48(11):3085-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14613270&#13;
                    # Imai K, Dalal SS, Hambor J, Mitchell P, Okada Y, Horton WC, D'Armiento J: Bone growth retardation in mouse embryos expressing human collagenase 1. Am J Physiol Cell Physiol. 2007 Oct;293(4):C1209-15. Epub 2007 Jul 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17652426&#13;
                    # Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP: Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther. 2006;8(1):R31. Epub 2006 Jan 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16507130&#13;
                    # Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP: Articular chondrocytes cultured in hypoxia: their response to interleukin-1beta and rhein, the active metabolite of diacerhein. Biorheology. 2004;41(3-4):549-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15299286&#13;
                    # Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC: Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003 Nov 14;278(46):45539-45. Epub 2003 Jul 30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12890681</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02458" source="Swiss-Prot">
                    <name>Collagen alpha-1(II) chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Collagen type II is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces</specific-function>
                    <gene-name>COL2A1</gene-name>
                    <locus>12q13.11-q13.2</locus>
                    <cellular-location/>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.89</theoretical-pi>
                    <molecular-weight>141787.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2200</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>COL2A1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>COL2A1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16468</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29516</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02458</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO2A1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Alpha-1 type II collagen</synonym>
                        <synonym>Collagen alpha-1(II) chain precursor</synonym>
                        <synonym>II</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Collagen alpha-1(II) chain
                        MIRLGAPQTLVLLTLLVAAVLRCQGQDVQEAGSCVQDGQRYNDKDVWKPEPCRICVCDTG
                        TVLCDDIICEDVKDCLSPEIPFGECCPICPTDLATASGQPGPKGQKGEPGDIKDIVGPKG
                        PPGPQGPAGEQGPRGDRGDKGEKGAPGPRGRDGEPGTPGNPGPPGPPGPPGPPGLGGNFA
                        AQMAGGFDEKAGGAQLGVMQGPMGPMGPRGPPGPAGAPGPQGFQGNPGEPGEPGVSGPMG
                        PRGPPGPPGKPGDDGEAGKPGKAGERGPPGPQGARGFPGTPGLPGVKGHRGYPGLDGAKG
                        EAGAPGVKGESGSPGENGSPGPMGPRGLPGERGRTGPAGAAGARGNDGQPGPAGPPGPVG
                        PAGGPGFPGAPGAKGEAGPTGARGPEGAQGPRGEPGTPGSPGPAGASGNPGTDGIPGAKG
                        SAGAPGIAGAPGFPGPRGPPGPQGATGPLGPKGQTGEPGIAGFKGEQGPKGEPGPAGPQG
                        APGPAGEEGKRGARGEPGGVGPIGPPGERGAPGNRGFPGQDGLAGPKGAPGERGPSGLAG
                        PKGANGDPGRPGEPGLPGARGLTGRPGDAGPQGKVGPSGAPGEDGRPGPPGPQGARGQPG
                        VMGFPGPKGANGEPGKAGEKGLPGAPGLRGLPGKDGETGAAGPPGPAGPAGERGEQGAPG
                        PSGFQGLPGPPGPPGEGGKPGDQGVPGEAGAPGLVGPRGERGFPGERGSPGAQGLQGPRG
                        LPGTPGTDGPKGASGPAGPPGAQGPPGLQGMPGERGAAGIAGPKGDRGDVGEKGPEGAPG
                        KDGGRGLTGPIGPPGPAGANGEKGEVGPPGPAGSAGARGAPGERGETGPPGPAGFAGPPG
                        ADGQPGAKGEQGEAGQKGDAGAPGPQGPSGAPGPQGPTGVTGPKGARGAQGPPGATGFPG
                        AAGRVGPPGSNGNPGPPGPPGPSGKDGPKGARGDSGPPGRAGEPGLQGPAGPPGEKGEPG
                        DDGPSGAEGPPGPQGLAGQRGIVGLPGQRGERGFPGLPGPSGEPGKQGAPGASGDRGPPG
                        PVGPPGLTGPAGEPGREGSPGADGPPGRDGAAGVKGDRGETGAVGAPGAPGPPGSPGPAG
                        PTGKQGDRGEAGAQGPMGPSGPAGARGIQGPQGPRGDKGEAGEPGERGLKGHRGFTGLQG
                        LPGPPGPSGDQGASGPAGPSGPRGPPGPVGPSGKDGANGIPGPIGPPGPRGRSGETGPAG
                        PPGNPGPPGPPGPPGPGIDMSAFAGLGPREKGPDPLQYMRADQAAGGLRQHDAEVDATLK
                        SLNNQIESIRSPEGSRKNPARTCRDLKLCHPEWKSGDYWIDPNQGCTLDAMKVFCNMETG
                        ETCVYPNPANVPKKNWWSSKSKEKKHIWFGETINGGFHFSYGDDNLAPNTANVQMTFLRL
                        LSTEGSQNITYHCKNSIAYLDEAAGNLKKALLIQGSNDVEIRAEGNSRFTYTALKDGCTK
                        HTGKWGKTVIEYRSQKTSRLPIIDIAPMDIGGPEQEFGVDIGPVCFL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4464 bp
                        ATGATTCGCCTCGGGGCTCCCCAGTCGCTGGTGCTGCTGACGCTGCTCGTCGCCGCTGTC
                        CTTCGGTGTCAGGGCCAGGATGTCCAGGAGGCTGGCAGCTGTGTGCAGGATGGGCAGAGG
                        TATAATGATAAGGATGTGTGGAAGCCGGAGCCCTGCCGGATCTGTGTCTGTGACACTGGG
                        ACTGTCCTCTGCGACGACATAATCTGTGAAGACGTGAAAGACTGCCTCAGCCCTGAGATC
                        CCCTTCGGAGAGTGCTGCCCCATCTGCCCAACTGACCTCGCCACTGCCAGTGGGCAACCA
                        GGACCAAAGGGACAGAAAGGAGAACCTGGAGACATCAAGGATATTGTAGGACCCAAAGGA
                        CCTCCTGGGCCTCAGGGACCTGCAGGGGAACAAGGACCCAGAGGGGATCGTGGTGACAAA
                        GGTGAAAAAGGTGCCCCTGGACCTCGTGGCAGAGATGGAGAACCTGGGACCCCTGGAAAT
                        CCTGGCCCCCCTGGTCCTCCCGGCCCCCCTGGTCCCCCTGGTCTTGGTGGAAACTTTGCT
                        GCCCAGATGGCTGGAGGATTTGATGAAAAGGCTGGTGGCGCCCAGTTGGGAGTAATGCAA
                        GGACCAATGGGCCCCATGGGACCTCGAGGACCTCCAGGCCCTGCAGGTGCTCCTGGGCCT
                        CAAGGATTTCAAGGCAATCCTGGTGAACCTGGTGAACCTGGTGTCTCTGGTCCCATGGGT
                        CCCCGTGGTCCTCCTGGTCCCCCTGGAAAGCCTGGTGATGATGGTGAAGCTGGAAAACCT
                        GGAAAAGCTGGTGAAAGGGGTCCGCCTGGTCCTCAGGGTGCTCGTGGTTTCCCAGGAACC
                        CCAGGCCTTCCTGGTGTCAAAGGTCACAGAGGTTATCCAGGCCTGGACGGTGCTAAGGGA
                        GAGGCGGGTGCTCCTGGTGTGAAGGGTGAGAGTGGTTCCCCGGGTGAGAACGGATCTCCG
                        GGCCCAATGGGTCCTCGTGGCCTGCCTGGTGAAAGAGGACGGACTGGCCCTGCTGGCGCT
                        GCGGGTGCCCGAGGCAACGATGGTCAGCCAGGCCCCGCAGGTCCTCCGGGTCCTGTCGGT
                        CCTGCTGGTGGTCCTGGCTTCCCTGGTGCTCCTGGAGCCAAGGGTGAAGCCGGCCCCACT
                        GGTGCCCGTGGTCCTGAAGGTGCTCAAGGTCCTCGCGGTGAACCTGGTACTCCTGGGTCC
                        CCTGGGCCTGCTGGTGCCTCCGGTAACCCTGGAACAGATGGAATTCCTGGAGCCAAAGGA
                        TCTGCTGGTGCTCCTGGCATTGCTGGTGCTCCTGGCTTCCCTGGGCCACGGGGTCCTCCT
                        GGCCCTCAAGGTGCAACTGGTCCTCTGGGCCCGAAAGGTCAGACGGGTGAACCTGGTATT
                        GCTGGCTTCAAAGGTGAACAAGGCCCCAAGGGAGAACCTGGCCCTGCTGGCCCCCAGGGA
                        GCCCCTGGACCCGCTGGTGAAGAAGGCAAGAGAGGTGCCCGTGGAGAGCCTGGTGGCGTT
                        GGGCCCATCGGTCCCCCTGGAGAAAGAGGTGCTCCCGGAAACCGCGGTTTCCCAGGTCAA
                        GATGGTCTGGCAGGTCCCAAGGGAGCCCCTGGAGAGCGAGGGCCCAGTGGTCTTGCTGGC
                        CCCAAGGGAGCCAACGGTGACCCTGGCCGTCCTGGAGAACCTGGCCTTCCTGGAGCCCGG
                        GGTCTCACTGGCCGCCCTGGTGATGCTGGTCCTCAAGGCAAAGTTGGCCCTTCTGGAGCC
                        CCTGGTGAAGATGGTCGTCCTGGACCTCCAGGTCCTCAGGGGGCTCGTGGGCAGCCTGGT
                        GTCATGGGTTTCCCTGGCCCCAAAGGTGCCAACGGTGAGCCTGGCAAAGCTGGTGAGAAG
                        GGACTGCCTGGTGCTCCTGGTCTGAGGGGTCTTCCTGGCAAAGATGGTGAGACAGGTGCT
                        GCAGGACCCCCTGGCCCTGCTGGACCTGCTGGTGAACGAGGCGAGCAGGGTGCTCCTGGG
                        CCATCTGGGTTCCAGGGACTTCCTGGCCCTCCTGGTCCCCCAGGTGAAGGTGGAAAACCA
                        GGTGACCAGGGTGTTCCCGGTGAAGCTGGAGCCCCTGGCCTCGTGGGTCCCAGGGGTGAA
                        CGAGGTTTCCCAGGTGAACGTGGCTCTCCCGGTGCCCAGGGCCTCCAGGGTCCCCGTGGC
                        CTCCCCGGCACTCCTGGCACTGATGGTCCCAAAGGTGCATCTGGCCCAGCAGGCCCCCCT
                        GGCGCACAGGGCCCTCCAGGTCTTCAGGGAATGCCTGGCGAGAGGGGAGCAGCTGGTATC
                        GCTGGGCCCAAAGGCGACAGGGGTGACGTTGGTGAGAAAGGCCCTGAGGGAGCCCCTGGA
                        AAGGATGGTGGACGAGGCCTGACAGGTCCCATTGGCCCCCCTGGCCCAGCTGGTGCTAAC
                        GGCGAGAAGGGAGAAGTTGGACCTCCTGGTCCTGCAGGAAGTGCTGGTGCTCGTGGCGCT
                        CCGGGTGAACGTGGAGAGACTGGCCCCCCCGGACCAGCGGGATTTGCTGGGCCTCCTGGT
                        GCTGATGGCCAGCCTGGGGCCAAGGGTGAGCAAGGAGAGGCCGGCCAGAAAGGCGATGCT
                        GGTGCCCCTGGTCCTCAGGGCCCCTCTGGAGCACCTGGGCCTCAGGGTCCTACTGGAGTG
                        ACTGGTCCTAAAGGAGCCCGAGGTGCCCAAGGCCCCCCGGGAGCCACTGGATTCCCTGGA
                        GCTGCTGGCCGCGTTGGACCCCCAGGCTCCAATGGCAACCCTGGACCCCCTGGTCCCCCT
                        GGTCCTTCTGGAAAAGATGGTCCCAAAGGTGCTCGAGGAGACAGCGGCCCCCCTGGCCGA
                        GCTGGTGAACCCGGCCTCCAAGGTCCTGCTGGACCCCCTGGCGAGAAGGGAGAGCCTGGA
                        GATGACGGTCCCTCTGGTGCCGAAGGTCCACCAGGTCCCCAGGGTCTGGCTGGTCAGAGA
                        GGCATCGTCGGTCTGCCTGGGCAACGTGGTGAGAGAGGATTCCCTGGCTTGCCTGGCCCA
                        TCGGGTGAGCCCGGCAAGCAGGGTGCTCCTGGAGCATCTGGAGACAGAGGTCCTCCTGGC
                        CCCGTGGGTCCTCCTGGCCTGACGGGTCCTGCAGGTGAACCCGGACGAGAGGGAAGCCCC
                        GGTGCTGATGGCCCCCCTGGCAGAGATGGCGCTGCTGGAGTCAAGGGTGATCGTGGTGAG
                        ACTGGTGCTGTGGGAGCTCCTGGAGCCCCTGGGCCCCCTGGCTCCCCTGGCCCCGCTGGT
                        CCAACTGGCAAGCAAGGAGACAGAGGAGAAGCTGGTGCACAAGGCCCCATGGGACCCTCA
                        GGACCAGCTGGAGCCCGGGGAATCCAGGGTCCTCAAGGCCCCAGAGGTGACAAAGGAGAG
                        GCTGGAGAGCCTGGCGAGAGAGGCCTGAAGGGACACCGTGGCTTCACTGGTCTGCAGGGT
                        CTGCCCGGCCCTCCTGGTCCTTCTGGAGACCAAGGTGCTTCTGGTCCTGCTGGTCCTTCT
                        GGCCCTAGAGGTCCTCCTGGCCCCGTCGGTCCCTCTGGCAAAGATGGTGCTAATGGAATC
                        CCTGGCCCCATTGGGCCTCCTGGTCCCCGTGGACGATCAGGCGAAACCGGTCCTGCTGGT
                        CCTCCTGGAAATCCTGGGCCCCCTGGTCCTCCAGGTCCCCCTGGCCCTGGCATCGACATG
                        TCCGCCTTTGCTGGCTTAGGCCCGAGAGAGAAGGGCCCCGACCCCCTGCAGTACATGCGG
                        GCCGACCAGGCAGCCGGTGGCCTGAGACAGCATGACGCCGAGGTGGATGCCACACTCAAG
                        TCCCTCAACAACCAGATTGAGAGCATCCGCAGCCCCGAGGGCTCCCGCAAGAACCCTGCT
                        CGCACCTGCAGAGACCTGAAACTCTGCCACCCTGAGTGGAAGAGTGGAGACTACTGGATT
                        GACCCCAACCAAGGCTGCACCTTGGACGCCATGAAGGTTTTCTGCAACATGGAGACTGGC
                        GAGACTTGCGTCTACCCCAATCCAGCAAACGTTCCCAAGAAGAACTGGTGGAGCAGCAAG
                        AGCAAGGAGAAGAAACACATCTGGTTTGGAGAAACCATCAATGGTGGCTTCCATTTCAGC
                        TATGGAGATGACAATCTGGCTCCCAACACTGCCAACGTCCAGATGACCTTCCTACGCCTG
                        CTGTCCACGGAAGGCTCCCAGAACATCACCTACCACTGCAAGAACAGCATTGCCTATCTG
                        GACGAAGCAGCTGGCAACCTCAAGAAGGCCCTGCTCATCCAGGGCTCCAATGACGTGGAG
                        ATCCGGGCAGAGGGCAATAGCAGGTTCACGTACACTGCCCTGAAGGATGGCTGCACGAAA
                        CATACCGGTAAGTGGGGCAAGACTGTTATCGAGTACCGGTCACAGAAGACCTCACGCCTC
                        CCCATCATTGACATTGCACCCATGGACATAGGAGGGCCCGAGCAGGAATTCGGTGTGGAC
                        ATAGGGCCGGTCTGCTTCTTGTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01410</identifier>
                            <name>COLFI</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00093</identifier>
                            <name>VWC</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix (sensu Metazoa)</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>collagen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>extracellular matrix structural constituent</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>structural molecule activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002130</id>
                <name>Collagen alpha-1(III) chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Cole WG, Chiodo AA, Lamande SR, Janeczko R, Ramirez F, Dahl HH, Chan D, Bateman JF: A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J Biol Chem. 1990 Oct 5;265(28):17070-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2145268</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02461" source="Swiss-Prot">
                    <name>Collagen alpha-1(III) chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Collagen type III occurs in most soft connective tissues along with type I collagen</specific-function>
                    <gene-name>COL3A1</gene-name>
                    <locus>2q31</locus>
                    <cellular-location/>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.57</theoretical-pi>
                    <molecular-weight>138566.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2201</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>COL3A1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>COL3A1</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X14420</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>30058</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02461</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO3A1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Collagen alpha-1(III) chain precursor</synonym>
                        <synonym>III</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Collagen alpha-1(III) chain
                        MMSFVQKGSWLLLALLHPTIILAQQEAVEGGCSHLGQSYADRDVWKPEPCQICVCDSGSV
                        LCDDIICDDQELDCPNPEIPFGECCAVCPQPPTAPTRPPNGQGPQGPKGDPGPPGIPGRN
                        GDPGIPGQPGSPGSPGPPGICESCPTGPQNYSPQYDSYDVKSGVAVGGLAGYPGPAGPPG
                        PPGPPGTSGHPGSPGSPGYQGPPGEPGQAGPSGPPGPPGAIGPSGPAGKDGESGRPGRPG
                        ERGLPGPPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMG
                        PRGAPGERGRPGLPGAAGARGNDGARGSDGQPGPPGPPGTAGFPGSPGAKGEVGPAGSPG
                        SNGAPGQRGEPGPQGHAGAQGPPGPPGINGSPGGKGEMGPAGIPGAPGLMGARGPPGPAG
                        ANGAPGLRGGAGEPGKNGAKGEPGPRGERGEAGIPGVPGAKGEDGKDGSPGEPGANGLPG
                        AAGERGAPGFRGPAGPNGIPGEKGPAGERGAPGPAGPRGAAGEPGRDGVPGGPGMRGMPG
                        SPGGPGSDGKPGPPGSQGESGRPGPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGERGGPG
                        GPGPQGPPGKNGETGPQGPPGPTGPGGDKGDTGPPGPQGLQGLPGTGGPPGENGKPGEPG
                        PKGDAGAPGAPGGKGDAGAPGERGPPGLAGAPGLRGGAGPPGPEGGKGAAGPPGPPGAAG
                        TPGLQGMPGERGGLGSPGPKGDKGEPGGPGADGVPGKDGPRGPTGPIGPPGPAGQPGDKG
                        EGGAPGLPGIAGPRGSPGERGETGPPGPAGFPGAPGQNGEPGGKGERGAPGEKGEGGPPG
                        VAGPPGGSGPAGPPGPQGVKGERGSPGGPGAAGFPGARGLPGPPGSNGNPGPPGPSGSPG
                        KDGPPGPAGNTGAPGSPGVSGPKGDAGQPGEKGSPGAQGPPGAPGPLGIAGITGARGLAG
                        PPGMPGPRGSPGPQGVKGESGKPGANGLSGERGPPGPQGLPGLAGTAGEPGRDGNPGSDG
                        LPGRDGSPGGKGDRGENGSPGAPGAPGHPGPPGPVGPAGKSGDRGESGPAGPAGAPGPAG
                        SRGAPGPQGPRGDKGETGERGAAGIKGHRGFPGNPGAPGSPGPAGQQGAIGSPGPAGPRG
                        PVGPSGPPGKDGTSGHPGPIGPPGPRGNRGERGSEGSPGHPGQPGPPGPPGAPGPCCGGV
                        GAAAIAGIGGEKAGGFAPYYGDEPMDFKINTDEIMTSLKSVNGQIESLISPDGSRKNPAR
                        NCRDLKFCHPELKSGEYWVDPNQGCKLDAIKVFCNMETGETCISANPLNVPRKHWWTDSS
                        AEKKHVWFGESMDGGFQFSYGNPELPEDVLDVHLAFLRLLSSRASQNITYHCKNSIAYMD
                        QASGNVKKALKLMGSNEGEFKAEGNSKFTYTVLEDGCTKHTGEWSKTVFEYRTRKAVRLP
                        IVDIAPYDIGGPDQEFGVDVGPVCFL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4401 bp
                        ATGATGAGCTTTGTGCAAAAGGGGAGCTGGCTACTTCTCGCTCTGCTTCATCCCACTATT
                        ATTTTGGCACAACAGGAAGCTGTTGAAGGAGGATGTTCCCATCTTGGTCAGTCCTATGCG
                        GATAGAGATGTCTGGAAGCCAGAACCATGCCAAATATGTGTCTGTGACTCAGGATCCGTT
                        CTCTGCGATGACATAATATGTGACGATCAAGAATTAGACTGCCCCAACCCAGAAATTCCA
                        TTTGGAGAATGTTGTGCAGTTTGCCCACAGCCTCCAACTGCTCCTACTCGCCCTCCTAAT
                        GGTCAAGGACCTCAAGGCCCCAAGGGAGATCCAGGCCCTCCTGGTATTCCTGGGAGAAAT
                        GGTGACCCTGGTATTCCAGGACAACCAGGGTCCCCTGGTTCTCCTGGCCCCCCTGGAATC
                        TGTGAATCATGCCCTACTGGTCCTCAGAACTATTCTCCCCAGTATGATTCATATGATGTC
                        AAGTCTGGAGTAGCAGTAGGAGGACTCGCAGGCTATCCTGGACCAGCTGGCCCCCCAGGC
                        CCTCCCGGTCCCCCTGGTACATCTGGTCATCCTGGTTCCCCTGGATCTCCAGGATACCAA
                        GGACCCCCTGGTGAACCTGGGCAAGCTGGTCCTTCAGGCCCTCCAGGACCTCCTGGTGCT
                        ATAGGTCCATCTGGTCCTGCTGGAAAAGATGGAGAATCAGGTAGACCCGGACGACCTGGA
                        GAGCGAGGATTGCCTGGACCTCCAGGTATCAAAGGTCCAGCTGGGATACCTGGATTCCCT
                        GGTATGAAAGGACACAGAGGCTTCGATGGACGAAATGGAGAAAAGGGTGAAACAGGTGCT
                        CCTGGATTAAAGGGTGAAAATGGTCTTCCAGGCGAAAATGGAGCTCCTGGACCCATGGGT
                        CCAAGAGGGGCTCCTGGTGAGCGAGGACGGCCAGGACTTCCTGGGGCTGCAGGTGCTCGG
                        GGTAATGACGGTGCTCGAGGCAGTGATGGTCAACCAGGCCCTCCTGGTCCTCCTGGAACT
                        GCCGGATTCCCTGGATCCCCTGGTGCTAAGGGTGAAGTTGGACCTGCAGGGTCTCCTGGT
                        TCAAATGGTGCCCCTGGACAAAGAGGAGAACCTGGACCTCAGGGACACGCTGGTGCTCAA
                        GGTCCTCCTGGCCCTCCTGGGATTAATGGTAGTCCTGGTGGTAAAGGCGAAATGGGTCCC
                        GCTGGCATTCCTGGAGCTCCTGGACTGATGGGAGCCCGGGGTCCTCCAGGACCAGCCGGT
                        GCTAATGGTGCTCCTGGACTGCGAGGTGGTGCAGGTGAGCCTGGTAAGAATGGTGCCAAA
                        GGAGAGCCCGGACCACGTGGTGAACGCGGTGAGGCTGGTATTCCAGGTGTTCCAGGAGCT
                        AAAGGCGAAGATGGCAAGGATGGATCACCTGGAGAACCTGGTGCAAATGGGCTTCCAGGA
                        GCTGCAGGAGAAAGGGGTGCCCCTGGGTTCCGAGGACCTGCTGGACCAAATGGCATCCCA
                        GGAGAAAAGGGTCCTGCTGGAGAGCGTGGTGCTCCAGGCCCTGCAGGGCCCAGAGGAGCT
                        GCTGGAGAACCTGGCAGAGATGGCGTCCCTGGAGGTCCAGGAATGAGGGGCATGCCCGGA
                        AGTCCAGGAGGACCAGGAAGTGATGGGAAACCAGGGCCTCCCGGAAGTCAAGGAGAAAGT
                        GGTCGACCAGGTCCTCCTGGGCCATCTGGTCCCCGAGGTCAGCCTGGTGTCATGGGCTTC
                        CCCGGTCCTAAAGGAAATGATGGTGCTCCTGGTAAGAATGGAGAACGAGGTGGCCCTGGA
                        GGACCTGGCCCTCAGGGTCCTCCTGGAAAGAATGGTGAAACTGGACCTCAAGGACCCCCA
                        GGGCCTACTGGGCCTGGTGGTGACAAAGGAGACACAGGACCCCCTGGTCCACAAGGATTA
                        CAAGGCTTGCCTGGTACAGGTGGTCCTCCAGGAGAAAATGGAAAACCTGGGGAACCAGGT
                        CCAAAGGGTGATGCCGGTGCACCTGGAGCTCCAGGAGGCAAGGGTGATGCTGGTGCCCCT
                        GGTGAACGTGGACCTCCTGGATTGGCAGGGGCCCCAGGACTTAGAGGTGGAGCTGGTCCC
                        CCTGGTCCCGAAGGAGGAAAGGGTGCTGCTGGTCCTCCTGGGCCACCTGGTGCTGCTGGT
                        ACTCCTGGTCTGCAAGGAATGCCTGGAGAAAGAGGAGGTCTTGGAAGTCCTGGTCCAAAG
                        GGTGACAAGGGTGAACCAGGCGGCCCAGGTGCTGATGGTGTCCCAGGGAAAGATGGCCCA
                        AGGGGTCCTACTGGTCCTATTGGTCCTCCTGGCCCAGCTGGCCAGCCTGGAGATAAGGGT
                        GAAGGTGGTGCCCCCGGACTTCCAGGTATAGCTGGACCTCGTGGTAGCCCTGGTGAGAGA
                        GGTGAAACTGGCCCTCCAGGACCTGCTGGTTTCCCTGGTGCTCCTGGACAGAATGGTGAA
                        CCTGGTGGTAAAGGAGAAAGAGGGGCTCCGGGTGAGAAAGGTGAAGGAGGCCCTCCTGGA
                        GTTGCAGGACCCCCTGGAGGTTCTGGACCTGCTGGTCCTCCTGGTCCCCAAGGTGTCAAA
                        GGTGAACGTGGCAGTCCTGGTGGACCTGGTGCTGCTGGCTTCCCTGGTGCTCGTGGTCTT
                        CCTGGTCCTCCTGGTAGTAATGGTAACCCAGGACCCCCAGGTCCCAGCGGTTCTCCAGGC
                        AAGGATGGGCCCCCAGGTCCTGCGGGTAACACTGGTGCTCCTGGCAGCCCTGGAGTGTCT
                        GGACCAAAAGGTGATGCTGGCCAACCAGGAGAGAAGGGATCGCCTGGTGCCCAGGGCCCA
                        CCAGGAGCTCCAGGCCCACTTGGGATTGCTGGGATCACTGGAGCACGGGGTCTTGCAGGA
                        CCACCAGGCATGCCAGGTCCTAGGGGAAGCCCTGGCCCTCAGGGTGTCAAGGGTGAAAGT
                        GGGAAACCAGGAGCTAACGGTCTCAGTGGAGAACGTGGTCCCCCTGGACCCCAGGGTCTT
                        CCTGGTCTGGCTGGTACAGCTGGTGAACCTGGAAGAGATGGAAACCCTGGATCAGATGGT
                        CTTCCAGGCCGAGATGGATCTCCTGGTGGCAAGGGTGATCGTGGTGAAAATGGCTCTCCT
                        GGTGCCCCTGGCGCTCCTGGTCATCCAGGCCCACCTGGTCCTGTCGGTCCAGCTGGAAAG
                        AGTGGTGACAGAGGAGAAAGTGGCCCTGCTGGCCCTGCTGGTGCTCCCGGTCCTGCTGGT
                        TCCCGAGGTGCTCCTGGTCCTCAAGGCCCACGTGGTGACAAAGGTGAAACAGGTGAACGT
                        GGAGCTGCTGGCATCAAAGGACATCGAGGATTCCCTGGTAATCCAGGTGCCCCAGGTTCT
                        CCAGGCCCTGCTGGTCAGCAGGGTGCAATCGGCAGTCCAGGACCTGCAGGCCCCAGAGGA
                        CCTGTTGGACCCAGTGGACCTCCTGGCAAAGATGGAACCAGTGGACATCCAGGTCCCATT
                        GGACCACCAGGGCCTCGAGGTAACAGAGGTGAAAGAGGATCTGAGGGCTCCCCAGGCCAC
                        CCAGGGCAACCAGGCCCTCCTGGACCTCCTGGTGCCCCTGGTCCTTGCTGTGGTGGTGTT
                        GGAGCCGCTGCCATTGCTGGGATTGGAGGTGAAAAAGCTGGCGGTTTTGCCCCGTATTAT
                        GGAGATGAACCAATGGATTTCAAAATCAACACCGATGAGATTATGACTTCACTCAAGTCT
                        GTTAATGGACAAATAGAAAGCCTCATTAGTCCTGATGGTTCTCGTAAAAACCCCGCTAGA
                        AACTGCAGAGACCTGAAATTCTGCCATCCTGAACTCAAGAGTGGAGAATACTGGGTTGAC
                        CCTAACCAAGGATGCAAATTGGATGCTATCAAGGTATTCTGTAATATGGAAACTGGGGAA
                        ACATGCATAAGTGCCAATCCTTTGAATGTTCCACGGAAACACTGGTGGACAGATTCTAGT
                        GCTGAGAAGAAACACGTTTGGTTTGGAGAGTCCATGGATGGTGGTTTTCAGTTTAGCTAC
                        GGCAATCCTGAACTTCCTGAAGATGTCCTTGATGTGCAGCTGGCATTCCTTCGACTTCTC
                        TCCAGCCGAGCTTCCCAGAACATCACATATCACTGCAAAAATAGCATTGCATACATGGAT
                        CAGGCCAGTGGAAATGTAAAGAAGGCCCTGAAGCTGATGGGGTCAAATGAAGGTGAATTC
                        AAGGCTGAAGGAAATAGCAAATTCACCTACACAGTTCTGGAGGATGGTTGCACGAAACAC
                        ACTGGGGAATGGAGCAAAACAGTCTTTGAATATCGAACACGCAAGGCTGTGAGACTACCT
                        ATTGTAGATATTGCACCCTATGACATTGGTGGTCCTGATCAAGAATTTGGTGTGGACGTT
                        GGCCCTGTTTGCTTTTTATAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01410</identifier>
                            <name>COLFI</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00093</identifier>
                            <name>VWC</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix (sensu Metazoa)</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>collagen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>extracellular matrix structural constituent</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>structural molecule activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002141</id>
                <name>Collagen alpha-2(I) chain</name>
                <organism>Human</organism>
                <actions/>
                <references># Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ: Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):646-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12101112</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08123" source="Swiss-Prot">
                    <name>Collagen alpha-2(I) chain</name>
                    <general-function>Carbohydrate transport and metabolism</general-function>
                    <specific-function>Type I collagen is a member of group I collagen (fibrillar forming collagen)</specific-function>
                    <gene-name>COL1A2</gene-name>
                    <locus>7q22.1</locus>
                    <cellular-location/>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.36</theoretical-pi>
                    <molecular-weight>129289.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:2198</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>COL1A2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>COL1A2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J03464</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>179596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08123</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>CO1A2_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Alpha-2 type I collagen</synonym>
                        <synonym>Collagen alpha-2(I) chain precursor</synonym>
                        <synonym>I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Collagen alpha-2(I) chain
                        MLSFVDTRTLLLLAVTLCLATCQSLQEETVRKGPAGDRGPRGERGPPGPPGRDGEDGPTG
                        PPGPPGPPGPPGLGGNFAAQYDGKGVGLGPGPMGLMGPRGPPGAAGAPGPQGFQGPAGEP
                        GEPGQTGPAGARGPAGPPGKAGEDGHPGKPGRPGERGVVGPQGARGFPGTPGLPGFKGIR
                        GHNGLDGLKGQPGAPGVKGEPGAPGENGTPGQTGARGLPGERGRVGAPGPAGARGSDGSV
                        GPVGPAGPIGSAGPPGFPGAPGPKGEIGAVGNAGPAGPAGPRGEVGLPGLSGPVGPPGNP
                        GANGLTGAKGAAGLPGVAGAPGLPGPRGIPGPVGAAGATGARGLVGEPGPAGSKGESGNK
                        GEPGSAGPQGPPGPSGEEGKRGPNGEAGSAGPPGPPGLRGSPGSRGLPGADGRAGVMGPP
                        GSRGASGPAGVRGPNGDAGRPGEPGLMGPRGLPGSPGNIGPAGKEGPVGLPGIDGRPGPI
                        GPAGARGEPGNIGFPGPKGPTGDPGKNGDKGHAGLAGARGAPGPDGNNGAQGPPGPQGVQ
                        GGKGEQGPAGPPGFQGLPGPSGPAGEVGKPGERGLHGEFGLPGPAGPRGERGPPGESGAA
                        GPTGPIGSRGPSGPPGPDGNKGEPGVVGAVGTAGPSGPSGLPGERGAAGIPGGKGEKGEP
                        GLRGEIGNPGRDGARGAPGAVGAPGPAGATGDRGEAGAAGPAGPAGPRGSPGERGEVGPA
                        GPNGFAGPAGAAGQPGAKGERGAKGPKGENGVVGPTGPVGAAGPAGPNGPPGPAGSRGDG
                        GPPGMTGFPGAAGRTGPPGPSGISGPPGPPGPAGKEGLRGPRGDQGPVGRTGEVGAVGPP
                        GFAGEKGPSGEAGTAGPPGTPGPQGLLGAPGILGLPGSRGERGLPGVAGAVGEPGPLGIA
                        GPPGARGPPGAVGSPGVNGAPGEAGRDGNPGNDGPPGRDGQPGHKGERGYPGNIGPVGAA
                        GAPGPHGPVGPAGKHGNRGETGPSGPVGPAGAVGPRGPSGPQGIRGDKGEPGEKGPRGLP
                        GLKGHNGLQGLPGIAGHHGDQGAPGSVGPAGPRGPAGPSGPAGKDGRTGHPGTVGPAGIR
                        GPQGHQGPAGPPGPPGPPGPPGVSGGGYDFGYDGDFYRADQPRSAPSLRPKDYEVDATLK
                        SLNNQIETLLTPEGSRKNPARTCRDLRLSHPEWSSGYYWIDPNQGCTMDAIKVYCDFSTG
                        ETCIRAQPENIPAKNWYRSSKDKKHVWLGETINAGSQFEYNVEGVTSKEMATQLAFMRLL
                        ANYASQNITYHCKNSIAYMDEETGNLKKAVILQGSNDVELVAEGNSRFTYTVLVDGCSKK
                        TNEWGKTIIEYKTNKPSRLPFLDIAPLDIGGADQEFFVDIGPVCFK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;4101 bp
                        ATGCTCAGCTTTGTGGATACGCGGACTTTGTTGCTGCTTGCAGTAACCTTATGCCTAGCA
                        ACATGCCAATCTTTACAAGAGGAAACTGTAAGAAAGGGCCCAGCCGGAGATAGAGGACCA
                        CGTGGAGAAAGGGGTCCACCAGGCCCCCCAGGCAGAGATGGTGAAGATGGTCCCACAGGC
                        CCTCCTGGTCCACCTGGTCCTCCTGGCCCCCCTGGTCTCGGTGGGAACTTTGCTGCTCAG
                        TATGATGGAAAAGGAGTTGGACTTGGCCCTGGACCAATGGGCTTAATGGGACCTAGAGGC
                        CCACCTGGTGCAGCTGGAGCCCCAGGCCCTCAAGGTTTCCAAGGACCTGCTGGTGAGCCT
                        GGTGAACCTGGTCAAACTGGTCCTGCAGGTGCTCGTGGTCCAGCTGGCCCTCCTGGCAAG
                        GCTGGTGAAGATGGTCACCCTGGAAAACCCGGACGACCTGGTGAGAGAGGAGTTGTTGGA
                        CCACAGGGTGCTCGTGGTTTCCCTGGAACTCCTGGACTTCCTGGCTTCAAAGGCATTAGG
                        GGACACAATGGTCTGGATGGATTGAAGGGACAGCCCGGTGCTCCTGGTGTGAAGGGTGAA
                        CCTGGTGCCCCTGGTGAAAATGGAACTCCAGGTCAAACAGGAGCCCGTGGTCTTCCTGGT
                        GAGAGAGGACGTGTTGGTGCCCCTGGTCCAGCTGGTGCCCGTGGAAGTGATGGAAGTGTG
                        GGTCCCGTAGGTCCTGCTGGTCCTAATGGGTCTGCTGGCCCTCCAGGTTTCCCAGGTGCC
                        CCTGGTCCCAAGGGTGAAATTGGAGCTGTTGGTAACGCTGGTCCTACTGGACCCGCCGGT
                        CCCCGTGGTGAAGTGGGTCTTCCAGGCCTCTCCGGCCCCGTTGGACCTCCTGGTAATCCT
                        GGAGCAAACGGCCTTACTGGTGCCAAGGGTGCTGCTGGCCTTCCCGGCGTTGCTGGGGCT
                        CCCGGCCTCCCTGGACCCCGCGGTATTCCTGGCCCTCCTGGTGCTGCCGGTACTACTGGT
                        GCCAGAGGACTTGTTGGTGAGCCTGGTCCAGCTGGCTCCAAAGGAGAGAGCGGTAACAAG
                        GGTGAGCCCGGCTCCGCTGGTCCCCAAGGTCCTCCTGGTCCCAGTGGTGAAGAAGGAAAG
                        AGAGGCCCTAATGGGGAAGCTGGATCTGCCGGCCCTCCAGGACCTCCTGGGCTGAGAGGT
                        AGTCCTGGTTCTCGTGGTCTTCCTGGAGCTGATGGCAGAGCTGGCGTCATGGGCCCTCCT
                        GGTAGTCGTGGTGCAAGTGGCCCTGCTGGAGTCCGAGGACCTAATGGAGATGCTGGTCGC
                        CCTGGGGAGCCTGGTCTCATGGGACCCAGAGGTCTTCCTGGTTCCCCTGGAAATATCGGC
                        CCCGCTGGAAAAGAAGGTCCTGTCGGCCTCCCTGGCATCGACGGCAGGCCTGGCCCAATT
                        GGCCCCGTTGGAGCAAGAGGAGAGCCTGGCAACATTGGATTCCCTGGACCCAAAGGCCCC
                        ACTGGTGACCCTGGCAAAAACGGTGATAAAGGTCATGCTGGTCTTGCTGGTGCTCGGGGT
                        GCTCCAGGTCCTGATGGAAACAATGGTGCTCAGGGACCTCCTGGACCACAGGGTGTTCAA
                        GGTGGAAAAGGTGAACAGGGTCCCGCTGGTCCTCCAGGCTTCCAGGGTCTGCCTGGCCCC
                        TCAGGTCCCGCTGGTGAAGTTGGCAAACCAGGAGAAAGGGGTCTCCATGGTGAGTTTGGT
                        CTCCCTGGTCCTGCTGGTCCAAGAGGGGAACGCGGTCCCCCAGGTGAGAGTGGTGCTGCC
                        GGTCCTACTGGTCCTATTGGAAGCCGAGGTCCTTCTGGACCCCCAGGGCCTGATGGAAAC
                        AAGGGTGAACCTGGTGTGGTTGGTGCTGTGGGCACTGCTGGTCCATCTGGTCCTAGTGGA
                        CTCCCAGGAGAGAGGGGTGCTGCTGGCATACCTGGAGGCAAGGGAGAAAAGGGTGAACCT
                        GGTCTCAGAGGTGAAATTGGTAACCCTGGCAGAGATGGTGCTCGTGGTGCTCATGGTGCT
                        GTAGGTGCCCCTGGTCCTGCTGGAGCCACAGGTGACCGGGGCGAAGCTGGGGCTGCTGGT
                        CCTGCTGGTCCTGCTGGTCCTCGGGGAAGCCCTGGTGAACGTGGCGAGGTCGGTCCTGCT
                        GGCCCCAACGGATTTGCTGGTCCGGCTGGTGCTGCTGGTCAACCGGGTGCTAAAGGAGAA
                        AGAGGAGGCAAAGGGCCTAAGGGTGAAAACGGTGTTGTTGGTCCCACAGGCCCCGTTGGA
                        GCTGCTGGCCCAGCTGGTCCAAATGGTCCCCCCGGTCCTGCTGGAAGTCGTGGTGATGGA
                        GGCCCCCCTGGTATGACTGGTTTCCCTGGTGCTGCTGGACGGACTGGTCCCCCAGGACCC
                        TCTGGTATTTCTGGCCCTCCTGGTCCCCCTGGTCCTGCTGGGAAAGAAGGGCTTCGTGGT
                        CCTCGTGGTGACCAAGGTCCAGTTGGCCGAACTGGAGAAGTAGGTGCAGTTGGTCCCCCT
                        GGCTTCGCTGGTGAGAAGGGTCCCTCTGGAGAGGCTGGTACTGCTGGACCTCCTGGCACT
                        CCAGGTCCTCAGGGTCTTCTTGGTGCTCCTGGTATTCTGGGTCTCCCTGGCTCGAGAGGT
                        GAACGTGGTCTACCTGGTGTTGCTGGTGCTGTGGGTGAACCTGGTCCTCTTGGCATTGCC
                        GGCCCTCCTGGGGCCCGTGGTCCTCCTGGTGCTGTGGGTAGTCCTGGAGTCAACGGTGCT
                        CCTGGTGAAGCTGGTCGTGATGGCAACCCTGGGAACGATGGTCCCCCAGGTCGCGATGGT
                        CAACCCGGACACAAGGGAGAGCGCGGTTACCCTGGCAATATTGGTCCCGTTGGTGCTGCA
                        GGTGCACCTGGTCCTCATGGCCCCGTGGGTCCTGCTGGCAAACATGGAAACCGTGGTGAA
                        ACTGGTCCTTCTGGTCCTGTTGGTCCTGCTGGTGCTGTTGGCCCAAGAGGTCCTAGTGGC
                        CCACAAGGCATTCGTGGCGATAAGGGAGAGCCCGGTGAAAAGGGGCCCAGAGGTCTTCCT
                        GGCTTCAAGGGACACAATGGATTGCAAGGTCTGCCTGGTATCGCTGGTCACCATGGTGAT
                        CAAGGTGCTCCTGGCTCCGTGGGTCCTGCTGGTCCTAGGGGCCCTGCTGGTCCTTCTGGC
                        CCTGCTGGAAAAGATGGTCGCACTGGACATCCTGGTACGGTTGGACCTGCTGGCATTCGA
                        GGCCCTCAGGGTCACCAAGGCCCTGCTGGCCCCCCTGGTCCCCCTGGCCCTCCTGGACCT
                        CCAGGTGTAAGCGGTGGTGGTTATGACTTTGGTTACGATGGAGACTTCTACAGGGCTGAC
                        CAGCCTCGCTCAGCACCTTCTCTCAGACCCAAGGACTATGAAGTTGATGCTACTCTGAAG
                        TCTCTCAACAACCAGATTGAGACCCTTCTTACTCCTGAAGGCTCTAGAAAGAACCCAGCT
                        CGCACATGCCGTGACTTGAGACTCAGCCACCCAGAGTGGAGCAGCGGTTACTACTGGATT
                        GACCCCAACCAAGGATGCACTATGGAAGCCATCAAAGTATACTGTGATTTCCCTACCGGC
                        GAAACCTGTATCCGGGCCCAACCTGAAAACATCCCAGCCAAGAACTGGTATAGGAGCTCC
                        AAGGACAAGAAACACGTCTGGCTAGGAGAAACTATCAATGCTGGCAGCCAGTTTGAATAT
                        AATGTTGAAGGAGTGACTTCCAAGGAAATGGCTACCCAACTTGCCTTCATGCGCCTGCTG
                        GCCAACTATGCCTCTCAGAACATCACCTACCACTGCAAGAACAGCATTGCATACATGGAT
                        GAGGAGACTGGCAACCTGAAAAAGGCTGTCATTCTACAGGGCTCTAATGATGTTGAACTT
                        GTTGCTGAGGGCAACAGCAGGTTCACTTACACTGTTCTTGTAGATGGCTGCTCTAAAAAG
                        ACAAATGAATGGGGAAAGACAATCATTGAATACAAAACAAATAAGCCATCACGCCTGCCC
                        TTCCTTGATATTGCACCTTTGGACATCGGTGGTGCTGACCATGAATTCTTTGTGGACATT
                        GGCCCAGTCTGTTTCAAATAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01410</identifier>
                            <name>COLFI</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular matrix (sensu Metazoa)</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>collagen</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>extracellular matrix structural constituent</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>structural molecule activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00049</drugbank-id>
        <drugbank-id>BIOD00090</drugbank-id>
        <drugbank-id>BTD00090</drugbank-id>
        <name>Rasburicase</name>
        <description>Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified &lt;i&gt;Saccharomyces cerevisiae&lt;/i&gt; strain. The cDNA coding for rasburicase was cloned from a strain of &lt;i&gt;Aspergillus flavus&lt;/i&gt;.</description>
        <cas-number>134774-45-1</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Giraldez M: A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults. Eur J Haematol. 2010 Apr 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/ 20394650&#13;
            # Collings I, Watier Y, Giffard M, Dagogo S, Kahn R, Bonnete F, Wright JP, Fitch AN, Margiolaki I: Polymorphism of microcrystalline urate oxidase from Aspergillus flavus. Acta Crystallogr D Biol Crystallogr. 2010 May;66(Pt 5):539-48. Epub 2010 Apr 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20445229</general-references>
        <synthesis-reference>Roy Eugene Snoke, Hugh Arthur Risley, Charles Thomas Goodhue, "Production of uricase from micrococcus luteus." U.S. Patent US4062731, issued May, 1974.</synthesis-reference>
        <indication>For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)</indication>
        <pharmacodynamics>Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.</pharmacodynamics>
        <mechanism-of-action>Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>18 hours</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution>* 110 to 127 mL/kg [pediatric patients]&#13;
            * 75.8 to 138 mL/kg [adult patients]</volume-of-distribution>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Urate oxidase</synonym>
            <synonym language="" coder="">Uricase</synonym>
        </synonyms>
        <products>
            <product>
                <name>Fasturtec</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02271397</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>7.5 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Fasturtec</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02248416</dpd-id>
                <started-marketing-on>2004-09-21</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1.5 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Fasturtec</name>
                <ingredients>Rasburicase</ingredients>
            </mixture>
            <mixture>
                <name>Fasturtec</name>
                <ingredients>Rasburicase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>GlaxoSmithKline Inc.</name>
                <url>http://www.gsk.com</url>
            </packager>
            <packager>
                <name>Sanofi-Aventis Inc.</name>
                <url>http://www.sanofi-aventis.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Elitek 1.5 mg vial</description>
                <cost currency="USD">627.23</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Elitek 7.5 mg vial</description>
                <cost currency="USD">3136.18</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Gout Suppressants</category>
                <mesh-id/>
            </category>
            <category>
                <category>Antihyperuricemic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>1.5 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>7.5 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="V03AF07">
                <level code="V">VARIOUS</level>
                <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
                <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
                <level code="V03AF">Detoxifying agents for antineoplastic treatment</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>44:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2148537</number>
                <country>Canada</country>
                <approved>2002-07-16</approved>
                <expires>2015-05-03</expires>
            </patent>
            <patent>
                <number>2175971</number>
                <country>Canada</country>
                <approved>2003-12-30</approved>
                <expires>2016-05-07</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00049 sequence
                SAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKADNSVIVATDSI
                KNTIYITAKQNPVTPPELFGSILGTHFIEKYNHIHAAHVNIVCHRWTRMDIDGKPHPHSF
                IRDSEEKRNVQVDVVEGKGIDIKSSLSGLTVLKSTNSQFWGFLRDEYTTLKETWDRILST
                DVDATWQWKNFSGLQEVRSHVPKFDATWATAREVTLKTFAEDNSASVQATMYKMAEQILA
                RQQLIETVEYSLPNKHYFEIDLSWHKGLQNTGKNAEVFAPQSDPNGLIKCTVGRSSLKSK
                L</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.465</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.16</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>34109.5000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C1521H2381N417O461S7</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13268</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0024-5150-10</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>X61766</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10176</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>Q00511</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Rasburicase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/elitek.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/rasburicase.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0004823</id>
                <name>Uric acid</name>
                <organism>Human</organism>
                <actions>
                    <action>metabolizer</action>
                </actions>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Cete S, Yasar A, Arslan F: An amperometric biosensor for uric acid determination prepared from uricase immobilized in polypyrrole film. Artif Cells Blood Substit Immobil Biotechnol. 2006;34(3):367-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16809136&#13;
                    # Gabison L, Chiadmi M, Colloc'h N, Castro B, El Hajji M, Prange T: Recapture of [S]-allantoin, the product of the two-step degradation of uric acid, by urate oxidase. FEBS Lett. 2006 Apr 3;580(8):2087-91. Epub 2006 Mar 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16545381&#13;
                    # Zhao Y, Zhao L, Yang G, Tao J, Bu Y, Liao F: Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method. Biotechnol Appl Biochem. 2006 Sep;45(Pt 2):75-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16689679&#13;
                    # Giraldez M: A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults. Eur J Haematol. 2010 Apr 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20394650</references>
                <known-action>yes</known-action>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="small molecule" created="2005-06-13" updated="2013-09-16">
        <drugbank-id primary="true">DB00050</drugbank-id>
        <drugbank-id>APRD00686</drugbank-id>
        <drugbank-id>BIOD00115</drugbank-id>
        <drugbank-id>BTD00115</drugbank-id>
        <name>Cetrorelix</name>
        <description>Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.</description>
        <cas-number>120287-85-6</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation</indication>
        <pharmacodynamics>Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.</pharmacodynamics>
        <mechanism-of-action>Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.</mechanism-of-action>
        <toxicity/>
        <metabolism>In in vitro studies, cetrorelix was stable against phase I- and phase II-metabolism. Cetrorelix was transformed by peptidases, and the (1-4) peptide was the predominant metabolite.</metabolism>
        <absorption>Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.</absorption>
        <half-life>~62.8 hours</half-life>
        <protein-binding>86%</protein-binding>
        <route-of-elimination>Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine.</route-of-elimination>
        <volume-of-distribution>* 1.16 L/kg</volume-of-distribution>
        <clearance>* 1.28 ml/min·kg [adult healthy female with 3 mg single SC administration]</clearance>
        <classification>
            <description>This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.</description>
            <direct-parent>Polypeptides</direct-parent>
            <kingdom>Organic compounds</kingdom>
            <superclass>Organic Polymers</superclass>
            <class>Polypeptides</class>
            <subclass/>
            <alternative-parent>Acetamides</alternative-parent>
            <alternative-parent>Alpha amino acid amides</alternative-parent>
            <alternative-parent>Amphetamines and derivatives</alternative-parent>
            <alternative-parent>Aryl chlorides</alternative-parent>
            <alternative-parent>Azacyclic compounds</alternative-parent>
            <alternative-parent>Carbonyl compounds</alternative-parent>
            <alternative-parent>Carboximidamides</alternative-parent>
            <alternative-parent>Chlorobenzenes</alternative-parent>
            <alternative-parent>Guanidines</alternative-parent>
            <alternative-parent>Heteroaromatic compounds</alternative-parent>
            <alternative-parent>Hydrocarbon derivatives</alternative-parent>
            <alternative-parent>Imines</alternative-parent>
            <alternative-parent>N-acyl amines</alternative-parent>
            <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
            <alternative-parent>N-acylpyrrolidines</alternative-parent>
            <alternative-parent>Naphthalenes</alternative-parent>
            <alternative-parent>Organochlorides</alternative-parent>
            <alternative-parent>Peptides</alternative-parent>
            <alternative-parent>Phenols and derivatives</alternative-parent>
            <alternative-parent>Phenylpropylamines</alternative-parent>
            <alternative-parent>Primary alcohols</alternative-parent>
            <alternative-parent>Primary carboxylic acid amides</alternative-parent>
            <alternative-parent>Pyridines and derivatives</alternative-parent>
            <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
            <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
            <alternative-parent>Tertiary amines</alternative-parent>
            <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
            <alternative-parent>Ureas</alternative-parent>
            <substituent>Acetamide</substituent>
            <substituent>Alcohol</substituent>
            <substituent>Alpha peptide</substituent>
            <substituent>Alpha-amino acid amide</substituent>
            <substituent>Amine</substituent>
            <substituent>Amphetamine or derivatives</substituent>
            <substituent>Aromatic heteropolycyclic compound</substituent>
            <substituent>Aryl chloride</substituent>
            <substituent>Aryl halide</substituent>
            <substituent>Azacycle</substituent>
            <substituent>Benzenoid</substituent>
            <substituent>Carbonyl group</substituent>
            <substituent>Carboxamide group</substituent>
            <substituent>Carboximidamide</substituent>
            <substituent>Carboxylic acid amide</substituent>
            <substituent>Carboxylic acid derivative</substituent>
            <substituent>Chlorobenzene</substituent>
            <substituent>Fatty acyl</substituent>
            <substituent>Fatty amide</substituent>
            <substituent>Guanidine</substituent>
            <substituent>Halobenzene</substituent>
            <substituent>Heteroaromatic compound</substituent>
            <substituent>Hydrocarbon derivative</substituent>
            <substituent>Imine</substituent>
            <substituent>Monocyclic benzene moiety</substituent>
            <substituent>N-acyl-alpha amino acid or derivatives</substituent>
            <substituent>N-acyl-amine</substituent>
            <substituent>N-acylpyrrolidine</substituent>
            <substituent>N-substituted-alpha-amino acid</substituent>
            <substituent>Naphthalene</substituent>
            <substituent>Organochloride</substituent>
            <substituent>Organohalogen compound</substituent>
            <substituent>Organoheterocyclic compound</substituent>
            <substituent>Organonitrogen compound</substituent>
            <substituent>Organooxygen compound</substituent>
            <substituent>Phenol</substituent>
            <substituent>Phenylpropylamine</substituent>
            <substituent>Polypeptide</substituent>
            <substituent>Primary alcohol</substituent>
            <substituent>Primary carboxylic acid amide</substituent>
            <substituent>Pyridine</substituent>
            <substituent>Pyrrolidine</substituent>
            <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
            <substituent>Pyrrolidine-2-carboxamide</substituent>
            <substituent>Secondary carboxylic acid amide</substituent>
            <substituent>Tertiary amine</substituent>
            <substituent>Tertiary carboxylic acid amide</substituent>
            <substituent>Urea</substituent>
        </classification>
        <salts>
            <salt>
                <drugbank-id primary="true">DBSALT000021</drugbank-id>
                <name>Cetrorelix Acetate</name>
                <cas-number>145672-81-7</cas-number>
                <inchikey>InChIKey=KFEFLCOCAHJBEA-ANRVCLKPSA-N</inchikey>
            </salt>
        </salts>
        <synonyms>
            <synonym language="Latin" coder="INN">Cetrorelixum</synonym>
        </synonyms>
        <products>
            <product>
                <name>Cetrotide</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02247766</dpd-id>
                <started-marketing-on>2004-03-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.25 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Cetrotide</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02247767</dpd-id>
                <started-marketing-on>2004-02-25</started-marketing-on>
                <ended-marketing-on>2014-10-20</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>3 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Cetrotide</name>
                <ingredients>Cetrorelix</ingredients>
            </mixture>
            <mixture>
                <name>Cetrotide</name>
                <ingredients>Cetrorelix</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Baxter International Inc.</name>
                <url>http://www.baxter.com</url>
            </packager>
            <packager>
                <name>EMD Canada Inc.</name>
                <url>http://www.emdcanada.com</url>
            </packager>
            <packager>
                <name>Solvay Pharmaceuticals</name>
                <url>http://global.abbottgrowth.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Emd serono inc</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Cetrotide 0.25 mg kit</description>
                <cost currency="USD">137.99</cost>
                <unit>kit</unit>
            </price>
            <price>
                <description>Cetrotide 3 mg kit</description>
                <cost currency="USD">689.92</cost>
                <unit>kit</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Hormone Antagonists</category>
                <mesh-id/>
            </category>
            <category>
                <category>Fertility Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>0.25 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>3 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="H01CC02">
                <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
                <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
                <level code="H01C">HYPOTHALAMIC HORMONES</level>
                <level code="H01CC">Anti-gonadotropin-releasing hormones</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>92:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2115943</number>
                <country>Canada</country>
                <approved>2003-08-05</approved>
                <expires>2014-02-18</expires>
            </patent>
            <patent>
                <number>5198533</number>
                <country>United States</country>
                <approved>1993-10-24</approved>
                <expires>2010-10-24</expires>
            </patent>
            <patent>
                <number>6319192</number>
                <country>United States</country>
                <approved>1998-04-23</approved>
                <expires>2018-04-23</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <calculated-properties>
            <property>
                <kind>logP</kind>
                <value>1.33</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>logS</kind>
                <value>-5.3</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>Water Solubility</kind>
                <value>6.94e-03 g/l</value>
                <source>ALOGPS</source>
            </property>
            <property>
                <kind>logP</kind>
                <value>-1.7</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>IUPAC Name</kind>
                <value>(2S)-N-[(2S)-5-carbamimidamido-1-[(2S)-2-{[(1R)-1-carbamoylethyl]carbamoyl}pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[(2R)-5-(carbamoylamino)-2-[(2S)-2-[(2S)-2-[(2R)-2-[(2R)-3-(4-chlorophenyl)-2-[(2R)-2-acetamido-3-(naphthalen-2-yl)propanamido]propanamido]-3-(pyridin-3-yl)propanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]pentanamido]-4-methylpentanamide</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Traditional IUPAC Name</kind>
                <value>cetrorelix</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>1431.038</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Monoisotopic Weight</kind>
                <value>1429.669818444</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>SMILES</kind>
                <value>CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C70H92ClN17O14</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>InChI</kind>
                <value>InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>InChIKey</kind>
                <value>InChIKey=SBNPWPIBESPSIF-MHWMIDJBSA-N</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Polar Surface Area (PSA)</kind>
                <value>495.67</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Refractivity</kind>
                <value>384.16</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Polarizability</kind>
                <value>148.09</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Rotatable Bond Count</kind>
                <value>38</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>H Bond Acceptor Count</kind>
                <value>18</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>H Bond Donor Count</kind>
                <value>17</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>pKa (strongest acidic)</kind>
                <value>9.49</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>pKa (strongest basic)</kind>
                <value>11.11</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Physiological Charge</kind>
                <value>1</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Number of Rings</kind>
                <value>6</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Bioavailability</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Rule of Five</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>Ghose Filter</kind>
                <value>0</value>
                <source>ChemAxon</source>
            </property>
            <property>
                <kind>MDDR-Like Rule</kind>
                <value>1</value>
                <source>ChemAxon</source>
            </property>
        </calculated-properties>
        <experimental-properties/>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13224</identifier>
            </external-identifier>
            <external-identifier>
                <resource>ChEBI</resource>
                <identifier>59224</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D01685</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>44087-1225-1</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164764506</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Cetrorelix</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/cetrorelix.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/cetrorelix-acetate.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000203</id>
                <name>Gonadotropin-releasing hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Volker P, Grundker C, Schmidt O, Schulz KD, Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol. 2002 Feb;186(2):171-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11854630&#13;
                    # Zapatero-Caballero H, Sanchez-Franco F, Guerra-Perez N, Fernandez-Mendez C, Fernandez-Vazquez G: Gonadotropin-releasing hormone receptor gene expression during pubertal development of male rats. Biol Reprod. 2003 May;68(5):1764-70. Epub 2002 Dec 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12606421&#13;
                    # Zapatero-Caballero H, Sanchez-Franco F, Fernandez-Mendez C, Garcia-San Frutos M, Botella-Cubells LM, Fernandez-Vazquez G: Gonadotropin-releasing hormone receptor gene expression during pubertal development of female rats. Biol Reprod. 2004 Feb;70(2):348-55. Epub 2003 Oct 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14561652&#13;
                    # Roth C, Hegemann F, Hildebrandt J, Balzer I, Witt A, Wuttke W, Jarry H: Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models. Pediatr Res. 2004 Jan;55(1):126-33. Epub 2003 Nov 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14605254&#13;
                    # Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16809153&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P30968" source="Swiss-Prot">
                    <name>Gonadotropin-releasing hormone receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for gonadotropin releasing hormone (GnRH) that mediate the action of GnRH to stimulate the secretion of the gonadotropic hormones (LH and FSH). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act a an inhibitor of GnRH-R signaling</specific-function>
                    <gene-name>GNRHR</gene-name>
                    <locus>4q21.2</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>39-58
                        78-97
                        116-137
                        165-184
                        213-232
                        282-300
                        307-326</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.93</theoretical-pi>
                    <molecular-weight>37731.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4421</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GNRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GNRHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>L03380</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>183422</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>256</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>31</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P30968</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GNRHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GnRH receptor</synonym>
                        <synonym>GnRH-R</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Gonadotropin-releasing hormone receptor
                        MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL
                        QKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL
                        KLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM
                        IHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR
                        VLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL
                        SDPVNHFFFLFAFLNPCFDPLIYGYFSL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;987 bp
                        ATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC
                        ATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG
                        GTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT
                        CAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA
                        AAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG
                        TGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA
                        AAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC
                        CTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT
                        GGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG
                        ATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC
                        AGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC
                        ATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG
                        GTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA
                        GCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG
                        ACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG
                        TCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA
                        CTTATCTATGGATATTTTTCTCTGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>gonadotropin-releasing hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000134</id>
                <name>Lutropin-choriogonadotropic hormone receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Ascoli M, Fanelli F, Segaloff DL: The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev. 2002 Apr;23(2):141-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11943741</references>
                <known-action>unknown</known-action>
                <polypeptide id="P22888" source="Swiss-Prot">
                    <name>Lutropin-choriogonadotropic hormone receptor</name>
                    <general-function>Involved in rhodopsin-like receptor activity</general-function>
                    <specific-function>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase</specific-function>
                    <gene-name>LHCGR</gene-name>
                    <locus>2p21</locus>
                    <cellular-location>Membrane; multi-pass membrane protein</cellular-location>
                    <transmembrane-regions>364-385
                        396-416
                        440-462
                        483-505
                        526-549
                        571-594
                        606-627</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>78617.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:6585</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>LHCGR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M73746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>903746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>IUPHAR</resource>
                            <identifier>254</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>Guide to Pharmacology</resource>
                            <identifier>30</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P22888</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>LSHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>LH/CG-R</synonym>
                        <synonym>LHR</synonym>
                        <synonym>LSH- R</synonym>
                        <synonym>Luteinizing hormone receptor</synonym>
                        <synonym>Lutropin-choriogonadotropic hormone receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Lutropin-choriogonadotropic hormone receptor precursor
                        MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP
                        VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI
                        NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK
                        LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY
                        GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF
                        SKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD
                        FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS
                        QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL
                        RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF
                        IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT
                        VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT
                        SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2058 bp
                        ATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG
                        CTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC
                        CTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA
                        GTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG
                        ATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA
                        ATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT
                        CCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG
                        AAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC
                        ACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT
                        GGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG
                        GAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA
                        GGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA
                        GAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA
                        CAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT
                        AGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA
                        CAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC
                        TGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC
                        ATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG
                        GGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT
                        TTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA
                        GCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA
                        GGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC
                        ACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC
                        CAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT
                        CTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC
                        CCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT
                        GTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC
                        CCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC
                        TTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA
                        GTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT
                        TCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT
                        CTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA
                        GATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT
                        CAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT
                        CGCTACACAGAGTGTTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00001</identifier>
                            <name>7tm_1</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intrinsic to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>integral to membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>G-protein coupled receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>rhodopsin-like receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>lutropin-choriogonadotropic hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-hormone receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>G-protein coupled receptor protein signaling pathway</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2015-04-20">
        <drugbank-id primary="true">DB00051</drugbank-id>
        <drugbank-id>BIOD00049</drugbank-id>
        <drugbank-id>BTD00049</drugbank-id>
        <name>Adalimumab</name>
        <description>Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.</description>
        <cas-number>331731-18-1</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># PDB sequence "Link":http://www.rcsb.org/pdb/download/downloadFile.do?fileFormat=FASTA&amp;compression=NO&amp;structureId=1IGT&#13;
            # Patent Information "Link":http://www.freepatentsonline.com/6090382.html</general-references>
        <synthesis-reference/>
        <indication>For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.</indication>
        <pharmacodynamics>Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.</pharmacodynamics>
        <mechanism-of-action>Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.</mechanism-of-action>
        <toxicity/>
        <metabolism>Most likely removed by opsonization via the reticuloendothelial system.</metabolism>
        <absorption/>
        <half-life>10-20 days.</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Ig gamma-1 chain C region</synonym>
        </synonyms>
        <products>
            <product>
                <name>Humira</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02258595</dpd-id>
                <started-marketing-on>2004-09-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>40 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Humira</name>
                <ndc-id>0074-3797_aa6f7aea-ddd9-b203-263b-0daad92b0ee4</ndc-id>
                <ndc-product-code>0074-3797</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2002-12-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>40 mg/.8mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA125057</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Humira Pen</name>
                <company>Abbott Laboratories</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Humira</name>
                <ingredients>Adalimumab</ingredients>
            </mixture>
            <mixture>
                <name>Humira</name>
                <ingredients>Adalimumab</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Abbott Laboratories Ltd.</name>
                <url>http://www.abbott.com</url>
            </packager>
            <packager>
                <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
                <url>http://www.vetter-pharma.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Humira 20 mg/0.4 ml syringe</description>
                <cost currency="USD">959.19</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Humira 40 mg/0.8 ml pen</description>
                <cost currency="USD">959.19</cost>
                <unit>pen</unit>
            </price>
            <price>
                <description>Humira crohn's starter pack</description>
                <cost currency="USD">959.19</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Humira psoriasis starter pack</description>
                <cost currency="USD">959.19</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Humira (1 Box = Two 40 mg/0.8ml Syringes) Box</description>
                <cost currency="USD">1995.1</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Humira 2 20 mg/0.4ml Kit 1 Box = Two 20 mg/0.4ml Syringes</description>
                <cost currency="USD">1995.1</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Humira Pen 2 40 mg/0.8ml Kit (1 Box = 1 Kit Containing Two 40 mg/0.8ml Pens)</description>
                <cost currency="USD">1995.1</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antirheumatic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-Inflammatory Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>40 mg/.8mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>40 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L04AB04">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L04">IMMUNOSUPPRESSANTS</level>
                <level code="L04A">IMMUNOSUPPRESSANTS</level>
                <level code="L04AB">Tumor necrosis factor alpha (TNF-α) inhibitors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>92:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2243459</number>
                <country>Canada</country>
                <approved>2002-09-17</approved>
                <expires>2017-02-10</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB01281</drugbank-id>
                <name>Abatacept</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01223</drugbank-id>
                <name>Aminophylline</name>
                <description>May decrease the serum concentration of Theophylline Derivatives.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00026</drugbank-id>
                <name>Anakinra</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08879</drugbank-id>
                <name>Belimumab</name>
                <description>Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06168</drugbank-id>
                <name>Canakinumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08904</drugbank-id>
                <name>Certolizumab pegol</name>
                <description>Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab pegol.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00091</drugbank-id>
                <name>Cyclosporine</name>
                <description>May decrease the serum concentration of Cyclosporine (Systemic).</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06643</drugbank-id>
                <name>Denosumab</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00065</drugbank-id>
                <name>Infliximab</name>
                <description>Adalimumab may enhance the immunosuppressive effect of Infliximab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01097</drugbank-id>
                <name>Leflunomide</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00108</drugbank-id>
                <name>Natalizumab</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00337</drugbank-id>
                <name>Pimecrolimus</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06372</drugbank-id>
                <name>Rilonacept</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01656</drugbank-id>
                <name>Roflumilast</name>
                <description>May enhance the immunosuppressive effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06688</drugbank-id>
                <name>Sipuleucel-T</name>
                <description>Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00277</drugbank-id>
                <name>Theophylline</name>
                <description>May decrease the serum concentration of Theophylline Derivatives.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06273</drugbank-id>
                <name>Tocilizumab</name>
                <description>May enhance the immunosuppressive effect of Anti-TNF Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08895</drugbank-id>
                <name>Tofacitinib</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08895</drugbank-id>
                <name>Tofacitinib</name>
                <description>Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00072</drugbank-id>
                <name>Trastuzumab</name>
                <description>May enhance the neutropenic effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09033</drugbank-id>
                <name>Vedolizumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>Adalimumab may decrease the serum concentration of Warfarin.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt; Light chain:
                DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPS
                RFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPP
                SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
                LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>
            <sequence format="FASTA">&gt; Heavy chain:
                EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDY
                ADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVS
                SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
                SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.441</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.25</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>144190.3000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C6428H9912N1694O1987S46</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13356</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0074-3799-02</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00228</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10004</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01857</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Adalimumab</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/humira.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/adalimumab.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000704</id>
                <name>Tumor necrosis factor</name>
                <organism>Human</organism>
                <actions>
                    <action>antibody</action>
                </actions>
                <references># Lorenz HM: Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther. 2002 Apr;4(2):185-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12044041&#13;
                    # Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14532145&#13;
                    # Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M: [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies] Rev Med Chil. 2003 Dec;131(12):1445-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15022409&#13;
                    # Bang LM, Keating GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121-39. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15046527&#13;
                    # Klinkhoff A: Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs. 2004;64(12):1267-83. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15200343&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P01375" source="Swiss-Prot">
                    <name>Tumor necrosis factor</name>
                    <general-function>Involved in tumor necrosis factor receptor binding</general-function>
                    <specific-function>Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin 1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation</specific-function>
                    <gene-name>TNF</gene-name>
                    <locus>6p21.3</locus>
                    <cellular-location>Cell membrane; single-pass type II membrane protein. Processed form:Secreted protein. Also exists as</cellular-location>
                    <transmembrane-regions>36-56</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.92</theoretical-pi>
                    <molecular-weight>25645.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>TNF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>TNF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M16441</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339741</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01375</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TNFA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Cachectin</synonym>
                        <synonym>TNF-a</synonym>
                        <synonym>TNF-alpha</synonym>
                        <synonym>Tumor necrosis factor ligand superfamily member 2</synonym>
                        <synonym>Tumor necrosis factor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tumor necrosis factor precursor
                        MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR
                        EEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR
                        DNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE
                        TPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG
                        ACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC
                        GTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG
                        GAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT
                        TCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG
                        CAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA
                        GATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC
                        AAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC
                        GTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG
                        ACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC
                        CAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT
                        GCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00229</identifier>
                            <name>TNF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cytokine activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tumor necrosis factor receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000901</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="O75015" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils</specific-function>
                    <gene-name>FCGR3B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.71</theoretical-pi>
                    <molecular-weight>26216.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3620</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16863</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31322</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O75015</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16b antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-beta</synonym>
                        <synonym>Fc-gamma RIIIb</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIb</synonym>
                        <synonym>IgG Fc receptor III-1</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-B precursor
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
                        VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
                        AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002093</id>
                <name>Complement C1r subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P00736" source="Swiss-Prot">
                    <name>Complement C1r subcomponent</name>
                    <general-function/>
                    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system</specific-function>
                    <gene-name>C1R</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.24</theoretical-pi>
                    <molecular-weight>80174.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1246</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04701</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29539</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00736</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1r subcomponent precursor</synonym>
                        <synonym>Complement component 1, r subcomponent</synonym>
                        <synonym>EC 3.4.21.41</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1r subcomponent
                        MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
                        QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
                        SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
                        ELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
                        DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
                        RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
                        DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
                        ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
                        TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
                        SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
                        EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
                        RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2118 bp
                        ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
                        ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
                        AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
                        CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
                        GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
                        GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
                        TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
                        GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
                        TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
                        GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
                        GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
                        AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
                        GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
                        GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
                        AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
                        CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
                        ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
                        GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
                        GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
                        AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
                        CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
                        GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
                        GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
                        AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
                        ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
                        GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
                        CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
                        AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
                        CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
                        AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
                        GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
                        GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
                        GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
                        AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
                        AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
                        ATGGAGGAGGAGGACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002094</id>
                <name>Complement C1q subcomponent subunit A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02745" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit A</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QA</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.45</theoretical-pi>
                    <molecular-weight>26017.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1241</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF135157</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4894854</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02745</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit A
                        MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
                        TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
                        RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
                        GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
                        IFPSA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
                        GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
                        AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
                        ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
                        AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA
                        GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
                        CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
                        GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
                        TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
                        GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
                        GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
                        CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
                        ATCTTCCCATCTGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002095</id>
                <name>Complement C1q subcomponent subunit B</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02746" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit B</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QB</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.87</theoretical-pi>
                    <molecular-weight>26460.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1242</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X03084</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>573114</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit B
                        MKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK
                        GLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI
                        AFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV
                        NLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF
                        SGFLLFPDMEA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;688 bp
                        CCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG
                        GACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC
                        AGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA
                        TCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG
                        AGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC
                        TGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT
                        GATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC
                        CGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT
                        GCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT
                        CCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA
                        GGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT
                        CCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002096</id>
                <name>Complement C1q subcomponent subunit C</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02747" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit C</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QC</gene-name>
                    <locus>1p36.11</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>25774.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1245</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF087892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33150626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QC_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit C precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit C
                        MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
                        GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
                        VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
                        LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
                        LLFPD</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
                        CTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
                        CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
                        GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
                        CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
                        CCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
                        GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
                        AACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC
                        AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
                        CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
                        CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
                        GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
                        CTGCTCTTCCCCGACTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002097</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08637" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis</specific-function>
                    <gene-name>FCGR3A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>209-229</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.21</theoretical-pi>
                    <molecular-weight>29089.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3619</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X52645</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31324</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16a antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-alpha</synonym>
                        <synonym>Fc-gamma RIIIa</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIa</synonym>
                        <synonym>IgG Fc receptor III-2</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-A
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
                        VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
                        KDHKFKWRKDPQDK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;765 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA
                        AAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG
                        AAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0001529</id>
                <name>Complement C1s subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P09871" source="Swiss-Prot">
                    <name>Complement C1s subcomponent</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4</specific-function>
                    <gene-name>C1S</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.59</theoretical-pi>
                    <molecular-weight>76685.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1247</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X06596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>763110</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P09871</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1S_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>C1 esterase</synonym>
                        <synonym>Complement C1s subcomponent precursor</synonym>
                        <synonym>EC 3.4.21.42</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1s subcomponent precursor
                        MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
                        LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
                        TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
                        TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
                        VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
                        NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
                        IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
                        CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
                        REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
                        MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
                        EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
                        TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2067 bp
                        ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
                        GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
                        GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
                        CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
                        AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
                        GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
                        ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
                        GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
                        GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
                        ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
                        AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
                        GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
                        GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
                        ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
                        AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
                        AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
                        TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
                        TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
                        ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
                        GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
                        TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
                        TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
                        GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
                        GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
                        AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
                        AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
                        GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
                        ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
                        GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
                        CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
                        GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
                        GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
                        CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
                        ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
                        GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000710</id>
                <name>High affinity immunoglobulin gamma Fc receptor I</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12314" source="Swiss-Prot">
                    <name>High affinity immunoglobulin gamma Fc receptor I</name>
                    <general-function>Involved in receptor signaling protein activity</general-function>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. High affinity receptor</specific-function>
                    <gene-name>FCGR1A</gene-name>
                    <locus>1q21.2-q21.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>293-313</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.08</theoretical-pi>
                    <molecular-weight>42632.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3613</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X14356</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31332</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12314</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCGR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD64 antigen</synonym>
                        <synonym>Fc-gamma RI</synonym>
                        <synonym>FcRI</synonym>
                        <synonym>High affinity immunoglobulin gamma Fc receptor I precursor</synonym>
                        <synonym>IgG Fc receptor I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin gamma Fc receptor I precursor
                        MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
                        TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
                        ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
                        ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
                        TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
                        IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
                        LQEGVHRKEPQGAT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1125 bp
                        ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
                        AAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
                        TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
                        ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
                        GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
                        CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
                        GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
                        GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
                        AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
                        ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
                        CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
                        CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
                        ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
                        GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
                        CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
                        ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
                        AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC
                        CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
                        CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002098</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12318" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens</specific-function>
                    <gene-name>FCGR2A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.78</theoretical-pi>
                    <molecular-weight>34990.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3616</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31932</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182474</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-a</synonym>
                        <synonym>Fc-gamma-RIIa</synonym>
                        <synonym>FcRII-a</synonym>
                        <synonym>IgG Fc receptor II-a</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-a precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-a
                        MAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
                        TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
                        SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS
                        HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
                        CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
                        KNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;954 bp
                        ATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
                        CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
                        GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
                        ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
                        CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
                        GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
                        TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
                        CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
                        AAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
                        CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
                        GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
                        GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
                        TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
                        CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
                        TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
                        AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002099</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31994" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis</specific-function>
                    <gene-name>FCGR2B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.12</theoretical-pi>
                    <molecular-weight>34044.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3618</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U87560</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4099445</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31994</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-b</synonym>
                        <synonym>Fc-gamma-RIIb</synonym>
                        <synonym>FcRII-b</synonym>
                        <synonym>IgG Fc receptor II-b</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-b precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-b
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
                        LEEPDDQNRI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;930 bp
                        ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG
                        TGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG
                        GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
                        CTGGAAGAGCCTGATGACCAGAACCGTATT</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002100</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31995" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells</specific-function>
                    <gene-name>FCGR2C</gene-name>
                    <locus>1q23.3</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>224-246</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.9</theoretical-pi>
                    <molecular-weight>35578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:15626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X17652</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>32074</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31995</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2C_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-c</synonym>
                        <synonym>Fc-gamma-RIIc</synonym>
                        <synonym>FcRII-c</synonym>
                        <synonym>IgG Fc receptor II-c</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-c precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-c
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
                        APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;972 bp
                        ATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
                        AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
                        GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
                        GCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC
                        AGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00052</drugbank-id>
        <drugbank-id>BIOD00086</drugbank-id>
        <drugbank-id>BTD00086</drugbank-id>
        <name>Somatropin recombinant</name>
        <description>Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli</description>
        <cas-number>12629-01-5</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Seltzer V, Tonge SR: Proceedings: Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine. J Pharm Pharmacol. 1975 Dec;27 Suppl?-2:16P. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2688&#13;
            # Alba-Roth J, Muller OA, Schopohl J, von Werder K: Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 1988 Dec;67(6):1186-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2903866&#13;
            # Scarth JP: Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review. Xenobiotica. 2006 Feb-Mar;36(2-3):119-218. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16702112&#13;
            # Takahashi Y, Kipnis DM, Daughaday WH: Growth hormone secretion during sleep. J Clin Invest. 1968 Sep;47(9):2079-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5675428</general-references>
        <synthesis-reference>Mandayam J. Narasimhan, John A. Anderson, "Process for the large scale production of human growth hormone by serial secondary suspension culture." U.S. Patent US4124448, issued January, 1963.</synthesis-reference>
        <indication>For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss</indication>
        <pharmacodynamics>Used in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).</pharmacodynamics>
        <mechanism-of-action>hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life/>
        <protein-binding/>
        <route-of-elimination>Although calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Somatropin stimulates the synthesis of chondroitin sulfate and collagen, and increases the urinary excretion of hydroxyproline.</route-of-elimination>
        <volume-of-distribution/>
        <clearance>* 2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">GH</synonym>
            <synonym language="" coder="">GH-N</synonym>
            <synonym language="" coder="">Growth hormone</synonym>
            <synonym language="" coder="">Growth hormone 1</synonym>
            <synonym language="" coder="">Pituitary growth hormone</synonym>
            <synonym language="" coder="">Somatotropin precursor</synonym>
            <synonym language="" coder="">Somatropin</synonym>
        </synonyms>
        <products>
            <product>
                <name>Bio-tropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231515</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>liquid; powder for solution</dosage-form>
                <strength>10 ml</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Bio-tropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02231516</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>liquid; powder for solution</dosage-form>
                <strength>10 ml</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401681</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401746</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.2 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401754</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.4 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401703</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>5.3 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401711</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>12 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401762</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.6 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401770</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>0.8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401789</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1.0 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401797</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1.2 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401800</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1.4 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401819</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1.6 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401827</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1.8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Genotropin</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02401835</dpd-id>
                <started-marketing-on>2013-09-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>2.0 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Humatrope Inj 1mg/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>00745626</dpd-id>
                <started-marketing-on>1987-12-31</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>1 mg</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Norditropin</name>
                <ndc-id>0169-7703_d3cd279e-c599-4d0c-b2e7-bf52e97fba13</ndc-id>
                <ndc-product-code>0169-7703</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2009-03-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>30 mg/3mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021148</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Norditropin</name>
                <ndc-id>0169-7704_d3cd279e-c599-4d0c-b2e7-bf52e97fba13</ndc-id>
                <ndc-product-code>0169-7704</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-01-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>5 mg/1.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021148</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Norditropin</name>
                <ndc-id>0169-7705_d3cd279e-c599-4d0c-b2e7-bf52e97fba13</ndc-id>
                <ndc-product-code>0169-7705</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-01-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>10 mg/1.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021148</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Norditropin</name>
                <ndc-id>0169-7708_d3cd279e-c599-4d0c-b2e7-bf52e97fba13</ndc-id>
                <ndc-product-code>0169-7708</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2005-01-03</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>15 mg/1.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021148</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Norditropin</name>
                <ndc-id>54868-6146_7af60e76-41ca-4324-8f44-c6cc00fdd694</ndc-id>
                <ndc-product-code>54868-6146</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2010-08-10</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>5 mg/1.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021148</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Norditropin Nordiflex</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02334852</dpd-id>
                <started-marketing-on>2014-08-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Norditropin Nordiflex</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02334860</dpd-id>
                <started-marketing-on>2014-08-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Norditropin Nordiflex</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02334879</dpd-id>
                <started-marketing-on>2014-08-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>15 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Norditropin Simplexx</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02334968</dpd-id>
                <started-marketing-on>2010-05-04</started-marketing-on>
                <ended-marketing-on>2015-06-19</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>15 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Norditropin Simplexx</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02334941</dpd-id>
                <started-marketing-on>2010-05-04</started-marketing-on>
                <ended-marketing-on>2015-06-19</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>10 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Norditropin Simplexx</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02334925</dpd-id>
                <started-marketing-on>2010-05-04</started-marketing-on>
                <ended-marketing-on>2015-06-19</ended-marketing-on>
                <dosage-form>solution</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nutropin - Kit  Pws(10mg) &amp; Liq(10ml) Im Sc</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02216191</dpd-id>
                <started-marketing-on>2002-10-08</started-marketing-on>
                <ended-marketing-on>2013-12-02</ended-marketing-on>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>10 mg</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nutropin - Kit  Pws(5mg) &amp; Liq(10ml) Im Sc</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02216183</dpd-id>
                <started-marketing-on>1997-01-20</started-marketing-on>
                <ended-marketing-on>2011-07-19</ended-marketing-on>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>5 mg</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nutropin Aq - Sc 5mg/ml</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02229722</dpd-id>
                <started-marketing-on>1997-10-14</started-marketing-on>
                <ended-marketing-on>2013-04-16</ended-marketing-on>
                <dosage-form>liquid</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nutropin Aq Nuspin 10</name>
                <ndc-id>50242-074_e18cba5f-c533-4435-83ea-9cf3867ad56f</ndc-id>
                <ndc-product-code>50242-074</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-12-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>10 mg/2mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020522</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Nutropin Aq Nuspin 10</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02376393</dpd-id>
                <started-marketing-on>2012-05-18</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nutropin Aq Nuspin 20</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02399083</dpd-id>
                <started-marketing-on>2013-09-09</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>20 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nutropin Aq Nuspin 20</name>
                <ndc-id>50242-076_e18cba5f-c533-4435-83ea-9cf3867ad56f</ndc-id>
                <ndc-product-code>50242-076</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-12-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>20 mg/2mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020522</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Nutropin Aq Nuspin 5</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02399091</dpd-id>
                <started-marketing-on>2013-09-09</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Nutropin Aq Nuspin 5</name>
                <ndc-id>50242-075_e18cba5f-c533-4435-83ea-9cf3867ad56f</ndc-id>
                <ndc-product-code>50242-075</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-12-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>5 mg/2mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020522</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Nutropin Aq Pen 10</name>
                <ndc-id>50242-043_e18cba5f-c533-4435-83ea-9cf3867ad56f</ndc-id>
                <ndc-product-code>50242-043</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-12-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>10 mg/2mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020522</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Nutropin Aq Pen 20</name>
                <ndc-id>50242-073_e18cba5f-c533-4435-83ea-9cf3867ad56f</ndc-id>
                <ndc-product-code>50242-073</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1995-12-29</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>20 mg/2mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA020522</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Nutropin Aq Pen Cartridge</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02249002</dpd-id>
                <started-marketing-on>2004-08-09</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Omnitrope</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02325063</dpd-id>
                <started-marketing-on>2009-04-20</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>5.0 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Omnitrope</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02325071</dpd-id>
                <started-marketing-on>2009-04-20</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>10.0 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Omnitrope</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02325055</dpd-id>
                <started-marketing-on/>
                <ended-marketing-on/>
                <dosage-form>kit; powder for solution</dosage-form>
                <strength>5.8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Omnitrope</name>
                <ndc-id>0781-3001_27a5c992-5724-4ed9-a72c-d7d7e1953fc9</ndc-id>
                <ndc-product-code>0781-3001</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-05-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>5 mg/1.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021426</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Omnitrope</name>
                <ndc-id>0781-3004_27a5c992-5724-4ed9-a72c-d7d7e1953fc9</ndc-id>
                <ndc-product-code>0781-3004</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2006-05-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>10 mg/1.5mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>NDA021426</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Saizen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02350122</dpd-id>
                <started-marketing-on>2010-12-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>5.83 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Saizen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02350130</dpd-id>
                <started-marketing-on>2010-12-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Saizen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02350149</dpd-id>
                <started-marketing-on>2010-12-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Saizen</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02237971</dpd-id>
                <started-marketing-on>1999-10-26</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>5 mg</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Saizen 10iu  -  Kit</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02215136</dpd-id>
                <started-marketing-on>1996-10-17</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>5 ml</strength>
                <route>intramuscular; subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Saizen 8.8mg (5.83mg/ml)</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02272083</dpd-id>
                <started-marketing-on>2006-01-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>8.8 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Serostim</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239046</dpd-id>
                <started-marketing-on>1999-07-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>5 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Serostim</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02239047</dpd-id>
                <started-marketing-on>1999-06-30</started-marketing-on>
                <ended-marketing-on>2013-07-15</ended-marketing-on>
                <dosage-form>powder for solution</dosage-form>
                <strength>6 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>BioTropin</name>
                <company>Biotech General</company>
            </international-brand>
            <international-brand>
                <name>NutropinAQ</name>
                <company>Genentech Inc.</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Norditropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Omnitrope</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Omnitrope</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Pen 10</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Pen 20</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Nuspin 10</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Nuspin 5</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Nuspin 20</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Saizen 10iu  -  Kit</name>
                <ingredients>Sodium Chloride + Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Saizen</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Serostim</name>
                <ingredients>Somatropin recombinant + Water</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Pen Cartridge</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Saizen 8.8mg (5.83mg/ml)</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Omnitrope</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Omnitrope</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Humatrope Inj 1mg/ml</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin Nordiflex</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin Nordiflex</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin Nordiflex</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Saizen</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Saizen</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Saizen</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Nuspin 10</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Nuspin 20</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq Nuspin 5</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin - Kit  Pws(5mg) &amp; Liq(10ml) Im Sc</name>
                <ingredients>Somatropin recombinant + Water</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin - Kit  Pws(10mg) &amp; Liq(10ml) Im Sc</name>
                <ingredients>Somatropin recombinant + Water</ingredients>
            </mixture>
            <mixture>
                <name>Nutropin Aq - Sc 5mg/ml</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Serostim</name>
                <ingredients>Somatropin recombinant + Water</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin Simplexx</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin Simplexx</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Norditropin Simplexx</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Bio-tropin</name>
                <ingredients>Sodium Chloride + Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Bio-tropin</name>
                <ingredients>Sodium Chloride + Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Omnitrope</name>
                <ingredients>Somatropin recombinant + Water</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
            <mixture>
                <name>Genotropin</name>
                <ingredients>Somatropin recombinant</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Bio Technology General Ltd.</name>
                <url/>
            </packager>
            <packager>
                <name>Bristol-Myers Squibb Co.</name>
                <url>http://www.bms.com</url>
            </packager>
            <packager>
                <name>BTG Pharmaceuticals Corp.</name>
                <url>http://www.btgplc.com</url>
            </packager>
            <packager>
                <name>Ebewe Pharma</name>
                <url>http://www.ebewe.at</url>
            </packager>
            <packager>
                <name>Eli Lilly &amp; Co.</name>
                <url>http://www.lilly.com</url>
            </packager>
            <packager>
                <name>EMD Canada Inc.</name>
                <url>http://www.emdcanada.com</url>
            </packager>
            <packager>
                <name>F Hoffmann-La Roche Ltd.</name>
                <url>http://www.roche.com</url>
            </packager>
            <packager>
                <name>First KJM Corporation</name>
                <url/>
            </packager>
            <packager>
                <name>Gate Pharmaceuticals</name>
                <url/>
            </packager>
            <packager>
                <name>Genentech Inc.</name>
                <url>http://www.gene.com</url>
            </packager>
            <packager>
                <name>Hospira Inc.</name>
                <url>http://www.hospira.com</url>
            </packager>
            <packager>
                <name>Merck KGaA</name>
                <url>http://www.merck.de</url>
            </packager>
            <packager>
                <name>Merck Serono SPA</name>
                <url>http://www.merckserono.net</url>
            </packager>
            <packager>
                <name>Novartis AG</name>
                <url>http://www.novartis.com</url>
            </packager>
            <packager>
                <name>Novo Nordisk Inc.</name>
                <url>http://www.novonordisk.com</url>
            </packager>
            <packager>
                <name>Pfizer Inc.</name>
                <url>http://www.pfizer.com</url>
            </packager>
            <packager>
                <name>Pharmacia Inc.</name>
                <url>http://www.pharmaciaupjohn.com</url>
            </packager>
            <packager>
                <name>Physicians Total Care Inc.</name>
                <url>http://www.physicianstotalcare.com</url>
            </packager>
            <packager>
                <name>Sandoz</name>
                <url>http://www.sandoz.ca</url>
            </packager>
            <packager>
                <name>Serono SA</name>
                <url>http://www.merckserono.net</url>
            </packager>
            <packager>
                <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
                <url>http://www.vetter-pharma.com</url>
            </packager>
            <packager>
                <name>Wasserburger Arzneimittelwerk GmbH</name>
                <url/>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Genentech inc</manufacturer>
            <manufacturer generic="false">Serono laboratories inc</manufacturer>
            <manufacturer generic="false">Cangene corp</manufacturer>
            <manufacturer generic="false">Ferring pharmaceuticals inc</manufacturer>
            <manufacturer generic="false">Pharmacia and upjohn co</manufacturer>
            <manufacturer generic="false">Eli lilly and co</manufacturer>
            <manufacturer generic="false">Novo nordisk inc</manufacturer>
            <manufacturer generic="false">Sandoz inc</manufacturer>
            <manufacturer generic="false">Emd serono inc</manufacturer>
            <manufacturer generic="false">Lg life sciences ltd</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Genotropin miniquick 0.2 mg</description>
                <cost currency="USD">15.05</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin miniquick 0.4 mg</description>
                <cost currency="USD">30.09</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin miniquick 0.6 mg</description>
                <cost currency="USD">45.14</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin miniquick 0.8 mg</description>
                <cost currency="USD">60.19</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin miniquick 1 mg</description>
                <cost currency="USD">75.23</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 1 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">77.36</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Genotropin miniquick 1.2 mg</description>
                <cost currency="USD">90.28</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 1.2 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">92.83</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Genotropin miniquick 1.4 mg</description>
                <cost currency="USD">105.32</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 1.4 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">108.78</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 0.2 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">110.52</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Genotropin miniquick 1.6 mg</description>
                <cost currency="USD">120.37</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 1.6 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">123.78</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Genotropin miniquick 1.8 mg</description>
                <cost currency="USD">135.41</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin miniquick 2 mg</description>
                <cost currency="USD">150.46</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 2 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">154.72</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Serostim 4 mg vial</description>
                <cost currency="USD">221.9</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 0.4 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">228.45</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Tev-tropin 5 mg vial</description>
                <cost currency="USD">239.51</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Tev-Tropin 5 mg Solution Vial</description>
                <cost currency="USD">259.45</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Protropin 5 mg Solution Vial</description>
                <cost currency="USD">274.95</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Serostim 5 mg vial</description>
                <cost currency="USD">277.38</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Omnitrope 5.8 mg Solution Vial</description>
                <cost currency="USD">283.38</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 0.6 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">326.67</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Serostim 6 mg vial</description>
                <cost currency="USD">332.86</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Saizen 5 mg vial</description>
                <cost currency="USD">376.26</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Norditropin 5 mg/1.5ml Solution 1.5ml Cartridge</description>
                <cost currency="USD">389.44</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Norditropin NordiFlex Pen 5 mg/1.5ml Solution 1 Syringe = 1.5ml</description>
                <cost currency="USD">389.44</cost>
                <unit>pen</unit>
            </price>
            <price>
                <description>Genotropin 5.8 mg Cartridge</description>
                <cost currency="USD">391.21</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Saizen 5 mg Solution Vial</description>
                <cost currency="USD">391.31</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Nutropin 5 mg vial</description>
                <cost currency="USD">392.35</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Serostim 8.8 mg vial</description>
                <cost currency="USD">418.66</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Genotropin MiniQuick 0.8 mg (7 Cartridges Per Box)</description>
                <cost currency="USD">433.56</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Humatrope 6 mg cartridge</description>
                <cost currency="USD">455.72</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Protropin 10 mg Solution Vial</description>
                <cost currency="USD">549.9</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Saizen 8.8 mg vial</description>
                <cost currency="USD">602.02</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Saizen 8.8 mg Solution Vial</description>
                <cost currency="USD">626.1</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Saizen Click.Easy 8.8 mg Solution Vial</description>
                <cost currency="USD">626.1</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Norditropin nordiflex 30 mg/3</description>
                <cost currency="USD">748.92</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Norditropin NordiFlex Pen 10 mg/1.5ml Solution 1 Syringe = 1.5ml</description>
                <cost currency="USD">753.86</cost>
                <unit>pen</unit>
            </price>
            <price>
                <description>Nutropin aq 20 mg/2ml pen cart</description>
                <cost currency="USD">759.55</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Nutropin aq nuspin 20 pen cart</description>
                <cost currency="USD">759.55</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Nutropin 10 mg vial</description>
                <cost currency="USD">784.7</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Humatrope 12 mg cartridge</description>
                <cost currency="USD">911.45</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Genotropin 12 mg Solution</description>
                <cost currency="USD">928.36</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Norditropin 15 mg/1.5 ml cartridge</description>
                <cost currency="USD">1123.38</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Norditropin nordiflx 15 mg/1.5</description>
                <cost currency="USD">1123.38</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Norditropin 15 mg/1.5ml Solution 1.5ml Cartridge</description>
                <cost currency="USD">1168.32</cost>
                <unit>cartridge</unit>
            </price>
            <price>
                <description>Norditropin NordiFlex Pen 15 mg/1.5ml Solution 1 Syringe = 1.5ml</description>
                <cost currency="USD">1168.32</cost>
                <unit>pen</unit>
            </price>
            <price>
                <description>Norditropin flexpro 15 mg/1.5</description>
                <cost currency="USD">1179.54</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Humatrope 24 mg cartridge</description>
                <cost currency="USD">1822.9</cost>
                <unit>cartridge</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Hormone Replacement Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Liquid; powder for solution</form>
                <route>subcutaneous</route>
                <strength>10 ml</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>0.2 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>0.4 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>0.6 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>0.8 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>1.0 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>1.2 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>1.4 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>1.6 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>1.8 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>12 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>2.0 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>5.3 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>1 mg</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>10 mg/1.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>15 mg/1.5mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>30 mg/3mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>5 mg/1.5mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>15 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>10 mg</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Liquid</form>
                <route>subcutaneous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>20 mg</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>5 mg/2mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>10 mg/2mL</strength>
            </dosage>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>20 mg/2mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>10 mg</strength>
            </dosage>
            <dosage>
                <form>Kit; powder for solution</form>
                <route>subcutaneous</route>
                <strength>5.8 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>10.0 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>5.0 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>5.83 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>8 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intramuscular; subcutaneous</route>
                <strength>5 ml</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>8.8 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>5 mg</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>subcutaneous</route>
                <strength>6 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="H01AC01">
                <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
                <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
                <level code="H01A">ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</level>
                <level code="H01AC">Somatropin and somatropin agonists</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents>
            <patent>
                <number>1326439</number>
                <country>Canada</country>
                <approved>1994-01-25</approved>
                <expires>2011-01-25</expires>
            </patent>
            <patent>
                <number>2252535</number>
                <country>Canada</country>
                <approved>2009-06-23</approved>
                <expires>2017-04-24</expires>
            </patent>
            <patent>
                <number>5288703</number>
                <country>United States</country>
                <approved>1994-10-07</approved>
                <expires>2011-10-07</expires>
            </patent>
            <patent>
                <number>6152897</number>
                <country>United States</country>
                <approved>1998-11-20</approved>
                <expires>2018-11-20</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB01380</drugbank-id>
                <name>Cortisone acetate</name>
                <description>May diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01395</drugbank-id>
                <name>Drospirenone</name>
                <description>Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00783</drugbank-id>
                <name>Estradiol</name>
                <description>Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04574</drugbank-id>
                <name>Estropipate</name>
                <description>Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00957</drugbank-id>
                <name>Norgestimate</name>
                <description>Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00592</drugbank-id>
                <name>Piperazine</name>
                <description>Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00635</drugbank-id>
                <name>Prednisone</name>
                <description>May diminish the therapeutic effect of Prednisone. Growth hormone may reduce the conversion of Prednisone to the active prednisolone metabolite.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;DB00052 sequence
                FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPT
                PSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEG
                IQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIV
                QCRSVEGSCGF</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>76 °C at pH 3.5</value>
                <source>Gomez-Orellana, I. et al., Protein Sci. 7:1352-1358 (1998)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.411</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>5.27</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>22129.0000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C990H1532N262O300S7</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>7364</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0169-7704-21</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>AF374232</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA451446</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P58756</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Somatropin_recombinant</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/nutropin.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/somatropin-rdna-origin-nonrefrigerated.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000075</id>
                <name>Growth hormone receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>binder</action>
                </actions>
                <references># Walenkamp MJ, Wit JM: Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res. 2006;66(5):221-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16917171&#13;
                    # Wu XY, Xu Z, Chen C, Liu FK, Li JS: [Correlation of growth hormone receptor expression to preoperative radiosensitivity of rectal cancer patients] Ai Zheng. 2006 Sep;25(9):1162-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16965663&#13;
                    # Adriani M, Garbi C, Amodio G, Russo I, Giovannini M, Amorosi S, Matrecano E, Cosentini E, Candotti F, Pignata C: Functional interaction of common gamma-chain and growth hormone receptor signaling apparatus. J Immunol. 2006 Nov 15;177(10):6889-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17082603&#13;
                    # Choi JH, Kim HS, Kim SH, Yang YR, Bae YS, Chang JS, Kwon HM, Ryu SH, Suh PG: Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B. Nat Cell Biol. 2006 Dec;8(12):1389-97. Epub 2006 Nov 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17128263&#13;
                    # Bernstein RM, Leigh SR, Donovan SM, Monaco MH: Hormones and body size evolution in papionin primates. Am J Phys Anthropol. 2007 Feb;132(2):247-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17133434&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P10912" source="Swiss-Prot">
                    <name>Growth hormone receptor</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling</specific-function>
                    <gene-name>GHR</gene-name>
                    <locus>5p13-p12</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. GHBP:Secreted protein. On growth hormone binding</cellular-location>
                    <transmembrane-regions>265-288</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.51</theoretical-pi>
                    <molecular-weight>71500.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:4263</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>GHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>GHR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X06562</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31738</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P10912</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>GHR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>GH receptor</synonym>
                        <synonym>Growth hormone receptor precursor</synonym>
                        <synonym>Somatotropin receptor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Growth hormone receptor precursor
                        MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPE
                        RETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTS
                        IWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRN
                        ADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNY
                        GEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPP
                        VPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEES
                        DTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGE
                        ADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSS
                        LSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADA
                        KKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHI
                        VQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1917 bp
                        ATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCT
                        GGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAAT
                        CCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAG
                        CGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGA
                        CCCATACAGCTGTTCTATACCAGAAGGAACACTCAAGAATGGACTCAAGAATGGAAAGAA
                        TGCCCTGATTATGTTTCTGCTGGGGAAAACAGCTGTTACTTTAATTCATCGTTTACCTCC
                        ATCTGGATACCTTATTGTATCAAGCTAACTAGCAATGGTGGTACAGTGGATGAAAAGTGT
                        TTCTCTGTTGATGAAATAGTGCAACCAGATCCACCCATTGCCCTCAACTGGACTTTACTG
                        AACGTCAGTTTAACTGGGATTCATGCAGATATCCAAGTGAGATGGGAAGCACCACGCAAT
                        GCAGATATTCAGAAAGGATGGATGGTTCTGGAGTATGAACTTCAATACAAAGAAGTAAAT
                        GAAACTAAATGGAAAATGATGGACCCTATATTGACAACATCAGTTCCAGTGTACTCATTG
                        AAAGTGGATAAGGAATATGAAGTGCGTGTGAGATCCAAACAACGAAACTCTGGAAATTAT
                        GGCGAGTTCAGTGAGGTGCTCTATGTAACACTTCCTCAGATGAGCCAATTTACATGTGAA
                        GAAGATTTCTACTTTCCATGGCTCTTAATTATTATCTTTGGAATATTTGGGCTAACAGTG
                        ATGCTATTTGTATTCTTATTTTCTAAACAGCAAAGGATTAAAATGCTGATTCTGCCCCCA
                        GTTCCAGTTCCAAAGATTAAAGGAATCGATCCAGATCTCCTCAAGGAAGGAAAATTAGAG
                        GAGGTGAACACAATCTTAGCCATTCATGATAGCTATAAACCCGAATTCCACAGTGATGAC
                        TCTTGGGTTGAATTTATTGAGCTAGATATTGATGAGCCAGATGAAAAGACTGAGGAATCA
                        GACACAGACAGACTTCTAAGCAGTGACCATGAGAAATCACATAGTAACCTAGGGGTGAAG
                        GATGGCGACTCTGGACGTACCAGCTGTTGTGAACCTGACATTCTGGAGACTGATTTCAAT
                        GCCAATGACATACATGAGGGTACCTCAGAGGTTGCTCAGCCACAGAGGTTAAAAGGGGAA
                        GCAGATCTCTTATGCCTTGACCAGAAGAATCAAAATAACTCACCTTATCATGATGCTTGC
                        CCTGCTACTCAGCAGCCCAGTGTTATCCAAGCAGAGAAAAACAAACCACAACCACTTCCT
                        ACTGAAGGAGCTGAGTCAACTCACCAAGCTGCCCATATTCAGCTAAGCAATCCAAGTTCA
                        CTGTCAAACATCGACTTTTATGCCCAGGTGAGCGACATTACACCAGCAGGTAGTGTGGTC
                        CTTTCCCCGGGCCAAAAGAATAAGGCAGGGATGTCCCAATGTGACATGCACCCGGAAATG
                        GTCTCACTCTGCCAAGAAAACTTCCTTATGGACAATGCCTACTTCTGTGAGGCAGATGCC
                        AAAAAGTGCATCCCTGTGGCTCCTCACATCAAGGTTGAATCACACATACAGCCAAGCTTA
                        AACCAAGAGGACATTTACATCACCACAGAAAGCCTTACCACTGCTGCTGGGAGGCCTGGG
                        ACAGGAGAACATGTTCCAGGTTCTGAGATGCCTGTCCCAGACTATACCTCCATTCATATA
                        GTACAGTCCCCACAGGGCCTCATACTCAATGCGACTGCCTTGCCCTTGCCTGACAAAGAG
                        TTTCTCTCATCATGTGGCTATGTGAGCACAGACCAACTGAACAAAATCATGCCTTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000345</id>
                <name>Prolactin receptor</name>
                <organism>Human</organism>
                <actions/>
                <references># Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME: The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 2007 Mar 6;46(9):2398-410. Epub 2007 Feb 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17279774&#13;
                    # Ahmed TA, Buzzelli MD, Lang CH, Capen JB, Shumate ML, Navaratnarajah M, Nagarajan M, Cooney RN: Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1793-803. Epub 2007 Mar 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17395896&#13;
                    # Moderscheim TA, Gorba T, Pathipati P, Kokay IC, Grattan DR, Williams CE, Scheepens A: Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience. 2007 Mar 30;145(3):963-73. Epub 2007 Feb 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17317019&#13;
                    # Cunningham BC, Bass S, Fuh G, Wells JA: Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 1990 Dec 21;250(4988):1709-12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2270485</references>
                <known-action>yes</known-action>
                <polypeptide id="P16471" source="Swiss-Prot">
                    <name>Prolactin receptor</name>
                    <general-function>Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity</general-function>
                    <specific-function>This is a receptor for the anterior pituitary hormone prolactin</specific-function>
                    <gene-name>PRLR</gene-name>
                    <locus>5p14-p13</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>235-258</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.08</theoretical-pi>
                    <molecular-weight>69506.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:9446</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>PRLR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>PRLR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31661</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>190362</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P16471</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PRLR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>PRL-R</synonym>
                        <synonym>Prolactin receptor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prolactin receptor precursor
                        MKENVASATVFTLLLFLNTCLLNGQLPPGKPEIFKCRSPNKETFTCWWRPGTDGGLPTNY
                        SLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMGSSFSDELYVD
                        VTYIVQPDPPLELAVEVKQPEDRKPYLWIKWSPPTLIDLKTGWFTLLYEIRLKPEKAAEW
                        EIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSPATFIQIPSDFTMNDTTVWIS
                        VAVLSAVICLIIVWAVALKGYSMVTCIFPPVPGPKIKGFDAHLLEKGKSEELLSALGCQD
                        FPPTSDYEDLLVEYLEVDDSEDQHLMSVHSKEHPSQGMKPTYLDPDTDSGRGSCDSPSLL
                        SEKCEEPQANPSTFYDPEVIEKPENPETTHTWDPQCISMEGKIPYFHAGGSKCSTWPLPQ
                        PSQHNPRSSYHNITDVCELAVGPAGAPATLLNEAGKDALKSSQTIKSREEGKATQQREVE
                        SFHSETDQDTPWLLPQEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGKPKKPGTP
                        ENNKEYAKVSGVMDNNILVLVPDPHAKNVACFEESAKEAPPSLEQNQAEKALANFTATSS
                        KCRLQLGGLDYLDPACFTHSFH</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1869 bp
                        ATGAAGGAAAATGTGGCATCTGCAACCGTTTTCACTCTGCTACTTTTTCTCAACACCTGC
                        CTTCTGAATGGACAGTTACCTCCTGGAAAACCTGAGATCTTTAAATGTCGTTCTCCCAAT
                        AAGGAAACATTCACCTGCTGGTGGAGGCCTGGGACAGATGGAGGACTTCCTACCAATTAT
                        TCACTGACTTACCACAGGGAAGGAGAGACACTCATGCATGAATGTCCAGACTACATAACC
                        GGTGGCCCCAACTCCTGCCACTTTGGCAAGCAGTACACCTCCATGTGGAGGACATACATC
                        ATGATGGTCAATGCCACTAACCAGATGGGAAGCAGTTTCTCGGATGAACTTTATGTGGAC
                        GTGACTTACATAGTTCAGCCAGACCCTCCTTTGGAGCTGGCTGTGGAAGTAAAACAGCCA
                        GAAGACAGAAAACCCTACCTGTGGATTAAATGGTCTCCACCTACCCTGATTGACTTAAAA
                        ACTGGTTGGTTCACGCTCCTGTATGAAATTCGATTAAAACCCGAGAAAGCAGCTGAGTGG
                        GAGATCCATTTTGCTGGGCAGCAAACAGAGTTTAAGATTCTCAGCCTACATCCAGGACAG
                        AAATACCTTGTCCAGGTTCGCTGCAAACCAGACCATGGATACTGGAGTGCATGGAGTCCA
                        GCGACCTTCATTCAGATACCTAGTGACTTCACCATGAATGATACAACCGTGTGGATCTCT
                        GTGGCTGTCCTTTCTGCTGTCATCTGTTTGATTATTGTCTGGGCAGTGGCTTTGAAGGGC
                        TATAGCATGGTGACCTGCATCTTTCCGCCAGTTCCTGGGCCAAAAATAAAAGGATTTGAT
                        GCTCATCTGTTGGAGAAGGGCAAGTCTGAAGAACTACTGAGTGCCTTGGGATGCCAAGAC
                        TTTCCTCCCACTTCTGACTATGAGGACTTGCTGGTGGAGTATTTAGAAGTAGATGATAGT
                        GAGGACCAGCATCTAATGTCAGTCCATTCAAAAGAACACCCAAGTCAAGGTATGAAACCC
                        ACATACCTGGATCCTGACACTGACTCAGGCCGGGGGAGCTGTGACAGCCCTTCCCTTTTG
                        TCTGAAAAGTGTGAGGAACCCCAGGCCAATCCCTCCACATTCTATGATCCTGAGGTCATT
                        GAGAAGCCAGAGAATCCTGAAACAACCCACACCTGGGACCCCCAGTGCATAAGCATGGAA
                        GGCAAAATCCCCTATTTTCATGCTGGTGGATCCAAATGTTCAACATGGCCCTTACCACAG
                        CCCAGCCAGCACAACCCCAGATCCTCTTACCACAATATTACTGATGTGTGTGAGCTGGCT
                        GTGGGCCCTGCAGGTGCACCGGCCACTCTGTTGAATGAAGCAGGTAAAGATGCTTTAAAA
                        TCCTCTCAAACCATTAAGTCTAGAGAAGAGGGAAAGGCAACCCAGCAGAGGGAGGTAGAA
                        AGCTTCCATTCTGAGACTGACCAGGATACGCCCTGGCTGCTGCCCCAGGAGAAAACCCCC
                        TTTGGCTCCGCTAAACCCTTGGATTATGTGGAGATTCACAAGGTCAACAAAGATGGTGCA
                        TTATCATTGCTACCAAAACAGAGAGAGAACAGCGGCAAGCCCAAGAAGCCCGGGACTCCT
                        GAGAACAATAAGGAGTATGCCAAGGTGTCCGGGGTCATGGATAACAACATCCTGGTGTTG
                        GTGCCAGATCCACATGCTAAAAACGTGGCTTGCTTTGAAGAATCAGCCAAAGAGGCCCCA
                        CCATCACTTGAACAGAATCAAGCTGAGAAAGCCCTGGCCAACTTCACTGCAACATCAAGC
                        AAGTGCAGGCTCCAGCTGGGTGGTTTGGATTACCTGGATCCCGCATGTTTTACACACTCC
                        TTTCACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00041</identifier>
                            <name>fn3</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hematopoietin/interferon-class (D200-domain) cytokine receptor activity</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2011-08-04">
        <drugbank-id primary="true">DB00053</drugbank-id>
        <drugbank-id>BIOD00026</drugbank-id>
        <drugbank-id>BTD00026</drugbank-id>
        <name>Imiglucerase</name>
        <description>Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues</description>
        <cas-number>143003-46-7</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># Pastores GM, Hughes DA: Gaucher Disease  "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20301446</general-references>
        <synthesis-reference/>
        <indication>For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)</indication>
        <pharmacodynamics>Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia</pharmacodynamics>
        <mechanism-of-action>Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.</mechanism-of-action>
        <toxicity/>
        <metabolism/>
        <absorption/>
        <half-life>3.6-10.4 min</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution>* 0.09 to 0.15 L/kg</volume-of-distribution>
        <clearance>* 14.5 +/- 4.0 mL/min/kg</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Cerezyme</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02230694</dpd-id>
                <started-marketing-on>1997-05-01</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>200 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Cerezyme</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02241751</dpd-id>
                <started-marketing-on>2000-06-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>400 unit</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Cerezyme</name>
                <ndc-id>58468-1983_c07ea20e-36bc-4f7b-a218-d79927f7c77e</ndc-id>
                <ndc-product-code>58468-1983</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1994-05-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>40 U/mL</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020367</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Cerezyme</name>
                <ndc-id>58468-4663_c07ea20e-36bc-4f7b-a218-d79927f7c77e</ndc-id>
                <ndc-product-code>58468-4663</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>1994-05-23</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>40 U/mL</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020367</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Cerezyme</name>
                <ingredients>Imiglucerase</ingredients>
            </mixture>
            <mixture>
                <name>Cerezyme</name>
                <ingredients>Imiglucerase</ingredients>
            </mixture>
            <mixture>
                <name>Cerezyme</name>
                <ingredients>Imiglucerase</ingredients>
            </mixture>
            <mixture>
                <name>Cerezyme</name>
                <ingredients>Imiglucerase</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Genzyme Inc.</name>
                <url>http://www.genzyme.ca</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">Genzyme corp</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Ceredase 80 unit/ml vial</description>
                <cost currency="USD">380.64</cost>
                <unit>ml</unit>
            </price>
            <price>
                <description>Cerezyme 200 unit vial</description>
                <cost currency="USD">951.6</cost>
                <unit>vial</unit>
            </price>
            <price>
                <description>Cerezyme 400 unit vial</description>
                <cost currency="USD">1903.2</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Enzyme Replacement Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>intravenous</route>
                <strength>40 U/mL</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>200 unit</strength>
            </dosage>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>400 unit</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="A16AB02">
                <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
                <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
                <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
                <level code="A16AB">Enzymes</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>44:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>5549892</number>
                <country>United States</country>
                <approved>1993-08-27</approved>
                <expires>2013-08-27</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;DB00053 sequence
                ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANH
                TGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIR
                VPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWT
                SPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGL
                LSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPE
                AAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRG
                MQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHL
                GHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFL
                ETISPGYSIHTYLWRRQ</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.168</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>7.41</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>55597.4000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C2532H3854N672O711S16</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>11365</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D02810</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>58468-4663-1</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>M16328</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA164742934</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P04062</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Imiglucerase</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic2/imiglucerase.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/imiglucerase.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0004806</id>
                <name>Glucocerebroside</name>
                <organism>Human</organism>
                <actions>
                    <action>other/unknown</action>
                </actions>
                <references># Pastores GM, Hughes DA: Gaucher Disease  "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20301446</references>
                <known-action>yes</known-action>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
</drugbank>